PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Felson, DT; McLaughlin, S; Goggins, J; LaValley, MP; Gale, E; Totterman, S; Li, W; Hill, C; Gale, D				Felson, DT; McLaughlin, S; Goggins, J; LaValley, MP; Gale, E; Totterman, S; Li, W; Hill, C; Gale, D			Bone marrow edema and its relation to progression of knee osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Article							JOINT SPACE WIDTH; RADIOGRAPHIC FEATURES; CLINICAL-TRIAL; MODIFYING DRUG; SCINTIGRAPHY; ALIGNMENT; PAIN	Background: While factors affecting the course of knee osteoarthritis are mostly unknown, lesions on bone scan and mechanical malalignment increase risk for radiographic deterioration. Bone marrow edema lesions on magnetic resonance imaging correspond to bone scan lesions. Objective: To determine whether edema lesions in the subarticular bone in patients with knee osteoarthritis identify knees at high risk for radiographic progression and whether these lesions are associated with limb malalignment. Design: Natural history study. Setting: A Veterans Administration hospital in Boston, Massachusetts. Patients: Persons 45 years of age and older with symptomatic knee osteoarthritis. Measurements: Baseline assessments included magnetic resonance imaging of the knee and fluoroscopically positioned radiography. During follow-up at 15 and 30 months, patients underwent repeated radiography; at 15 months, long-limb films were obtained to assess mechanical alignment. Progression was defined as an increase over follow-up in medial or lateral joint space narrowing, based on a semi-quantitative grading. Generalized estimating equations were used to evaluate the relation of medial bone marrow edema lesions to medial progression and lateral lesions to lateral progression, before and after adjustment for limb alignment. Results: Of 256 patients, 223 (87.1%) participated in at least one follow-up examination. Medial bone marrow lesions were seen mostly in patients with varus limbs, and lateral lesions were seen mostly in those with valgus limbs. Twenty-seven of 75 knees with medial lesions (36.0%) showed medial progression versus 12 of 148 knees without lesions (8.1%) (odds ratio for progression, 6.5 [95% Cl, 3.0 to 14.0]). Approximately 69% of knees that progressed medially had medial lesions, and lateral lesions conferred a marked risk for lateral progression. These increased risks were attenuated by 37% to 53% after adjustment for limb alignment. Conclusion: Bone marrow edema is a potent risk factor for structural deterioration in knee osteoarthritis, and its relation to progression is explained in part by its association with limb alignment.	Boston Univ, Sch Med, Boston, MA 02118 USA; Vet Affairs Boston Hlth Care Syst, Boston, MA USA; Univ Rochester, Rochester, NY USA	Boston University; University of Rochester	Felson, DT (corresponding author), Boston Univ, Sch Med, 715 Albany St,A203, Boston, MA 02118 USA.		McLaughlin, Sara/S-3521-2019; LaValley, Michael/AAA-2030-2020	LaValley, Michael/0000-0002-8488-5170; Felson, David/0000-0002-2668-2447	NIAMS NIH HHS [AR47785] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; ANDRIACCHI TP, 1994, ORTHOP CLIN N AM, V25, P395; BERGMAN AG, 1994, SKELETAL RADIOL, V23, P445; Boegard T, 1999, ANN RHEUM DIS, V58, P20, DOI 10.1136/ard.58.1.20; Brandt KD, 2002, J RHEUMATOL, V29, P1308; Buckland-Wright JC, 2003, J RHEUMATOL, V30, P329; BUCKLANDWRIGHT C, 1995, OSTEOARTHR CARTILAGE, V3, P71; BUCKLANDWRIGHT JC, 1995, ANN RHEUM DIS, V54, P263, DOI 10.1136/ard.54.4.263; DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557; Felson DT, 2001, ANN INTERN MED, V134, P541, DOI 10.7326/0003-4819-134-7-200104030-00007; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; HUTTON CW, 1986, ANN RHEUM DIS, V45, P622, DOI 10.1136/ard.45.8.622; JOHNSON F, 1980, J BONE JOINT SURG BR, V62, P346, DOI 10.1302/0301-620X.62B3.7410467; Lavalley MP, 2002, ARTHRIT RHEUM-ARTHR, V47, P255, DOI 10.1002/art.10453; Lazzarini KM, 1997, RADIOLOGY, V202, P540, DOI 10.1148/radiology.202.2.9015087; LEDINGHAM J, 1995, ANN RHEUM DIS, V54, P53, DOI 10.1136/ard.54.1.53; MAZZUCA S, 2000, 46 ANN ORTH RES SOC; Mazzuca SA, 1997, OSTEOARTHR CARTILAGE, V5, P217, DOI 10.1016/S1063-4584(97)80017-9; MCALINDON TEM, 1991, ANN RHEUM DIS, V50, P14, DOI 10.1136/ard.50.1.14; MORELAND JR, 1987, J BONE JOINT SURG AM, V69A, P745, DOI 10.2106/00004623-198769050-00016; Rangger C, 1998, ACTA ORTHOP SCAND, V69, P291, DOI 10.3109/17453679809000933; Rothman KJ., 2002, EPIDEMIOLOGY INTRO, P181; SCHOUTEN JSAG, 1992, ANN RHEUM DIS, V51, P932, DOI 10.1136/ard.51.8.932; Sharma L, 2001, JAMA-J AM MED ASSOC, V286, P188, DOI 10.1001/jama.286.2.188; Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835; Zhang YQ, 1996, J RHEUMATOL, V23, P1130	27	532	556	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				330	336		10.7326/0003-4819-139-5_Part_1-200309020-00008	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965956				2022-12-28	WOS:000185037500003
J	Matsuo, T; Yamaguchi, S; Mitsui, S; Emi, A; Shimoda, F; Okamura, H				Matsuo, T; Yamaguchi, S; Mitsui, S; Emi, A; Shimoda, F; Okamura, H			Control mechanism of the circadian clock for timing of cell division in vivo	SCIENCE			English	Article							DNA-SYNTHESIS; PARTIAL-HEPATECTOMY; WEE1 KINASE; LIVER; RHYTHM; PROLIFERATION; MOUSE; RAT; EXPRESSION; CDC2	Cell division in many mammalian tissues is associated with specific times of day, but just how the circadian clock controls this timing has not been clear. Here, we show in the regenerating liver ( of mice) that the circadian clock controls the expression of cell cycle-related genes that in turn modulate the expression of active Cyclin B1-Cdc2 kinase, a key regulator of mitosis. Among these genes, expression of wee1 was directly regulated by the molecular components of the circadian clockwork. In contrast, the circadian clockwork oscillated independently of the cell cycle in single cells. Thus, the intracellular circadian clockwork can control the cell-division cycle directly and unidirectionally in proliferating cells.	Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan; Yamaguchi Univ, Dept Phys Informat & Biol, Yamaguchi 7538512, Japan	Kobe University; Yamaguchi University	Okamura, H (corresponding author), Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan.	okamurah@kobe-u.ac.jp	MATSUO, Takuya/I-7493-2014	Okamura, Hitoshi/0000-0002-3013-4881				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; BADE EG, 1966, EXP CELL RES, V44, P676, DOI 10.1016/0014-4827(66)90484-8; Barbason H, 1995, IN VIVO, V9, P539; BARBIROLI B, 1971, SCIENCE, V172, P738, DOI 10.1126/science.172.3984.738; BARNUM CYRUS P., 1957, TEXAS REPTS BIOL AND MED, V15, P134; Bjarnason GA, 2001, AM J PATHOL, V158, P1793, DOI 10.1016/S0002-9440(10)64135-1; Bjarnason GA, 2000, PROG CELL CYC RES, V4, P193; BROWN WR, 1991, J INVEST DERMATOL, V97, P273, DOI 10.1111/1523-1747.ep12480379; BUCHI KN, 1991, GASTROENTEROLOGY, V101, P410, DOI 10.1016/0016-5085(91)90019-H; Garcia MN, 2001, CELL BIOL INT, V25, P179, DOI 10.1006/cbir.2000.0585; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Higgins GM, 1931, ARCH PATHOL, V12, P186; JAFFE JJ, 1954, ANAT REC, V120, P935, DOI 10.1002/ar.1091200408; Kawasaki H, 2001, EMBO J, V20, P4618, DOI 10.1093/emboj/20.16.4618; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Laconi S, 1999, J HEPATOL, V31, P1069, DOI 10.1016/S0168-8278(99)80320-1; Levi F, 2002, CHRONOBIOL INT, V19, P1, DOI 10.1081/CBI-120002676; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MATSUO T, UNPUB; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Rothblum-Oviatt CJ, 2001, CELL GROWTH DIFFER, V12, P581; SCHEVING LE, 1983, AM J ANAT, V168, P433, DOI 10.1002/aja.1001680405; SCHEVING LE, 1974, ACTA ANAT, V88, P411; Smaaland R, 1996, Prog Cell Cycle Res, V2, P241; SOUTO M, 1985, Chronobiology International, V2, P169, DOI 10.3109/07420528509055556; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323	32	854	896	4	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					255	259		10.1126/science.1086271	http://dx.doi.org/10.1126/science.1086271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12934012				2022-12-28	WOS:000185825900033
J	Hylek, EM; Go, AS; Chang, YC; Jensvold, NG; Henault, LE; Selby, JV; Singer, DE				Hylek, EM; Go, AS; Chang, YC; Jensvold, NG; Henault, LE; Selby, JV; Singer, DE			Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTITHROMBOTIC THERAPY; BLEEDING COMPLICATIONS; COST-EFFECTIVENESS; RISK-FACTORS; WARFARIN; ASPIRIN; THROMBOEMBOLISM; COMMUNITY; PROPHYLAXIS; OUTPATIENTS	Background: The incidence of stroke in patients with atrial fibrillation is greatly reduced by oral anticoagulation, with the full effect seen at international normalized ratio (INR) values of 2.0 or greater. The effect of the intensity of oral anticoagulation on the severity of atrial fibrillation-related stroke is not known but is central to the choice of the target INR. Methods: We studied incident ischemic strokes in a cohort of 13,559 patients with nonvalvular atrial fibrillation. Strokes were identified through hospitalization data bases and validated on the basis of medical records, which also provided information on the use of warfarin or aspirin, the INR at admission, and coexisting illnesses. The severity of stroke was graded according to a modified Rankin scale. Thirty-day mortality was ascertained from hospitalization and mortality files. Results: Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy. Among patients who were taking warfarin, an INR of less than 2.0 at admission, as compared with an INR of 2.0 or greater, independently increased the odds of a severe stroke in a proportional-odds logistic-regression model (odds ratio, 1.9; 95 percent confidence interval, 1.1 to 3.4) across three severity categories and the risk of death within 30 days (hazard ratio, 3.4; 95 percent confidence interval, 1.1 to 10.1). An INR of 1.5 to 1.9 at admission was associated with a mortality rate similar to that for an INR of less than 1.5 (18 percent and 15 percent, respectively). The 30-day mortality rate among patients who were taking aspirin at the time of the stroke was similar to that among patients who were taking warfarin and who had an INR of less than 2.0. Conclusions: Among patients with nonvalvular atrial fibrillation, anticoagulation that results in an INR of 2.0 or greater reduces not only the frequency of ischemic stroke but also its severity and the risk of death from stroke. Our findings provide further evidence against the use of lower INR target levels in patients with atrial fibrillation.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gen Med Div,Clin Epidemiol Unit, Boston, MA 02114 USA; Kaiser Permanente No Calif, Div Res, Oakland, CA USA; Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hylek, EM (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gen Med Div,Clin Epidemiol Unit, 50 Staniford St,9th Fl, Boston, MA 02114 USA.		Go, Alan S./AAE-7745-2019	Hylek, Elaine/0000-0001-8263-8304	NIA NIH HHS [5 R01 AG15478] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; *AM MED ASS, 1999, INT CLASS DIS, V2; *AM MED ASS, 1999, INT CLASS DIS, V1; [Anonymous], 2001, CIRCULATION, V104, P2118; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; Blackshear JL, 1996, LANCET, V348, P633; BOGOUSSLAVSKY J, 1990, NEUROLOGY, V40, P1046, DOI 10.1212/WNL.40.7.1046; BRITTON M, 1985, STROKE, V16, P182, DOI 10.1161/01.STR.16.2.182; CANDELISE L, 1991, STROKE, V22, P169, DOI 10.1161/01.STR.22.2.169; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; Eckman MH, 1998, ARCH INTERN MED, V158, P1669, DOI 10.1001/archinte.158.15.1669; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; Go AS, 2002, CIRCULATION, V106, P515; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; GUSTAFSSON C, 1991, J INTERN MED, V230, P11, DOI 10.1111/j.1365-2796.1991.tb00400.x; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2000, CEREBROVASC DIS, V10, P39, DOI 10.1159/000016023; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Kaarisalo MM, 1997, STROKE, V28, P311, DOI 10.1161/01.STR.28.2.311; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Lamassa M, 2001, STROKE, V32, P392, DOI 10.1161/01.STR.32.2.392; LANDEFELD CS, 1989, AM J MED, V87, P144; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lin HJ, 1996, STROKE, V27, P1760, DOI 10.1161/01.STR.27.10.1760; Longstreth WT, 2001, NEUROLOGY, V56, P368, DOI 10.1212/WNL.56.3.368; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; MANNING WJ, 1995, ARCH INTERN MED, V155, P2193, DOI 10.1001/archinte.155.20.2193; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; Miller VT, 1996, NEUROLOGY, V46, P238, DOI 10.1212/WNL.46.1.238; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Penado S, 2002, AM J MED, V112, P572, DOI 10.1016/S0002-9343(02)01063-X; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SANDERCOCK P, 1992, BRIT MED J, V305, P1460, DOI 10.1136/bmj.305.6867.1460; SHERMAN DG, 1984, ARCH NEUROL-CHICAGO, V41, P708, DOI 10.1001/archneur.1984.04050180030011; Thomson R, 2000, LANCET, V355, P1466; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	45	947	993	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1019	1026		10.1056/NEJMoa022913	http://dx.doi.org/10.1056/NEJMoa022913			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968085				2022-12-28	WOS:000185223100003
J	Melendez, A; Talloczy, Z; Seaman, M; Eskelinen, EL; Hall, DH; Levine, B				Melendez, A; Talloczy, Z; Seaman, M; Eskelinen, EL; Hall, DH; Levine, B			Autophagy genes are essential for dauer development and life-span extension in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; MACROAUTOPHAGY; SENESCENCE; LONGEVITY; NEMATODE; MUTANTS; VACUOLE; DAF-2	Both dauer formation (a stage of developmental arrest) and adult life-span in Caenorhabditis elegans are negatively regulated by insulin-like signaling, but little is known about cellular pathways that mediate these processes. Autophagy, through the sequestration and delivery of cargo to the lysosomes, is the major route for degrading long-lived proteins and cytoplasmic organelles in eukaryotic cells. Using nematodes with a loss-of-function mutation in the insulin-like signaling pathway, we show that bec-1, the C. elegans ortholog of the yeast and mammalian autophagy gene APG6/VPS30/beclin1, is essential for normal dauer morphogenesis and life-span extension. Dauer formation is associated with increased autophagy and also requires C. elegans orthologs of the yeast autophagy genes APG1, APG7, APG8, and AUT10. Thus, autophagy is a cellular pathway essential for dauer development and life-span extension in C. elegans.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Kiel, Inst Biochem, D-24098 Kiel, Germany; Albert Einstein Coll Med, Ctr C Elegans Anat, Bronx, NY 10461 USA	Columbia University; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Kiel; Yeshiva University; Albert Einstein College of Medicine	Levine, B (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.	levine@cancercenter.columbia.edu	Eskelinen, Eeva-Liisa/AAF-3496-2019	Eskelinen, Eeva-Liisa/0000-0003-0006-7785	NATIONAL CANCER INSTITUTE [R01CA084254] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR012596] Funding Source: NIH RePORTER; NCI NIH HHS [CA84254] Funding Source: Medline; NCRR NIH HHS [RR 12596, R24 RR012596] Funding Source: Medline; NIH HHS [R24 OD010943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALBERT PS, 1988, DEV BIOL, V126, P270, DOI 10.1016/0012-1606(88)90138-8; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bergamini E, 1995, AGING-CLIN EXP RES, V7, P473, DOI 10.1007/BF03324374; Doelling JH, 2002, J BIOL CHEM, V277, P33105, DOI 10.1074/jbc.M204630200; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gems D, 1998, GENETICS, V150, P129; GOLDEN JW, 1985, MOL GEN GENET, V198, P534, DOI 10.1007/BF00332953; GORDON PB, 1987, BIOCHIM BIOPHYS ACTA, V929, P128, DOI 10.1016/0167-4889(87)90167-4; Hanaoka H, 2002, PLANT PHYSIOL, V129, P1181, DOI 10.1104/pp.011024; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; KENYON C, 1997, C ELEGANS, V2, P791; Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; MELENDEZ A, UNPUB; OGURA K, 1994, GENE DEV, V8, P2389, DOI 10.1101/gad.8.20.2389; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; QU X, UNPUB; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Riddle DL, 1997, C ELEGANS, P739; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E	31	979	1037	6	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1387	1391		10.1126/science.1087782	http://dx.doi.org/10.1126/science.1087782			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958363				2022-12-28	WOS:000185116400044
J	Korner, J; Leibel, RL				Korner, J; Leibel, RL			To eat or not to eat - How the gut talks to the brain	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Korner, J (corresponding author), Columbia Univ, Coll Phys & Surg, New York, NY 10032 USA.								0	144	168	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					926	928		10.1056/NEJMp038114	http://dx.doi.org/10.1056/NEJMp038114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954739				2022-12-28	WOS:000185081400002
J	Kurtz, J; Franz, K				Kurtz, J; Franz, K			Evidence for memory in invertebrate immunity	NATURE			English	Editorial Material							HOST		Max Planck Inst Limnol, Dept Evolut Ecol, D-24306 Plon, Germany	Max Planck Society	Kurtz, J (corresponding author), Max Planck Inst Limnol, Dept Evolut Ecol, August Thienemann Str 2, D-24306 Plon, Germany.		Kurtz, Joachim/A-9678-2008	Kurtz, Joachim/0000-0002-7258-459X				Carius HJ, 2001, EVOLUTION, V55, P1136, DOI 10.1111/j.0014-3820.2001.tb00633.x; FAULHABER LM, 1992, IMMUNOLOGY, V75, P378; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; KLEIN J, 1989, SCAND J IMMUNOL, V29, P499, DOI 10.1111/j.1365-3083.1989.tb01152.x; Kurtz J, 2002, EXP PARASITOL, V100, P36, DOI 10.1006/expr.2001.4681; Little TJ, 2003, CURR BIOL, V13, P489, DOI 10.1016/S0960-9822(03)00163-5; Marques MRF, 2000, AQUACULTURE, V191, P23, DOI 10.1016/S0044-8486(00)00417-8; Rolff J, 2003, SCIENCE, V301, P472, DOI 10.1126/science.1080623; Schmid-Hempel P, 2003, TRENDS ECOL EVOL, V18, P27, DOI 10.1016/S0169-5347(02)00013-7; SCOFIELD VL, 1982, NATURE, V295, P499, DOI 10.1038/295499a0	11	295	308	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					37	38		10.1038/425037a	http://dx.doi.org/10.1038/425037a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955131				2022-12-28	WOS:000185089200028
J	Schneiderman, LJ; Gilmer, T; Teetzel, HD; Dugan, DO; Blustein, J; Cranford, R; Briggs, KB; Komatsu, GI; Goodman-Crews, P; Cohn, F; Young, EWD				Schneiderman, LJ; Gilmer, T; Teetzel, HD; Dugan, DO; Blustein, J; Cranford, R; Briggs, KB; Komatsu, GI; Goodman-Crews, P; Cohn, F; Young, EWD			Effect of ethics consultations on nonbeneficial life-sustaining treatments in the intensive care setting - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERVICE	Context Ethics consultations increasingly are being used to resolve conflicts about life-sustaining interventions, but few studies have reported their outcomes. Objective To investigate whether ethics consultations in the intensive care setting reduce the use of life-sustaining treatments delivered to patients who ultimately did not survive to hospital discharge, as well as the reactions to the consultations of physicians, nurses, and patients/surrogates. Design Prospective, multicenter, randomized controlled trial from November 2000 to December 2002. Setting Adult intensive care units (ICUs) of 7 US hospitals representing a spectrum of institutional characteristics. Patients Five hundred fifty-one patients in whom value-related treatment conflicts arose during the course of treatment. Interventions Patients were randomly assigned either to an intervention (ethics consultation offered) (n=278) or to usual care (n=273). Main Outcome Measures The primary outcomes were ICU days and life-sustaining treatments in those patients who did not survive to hospital discharge. We examined the same measures in those who did survive to discharge and also compared the overall mortality rates of the intervention and usual care groups. We also interviewed physicians and nurses and patients/surrogates about their views of the ethics consultation. Results The intervention and usual-care groups showed no difference in mortality. However, ethics consultations were associated with reductions in hospital (-2.95 days, P=.01) and ICU (-1.44 days, P=.03) days and life-sustaining treatments (-1.7 days with ventilation, P=.03) in those patients who ultimately did not survive to discharge. The majority (87%) of physicians, nurses, and patients/surrogates agreed that ethics consultations in the ICU were helpful in addressing treatment conflicts. Conclusion Ethics consultations were useful in resolving conflicts that may have inappropriately prolonged nonbeneficial or unwanted treatments in the ICU.	Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Swedish Covenant Hosp, Eth Dept, Chicago, IL USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, New York, NY USA; Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Social Serv Dept, Minneapolis, MN 55415 USA; Mary Hosp, Little co, Neonatol & Bioeth Intens Care Unit, Torrance, CA USA; Kaiser Permanente San Diego, Bioeth Consultant Qual Resource Management, San Diego, CA USA; Univ Calif Irvine, Coll Med, Dept Med, Irvine, CA 92717 USA; Stanford Univ, Sch Med, Ctr Biomed Eth, Stanford, CA 94305 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Montefiore Medical Center; Hennepin County Medical Center; Hennepin County Medical Center; Kaiser Permanente; University of California System; University of California Irvine; Stanford University	Schneiderman, LJ (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr,MC 0622, La Jolla, CA 92093 USA.				AHRQ HHS [1 R01 HS10251] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010251] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM SOC BIOETH HUM, 1998, COR COMP HLTH CAR ET; Berger VW, 2000, STAT MED, V19, P1319, DOI 10.1002/(SICI)1097-0258(20000530)19:10<1319::AID-SIM490>3.0.CO;2-0; Dowdy MD, 1998, CRIT CARE MED, V26, P252, DOI 10.1097/00003246-199802000-00020; ESSERMAN L, 1995, JAMA-J AM MED ASSOC, V274, P1544, DOI 10.1001/jama.274.19.1544; Fletcher JC, 1996, J CLIN ETHIC, V7, P122; LAPUMA J, 1988, JAMA-J AM MED ASSOC, V260, P808, DOI 10.1001/jama.260.6.808; LAPUMA J, 1992, AM J MED, V92, P346, DOI 10.1016/0002-9343(92)90262-A; McClung JA, 1996, AM J MED, V100, P456, DOI 10.1016/S0002-9343(97)89523-X; Orr RD, 1996, AM J MED, V101, P135, DOI 10.1016/S0002-9343(96)80067-2; ORR RD, 1994, J CLIN ETHIC, V5, P323; Schneiderman LJ, 2000, CRIT CARE MED, V28, P3920, DOI 10.1097/00003246-200012000-00033; Wenger N. S., 1996, JGIM, V11, P120; Yen B M, 1999, J Perinatol, V19, P373, DOI 10.1038/sj.jp.7200188	13	435	445	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1166	1172		10.1001/jama.290.9.1166	http://dx.doi.org/10.1001/jama.290.9.1166			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LK	12952998				2022-12-28	WOS:000185090400011
J	Kane, RL				Kane, RL			The contribution of geriatric health services research to successful aging	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				CHRONIC CARE; DISEASE MANAGEMENT; RANDOMIZED TRIAL; CHRONIC ILLNESS; OLDER-PEOPLE; INTERVENTION; PREVENT	Successful aging seems to refer to a broad set of circumstances that include but transcend healthy aging. The contribution of medical care to successful aging may lie in better management of chronic diseases. Health services research can contribute to successful aging by informing the delivery of medical care in this area. It can provide useful insights into what kinds of new approaches have proven successful and how to implement and sustain these changes. However, many of these lessons from health services research have been ignored in practice to date.	Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kane, RL (corresponding author), Univ Minnesota, Sch Publ Hlth, Div Hlth Serv Res & Policy, D351 Mayo MMC 197,420 Delaware St SE, Minneapolis, MN 55455 USA.	kanex001@umn.edu						ANTONUCCI TC, 1990, HDB AGING SOCIAL SCI; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Bengston V. L., 1999, HDB THEORIES AGING, P3; Bodenheimer T, 1999, NEW ENGL J MED, V340, P1202, DOI 10.1056/NEJM199904153401511; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Boult C, 2000, BRIT MED J, V321, P1011, DOI 10.1136/bmj.321.7267.1011; Casalino L, 2003, JAMA-J AM MED ASSOC, V289, P434, DOI 10.1001/jama.289.4.434; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; DeBaggio Thomas, 2002, LOSING MY MIND INTIM; Garber J., 1980, HUMAN HELPLESSNESS T; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Grol R, 2001, MED CARE, V39, pII46; Hanlon JT, 2002, J AM GERIATR SOC, V50, P26, DOI 10.1046/j.1532-5415.2002.50004.x; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kane RL, 1998, J AM GERIATR SOC, V46, P1034; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Phelan EA, 2002, J AM GERIATR SOC, V50, P1306, DOI 10.1046/j.1532-5415.2002.50324.x; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rowe JW, 1998, SUCCESSFUL AGING; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; THORNTON C, 2002, CONSTRAINED INNOVATI; Vaillant G. E., 2002, AGING WELL SURPRISIN; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Wagner EH, 2001, JAMA-J AM MED ASSOC, V285, P182, DOI 10.1001/jama.285.2.182; Wagner EH, 2001, DIABETES CARE, V24, P695, DOI 10.2337/diacare.24.4.695; Wagner EH, 2000, BMJ-BRIT MED J, V320, P569, DOI 10.1136/bmj.320.7234.569; WAN TTH, 1981, RES AGING, V3, P240, DOI 10.1177/016402758132009; WHO, 2002, INNOVATIVE CARE CHRO	30	6	8	2	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			460	462		10.7326/0003-4819-139-5_Part_2-200309021-00016	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00016			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965977				2022-12-28	WOS:000185133800016
J	Koretz, RL				Koretz, RL			Update in gastroenterology	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED TRIAL; HELICOBACTER-PYLORI; CROHNS-DISEASE; THERAPY; ERADICATION		Olive View UCLA Med Ctr, Dept Med, Sylmar, CA 91342 USA	University of California System; University of California Los Angeles	Koretz, RL (corresponding author), Olive View UCLA Med Ctr, Dept Med, 14445 Olive View Dr, Sylmar, CA 91342 USA.	rkoretz@dhs.co.la.ca.us						AMBROSE NS, 1985, DIS COLON RECTUM, V28, P81, DOI 10.1007/BF02552649; Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304; Chan FKL, 1997, LANCET, V350, P975, DOI 10.1016/S0140-6736(97)04523-6; Hawkey CJ, 1998, LANCET, V352, P1016, DOI 10.1016/S0140-6736(98)04206-8; Moayyedi P, 2000, LANCET, V355, P1665, DOI 10.1016/S0140-6736(00)02236-4; Ortega R, 2002, HEPATOLOGY, V36, P941, DOI 10.1053/jhep.2002.35819; SUTHERLAND L, 1991, GUT, V32, P1071, DOI 10.1136/gut.32.9.1071	7	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				352	358		10.7326/0003-4819-139-5_Part_1-200309020-00011	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965944				2022-12-28	WOS:000185037500006
J	Chene, G; Sterne, JA; May, M; Costagliola, D; Ledergerber, B; Phillips, AN; Dabis, F; Lundgren, J; Monforte, AD; de Wolf, F; Hogg, R; Reiss, P; Justice, A; Leport, C; Staszewski, S; Gill, J; Fatkenheuer, G; Egger, ME				Chene, G; Sterne, JA; May, M; Costagliola, D; Ledergerber, B; Phillips, AN; Dabis, F; Lundgren, J; Monforte, AD; de Wolf, F; Hogg, R; Reiss, P; Justice, A; Leport, C; Staszewski, S; Gill, J; Fatkenheuer, G; Egger, ME		ART Cohort Collaboration	Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies	LANCET			English	Article							HEPATITIS-C VIRUS; VIROLOGICAL TREATMENT FAILURE; PROTEASE INHIBITOR THERAPY; CD4 CELL COUNT; CLINICAL PROGRESSION; VIRAL LOAD; HIV; COHORT; COINFECTION; COMBINATION	Background We examined whether the initial virological and immunological response to highly active antiretroviral treatment (HAART) is prognostic in patients with HIV-1 who start HAART. Methods We analysed 13 cohort studies from Europe and North America including 9323 adult treatment-naive patients who were starting HAART with a combination of at least three drugs. We modelled clinical progression from month 6 after starting HAART, taking into account CD4 count and HIV-1 RNA measured at baseline and 6 months. Findings During 13 408 years of follow-up 152 patients died and 874 developed AIDS or died. Compared with patients who had a 6-month CD4 count of fewer than 25 cells/muL, adjusted hazard ratios for AIDS or death were 0.55 (95%CI 0.32-0.96) for 25-49 cells/muL, 0.62 (0.40-0.96) for 50-99 cells/muL, 0.42 (0.28-0.64) for 100-199 cells/muL, 0.25 (0.16-0.38) for 200-349 cells/muL, and 0.18 (0.11-0.29) for 350 or more cells/muL at 6 months. Compared with patients who had a 6-month HIV-1 RNA of 100 000 copies/mL or greater, adjusted hazard ratios for AIDS or death were 0.59 (0.41-0.86) for 10 000-99 999 copies/mL, 0.42 (0.29-0.61) for 500-9999 copies/mL, and 0.29 (0.21-0.39) for 6-month HIV-1 RNA of 500 copies/mL or fewer. Baseline CD4 and HIV-1 RNA were not associated with progression after controlling for 6-month concentrations. The probability of progression at 3 years ranged from 2.4% in the patients in the lowest-risk stratum to 83% in patients in the highest-risk stratum. Interpretation At 6 months after starting HAART, the current CD4 cell count and viral load, but not values at baseline, are strongly associated with subsequent disease progression. Our findings should inform guidelines on when to modify HAART.	Univ Victor Segalen Bordeaux 2, Inst Sante Publ Epidemiol & Dev, F-33076 Bordeaux, France; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland	UDICE-French Research Universities; Universite de Bordeaux; University of Bern	Chene, G (corresponding author), Univ Victor Segalen Bordeaux 2, Inst Sante Publ Epidemiol & Dev, 146 rue Leo Saignat, F-33076 Bordeaux, France.	genevieve.chene@isped.u-bordeaux2.fr	Lundgren, Jens/AAE-6876-2019; VALLET, Yannick/F-9979-2011; Ledergerber, Bruno/B-5656-2009; DABIS, FRANCOIS/S-9298-2019; Costagliola, Dominique/H-5849-2011; chene, genevieve/H-8665-2014; Dodsley, Maria/G-7083-2016; Hogg, Robert S/B-2783-2012; Sterne, Jonathan/Z-3106-2019; Phillips, Andrew N/B-4427-2008; Gill, Michael John/G-7083-2016	Ledergerber, Bruno/0000-0002-6881-4401; DABIS, FRANCOIS/0000-0002-1614-8857; Costagliola, Dominique/0000-0003-0765-0869; chene, genevieve/0000-0002-8368-6460; Dodsley, Maria/0000-0001-7587-558X; Hogg, Robert S/0000-0003-3463-5488; Sterne, Jonathan/0000-0001-8496-6053; Phillips, Andrew N/0000-0003-2384-4807; Gill, Michael John/0000-0002-8546-8790; Egger, Matthias/0000-0001-7462-5132	MRC [G0100221] Funding Source: UKRI; Medical Research Council [G0100221] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Binquet C, 2001, AM J EPIDEMIOL, V153, P386, DOI 10.1093/aje/153.4.386; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; DARMINIO MA, 1999, AIDS, V13, P1669; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Deeks SG, 1999, AIDS, V13, pF35, DOI 10.1097/00002030-199904160-00001; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Fatkenheuer G, 1997, AIDS, V11, pF113, DOI 10.1097/00002030-199714000-00001; Grabar S, 2000, ANN INTERN MED, V133, P401, DOI 10.7326/0003-4819-133-6-200009190-00007; Grabar S, 2000, AIDS, V14, P141, DOI 10.1097/00002030-200001280-00009; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Kitchen CM, 2001, CLIN INFECT DIS, V33, P466, DOI 10.1086/321900; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lewden C, 2002, J INFECT DIS, V186, P710, DOI 10.1086/342047; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Lundgren JD, 1997, J ACQ IMMUN DEF SYND, V16, P153, DOI 10.1097/00042560-199711010-00003; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Mocroft A, 1999, AIDS, V13, P1255, DOI 10.1097/00002030-199907090-00016; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Mocroft A, 2000, AIDS, V14, P1545, DOI 10.1097/00002030-200007280-00010; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phillips AN, 2001, JAMA-J AM MED ASSOC, V286, P2560, DOI 10.1001/jama.286.20.2560; Rancinan C, 2002, AIDS, V16, P1357, DOI 10.1097/00002030-200207050-00007; Rhone SA, 1998, AIDS, V12, P619, DOI 10.1097/00002030-199806000-00011; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; Spiegelhalter DJ, 2002, J R STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353; Staszewski S, 1999, AIDS, V13, P951, DOI 10.1097/00002030-199905280-00011; Tedaldi EM, 2003, CLIN INFECT DIS, V36, P363, DOI 10.1086/345953; Wit FWNM, 1999, J INFECT DIS, V179, P790, DOI 10.1086/314675	35	206	210	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					679	686						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957089				2022-12-28	WOS:000185034800007
J	Hollander, E; Phillips, AT; Yeh, CC				Hollander, E; Phillips, AT; Yeh, CC			Targeted treatments for symptom domains in child and adolescent autism	LANCET			English	Review							PERVASIVE DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; OPEN-LABEL; OPEN TRIAL; ADULTS; RISPERIDONE; STRATEGIES	Context The number of people with autism spectrum disorders has dramatically increased over the past decade, and problem behaviours in autism are an increasing challenge to families, schools, physicians, and other health-care professionals. Pharmacological treatments can effectively target problem behaviours associated with autism. Starting point Recently, L Namerow and colleagues (J Dev Behav Pediatr 2003;, 24: 104-08) presented preliminary data in children and adolescents with autism treated with citalopram, which suggested that selective serotonin-reuptake inhibitors are useful in the reduction of symptom domains such as repetitive behaviours and mood disorders. J McCracken and colleagues (N Engl J Med 2000; 347: 314-21) showed that the atypical antipsychotic risperidone reduced serious behavioural problems, such as tantrums, aggression, or self-injury in children with autism and in children with below-average intelligence quotients. These and other studies show how 1 developments in study, design, selection of patients, and outcome measures have allowed treatment trials in autism to progress beyond anecdotal reports and case observations, and show reduction in the severity of specific symptom domains within these disorders. Where next? In therapeutic intervention the risk of treatment toxicity must be balanced against the benefits of improved symptom severity. The newer methods enable informed decisions about which patients will benefit from which treatments. Other symptom domains within autism and effects on development need to be evaluated in adequately designed clinical trials. Future strategies include extending treatment to children as young as the preschool years.	Mt Sinai Sch Med, Dept Psychiat, Seaver & New York Autism Ctr Excellence, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Hollander, E (corresponding author), Mt Sinai Sch Med, Dept Psychiat, Seaver & New York Autism Ctr Excellence, Box 1230,1 Gustave Levy Pl, New York, NY 10029 USA.							California Department of Developmental Services, 2003, AUT SPECTR DIS CHANG; Chugani DC, 1999, ANN NEUROL, V45, P287, DOI 10.1002/1531-8249(199903)45:3<287::AID-ANA3>3.0.CO;2-9; DeLong GR, 2002, DEV MED CHILD NEUROL, V44, P652; DELONG R, 1994, DEV MED CHILD NEUROL, V36, P674; Greenhill LL, 2003, J AM ACAD CHILD PSY, V42, P406, DOI 10.1097/01.CHI.0000046812.95464.FA; Gringras P, 1999, CHILD CARE HLTH DEV, V25, P223, DOI 10.1046/j.1365-2214.1999.00108.x; Hollander E, 2001, J CLIN PSYCHIAT, V62, P530, DOI 10.4088/JCP.v62n07a05; Hollander E, 2000, J CHILD NEUROL, V15, P132, DOI 10.1177/088307380001500214; Kemner C, 2002, J CLIN PSYCHOPHARM, V22, P455, DOI 10.1097/00004714-200210000-00003; Masi G, 2001, J AM ACAD CHILD PSY, V40, P1206, DOI 10.1097/00004583-200110000-00015; McCracken JT, 2002, NEW ENGL J MED, V347, P314, DOI 10.1056/NEJMoa013171; McDougle CJ, 2000, CHILD ADOL PSYCH CL, V9, P201; McDougle CJ, 1998, J CLIN PSYCHOPHARM, V18, P62, DOI 10.1097/00004714-199802000-00010; McDougle CJ, 2003, J CLIN PSYCHIAT, V64, P16; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001; MCDOUGLE CJ, 2003, AUTISTIC OTHER PERVA, P563; Namerow LB, 2003, J DEV BEHAV PEDIATR, V24, P104, DOI 10.1097/00004703-200304000-00005; Rugino TA, 2002, J DEV BEHAV PEDIATR, V23, DOI 10.1097/00004703-200208000-00006; Towbin KE, 2003, CHILD ADOL PSYCH CL, V12, P23, DOI 10.1016/S1056-4993(02)00049-4; Van Bourgondien ME, 2003, J AUTISM DEV DISORD, V33, P131, DOI 10.1023/A:1022931224934	20	57	58	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					732	734		10.1016/S0140-6736(03)14236-5	http://dx.doi.org/10.1016/S0140-6736(03)14236-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	716NH	12957098				2022-12-28	WOS:000185034800025
J	Stark, J; Hardy, K				Stark, J; Hardy, K			Chaos: Useful at last?	SCIENCE			English	Editorial Material							SYSTEMS; EPIDEMIC		Univ London Imperial Coll Sci Technol & Med, Dept Math, London SW7 2AZ, England; Hammersmith Hosp, Imperial Coll London, Inst Reprod & Dev Biol, London W12 0NN, England	Imperial College London; Imperial College London	Stark, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Math, Huxley Bldg, London SW7 2AZ, England.							Bartholdi JJ, 1999, OPER RES, V47, P488, DOI 10.1287/opre.47.3.488; Bray D, 2001, NATURE, V412, P863, DOI 10.1038/35091132; de Leval MR, 2003, J THORAC CARDIOV SUR, V125, P12, DOI 10.1067/mtc.2003.59; Dye C, 2003, SCIENCE, V300, P1884, DOI 10.1126/science.1086925; Enserink M, 2001, SCIENCE, V294, P26, DOI 10.1126/science.294.5540.26; Howell KC, 1997, J ASTRONAUT SCI, V45, P161; Kitano H, 2002, SCIENCE, V295, P1662, DOI 10.1126/science.1069492; KOUDA T, 2001, 52 INT APPL TECHN C; LORENZ EN, 1963, J ATMOS SCI, V20, P130, DOI 10.1175/1520-0469(1963)020<0130:DNF>2.0.CO;2; MACKENZIE D, 2003, SIAM NEWS, V36, P4; Molteni F, 1996, Q J ROY METEOR SOC, V122, P73, DOI 10.1002/qj.49712252905; Rem B, 2003, CHAOS, V13, P128, DOI 10.1063/1.1500284; Stark J, 2000, PHILOS T R SOC A, V358, P41, DOI 10.1098/rsta.2000.0518; TAKENS F, 1980, DYNAMICAL SYSTEMS TU	15	33	35	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1192	1193		10.1126/science.1087822	http://dx.doi.org/10.1126/science.1087822			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947188				2022-12-28	WOS:000185003500029
J	Xu, BQ; Tao, NJJ				Xu, BQ; Tao, NJJ			Measurement of single-molecule resistance by repeated formation of molecular junctions	SCIENCE			English	Article							ELECTRON-TRANSFER; ALKANETHIOL MONOLAYERS; METAL JUNCTIONS; TRANSPORT; CONDUCTION	The conductance of a single molecule connected to two gold electrodes was determined by repeatedly forming thousands of gold-molecule-gold junctions. Conductance histograms revealed well-defined peaks at integer multiples of a fundamental conductance value, which was used to identify the conductance of a single molecule. The resistances near zero bias were 10.5+/-0.5, 51+/-5, 630+/-50, and 1.3+/-0.1 megohms for hexanedithiol, octanedithiol, decanedithiol, and 4,4' bipyridine, respectively. The tunneling decay constant (beta(N)) for N-alkanedithiols was 1.0+/-0.1 per carbon atom and was weakly dependent on the applied bias. The resistance and beta(N) values are consistent with first-principles calculations.	Arizona State Univ, Dept Elect Engn, Tempe, AZ 85287 USA; Arizona State Univ, Ctr Solid State Elect Res, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe	Tao, NJJ (corresponding author), Arizona State Univ, Dept Elect Engn, Tempe, AZ 85287 USA.		Tao, NJ/B-1628-2008					AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; CHIDSEY CED, 1991, SCIENCE, V251, P919, DOI 10.1126/science.251.4996.919; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui XD, 2002, NANOTECHNOLOGY, V13, P5, DOI 10.1088/0957-4484/13/1/302; Cui XD, 2002, J PHYS CHEM B, V106, P8609, DOI 10.1021/jp0206065; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Cunha F, 1996, LANGMUIR, V12, P6410, DOI 10.1021/la9606254; CUNHA F, 1995, PHYS REV LETT, V75, P2376, DOI 10.1103/PhysRevLett.75.2376; Fink HW, 1999, NATURE, V398, P407, DOI 10.1038/18855; Gittins DI, 2000, NATURE, V408, P67, DOI 10.1038/35040518; Holmlin RE, 2001, J AM CHEM SOC, V123, P5075, DOI 10.1021/ja004055c; Kasumov AY, 2001, SCIENCE, V291, P280, DOI 10.1126/science.291.5502.280; KRANS JM, 1995, NATURE, V375, P767, DOI 10.1038/375767a0; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Nitzan A, 2001, J PHYS CHEM A, V105, P2677, DOI 10.1021/jp003884h; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; PASCUAL JI, 1993, PHYS REV LETT, V71, P1852, DOI 10.1103/PhysRevLett.71.1852; Porath D, 2000, NATURE, V403, P635, DOI 10.1038/35001029; Ramachandran GK, 2003, J PHYS CHEM B, V107, P6162, DOI 10.1021/jp0343786; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804; Segal D, 2000, J PHYS CHEM B, V104, P2790, DOI 10.1021/jp994296a; Slowinski K, 1997, J AM CHEM SOC, V119, P11910, DOI 10.1021/ja971921l; SMALLEY JF, 1995, J PHYS CHEM-US, V99, P13141, DOI 10.1021/j100035a016; Tomfohr JK, 2002, PHYS STATUS SOLIDI B, V233, P59, DOI 10.1002/1521-3951(200209)233:1<59::AID-PSSB59>3.0.CO;2-6; Tomfohr JK, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.245105; Wold DJ, 2001, J AM CHEM SOC, V123, P5549, DOI 10.1021/ja0101532; York RL, 2003, J AM CHEM SOC, V125, P5948, DOI 10.1021/ja0211353	28	1896	1924	39	638	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1221	1223		10.1126/science.1087481	http://dx.doi.org/10.1126/science.1087481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947193				2022-12-28	WOS:000185003500036
J	Agrawal, M; Emanuel, EJ				Agrawal, M; Emanuel, EJ			Ethics of phase 1 oncology studies - Reexamining the arguments and data	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							I CLINICAL-TRIALS; QUALITY-OF-LIFE; RENAL-CELL CARCINOMA; ABL TYROSINE KINASE; INFORMED CONSENT; CANCER-PATIENTS; THERAPEUTIC RESPONSE; ANTICANCER AGENTS; FUNCTIONAL STATUS; DESIGN	Phase 1 oncology trials are critical to improving the treatment of cancer. Critics have raised 2 fundamental ethical challenges about phase 1 cancer research: the paucity of benefits with substantial risks and poor-quality informed consent. Despite 3 decades of controversy about phase 1 oncology research, there is little critical analysis of the arguments or of the data relevant to these questions. Existing but old data reveal that about 5% of patients in phase 1 trials experience shrinkage of their tumor, with a 0.5% mortality rate. In some notable cases, patients in phase 1 trials have been cured or sustained long-term remissions. Limited data suggest that patients in phase 1 trials may have better quality of life than comparable patients receiving supportive care. More important, the risks and benefits of phase 1 trials are not clearly worse than risk-benefit ratios used by the US Food and Drug Administration to approve chemotherapeutic agents for clinical use. The objections based on informed consent are deficiencies of disclosure, understanding, and voluntariness. The available data do not support the claim that disclosure is deficient. Although studies evaluating patient understanding have substantial methodological problems, they demonstrate that more than 70% of patients understand that they may not directly benefit even when they hope they will personally benefit. Finally, a closer look at issues of voluntariness reveals that patients with advanced cancer who participate in phase 1 research may have a different set of values than do critics and are not coerced. Overall, it appears that phase 1 oncology trials satisfy the requirement for a favorable risk-benefit ratio and that patients who enroll provide adequate informed consent.	NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA; NCI, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Agrawal, M (corresponding author), NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bldg 10,Room 1C118,10 Ctr Dr, Bethesda, MD 20892 USA.							Agrawal Manish, 2002, J Palliat Med, V5, P729, DOI 10.1089/109662102320880552; *AM CANC SOC, 2003, CANC FACTS FIG; Annas G J, 1992, Health Matrix Clevel, V2, P119; [Anonymous], 1986, HIST THEORY INFORM C; Arbuck SG, 1996, ANN ONCOL, V7, P567; BERDEL WE, 1988, ANTICANCER RES, V8, P313; BERG JW, 2001, INFORMED CONSENT LEG; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Campbell S, 1999, J ADV NURS, V30, P335, DOI 10.1046/j.1365-2648.1999.01079.x; Cheng JD, 2000, J CLIN ONCOL, V18, P421, DOI 10.1200/JCO.2000.18.2.421; Cohen L, 2002, UROL ONCOL, V7, P119, DOI 10.1016/S1078-1439(01)00182-X; Cox K, 2000, PSYCHO-ONCOL, V9, P314, DOI 10.1002/1099-1611(200007/08)9:4<314::AID-PON464>3.3.CO;2-3; Creemers GJ, 1996, J CLIN ONCOL, V14, P3056, DOI 10.1200/JCO.1996.14.12.3056; DAUGHERTY C, 1995, J CLIN ONCOL, V13, P1062, DOI 10.1200/JCO.1995.13.5.1062; Daugherty C K, 2000, IRB, V22, P6, DOI 10.2307/3564113; Daugherty CK, 1997, ANN INTERN MED, V126, P892, DOI 10.7326/0003-4819-126-11-199706010-00008; DECOSTER G, 1990, ANN ONCOL, V1, P175, DOI 10.1093/oxfordjournals.annonc.a057716; Dent SF, 1996, ANN ONCOL, V7, P561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V283, P2701, DOI 10.1001/jama.283.20.2701; EMANUEL EJ, 1995, J CLIN ONCOL, V13, P1049, DOI 10.1200/JCO.1995.13.5.1049; EPSTEIN AM, 1989, MED CARE, V27, P91; ESTEY E, 1986, CANCER TREAT REP, V70, P1105; Fisher B, 2001, JNCI-J NATL CANCER I, V93, P112, DOI 10.1093/jnci/93.2.112; Francis RJ, 2002, BRIT J CANCER, V87, P600, DOI 10.1038/sj.bjc.6600517; Frei E, 1997, CANCER J, V3, P127; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; HIGBY DJ, 1974, CANCER, V33, P1219, DOI 10.1002/1097-0142(197405)33:5<1219::AID-CNCR2820330505>3.0.CO;2-U; Hope-Stone L D, 1997, Eur J Cancer Care (Engl), V6, P267, DOI 10.1046/j.1365-2354.1997.00053.x; Horng S, 2002, NEW ENGL J MED, V347, P2134, DOI 10.1056/NEJMsa021182; Hutchison C, 1998, Eur J Cancer Care (Engl), V7, P15, DOI 10.1046/j.1365-2354.1998.00062.x; Itoh K, 1997, BRIT J CANCER, V76, P107, DOI 10.1038/bjc.1997.344; ITOH K, 1994, CANCER CHEMOTH PHARM, V34, P451, DOI 10.1007/BF00685653; Joffe S, 2001, LANCET, V358, P1772, DOI 10.1016/S0140-6736(01)06805-2; King NMP, 2000, J LAW MED ETHICS, V28, P332, DOI 10.1111/j.1748-720X.2000.tb00685.x; KODISH E, 1992, J CLIN ONCOL, V10, P1810, DOI 10.1200/JCO.1992.10.11.1810; Lippman ME, 2001, JNCI-J NATL CANCER I, V93, P80, DOI 10.1093/jnci/93.2.80; LIPSETT MB, 1982, JAMA-J AM MED ASSOC, V248, P941, DOI 10.1001/jama.248.8.941; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCCUSKER J, 1984, MED CARE, V22, P789, DOI 10.1097/00005650-198409000-00002; MELINK TJ, 1992, ANTI-CANCER DRUG, V3, P571, DOI 10.1097/00001813-199212000-00003; MEROPOL NJ, 2002, P AM SOC CLIN ONC MA; Meslin Eric M, 1990, IRB, V12, P7, DOI 10.2307/3563683; Miller M, 2000, HASTINGS CENT REP, V30, P34, DOI 10.2307/3527646; Miller M, 2001, Int Anesthesiol Clin, V39, P13; Moore S, 2001, J ADV NURS, V33, P738, DOI 10.1046/j.1365-2648.2001.01715.x; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; PENMAN DT, 1984, J CLIN ONCOL, V2, P849, DOI 10.1200/JCO.1984.2.7.849; Quantin X, 2000, AM J CLIN ONCOL-CANC, V23, P192, DOI 10.1097/00000421-200004000-00017; RATAIN MJ, 1993, J NATL CANCER I, V85, P1637, DOI 10.1093/jnci/85.20.1637; RODENHUIS S, 1984, EUR J CANCER CLIN ON, V20, P457, DOI 10.1016/0277-5379(84)90229-3; RUBENSTEIN LZ, 1984, J GERONTOL, V39, P686, DOI 10.1093/geronj/39.6.686; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Sherliker L, 2000, PATIENT EDUC COUNS, V40, P11, DOI 10.1016/S0738-3991(99)00047-6; Simon R, 1997, JNCI-J NATL CANCER I, V89, P1138, DOI 10.1093/jnci/89.15.1138; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Smith TL, 1996, J CLIN ONCOL, V14, P287, DOI 10.1200/JCO.1996.14.1.287; Stolberg Sheryl Gay, 2000, NY TIMES 0215 NY TIMES 0215, P20; TOMAMICHEL M, 1995, ANN ONCOL, V6, P363, DOI 10.1093/oxfordjournals.annonc.a059185; van Luijn HEM, 2002, ANN ONCOL, V13, P1307, DOI 10.1093/annonc/mdf209; VONHOFF DD, 1991, INVEST NEW DRUG, V9, P115, DOI 10.1007/BF00194562; Weijer C, 2000, J LAW MED ETHICS, V28, P344, DOI 10.1111/j.1748-720X.2000.tb00686.x; Wertheimer Alan, 1987, COERCION; Yoder L H, 1997, Oncol Nurs Forum, V24, P891; ZWEIBEL NR, 1989, GERONTOLOGIST, V29, P615, DOI 10.1093/geront/29.5.615	66	142	143	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1075	1082		10.1001/jama.290.8.1075	http://dx.doi.org/10.1001/jama.290.8.1075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715FA	12941681				2022-12-28	WOS:000184958900027
J	Young, TK				Young, TK			Review of research on aboriginal populations in Canada: relevance to their health needs	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To determine if research has adequately examined the health needs of the aboriginal population of Canada. Design Review Study selection Medline search of journal articles published during 1992-2001. The search terms used were "Canada" and various synonyms and categories for Canadian aboriginal people. Each paper was categorised according to the aboriginal group, age-sex group, comparison group, geographic location, and type of research topic (health determinant, health status, or health care). Results Of 352 citations found, 254 were selected after elimination of those without abstracts, not containing data on Canada, or not focusing on health issues. The proportion of papers does not reflect the demographic composition of aboriginal people in Canada, with severe under-representation of Metis, urban aboriginal people, and First Nations people not living on reserves and over-representation of the Inuit. Children and women received less attention proportional to their share of the population. A few prolific research groups have generated a disproportionate amount of publications from a few communities and regions. 174 papers dealt with health determinants (for example, genetics, diet, and contaminants), 173 with health status, and 75 with health care. Injuries, which account for a third of all deaths, were studied in only 8 papers. None of the health care papers examined rehabilitation. Conclusion Researchers have not adequately examined several important health needs of the aboriginal population.	Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON M5S 1A8, Canada	University of Toronto	Young, TK (corresponding author), Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON M5S 1A8, Canada.	kue.young@utoronto.ca						BJERREGAARD P, 1998, CIRCUMPOLAR INUIT HL; Global Forum for Health Research, 2002, 10 90 REP HLTH RES 2; Harris SB, 1997, DIABETES CARE, V20, P185, DOI 10.2337/diacare.20.2.185; MacMillan HL, 1996, CAN MED ASSOC J, V155, P1569; Reading J, 2002, AM J PUBLIC HEALTH, V92, P1396, DOI 10.2105/AJPH.92.9.1396; *STAT CAN, 2003, 2001 CENS AB PEOPL C; The Commission on Health Research for Development, 1990, HLTH RES ESS LINK EQ; Waldram JB., 2006, ABORIGINAL HLTH CANA; WHO, 2002, RED RISKS PROM HLTH; Young TK, 2000, CAN MED ASSOC J, V163, P561; YOUNG TK, 1988, SOC SCI MED, V26, P659; Young TK., 1994, HLTH NATIVE AM BIOCU	12	126	126	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2003	327	7412					419	422		10.1136/bmj.327.7412.419	http://dx.doi.org/10.1136/bmj.327.7412.419			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933728	Green Published			2022-12-28	WOS:000185003100015
J	Kenniston, JA; Baker, TA; Fernandez, JM; Sauer, RT				Kenniston, JA; Baker, TA; Fernandez, JM; Sauer, RT			Linkage between ATP consumption and mechanical unfolding during the protein processing reactions of an AAA(+) degradation machine	CELL			English	Article							PROTEASES DEGRADE; ESCHERICHIA-COLI; CLPXP; SPECIFICITY; HYDROLYSIS; STABILITY; TRANSLOCATION; RECOGNITION; DYNAMICS; ATPASES	Proteolytic machines powered by ATP hydrolysis bind proteins with specific peptide tags, denature these substrates, and translocate them into a sequestered compartment for degradation. To determine how ATP is used during individual reaction steps, we assayed ClpXP degradation of ssrA-tagged titin variants with different stabilities in native and denatured forms. The rate of ATP turnover was 4-fold slower during denaturation than translocation. Importantly, this reduced turnover rate was constant during denaturation of native variants with different stabilities, but total ATP consumption increased with substrate stability, suggesting an iterative application of a uniform, mechanical unfolding force. Destabilization of substrate structure near the degradation tag accelerated degradation and dramatically reduced ATP consumption, revealing an important role for local protein stability in resisting denaturation. The ability to denature more stable proteins simply by using more ATP endows ClpX with a robust unfolding activity required for its biological roles in degradation and complex disassembly.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Columbia University	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@mit.edu		Sauer, Robert/0000-0002-1719-5399	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-15706] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Benaroudj N, 2003, MOL CELL, V11, P69, DOI 10.1016/S1097-2765(02)00775-X; Burton BM, 2001, MOL CELL, V8, P449, DOI 10.1016/S1097-2765(01)00307-0; Burton RE, 2003, PROTEIN SCI, V12, P893, DOI 10.1110/ps.0237603; Burton RE, 2001, EMBO J, V20, P3092, DOI 10.1093/emboj/20.12.3092; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; CARRIONVASQUEZ M, 2003, IN PRESS NAT STRUCT; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Fowler SB, 2001, STRUCTURE, V9, P355, DOI 10.1016/S0969-2126(01)00596-2; Fowler SB, 2002, J MOL BIOL, V322, P841, DOI 10.1016/S0022-2836(02)00805-7; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Herman C, 2003, MOL CELL, V11, P659, DOI 10.1016/S1097-2765(03)00068-6; Hollien J, 1999, P NATL ACAD SCI USA, V96, P13674, DOI 10.1073/pnas.96.24.13674; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lee C, 2001, MOL CELL, V7, P627, DOI 10.1016/S1097-2765(01)00209-X; Li HB, 2000, NAT STRUCT BIOL, V7, P1117; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Maier B, 2002, P NATL ACAD SCI USA, V99, P16012, DOI 10.1073/pnas.242523299; Marszalek PE, 1999, NATURE, V402, P100, DOI 10.1038/47083; Matouschek A, 2003, CURR OPIN STRUC BIOL, V13, P98, DOI 10.1016/S0959-440X(03)00010-1; Neuwald AF, 1999, GENOME RES, V9, P27; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Ortega J, 2002, EMBO J, V21, P4938, DOI 10.1093/emboj/cdf483; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wah DA, 2002, CHEM BIOL, V9, P1237, DOI 10.1016/S1074-5521(02)00268-5	36	220	222	1	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					511	520		10.1016/S0092-8674(03)00612-3	http://dx.doi.org/10.1016/S0092-8674(03)00612-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941278	Bronze			2022-12-28	WOS:000184928800013
J	Tomassini, C; Juel, K; Holm, NV; Skytthe, A; Christensen, K				Tomassini, C; Juel, K; Holm, NV; Skytthe, A; Christensen, K			Risk of suicide in twins: 51 year follow up study	BRITISH MEDICAL JOURNAL			English	Article							DENMARK		Univ So Denmark, Inst Publ Hlth, Danish Twin Registry, DK-5000 Odense, Denmark; Univ London London Sch Hyg & Trop Med, Ctr Populat Studies, London WC1E 7HT, England; Natl Inst Publ Hlth, DK-2100 Copenhagen, Denmark	University of Southern Denmark; University of London; London School of Hygiene & Tropical Medicine	Christensen, K (corresponding author), Univ So Denmark, Inst Publ Hlth, Danish Twin Registry, Sdr Blvd 23A, DK-5000 Odense, Denmark.		Christensen, Kaare/C-2360-2009; Juel, Knud/C-8916-2013; Skytthe, Axel E/G-4820-2019	Christensen, Kaare/0000-0002-5429-5292; Skytthe, Axel E/0000-0002-8629-4913; Tomassini, Cecilia/0000-0002-2819-7779; Juel, Knud/0000-0002-4134-1173	NATIONAL CANCER INSTITUTE [R35CA042581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 42581] Funding Source: Medline; NIA NIH HHS [P01-AG08761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agerbo E, 2002, BMJ-BRIT MED J, V325, P74, DOI 10.1136/bmj.325.7355.74; Christensen K, 2001, Twin Res, V4, P344, DOI 10.1375/twin.4.5.344; Klaning U, 1996, BRIT J PSYCHIAT, V168, P688, DOI 10.1192/bjp.168.6.688; Mortensen PB, 2000, LANCET, V355, P9, DOI 10.1016/S0140-6736(99)06376-X; Qin P, 2000, BRIT J PSYCHIAT, V177, P546, DOI 10.1192/bjp.177.6.546	5	38	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					373	374		10.1136/bmj.327.7411.373	http://dx.doi.org/10.1136/bmj.327.7411.373			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919989	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000184864200019
J	Thompson, W; Hutwagner, L; Kolczak, M				Thompson, W; Hutwagner, L; Kolczak, M			Monitoring mortality events associated with individual physicians and practices	LANCET			English	Editorial Material									US Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Thompson, W (corresponding author), US Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA.	WThompson1@cdc.gov						Baker R, 2003, BRIT MED J, V326, P274, DOI 10.1136/bmj.326.7383.274; Chen RT, 1999, VACCINE, V17, pS41, DOI 10.1016/S0264-410X(99)00292-3; EVANS S, 2002, PHARMACOVIGILANCE, P273; FARR W, 1948, VIT STAT 1885, P330; Farrington CP, 1996, J ROY STAT SOC A STA, V159, P547, DOI 10.2307/2983331; Grigg OA, 2003, STAT METHODS MED RES, V12, P147, DOI 10.1177/096228020301200205; Hutwagner L, 2003, J URBAN HEALTH, V80, pI89; McPhillips HA, 2001, ARCH PEDIAT ADOL MED, V155, P1051, DOI 10.1001/archpedi.155.9.1051; Steiner S H, 2000, Biostatistics, V1, P441, DOI 10.1093/biostatistics/1.4.441; STROUP DF, 1989, STAT MED, V8, P323, DOI 10.1002/sim.4780080312	10	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					417	418		10.1016/S0140-6736(03)14098-6	http://dx.doi.org/10.1016/S0140-6736(03)14098-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927425				2022-12-28	WOS:000184651100005
J	Perkins, TT; Dalal, RV; Mitsis, PG; Block, SM				Perkins, TT; Dalal, RV; Mitsis, PG; Block, SM			Sequence-dependent pausing of single lambda exonuclease molecules	SCIENCE			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; RNA-POLYMERASE; DNA; FORCE; TRANSLOCATION; ENDS	Lambda exonuclease processively degrades one strand of duplex DNA, moving 5'-to-3' in an ATP-independent fashion. When examined at the single-molecule level, the speeds of digestion were nearly constant at 4 nanometers per second (12 nucleotides per second), interspersed with pauses of variable duration. Long pauses, occurring at stereotypical locations, were strand-specific and sequence-dependent. Pause duration and probability varied widely. The strongest pause, GGCGATTCT, was identified by gel electrophoresis. Correlating single-molecule dwell positions with sequence independently identified the motif GGCGA. This sequence is found in the left lambda cohesive end, where exonuclease inhibition may contribute to the reduced recombination efficiency at that end.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Praelux Inc, Lawrenceville, NJ 08646 USA	Stanford University; Stanford University; Stanford University	Perkins, TT (corresponding author), Natl Inst Stand & Technol, 325 Broadway, Boulder, CO 80309 USA.			Perkins, Thomas/0000-0003-4826-9490	NHGRI NIH HHS [HG 011821-01] Funding Source: Medline; NIGMS NIH HHS [GM 57035, R01 GM057035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057035, R37GM057035] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; DOKTYCZ MJ, 1995, J BIOL CHEM, V270, P8439, DOI 10.1074/jbc.270.15.8439; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; LITTLE JW, 1967, J BIOL CHEM, V242, P679; Mitsis PG, 1999, NUCLEIC ACIDS RES, V27, P3057, DOI 10.1093/nar/27.15.3057; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; STAHL FW, 1972, P NATL ACAD SCI USA, V69, P3598, DOI 10.1073/pnas.69.12.3598; Subramanian K, 2003, NUCLEIC ACIDS RES, V31, P1585, DOI 10.1093/nar/gkg266; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; Yang Q, 1997, BIOCHEMISTRY-US, V36, P2744, DOI 10.1021/bi9622682	22	117	126	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1914	1918		10.1126/science.1088047	http://dx.doi.org/10.1126/science.1088047			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	12947034	Green Accepted			2022-12-28	WOS:000185536700053
J	Cecchi, F; Olivotto, I; Gistri, R; Lorenzoni, R; Chiriatti, G; Camici, PG				Cecchi, F; Olivotto, I; Gistri, R; Lorenzoni, R; Chiriatti, G; Camici, PG			Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; POSITRON-EMISSION TOMOGRAPHY; MYOCARDIAL PERFUSION ABNORMALITIES; SUDDEN-DEATH; VASODILATOR RESERVE; ATRIAL-FIBRILLATION; CLINICAL COURSE; CARDIAC-ARREST; ISCHEMIA; RISK	Background: Microvascular dysfunction, reflected by an inadequate increase in myocardial blood flow in response to dipyridamole infusion, is a recognized feature of hypertrophic cardiomyopathy. Its long-term effect on the prognosis is unknown. We prospectively evaluated a cohort of patients with hypertrophic cardiomyopathy after they had undergone quantitative assessment of myocardial blood flow by positron-emission tomography (PET). Methods: Fifty-one patients (New York Heart Association class I or II) were followed for a mean (+/-SD) of 8.1+/-2.1 years after PET. Twelve subjects with atypical chest pain served as controls. Measurement of flow was performed at base line and after the infusion of the coronary vasodilator dipyridamole, with the use of nitrogen-13-labeled ammonia. Patients were then divided into three equal groups with increasing values of myocardial blood flow. Results: The response of myocardial blood flow to dipyridamole was severely blunted in the patients, as compared with the controls (1.50+/-0.69 vs. 2.71+/-0.94 ml per minute per gram of tissue, P<0.001). Sixteen patients (31 percent) had an unfavorable outcome (death from cardiovascular causes, progression to New York Heart Association class III or IV, or sustained ventricular arrhythmias requiring the implantation of a cardioverter-defibrillator) 2.2 to 9.1 years after PET. Reduced blood flow in response to dipyridamole was strongly associated with an unfavorable outcome. Multivariate analysis showed that among patients in the lowest of the three flow groups the age-adjusted relative hazard of death from cardiovascular causes was 9.6 (P=0.02) and the relative hazard of an unfavorable outcome (a combined end point) was 20.1 (P=0.003), as compared with patients in the two other flow groups. Specifically, all four patients who died from heart failure and three of five who died suddenly were in this subgroup. Conclusions: In patients with hypertrophic cardiomyopathy, the degree of microvascular dysfunction is a strong, independent predictor of clinical deterioration and death. Severe microvascular dysfunction is often present in patients with mild or no symptoms and may precede clinical deterioration by years.	Azienda Osped Careggi, Reg Referral Ctr Myocardial Dis, Florence, Italy; Osped Lucca, Cardiol Unit, Lucca, Italy; Osped Pescia, Cardiol Unit, Pescia, Italy; CNR, Inst Clin Physiol, I-56100 Pisa, Italy; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Med Res Ctr, London SW7 2AZ, England	University of Florence; Azienda Ospedaliero Universitaria Careggi; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Imperial College London	Cecchi, F (corresponding author), Via Jacopo Nardi 30, I-50132 Florence, Italy.		Olivotto, Iacopo/AAC-5950-2022; Camici, Paolo/AAN-1959-2020; Lorenzoni, Roberto/G-4139-2018	Olivotto, Iacopo/0000-0003-1751-9266; Camici, Paolo/0000-0001-5584-0750; Cecchi, Franco/0000-0002-2035-5621; Lorenzoni, Roberto/0000-0002-5703-715X				Basso C, 2000, HUM PATHOL, V31, P988, DOI 10.1053/hupa.2000.16659; CAMICI P, 1991, J AM COLL CARDIOL, V17, P879, DOI 10.1016/0735-1097(91)90869-B; CAMICI PG, 1991, CORONARY ARTERY DIS, V2, P837; CANNON RO, 1991, CIRCULATION, V83, P1660, DOI 10.1161/01.CIR.83.5.1660; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; CECCHI F, 1995, J AM COLL CARDIOL, V26, P1529, DOI 10.1016/0735-1097(95)00353-3; Choudhury L, 1997, EUR HEART J, V18, P108; Choudhury L, 1999, BASIC RES CARDIOL, V94, P49, DOI 10.1007/s003950050126; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; Elliott PM, 1996, EUR HEART J, V17, P1056; Elliott PM, 2001, LANCET, V357, P420, DOI 10.1016/S0140-6736(00)04005-8; Elliott PM, 2000, J AM COLL CARDIOL, V36, P2212, DOI 10.1016/S0735-1097(00)01003-2; GISTRI R, 1994, AM J CARDIOL, V74, P363, DOI 10.1016/0002-9149(94)90404-9; Gnecchi-Ruscone T, 1999, MUSCLE NERVE, V22, P1549, DOI 10.1002/(SICI)1097-4598(199911)22:11<1549::AID-MUS10>3.0.CO;2-A; Krams R, 1998, CIRCULATION, V97, P230, DOI 10.1161/01.CIR.97.3.230; Lazzeroni E, 1997, CIRCULATION, V96, P4268; Lorenzoni R, 1998, AM HEART J, V136, P972, DOI 10.1016/S0002-8703(98)70152-8; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Maron BJ, 2000, CIRCULATION, V102, P858; Maron BJ, 2000, NEW ENGL J MED, V342, P365, DOI 10.1056/NEJM200002103420601; MARON BJ, 1981, AM J CARDIOL, V48, P418, DOI 10.1016/0002-9149(81)90068-0; MARON BJ, 1986, J AM COLL CARDIOL, V8, P545, DOI 10.1016/S0735-1097(86)80181-4; Maron MS, 2003, NEW ENGL J MED, V348, P295, DOI 10.1056/NEJMoa021332; MCKENNA WJ, 1990, BRIT HEART J, V63, P287; Neglia D, 2002, CIRCULATION, V105, P186, DOI 10.1161/hc0202.102119; OGARA PT, 1987, CIRCULATION, V76, P1214, DOI 10.1161/01.CIR.76.6.1214; Olivotto I, 2003, J AM COLL CARDIOL, V41, P315, DOI 10.1016/S0735-1097(02)02713-4; Olivotto I, 2001, CIRCULATION, V104, P2517, DOI 10.1161/hc4601.097997; Rajappan K, 2002, CIRCULATION, V105, P470, DOI 10.1161/hc0402.102931; Schwartzkopff B, 1998, J AM COLL CARDIOL, V31, P1089, DOI 10.1016/S0735-1097(98)00036-9; Spirito P, 2000, NEW ENGL J MED, V342, P1778, DOI 10.1056/NEJM200006153422403; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; STAFFORD WJ, 1986, J AM COLL CARDIOL, V7, P701, DOI 10.1016/S0735-1097(86)80484-3; TANAKA M, 1986, BRIT HEART J, V55, P575; UDELSON JE, 1989, CIRCULATION, V79, P1052, DOI 10.1161/01.CIR.79.5.1052; Yoshida N, 1998, J AM COLL CARDIOL, V32, P1938, DOI 10.1016/S0735-1097(98)00498-7	36	526	550	2	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1027	1035		10.1056/NEJMoa025050	http://dx.doi.org/10.1056/NEJMoa025050			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968086				2022-12-28	WOS:000185223100004
J	Blackledge, HM; Newton, J; Squire, IB				Blackledge, HM; Newton, J; Squire, IB			Prognosis for South Asian and white patients newly admitted to hospital with heart failure in the United Kingdom: historical cohort study	BRITISH MEDICAL JOURNAL			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CORONARY-ARTERY DISEASE; RACIAL-DIFFERENCES; RISK-FACTORS; POPULATION; MORTALITY; ENGLAND; SINGAPORE; SURVIVAL; CHINESE	Objectives To compare patterns of admission to hospital and prognosis in white and South Asian patients newly admitted with heart failure, and to evaluate the effect of personal characteristics and comorbidity on outcome. Design Historical cohort study. Setting UK district health authority (population 960 000). Participants 5789 consecutive patients newly admitted with heart failure. Main outcome measures Population admission rates, incidence rates for first admission with heart failure, survival, and readmission rates. Results When compared with the white population, South Asian patients had significantly higher age adjusted admission rates (rate ratio 3.8 for men and 5.2 for women) and hospital incidence rates (2.2 and 2.9). Among 5789 incident cases of heart failure, South Asian patients were younger and more often male than white patients (70 (SD 0.6) upsilon 78 (SD 0.1) years and 56.5% (190/336) upsilon 49.3% (2494/5057)). South Asian patients were also more likely to have previous myocardial infarction (10.1% (n = 34) upsilon 5.5% (n = 278)) or concomitant myocardial infarction (18.8% (n = 63) upsilon 10.7% (n = 539)) or diabetes (45.8% (n = 154) upsilon 16.2% (n = 817), all P < 0.001). A trend was shown to longer unadjusted survival for both sexes among South Asian patients. After adjustment for covariables, South Asian patients had a significantly lower risk of death (hazard ratio 0.82, 95% confidence interval 0.68 to 0.99) and a similar probability of death or readmission (0.96, 0.81 to 1.09) compared with white patients. Conclusions Population admission rates for heart failure are higher among South Asian patients than white patients in Leicestershire. At first admission South Asian patients were younger and more often had concomitant diabetes or acute ischaemic heart disease than white patients. Despite major differences in personal characteristics and risk factors between white and South Asian patients, outcome was similar, if not better, in South Asian patients.	Univ Leicester, Leicester Royal Infirm, Dept Med & Therapeut, Leicester, Leics, England; Leicestershire Area Hlth Author, Dept Publ Hlth Med, Leicester, Leics, England	University of Leicester	Squire, IB (corresponding author), Univ Leicester, Leicester Royal Infirm, Dept Med & Therapeut, Leicester, Leics, England.							ALEXANDER M, 1995, JAMA-J AM MED ASSOC, V274, P1037, DOI 10.1001/jama.274.13.1037; Alexander M, 1999, AM HEART J, V137, P919, DOI 10.1016/S0002-8703(99)70417-5; Armitage P, 1998, STAT METHODS MED RES; BALARAJAN R, 1991, BMJ-BRIT MED J, V302, P560, DOI 10.1136/bmj.302.6776.560; Balarajan R, 1996, HLTH TRENDS, V28, P45; Collet D., 1994, MODELLING SURVIVAL D; Davies MK, 2001, LANCET, V358, P439, DOI 10.1016/S0140-6736(01)05620-3; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Goldsmith I, 1999, EUR HEART J, V20, P1094, DOI 10.1053/euhj.1998.1450; Heiat A, 2002, ARCH INTERN MED, V162, P1682, DOI 10.1001/archinte.162.15.1682; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P24, DOI 10.1136/jech.44.1.24; Iribarren C, 2001, CIRCULATION, V103, P2668; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Lee J, 2001, INT J EPIDEMIOL, V30, P983, DOI 10.1093/ije/30.5.983; Lip GYH, 1997, INT J CLIN PRACT, V51, P223; LOWRY PJ, 1984, BRIT HEART J, V52, P610, DOI 10.1136/hrt.52.6.610; LOWY AGJ, 1991, J PUBLIC HEALTH MED, V13, P276; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; MCKEIGUE PM, 1993, CIRCULATION, V87, P152, DOI 10.1161/01.CIR.87.1.152; MCKEIGUE PM, 1985, LANCET, V2, P1086; MUHKTAR HT, 1995, BRIT HEART J, V73, P122; Sheifer SE, 2000, AM HEART J, V139, P848, DOI 10.1016/S0002-8703(00)90017-6; Stewart S, 2001, EUR HEART J, V22, P209, DOI 10.1053/euhj.2000.2291; Taira DA, 2001, CELL MOL BIOL, V47, P1209; Wild S, 1997, BRIT MED J, V314, P705, DOI 10.1136/bmj.314.7082.705	26	64	65	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					526	530		10.1136/bmj.327.7414.526	http://dx.doi.org/10.1136/bmj.327.7414.526			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958110	Bronze, Green Published			2022-12-28	WOS:000185283700015
J	Cami, J; Farre, M				Cami, J; Farre, M			Drug addiction	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OFFICE-BASED TREATMENT; OPIATE WITHDRAWAL; ABUSE LIABILITY; MOLECULAR-MECHANISMS; LOCUS-CERULEUS; DELTA-FOSB; COCAINE; DOPAMINE; RECEPTOR; HEROIN		Inst Municipal Invest Med, E-08003 Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Univ Autonoma Barcelona, E-08193 Barcelona, Spain	Pompeu Fabra University; Autonomous University of Barcelona	Cami, J (corresponding author), Inst Municipal Invest Med, Doctor Aiguader 80, E-08003 Barcelona, Spain.							Abraham HD, 2002, NEUROPSYCHOPHARMACOL, P1545; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BALSTER RL, 1991, BRIT J ADDICT, V86, P1549; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bolla KI, 2002, NEUROLOGY, V59, P1337, DOI 10.1212/01.WNL.0000031422.66442.49; Budney AJ, 2001, ARCH GEN PSYCHIAT, V58, P917, DOI 10.1001/archpsyc.58.10.917; Caille S, 1999, J PHARMACOL EXP THER, V290, P881; Cami J, 2000, J CLIN PSYCHOPHARM, V20, P455, DOI 10.1097/00004714-200008000-00010; CAMI J, 1992, BRIT J ADDICT, V87, P1145; CAMI J, 1991, BRIT J ADDICT, V86, P1525; Carlezon WA, 2002, TRENDS NEUROSCI, V25, P610, DOI 10.1016/S0166-2236(02)02289-0; Crabbe JC, 2002, ANNU REV PSYCHOL, V53, P435, DOI 10.1146/annurev.psych.53.100901.135142; De Vries TJ, 2002, J NEUROSCI, V22, P3321; Di Chiara G, 1999, EUR J PHARMACOL, V375, P13, DOI 10.1016/S0014-2999(99)00372-6; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Everitt BJ, 2002, J NEUROSCI, V22, p1A; Everitt BJ, 2002, J NEUROSCI, V22, P3312; Farre M, 1997, J PHARMACOL EXP THER, V283, P164; FARRE M, 1991, BRIT J ADDICT, V86, P1601; Farre M, 2002, DRUG ALCOHOL DEPEN, V65, P283, DOI 10.1016/S0376-8716(01)00171-5; Farre M, 1998, PSYCHOPHARMACOLOGY, V140, P486, DOI 10.1007/s002130050793; Fattore L, 2001, PSYCHOPHARMACOLOGY, V156, P410, DOI 10.1007/s002130100734; Fiellin DA, 2002, NEW ENGL J MED, V347, P817, DOI 10.1056/NEJMcp013579; Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0; Fudala PJ, 2003, NEW ENGL J MED, V349, P949, DOI 10.1056/NEJMoa022164; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gonzalez G, 2002, DRUGS, V62, P1331, DOI 10.2165/00003495-200262090-00004; Hall W, 1998, LANCET, V352, P1611, DOI 10.1016/S0140-6736(98)05021-1; Harris DS, 2002, PSYCHOPHARMACOLOGY, V162, P396, DOI 10.1007/s00213-002-1131-1; Hatsukami DK, 1996, JAMA-J AM MED ASSOC, V276, P1580; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; Helmus TC, 2001, DRUG ALCOHOL DEPEN, V61, P287, DOI 10.1016/S0376-8716(00)00153-8; Holdstock L, 1998, ALCOHOL CLIN EXP RES, V22, P1903, DOI 10.1097/00000374-199812000-00004; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Kalivas P., 2002, NEUROPSYCHOPHARMACOL, P1357; Kathiramalainathan K, 2000, J CLIN PSYCHOPHARM, V20, P435, DOI 10.1097/00004714-200008000-00008; Kavanagh DJ, 2002, DRUGS, V62, P743, DOI 10.2165/00003495-200262050-00003; Kelz MB, 2000, CURR OPIN NEUROL, V13, P715, DOI 10.1097/00019052-200012000-00017; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; KONIPSKY KL, 2002, NEUROPSYCHOPHARMACOL, P1367; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P920, DOI 10.1038/nrd968; Kreek MJ, 2001, ANN NY ACAD SCI, V937, P27; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; Laakso A, 2002, NEURON, V36, P213, DOI 10.1016/S0896-6273(02)00972-8; Lappalainen J, 2002, ARCH GEN PSYCHIAT, V59, P825, DOI 10.1001/archpsyc.59.9.825; Leri F, 2003, ADDICTION, V98, P7, DOI 10.1046/j.1360-0443.2003.00236.x; Maddux JF, 2000, ADDICTION, V95, P661, DOI 10.1046/j.1360-0443.2000.9556611.x; Maldonado R, 2002, PHARMACOL THERAPEUT, V95, P153, DOI 10.1016/S0163-7258(02)00254-1; Maldonado R, 2002, J NEUROSCI, V22, P3326; Mansvelder HD, 2002, J NEUROBIOL, V53, P606, DOI 10.1002/neu.10148; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Martin BR, 2002, J PHARMACOL EXP THER, V301, P790, DOI 10.1124/jpet.301.3.790; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Mello NK, 1997, PHARMACOL BIOCHEM BE, V57, P571, DOI 10.1016/S0091-3057(96)00433-9; Mendelson JH, 1996, NEW ENGL J MED, V334, P965, DOI 10.1056/NEJM199604113341507; MERLO E, 2002, MOL BIOL DRUG ADDICT, P315; MUMFORD GK, 1995, CLIN PHARMACOL THER, V57, P356, DOI 10.1016/0009-9236(95)90162-0; Navarro M, 1998, NEUROREPORT, V9, P3397, DOI 10.1097/00001756-199810260-00012; Nestler EJ, 2000, NAT GENET, V26, P277, DOI 10.1038/81570; Nestler EJ, 2001, NATURE, V409, P834, DOI 10.1038/35057015; Nestler EJ, 2001, AM J ADDICTION, V10, P201, DOI 10.1080/105504901750532094; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nestler EJ, 2001, P NATL ACAD SCI USA, V98, P11042, DOI 10.1073/pnas.191352698; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P215; Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005; O'Connor PG, 1998, NEW ENGL J MED, V338, P592, DOI 10.1056/NEJM199802263380907; Picciotto MR, 2002, J NEUROSCI, V22, P3338; Rao YS, 2000, MOL PHARMACOL, V58, P747, DOI 10.1124/mol.58.4.747; RASMUSSEN K, 1990, J NEUROSCI, V10, P2308; Ricaurte GA, 2002, SCIENCE, V297, P2260, DOI 10.1126/science.1074501; Robbe D, 2001, J NEUROSCI, V21, P109, DOI 10.1523/JNEUROSCI.21-01-00109.2001; Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x; Robinson TE, 2001, SYNAPSE, V39, P257; Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237; Roset PN, 2001, DRUG ALCOHOL DEPEN, V64, P285, DOI 10.1016/S0376-8716(01)00127-2; Roth BL, 2002, P NATL ACAD SCI USA, V99, P11934, DOI 10.1073/pnas.182234399; Saal D, 2003, NEURON, V37, P577, DOI 10.1016/S0896-6273(03)00021-7; Saal D, 2003, NEURON, V38, P359, DOI 10.1016/S0896-6273(03)00208-3; Sarnyai Z, 2001, PHARMACOL REV, V53, P209; Schuckit MA, 2001, ALCOHOL CLIN EXP RES, V25, P323, DOI 10.1097/00000374-200103000-00002; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; Sipe JC, 2002, P NATL ACAD SCI USA, V99, P8394, DOI 10.1073/pnas.082235799; SklairTavron L, 1996, P NATL ACAD SCI USA, V93, P11202, DOI 10.1073/pnas.93.20.11202; Smith D. E., 1999, AM PSYCHIAT PRESS TX, P239; Solowij N, 2002, JAMA-J AM MED ASSOC, V287, P1123, DOI 10.1001/jama.287.9.1123; SOLOWIJ N, 2002, JAMA-J AM MED ASSOC, V287, P1651; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; Spanagel R, 2003, MOLECULAR BIOLOGY OF DRUG ADDICTION, P295; STOLERMAN I, 1992, TRENDS PHARMACOL SCI, V13, P170, DOI 10.1016/0165-6147(92)90059-F; Swift RM, 1999, NEW ENGL J MED, V340, P1482, DOI 10.1056/NEJM199905133401907; Taylor DA, 2001, J PHARMACOL EXP THER, V297, P11; Uhl GR, 2002, TRENDS GENET, V18, P420, DOI 10.1016/S0168-9525(02)02719-1; VOLKOW ND, 2002, NEUROPSYCHOPHARMACOL, P1475; Watts VJ, 2002, J PHARMACOL EXP THER, V302, P1, DOI 10.1124/jpet.302.1.1; Weiss F, 2002, J NEUROSCI, V22, P3332; Wilson RI, 2002, SCIENCE, V296, P678, DOI 10.1126/science.1063545; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; Zammit S, 2002, BRIT MED J, V325, P1199, DOI 10.1136/bmj.325.7374.1199; Zhang L, 2002, J BIOL CHEM, V277, P46256, DOI 10.1074/jbc.M207683200	103	334	398	0	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					975	986		10.1056/NEJMra023160	http://dx.doi.org/10.1056/NEJMra023160			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717HJ	12954747				2022-12-28	WOS:000185081400011
J	Kincaid, C; Griffiths, RW				Kincaid, C; Griffiths, RW			Laboratory models of the thermal evolution of the mantle during rollback subduction	NATURE			English	Article							OCEANIC-CRUST; ISLAND-ARC; SLAB; FLOW; BENEATH; CONSTRAINTS; PLATE; ANISOTROPY; MIGRATION; DYNAMICS	The subduction of oceanic lithosphere plays a key role in plate tectonics, the thermal evolution of the mantle and recycling processes between Earth's interior and surface. Information on mantle flow, thermal conditions and chemical transport in subduction zones come from the geochemistry of arc volcanoes(1-3), seismic images(4,5) and geodynamic models(6-10). The majority of this work considers subduction as a two-dimensional process, assuming limited variability in the direction parallel to the trench. In contrast, observationally based models increasingly appeal to three-dimensional flow associated with trench migration and the sinking of oceanic plates with a translational component of motion(11) (rollback). Here we report results from laboratory experiments that reveal fundamental differences in three-dimensional mantle circulation and temperature structure in response to subduction with and without a rollback component. Without rollback motion, flow in the mantle wedge is sluggish, there is no mass flux around the plate and plate edges heat up faster than plate centres. In contrast, during rollback subduction flow is driven around and beneath the sinking plate, velocities increase within the mantle wedge and are focused towards the centre of the plate, and the surface of the plate heats more along the centreline.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA; Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia	University of Rhode Island; Australian National University	Kincaid, C (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.	kincaid@gso.uri.edu	griffiths, ross w/E-6121-2010	griffiths, ross w/0000-0002-5291-1178				Buttles J, 1998, EARTH PLANET SC LETT, V164, P245, DOI 10.1016/S0012-821X(98)00211-8; DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; DRUMMOND MS, 1990, J GEOPHYS RES-SOLID, V95, P21503, DOI 10.1029/JB095iB13p21503; ELSASSER WM, 1971, J GEOPHYS RES, V76, P1101, DOI 10.1029/JB076i005p01101; GARFUNKEL Z, 1986, J GEOPHYS RES-SOLID, V91, P7205, DOI 10.1029/JB091iB07p07205; GRIFFITHS RW, 1995, EARTH PLANET SC LETT, V133, P1, DOI 10.1016/0012-821X(95)00027-A; GUILLOU-FROTTIER L, 1995, EARTH PLANET SC LETT, V133, P19, DOI 10.1016/0012-821X(95)00045-E; Gvirtzman Z, 1999, NATURE, V401, P782, DOI 10.1038/44555; HSUI AT, 1983, TECTONOPHYSICS, V99, P207, DOI 10.1016/0040-1951(83)90103-8; HUDSON JD, 1985, J FLUID MECH, V160, P369, DOI 10.1017/S0022112085003524; Kincaid C, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001174; KINCAID C, 1987, J GEOPHYS RES-SOLID, V92, P13832, DOI 10.1029/JB092iB13p13832; Kincaid C, 1997, J GEOPHYS RES-SOL EA, V102, P12295, DOI 10.1029/96JB03553; Klosko ER, 1999, GEOPHYS RES LETT, V26, P1497, DOI 10.1029/1999GL900273; Koper KD, 1999, J GEOPHYS RES-SOL EA, V104, P15089, DOI 10.1029/1999JB900130; MCCULLOCH MT, 1991, EARTH PLANET SC LETT, V102, P358, DOI 10.1016/0012-821X(91)90029-H; PEACOCK SM, 1994, EARTH PLANET SC LETT, V121, P227, DOI 10.1016/0012-821X(94)90042-6; Pearce JA, 2001, NATURE, V410, P457, DOI 10.1038/35068542; Peyton V, 2001, GEOPHYS RES LETT, V28, P379, DOI 10.1029/2000GL012200; RIBE NM, 1989, GEOPHYS J INT, V98, P85, DOI 10.1111/j.1365-246X.1989.tb05515.x; Russo RM, 1996, GEOLOGY, V24, P511, DOI 10.1130/0091-7613(1996)024<0511:CFMDAT>2.3.CO;2; Sigmarsson O, 1998, NATURE, V394, P566, DOI 10.1038/29052; Sisson TW, 1998, NATURE, V391, P883, DOI 10.1038/36087; Turner S, 1997, NATURE, V389, P568, DOI 10.1038/39257; Turner S, 1998, GEOLOGY, V26, P1019, DOI 10.1130/0091-7613(1998)026<1019:UGTMMF>2.3.CO;2; VANDERHILST R, 1993, EARTH PLANET SC LETT, V120, P395, DOI 10.1016/0012-821X(93)90253-6; Wendt JI, 1997, GEOLOGY, V25, P611, DOI 10.1130/0091-7613(1997)025<0611:EFACFT>2.3.CO;2; WOODHEAD J, 1993, EARTH PLANET SC LETT, V114, P491, DOI 10.1016/0012-821X(93)90078-N; Yogodzinski GM, 2001, NATURE, V409, P500, DOI 10.1038/35054039; ZHAO DP, 1992, J GEOPHYS RES-SOL EA, V97, P19909, DOI 10.1029/92JB00603	30	206	213	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					58	62		10.1038/nature01923	http://dx.doi.org/10.1038/nature01923			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955138				2022-12-28	WOS:000185089200035
J	Dorsey, ER; Jarjoura, D; Rutecki, GW				Dorsey, ER; Jarjoura, D; Rutecki, GW			Influence of controllable lifestyle on recent trends in specialty choice by US medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESIDENT MATCHING PROGRAM; PRIMARY-CARE; GENERAL-SURGERY; SELECTION; INCOME; SATISFACTION; LIFESTYLE	Context Recent specialty choices of graduating US medical students suggest that lifestyle may be an increasingly important factor in their career decision making. Objective To determine whether and to what degree controllable lifestyle and other specialty-related characteristics are associated with recent (1996-2002) changes in the specialty preferences of US senior medical students. Design and Setting Specialty preference was based on analysis of results from the National Resident Matching Program, the San Francisco Matching Program, and the American Urological Association Matching Program from 1996 to 2002. Specialty lifestyle (controllable vs uncontrollable) was classified using earlier research. Log-linear models were developed that examined specialty preference and the specialty's controllability, income, work hours, and years of graduate medical education required. Main Outcome Measure Proportion of variability in specialty preference from 1996 to 2002 explained by controllable lifestyle. Results The specialty preferences of US senior medical students, as determined by the distribution of applicants across selected specialties, changed significantly from 1996 to 2002 (P<.001). In the log-linear model, controllable lifestyle explained 55% of the variability in specialty preference from 1996 to 2002 after controlling for income, work hours, and years of graduate medical education required (P<.001). Conclusion Perception of controllable lifestyle accounts for most of the variability in recent changing patterns in the specialty choices of graduating US medical students.	Northwestern Univ, Evanston NW Healthcare, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; NE Ohio Univ, Coll Med, Rootstown, OH 44272 USA	NorthShore University Health System; Northwestern University; Northwestern University; Feinberg School of Medicine; Northeast Ohio Medical University (NEOMED)	Rutecki, GW (corresponding author), Northwestern Univ, Evanston Hosp, Dept Med, Evanston, IL 60201 USA.		Mikhailova, Elena/G-8352-2014	Mikhailova, Elena/0000-0002-5280-6327				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Anzilotti K, 2001, RADIOLOGY, V221, P87, DOI 10.1148/radiol.2211001499; Barzansky B, 2001, JAMA-J AM MED ASSOC, V286, P1049, DOI 10.1001/jama.286.9.1049; Bland KI, 2002, ARCH SURG-CHICAGO, V137, P259, DOI 10.1001/archsurg.137.3.259; Bond JT, 1998, NATL STUDY CHANGING, P14; Burack JH, 1997, ACAD MED, V72, P534, DOI 10.1097/00001888-199706000-00021; Donini-Lenhoff FG, 2000, JAMA-J AM MED ASSOC, V284, P1284, DOI 10.1001/jama.284.10.1284; FINCHER RME, 1992, ACAD MED, V67, P324, DOI 10.1097/00001888-199205000-00011; Gelfand DV, 2002, ARCH SURG-CHICAGO, V137, P941, DOI 10.1001/archsurg.137.8.941; Gutner T, 2002, BUS WEEK, P82; JARECKY RK, 1991, ACAD MED, V66, P756, DOI 10.1097/00001888-199112000-00011; Kassebaum D G, 1994, Acad Med, V69, P163, DOI 10.1097/00001888-199402000-00027; Kiker BF, 1998, J HEALTH SOC BEHAV, V39, P152, DOI 10.2307/2676397; Lang J., 2000, J COMMERCE, V1, P7; Leigh JP, 2002, ARCH INTERN MED, V162, P1577, DOI 10.1001/archinte.162.14.1577; *NAT ENV ED TRAIN, 1998, NAT REP CARD ENV KNO, P23; *NAT RAD PROT BOAR, 1999, 101 NRPB, P21; *NAT RES COUNC, 2000, RECONCILING OBSERVAT, P21; *NAT RES MATCH PRO, 2001, RES DAT 2001 MATCH, P20; *NAT RES MATCH PRO, 1996, NRMP DAT, P14; National Resident Matching Program, 2002, RES DAT 2002 MATCH, P20; National Resident Matching Program, 1997, NKF DOQI CLIN PRACT, P23; Pugno PA, 2000, FAM MED, V32, P543; Pugno PA, 2001, FAM MED, V33, P594; ROSENTHAL MP, 1994, JAMA-J AM MED ASSOC, V271, P914, DOI 10.1001/jama.271.12.914; SCHWARTZ RW, 1990, ACAD MED, V65, P207, DOI 10.1097/00001888-199003000-00016; SCHWARTZ RW, 1989, J SURG RES, V47, P189, DOI 10.1016/0022-4804(89)90105-4; SCHWARTZ RW, 1989, ACAD MED, V64, P606, DOI 10.1097/00001888-198910000-00012; Stoddard JJ, 2001, J GEN INTERN MED, V16, P675, DOI 10.1111/j.1525-1497.2001.01206.x; WASSENAAR JD, 2001, PHYSICIAN SOCIOECONO, P36; Weinberg DJ, 1996, ARCH DERMATOL, V132, P1057, DOI 10.1001/archderm.132.9.1057; Woodworth PA, 2000, AM J SURG, V180, P570, DOI 10.1016/S0002-9610(00)00543-2; ZELDOW PB, 1991, ACAD MED, V66, P283, DOI 10.1097/00001888-199105000-00012; ZHANG P, 1999, PHYSICIAN SOCIOECONO, P40; 1999, ELECT ENG TIMES 0830, pC3; 2002, NEUROLOGY MATCH REPO; 2002, OPHTHALMOLOGY MATCH; 1989, JAMA, V262, P1630	38	488	502	2	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1173	1178		10.1001/jama.290.9.1173	http://dx.doi.org/10.1001/jama.290.9.1173			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12952999	Bronze			2022-12-28	WOS:000185090400012
J	Garrison, A				Garrison, A			Between a rock and a hard place	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUNTINGTONS-DISEASE		Duke Univ, Sch Med, Durham, NC 27706 USA	Duke University	Garrison, A (corresponding author), Duke Univ, Sch Med, Durham, NC 27706 USA.							Beauchamp T L, 2012, PRINCIPLES BIOMEDICA; Bernstein T, 1994, RADON RENTAL HOUSING; CLOUSER KD, 1990, J MED PHILOS, V15, P219, DOI 10.1093/jmp/15.2.219; FAGOTLARGEAULT A, 1994, PRINCIPLES HLTH CARE; Feigin A, 2002, CURR OPIN NEUROL, V15, P483, DOI 10.1097/00019052-200208000-00013; Goizet C, 2002, NEUROLOGY, V59, P1330, DOI 10.1212/01.WNL.0000032255.75650.C2; Jonsen A. R., 1988, ABUSE CASUISTRY HIST; Lammers, 1998, MORAL MED THEOLOGICA; LUYNCH A, 1990, HASTINGS CENT REP, V20, P31; McAbee GN, 1998, PEDIATRICS, V102, P140, DOI 10.1542/peds.102.1.140; NICHOLSON RH, 1994, PRINCIPLES HLTH CARE; NOZICK R, 1968, NATURAL LAW FORUM, V13, P1; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, SCREEN COUNS GEN CON; TERRENOIRE G, 1943, J MED ETHICS, V1879, P92	14	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1217	1218		10.1001/jama.290.9.1217	http://dx.doi.org/10.1001/jama.290.9.1217			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953008				2022-12-28	WOS:000185090400021
J	Ruger, JP				Ruger, JP			Health and development	LANCET			English	Editorial Material									Washington Univ, Sch Med, Dept Med, Div Gen Med Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Ruger, JP (corresponding author), Washington Univ, Sch Med, Dept Med, Div Gen Med Sci, St Louis, MO 63110 USA.				NIDA NIH HHS [K01 DA016358, 1K01DA016358-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K01DA016358] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 1999, DEV FREEDOM; LORD D, 1994, ARISTOTLE POLITICS; MARMOT M, 1995, SOC HLTH; Nussbaum Martha C., 1998, ETHICS CONSUMPTION G, P312; NUSSBAUM MC, 1992, POLIT THEORY, V20, P202, DOI 10.1177/0090591792020002002; NUSSBAUM MC, 1990, NATURE FUNCTION CAPA; Ruger J., 2001, INT PUBLIC HLTH DIS; Sen A, 1992, INEQUALITY RE EXAMIN; Sen A., 1999, COMMODITIES CAPABILI; WELLDON JEC, 1987, ARISTOTLE NICOMACHEA	10	23	24	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					678	678		10.1016/S0140-6736(03)14243-2	http://dx.doi.org/10.1016/S0140-6736(03)14243-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957088	Green Accepted			2022-12-28	WOS:000185034800006
J	van Oijen, AM; Blainey, PC; Crampton, DJ; Richardson, CC; Ellenberger, T; Xie, XS				van Oijen, AM; Blainey, PC; Crampton, DJ; Richardson, CC; Ellenberger, T; Xie, XS			Single-molecule kinetics of lambda exonuclease reveal base dependence and dynamic disorder	SCIENCE			English	Article							DNA DIGESTION; ELASTICITY; TENSION	We used a multiplexed approach based on flow-stretched DNA to monitor the enzymatic digestion of lambda-phage DNA by individual bacteriophage lambda exonuclease molecules. Statistical analyses of multiple single-molecule trajectories observed simultaneously reveal that the catalytic rate is dependent on the local base content of the substrate DNA. By relating single-molecule kinetics to the free energies of hydrogen bonding and base stacking, we establish that the melting of a base from the DNA is the rate-limiting step in the catalytic cycle. The catalytic rate also exhibits large fluctuations independent of the sequence, which we attribute to conformational changes of the enzyme-DNA complex.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Xie, XS (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	xie@chemistry.harvard.edu	van Oijen, Antoine/I-3167-2014	van Oijen, Antoine/0000-0002-1794-5161; Blainey, Paul/0000-0002-4889-8783	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061577, R01GM055390] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01GM61577-03, R01GM55390-07] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bommarito S, 2000, NUCLEIC ACIDS RES, V28, P1929, DOI 10.1093/nar/28.9.1929; Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Dapprich J, 1999, CYTOMETRY, V36, P163, DOI 10.1002/(SICI)1097-0320(19990701)36:3<163::AID-CYTO3>3.0.CO;2-R; Dickson KS, 2000, J BIOL CHEM, V275, P15828, DOI 10.1074/jbc.M910044199; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kovall RA, 1998, P NATL ACAD SCI USA, V95, P7893, DOI 10.1073/pnas.95.14.7893; Lam WC, 2002, BIOCHEMISTRY-US, V41, P3943, DOI 10.1021/bi0120603; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; Matsuura S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e79; Mitsis PG, 1999, NUCLEIC ACIDS RES, V27, P3057, DOI 10.1093/nar/27.15.3057; Polakowski R, 2000, J AM CHEM SOC, V122, P4853, DOI 10.1021/ja994488j; Rauch C, 2002, J MOL BIOL, V324, P491, DOI 10.1016/S0022-2836(02)01089-6; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; Strick TR, 1998, BIOPHYS J, V74, P2016, DOI 10.1016/S0006-3495(98)77908-1; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; Subramanian K, 2003, NUCLEIC ACIDS RES, V31, P1585, DOI 10.1093/nar/gkg266; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; Xie XS, 2002, J CHEM PHYS, V117, P11024, DOI 10.1063/1.1521159; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	28	274	289	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1235	1238		10.1126/science.1084387	http://dx.doi.org/10.1126/science.1084387			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947199	Green Submitted			2022-12-28	WOS:000185003500042
J	Finne, AP; Araki, T; Blaauwgeers, R; Eltsov, VB; Kopnin, NB; Krusius, M; Skrbek, L; Tsubota, M; Volovik, GE				Finne, AP; Araki, T; Blaauwgeers, R; Eltsov, VB; Kopnin, NB; Krusius, M; Skrbek, L; Tsubota, M; Volovik, GE			An intrinsic velocity-independent criterion for superfluid turbulence	NATURE			English	Article							QUANTUM TURBULENCE; VORTEX FORMATION; MUTUAL FRICTION; HE-3-B; DYNAMICS; FLOW; HE-4	Hydrodynamic flow in classical and quantum fluids can be either laminar or turbulent. Vorticity in turbulent flow is often modelled with vortex filaments. While this represents an idealization in classical fluids, vortices are topologically stable quantized objects in superfluids. Superfluid turbulence(1) is therefore thought to be important for the understanding of turbulence more generally. The fermionic He-3 superfluids are attractive systems to study because their characteristics vary widely over the experimentally accessible temperature regime. Here we report nuclear magnetic resonance measurements and numerical simulations indicating the existence of sharp transition to turbulence in the B phase of superfluid He-3. Above 0.60T(c) (where T-c is the transition temperature for superfluidity) the hydrodynamics are regular, while below this temperature we see turbulent behaviour. The transition is insensitive to the fluid velocity, in striking contrast to current textbook knowledge of turbulence(2). Rather, it is controlled by an intrinsic parameter of the superfluid: the mutual friction between the normal and superfluid components of the flow, which causes damping of the vortex motion.	Aalto Univ, Low Temp Lab, FIN-02015 Helsinki, Finland; Osaka City Univ, Dept Phys, Sumiyoshi Ku, Osaka 5588585, Japan; Leiden Univ, Kamerlingh Onnes Lab, NL-2300 RA Leiden, Netherlands; PL Kapitza Phys Problems Inst, Moscow 119334, Russia; LD Landau Theoret Phys Inst, Moscow 119334, Russia; Acad Sci Czech Republic, Inst Phys, Joint Low Temp Lab, Prague 18000, Czech Republic; Charles Univ Prague, CR-18000 Prague, Czech Republic	Aalto University; Osaka Metropolitan University; Leiden University; Leiden University - Excl LUMC; PL Kapitza Institute for Physical Problems of Russian Academy of Sciences; Russian Academy of Sciences; Landau Institute for Theoretical Physics; Czech Academy of Sciences; Institute of Physics of the Czech Academy of Sciences; Charles University Prague	Volovik, GE (corresponding author), Aalto Univ, Low Temp Lab, POB 2200, FIN-02015 Helsinki, Finland.	ve@boojum.hut.fi	Volovik, Grigory E/F-6396-2015; Eltsov, Vladimir/M-8767-2015; Skrbek, Ladislav/P-5146-2017; Krusius, Matti/F-8896-2013	Eltsov, Vladimir/0000-0002-6949-5334; Skrbek, Ladislav/0000-0002-6016-1194; 				BARENGHI CF, 1985, PHYS FLUIDS, V28, P498, DOI 10.1063/1.865113; Bevan TDC, 1997, J LOW TEMP PHYS, V109, P423, DOI 10.1007/s10909-005-0095-z; Blaauwgeers R, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.155301; Fisher SN, 2001, PHYS REV LETT, V86, P244, DOI 10.1103/PhysRevLett.86.244; KOPNIN NB, 2001, THEORY NONEQUILIBRIU, P271; MCCOMB WD, 1990, PHYSICS FLUID TURBUL, P2; OSTERMEIER RM, 1975, J LOW TEMP PHYS, V21, P191, DOI 10.1007/BF01141298; Ruutu VMH, 1997, J LOW TEMP PHYS, V107, P93, DOI 10.1007/BF02396838; Ruutu VMH, 1996, NATURE, V382, P334, DOI 10.1038/382334a0; SCHWARZ KW, 1988, PHYS REV B, V38, P2398, DOI 10.1103/PhysRevB.38.2398; Skrbek L, 2003, PHYSICA B, V329, P106, DOI 10.1016/S0921-4526(02)01903-8; SONIN EB, 1987, REV MOD PHYS, V59, P87, DOI 10.1103/RevModPhys.59.87; Tsubota M, 2000, PHYS REV B, V62, P11751, DOI 10.1103/PhysRevB.62.11751; Tsubota M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.205301; Vinen WF, 2002, J LOW TEMP PHYS, V128, P167, DOI 10.1023/A:1019695418590	15	160	161	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1022	1025		10.1038/nature01880	http://dx.doi.org/10.1038/nature01880			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944960	Green Submitted			2022-12-28	WOS:000184984200034
J	Srivastava, R				Srivastava, R			Help less	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					998	1000		10.1001/jama.290.8.998	http://dx.doi.org/10.1001/jama.290.8.998			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941659				2022-12-28	WOS:000184958900001
J	Taubert, D; Berkels, R; Roesen, R; Klaus, W				Taubert, D; Berkels, R; Roesen, R; Klaus, W			Chocolate and blood pressure in elderly individuals with isolated systolic hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Univ Cologne, Dept Pharmacol, Cologne, Germany; Univ Cologne, Coll Med, Cologne, Germany	University of Cologne; University of Cologne	Taubert, D (corresponding author), Univ Cologne, Dept Pharmacol, Cologne, Germany.							Diebolt M, 2001, HYPERTENSION, V38, P159, DOI 10.1161/01.HYP.38.2.159; Holt RR, 2002, AM J CLIN NUTR, V76, P798, DOI 10.1093/ajcn/76.4.798; Keen CL, 2001, J AM COLL NUTR, V20, p436S, DOI 10.1080/07315724.2001.10719181; Luna F, 2002, J AGR FOOD CHEM, V50, P3527, DOI 10.1021/jf0116597	4	213	217	1	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1029	1030		10.1001/jama.290.8.1029	http://dx.doi.org/10.1001/jama.290.8.1029			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941673				2022-12-28	WOS:000184958900019
J	Eddy, AA; Symons, JM				Eddy, AA; Symons, JM			Nephrotic syndrome in childhood	LANCET			English	Review							FOCAL SEGMENTAL GLOMERULOSCLEROSIS; GLOMERULAR-PERMEABILITY FACTOR; SPLICE-SITE MUTATIONS; LIPOPROTEIN CATABOLISM; PULSE CYCLOPHOSPHAMIDE; PODOCIN MUTATIONS; SODIUM RETENTION; RANDOMIZED-TRIAL; CHANGING TRENDS; KIDNEY-DISEASE	Childhood nephrotic syndromes are most commonly caused by one of two idiopathic diseases: minimal-change nephrotic syndrome (MCNS) and focal segmental glomerulosclerosis (FSGS). A third distinct type, membranous nephropathy, is rare in children. Other causes of isolated nephrotic syndrome can be subdivided into two major categories: rare genetic disorders, and secondary diseases associated with drugs, infections, or neoplasia. The cause of Idiopathic nephrotic syndrome remains unknown, but evidence suggests it may be a primary T-cell disorder that leads to glomerular podocyte dysfunction. Genetic studies in children with familial nephrotic syndrome have identified mutations in genes that encode important podocyte proteins. Patients with idiopathic nephrotic syndrome are initially treated with corticosterolds. Steroid-responsiveness is of greater prognostic use than renal histology. Several second-line drugs, including alkylating agents, ciclosporin, and levamisole, may be effective for complicated and steroid-unresponsive MCNS and FSGS patients. Nephrotic syndrome is associated with several medical complications, the most severe and potentially fatal being bacterial infections and thromboembolism. Idiopathic nephrotic syndrome is a chronic relapsing disease for most steroid-responsive patients, whereas most children with refractory FSGS ultimately develop end-stage renal disease. Research is being done to further elucidate the disorder's molecular pathogenesis, identify new prognostic indicators, and to develop better approaches to treatment.	Univ Washington, Childrens Hosp & Reg Med Ctr, Dept Pediat, Div Nephrol, Seattle, WA 98105 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle	Eddy, AA (corresponding author), Univ Washington, Childrens Hosp & Reg Med Ctr, Dept Pediat, Div Nephrol, 4800 Sand Point Way NE, Seattle, WA 98105 USA.	allison.eddy@seattlechildrens.org		NOIRI, Eisei/0000-0002-9515-7582; Eddy, Allison/0000-0002-3560-7510	NIDDK NIH HHS [DK54500] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson JS, 2000, PEDIATRICS, V106, P367, DOI 10.1542/peds.106.2.367; Alpay H, 2002, PEDIATR NEPHROL, V17, P181, DOI 10.1007/s00467-001-0789-7; Alsaran K, 2001, CLIN NEPHROL, V56, P289; Andrew M, 1998, J PEDIATR-US, V132, P575, DOI 10.1016/S0022-3476(98)70343-9; [Anonymous], 1978, Kidney Int, V13, P159; [Anonymous], 1981, J PEDIATR-US, V98, P561, DOI 10.1016/s0022-3476(81)80760-3; ARNEIL GC, 1971, PEDIATR CLIN N AM, V18, P547; Aros C, 2002, J HYPERTENS, V20, pS45; AUWERX J, 1986, NEPHRON, V42, P231, DOI 10.1159/000183672; Baqi N, 1998, PEDIATR NEPHROL, V12, P105, DOI 10.1007/s004670050414; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bargman JM, 1999, KIDNEY INT, V55, pS3, DOI 10.1046/j.1523-1755.1999.07002.x; BEATTIE TJ, 1991, LANCET, V337, P1555; Birmele B, 2001, KIDNEY INT, V59, P913, DOI 10.1046/j.1523-1755.2001.00574.x; Boerkoel CF, 2002, NAT GENET, V30, P215, DOI 10.1038/ng821; Bonilla-Felix M, 1999, KIDNEY INT, V55, P1885, DOI 10.1046/j.1523-1755.1999.00408.x; Bosch T, 2001, THER APHER, V5, P155, DOI 10.1046/j.1526-0968.2001.00318.x; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Burgess E, 1999, KIDNEY INT, V55, pS26, DOI 10.1046/j.1523-1755.1999.07004.x; Candiano G, 2001, J AM SOC NEPHROL, V12, P143, DOI 10.1681/ASN.V121143; Caridi G, 2001, J AM SOC NEPHROL, V12, P2742, DOI 10.1681/ASN.V12122742; Carraro M, 2002, J AM SOC NEPHROL, V13, P1946, DOI 10.1097/01.ASN.0000016445.29513.AB; Cattran DC, 2001, KIDNEY INT, V59, P1983, DOI 10.1046/j.1523-1755.2001.0590051983.x; Cattran DC, 1999, KIDNEY INT, V56, P2220, DOI 10.1046/j.1523-1755.1999.00778.x; Chadha V, 1999, PEDIATR NEPHROL, V13, P209, DOI 10.1007/s004670050594; Choi MJ, 2002, KIDNEY INT, V61, P1098, DOI 10.1046/j.1523-1755.2002.00214.x; Citak A, 2000, PEDIATR NEPHROL, V14, P138, DOI 10.1007/s004670050029; Coleman JE, 1996, PEDIATR NEPHROL, V10, P171; Constantinescu AR, 2000, PEDIATRICS, V105, P492, DOI 10.1542/peds.105.3.492; Cunard R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016406.82019.B3; Dantal J, 1998, J AM SOC NEPHROL, V9, P1709; Denamur E, 2000, KIDNEY INT, V57, P1868, DOI 10.1046/j.1523-1755.2000.00036.x; Dogra GK, 2002, KIDNEY INT, V62, P550, DOI 10.1046/j.1523-1755.2002.00483.x; Durkan AM, 2001, KIDNEY INT, V59, P1919, DOI 10.1046/j.1523-1755.2001.0590051919.x; EHRICH JHH, 1993, EUR J PEDIATR, V152, P357, DOI 10.1007/BF01956754; Ekka BK, 1997, PEDIATR NEPHROL, V11, P597, DOI 10.1007/s004670050344; Esnault VLM, 1999, J AM SOC NEPHROL, V10, P2014; FEINSTEIN EI, 1988, AM J NEPHROL, V8, P147, DOI 10.1159/000167575; Feinstein S, 2001, AM J KIDNEY DIS, V37, P736, DOI 10.1016/S0272-6386(01)80122-0; Feld SM, 1998, AM J KIDNEY DIS, V32, P230, DOI 10.1053/ajkd.1998.v32.pm9708606; Frank C, 2000, KIDNEY INT, V57, P510, DOI 10.1046/j.1523-1755.2000.00870.x; FREUNDLICH M, 1986, J PEDIATR-US, V108, P383, DOI 10.1016/S0022-3476(86)80877-0; Frishberg Y, 2002, J AM SOC NEPHROL, V13, P400, DOI 10.1681/ASN.V132400; Fuchshuber A, 2001, J AM SOC NEPHROL, V12, P374, DOI 10.1681/ASN.V122374; Fuke Y, 2002, NEPHRON, V91, P769, DOI 10.1159/000065049; Gaedeke J, 2002, CURR HYPERTENS REP, V4, P403, DOI 10.1007/s11906-002-0071-9; Garin EH, 2000, PEDIATR NEPHROL, V14, P872, DOI 10.1007/s004679900269; GEERS AB, 1984, NEPHRON, V38, P170, DOI 10.1159/000183302; Gheith OA, 2002, NEPHRON, V91, P612, DOI 10.1159/000065021; Goldstein SL, 2000, PEDIATR NEPHROL, V14, P305, DOI 10.1007/s004670050764; Green GB, 2002, J AM SOC NEPHROL, V13, p39A; Gregory MJ, 1996, J AM SOC NEPHROL, V7, P543; Gulati S, 2002, PEDIATR NEPHROL, V17, P404, DOI 10.1007/s00467-002-0840-3; Gulati S, 2001, NEPHROL DIAL TRANSPL, V16, P2013, DOI 10.1093/ndt/16.10.2013; Gulati S, 1999, AM J KIDNEY DIS, V34, P646, DOI 10.1016/S0272-6386(99)70388-4; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; Hodson EM, 2000, ARCH DIS CHILD, V83, P45, DOI 10.1136/adc.83.1.45; Hogg RJ, 2000, PEDIATRICS, V105, P1242, DOI 10.1542/peds.105.6.1242; HOYER PF, 1986, LANCET, V2, P335; HULTON SA, 1994, PEDIATR NEPHROL, V8, P401, DOI 10.1007/BF00856511; HUMPHREYS MH, 1994, KIDNEY INT, V45, P266, DOI 10.1038/ki.1994.33; ICHIKAWA I, 1983, J CLIN INVEST, V71, P91, DOI 10.1172/JCI110756; Iijima K, 2002, KIDNEY INT, V61, P1801, DOI 10.1046/j.1523-1755.2002.00303.x; INGULLI E, 1991, PEDIATR NEPHROL, V5, P393, DOI 10.1007/BF01453661; INGULLI E, 1992, J AM SOC NEPHROL, V3, P254; *INT STUD KIDN DIS, 1984, PEDIATRICS, V73, P497; Ito S, 1999, PEDIATR NEPHROL, V13, P790, DOI 10.1007/s004670050702; Kabuki N, 1998, PEDIATR NEPHROL, V12, P467, DOI 10.1007/s004670050489; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kari JA, 2002, SAUDI MED J, V23, P317; Karle SM, 2002, J AM SOC NEPHROL, V13, P388, DOI 10.1681/ASN.V132388; Kemper MJ, 2001, NEW ENGL J MED, V344, P386, DOI 10.1056/NEJM200102013440517; Kemper MJ, 2000, PEDIATR NEPHROL, V14, P772, DOI 10.1007/PL00013435; Kirpekar R, 2002, AM J KIDNEY DIS, V39, P1143, DOI 10.1053/ajkd.2002.33382; Koomans HA, 2001, NEPHROL DIAL TRANSPL, V16, P221, DOI 10.1093/ndt/16.2.221; KOOMANS HA, 1984, AM J NEPHROL, V4, P227, DOI 10.1159/000166814; KOYAMA A, 1991, KIDNEY INT, V40, P453, DOI 10.1038/ki.1991.232; Krause TG, 2002, CLIN EXP ALLERGY, V32, P367, DOI 10.1046/j.1365-2222.2002.01316.x; Lama G, 2002, AM J KIDNEY DIS, V39, P958, DOI 10.1053/ajkd.2002.32769; Lama G, 2000, CLIN NEPHROL, V53, P432; Latta K, 2001, PEDIATR NEPHROL, V16, P271, DOI 10.1007/s004670000523; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; Lieberman KV, 1996, J AM SOC NEPHROL, V7, P56; MALLUCHE HH, 1979, J CLIN INVEST, V63, P494, DOI 10.1172/JCI109327; Matsumoto K, 2001, AM J NEPHROL, V21, P20, DOI 10.1159/000046214; MCCAULEY J, 1993, NEPHROL DIAL TRANSPL, V8, P1286; McIntyre P, 1998, J PAEDIATR CHILD H, V34, P314, DOI 10.1046/j.1440-1754.1998.00232.x; MEES EJD, 1984, NEPHRON, V36, P201, DOI 10.1159/000183155; MELVIN T, 1984, CONTEMP ISS NEPHROL, P191; MENDOZA SA, 1992, J AM SOC NEPHROL, V3, P889; Meyrier A, 1997, J NEPHROL, V10, P14; Morello R, 2002, PEDIATR RES, V51, P551, DOI 10.1203/00006450-200205000-00002; Musante L, 2001, J NEPHROL, V14, pS48; Nakahara C, 1999, PEDIATR NEPHROL, V13, P657, DOI 10.1007/s004670050676; NIAUDET P, 1994, J PEDIATR-US, V125, P981, DOI 10.1016/S0022-3476(05)82020-7; NIAUDET P, 1994, J AM SOC NEPHROL, V5, P1049; ORDONEZ JD, 1993, KIDNEY INT, V44, P638, DOI 10.1038/ki.1993.292; Palmer BF, 1997, KIDNEY INT, pS21; Patiroglu T, 1998, ACTA PAEDIATR JAPON, V40, P333; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PETERSON C, 1988, KIDNEY INT, V34, P825, DOI 10.1038/ki.1988.256; PICKERING L, 2000, 2000 RED BOOK REPORT, P26; PONTICELLI C, 1993, KIDNEY INT, V43, P1377, DOI 10.1038/ki.1993.194; Querfeld U, 1999, PEDIATR NEPHROL, V13, P77, DOI 10.1007/s004670050568; Quien RM, 1997, J PEDIATR-US, V131, P688, DOI 10.1016/S0022-3476(97)70094-5; Rennert WP, 1999, PEDIATR NEPHROL, V13, P113, DOI 10.1007/s004670050574; RIVKEES SA, 1988, JAMA-J AM MED ASSOC, V259, P2123; SAGRIPANTI A, 1995, NEPHRON, V70, P271, DOI 10.1159/000188604; Sahali D, 2001, J AM SOC NEPHROL, V12, P1648, DOI 10.1681/ASN.V1281648; Sanjad SA, 1997, J PEDIATR-US, V130, P470, DOI 10.1016/S0022-3476(97)70213-0; Savin VJ, 1996, NEW ENGL J MED, V334, P878, DOI 10.1056/NEJM199604043341402; Schachter AD, 2001, PEDIATR TRANSPLANT, V5, P406, DOI 10.1034/j.1399-3046.2001.t01-2-00024.x; Schrier RW, 1998, KIDNEY INT, V53, P1111, DOI 10.1046/j.1523-1755.1998.00864.x; Schweda F, 1997, NEPHROL DIAL TRANSPL, V12, P2433, DOI 10.1093/ndt/12.11.2433; Shearer GC, 2001, AM J KIDNEY DIS, V37, pS119, DOI 10.1053/ajkd.2001.20766; Shearer GC, 2001, KIDNEY INT, V59, P179, DOI 10.1046/j.1523-1755.2001.00478.x; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Silva JMP, 2002, PEDIATR NEPHROL, V17, P169, DOI 10.1007/s00467-001-0793-y; Soliday E, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.4.e51; Srivastava T, 1999, PEDIATR NEPHROL, V13, P13, DOI 10.1007/s004670050555; Stehman-Breen C, 1999, NEPHRON, V81, P37, DOI 10.1159/000045243; Stiles KP, 2001, CLIN NEPHROL, V56, P89; Tain YL, 1999, PEDIATR NEPHROL, V13, P835, DOI 10.1007/s004670050710; Tanawattanacharoen S, 2000, AM J KIDNEY DIS, V35, P1166, DOI 10.1016/S0272-6386(00)70055-2; Tarshish P, 1997, J AM SOC NEPHROL, V8, P769; Tarshish P, 1996, PEDIATR NEPHROL, V10, P590, DOI 10.1007/s004670050167; Tryggvason K, 1999, INT J DEV BIOL, V43, P445; USBERTI M, 1995, AM J NEPHROL, V15, P38, DOI 10.1159/000168800; VandeWalle J, 1996, KIDNEY INT, V49, P1471, DOI 10.1038/ki.1996.207; Vaziri ND, 2002, KIDNEY INT, V61, P1769, DOI 10.1046/j.1523-1755.2002.00319.x; Vaziri ND, 2001, AM J KIDNEY DIS, V38, P1, DOI 10.1053/ajkd.2001.25174; Walle JGV, 2001, PEDIATR NEPHROL, V16, P283, DOI 10.1007/s004670000512; Wardle EN, 1996, NEPHRON, V74, P422; Webb NJA, 1996, AM J KIDNEY DIS, V27, P484, DOI 10.1016/S0272-6386(96)90157-2; Wheeler DC, 2001, J NEPHROL, V14, pS70; Winn MP, 2002, J AM SOC NEPHROL, V13, P577, DOI 10.1681/ASN.V132577; Winston JA, 2001, NEW ENGL J MED, V344, P1979, DOI 10.1056/NEJM200106283442604; Yap HK, 1999, J AM SOC NEPHROL, V10, P529; Yap HK, 2001, PEDIATR NEPHROL, V16, P1049, DOI 10.1007/s004670100024; Yoshioka K, 2000, KIDNEY INT, V58, P317, DOI 10.1046/j.1523-1755.2000.00168.x	140	536	587	6	72	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					629	639		10.1016/S0140-6736(03)14184-0	http://dx.doi.org/10.1016/S0140-6736(03)14184-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944064				2022-12-28	WOS:000184904100024
J	Geng, Y; Yu, QY; Sicinska, E; Das, M; Schneider, JE; Bhattacharya, S; Rideout, WM; Bronson, RT; Gardner, H; Sicinski, P				Geng, Y; Yu, QY; Sicinska, E; Das, M; Schneider, JE; Bhattacharya, S; Rideout, WM; Bronson, RT; Gardner, H; Sicinski, P			Cyclin E ablation in the mouse	CELL			English	Article							MINICHROMOSOME MAINTENANCE PROTEINS; HISTONE GENE-TRANSCRIPTION; CELL-FREE SYSTEM; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; HUMAN CANCERS; COMPLEX; CDK2	E type cyclins (E1 and E2) are believed to drive cell entry into the S phase. It is widely assumed that the two E type cyclins are critically required for proliferation of all cell types. Here, we demonstrate that E type cyclins are largely dispensable for mouse development. However, endoreplication of trophoblast giant cells and megakaryocytes is severely impaired in the absence of cyclin E. Cyclin E-deficient cells proliferate actively under conditions of continuous cell cycling but are unable to reenter the cell cycle from the quiescent Go state. Molecular analyses revealed that cells lacking cyclin E fail to normally incorporate MCM proteins into DNA replication origins during G(0)-->S progression. We also found that cyclin E-deficient cells are relatively resistant to oncogenic transformation. These findings define a molecular function for E type cyclins in cell cycle reentry and reveal a differential requirement for cyclin E in normal versus oncogenic proliferation.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Oxford, Dept Cardiovasc Med, Oxford OX3 7BN, England; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA; Biogen Inc, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Oxford; Massachusetts Institute of Technology (MIT); Whitehead Institute; Tufts University; Tufts University; Biogen	Sicinski, P (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.		Bhattacharya, Shoumo/F-4127-2010	Bhattacharya, Shoumo/0000-0002-5571-0478	NATIONAL CANCER INSTITUTE [R01CA083688, R01CA085296] Funding Source: NIH RePORTER; NCI NIH HHS [CA83688, CA85296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Cross JC, 2002, MOL CELL ENDOCRINOL, V187, P207, DOI 10.1016/S0303-7207(01)00703-1; Cross JC, 2000, SEMIN CELL DEV BIOL, V11, P105, DOI 10.1006/scdb.2000.0156; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Fay DS, 2000, DEVELOPMENT, V127, P4049; Geisen C, 2002, J BIOL CHEM, V277, P39909, DOI 10.1074/jbc.M205919200; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOGAN B, 1986, MANIPULATING MOUSE E; Kaufman M.H., 1999, ANATOMICAL BASIS MOU; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Kohn MJ, 2003, DEVELOPMENT, V130, P1295, DOI 10.1242/dev.00355; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Madine MA, 2000, J STRUCT BIOL, V129, P198, DOI 10.1006/jsbi.2000.4218; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; Schneider JE, 2003, J MOL CELL CARDIOL, V35, P217, DOI 10.1016/S0022-2828(02)00291-2; SEARLE AG, 1974, MUTAT RES, V22, P63, DOI 10.1016/0027-5107(74)90009-8; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Su TT, 1998, J CELL BIOL, V140, P451, DOI 10.1083/jcb.140.3.451; Tanaka M, 1997, DEV BIOL, V190, P55, DOI 10.1006/dbio.1997.8685; Webb S, 1998, CIRC RES, V82, P645, DOI 10.1161/01.RES.82.6.645; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zybina EV, 1996, INT REV CYTOL, V165, P53, DOI 10.1016/S0074-7696(08)62220-2	53	538	546	1	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					431	443		10.1016/S0092-8674(03)00645-7	http://dx.doi.org/10.1016/S0092-8674(03)00645-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941272	Bronze			2022-12-28	WOS:000184928800007
J	Detsky, AS; Naylor, CD				Detsky, AS; Naylor, CD			Canada's health care system - Reform delayed	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRIVATE FOR-PROFIT; METAANALYSIS; MORTALITY		Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Off Dean, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada.							*ASS CAN MED COLL, 2002, CAN MED ED STAT 2002; BARER ML, 1991, FED PROV TERR C DEP; Blendon RJ, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.3.233; Blendon RJ, 2003, HEALTH AFFAIR, V22, P106, DOI 10.1377/hlthaff.22.3.106; Blendon RJ, 2002, HEALTH AFFAIR, V21, P182, DOI 10.1377/hlthaff.21.3.182; *COMM ET SERV SANT, 2001, EM SOL REP REC; *DEP FIN, 2003, CAN HLTH SOC TRANSF; *DEP FIN, 2002, EC FISC UPD; *DEP FIN, 2003, CAN FISC PROGR 2000; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; Devereaux PJ, 2002, JAMA-J AM MED ASSOC, V288, P2449, DOI 10.1001/jama.288.19.2449; Donelan K, 1999, HEALTH AFFAIR, V18, P206, DOI 10.1377/hlthaff.18.3.206; *FAM HLTH NETW, 2001, EV PRIM CAR REF PIL; Fyke Kenneth J, 2001, CARING MEDICARE SUST; Gratzer D, 2002, BETTER MED REFORMING; Hastings JEF, 1972, COMM HLTH CTR PROJ C; *HLTH CAN, 2003, 2003 1ST MIN ACC HLT; Iglehart JK, 2000, NEW ENGL J MED, V342, P2007, DOI 10.1056/NEJM200006293422624; Katz SJ, 2002, HEALTH AFFAIR, V21, P19, DOI 10.1377/hlthaff.21.3.19; Kirby MJ, 2002, HLTH CANADIANS FEDER, V6; MAZANKOWSKI D, 2001, FRAMEWORK REFORM REP; Naylor CD, 1999, HEALTH AFFAIR, V18, P9, DOI 10.1377/hlthaff.18.3.9; PRIEST L, 2003, GLOBAL MAIL TOR 0215, pA8; Romanow RJ, 2002, BUILDING VALUES FUTU	24	44	44	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					804	810		10.1056/NEJMhpr035304	http://dx.doi.org/10.1056/NEJMhpr035304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930935				2022-12-28	WOS:000184843300014
J	Rahn, T; Eiler, JM; Boering, KA; Wennberg, PO; McCarthy, MC; Tyler, S; Schauffler, S; Donnelly, S; Atlas, E				Rahn, T; Eiler, JM; Boering, KA; Wennberg, PO; McCarthy, MC; Tyler, S; Schauffler, S; Donnelly, S; Atlas, E			Extreme deuterium enrichment in stratospheric hydrogen and the global atmospheric budget of H-2	NATURE			English	Article							LIQUEFIED PETROLEUM GAS; ISOTOPIC COMPOSITION; MOLECULAR-HYDROGEN; RATE COEFFICIENTS; AIR; TRITIUM; LEAKAGE; CARBON; IMPACT	Molecular hydrogen (H-2) is the second most abundant trace gas in the atmosphere after methane(1) (CH4). In the troposphere, the D/H ratio of H-2 is enriched by 120parts per thousand relative to the world's oceans(2-4). This cannot be explained by the sources of H-2 for which the D/H ratio has been measured to date (for example, fossil fuels and biomass burning)(5,6). But the isotopic composition of H-2 from its single largest source-the photochemical oxidation of methane-has yet to be determined. Here we show that the D/H ratio of stratospheric H-2 develops enrichments greater than 440parts per thousand, the most extreme D/H enrichment observed in a terrestrial material. We estimate the D/H ratio of H-2 produced from CH4 in the stratosphere, where production is isolated from the influences of non-photochemical sources and sinks, showing that the chain of reactions producing H-2 from CH4 concentrates D in the product H-2. This enrichment, which we estimate is similar on a global average in the troposphere, contributes substantially to the D/H ratio of tropospheric H-2.	CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Irvine, Earth Syst Sci Dept, Irvine, CA 92697 USA; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Irvine; National Center Atmospheric Research (NCAR) - USA; California Institute of Technology	Rahn, T (corresponding author), Los Alamos Natl Lab, EES-6,MS-D462, Los Alamos, NM 87545 USA.	trahn@lanl.gov	Rahn, Thom/C-5211-2012; McCarthy, Michael/E-5970-2010; Atlas, Elliot/AAE-4605-2021; Atlas, Elliot/J-8171-2015; Wennberg, Paul O/A-5460-2012	Wennberg, Paul O/0000-0002-6126-3854; Boering, Kristie/0000-0003-0920-0503; Atlas, Elliot/0000-0003-3847-5346				BLAKE DR, 1995, SCIENCE, V269, P953, DOI 10.1126/science.269.5226.953; Boering KA, 1996, SCIENCE, V274, P1340, DOI 10.1126/science.274.5291.1340; Brasseur G., 1984, AERONOMY MIDDLE ATMO; Chen TY, 2001, GEOPHYS RES LETT, V28, P2193, DOI 10.1029/2000GL012703; DEMORE WB, 1997, CHEM KINETICS PHOTOC, P278; EHHALT D, 1963, J GEOPHYS RES, V68, P3747, DOI 10.1029/JZ068i013p03747; EHHALT DH, 1989, J GEOPHYS RES-ATMOS, V94, P9831, DOI 10.1029/JD094iD07p09831; FRIEDMAN I, 1974, J GEOPHYS RES, V79, P785, DOI 10.1029/JC079i006p00785; Gerst S, 2000, J GEOPHYS RES-ATMOS, V105, P26433, DOI 10.1029/2000JD900387; Gerst S, 2001, J GEOPHYS RES-ATMOS, V106, P5021, DOI 10.1029/2000JD900593; GONSIOR B, 1966, TELLUS, V18, P256; Hauglustaine DA, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001156; HOLTON JR, 1990, J ATMOS SCI, V47, P392, DOI 10.1175/1520-0469(1990)047<0392:OTGEOM>2.0.CO;2; Hurst DF, 1999, J GEOPHYS RES-ATMOS, V104, P8191, DOI 10.1029/1998JD100092; KHALIL MAK, 1990, NATURE, V347, P743, DOI 10.1038/347743a0; Leshin LA, 1996, GEOCHIM COSMOCHIM AC, V60, P2635, DOI 10.1016/0016-7037(96)00122-6; MOORTGAT GK, 1983, J CHEM PHYS, V78, P1185, DOI 10.1063/1.444911; NEWMAN PA, 2002, J GEOPHYS RES, V107; Novelli PC, 1999, J GEOPHYS RES-ATMOS, V104, P30427, DOI 10.1029/1999JD900788; Rahn T, 2002, GEOCHIM COSMOCHIM AC, V66, P2475, DOI 10.1016/S0016-7037(02)00858-X; Rice AL, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003042; ROBERT F, 1982, GEOCHIM COSMOCHIM AC, V46, P81, DOI 10.1016/0016-7037(82)90293-9; Saueressig G, 2001, J GEOPHYS RES-ATMOS, V106, P23127, DOI 10.1029/2000JD000120; Saueressig G, 1996, GEOPHYS RES LETT, V23, P3619, DOI 10.1029/96GL03292; SCHAUFFLER SM, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2001JGD002040; Taatjes CA, 1999, CHEM PHYS LETT, V306, P33, DOI 10.1016/S0009-2614(99)00420-0; Talukdar RK, 1996, CHEM PHYS LETT, V253, P177, DOI 10.1016/0009-2614(96)00203-5; Talukdar RK, 1996, J PHYS CHEM-US, V100, P3037, DOI 10.1021/jp9518724	28	73	74	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					918	921		10.1038/nature01917	http://dx.doi.org/10.1038/nature01917			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931182				2022-12-28	WOS:000184843600035
J	Henderson, S; Whiteford, H				Henderson, S; Whiteford, H			Social capital and mental health	LANCET			English	Editorial Material									Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia; Univ Queensland, Brisbane, Qld, Australia	Australian National University; University of Queensland	Henderson, S (corresponding author), Australian Natl Univ, Mental Hlth Res Ctr, Canberra, ACT 0200, Australia.	as.henderson@bigpond.com	Whiteford, Harvey A/A-4840-2009	Whiteford, Harvey A/0000-0003-4667-6623				JACKMAN RW, 2001, INT ENCY SOCIAL BEHA, V9, P14216; Jenkins R, 2003, INT REV PSYCHIATR, V15, P188, DOI 10.1080/0954026021000046164; Kawachi I, 2001, J URBAN HEALTH, V78, P458, DOI 10.1093/jurban/78.3.458; Kawachi I., 2000, SOCIAL EPIDEMIOLOGY, P174; Lochner K, 1999, HEALTH PLACE, V5, P259, DOI 10.1016/S1353-8292(99)00016-7; Marmot M, 2001, INT J EPIDEMIOL, V30, P1165, DOI 10.1093/ije/30.5.1165; McCulloch A, 2001, BRIT MED J, V323, P208, DOI 10.1136/bmj.323.7306.208; McKenzie K, 2002, BRIT J PSYCHIAT, V181, P280, DOI 10.1192/bjp.181.4.280; McKenzie K, 2003, BRIT J PSYCHIAT, V182, P458, DOI 10.1192/S000712500022881X; *NHAT I MED, 2001, M CHALL DEV WORLD; Portes A, 1998, ANNU REV SOCIOL, V24, P1, DOI 10.1146/annurev.soc.24.1.1; PUTNAM R, 2000, BOWLING ALONE COLLA; Sartorius N, 2003, CURR OPIN PSYCHIATR, V16, pS101, DOI 10.1097/00001504-200304002-00015; Walkup J, 2003, BRIT J PSYCHIAT, V182, P458, DOI 10.1192/bjp.182.5.458; Whitehead M, 2001, LANCET, V358, P165, DOI 10.1016/S0140-6736(01)05398-3; *WORLD BANK GROUP, 2003, SOC CAP DEV	16	50	51	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					505	506		10.1016/S0140-6736(03)14150-5	http://dx.doi.org/10.1016/S0140-6736(03)14150-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712UW	12932380				2022-12-28	WOS:000184817600005
J	Hind, D; Calvert, N; McWilliams, R; Davidson, A; Paisley, S; Beverley, C; Thomas, S				Hind, D; Calvert, N; McWilliams, R; Davidson, A; Paisley, S; Beverley, C; Thomas, S			Ultrasonic locating devices for central venous cannulation: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CATHETERIZATION	Objectives To assess the evidence for the clinical effectiveness of ultrasound guided central venous cannulation. Data sources 15 electronic bibliographic databases, covering biomedical, science, social science, health economics, and grey literature. Design Systematic review and meta-analysis of randomised controlled trials. Populations Patients scheduled for central venous access. Intervention reviewed Guidance using real time two dimensional ultrasonography or Doppler needles and probes compared with the anatomical landmark method of cannulation. Data extraction Risk of failed catheter placement (primary outcome), risk of complications from placement, risk of failure on first attempt at placement, number of attempts to successful catheterisation, and time (seconds) to successful catheterisation. Data synthesis 18 trials (1646 participants) were identified. Compared with the landmark method, real time two dimensional ultrasound guidance for cannulating the internal jugular vein in adults was associated with a significantly lower failure rate both overall (relative risk 0.14, 95% confidence interval 0.06 to 0.33) and on the first attempt (0.59, 0.39 to 0.88). Limited evidence favoured two dimensional ultrasound guidance for subclavian vein and femoral vein procedures in adults (0.14, 0.04 to 0.57 and 0.29, 0.07 to 1.21, respectively). Three studies in infants confirmed a higher success rate with two dimensional ultrasonography for internal jugular procedures (0.15, 0.03 to 0.64). Doppler guided cannulation of the internal jugular vein in adults was more successful than the landmark method (0.39, 0.17 to 0.92), but the landmark method was more successful for subclavian vein procedures (1.48, 1.03 to 2.14). No significant difference was found between these techniques for cannulation of the internal jugular vein in infants. An indirect comparison of relative risks suggested that two dimensional ultrasonography would be more successful than Doppler guidance for subclavian vein procedures in adults (0.09, 0.02 to 0.38). Conclusions Evidence supports the use of two dimensional ultrasonography for central venous cannulation.	ScHARR, Rapid Reviews Grp, Sheffield S1 4DA, S Yorkshire, England; Fourth Hurdle Consulting, London WC1R 4QA, England; Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England; Royal Hallamshire Hosp, Sheffield Teaching Hosp NHS Trust, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, No Gen Hosp, Dept Acad Radiol, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Sheffield; Northern General Hospital; University of Sheffield	Hind, D (corresponding author), ScHARR, Rapid Reviews Grp, Regent Court, Sheffield S1 4DA, S Yorkshire, England.	d.hind@shef.ac.uk	Hind, Daniel/AAE-1769-2020; Hind, Daniel/A-2180-2010	Hind, Daniel/0000-0002-6409-4793; Hind, Daniel/0000-0002-6409-4793				Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Callum KG, 2000, INTERVENTIONAL VASCU; CALVERT N, 2003, HLTH TECHNOL ASSESS, V7; ELLIOTT TSJ, 1994, J HOSP INFECT, V28, P163, DOI 10.1016/0195-6701(94)90100-7; KHAN K, 2001, UNDERTAKING SYSTEMAT; *NAT I CLIN EXC, 2002, 49 NICE; Randolph AG, 1996, CRIT CARE MED, V24, P2053, DOI 10.1097/00003246-199612000-00020; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; TROTTIER SJ, 1995, CRIT CARE MED, V23, P52, DOI 10.1097/00003246-199501000-00011	9	673	705	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 16	2003	327	7411					361	364		10.1136/bmj.327.7411.361	http://dx.doi.org/10.1136/bmj.327.7411.361			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919984	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000184864200014
J	Flanagan, JR; Johansson, RS				Flanagan, JR; Johansson, RS			Action plans used in action observation	NATURE			English	Article							GRASP REPRESENTATIONS; MAGNETIC STIMULATION; PREMOTOR CORTEX; MIRROR NEURONS; EYE-MOVEMENTS; MOTOR; IMITATION; COORDINATION; MODULATION; LOCALIZATION	How do we understand the actions of others? According to the direct matching hypothesis, action understanding results from a mechanism that maps an observed action onto motor representations of that action(1-4). Although supported by neurophysiological (1,5-13) and brain- imaging(3,14-18) studies, direct evidence for this hypothesis is sparse. In visually guided actions, task-specific proactive eye movements are crucial for planning and control (19-22). Because the eyes are free to move when observing such actions, the direct matching hypothesis predicts that subjects should produce eye movements similar to those produced when they perform the tasks. If an observer analyses action through purely visual means, however, eye movements will be linked reactively to the observed action. Here we show that when subjects observe a block stacking task, the coordination between their gaze and the actor's hand is predictive, rather than reactive, and is highly similar to the gaze-hand coordination when they perform the task themselves. These results indicate that during action observation subjects implement eye motor programs directed by motor representations of manual actions and thus provide strong evidence for the direct matching hypothesis.	Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; Queens Univ, Ctr Neurosci Studies, Kingston, ON K7L 3N6, Canada; Umea Univ, Dept Integrat Med Biol, Physiol Sect, SE-90187 Umea, Sweden	Queens University - Canada; Queens University - Canada; Umea University	Flanagan, JR (corresponding author), Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada.		Johansson, Roland S/A-5890-2009	Johansson, Roland S/0000-0003-3288-8326				Allison T, 2000, TRENDS COGN SCI, V4, P267, DOI 10.1016/S1364-6613(00)01501-1; Avikainen S, 2002, NEUROIMAGE, V15, P640, DOI 10.1006/nimg.2001.1029; BALLARD DH, 1995, J COGNITIVE NEUROSCI, V7, P66, DOI 10.1162/jocn.1995.7.1.66; BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; Decety J, 1997, BRAIN, V120, P1763, DOI 10.1093/brain/120.10.1763; DIPELLEGRINO G, 1992, EXP BRAIN RES, V91, P176, DOI 10.1007/BF00230027; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Gallese V, 1996, BRAIN, V119, P593, DOI 10.1093/brain/119.2.593; Gangitano M, 2001, NEUROREPORT, V12, P1489, DOI 10.1097/00001756-200105250-00038; Grafton ST, 1996, EXP BRAIN RES, V112, P103; Hari R, 1998, P NATL ACAD SCI USA, V95, P15061, DOI 10.1073/pnas.95.25.15061; Iacoboni M, 1999, SCIENCE, V286, P2526, DOI 10.1126/science.286.5449.2526; Iacoboni M, 2001, P NATL ACAD SCI USA, V98, P13995, DOI 10.1073/pnas.241474598; Johansson RS, 2001, J NEUROSCI, V21, P6917, DOI 10.1523/JNEUROSCI.21-17-06917.2001; JOHANSSON RS, 1992, CURR OPIN NEUROBIOL, V2, P815, DOI 10.1016/0959-4388(92)90139-C; Kohler E, 2002, SCIENCE, V297, P846, DOI 10.1126/science.1070311; Koski L, 2002, CEREB CORTEX, V12, P847, DOI 10.1093/cercor/12.8.847; Land MF, 2000, NAT NEUROSCI, V3, P1340, DOI 10.1038/81887; Land MF, 1997, PHILOS T ROY SOC B, V352, P1231, DOI 10.1098/rstb.1997.0105; Mataric MJ, 1998, COGNITIVE BRAIN RES, V7, P191, DOI 10.1016/S0926-6410(98)00025-1; Nishitani N, 2000, P NATL ACAD SCI USA, V97, P913, DOI 10.1073/pnas.97.2.913; PERRY HM, 1989, BONE MINERAL RES, V6, P113; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 1996, EXP BRAIN RES, V111, P246; Rizzolatti G, 1999, ARCH ITAL BIOL, V137, P85; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Strafella AP, 2000, NEUROREPORT, V11, P2289, DOI 10.1097/00001756-200007140-00044; Umilta MA, 2001, NEURON, V31, P155, DOI 10.1016/S0896-6273(01)00337-3	29	473	479	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					769	771		10.1038/nature01861	http://dx.doi.org/10.1038/nature01861			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917683				2022-12-28	WOS:000184733900038
J	Fries, JF				Fries, JF			Measuring and monitoring success in compressing morbidity	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				RANDOMIZED CONTROLLED TRIAL; CUMULATIVE DISABILITY; UNITED-STATES; HEALTH; POPULATION; PROGRAM; AGE; MORTALITY; TRENDS; LIFE	The Compression of Morbidity paradigm, introduced in 1980, maintains that if the average age at first infirmity, disability, or other morbidity is postponed and if this postponement is greater than increases in life expectancy, then cumulative lifetime morbidity will decrease-compressed between a later onset and the time of death. The National Long-Term Care Survey, the National Health Interview Survey, and other data now document declining disability trends beginning in 1982 and accelerating more recently. The decline is about 2% per year, contrasted with a decline in mortality rates of about 1% per year, thereby documenting compression of morbidity in the United States at the population level. Longitudinal studies now link good health risk status with long-term reductions in cumulative lifetime disability; persons with few behavioral health risks have only one-fourth the disability of those who have more risk factors, and the onset of disability is postponed from 7 to 12 years, far more than any increases in longevity in the groups. Randomized, controlled trials of health enhancement programs in elderly populations show reduction in health risks, improved health status, and decreased medical care utilization. Health policy initiatives now being undertaken have promise of increasing and consolidating health gains for the elderly.	Stanford Univ, Sch Med, Palo Alto, CA 94304 USA	Stanford University	Fries, JF (corresponding author), Stanford Univ, Sch Med, 100 Welch Rd,Suite 203, Palo Alto, CA 94304 USA.		Fries, James F/F-6271-2011		NATIONAL INSTITUTE ON AGING [R01AG015815] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR43585] Funding Source: Medline; NIA NIH HHS [AG15815] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bandura A., 2000, UNDERSTANDING CHANGI, P299; Bruce B, 2003, J RHEUMATOL, V30, P167; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Fries J F, 1994, Am J Health Promot, V8, P216; Fries JF, 1997, J RHEUMATOL, V24, P1378; FRIES JF, 1993, AM J MED, V94, P455, DOI 10.1016/0002-9343(93)90078-4; Fries JF, 2002, JAMA-J AM MED ASSOC, V288, P3164, DOI 10.1001/jama.288.24.3164; Fries JF, 2001, COMPR THER, V27, P322, DOI 10.1007/s12019-001-0030-4; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; Hubert HB, 2002, J GERONTOL A-BIOL, V57, pM347, DOI 10.1093/gerona/57.6.M347; KRANCZER S, 1999, STAT B           OCT, P20; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; MYERS GC, 1984, GERONTOLOGIST, V24, P346, DOI 10.1093/geront/24.4.346; OLSHANSKY SJ, 1986, MILBANK Q, V64, P355, DOI 10.2307/3350025; *RAND, 2002, EV REP EV BAS REC HL; Rowe JW, 1999, NEW ENGL J MED, V340, P720, DOI 10.1056/NEJM199903043400908; Schoeni RF, 2001, J GERONTOL B-PSYCHOL, V56, pS206, DOI 10.1093/geronb/56.4.S206; Singer BH, 1998, P NATL ACAD SCI USA, V95, P15618, DOI 10.1073/pnas.95.26.15618; VERBRUGGE LM, 1984, MILBANK FUND Q, V62, P475, DOI 10.2307/3349861; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Wang BWE, 2002, ARCH INTERN MED, V162, P2285, DOI 10.1001/archinte.162.20.2285	24	184	190	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			455	459		10.7326/0003-4819-139-5_Part_2-200309021-00015	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965976				2022-12-28	WOS:000185133800015
J	Goodman, R; Gledhill, J; Ford, T				Goodman, R; Gledhill, J; Ford, T			Child psychiatric disorder and relative age within school year: cross sectional survey of large population sample	BMJ-BRITISH MEDICAL JOURNAL			English	Review							OSTEOLYTIC BONE-DISEASE; BREAST-CANCER PATIENTS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL CLODRONATE; MULTIPLE-MYELOMA; ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; PROSTATE-CANCER; DICHLOROMETHYLENE BISPHOSPHONATE	Objective To test the hypothesis that younger children in, a school year are at greater risk of emotional and behavioural problems. Design Cross sectional survey. Setting Community sample from England, Scotland, and Wales. Participants 10438 British 5-15 year olds. Main outcome measures Total symptom scores on psychopathology questionnaires completed by parents, teachers, and 11-15 year olds; psychiatric diagnoses based on a clinical review of detailed interview data. Results Younger children in a school year were significantly more likely to have higher symptom scores and psychiatric disorder. The adjusted regression coefficients for relative age were 0.51 (95% confidence interval 0.36 to 0.65, P<0.0001) according to teacher report and 0.35 (0.23 to 0.47, P=0.0001) for parental report. The adjusted odds ratio for psychiatric diagnoses for decreasing relative age was 1.14 (1.03 to 1.25, P=0.009). The effect was evident across different measures, raters, and age bands. Cross national comparisons supported a "relative age" explanation based on the disadvantages of immaturity rather than a "season of birth" explanation based on seasonal variation in biological risk. Conclusions The younger children in a school year are at slightly greater psychiatric risk than older children. Increased awareness by teachers of the relative age of their pupils and a more flexible approach to children's progression through school might reduce the number of children with impairing psychiatric disorders in the general population.	Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England; Imperial Coll Sch Med St Marys, London W2 1PG, England	University of London; King's College London; Imperial College London	Goodman, R (corresponding author), Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, London SE5 8AF, England.	r.goodman@iop.kcl.ac.uk	Ford, Tamsin/V-5908-2019	Ford, Tamsin/0000-0001-5295-4904; Goodman, Robert/0000-0001-5596-1667				ABDULKADYROV KM, 1993, TERAPEVT ARKH, V65, P70; Abildgaard N, 1998, EUR J HAEMATOL, V61, P128; ADAMI S, 1989, RECENT RES CANCER, V116, pS67; Ali SM, 2001, J CLIN ONCOL, V19, P3434, DOI 10.1200/JCO.2001.19.14.3434; [Anonymous], 1994, ICD 10 CLASS MENT BE; Arican A, 1999, MED ONCOL, V16, P204, DOI 10.1007/BF02906133; ATTARDOPARRINELLO G, 1987, ARCH INTERN MED, V147, P1629, DOI 10.1001/archinte.147.9.1629; AUSGABE A, 1997, UROLOGE, V36, P568; Ausili-Cefaro Giampiero, 1999, Rays (Rome), V24, P49; BELCH AR, 1991, J CLIN ONCOL, V9, P1397, DOI 10.1200/JCO.1991.9.8.1397; Berenson JR, 1998, REV CONTEMP PHARMACO, V9, P195; Berenson JR, 2001, SEMIN ONCOL, V28, P25; Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0; Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802; Berenson JR, 1998, J CLIN ONCOL, V16, P593, DOI 10.1200/JCO.1998.16.2.593; BERGLUND GW, 1967, BRIT J PSYCHOL, V58, P147, DOI 10.1111/j.2044-8295.1967.tb01069.x; Bishop HM, 1999, EUR J SURG ONCOL, V25, P4; BODY JJ, 1999, P AN M AM SOC CLIN, V18, pA2222; Brincker H, 1998, BRIT J HAEMATOL, V101, P280, DOI 10.1046/j.1365-2141.1998.00695.x; Cascinu S, 1998, SUPPORT CARE CANCER, V6, P139, DOI 10.1007/s005200050148; Clarke M, 2001, COCHRANE REV HDB; CLEMENS MR, 1993, ANN HEMATOL, V66, P141, DOI 10.1007/BF01697625; Cleton F J, 1989, Recent Results Cancer Res, V116, P73; Coleman RE, 1999, ANN ONCOL, V10, P311, DOI 10.1023/A:1008386501738; Coleman RE, 1998, EUR J CANCER, V34, P820, DOI 10.1016/S0959-8049(97)10155-1; Coleman RE, 1997, CANCER, V80, P1686, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.3.CO;2-T; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; CONTE N, 1991, ONCOLOGY, V48, P54; Conte P F, 1994, Ann Oncol, V5 Suppl 7, pS41; Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552; Costa L, 1993, Acta Med Port, V6, P71; COSTELLO EJ, 1993, J AM ACAD CHILD PSY, V32, P1106, DOI 10.1097/00004583-199311000-00002; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; Croll P., 1985, ONE 5 ASSESSMENT INC; Daragon A, 1993, Eur J Med, V2, P449; DEARNALEY DP, 2001, J CLIN ONCOL ASCO, pA693; DEARNALEY DP, 2001, J CLIN ONCOL ASCO; DELMAS PD, 1982, METAB BONE DIS RELAT, V4, P163, DOI 10.1016/0221-8747(82)90013-3; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Diel IJ, 1999, EUR J CANCER, V35, pS83, DOI 10.1016/S0959-8049(99)80703-5; DIEL IJ, 1999, J CLIN ONCOL ASCO; DJULBEGOVIC B, 2003, COCHRANE DB SYST REV; ELOMAA I, 1988, BIOMED PHARMACOTHER, V42, P111; ELOMAA I, 1983, LANCET, V1, P146; Elomaa I, 1996, EUR J CANCER, V32A, P1166, DOI 10.1016/0959-8049(95)00653-2; ELOMAA I, 1992, International Urology and Nephrology, V24, P159, DOI 10.1007/BF02549644; ELOMAA I, 1987, BONE, V8, pS53; ERNST DS, 1992, J PAIN SYMPTOM MANAG, V7, P4, DOI 10.1016/0885-3924(92)90101-M; Ernst DS, 1997, J PAIN SYMPTOM MANAG, V13, P319; FernandezConde M, 1997, AM J CLIN ONCOL-CANC, V20, P471, DOI 10.1097/00000421-199710000-00007; FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495-199141020-00009; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; Ford J M, 1996, Cancer Treat Res, V87, P3; FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264; Gessner U, 2000, SUPPORT CARE CANCER, V8, P115, DOI 10.1007/s005200050025; GLEDHILL J, 2002, RES EDUC, V68, P41, DOI DOI 10.7227/RIE.68.4; GLOVER D, 1994, CANCER, V74, P2949, DOI 10.1002/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q; GOMEZPASTRANA E, 1996, PROGR OBSTET GYNECOL, V39, P357; Goodman R, 2000, J CHILD PSYCHOL PSYC, V41, P645, DOI 10.1017/S0021963099005909; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; GRILL V, 2001, REV ENDOCR METAB DIS, V1, P253; HARRIS AL, 1993, OSTEOCLAST INHIBITIO, pA73; Healey John H., 2000, Cancer, V88, P2940, DOI 10.1002/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W; Heim ME, 1995, ONKOLOGIE, V18, P439; Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378; HOLTENVERZANTVO.AT, 1991, EUR J CANCER, V27, P544; HOLTENVERZANTVO.AT, 1987, LANCET, V2, P983; HOLTENVERZANTVO.AT, 1993, J CLIN ONCOL, V11, P491; Hortobagyi GN, 1998, J CLIN ONCOL, V16, P2038, DOI 10.1200/JCO.1998.16.6.2038; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; HULIN MT, 1994, ANN ONCOL S8, V5, P198; Hultborn R, 1999, ANTICANCER RES, V19, P3383; Hultborn R, 1996, ACTA ONCOL, V35, P73, DOI 10.3109/02841869609083974; JINKS PC, 1964, EDUC RES, V6, P220, DOI 10.1080/0013188640060308; JUNG A, 1983, NEW ENGL J MED, V308, P1499, DOI 10.1056/NEJM198306233082503; Koeberle D, 1999, SUPPORT CARE CANCER, V7, P21, DOI 10.1007/s005200050218; Kraj M, 2000, Acta Pol Pharm, V57 Suppl, P113; Kraj Maria, 2000, Acta Haematologica Polonica, V31, P379; Kristensen B, 1999, J INTERN MED, V246, P67, DOI 10.1046/j.1365-2796.1999.00507.x; KYLMALA T, 1993, EUR J CANCER, V29A, P821, DOI 10.1016/S0959-8049(05)80417-4; Kylmala T, 1997, BRIT J CANCER, V76, P939, DOI 10.1038/bjc.1997.488; LAAKSO M, 1994, BRIT J HAEMATOL, V87, P725, DOI 10.1111/j.1365-2141.1994.tb06730.x; LAHTINEN R, 1992, LANCET, V340, P1049, DOI 10.1016/0140-6736(92)93075-X; Lipton A, 1994, Ann Oncol, V5 Suppl 7, pS31; Lipton A, 1998, EUR J CANCER, V34, P2021, DOI 10.1016/S0959-8049(98)00277-9; Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z; Lipton A, 1996, BRIT J CLIN PRACT, P21; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MARTONI A, 1991, ONCOLOGY, V48, P97; McCloskey EV, 1998, BRIT J HAEMATOL, V100, P317; Meltzer H., 2000, MENTAL HLTH CHILDREN; MERLINI G, 1990, HEMATOL ONCOL, V8, P23, DOI 10.1002/hon.2900080104; Moiseenko V. M., 1998, Voprosy Onkologii (St. Petersburg), V44, P725; MORTIMORE P, 1988, SCH MATTERS JUNIOR Y; Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158; MUNDY GR, 1990, CALCIUM HOMEOSTASIS, P100; MURPHY RY, 2001, UNPUB; OROURKE N, 1995, J CLIN ONCOL, V13, P929, DOI 10.1200/JCO.1995.13.4.929; PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59; PAVOAKIS N, 2003, COCHRANE DB SYST REV; Peest D, 1996, EUR J CANCER, V32A, P2053, DOI 10.1016/S0959-8049(96)00228-6; Piga A, 1998, J EXP CLIN CANC RES, V17, P213; Poliakov P Iu, 1999, Vopr Onkol, V45, P311; Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080; RINGENBERG QS, 1987, CLIN THER, V9, P318; ROBERTSON AG, 1995, J CLIN ONCOL, V13, P2427, DOI 10.1200/JCO.1995.13.9.2427; Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8; Rosen LS, 2002, SEMIN ONCOL, V29, P28, DOI 10.1053/sonc.2002.37416; Rosen LS, 2001, CANCER J, V7, P377; ROSS JR, 2003, IN PRESS HLTH TECHNO; Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212; RUSSELL RJH, 1986, PERS INDIV DIFFER, V7, P839, DOI 10.1016/0191-8869(86)90082-6; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; SCHILLER JH, 1987, ARCH INTERN MED, V147, P963, DOI 10.1001/archinte.147.5.963; SHARP C, 1995, SCH ENTRY IMPACT SEA; Slaby J, 1997, Cas Lek Cesk, V136, P57; SMITH JA, 1989, J UROLOGY, V141, P85, DOI 10.1016/S0022-5347(17)40597-0; Statacorp, 2001, STAT STAT SOFTW REL; Strang P, 1997, ANTICANCER RES, V17, P4717; TARNOWSKI KJ, 1990, J CONSULT CLIN PSYCH, V58, P240, DOI 10.1037/0022-006X.58.2.240; TAUBE T, 1993, EUR J CANCER, V29A, P1677, DOI 10.1016/0959-8049(93)90103-M; TAUBE T, 1994, EUR J CANCER, V30A, P751, DOI 10.1016/0959-8049(94)90287-9; Terpos E, 2000, EUR J HAEMATOL, V65, P331, DOI 10.1034/j.1600-0609.2000.065005331.x; Theriault R, 1996, BRIT J CLIN PRACT, P8; Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846; THURLIMANN B, 1994, SUPPORT CARE CANCER, V2, P61, DOI 10.1007/BF00355241; Tubiana-Hulin M, 2001, B CANCER, V88, P701; Vinholes J, 1999, BRIT J CANCER, V80, P221, DOI 10.1038/sj.bjc.6690506; Vinholes J, 1996, BRIT J CANCER, V73, P1089, DOI 10.1038/bjc.1996.210; Vinholes JJF, 1997, ANN ONCOL, V8, P1243, DOI 10.1023/A:1008238422151; Wallingford EL, 2000, PSYCHOL SCHOOLS, V37, P379, DOI 10.1002/1520-6807(200007)37:4<389::AID-PITS9>3.0.CO;2-K; WONG R, 2003, COCHRANE DB SYST REV; Wright P, 1999, PROG PSYCH, P89; YAKATAN GJ, 1982, CLIN PHARMACOL THER, V31, P402, DOI 10.1038/clpt.1982.51; ZHANG J, 1999, CHINESE J CLIN ONCOL, V26, P762; ZHANG L, 1997, CHIN J CANCER, V16, P430	136	87	87	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2003	327	7413					472	475		10.1136/bmj.327.7413.472	http://dx.doi.org/10.1136/bmj.327.7413.472			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LA	12946967	Bronze, Green Published			2022-12-28	WOS:000185088900013
J	Pacala, SW; Bulte, E; List, JA; Levin, SA				Pacala, SW; Bulte, E; List, JA; Levin, SA			False alarm over environmental false alarms	SCIENCE			English	Editorial Material							ECONOMIC-GROWTH; KUZNETS CURVE; AIR-POLLUTION		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Tilburg Univ, Dept Econ, NL-5000 LE Tilburg, Netherlands; Univ Maryland, Dept Econ, College Pk, MD 20742 USA; Univ Maryland, AREC Dept, Presidents Council Econ Advisers, College Pk, MD 20742 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA	Princeton University; Tilburg University; University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; National Bureau of Economic Research	Pacala, SW (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.		Levin, Simon A/J-1218-2014	Levin, Simon A/0000-0002-8216-5639; List, John/0000-0002-1740-3848; Bulte, Erwin/0000-0001-9491-5268				Andreoni J, 2001, J PUBLIC ECON, V80, P269, DOI 10.1016/S0047-2727(00)00110-9; AOROA S, 1998, S EC J, V65, P691; ARROW K, 1995, SCIENCE, V268, P520, DOI 10.1126/science.268.5210.520; GROSSMAN GM, 1995, Q J ECON, V110, P353, DOI 10.2307/2118443; Grubb M, 2002, ANNU REV ENERG ENV, V27, P271, DOI 10.1146/annurev.energy.27.122001.083408; Jaeger W., 1998, THEORETICAL BASIS EN; Kinzig AP, 2003, AMBIO, V32, P330, DOI 10.1639/0044-7447(2003)032[0330:CWUACF]2.0.CO;2; Lesser J. A., 1997, ENV EC POLICY; LOMBORG B, 2001, SKEPTICAL ENV, P168; LUTTER R, 2000, REGULATION, V23; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; SELDEN TM, 1994, J ENVIRON ECON MANAG, V27, P147, DOI 10.1006/jeem.1994.1031; VISCUSI WK, 1993, J ECON LIT, V31, P1912; POLLUTION ABATEMENT	14	18	18	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1187	1188		10.1126/science.1086646	http://dx.doi.org/10.1126/science.1086646			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	715ZC	12947184	Green Published			2022-12-28	WOS:000185003500025
J	Avery, RK				Avery, RK			Cardiac-allograft vasculopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Fdn, Dept Infect Dis, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Transplant Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Avery, RK (corresponding author), Cleveland Clin Fdn, Dept Infect Dis, 9500 Euclid Ave, Cleveland, OH 44195 USA.							KIRKLIN JK, 2002, HEART TRANSPLANTATIO, P615; Mancini D, 2003, CIRCULATION, V108, P48, DOI 10.1161/01.CIR.0000070421.38604.2B	2	70	77	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					829	830		10.1056/NEJMp038124	http://dx.doi.org/10.1056/NEJMp038124			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944567				2022-12-28	WOS:000184968400002
J	Mehler, PS				Mehler, PS			Bulimia nervosa	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; EATING-DISORDERS; YOUNG-WOMEN; ANOREXIA; ANTIDEPRESSANTS; PREVALENCE; FLUOXETINE; SYMPTOMS; PLACEBO		Denver Hlth, Internal Med & Community Hlth Serv, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Mehler, PS (corresponding author), Denver Hlth, Internal Med & Community Hlth Serv, 660 Bannock St,MC1914, Denver, CO 80204 USA.	pmehler@dhha.org						Agras WS, 2000, AM J PSYCHIAT, V157, P1302, DOI 10.1176/appi.ajp.157.8.1302; Agras WS, 2000, ARCH GEN PSYCHIAT, V57, P459, DOI 10.1001/archpsyc.57.5.459; [Anonymous], 1992, Arch Gen Psychiatry, V49, P139; Bacaltchuk J, 2000, ACTA PSYCHIAT SCAND, V101, P256, DOI 10.1111/j.1600-0447.2000.tb10923.x; Bacaltchuk J, 2000, AUST NZ J PSYCHIAT, V34, P310, DOI 10.1080/j.1440-1614.2000.00709.x; BIHUN JAP, 1993, INT J EAT DISORDER, V14, P197, DOI 10.1002/1098-108X(199309)14:2&lt;197::AID-EAT2260140209&gt;3.0.CO;2-C; Bulik CM, 2003, AM J HUM GENET, V72, P200, DOI 10.1086/345801; Chen E, 2003, INT J EAT DISORDER, V33, P241, DOI 10.1002/eat.10137; Colton P, 1999, INT J EAT DISORDER, V25, P311; Conrad R, 2003, PSYCHOSOMATICS, V44, P76, DOI 10.1176/appi.psy.44.1.76; Cotton MA, 2003, J GEN INTERN MED, V18, P53, DOI 10.1046/j.1525-1497.2003.20374.x; Crow SJ, 2002, AM J PSYCHIAT, V159, P1048, DOI 10.1176/appi.ajp.159.6.1048; FAIRBURN CG, 1995, ARCH GEN PSYCHIAT, V52, P304; Faris PL, 2000, LANCET, V355, P792, DOI 10.1016/S0140-6736(99)09062-5; Felstrom A, 2002, AM J PSYCHIAT, V159, P1246, DOI 10.1176/appi.ajp.159.7.1246-a; Gennari FJ, 1998, NEW ENGL J MED, V339, P451, DOI 10.1056/NEJM199808133390707; GOLDSTEIN DJ, 1995, BRIT J PSYCHIAT, V166, P660, DOI 10.1192/bjp.166.5.660; GREENFELD D, 1995, AM J PSYCHIAT, V152, P60; Grinspoon S, 2000, ANN INTERN MED, V133, P790, DOI 10.7326/0003-4819-133-10-200011210-00011; Hay PJ, 2001, BMJ-BRIT MED J, V323, P33, DOI 10.1136/bmj.323.7303.33; Ho PC, 1998, CLIN CARDIOL, V21, P780, DOI 10.1002/clc.4960211018; JAMISON RL, 1982, AM J MED, V73, P142, DOI 10.1016/0002-9343(82)90941-X; Jimerson DC, 1996, PSYCHIAT CLIN N AM, V19, P739, DOI 10.1016/S0193-953X(05)70378-6; Keel PK, 2002, INT J EAT DISORDER, V31, P151, DOI 10.1002/eat.10017; Keel PK, 1997, AM J PSYCHIAT, V154, P313; Kreipe RE, 2000, MED CLIN N AM, V84, P1027, DOI [10.1016/S0025-7125(05)70272-8, 10.1016/S0889-8545(00)80009-1]; Lewinsohn PM, 2000, J AM ACAD CHILD PSY, V39, P1284, DOI 10.1097/00004583-200010000-00016; Little JW, 2002, ORAL SURG ORAL MED O, V93, P138, DOI 10.1067/moe.2002.116598; MEHLER PS, 1993, ARCH OTOLARYNGOL, V119, P787; Mehler PS, 2001, ANN INTERN MED, V134, P1048, DOI 10.7326/0003-4819-134-11-200106050-00011; Mehler PS, 1997, EAT DISORD, V5, P41; Mendell DA, 2001, INT J EAT DISORDER, V30, P252, DOI 10.1002/eat.1082; Milosevic A, 1997, INT J EAT DISORDER, V21, P195, DOI 10.1002/(SICI)1098-108X(199703)21:2&lt;195::AID-EAT11&gt;3.0.CO;2-1; Mitchell JE, 2002, INT J EAT DISORDER, V32, P271, DOI 10.1002/eat.10092; NeumarkSztainer D, 1996, ARCH PEDIAT ADOL MED, V150, P304, DOI 10.1001/archpedi.1996.02170280074014; Nickl NJ, 1996, AM J GASTROENTEROL, V91, P2544; O'Brien KM, 2003, CLIN PSYCHOL REV, V23, P57, DOI 10.1016/S0272-7358(02)00201-5; Peterson CB, 1999, J CLIN PSYCHOL, V55, P685, DOI 10.1002/(SICI)1097-4679(199906)55:6<685::AID-JCLP3>3.0.CO;2-Y; PRYOR T, 1995, PSYCHIAT ANN, V25, P40, DOI 10.3928/0048-5713-19950101-10; Roerig JL, 2003, INT J EAT DISORDER, V33, P443, DOI 10.1002/eat.10159; Romano SJ, 2002, AM J PSYCHIAT, V159, P96, DOI 10.1176/appi.ajp.159.1.96; Rydall AC, 1997, NEW ENGL J MED, V336, P1849, DOI 10.1056/NEJM199706263362601; SCHULTE M, 1999, EATING DISORDERS GUI, P76; Spear BA, 2001, J AM DIET ASSOC, V101, P810, DOI 10.1016/S0002-8223(01)00201-2; Steinhausen H. C., 1999, RISKS OUTCOMES DEV P, P210; Takii M, 2002, DIABETES CARE, V25, P1571, DOI 10.2337/diacare.25.9.1571; Tramonte SM, 1997, J GEN INTERN MED, V12, P15, DOI 10.1046/j.1525-1497.1997.12103.x; Vaz FJ, 1998, J PSYCHOSOM RES, V45, P391, DOI 10.1016/S0022-3999(98)00017-8; Wolfe BE, 2001, INT J EAT DISORDER, V30, P288, DOI 10.1002/eat.1086; Woodmansey Karl F., 2000, General Dentistry, V48, P48; Woodside DB, 2001, AM J PSYCHIAT, V158, P570, DOI 10.1176/appi.ajp.158.4.570; WOODSIDE DB, 2002, EATING DISORDERS OBE, P335; Zipfel S, 2001, J CLIN ENDOCR METAB, V86, P5227, DOI 10.1210/jc.86.11.5227; 2000, AM J PSYCHIAT S, V1575, P39	54	36	38	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					875	881		10.1056/NEJMcp022813	http://dx.doi.org/10.1056/NEJMcp022813			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715JM	12944574				2022-12-28	WOS:000184968400010
J	Cunningham, C; Reading, J; Eades, S				Cunningham, C; Reading, J; Eades, S			Health research and indigenous health	BRITISH MEDICAL JOURNAL			English	Article									Massey Univ, Sch Maori Studies, Wellington, New Zealand; Univ Toronto, Fac Med, Inst Aboriginal Peoples Hlth, Canadian Inst Hlth Res, Toronto, ON M5S 1A1, Canada; Menzies Sch Hlth Res, Casuarina, NT 0811, Australia	Massey University; Institute for Work & Health; University of Toronto; Charles Darwin University; Menzies School of Health Research	Cunningham, C (corresponding author), Massey Univ, Sch Maori Studies, Private Bag 756, Wellington, New Zealand.		Eades, Sandra J/F-1137-2010; Health, Hauora/HCH-4744-2022; Eades, Sandra/C-1286-2014	Eades, Sandra J/0000-0003-3663-7807; Eades, Sandra/0000-0001-8629-3390				*AB TORR STRAIT IS, 2002, NHMRC ROAD MAP STRAT; *HLTH RES COUNC NZ, 1998, GUID RES HLTH RES IN; *HLTH RES COUNC NZ, 1998, PUK TAU WHAK STRAT P; *HOUS REPR STAND C, 2000, HLTH IS LIF REP INQ; *I AB PEOPL HLTH, 5 YEAR STRAT PLAN 20; *NAT HLTH MED RES, 2003, 148 SESS NAT HLTH ME; *NAT HLTH MED RES, 2002, 144 SESS NAT HLTH ME; *NAT HLTH MED RES, 1991, NHMRC GUID ETH MATT; *NAT HLTH MED RES, 2000, STRAT PLAN 2000 2003; National Health and Medical Research Council, 2003, VAL ETH GUID ETH CON	10	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					445	447		10.1136/bmj.327.7412.445	http://dx.doi.org/10.1136/bmj.327.7412.445			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715YY	12933737	Green Published			2022-12-28	WOS:000185003100027
J	Balakirev, FF; Betts, JB; Migliori, A; Ono, S; Ando, Y; Boebinger, GS				Balakirev, FF; Betts, JB; Migliori, A; Ono, S; Ando, Y; Boebinger, GS			Signature of optimal doping in Hall-effect measurements on a high-temperature superconductor	NATURE			English	Article							NORMAL-STATE; HIGH-T(C) SUPERCONDUCTORS; QUANTUM CRITICALITY; INSULATOR; CUPRATE; PHASE; METAL; ANGLE; FIELD; TC	High-temperature superconductivity is achieved by doping copper oxide insulators with charge carriers. The density of carriers in conducting materials can be determined from measurements of the Hall voltage-the voltage transverse to the flow of the electrical current that is proportional to an applied magnetic field. In common metals, this proportionality (the Hall coefficient) is robustly temperature independent. This is in marked contrast to the behaviour seen in high-temperature superconductors when in the 'normal' (resistive) state(1-5); the departure from expected behaviour is a key signature of the unconventional nature of the normal state, the origin of which remains a central controversy in condensed matter physics(6). Here we report the evolution of the low-temperature Hall coefficient in the normal state as the carrier density is increased, from the onset of superconductivity and beyond (where superconductivity has been suppressed by a magnetic field). Surprisingly, the Hall coefficient does not vary monotonically with doping but rather exhibits a sharp change at the optimal doping level for superconductivity. This observation supports the idea that two competing ground states underlie the high-temperature superconducting phase.	Los Alamos Natl Lab, Natl High Magnet Field Lab, Los Alamos, NM 87545 USA; Cent Res Inst Elect Power Ind, Tokyo 2018511, Japan	United States Department of Energy (DOE); Los Alamos National Laboratory; Central Research Institute of Electric Power Industry - Japan	Balakirev, FF (corresponding author), Los Alamos Natl Lab, Natl High Magnet Field Lab, Los Alamos, NM 87545 USA.	fedor@lanl.gov	Balakirev, Fedor/AAS-6827-2020; Ando, Yoichi/B-8163-2013; Migliori, Albert/F-6961-2015; Balakirev, Fedor/AAY-2860-2020; Ono, Shimpei/D-2918-2017	Balakirev, Fedor/0000-0003-4887-5140; Ando, Yoichi/0000-0002-3553-3355; Balakirev, Fedor/0000-0003-4887-5140; Ando, Yukio/0000-0001-7115-9105; Ono, Shimpei/0000-0003-1514-8879				Andersen H. W., 1992, Journal of Process Control, V2, P67, DOI 10.1016/0959-1524(92)80002-F; Ando Y, 2000, PHYS REV B, V61, P14956, DOI 10.1103/PhysRevB.61.R14956; Ando Y, 1999, PHYS REV B, V60, pR6991, DOI 10.1103/PhysRevB.60.R6991; Ando Y, 2000, PHYSICA C, V341, P1913, DOI 10.1016/S0921-4534(00)01363-0; Chakravarty S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.277003; CHIEN TR, 1991, PHYS REV LETT, V67, P2088, DOI 10.1103/PhysRevLett.67.2088; CLAYHOLD J, 1989, PHYS REV B, V39, P7324, DOI 10.1103/PhysRevB.39.7324; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; Hoffman JE, 2002, SCIENCE, V297, P1148, DOI 10.1126/science.1072640; HWANG HY, 1994, PHYS REV LETT, V72, P2636, DOI 10.1103/PhysRevLett.72.2636; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; Lee PA, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.224517; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; Norman MR, 1998, NATURE, V392, P157, DOI 10.1038/32366; Ono S, 2000, PHYS REV LETT, V85, P638, DOI 10.1103/PhysRevLett.85.638; Ono S, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.104512; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; Perali A, 1996, PHYS REV B, V54, P16216, DOI 10.1103/PhysRevB.54.16216; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; Sato T, 2001, J PHYS CHEM SOLIDS, V62, P157, DOI 10.1016/S0022-3697(00)00119-0; Sato T, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.054502; Tallon JL, 1999, PHYS STATUS SOLIDI B, V215, P531, DOI 10.1002/(SICI)1521-3951(199909)215:1<531::AID-PSSB531>3.0.CO;2-W; UEMURA YJ, 1991, PHYS REV LETT, V66, P2665, DOI 10.1103/PhysRevLett.66.2665; UEMURA YJ, 1989, PHYS REV LETT, V62, P2317, DOI 10.1103/PhysRevLett.62.2317; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996; Wang YY, 2003, SCIENCE, V299, P86, DOI 10.1126/science.1078422; Yamauchi T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.057002; Yeh A, 2002, NATURE, V419, P459, DOI 10.1038/nature01044	29	111	112	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					912	915		10.1038/nature01890	http://dx.doi.org/10.1038/nature01890			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931180				2022-12-28	WOS:000184843600033
J	Takagi, J; Yang, YT; Liu, JH; Wang, JH; Springer, TA				Takagi, J; Yang, YT; Liu, JH; Wang, JH; Springer, TA			Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface	NATURE			English	Article							BASEMENT-MEMBRANE FORMATION; RECEPTOR-RELATED PROTEIN-5; EGF-LIKE MOTIF; GAMMA-1 CHAIN; BINDING-SITE; BONE-DENSITY; MODULE; GENE; PROTEOGLYCAN; LIPOPROTEIN	Basement membranes are fundamental to tissue organization and physiology in all metazoans. The interaction between laminin and nidogen is crucial to the assembly of basement membranes(1-4). The structure of the interacting domains reveals a six-bladed Tyr-Trp-Thr-Asp (YWTD) beta-propeller domain in nidogen bound to laminin epidermal-growth-factor-like (LE) modules III3-5 in laminin (LE3-5). Laminin LE module 4 binds to an amphitheatre-shaped surface on the pseudo-6-fold axis of the beta-propeller, and LE module 3 binds over its rim. A Phe residue that shutters the water-filled central aperture of the beta-propeller, the rigidity of the amphitheatre, and high shape complementarity enable the construction of an evolutionarily conserved binding surface for LE4 of unprecedentedly high affinity for its small size(5). Hypermorphic mutations in the Wnt co-receptor LRP5 (refs 6-9) suggest that a similar YWTD beta-propeller interface is used to bind ligands that function in developmental pathways. A related interface, but shifted off-centre from the pseudo-6-fold axis and lacking the shutter over the central aperture, is used in the low-density lipoprotein receptor for an intramolecular interaction that is regulated by pH in receptor recycling(10).	Ctr Blood Res, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wang, JH (corresponding author), Ctr Blood Res, 800 Huntington Ave, Boston, MA 02115 USA.							Baumgartner R, 1996, J MOL BIOL, V257, P658, DOI 10.1006/jmbi.1996.0192; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dong LJ, 2002, LAB INVEST, V82, P1617, DOI 10.1097/01.LAB.0000042240.52093.0F; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Jeon H, 2001, NAT STRUCT BIOL, V8, P499, DOI 10.1038/88556; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Mayer U, 1997, EUR J BIOCHEM, V245, P745, DOI 10.1111/j.1432-1033.1997.t01-1-00745.x; Mayer U, 1998, ANN NY ACAD SCI, V857, P130, DOI 10.1111/j.1749-6632.1998.tb10113.x; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; Murshed M, 2000, MOL CELL BIOL, V20, P7007, DOI 10.1128/MCB.20.18.7007-7012.2000; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Poschl E, 1996, EMBO J, V15, P5154, DOI 10.1002/j.1460-2075.1996.tb00899.x; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schymeinsky J, 2002, MOL CELL BIOL, V22, P6820, DOI 10.1128/MCB.22.19.6820-6830.2002; Springer TA, 1998, J MOL BIOL, V283, P837, DOI 10.1006/jmbi.1998.2115; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; TIMPL R, 1999, GUIDEBOOK EXTRACELLU, P455; Van Wesenbeeck L, 2003, AM J HUM GENET, V72, P763, DOI 10.1086/368277; Willem M, 2002, DEVELOPMENT, V129, P2711; YNES RO, 2000, J CELL BIOL, V150, pF89	30	116	122	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					969	974		10.1038/nature01873	http://dx.doi.org/10.1038/nature01873			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931195				2022-12-28	WOS:000184843600048
J	Roberts, R; Rodriguez, W; Murphy, D; Crescenzi, T				Roberts, R; Rodriguez, W; Murphy, D; Crescenzi, T			Pediatric drug labeling - Improving the safety and efficacy of pediatric therapies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILDREN	Context Approximately 50% to 75% of drugs used in pediatric medicine have not been studied adequately to provide appropriate labeling information. In 1997, Congress passed the Food and Drug Administration Modernization Act (FDAMA), which encouraged pediatric drug development by providing an incentive in the form of additional marketing exclusivity. Objective To identify new drug labeling information from pediatric studies submitted to the FDA in response to written requests. Design and Setting Between July 1998 and April 1, 2002, the FDA requested studies on 242 drugs, and 53 drugs were granted exclusivity. As of January 2003, 49 drugs have dew labels. Data from the studies of the first 33 drugs with new pediatric information on the label as of April 2002 are included. Significant labeling information was analyzed along with baseline data and types of studies requested. Main Outcome Measures Safety data and pediatric information for labeled drugs. Results There were 53 studies for 33 drug products, 12 (23%)were evaluated for safety only; 23 (43%), safety and efficacy; and 18 (34%), pharmacokinetics and/or pharmacodynamics. Significant new dosing and/or safety information was identified for 12 (36%) drugs. New dosing information was determined for 7 of these drugs. Safety information was defined for gabapentin, propofol, sevoflurane, the combination of ribavirin and interferon alfa-2b, and various betamethasone-containing dermatologic preparations. There was a higher percentage of deaths reported with patients who received propofol compared with controls in the pediatric intensive care unit. Seizures were seen in patients administered sevoflurane. Patients receiving a combination of ribavirin and interferon alfa-2b experienced an increased incidence of suicidal ideation when compared with adults. An unexpectedly high percentage of those receiving betamethasone-containing dermatologic preparations had documented hypopituitary-ad renal axis suppression. Conclusion The FDAMA has stimulated pediatric clinical studies resulting in improved understanding of the pharmacokinetics of drugs prescribed in pediatric medicine, important dose changes, and improved safety for children taking certain drugs.	US FDA, Off Counter Terrorism & Pediat Drug Dev, Ctr Drug Evaluat & Res, Rockville, MD 20855 USA	US Food & Drug Administration (FDA)	Roberts, R (corresponding author), US FDA, Off Counter Terrorism & Pediat Drug Dev, Ctr Drug Evaluat & Res, Metro Pk N 1,7520 Standish Pl,Room 220, Rockville, MD 20855 USA.							[Anonymous], 1979, FED REG, V44, P37434; Avenel S, 2000, ARCH PEDIATRIE, V7, P143, DOI 10.1016/S0929-693X(00)88083-5; Berlin CM, 1996, PEDIATRICS, V98, P143; Conroy S, 1999, ARCH DIS CHILD-FETAL, V80, pF142, DOI 10.1136/fn.80.2.F142; Conroy S, 2000, BRIT MED J, V320, P79, DOI 10.1136/bmj.320.7227.79; CONROY S, 2000, ARCH DIS CHILD, V82, pF77; Cote CJ, 1996, PEDIATRICS, V98, P118; Food and Drug Administration HHS, 2000, Fed Regist, V65, P78493; GRAVILLOV V, 2000, ISRAEL MED ASSOC J, V2, P595; McIntyre J, 2000, ARCH DIS CHILD, V83, P498, DOI 10.1136/adc.83.6.498; *MED EC CO INC, 2000, PHYS DESK REF; Rodriguez W, 2001, CURR THER RES CLIN E, V62, P711, DOI 10.1016/S0011-393X(01)80078-3; SHIRKEY H, 1968, J PEDIATR-US, V72, P119, DOI 10.1016/S0022-3476(68)80414-7; SIBERRY GK, 2000, H LANE HDB; Steinbrook R, 2002, NEW ENGL J MED, V347, P1462, DOI 10.1056/NEJMhpr021646; 'T Jong GW, 2000, NEW ENGL J MED, V343, P1125, DOI 10.1056/NEJM200010123431515; *US FDA, 2001, PED EXCL PROV STAT R; US Food and Drug Administration, 1994, FED REGISTER, V59, P64240; US Food and Drug Administration, 1998, FED REGISTER, V63, P66631	19	215	226	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					905	911		10.1001/jama.290.7.905	http://dx.doi.org/10.1001/jama.290.7.905			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928467				2022-12-28	WOS:000184828800027
J	Sheffield, JVL; Larson, EB				Sheffield, JVL; Larson, EB			Update in general internal medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HORMONE REPLACEMENT THERAPY; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; PREVENTION; MEMORY; RHYTHM		Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	Group Health Cooperative; Harborview Medical Center; University of Washington; University of Washington Seattle	Larson, EB (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.							Barrett BP, 2002, ANN INTERN MED, V137, P939, DOI 10.7326/0003-4819-137-12-200212170-00006; Berg AO, 2002, ANN INTERN MED, V137, P915, DOI 10.7326/0003-4819-137-11-200212030-00013; Berg AO, 2002, ANN INTERN MED, V137, P205, DOI 10.7326/0003-4819-137-3-200208060-00014; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Humphrey LL, 2002, ANN INTERN MED, V137, P273, DOI 10.7326/0003-4819-137-4-200208200-00012; Kirschstein R, 2003, ANN INTERN MED, V138, P361, DOI 10.7326/0003-4819-138-4-200302180-00029; Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; Steineck G, 2002, NEW ENGL J MED, V347, P790, DOI 10.1056/NEJMoa021483; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432	18	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					285	293		10.7326/0003-4819-139-4-200308190-00011	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965984				2022-12-28	WOS:000184795600007
J	Christensen, EF; Hoyer, CCS				Christensen, EF; Hoyer, CCS			Prehospital tracheal intubation in severely injured patients: a Danish observational study	BRITISH MEDICAL JOURNAL			English	Article							TRAUMA		Aarhus Univ Hosp, Dept Anaesthesiol & Intens Care Med, DK-8000 Aarhus, Denmark	Aarhus University	Christensen, EF (corresponding author), Aarhus Univ Hosp, Dept Anaesthesiol & Intens Care Med, DK-8000 Aarhus, Denmark.		Høyer, Christian Bjerre/H-3393-2019; Christensen, Erika Frischknecht/H-8753-2017	Høyer, Christian Bjerre/0000-0001-5917-1777; Christensen, Erika Frischknecht/0000-0003-3673-9694				Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lockey D, 2001, BRIT MED J, V323, P141, DOI 10.1136/bmj.323.7305.141; Sethi D, 2003, COCHRANE LIB	3	19	21	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					533	534		10.1136/bmj.327.7414.533	http://dx.doi.org/10.1136/bmj.327.7414.533			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958112	Green Published, Bronze			2022-12-28	WOS:000185283700017
J	Lea, DW; Pak, DK; Peterson, LC; Hughen, KA				Lea, DW; Pak, DK; Peterson, LC; Hughen, KA			Synchroneity of tropical and high-latitude Atlantic temperatures over the last glacial termination	SCIENCE			English	Article							ABRUPT CLIMATE-CHANGE; ANOXIC CARIACO BASIN; THERMOHALINE CIRCULATION; PLANKTONIC-FORAMINIFERA; ATMOSPHERIC METHANE; OCEAN; GREENLAND; SEA; RADIOCARBON; CALIBRATION	A high-resolution western tropical Atlantic sea surface temperature (SST) record from the Cariaco Basin on the northern Venezuelan shelf, based on Mg/Ca values in surface-dwelling planktonic foraminifera, reveals that changes in SST over the last glacial termination are synchronous, within +/-30 to +/-90 years, with the Greenland Ice Sheet Project 2 air temperature proxy record and atmospheric methane record. The most prominent deglacial event in the Cariaco record occurred during the Younger Dryas time interval, when SSTs dropped by 3degrees to 4degrees C. A rapid southward shift in the atmospheric intertropical convergence zone could account for the synchroneity of tropical temperature, atmospheric methane, and high-latitude changes during the Younger Dryas.	Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of Miami; Woods Hole Oceanographic Institution	Lea, DW (corresponding author), Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA.	lea@geol.ucsb.edu						Anand P, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000846; Anderson, 1996, GEOLOGICAL SOC SPECI, V116, P171, DOI [10.1144/GSL.SP.1996.116.01.15, DOI 10.1144/GSL.SP.1996.116.01.15]; Baker PA, 2001, SCIENCE, V291, P640, DOI 10.1126/science.291.5504.640; Bard E, 2000, SCIENCE, V289, P1321, DOI 10.1126/science.289.5483.1321; Black DE, 1999, SCIENCE, V286, P1709, DOI 10.1126/science.286.5445.1709; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Brook EJ, 1999, GEOPH MONOG SERIES, V112, P165; Dallenbach A, 2000, GEOPHYS RES LETT, V27, P1005, DOI 10.1029/1999GL010873; Dekens PS, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000200; Gadgil S, 2003, ANNU REV EARTH PL SC, V31, P429, DOI 10.1146/annurev.earth.31.100901.141251; Haug GH, 2001, SCIENCE, V293, P1304, DOI 10.1126/science.1059725; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; Kennett JP, 2003, METHANE HYDRATES QUA; Kienast M, 2001, SCIENCE, V291, P2132, DOI 10.1126/science.1057131; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; LEA DW, UNPUB; Lin HL, 1997, PALEOCEANOGRAPHY, V12, P415, DOI 10.1029/97PA00230; OVERPECK JT, 1989, NATURE, V338, P553, DOI 10.1038/338553a0; Peterson LC, 1991, PALEOCEANOGRAPHY, V6, P99, DOI 10.1029/90PA02497; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Rosenthal Y, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016612; Ruhlemann C, 1999, NATURE, V402, P511, DOI 10.1038/990069; Schiller A, 1997, CLIM DYNAM, V13, P325, DOI 10.1007/s003820050169; Severinghaus JP, 1998, NATURE, V391, P141, DOI 10.1038/34346; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; TEDESCO KA, IN PRESS J FORAMINIF; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; Vellinga M, 2002, CLIMATIC CHANGE, V54, P251, DOI 10.1023/A:1016168827653; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	33	339	351	2	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1361	1364		10.1126/science.1088470	http://dx.doi.org/10.1126/science.1088470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958356				2022-12-28	WOS:000185116400036
J	Wegner, KM; Kalbe, M; Kurtz, J; Reusch, TBH; Milinski, M				Wegner, KM; Kalbe, M; Kurtz, J; Reusch, TBH; Milinski, M			Parasite selection for immunogenetic optimality	SCIENCE			English	Article							MHC; STICKLEBACKS		Max Planck Inst Limnol, Dept Evolutionary Ecol, D-24306 Plon, Germany	Max Planck Society	Wegner, KM (corresponding author), Max Planck Inst Limnol, Dept Evolutionary Ecol, August Thienemann Str 2, D-24306 Plon, Germany.	wegner@mpil-ploen.mpg.de	Reusch, Thorsten B.H./G-4141-2011; Reusch, Thorsten B. H./B-9311-2019; Wegner, Mathias/B-6674-2009; Kurtz, Joachim/A-9678-2008; Wegner, K. Mathias/P-1149-2015	Kurtz, Joachim/0000-0002-7258-459X; Wegner, K. Mathias/0000-0002-2410-8898; Reusch, Thorsten B. H./0000-0002-8961-4337				Bernatchez L, 2003, J EVOLUTION BIOL, V16, P363, DOI 10.1046/j.1420-9101.2003.00531.x; DEBOER RJ, 1993, P ROY SOC B-BIOL SCI, V252, P171, DOI 10.1098/rspb.1993.0062; Kalbe M, 2002, J FISH BIOL, V60, P1529, DOI [10.1111/j.1095-8649.2002.tb02445.x, 10.1006/jfbi.2002.2013]; NOWAK MA, 1992, P NATL ACAD SCI USA, V89, P10896, DOI 10.1073/pnas.89.22.10896; Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499; Reusch TBH, 2001, NATURE, V414, P300, DOI 10.1038/35104547; VIDOVIC D, 1988, NATURE, V336, P222, DOI 10.1038/336222a0; Wegner KM, 2003, J EVOLUTION BIOL, V16, P224, DOI 10.1046/j.1420-9101.2003.00519.x; Wootton R.J., 1976, BIOL STICKLEBACKS	9	238	241	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1343	1343		10.1126/science.1088293	http://dx.doi.org/10.1126/science.1088293			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958352				2022-12-28	WOS:000185116400029
J	Clark, HW				Clark, HW			Office-based practice and opioid-use disorders	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Subst Abuse & Mental Hlth Serv Adm, Ctr Subst Abuse Treatment, US Dept HHS, Rockville, MD USA		Clark, HW (corresponding author), Subst Abuse & Mental Hlth Serv Adm, Ctr Subst Abuse Treatment, US Dept HHS, Rockville, MD USA.							Gibson AE, 2003, MED J AUSTRALIA, V179, P38, DOI 10.5694/j.1326-5377.2003.tb05417.x; Gueye PN, 2002, ADDICTION, V97, P1295, DOI 10.1046/j.1360-0443.2002.00189.x; *SUBST AB MENT HLT, 2003, NHSDA REP NONM US PR; *SUBST AB MENT HLT, 2002, DAWN SER D, V21	4	19	19	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					928	930		10.1056/NEJMp038126	http://dx.doi.org/10.1056/NEJMp038126			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717HJ	12954740				2022-12-28	WOS:000185081400003
J	Marty, B; Dewonck, S; France-Lanord, C				Marty, B; Dewonck, S; France-Lanord, C			Geochemical evidence for efficient aquifer isolation over geological timeframes	NATURE			English	Article							PARIS BASIN; RHINE GRABEN; NOBLE-GASES; HELIUM; GROUNDWATER; ORIGIN; WATER; FLUXES; FLUIDS; FRANCE	Aquitards-layers of rock having low permeability-have been suggested as potential long-term reservoirs for toxic materials such as nuclear or chemical waste. But information about the isolation properties of aquitard layers is essential to evaluate whether they can indeed be used safely as reservoirs. Here we investigate the long-term mobility of groundwaters between two aquifers surrounding an aquitard layer in the eastern recharge area of the Paris basin, France, using helium isotopes as a geochemical tracer. The deeper Trias sandstone aquifer, which lies above the crystalline basement, accumulates radiogenic He-4 and primordial He-3 from large regions of the crust and mantle at rates comparable to the degassing of the whole crust(1) and of mid-ocean ridges(2). We show that the overlying carbonate Dogger aquifer, which is separated from the Trias aquifer by an aquitard layer consisting of a similar to600 m succession of shales and clays, is stagnant and has been extremely well isolated from the Trias over the past several million years. This finding, together with previous studies at the centre of the Paris basin(3,4), shows that diffusive mass transfer across aquitards is negligible and that cross-formational flow in basins takes place preferentially in faulted areas.	Ctr Rech Petrog & Geochim, F-54501 Vandoeuvre Les Nancy, France; Ecole Natl Super Geol, F-54501 Vandoeuvre Les Nancy, France	Universite de Lorraine; Universite de Lorraine	Marty, B (corresponding author), Ctr Rech Petrog & Geochim, 15 Rue Notre Dame Pauvres, F-54501 Vandoeuvre Les Nancy, France.	bmarty@crpg.cnrs-nancy.fr	France-Lanord, Christian/F-8848-2010	France-Lanord, Christian/0000-0002-4873-5546				*ANDRA, 2002, 9ANT01010B B RP ANDR, P1; ANDREWS JN, 1985, EARTH PLANET SC LETT, V73, P317, DOI 10.1016/0012-821X(85)90080-9; [Anonymous], 1964, RECENT RES FIELDS HY, P263; Ballentine CJ, 2002, REV MINERAL GEOCHEM, V47, P539, DOI 10.2138/rmg.2002.47.13; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; BLAVOUX B, 1981, J HYDROL, V54, P167, DOI 10.1016/0022-1694(81)90158-X; Castro MC, 1998, WATER RESOUR RES, V34, P2443, DOI 10.1029/98WR01956; CRAIG H, 1975, EARTH PLANET SC LETT, V26, P125, DOI 10.1016/0012-821X(75)90079-5; FONTES JC, 1979, WATER RESOUR RES, V15, P399, DOI 10.1029/WR015i002p00399; GRIESSHABER E, 1992, CHEM GEOL, V99, P213, DOI 10.1016/0009-2541(92)90178-8; KELLOGG LH, 1990, EARTH PLANET SC LETT, V99, P276, DOI 10.1016/0012-821X(90)90116-F; Kloppmann W, 2001, APPL GEOCHEM, V16, P1083, DOI 10.1016/S0883-2927(01)00008-7; MARINE IW, 1979, WATER RESOUR RES, V15, P1130, DOI 10.1029/WR015i005p01130; MARTY B, 1993, WATER RESOUR RES, V29, P1025, DOI 10.1029/93WR00007; MATRAY JM, 1994, APPL GEOCHEM, V9, P297, DOI 10.1016/0883-2927(94)90040-X; Megnien C., 1980, MEMOIRES DU BRGM, V101, P1; MENJOZ A, 1994, PHIL T R SOC LOND A, V344, P141; OHSUMI T, 1984, EARTH PLANET SC LETT, V70, P61, DOI 10.1016/0012-821X(84)90209-7; Ozima M., 2022, NOBLE GAS GEOCHEMIST; PINTI DL, 1995, GEOCHIM COSMOCHIM AC, V59, P3389, DOI 10.1016/0016-7037(95)00213-J; Pinti DL, 1998, GEOL SOC SPEC PUBL, V144, P53, DOI 10.1144/GSL.SP.1998.144.01.05; Rebour V, 1997, J CONTAM HYDROL, V28, P71, DOI 10.1016/S0169-7722(96)00051-4; Richard D, 1996, SCIENCE, V273, P93, DOI 10.1126/science.273.5271.93; ROUSSET D, 1993, TECTONOPHYSICS, V221, P135, DOI 10.1016/0040-1951(93)90329-I; Tolstikhin I, 1996, GEOCHIM COSMOCHIM AC, V60, P1497, DOI 10.1016/0016-7037(96)00036-1; TORGERSEN T, 1985, GEOCHIM COSMOCHIM AC, V49, P1211, DOI 10.1016/0016-7037(85)90011-0; TORGERSEN T, 1989, CHEM GEOL, V79, P1, DOI 10.1016/0168-9622(89)90002-X; UNGEMACH T, 1984, HYDROLOGIE GEOLOGIE, V1, P11; WORDEN RH, 1995, BASIN RES, V7, P53, DOI 10.1111/j.1365-2117.1995.tb00095.x; WORNER G, 1984, J PETROL, V25, P836, DOI 10.1093/petrology/25.4.836	30	52	52	4	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					55	58		10.1038/nature01966	http://dx.doi.org/10.1038/nature01966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955137				2022-12-28	WOS:000185089200034
J	Rao, SG; Huang, L; Setyawan, W; Hong, SH				Rao, SG; Huang, L; Setyawan, W; Hong, SH			Large-scale assembly of carbon nanotubes	NATURE			English	Editorial Material									Florida State Univ, Ctr Mat Res & Technol, Dept Phys, Tallahassee, FL 32306 USA; Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University; State University System of Florida; Florida State University	Hong, SH (corresponding author), Florida State Univ, Ctr Mat Res & Technol, Dept Phys, Tallahassee, FL 32306 USA.	shong@phya.snu.ac.kr	Hong, Seunghun/B-2545-2012; Huang, Ling/G-6200-2010	Huang, Ling/0000-0003-1244-3522				Bockrath M, 2001, SCIENCE, V291, P283, DOI 10.1126/science.291.5502.283; Chen XQ, 2001, APPL PHYS LETT, V78, P3714, DOI 10.1063/1.1377627; Fuhrer MS, 2000, SCIENCE, V288, P494, DOI 10.1126/science.288.5465.494; Hone J, 2000, APPL PHYS LETT, V77, P666, DOI 10.1063/1.127079; Hong SH, 2000, SCIENCE, V288, P1808, DOI 10.1126/science.288.5472.1808; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Kong J, 1998, NATURE, V395, P878, DOI 10.1038/27632; Lee J, 2002, NATURE, V415, P1005, DOI 10.1038/4151005a; Liu J, 1999, CHEM PHYS LETT, V303, P125, DOI 10.1016/S0009-2614(99)00209-2; Manandhar P, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.115505; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; XIA YN, 1995, J AM CHEM SOC, V117, P3274, DOI 10.1021/ja00116a033; Zhang M, 2002, NANOTECHNOLOGY, V13, P212, DOI 10.1088/0957-4484/13/2/315	13	409	449	6	153	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					36	37		10.1038/425036a	http://dx.doi.org/10.1038/425036a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955130				2022-12-28	WOS:000185089200027
J	Inui, TS				Inui, TS			The need for an integrated biopsychosocial approach to research on successful aging	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				OLDER JAPANESE-AMERICANS; KAME-PROJECT; KING COUNTY; COHORT	Successful aging is defined not by longevity alone but also by sufficient well-being (in multiple domains) to sustain a capacity for functioning adequately in changing circumstances. The determinants of such well-being and functional status are manifold and include the genetic endowment, physical environment, social environment, population and individual responses to challenges, the occurrence of disease, availability and effectiveness of health care, and personal prosperity. In the face of such complexity, scientific approaches to the phenomena associated with successful aging should be appreciative and wholistic as well as reductionistic. Such a "natural science" of aging will be required to uncover and use information about linear, cause-and-effect phenomena, as well as about higher-order emergent patterns that are of relevance to the health of elderly persons, such as "resilience" and "generativity." Taken as a whole, this multimethod research agenda will truly express an integrated biopsychosocial approach to research on successful aging.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	Inui, TS (corresponding author), Regenstrief Inst Hlth Care, 1050 Wishard Blvd RG-6, Indianapolis, IN 46202 USA.							Bond GE, 2001, INT PSYCHOGERIATR, V13, P207, DOI 10.1017/S1041610201007591; DURCH JS, 1997, IMPROVING HLTH COMMU; Evans R. G., 1994, WHY ARE SOME PEOPLE; Gleick J., 1988, CHAOS MAKING NEW SCI; GLOUBERMAN S, NEW PERSPECTIVE HLTH; Goldensohn E, 2002, NAT HIST, V111, P6; Graves AB, 1996, AM J EPIDEMIOL, V144, P760, DOI 10.1093/oxfordjournals.aje.a009000; Graves AB, 1999, J GERONTOL B-PSYCHOL, V54, pS154, DOI 10.1093/geronb/54B.3.S154; Halfon N, 2002, MILBANK Q, V80, P433, DOI 10.1111/1468-0009.00019; McCormick WC, 1996, J AM GERIATR SOC, V44, P769, DOI 10.1111/j.1532-5415.1996.tb03732.x; PLSEK P, 2001, I MED COMMITTEE QUAL, P322; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Vaughn G, 2000, J AM GERIATR SOC, V48, P554, DOI 10.1111/j.1532-5415.2000.tb05003.x	14	40	42	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			391	394		10.7326/0003-4819-139-5_Part_2-200309021-00002	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965963				2022-12-28	WOS:000185133800002
J	Syme, SL				Syme, SL			Psychosocial interventions to improve successful aging	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				CORONARY HEART-DISEASE; RISK FACTOR CHANGES; HEALTH-PROGRAM; NORTH KARELIA; COMMUNITY; TRIAL; MORTALITY; EDUCATION; PROJECT; FINLAND	Interventions designed to encourage people to change high-risk behavior have not been very successful. This is an important challenge because the number of older people in the population will double within the next 20 to 30 years. The increase will put enormous strain on an already overburdened medical care system. We therefore will need to put more emphasis on disease prevention programs. Helping people change high-risk behavior will be the key to prevention. To develop more effective prevention programs, we will have to train a new generation of experts who can not only provide people with risk information but also work with them as partners in achieving mutually agreed upon goals.	Univ Calif Berkeley, Sch Publ Hlth, Div Publ Hlth Biol & Epidemiol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Syme, SL (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Publ Hlth Biol & Epidemiol, 140 Warren Hall, Berkeley, CA 94720 USA.	slsyme@uclink4.berkeley.edu						FARQUHAR JW, 1990, JAMA-J AM MED ASSOC, V264, P359, DOI 10.1001/jama.264.3.359; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LEFEBVRE RC, 1987, PREV MED, V16, P80, DOI 10.1016/0091-7435(87)90008-9; LUEPKER RV, 1994, AM J PUBLIC HEALTH, V84, P1383, DOI 10.2105/AJPH.84.9.1383; LYNN WR, 1995, AM J PUBLIC HEALTH, V85, P193; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; Salomaa V, 1996, CIRCULATION, V94, P3130, DOI 10.1161/01.CIR.94.12.3130; SLATER MD, 1996, J HEALTH COMMUN, V1, P262; Smedley BD, 2000, PROMOTING HLTH INTER, P1; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; ZUKEL WJ, 1981, PREV MED, V10, P387, DOI 10.1016/0091-7435(81)90057-8	12	9	10	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			400	402		10.7326/0003-4819-139-5_Part_2-200309021-00004	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00004			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965965				2022-12-28	WOS:000185133800004
J	Crown, J				Crown, J			Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?	LANCET			English	Editorial Material							RANDOMIZED-TRIAL		St Vincents Univ Hosp, Dublin 4, Ireland	University College Dublin; Saint Vincent's University Hospital	Crown, J (corresponding author), St Vincents Univ Hosp, Dublin 4, Ireland.		Crown, John/AAL-3367-2020	Crown, John/0000-0002-3125-7613				Bergh J, 2000, LANCET, V356, P1384, DOI 10.1016/S0140-6736(00)02841-5; Bergh J, 2000, LANCET, V356, P2196; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; CROWN J, 1995, ANN ONCOL         S4, V6, pS21; CROWN J, 2003, P AN M AM SOC CLIN, V22, pA23; *EARL BREAST CANC, 1992, LANCET, V339, P1; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; HRYNIUK W, 1984, J CLIN ONCOL, V2, P81; Nabholtz JM PT, 2002, P AN M AM SOC CLIN, V21, p36a; NITZ UA, 2003, P AN M AM SOC CLIN, V22, pA832; NORTON L, 1988, CANCER RES, V48, P7067; RODENHUIS S, 2003, P ASCO, V22, pA6; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101	13	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					677	678		10.1016/S0140-6736(03)14242-0	http://dx.doi.org/10.1016/S0140-6736(03)14242-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957087				2022-12-28	WOS:000185034800005
J	Belonoshko, AB; Ahuja, R; Johansson, B				Belonoshko, AB; Ahuja, R; Johansson, B			Stability of the body-centred-cubic phase of iron in the Earth's inner core	NATURE			English	Article							SITU X-RAY; HIGH-PRESSURE; IN-SITU; MELTING CURVE; TEMPERATURES; ELASTICITY; DIAGRAM	Iron is thought to be the main constituent of the Earth's core(1), and considerable efforts(2-14) have therefore been made to understand its properties at high pressure and temperature. While these efforts have expanded our knowledge of the iron phase diagram, there remain some significant inconsistencies, the most notable being the difference between the 'low' and 'high' melting curves(15). Here we report the results of molecular dynamics simulations of iron based on embedded atom models fitted to the results of two implementations of density functional theory. We tested two model approximations and found that both point to the stability of the body-centred-cubic (b.c.c.) iron phase at high temperature and pressure. Our calculated melting curve is in agreement with the 'high' melting curve, but our calculated phase boundary between the hexagonal close packed (h. c. p.) and b.c.c. iron phases is in good agreement with the 'low' melting curve. We suggest that the h.c.p.-b.c.c. transition was previously misinterpreted as a melting transition, similar to the case of xenon(16-18), and that the b.c.c. phase of iron is the stable phase in the Earth's inner core.	Royal Inst Technol, Dept Mat Sci & Engn, SE-10044 Stockholm, Sweden; Royal Inst Technol, Dept Phys, Stockholm Ctr Phys Astron & Biotechnol, Condensed Matter Theory Grp, SE-10691 Stockholm, Sweden; Uppsala Univ, Dept Phys, Condensed Matter Theory Grp, SE-75121 Uppsala, Sweden	Royal Institute of Technology; Royal Institute of Technology; Uppsala University	Belonoshko, AB (corresponding author), Royal Inst Technol, Dept Mat Sci & Engn, SE-10044 Stockholm, Sweden.	anatoly@fysik.uu.se	Belonoshko, Anatoly/AAC-4815-2021	Ahuja, Rajeev/0000-0003-1231-9994; Belonoshko, Anatoly/0000-0001-7531-3210				Alfe D, 2002, J CHEM PHYS, V116, P6170, DOI 10.1063/1.1460865; Alfe D, 1999, NATURE, V401, P462, DOI 10.1038/46758; Andrault D, 1997, SCIENCE, V278, P831, DOI 10.1126/science.278.5339.831; Belonoshko AB, 2000, PHYS REV LETT, V84, P3638, DOI 10.1103/PhysRevLett.84.3638; Belonoshko AB, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.165505; BIRCH F, 1952, J GEOPHYS RES, V57, P227, DOI 10.1029/JZ057i002p00227; BOEHLER R, 1993, NATURE, V363, P534, DOI 10.1038/363534a0; Boehler R, 2001, PHYS REV LETT, V86, P5731, DOI 10.1103/PhysRevLett.86.5731; Boness DA, 2000, AIP CONF PROC, V505, P77, DOI 10.1063/1.1303425; BROWN JM, 1986, J GEOPHYS RES-SOLID, V91, P7485, DOI 10.1029/JB091iB07p07485; Dubrovinsky LS, 2000, PHYS REV LETT, V84, P1720, DOI 10.1103/PhysRevLett.84.1720; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Errandonea D, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.214110; Hemley RJ, 2001, INT GEOL REV, V43, P1; Laio A, 2000, SCIENCE, V287, P1027, DOI 10.1126/science.287.5455.1027; Matsui M, 1997, PHYS EARTH PLANET IN, V103, P55, DOI 10.1016/S0031-9201(97)00020-4; NGUYEN J, 1998, EOS T AM GEOPHYS UN, V79, pF846; Pinsook U, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.024109; ROSS M, 1990, J GEOPHYS RES-SOLID, V95, P21713, DOI 10.1029/JB095iB13p21713; SAXENA SK, 1995, SCIENCE, V269, P1703, DOI 10.1126/science.269.5231.1703; Shen GY, 1998, GEOPHYS RES LETT, V25, P373, DOI 10.1029/97GL03776; Singh SC, 2000, SCIENCE, V287, P2471, DOI 10.1126/science.287.5462.2471; Soderlind P, 1996, PHYS REV B, V53, P14063, DOI 10.1103/PhysRevB.53.14063; Steinle-Neumann G, 2001, NATURE, V413, P57, DOI 10.1038/35092536; STIXRUDE L, 1994, PHYS REV B, V50, P6442, DOI 10.1103/PhysRevB.50.6442; WILLIAMS Q, 1991, J GEOPHYS RES-SOLID, V96, P2171, DOI 10.1029/90JB01999; YOO CS, 1995, SCIENCE, V270, P1473, DOI 10.1126/science.270.5241.1473; YOO CS, 1993, PHYS REV LETT, V70, P3931, DOI 10.1103/PhysRevLett.70.3931	28	174	188	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1032	1034		10.1038/nature01954	http://dx.doi.org/10.1038/nature01954			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944963				2022-12-28	WOS:000184984200037
J	Abrams, DM; Strogatz, SH				Abrams, DM; Strogatz, SH			Linguistics - Modelling the dynamics of language death	NATURE			English	Editorial Material									Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA	Cornell University	Abrams, DM (corresponding author), Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA.		Strogatz, Steven H/A-1641-2014; Abrams, Daniel M/F-2297-2011; Abrams, Daniel M/H-5532-2012	Strogatz, Steven H/0000-0003-2923-3118; Abrams, Daniel M/0000-0002-6015-8358; 				Aitchison John, 1994, GEOGRAPHY WELSH LANG; [Anonymous], 1984, GAELIC SCOTLAND 1698; Chomsky N., 2002, JANUA LINGUARUM; FISHMAN JOSHUA A, 1991, MULTILINGUAL MATTERS, V76; Hawkins J. A., 1992, EVOLUTION HUMAN LANG, VXI; KRAUSS M, 1992, LANGUAGE, V68, P4, DOI 10.1353/lan.1992.0075; Kroch A., 1989, J LANGUAGE VARIATION, V1, P199, DOI [DOI 10.1017/S0954394500000168, 10.1017/S0954394500000168]; Lightfoot D, 1999, DEV LANGUAGE ACQUISI; Niyogi P, 1997, LINGUIST PHILOS, V20, P697, DOI 10.1023/A:1005319718167; Nowak MA, 2002, NATURE, V417, P611, DOI 10.1038/nature00771; *UK OFF POP CENS S, 1993, 1991 CENS REP WAL, V1	11	288	302	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					900	900		10.1038/424900a	http://dx.doi.org/10.1038/424900a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931177				2022-12-28	WOS:000184843600030
J	Greenland, P; Knoll, MD; Stamler, J; Neaton, JD; Dyer, AR; Garside, DB; Wilson, PW				Greenland, P; Knoll, MD; Stamler, J; Neaton, JD; Dyer, AR; Garside, DB; Wilson, PW			Major risk factors as antecedents of fatal and nonfatal coronary heart disease events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; CHOLESTEROL LEVELS; CURRENT KNOWLEDGE; FOLLOW-UP; MORTALITY; ASSOCIATION; PREDICTION; BURDEN	Context A frequently cited concept is that individual major risk factors for coronary heart disease (CHD) are absent in many patients (perhaps >50%) with CHD. However, prior studies have not systematically evaluated the extent to which CHD patients have previous exposure to at least 1 risk factor, including diabetes, cigarette smoking, or clinically elevated levels of cholesterol or blood pressure. Objective To determine the, frequency of exposure to major CHD risk factors. Design, Setting, and Participants Three prospective cohort studies were included: the Chicago Heart Association Detection Project in Industry, with a population sample of 35642 employed men and women aged 18 to 59 years; screenees for the Multiple Risk Factor Intervention Trial, including 347978 men aged 35 to 57 years; and a population-based sample of 3295 men and women aged 34 to 59 years from the Framingham Heart Study (FHS). Follow-up lasted 21 to 30 years across the studies. Main Outcome Measures Fatal CHD in all cohorts and nonfatal myocardial infarction (MI) in the FHS, compared by exposure to major CHD risk factors, defined as total cholesterol of at least 240 mg/dL (greater than or equal to6.22 mmol/L), systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, cigarette smoking, and diabetes. Participants were stratified by sex and age (18-39 vs 40-59 years). Results For fatal CHD (n=20995), exposure to at least 1 clinically elevated major risk factor ranged from 87% to 100%. Among those aged 40 to 59 years at baseline with fatal CHD (n=19263), exposure to at least 1 major risk factor ranged from 87% to 94%. For nonfatal MI, prior exposure was documented in 92% (95% Cl, 87%-96%) (n=167) of men aged 40 to 59 years at baseline and in 87% (95% Cl, 80%-94%) (n=94) of women in this age group. Conclusions Antecedent major CHD risk factor exposures were very common among those who developed CHD, emphasizing the importance of considering all major risk factors in determining CHD risk estimation and in attempting to prevent clinical CHD. These results challenge claims that CHD events commonly occur in persons without exposure to at least 1 major CHD risk factor.	Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA; Boston Univ, Sch Med, Boston, MA 02118 USA	Northwestern University; Feinberg School of Medicine; University of Minnesota System; University of Minnesota Twin Cities; Boston University	Greenland, P (corresponding author), 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.	p-greenland@northwestern.edu	Greenland, Philip/ABD-5528-2021; Wilson, Peter W.F./J-2455-2016	Deloria Knoll, Maria/0000-0001-9041-2671	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068140, R01HL021010] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; AGMON J, 1992, CIRCULATION, V86, P839; Barker MH, 1939, AM HEART J, V18, P95; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; Grundy SM, 1999, CIRCULATION, V100, P1481, DOI 10.1161/01.CIR.100.13.1481; Hennekens CH, 1998, CIRCULATION, V97, P1095, DOI 10.1161/01.CIR.97.11.1095; JOHNSON NL, 1969, DISCRETE DISTRIBUTIO, P58; Lefkowitz RJ, 2001, JAMA-J AM MED ASSOC, V285, P581, DOI 10.1001/jama.285.5.581; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; Mosca L, 2002, NEW ENGL J MED, V347, P1615, DOI 10.1056/NEJMe020127; Nelson N, 1944, J BIOL CHEM, V153, P375; *NIH, 1974, PUBL NIH, P1; Pasternak RC, 1996, J AM COLL CARDIOL, V27, P978, DOI 10.1016/0735-1097(96)87731-X; Ridker PM, 1999, ANN INTERN MED, V130, P933, DOI 10.7326/0003-4819-130-11-199906010-00018; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; ROSE G, 1982, BRIT MED J, V284, P1600, DOI 10.1136/bmj.284.6329.1600; ROSENMAN RH, 1974, MED CLIN N AM, V58, P269, DOI 10.1016/S0025-7125(16)32158-7; RUBINS HB, 1995, AM J CARDIOL, V75, P1196, DOI 10.1016/S0002-9149(99)80761-9; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; The Inter-Society Commission for Heart Disease Resources, 1970, CIRCULATION, V42, pA55; Vasan RS, 2002, CIRCULATION, V105, P48, DOI 10.1161/hc0102.101774; Wilson PWF, 1997, NEW ENGL J MED, V337, P516, DOI 10.1056/NEJM199708213370802; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Winkelmann BR, 2000, AM HEART J, V140, pS11, DOI 10.1067/mhj.2000.109636; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488	29	700	738	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					891	897		10.1001/jama.290.7.891	http://dx.doi.org/10.1001/jama.290.7.891			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928465	Bronze			2022-12-28	WOS:000184828800025
J	Kwiterovich, PO; Vining, EPG; Pyzik, P; Skolasky, R; Freeman, JM				Kwiterovich, PO; Vining, EPG; Pyzik, P; Skolasky, R; Freeman, JM			Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; A-I; CHOLESTEROL; EFFICACY; DISEASE; HEALTH; ARTERY	Context Little prospective long-term information is available on the effect of a ketogenic diet on plasma lipoproteins in children with difficult-to-control seizures. Objective To determine the effect in children with intractable seizures of a high-fat ketogenic diet on plasma levels of the major apolipoprotein B (apoB)-containing lipoproteins, low-density lipoprotein (LDL) and very LDL (VLDL); and the major apolipoprotein A-I (apoA-I)-containing lipoprotein, high-density lipoprotein (HDL). Design, Setting, and Patients A 6-month prospective cohort study of 141 children (mean [SD] age, 5.2 [3.8] years for 70 boys and 6.1 [4.4] years for 71 girls) with difficult-to-treat seizures who were hospitalized for initiation of a high-fat ketogenic diet and followed up as outpatients. This cohort constituted a subgroup of the 371 patients accepted into the ketogenic diet program between 1994 and 2001. A subset of the cohort was also studied after 12 (n = 59) and 24 (n = 27) months. Intervention A ketogenic diet consisting of a high ratio of fat to carbohydrate and protein combined (4:1 [n = 102], 3.5:1 [n = 7], or 3:1 [n = 32]). After diet initiation, the calories and ratio were adjusted to maintain ideal body weight for height and maximal urinary ketosis for seizure control. Main Outcome Measures Differences at baseline and 6-month follow-up for levels of total, VLDL, LDL, HDL, and non-HDL cholesterol; triglycerides; total apoB; and apoA-I., Results At 6 months, the high-fat ketogenic diet significantly increased the mean plasma levels of total (58 mg/dL [1.50 mmol/L]), LDL (50 mg/dL (1.30 mmol/L]), VLDL (8 mg/dL [0.21 mmol/L]), and non-HDL cholesterol (63 mg/dL [1.63 mmol/L]) (P<.001 vs baseline for each); triglycerides (58 mg/dL [0.66 mmol/L]) (P<.001); and total apoB (49 mg/dL) (P<.001). Mean HDL cholesterol decreased significantly (P<.001), although apoA-I increased (4 mg/dL) (P =.23). Significant but less marked changes persisted in children observed after 12 and 24 months. Conclusions A high-fat ketogenic diet produced significant increases in the atherogenic apoB-containing lipoproteins and a decrease in the antiatherogenic HDL cholesterol. Further studies are necessary to determine if such a diet adversely affects endothelial vascular function and promotes inflammation and formation of atherosclerotic lesions.	Johns Hopkins Med Inst, Dept Neurol, Lipid Res Atherosclerosis Div, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Neurol, Pediat Epilepsy Ctr, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Kwiterovich, PO (corresponding author), Johns Hopkins Univ, Lipid Clin, Lipid Res Atherosclerosis Div, 550 N Broadway,Suite 308, Baltimore, MD 21205 USA.	pkwitero@jhmi.edu		Skolasky, Richard/0000-0002-2598-4427	NCRR NIH HHS [M01-RR-00052] Funding Source: Medline; NICHD NIH HHS [N01-HD-7-3268] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073268] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Anderson JW, 2000, J AM COLL NUTR, V19, P578, DOI 10.1080/07315724.2000.10718955; BACHORIK PS, 1994, CLIN CHEM, V40, P1915; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Chesney D, 1999, CLIN PEDIATR, V38, P107, DOI 10.1177/000992289903800207; CORTNER JA, 1990, J PEDIATR-US, V116, P514, DOI 10.1016/S0022-3476(05)81595-1; de Jongh S, 2002, ATHEROSCLEROSIS, V163, P193, DOI 10.1016/S0021-9150(02)00003-5; DEKABAN AS, 1966, ARCH NEUROL-CHICAGO, V15, P177, DOI 10.1001/archneur.1966.00470140067009; DIGGLE PJ, 1994, OXFORD STAT SCI SERI, V13; *EXP PAN BLOOD CHO, 1992, PEDIATRICS, V89, P524; Freeman J. M., 2000, KETOGENIC DIET TREAT; Freeman JM, 1998, PEDIATRICS, V102, P1358, DOI 10.1542/peds.102.6.1358; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gilbert DL, 2000, J CHILD NEUROL, V15, P787, DOI 10.1177/088307380001501203; Hemingway C, 2001, PEDIATRICS, V108, P898, DOI 10.1542/peds.108.4.898; HUTTENLOCHER PR, 1976, PEDIATR RES, V10, P536, DOI 10.1203/00006450-197605000-00006; Katyal NG, 2000, CLIN PEDIATR, V39, P153, DOI 10.1177/000992280003900303; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; Kwiterovich PO, 2002, AM J CARDIOL, V90, p30I; Kwiterovich PO, 2002, AM J CARDIOL, V90, p1I, DOI 10.1016/S0002-9149(02)02796-0; Lefevre F, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e46; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; Rice JA, 1988, MATH STAT DATA ANAL; SCHWARTZ RM, 1989, DEV MED CHILD NEUROL, V31, P152; Schwartzkroin PA, 1999, EPILEPSY RES, V37, P171, DOI 10.1016/S0920-1211(99)00069-8; Sharman MJ, 2002, J NUTR, V132, P1879, DOI 10.1093/jn/132.7.1879; Shih WJ, 2000, CLIN CHEM, V46, P351; Srinivasan SR, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e29; SRINIVASAN SR, 1994, METABOLISM, V43, P1042, DOI 10.1016/0026-0495(94)90187-2; SRINIVASAN SR, 1995, CLIN CHEM, V41, P159; Stafstrom CE, 2000, NEUROLOGY, V54, P282, DOI 10.1212/WNL.54.2.282; Swink T D, 1997, Adv Pediatr, V44, P297; Urbina EM, 2002, AM J CARDIOL, V90, P953, DOI 10.1016/S0002-9149(02)02660-7; *US DEP HHS, 1980, PHS NIH PUBL; Vining EPG, 2002, DEV MED CHILD NEUROL, V44, P796, DOI 10.1017/S0012162201002961; Volek JS, 2000, J AM COLL NUTR, V19, P383, DOI 10.1080/07315724.2000.10718935; Willi SM, 1998, PEDIATRICS, V101, P61, DOI 10.1542/peds.101.1.61	38	190	201	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					912	920		10.1001/jama.290.7.912	http://dx.doi.org/10.1001/jama.290.7.912			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928468	Bronze			2022-12-28	WOS:000184828800028
J	Kerlikowske, K; Smith-Bindman, R; Ljung, BM; Grady, D				Kerlikowske, K; Smith-Bindman, R; Ljung, BM; Grady, D			Evaluation of abnormal mammography results and palpable breast abnormalities	ANNALS OF INTERNAL MEDICINE			English	Article							FINE-NEEDLE-ASPIRATION; PROBABLY BENIGN LESIONS; FOLLOW-UP MAMMOGRAPHY; MULTICENTER CLINICAL-TRIAL; SCREENING MAMMOGRAPHY; CORE-NEEDLE; DIAGNOSTIC-ACCURACY; PHYSICAL-EXAMINATION; HISTOPATHOLOGIC CORRELATION; CYTOLOGIC EXAMINATION	Background: Because approximately 1 in 10 women with a breast lump or abnormal mammography result will have breast cancer, a series of decisions must be taken by a primary care practitioner to exclude or establish a diagnosis of breast cancer among these women. Purpose: To determine the most accurate and least invasive means to evaluate an abnormal mammography result and a palpable breast abnormality. Data Source: MEDLINE search (January 1966 to March 2003) for articles and reviews describing the accuracy of clinical examination, biopsy procedures, and radiographic examination for patients with abnormal mammography results or palpable breast abnormalities. Study Selection: The authors reviewed abstracts and selected articles that provided relevant primary data. Studies were included if 1) mammography, fine-needle aspiration biopsy, or core-needle biopsy was performed before a definitive diagnosis was obtained; 2) the study sample included 100 or more women; and 3) breast cancer status was determined from histopathology review of excisional biopsy specimens, from linkage with a state cancer registry or the Surveillance, Epidemiology, and End Results program, or from clinical follow-up of 95% or more of the study sample. Data Extraction: One investigator abstracted results. Methods were evaluated for major potential biases, but methodologic scoring was not performed. Data Synthesis: Likelihood ratios for first screening mammography were 0.1 for the Breast Imaging Reporting and Data System (BI-RADS) assessment category "negative or benign finding," 1.2 for "probably benign finding," 7 for "need additional imaging evaluation," 125 for "suspicious abnormality," and 2200 for "highly suggestive of malignancy." For fine-needle aspiration biopsy of a palpable lump performed by formally trained physicians, the likelihood ratio was infinity for an assessment of "malignant," 2.6 for "atypical/suspicious," and 0.02 for "benign." When diagnostic mammography was used to evaluate a palpable lump or nonpalpable breast abnormality, the positive likelihood ratios were 5.6 and 9.4, and the negative likelihood ratios were 0.15 and 0.19, respectively. Conclusions: Women whose screening mammography results are interpreted as "suspicious abnormality" or "highly suggestive of malignancy" have a high risk for breast cancer and should undergo core-needle biopsy or needle localization with surgical biopsy. Women whose screening mammography results are interpreted as "need additional imaging evaluation" have a moderate risk for breast cancer and should undergo diagnostic mammography or ultrasonography to decide whether a nonpalpable breast lesion should be biopsied. Women whose screening mammography results are interpreted as "probably benign finding" have a low risk for breast cancer and can undergo follow-up mammography in 6 months. Either fine-needle aspiration biopsy or ultrasonography is recommended as the first diagnostic test of a palpable breast abnormality to distinguish simple cysts from solid masses. Fine-needle aspiration biopsy also allows characterization of a solid mass. Diagnostic mammography does not help determine whether a palpable breast mass should be biopsied and should not affect the decision to perform a biopsy.	Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kerlikowske, K (corresponding author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	kerliko@itsa.ucsf.edu			NATIONAL CANCER INSTITUTE [P50CA058207, U01CA063740] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA63740, P50 CA58207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abati A, 1997, DIAGN CYTOPATHOL, V16, P295; *AM AC FAM PHYS, 2002, AG CHARTS PER HLTH E; American College of Radiology, 1998, AM COLL RAD BREAST I; Andreu FJ, 1998, EUR RADIOL, V8, P1468, DOI 10.1007/s003300050577; [Anonymous], 2002, SEER CANC STAT REV 1; ANTLEY CM, 1998, BREAST J, V4, P3; Apesteguia L, 1997, EUR RADIOL, V7, P1235, DOI 10.1007/s003300050282; Ariga R, 2002, AM J SURG, V184, P410, DOI 10.1016/S0002-9610(02)01014-0; BAINES CJ, 1989, CANCER, V63, P1816; Ballo MS, 1996, CANCER, V78, P773; Barlow WE, 2002, J NATL CANCER I, V94, P1151; Barton MB, 1999, JAMA-J AM MED ASSOC, V282, P1270, DOI 10.1001/jama.282.13.1270; Barton MB, 1999, ANN INTERN MED, V130, P651, DOI 10.7326/0003-4819-130-8-199904200-00005; Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; Bobo JK, 2000, J NATL CANCER I, V92, P971, DOI 10.1093/jnci/92.12.971; BROWN ML, 1995, RADIOLOGY, V195, P529, DOI 10.1148/radiology.195.2.7724778; Burkhardt JH, 1999, RADIOLOGY, V212, P181, DOI 10.1148/radiology.212.1.r99jl46181; *CAN ASS RAD ONC, 1998, CMAJ S3, V158, pS3; CARIAGGI MP, 1995, CYTOPATHOLOGY, V6, P156, DOI 10.1111/j.1365-2303.1995.tb00468.x; Carney PA, 2003, ANN INTERN MED, V138, P168, DOI 10.7326/0003-4819-138-3-200302040-00008; Chaiwun B, 2002, DIAGN CYTOPATHOL, V26, P201, DOI 10.1002/dc.10067; Ciatto S, 1997, ACTA RADIOL, V38, P815; CIATTO S, 1987, ACTA CYTOL, V31, P301; Ciatto S, 1993, BREAST, V2, P87, DOI DOI 10.1016/0960-9776(93)90163-A; COHEN MB, 1987, ARCH PATHOL LAB MED, V111, P518; Dahlstrom JE, 1996, HISTOPATHOLOGY, V28, P421, DOI 10.1046/j.1365-2559.1996.332376.x; DAWSON C, 1993, ANN ROY COLL SURG, V75, P79; DEPAREDES ES, 1994, CANCER, V74, P342, DOI 10.1002/cncr.2820741320; DIXON JM, 1988, BRIT J SURG, V75, P918, DOI 10.1002/bjs.1800750931; Dominguez F, 1997, ACTA CYTOL, V41, P341, DOI 10.1159/000332522; Duijm LEM, 1998, BRIT J GEN PRACT, V48, P1421; Feichter GE, 1997, ACTA CYTOL, V41, P327, DOI 10.1159/000332520; Ferrini R, 1996, AM J PREV MED, V12, P340, DOI 10.1016/S0749-3797(18)30289-7; Francescatti D, 2000, AM SURGEON, V66, P442; Giard RWM, 1996, EUR J CANCER, V32A, P2042, DOI 10.1016/S0959-8049(96)00282-1; GIARD RWM, 1992, CANCER, V69, P2104, DOI 10.1002/1097-0142(19920415)69:8<2104::AID-CNCR2820690816>3.0.CO;2-O; Goodson WH, 1996, WESTERN J MED, V164, P355; Goodson WH, 2002, ARCH INTERN MED, V162, P1343, DOI 10.1001/archinte.162.12.1343; GRADY D, 1988, WESTERN J MED, V149, P226; Gundry KR, 1998, AM J ROENTGENOL, V171, P41, DOI 10.2214/ajr.171.1.9648760; HAMED H, 1989, ARCH SURG-CHICAGO, V124, P253; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HELVIE MA, 1991, RADIOLOGY, V178, P155, DOI 10.1148/radiology.178.1.1984295; Hindle WH, 1999, AM J OBSTET GYNECOL, V180, P1484, DOI 10.1016/S0002-9378(99)70043-8; Hindle WH, 1997, AM J OBSTET GYNECOL, V176, P1286, DOI 10.1016/S0002-9378(97)70347-8; Hyser MJ, 2000, AM SURGEON, V66, P438; Jackman RJ, 1999, RADIOLOGY, V210, P799, DOI 10.1148/radiology.210.3.r99mr19799; Jackman RJ, 1997, RADIOLOGY, V204, P485, DOI 10.1148/radiology.204.2.9240540; Jacobs TW, 2002, AM J SURG PATHOL, V26, P1095, DOI 10.1097/00000478-200209000-00001; KAUFMAN Z, 1994, J SURG ONCOL, V56, P254, DOI 10.1002/jso.2930560413; Kerlikowske K, 2000, ANN INTERN MED, V133, P855, DOI 10.7326/0003-4819-133-11-200012050-00009; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P39, DOI 10.1001/jama.276.1.39; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kossoff MB, 2000, WORLD J SURG, V24, P143, DOI 10.1007/s002689910027; LAYFIELD LJ, 1989, PATHOL ANNU, V24, P23; Leitch AM, 1997, CA-CANCER J CLIN, V47, P150, DOI 10.3322/canjclin.47.3.150; Liberman L, 2002, RADIOL CLIN N AM, V40, P483, DOI 10.1016/S0033-8389(01)00011-2; Liberman L, 1998, RADIOLOGY, V208, P717, DOI 10.1148/radiology.208.3.9722851; Litherland JC, 2002, CLIN RADIOL, V57, P81, DOI 10.1053/crad.2001.0875; Ljung BM, 2001, CANCER CYTOPATHOL, V93, P263, DOI 10.1002/cncr.9040; LOCKER AP, 1989, LANCET, V1, P887; Logan-Young W, 1998, CANCER, V82, P1867, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1867::AID-CNCR8>3.0.CO;2-K; May DS, 1998, AM J ROENTGENOL, V170, P97, DOI 10.2214/ajr.170.1.9423608; MINKOWITZ S, 1986, CANCER, V57, P320, DOI 10.1002/1097-0142(19860115)57:2<320::AID-CNCR2820570221>3.0.CO;2-C; Morris A, 1998, ARCH SURG-CHICAGO, V133, P930, DOI 10.1001/archsurg.133.9.930; Mushlin AI, 1998, AM J PREV MED, V14, P143, DOI 10.1016/S0749-3797(97)00019-6; OLSON LK, 1993, AM FAM PHYSICIAN, V47, P396; ONeil S, 1997, SURGERY, V122, P824, DOI 10.1016/S0039-6060(97)90093-3; PADEL AF, 1993, CYTOPATHOLOGY, V4, P161, DOI 10.1111/j.1365-2303.1993.tb00081.x; PARKER SH, 1994, RADIOLOGY, V193, P359, DOI 10.1148/radiology.193.2.7972743; Pijnappel RM, 1997, EUR J RADIOL, V24, P120, DOI 10.1016/S0720-048X(96)01140-0; Pisano ED, 1998, CANCER, V82, P679; Pisano ED, 2001, RADIOLOGY, V219, P785, DOI 10.1148/radiology.219.3.r01jn28785; Ringash J, 2001, CAN MED ASSOC J, V164, P469; Rosenberg RD, 1998, RADIOLOGY, V209, P511, DOI 10.1148/radiology.209.2.9807581; Rosenberg RD, 1996, CANCER, V78, P1731, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1731::AID-CNCR13>3.0.CO;2-Z; ROSNER D, 1985, J SURG ONCOL, V28, P308, DOI 10.1002/jso.2930280415; Shannon J, 2001, J CLIN PATHOL, V54, P762, DOI 10.1136/jcp.54.10.762; SICKLES EA, 1984, RADIOLOGY, V151, P467, DOI 10.1148/radiology.151.2.6709920; SICKLES EA, 1995, RADIOL CLIN N AM, V33, P1123; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; STAVROS AT, 1995, RADIOLOGY, V196, P123, DOI 10.1148/radiology.196.1.7784555; Steinberg JL, 1996, CAN J SURG, V39, P302; STERNS EE, 1992, CAN J SURG, V35, P41; Tabbara SO, 2000, DIAGN CYTOPATHOL, V22, P126, DOI 10.1002/(SICI)1097-0339(200002)22:2<126::AID-DC15>3.3.CO;2-F; VARAS X, 1992, RADIOLOGY, V184, P409, DOI 10.1148/radiology.184.2.1620838; Varas X, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.3.1790691; Verkooijen HM, 2002, INT J CANCER, V99, P853, DOI 10.1002/ijc.10419; Verkooijen HM, 2000, BRIT J SURG, V87, P344, DOI 10.1046/j.1365-2168.2000.01380.x; Verkooijen HM, 2000, BRIT J CANCER, V82, P1017; VETTO J, 1995, AM J SURG, V169, P519, DOI 10.1016/S0002-9610(99)80209-8; Vizcaino I, 2001, RADIOLOGY, V219, P475, DOI 10.1148/radiology.219.2.r01ma11475; WILLIS SL, 1995, ACTA CYTOL, V39, P858; WOLFE JN, 1987, RADIOLOGY, V165, P305, DOI 10.1148/radiology.165.2.3659348; Yasmeen S, 2003, JNCI-J NATL CANCER I, V95, P429, DOI 10.1093/jnci/95.6.429	95	89	93	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					274	284		10.7326/0003-4819-139-4-200308190-00010	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00010			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965983				2022-12-28	WOS:000184795600006
J	Thomas, JW; Touchman, JW; Blakesley, RW; Bouffard, GG; Beckstrom-Sternberg, SM; Margulies, EH; Blanchette, M; Siepel, AC; Thomas, PJ; McDowell, JC; Maskeri, B; Hansen, NF; Schwartz, MS; Weber, RJ; Kent, WJ; Karolchik, D; Bruen, TC; Bevan, R; Cutler, DJ; Schwartz, S; Elnitski, L; Idol, JR; Prasad, AB; Lee-Lin, SQ; Maduro, VVB; Summers, TJ; Portnoy, ME; Dietrich, NL; Akhter, N; Ayele, K; Benjamin, B; Cariaga, K; Brinkley, CP; Brooks, SY; Granite, S; Guan, X; Gupta, J; Haghighi, P; Ho, SL; Huang, MC; Karlins, E; Laric, PL; Legaspi, R; Lim, MJ; Maduro, QL; Masiello, CA; Mastrian, SD; McCloskey, JC; Pearson, R; Stantripop, S; Tiongson, EE; Tran, JT; Tsurgeon, C; Vogt, JL; Walker, MA; Wetherby, KD; Wiggins, LS; Young, AC; Zhang, LH; Osoegawa, K; Zhu, B; Zhao, B; Shu, CL; De Jong, PJ; Lawrence, CE; Smit, AF; Chakravarti, A; Haussler, D; Green, P; Miller, W; Green, ED				Thomas, JW; Touchman, JW; Blakesley, RW; Bouffard, GG; Beckstrom-Sternberg, SM; Margulies, EH; Blanchette, M; Siepel, AC; Thomas, PJ; McDowell, JC; Maskeri, B; Hansen, NF; Schwartz, MS; Weber, RJ; Kent, WJ; Karolchik, D; Bruen, TC; Bevan, R; Cutler, DJ; Schwartz, S; Elnitski, L; Idol, JR; Prasad, AB; Lee-Lin, SQ; Maduro, VVB; Summers, TJ; Portnoy, ME; Dietrich, NL; Akhter, N; Ayele, K; Benjamin, B; Cariaga, K; Brinkley, CP; Brooks, SY; Granite, S; Guan, X; Gupta, J; Haghighi, P; Ho, SL; Huang, MC; Karlins, E; Laric, PL; Legaspi, R; Lim, MJ; Maduro, QL; Masiello, CA; Mastrian, SD; McCloskey, JC; Pearson, R; Stantripop, S; Tiongson, EE; Tran, JT; Tsurgeon, C; Vogt, JL; Walker, MA; Wetherby, KD; Wiggins, LS; Young, AC; Zhang, LH; Osoegawa, K; Zhu, B; Zhao, B; Shu, CL; De Jong, PJ; Lawrence, CE; Smit, AF; Chakravarti, A; Haussler, D; Green, P; Miller, W; Green, ED			Comparative analyses of multi-species sequences from targeted genomic regions	NATURE			English	Article							NONCODING SEQUENCES; MAMMALIAN GENOMES; DNA-SEQUENCES; GENE; SUBSTITUTION; ALIGNMENTS; DIVERGENCE; PREDICTION; EVOLUTION; DELETIONS	The systematic comparison of genomic sequences from different organisms represents a central focus of contemporary genome analysis. Comparative analyses of vertebrate sequences can identify coding(1-6) and conserved non-coding(4,6,7) regions, including regulatory elements(8-10), and provide insight into the forces that have rendered modern-day genomes(6). As a complement to whole-genome sequencing efforts(3,5, 6), we are sequencing and comparing targeted genomic regions in multiple, evolutionarily diverse vertebrates. Here we report the generation and analysis of over 12 megabases (Mb) of sequence from 12 species, all derived from the genomic region orthologous to a segment of about 1.8 Mb on human chromosome 7 containing ten genes, including the gene mutated in cystic fibrosis. These sequences show conservation reflecting both functional constraints and the neutral mutational events that shaped this genomic region. In particular, we identify substantial numbers of conserved non- coding segments beyond those previously identified experimentally, most of which are not detectable by pair-wise sequence comparisons alone. Analysis of transposable element insertions highlights the variation in genome dynamics among these species and confirms the placement of rodents as a sister group to the primates.	NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NIH, NIH Intramural Sequencing Ctr, Bethesda, MD 20892 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21287 USA; Penn State Univ, Dept Comp Sci & Engn, University Pk, PA 16802 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; Inst Syst Biol, Seattle, WA 98103 USA; Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of California System; University of California Santa Cruz; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; State University of New York (SUNY) System; Wadsworth Center; Institute for Systems Biology (ISB); Howard Hughes Medical Institute; University of California System; University of California Santa Cruz; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Green, ED (corresponding author), NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA.	egreen@nhgri.nih.gov	Elnitski, Laura/AAD-3595-2021; Yang, Chen/G-1379-2010; Prasad, Arjun/C-6736-2008; Granite, Stephen/J-9487-2013	Granite, Stephen/0000-0002-0956-7500; Elnitski, Laura/0000-0003-1065-019X; Karlins, Eric/0000-0002-7541-393X; Laric, Pnina/0000-0002-2489-4032; Siepel, Adam/0000-0002-3557-7219	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000196, ZIAHG000060, Z01HG000060, ZIBHG000196] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Batzoglou S, 2000, GENOME RES, V10, P950, DOI 10.1101/gr.10.7.950; Britten RJ, 2002, P NATL ACAD SCI USA, V99, P13633, DOI 10.1073/pnas.172510699; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Chen R, 2001, GENOME RES, V11, P1807, DOI 10.1101/gr.203601; Cooper GM, 2003, GENOME RES, V13, P813, DOI 10.1101/gr.1064503; Dubchak I, 2000, GENOME RES, V10, P1304, DOI 10.1101/gr.142200; Felsenfeld A, 1999, GENOME RES, V9, P1; Frazer KA, 2003, GENOME RES, V13, P341, DOI 10.1101/gr.554603; Gottgens B, 2000, NAT BIOTECHNOL, V18, P181, DOI 10.1038/72635; Green P, 2003, NAT GENET, V33, P514, DOI 10.1038/ng1103; Hardison RC, 2000, TRENDS GENET, V16, P369, DOI 10.1016/S0168-9525(00)02081-3; Hardison RC, 2003, GENOME RES, V13, P13, DOI 10.1101/gr.844103; Huelsenbeck JP, 2000, GENETICS, V154, P1879; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kumar S, 2002, P NATL ACAD SCI USA, V99, P803, DOI 10.1073/pnas.022629899; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Pennacchio LA, 2001, NAT REV GENET, V2, P100, DOI 10.1038/35052548; Poux C, 2002, MOL BIOL EVOL, V19, P2035, DOI 10.1093/oxfordjournals.molbev.a004028; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Schwartz S, 2003, NUCLEIC ACIDS RES, V31, P3518, DOI 10.1093/nar/gkg579; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SIEPEL A, 2003, P 7 ANN INT C RES CO; Springer MS, 2003, P NATL ACAD SCI USA, V100, P1056, DOI 10.1073/pnas.0334222100; Thomas JW, 2002, GENOME RES, V12, P1277, DOI 10.1101/gr.283202; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	30	473	555	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					788	793		10.1038/nature01858	http://dx.doi.org/10.1038/nature01858			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917688	Green Published			2022-12-28	WOS:000184733900043
J	Witte, U; Wenzhofer, F; Sommer, S; Boetius, A; Heinz, P; Aberle, N; Sand, M; Cremer, A; Abraham, WR; Jorgensen, BB; Pfannkuche, O				Witte, U; Wenzhofer, F; Sommer, S; Boetius, A; Heinz, P; Aberle, N; Sand, M; Cremer, A; Abraham, WR; Jorgensen, BB; Pfannkuche, O			In situ experimental evidence of the fate of a phytodetritus pulse at the abyssal sea floor	NATURE			English	Article							EASTERN NORTH PACIFIC; DEEP-SEA; ORGANIC-MATTER; BENTHIC COMMUNITY; SEASONAL DEPOSITION; ARABIAN SEA; NE ATLANTIC; CARBON; BACTERIA; SEDIMENTATION	More than 50% of the Earth's surface is sea floor below 3,000 m of water. Most of this major reservoir in the global carbon cycle and final repository for anthropogenic wastes is characterized by severe food limitation. Phytodetritus is the major food source for abyssal benthic communities, and a large fraction of the annual food load can arrive in pulses within a few days(1,2). Owing to logistical constraints, the available data concerning the fate of such a pulse are scattered(3,4) and often contradictory(5-10), hampering global carbon modelling and anthropogenic impact assessments. We quantified (over a period of 2.5 to 23 days) the response of an abyssal benthic community to a phytodetritus pulse, on the basis of 11 in situ experiments. Here we report that, in contrast to previous hypotheses(5-11), the sediment community oxygen consumption doubled immediately, and that macrofauna were very important for initial carbon degradation. The retarded response of bacteria and Foraminifera, the restriction of microbial carbon degradation to the sediment surface, and the low total carbon turnover distinguish abyssal from continental-slope 'deep-sea' sediments.	Max Planck Inst Marine Microbiol, D-28359 Bremen, Germany; GEOMAR Res Ctr, D-24148 Kiel, Germany; Univ Tubingen, Inst Geosci, D-72076 Tubingen, Germany; Gesell Biotechnol Forsch mbH, D-38124 Braunschweig, Germany	Max Planck Society; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; Eberhard Karls University of Tubingen; Gesellschaft fur Biotechnologische Forschung mbH	Witte, U (corresponding author), Max Planck Inst Marine Microbiol, Celsiusstr 1, D-28359 Bremen, Germany.	uwitte@mpi-bremen.de	Jorgensen, Bo B/C-2214-2013; Abraham, Wolf-Rainer/I-2179-2019; Boetius, Antje/D-5459-2013; Aberle, Nicole/C-7366-2014	Jorgensen, Bo B/0000-0001-9398-8027; Abraham, Wolf-Rainer/0000-0002-2850-2649; Boetius, Antje/0000-0003-2117-4176; Aberle, Nicole/0000-0003-3254-5710; Heinz, Petra/0000-0002-3428-3374				Aberle N, 2003, MAR ECOL PROG SER, V251, P37, DOI 10.3354/meps251037; Bett BJ, 2001, PROG OCEANOGR, V50, P349, DOI 10.1016/S0079-6611(01)00066-0; BILLETT DSM, 1983, NATURE, V302, P520, DOI 10.1038/302520a0; Billett DSM, 2001, PROG OCEANOGR, V50, P13, DOI 10.1016/S0079-6611(01)00046-5; Billett DSM, 2001, PROG OCEANOGR, V50, P325, DOI 10.1016/S0079-6611(01)00060-X; Boetius A, 2000, DEEP-SEA RES PT II, V47, P2835, DOI 10.1016/S0967-0645(00)00051-5; Boetius A, 1996, MAR ECOL PROG SER, V140, P239, DOI 10.3354/meps140239; Boschker HTS, 1999, LIMNOL OCEANOGR, V44, P309, DOI 10.4319/lo.1999.44.2.0309; Drazen JC, 1998, DEEP-SEA RES PT II, V45, P893, DOI 10.1016/S0967-0645(98)00007-1; Gooday AJ, 2002, J OCEANOGR, V58, P305, DOI 10.1023/A:1015865826379; GRAF G, 1989, NATURE, V341, P437, DOI 10.1038/341437a0; LAMPITT RS, 1985, DEEP-SEA RES, V32, P885, DOI 10.1016/0198-0149(85)90034-2; Lampitt RS, 2001, PROG OCEANOGR, V50, P27, DOI 10.1016/S0079-6611(01)00047-7; Levin L, 1997, J MAR RES, V55, P595, DOI 10.1357/0022240973224337; LOCHTE K, 1988, NATURE, V333, P67, DOI 10.1038/333067a0; Middelburg JJ, 2000, LIMNOL OCEANOGR, V45, P1224, DOI 10.4319/lo.2000.45.6.1224; Moodley L, 2002, MAR ECOL PROG SER, V236, P23, DOI 10.3354/meps236023; PFANNKUCHE O, 1993, DEEP-SEA RES PT II, V40, P135, DOI 10.1016/0967-0645(93)90010-K; ROWE G, 1991, MAR ECOL PROG SER, V79, P99, DOI 10.3354/meps079099; SAYLES FL, 1994, NATURE, V371, P686, DOI 10.1038/371686a0; Smith KL, 1999, SCIENCE, V284, P1174, DOI 10.1126/science.284.5417.1174; Smith KL, 2002, DEEP-SEA RES PT I, V49, P971, DOI 10.1016/S0967-0637(02)00006-7; SMITH KL, 1984, NATURE, V307, P624, DOI 10.1038/307624a0; Turley C, 2000, FEMS MICROBIOL ECOL, V33, P89, DOI 10.1111/j.1574-6941.2000.tb00731.x; TYLER PA, 1988, OCEANOGR MAR BIOL, V26, P227; Wenzhofer F, 2001, DEEP-SEA RES PT I, V48, P1741, DOI 10.1016/S0967-0637(00)00108-4; Witbaard R, 2000, J SEA RES, V43, P15, DOI 10.1016/S1385-1101(99)00040-4; Witte U, 2000, DEEP-SEA RES PT II, V47, P2785, DOI 10.1016/S0967-0645(00)00049-7; Witte U, 2003, MAR ECOL PROG SER, V251, P27, DOI 10.3354/meps251027	29	188	194	0	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					763	766		10.1038/nature01799	http://dx.doi.org/10.1038/nature01799			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917681	Green Published			2022-12-28	WOS:000184733900036
J	Renesto, P; Crapoulet, N; Ogata, H; La Scola, B; Vestris, G; Claverie, JM; Raoult, D				Renesto, P; Crapoulet, N; Ogata, H; La Scola, B; Vestris, G; Claverie, JM; Raoult, D			Genome-based design of a cell-free culture medium for Tropheryma whipplei	LANCET			English	Article								Empirical approaches have guided the development of bacterial cultures. The availability of sequenced genomes now provides opportunities to define culture media for growth of fastidious pathogens with computer modelling of metabolic networks. A key issue the possibility of growing host-dependent bacteria in cell-free conditions. The sequenced Tropheryma whipplei genome was analysed to identify specific metabolic deficiencies. We used this information to design a comprehensive medium that allowed three established T whipplei strains from culture with human cells and one new strain from a clinical sample to grow axenically. Genomic information can, therefore, provide sufficient clues for designing axenic media for fastidious and uncultured pathogens.	CNRS, Fac Med, UMR 6020, Unite Rickettsies, F-13385 Marseille, France; Informat Genom & Struct, UPR 2589, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Raoult, D (corresponding author), CNRS, Fac Med, UMR 6020, Unite Rickettsies, 27 Blvd Jean Moulin, F-13385 Marseille, France.	Didier.Raoult@medecine.univ-mrs.fr	RAOULT, Didier/A-8434-2008; renesto, patricia/T-6446-2019; Claverie, Jean-Michel/AAG-4889-2019; Renesto, patricia/M-6105-2014; LA SCOLA, Bernard/P-6477-2016; Claverie, Jean Michel/Z-2183-2019	RAOULT, Didier/0000-0002-0633-5974; renesto, patricia/0000-0002-6749-7862; Claverie, Jean-Michel/0000-0003-1424-0315; LA SCOLA, Bernard/0000-0001-8006-7704; 				Bentley SD, 2003, LANCET, V361, P637, DOI 10.1016/S0140-6736(03)12597-4; Davey HM, 1996, MICROBIOL REV, V60, P641, DOI 10.1128/MMBR.60.4.641-696.1996; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; La Scola B, 2001, INT J SYST EVOL MICR, V51, P1471, DOI 10.1099/00207713-51-4-1471; RAOULT D, IN PRESS GENOME RES; Zengler K, 2002, P NATL ACAD SCI USA, V99, P15681, DOI 10.1073/pnas.252630999	6	142	147	3	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					447	449		10.1016/S0140-6736(03)14071-8	http://dx.doi.org/10.1016/S0140-6736(03)14071-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927433				2022-12-28	WOS:000184651100013
J	Lubitz, J; Cai, LM; Kramarow, E; Lentzner, H				Lubitz, J; Cai, LM; Kramarow, E; Lentzner, H			Health, life expectancy, and health care spending among the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; DISABILITY; TRENDS; AGE; LONGEVITY	Background: Life expectancy among the elderly has been improving for many decades, and there is evidence that health among the elderly is also improving. We estimated the relation of health status at 70 years of age to life expectancy and to cumulative health care expenditures from the age of 70 until death. Methods: Using the 1992-1998 Medicare Current Beneficiary Survey, we classified persons' health according to functional status and whether or not they were institutionalized and according to self-reported health. We used multistate life-table methods and microsimulation to estimate life expectancy for persons in various states of health. We linked annual health care expenditures with transitions between health states. Results: Elderly persons in better health had a longer life expectancy than those in poorer health but had similar cumulative health care expenditures until death. A person with no functional limitation at 70 years of age had a life expectancy of 14.3 years and expected cumulative health care expenditures of about $136,000 (in 1998 dollars); a person with a limitation in at least one activity of daily living had a life expectancy of 11.6 years and expected cumulative expenditures of about $145,000. Expenditures varied little according to self-reported health at the age of 70. Persons who were institutionalized at the age of 70 had cumulative expenditures that were much higher than those for persons who were not institutionalized. Conclusions: The expected cumulative health expenditures for healthier elderly persons, despite their greater longevity, were similar to those for less healthy persons. Health-promotion efforts aimed at persons under 65 years of age may improve the health and longevity of the elderly without increasing health expenditures.	Ctr Dis Control & Prevent, Off Anal Epidemiol & Hlth Promot, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Lubitz, J (corresponding author), Ctr Dis Control & Prevent, Off Anal Epidemiol & Hlth Promot, Natl Ctr Hlth Stat, 3311 Toledo Rd,Mail Stop 6226, Hyattsville, MD 20782 USA.	jlubitz@cdc.gov						Crimmins EM, 1996, J GERONTOL B-PSYCHOL, V51, pS111, DOI 10.1093/geronb/51B.3.S111; CRIMMINS EM, 1994, DEMOGRAPHY, V31, P159, DOI 10.2307/2061913; *CTR MED MED SERV, TECHN PAN REV MED TR; *CTR MED MED SERV, 2003, LINK SURV DAT MED CL; Daviglus ML, 1998, NEW ENGL J MED, V339, P1122, DOI 10.1056/NEJM199810153391606; *DHHS, 2001, DHHS PUB L; Eppig FJ, 1997, HEALTH CARE FINANC R, V18, P211; *FED HOSP INS TRUS, 2001, BOARD TRUST ANN REP; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; GABREL CS, 2000, DHHS PUBLICATION; GURALNIK JM, 1993, NEW ENGL J MED, V329, P110, DOI 10.1056/NEJM199307083290208; HODGSON TA, 1992, MILBANK Q, V70, P81, DOI 10.2307/3350086; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Laditka SB, 1998, J AGING HEALTH, V10, P214, DOI 10.1177/089826439801000206; LAND KC, 1994, DEMOGRAPHY, V31, P297, DOI 10.2307/2061887; Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x; LENTZNER HR, 1992, AM J PUBLIC HEALTH, V82, P1093, DOI 10.2105/AJPH.82.8.1093; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; Miller T, 2001, DEMOGRAPHY, V38, P215, DOI 10.1353/dem.2001.0018; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; *NAT CTR HLTH STAT, 1998, DHHS PUBL, V2; POPE AM, 1991, DISABILITY AM NATL A; Schoeni RF, 2001, J GERONTOL B-PSYCHOL, V56, pS206, DOI 10.1093/geronb/56.4.S206; Shao J., 2012, JACKKNIFE BOOTSTRAP; SHARMA R, 2001, HLTH HLTH CARE MEDIC; Singer BH, 1998, P NATL ACAD SCI USA, V95, P15618, DOI 10.1073/pnas.95.26.15618; Spillman BC, 2000, NEW ENGL J MED, V342, P1409, DOI 10.1056/NEJM200005113421906; Spillman BC, 2000, MILBANK Q, V78, P347, DOI 10.1111/1468-0009.00177; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Waidmann TA, 2000, J GERONTOL B-PSYCHOL, V55, pS298, DOI 10.1093/geronb/55.5.S298; WRIGHT B, 2001, ASSISTED LIVING US	33	308	315	1	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1048	1055		10.1056/NEJMsa020614	http://dx.doi.org/10.1056/NEJMsa020614			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	719UH	12968089				2022-12-28	WOS:000185223100008
J	Barnes, PJ; Adcock, IM				Barnes, PJ; Adcock, IM			How do corticosteroids work in asthma?	ANNALS OF INTERNAL MEDICINE			English	Review							FACTOR-KAPPA-B; GLUCOCORTICOID RECEPTOR PHOSPHORYLATION; OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE-CELLS; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; DNA-BINDING; IN-VIVO; HISTONE ACETYLTRANSFERASES; MOLECULAR MECHANISMS		Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.	p.j.barnes@ic.ac.uk	Adcock, Ian/L-3217-2019	Barnes, Peter/0000-0002-5122-4018; Adcock, Ian/0000-0003-2101-8843				Adcock IM, 1999, BRIT J PHARMACOL, V127, P1003, DOI 10.1038/sj.bjp.0702613; Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820; Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BARNES PJ, 2000, EUR RESPIR REV, V10, P74; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Bergmann M, 2000, AM J RESP CELL MOL, V22, P582, DOI 10.1165/ajrcmb.22.5.3889; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Donovan CE, 1999, J IMMUNOL, V163, P6827; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Hall SE, 1999, AM J PHYSIOL-LUNG C, V276, pL114, DOI 10.1152/ajplung.1999.276.1.L114; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600, DOI 10.1164/ajrccm.159.5.9804131; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Ito K, 2001, FASEB J, V15, pA473; ITO K, 2001, EUR RESPIR J, V18, pS316; ITO K, 2002, AM J RESP CRIT CARE, V165, pA625; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kagoshima M, 2001, EUR J PHARMACOL, V429, P327, DOI 10.1016/S0014-2999(01)01332-2; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Korn SH, 1998, BIOCHEM PHARMACOL, V56, P1561, DOI 10.1016/S0006-2952(98)00179-8; Kurihara I, 2002, MOL CELL ENDOCRINOL, V189, P181, DOI 10.1016/S0303-7207(01)00717-1; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Lim S, 2000, THORAX, V55, P837, DOI 10.1136/thorax.55.10.837; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; Mak JCW, 2002, BRIT J PHARMACOL, V135, P987, DOI 10.1038/sj.bjp.0704545; MATTOS IL, 2000, ANAL SCI, V16, P1; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Nightingale JA, 2000, AM J RESP CRIT CARE, V161, P479, DOI 10.1164/ajrccm.161.2.9905031; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Peterson CL, 2002, MOL CELL, V9, P921, DOI 10.1016/S1097-2765(02)00534-8; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16, DOI 10.1164/ajrccm/154.2_Pt_2.S16; Spahn JD, 1996, J IMMUNOL, V157, P2654; Szefler SJ, 1997, EUR RESPIR J, V10, P1640, DOI 10.1183/09031936.97.10071640; Ukena D, 1997, EUR RESPIR J, V10, P2754, DOI 10.1183/09031936.97.10122754; USMANI O, 2002, AM J RESP CRIT CARE, V165, pA616; Vanden Berghe W, 2000, BIOCHEM PHARMACOL, V60, P1185, DOI 10.1016/S0006-2952(00)00412-3; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yudt MR, 2002, MOL ENDOCRINOL, V16, P1719, DOI 10.1210/me.2002-0106	77	239	276	1	36	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				359	370		10.7326/0003-4819-139-5_Part_1-200309020-00012	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00012			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965945				2022-12-28	WOS:000185037500007
J	Rothberg, MB; Bellantonio, S; Rose, DN				Rothberg, MB; Bellantonio, S; Rose, DN			Management of influenza in adults older than 65 years of age: Cost-effectiveness of rapid testing and antiviral therapy	ANNALS OF INTERNAL MEDICINE			English	Article							NEURAMINIDASE INHIBITOR OSELTAMIVIR; TREATING INFLUENZA; INHALED ZANAMIVIR; NURSING-HOME; EFFICACY; SAFETY; VACCINATION; AMANTADINE; IMPACT; PROPHYLAXIS	Background: Although antiviral therapy is cost-effective in adults, its cost-effectiveness in older adults has not been studied. Objective: To determine the cost-effectiveness of influenza testing and treatment strategies for older adults. Design: Cost-utility decision model. Data Sources: Clinical trials of antiviral drugs and epidemiologic data. Target Population: Noninstitutionalized adults older than 65 years of age with influenza-like illness. Time Horizon: Lifetime. Perspective: Societal. Interventions: Rapid diagnostic testing or empirical therapy with antiviral drugs. Outcome Measures: Cost per quality-adjusted life-year (QALY) saved. Results of Base-Case Analysis: Compared with no intervention, empirically treating an unvaccinated 75-year-old patient with amantadine increased life expectancy by 0.0014 QALY at a cost of $1.57, a cost-effectiveness ratio of $1129 per QALY saved. Compared with amantadine, rapid diagnostic testing followed by treatment with oseltamivir cost $5025 per QALY saved and empirical treatment with oseltamivir cost $10 296 per QALY saved. Testing and treatment strategies were less cost-effective if the patient was vaccinated, ranging from $2483 per QALY saved with amantadine to $70 300 per QALY saved with oseltamivir. Results of Sensitivity Analysis: The decision was sensitive to the probability of influenza, the efficacy of oseltamivir in preventing hospitalizations, and hospitalization and case-fatality rates. The decision was not sensitive to the probability or severity of medication side effects, the quality of life for influenza illness or hospitalization, the efficacy of antiviral therapy in shortening influenza illness, or the rapid diagnostic test characteristics. Conclusions: For unvaccinated or high-risk vaccinated patients during the influenza season, empirical oseltamivir treatment is cost-effective. For other patients, rapid diagnostic testing followed by treatment with oseltamivir is cost-effective. Empirical amantadine treatment offers a low-cost alternative if patients cannot afford oseltamivir.	Baystate Med Ctr, Div Gen Med & Geriatr, Springfield, MA 01199 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Baystate Medical Center; Tufts University	Rothberg, MB (corresponding author), Baystate Med Ctr, Div Gen Med & Geriatr, 759 Chestnut St, Springfield, MA 01199 USA.	Michael.Rothberg@bhs.org						[Anonymous], 1999, MED LETT DRUGS THER, V41, P121; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Bowles SK, 2002, J AM GERIATR SOC, V50, P608, DOI 10.1046/j.1532-5415.2002.50153.x; Bridges Carolyn B, 2002, MMWR Recomm Rep, V51, P1; *CDCP, 2002, REP SURV METH US CUR; Cox FM, 2000, AM J MANAG CARE, V6, P205; Crane M, 2001, Med Econ, V78, P50; CRANE M, 2001, MED ECON, V78, P55; DEMICHELI V, 2001, COCHRANE DB SYST REV; Diggory P, 2001, BRIT MED J, V322, P577, DOI 10.1136/bmj.322.7286.577; DOLIN R, 1982, NEW ENGL J MED, V307, P580, DOI 10.1056/NEJM198209023071002; *GLAX WELLC, 2001, REL ZAN INH PACK INS; Gold MR, 1996, COST EFFECTIVENESS H; GOVAERT TME, 1994, JAMA-J AM MED ASSOC, V272, P1661, DOI 10.1001/jama.272.21.1661; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; Gravenstein S, 2002, CLIN INFECT DIS, V35, P729, DOI 10.1086/341246; Griffin AD, 2001, PHARMACOECONOMICS, V19, P293, DOI 10.2165/00019053-200119030-00007; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Hayden FG, 1996, JAMA-J AM MED ASSOC, V275, P295, DOI 10.1001/jama.275.4.295; Hayden FG, 1999, JAMA-J AM MED ASSOC, V282, P1240, DOI 10.1001/jama.282.13.1240; Hayden FG, 1997, NEW ENGL J MED, V337, P874, DOI 10.1056/NEJM199709253371302; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Jefferson T, 1999, PHARMACOECONOMICS, V16, P85, DOI 10.2165/00019053-199916001-00011; Kaiser L, 2000, ARCH INTERN MED, V160, P3234, DOI 10.1001/archinte.160.21.3234; Kerlikowske K, 1999, JAMA-J AM MED ASSOC, V282, P2156, DOI 10.1001/jama.282.22.2156; Keyser LA, 2000, ARCH INTERN MED, V160, P1485, DOI 10.1001/archinte.160.10.1485; Lalezari J, 2001, ARCH INTERN MED, V161, P212, DOI 10.1001/archinte.161.2.212; Lee PY, 2002, ANN INTERN MED, V137, P225, DOI 10.7326/0003-4819-137-4-200208200-00005; Libow LS, 1996, J AM GERIATR SOC, V44, P1153, DOI 10.1111/j.1532-5415.1996.tb01363.x; Matsumoto K, 1999, ANTIVIR THER, V4, P61; *MED EC, 2001, 2001 DRUG TOP RED BO; Monto AS, 1999, J ANTIMICROB CHEMOTH, V44, P23, DOI 10.1093/jac/44.suppl_2.23; Monto AS, 1999, J INFECT DIS, V180, P254, DOI 10.1086/314904; Muennig PA, 2001, CLIN INFECT DIS, V33, P1879, DOI 10.1086/324491; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Silagy C, 1998, LANCET, V352, P1877, DOI 10.1016/S0140-6736(98)10190-3; Simonsen L, 2000, J INFECT DIS, V181, P831, DOI 10.1086/315320; Smith KJ, 2002, AM J MED, V113, P300, DOI 10.1016/S0002-9343(02)01222-6; STANGE KC, 1991, J AM GERIATR SOC, V39, P700, DOI 10.1111/j.1532-5415.1991.tb03625.x; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; US Department of Labor Bureau of Labor Statistic, CONS PRIC IND ALL UR; Wenzel RP, 2000, JAMA-J AM MED ASSOC, V283, P1057, DOI 10.1001/jama.283.8.1057; Zambon M, 2001, ARCH INTERN MED, V161, P2116, DOI 10.1001/archinte.161.17.2116; 1999, MED LETT DRUGS THER, V41, P91	47	59	63	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				321	329		10.7326/0003-4819-139-5_Part_1-200309020-00007	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965940				2022-12-28	WOS:000185037500002
J	Snowdon, DA				Snowdon, DA			Healthy aging and dementia: Findings from the Nun Study	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				ALZHEIMERS-DISEASE; EARLY-LIFE; LINGUISTIC ABILITY; COGNITIVE FUNCTION	The Nun Study is a longitudinal study of 678 Catholic sisters 75 to 107 years of age who are members of the School Sisters of Notre Dame congregation. Data collected for this study include early and middle-life risk factors from the convent archives, annual cognitive and physical function evaluations during old age, and postmortem neuropathologic evaluations of the participants' brains. The case histories presented include a centenarian who was a model of healthy aging, a 92-year-old with dementia and clinically significant Alzheimer disease neuropathology and vascular lesions, a cognitively and physically intact centenarian with almost no neuropathology, and an 85-year-old with well-preserved cognitive and physical function despite a genetic predisposition to Alzheimer disease and an abundance of Alzheimer disease lesions. These case histories provide examples of how healthy aging and dementia relate to the degree of pathology present in the brain and the level of resistance to the clinical expression of the neuropathology.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	University of Kentucky	Snowdon, DA (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 320 Hlth Sci Bldg, Lexington, KY 40536 USA.	dsnowdon@nunstudy.mi8.com			NIA NIH HHS [R01AG09862, 5P50AG05144, K04AG00553] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K04AG000553, R01AG009862, P50AG005144] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Butler SM, 1996, J GERONTOL B-PSYCHOL, V51, pS201, DOI 10.1093/geronb/51B.4.S201; Danner DD, 2001, J PERS SOC PSYCHOL, V80, P804, DOI 10.1037/0022-3514.80.5.804; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P; Riley KP, 2002, ANN NEUROL, V51, P567, DOI 10.1002/ana.10161; Snowdon DA, 1997, GERONTOLOGIST, V37, P150, DOI 10.1093/geront/37.2.150; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Snowdon DA, 1999, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, P19; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Snowdon DA, 2000, ANN NY ACAD SCI, V903, P34, DOI 10.1111/j.1749-6632.2000.tb06347.x; SNOWDON DA, 1999, PARADOXES LONGEVITY, P103, DOI DOI 10.1007/978-3-642-60100-2_9; Snowdon David, 2001, AGING GRACE WHAT NUN; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248	15	192	204	4	47	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			450	454		10.7326/0003-4819-139-5_Part_2-200309021-00014	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00014			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965975				2022-12-28	WOS:000185133800014
J	Taylor, A				Taylor, A			ABC of subfertility - Making a diagnosis	BRITISH MEDICAL JOURNAL			English	Review									Guys & St Thomass Assisted Concept Unit, London, England		Taylor, A (corresponding author), Guys & St Thomass Assisted Concept Unit, London, England.							BALEN AH, 2003, INFERTILITY PRACTICE; *ROYAL COLL OBST G, 1998, IN INV MAN SUBF COUP; TEMPLETON A, 2000, MANAGEMENT INFERTILI; TEMPLETON A, 2000, EVIDENCE BASED FERTI	4	17	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					494	497		10.1136/bmj.327.7413.494	http://dx.doi.org/10.1136/bmj.327.7413.494			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946973	Green Published			2022-12-28	WOS:000185088900021
J	Harris, HH; Pickering, IJ; George, GN				Harris, HH; Pickering, IJ; George, GN			The chemical form of mercury in fish	SCIENCE			English	Article									SLAC, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	George, GN (corresponding author), Univ Saskatchewan, Dept Geol Sci, 114 Sci Pl, Saskatoon, SK S7N 5E2, Canada.		Pickering, Ingrid J/A-4547-2013; George, Graham N/E-3290-2013; Harris, Hugh/A-4983-2008	Pickering, Ingrid J/0000-0002-0936-2994; Harris, Hugh/0000-0002-3472-8628; George, Graham/0000-0002-0420-7493				Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Goyer R., 2000, TOXICOLOGICAL EFFECT; Guallar E, 2002, NEW ENGL J MED, V347, P1747, DOI 10.1056/NEJMoa020157; Wagemann R, 1998, SCI TOTAL ENVIRON, V218, P19, DOI 10.1016/S0048-9697(98)00192-2	4	1141	1184	4	321	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1203	1203		10.1126/science.1085941	http://dx.doi.org/10.1126/science.1085941			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947190				2022-12-28	WOS:000185003500031
J	Gratwohl, A				Gratwohl, A			On the distinction between males and females	LANCET			English	Editorial Material							MINOR HISTOCOMPATIBILITY ANTIGENS; BONE-MARROW TRANSPLANTATION; HUMAN H-Y; DONORS; HLA		Univ Basel, Haematol & Stem Cell Transplantat Unit, CH-4031 Basel, Switzerland	University of Basel	Gratwohl, A (corresponding author), Univ Basel, Haematol & Stem Cell Transplantat Unit, CH-4031 Basel, Switzerland.							Bergen AW, 1998, MOL BIOL EVOL, V15, P1412, DOI 10.1093/oxfordjournals.molbev.a025869; GOULMY E, 1976, LANCET, V2, P1206; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Gratwohl A, 2001, Hematol J, V2, P363, DOI 10.1038/sj.thj.6200117; Gratwohl A, 1998, LANCET, V352, P1087, DOI 10.1016/S0140-6736(98)03030-X; RANDOLPH SB, 2002, AM SOC HEM 44 ANN M; Rufer N, 1998, TRANSPLANTATION, V66, P910, DOI 10.1097/00007890-199810150-00016; UPHOFF DE, 1975, J NATL CANCER I, V54, P1343, DOI 10.1093/jnci/54.6.1343; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; ZWAAN FE, 1989, BONE MARROW TRANS S2, V4, P8	11	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					590	591		10.1016/S0140-6736(03)14207-9	http://dx.doi.org/10.1016/S0140-6736(03)14207-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944055				2022-12-28	WOS:000184904100004
J	Svejstrup, JQ				Svejstrup, JQ			Transcription - Histones face the FACT	SCIENCE			English	Editorial Material							CHROMATIN-STRUCTURE; RNA-POLYMERASE; NUCLEOSOME		London Res Inst, Clare Hall Labs, S Mimms, Herts, England		Svejstrup, JQ (corresponding author), London Res Inst, Clare Hall Labs, S Mimms, Herts, England.			Svejstrup, Jesper/0000-0003-4964-6147				Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Formosa T, 2002, GENETICS, V162, P1557; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790	10	31	33	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1053	+		10.1126/science.1088901	http://dx.doi.org/10.1126/science.1088901			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12933997				2022-12-28	WOS:000184872400025
J	Andersen, HR; Nielsen, TT; Rasmussen, K; Thuesen, L; Kelbaek, H; Thayssen, P; Abildgaard, U; Pedersen, F; Madsen, JK; Grande, P; Villadsen, AB; Krusell, LR; Haghfelt, T; Lomholt, P; Husted, SE; Vigholt, E; Kjaergard, HK; Mortensen, LS				Andersen, HR; Nielsen, TT; Rasmussen, K; Thuesen, L; Kelbaek, H; Thayssen, P; Abildgaard, U; Pedersen, F; Madsen, JK; Grande, P; Villadsen, AB; Krusell, LR; Haghfelt, T; Lomholt, P; Husted, SE; Vigholt, E; Kjaergard, HK; Mortensen, LS		DANAMI 2 Investigators	A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSERVATIVE TREATMENT; IMMEDIATE ANGIOPLASTY; THROMBOLYTIC THERAPY; TRIAL; VOLUME	BACKGROUND For the treatment of myocardial infarction with ST-segment elevation, primary angioplasty is considered superior to fibrinolysis for patients who are admitted to hospitals with angioplasty facilities. Whether this benefit is maintained for patients who require transportation from a community hospital to a center where invasive treatment is available is uncertain. METHODS We randomly assigned 1572 patients with acute myocardial infarction to treatment with angioplasty or accelerated treatment with intravenous alteplase; 1129 patients were enrolled at 24 referral hospitals and 443 patients at 5 invasive-treatment centers. The primary study end point was a composite of death, clinical evidence of reinfarction, or disabling stroke at 30 days. RESULTS Among patients who underwent randomization at referral hospitals, the primary end point was reached in 8.5 percent of the patients in the angioplasty group, as compared with 14.2 percent of those in the fibrinolysis group (P=0.002). The results were similar among patients who were enrolled at invasive-treatment centers: 6.7 percent of the patients in the angioplasty group reached the primary end point, as compared with 12.3 percent in the fibrinolysis group (P=0.05). Among all patients, the better outcome after angioplasty was driven primarily by a reduction in the rate of reinfarction (1.6 percent in the angioplasty group vs. 6.3 percent in the fibrinolysis group, P<0.001); no significant differences were observed in the rate of death (6.6 percent vs. 7.8 percent, P=0.35) or the rate of stroke (1.1 percent vs. 2.0 percent, P=0.15). Ninety-six percent of patients were transferred from referral hospitals to an invasive-treatment center within two hours. CONCLUSIONS A strategy for reperfusion involving the transfer of patients to an invasive-treatment center for primary angioplasty is superior to on-site fibrinolysis, provided that the transfer takes two hours or less.	Aarhus Univ Hosp, Skejby Hosp, Dept Cardiol, DK-8200 Aarhus N, Denmark; Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark; Rigshosp Univ Hosp, Dept Cardiol, Copenhagen, Denmark; Odense Univ Hosp, Dept Cardiol, Odense, Denmark; Gentofte Univ Hosp, Dept Cardiol, Hellerup, Denmark; Hilleroed Hosp, Dept Med, Hillerod, Denmark; Randers Cent Hosp, Dept Med, Randers, Denmark; Aarhus Cty Hosp, Dept Med, Aarhus, Denmark; Aarhus Univ Hosp, Dept Med, Aarhus, Denmark; Horsens Hosp, Dept Med, Horsens, Denmark; Gentofte Univ Hosp, Dept Cardiothorac Surg, Hellerup, Denmark; UNI C, Danish Informat Technol Ctr Educ & Res, Aarhus, Denmark	Aarhus University; Aalborg University; Aalborg University Hospital; Rigshospitalet; University of Southern Denmark; Odense University Hospital; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Aarhus University; Aarhus University; Aarhus University; Aarhus University; University of Copenhagen; Herlev & Gentofte Hospital	Andersen, HR (corresponding author), Aarhus Univ Hosp, Skejby Hosp, Dept Cardiol, DK-8200 Aarhus N, Denmark.	henning.rud.andersen@iekf.au.dk		Thuesen, Leif/0000-0003-0916-9868				Andersen HR, 2003, AM HEART J, V146, P234, DOI 10.1016/S0002-8703(03)00316-8; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bonnefoy E, 2002, LANCET, V360, P825, DOI 10.1016/S0140-6736(02)09963-4; Canto JG, 2000, NEW ENGL J MED, V342, P1573, DOI 10.1056/NEJM200005253422106; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; Gibson M, 2002, J AM COLL CARDIOL, V39, p280A; Grines CL, 2002, J AM COLL CARDIOL, V39, P1713, DOI 10.1016/S0735-1097(02)01870-3; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Madsen JK, 1997, CIRCULATION, V96, P748; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Widimsky P, 2003, EUR HEART J, V24, P94, DOI 10.1016/S0195-668X(02)00468-2; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	18	962	1016	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					733	742		10.1056/NEJMoa025142	http://dx.doi.org/10.1056/NEJMoa025142			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930925	Bronze			2022-12-28	WOS:000184843300003
J	D'Anna, G; Mayor, P; Barrat, A; Loreto, V; Nori, F				D'Anna, G; Mayor, P; Barrat, A; Loreto, V; Nori, F			Observing brownian motion in vibration-fluidized granular matter	NATURE			English	Article							GLASS; BEHAVIOR; MEDIA	Observation of the rotational brownian motion(1,2) of a very fine wire immersed in a gas led to one of the most important ideas of equilibrium statistical mechanics. Namely, the many-particle problem of a large number of molecules colliding with the wire can be represented by just two macroscopic parameters: viscosity and temperature. Interest has arisen in the question of whether this idea (mathematically developed in the Langevin model and the fluctuation-dissipation theorem(3,4)) can also be used to describe systems that are far from equilibrium. Here we report an experimental investigation of an archetypal non-equilibrium system, involving a sensitive torsion oscillator immersed in a granular system(5,6) of millimetre-size grains that are fluidized by strong external vibrations. The vibro-fluidized granular medium is a driven environment, with continuous injection and dissipation of energy, and the immersed oscillator can be seen as analogous to an elastically bound brownian particle. By measuring the noise and the susceptibility, we show that the experiment can be treated (to a first approximation) with the equilibrium formalism. This gives experimental access to a granular viscosity and an effective temperature; however, these quantities are anisotropic and inhomogeneous. Surprisingly, the vibrofluidized granular matter behaves as a 'thermal' bath satisfying a fluctuation-dissipation relation.	Ecole Polytech Fed Lausanne, Fac Sci Base, Inst Phys Mat Complexe, CH-1015 Lausanne, Switzerland; Univ Paris 11, UMR 8627, Phys Theor Lab, F-91405 Orsay, France; Univ Roma La Sapienza, Dipartimento Fis, I-00185 Rome, Italy; INFM, I-00185 Rome, Italy; RIKEN, Inst Phys & Chem Res, Frontier Res Syst, Wako, Saitama 3510198, Japan; Univ Michigan, Dept Phys, CSCS, Ctr Theoret Phys, Ann Arbor, MI 48109 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Universite Paris Saclay; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); RIKEN; University of Michigan System; University of Michigan	D'Anna, G (corresponding author), Ecole Polytech Fed Lausanne, Fac Sci Base, Inst Phys Mat Complexe, CH-1015 Lausanne, Switzerland.	gianfranco.danna@epfl.ch	Nori, Franco/B-1222-2009	Nori, Franco/0000-0003-3682-7432				Barrat A, 2000, J PHYS A-MATH GEN, V33, P4401, DOI 10.1088/0305-4470/33/24/301; Bellon L, 2001, EUROPHYS LETT, V53, P511, DOI 10.1209/epl/i2001-00182-9; D'Anna G, 2003, EUROPHYS LETT, V61, P60, DOI 10.1209/epl/i2003-00245-y; DANNA G, 2001, PHYS REV LETT, V87, P254; Dixon PK, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.184302; Gerlach W, 1927, NATURWISSENSCHAFTEN, V15, P15, DOI 10.1007/BF01504873; Jaeger HM, 1996, REV MOD PHYS, V68, P1259, DOI 10.1103/RevModPhys.68.1259; KUBO R, 1991, STAT PHYSICS, V2; MEHTA A, 2001, ADV COMPLEX SYST, V4, P287; Olivi-Tran N, 2002, EUR PHYS J B, V25, P217, DOI 10.1140/epjb/e20020024; Philippe P, 2002, EUROPHYS LETT, V60, P677, DOI 10.1209/epl/i2002-00362-7; Uhlenbeck GE, 1929, PHYS REV, V34, P145, DOI 10.1103/PhysRev.34.145; WANG MC, 1945, REV MOD PHYS, V17, P323, DOI 10.1103/RevModPhys.17.323; Yang XY, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.044301; ZIK O, 1992, EUROPHYS LETT, V17, P315, DOI 10.1209/0295-5075/17/4/006	16	185	186	2	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					909	912		10.1038/nature01867	http://dx.doi.org/10.1038/nature01867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931179	Green Published, Green Submitted			2022-12-28	WOS:000184843600032
J	Hackam, DG; Anand, SS				Hackam, DG; Anand, SS			Emerging risk factors for atherosclerotic vascular disease - A critical review of the evidence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; MEASURING PLASMA-FIBRINOGEN; BETA-SYNTHASE DEFICIENCY; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; ARTERY-DISEASE; GLOBAL BURDEN	Context Atherosclerotic vascular disease is an enormous public health problem. A number of emerging risk factors for atherosclerosis have recently been proposed to help identify high-risk individuals. Objective To review the epidemiological, basic science, and clinical trial evidence concerning 4 emerging risk factors: C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine. Data Sources Using the terms atherosclerosis, cardiovascular disease, risk factors, prevention, screening, C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine, we searched the MEDLINE database from January 1990 to January 2003. Conference proceedings, abstract booklets, bibliographies of pertinent articles and books, and personal files were hand searched to identify additional articles. Study Selection Original investigations and reviews of the epidemiology of atherosclerosis and the association of conventional and novel risk factors with vascular risk were selected. On the basis of the search strategy, 373 relevant studies were identified. Data Extraction A diverse array of studies were examined, including randomized controlled trials, prospective cohort studies, systematic overviews, case-control, cross-sectional, and mechanistic studies. Data extraction was performed by one of the authors. Data Synthesis The available epidemiological and basic science evidence supports, to varying degrees, independent associations between these 4 candidate risk factors and atherosclerotic vascular disease. However, there is relatively little data regarding the additive yield of screening for these factors over that of validated global risk assessment strategies currently in use. Furthermore, controlled intervention studies targeting individuals with these factors for proven risk-reduction therapies, or specifically treating these factors with available therapies, are few. The explanatory power of the major, established cardiovascular risk factors has been systematically underestimated. Conclusions Although C-reactive protein, lipoprotein(a), fibrinogen, and homocysteine are associated with vascular disease risk, their optimal use in routine screening and risk stratification remains to be determined.	McMaster Univ, Fac Hlth Sci, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Fac Hlth Sci, Populat Hlth Res Inst, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University; Population Health Research Institute	Anand, SS (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Med, 1200 Main St W,HSC Rm 3X28, Hamilton, ON L8N 3Z5, Canada.	anands@mcmaster.ca	Hackam, Dan G/A-1143-2009					Acevedo M, 2002, ARTERIOSCL THROM VAS, V22, P1042, DOI 10.1161/01.ATV.0000020007.25154.62; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Baker RI, 2002, CEREBROVASC DIS, V13, P120; Barzilay JI, 2001, DIABETES, V50, P2384, DOI 10.2337/diabetes.50.10.2384; Bautista LE, 2002, J CLIN EPIDEMIOL, V55, P882, DOI 10.1016/S0895-4356(02)00434-1; Beaglehole R, 2002, INT J EPIDEMIOL, V31, P1117, DOI 10.1093/ije/31.6.1117; Bhatt DL, 2002, CIRCULATION, V106, P136, DOI 10.1161/01.CIR.0000021112.29409.A2; Biasucci LM, 1999, CIRCULATION, V99, P855, DOI 10.1161/01.CIR.99.7.855; Blake GJ, 2003, AM J MED, V114, P485, DOI 10.1016/S0002-9343(03)00074-3; Bostom AG, 2001, ANN INTERN MED, V135, P133, DOI 10.7326/0003-4819-135-2-200107170-00014; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; Cantin B, 2002, AM J CARDIOL, V89, P662, DOI 10.1016/S0002-9149(01)02336-0; CARLSON LA, 1989, J INTERN MED, V226, P271, DOI 10.1111/j.1365-2796.1989.tb01393.x; Chew DP, 2001, CIRCULATION, V104, P992, DOI 10.1161/hc3401.095074; Christen WG, 2000, ARCH INTERN MED, V160, P422, DOI 10.1001/archinte.160.4.422; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cleophas TJ, 2000, AM J CARDIOL, V86, P1005, DOI 10.1016/S0002-9149(00)01137-1; CRAIG WY, 1992, CLIN CHIM ACTA, V210, P231, DOI 10.1016/0009-8981(92)90209-9; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; De Bree A, 2002, PHARMACOL REV, V54, P599, DOI 10.1124/pr.54.4.599; Di Napoli M, 2001, STROKE, V32, P133, DOI 10.1161/01.STR.32.1.133; DIMINNO G, 1990, ARTERIOSCLEROSIS, V10, P1, DOI 10.1161/01.ATV.10.1.1; Doshi SN, 2002, ATHEROSCLEROSIS, V165, P1, DOI 10.1016/S0021-9150(02)00191-0; ERNST E, 1995, EUR HEART J, V16, P47, DOI 10.1093/eurheartj/16.suppl_A.47; FEY GH, 1987, MOL BIOL MED, V4, P323; Folsom AR, 1999, CIRCULATION, V100, P736, DOI 10.1161/01.CIR.100.7.736; Folsom AR, 2002, AM HEART J, V144, P233, DOI 10.1067/mhj.2002.124054; Foody JM, 2000, ARTERIOSCL THROM VAS, V20, P493, DOI 10.1161/01.ATV.20.2.493; Ford ES, 2002, INT J EPIDEMIOL, V31, P59, DOI 10.1093/ije/31.1.59; FOWKES FGR, 1995, EUR HEART J, V16, P36, DOI 10.1093/eurheartj/16.suppl_A.36; Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GAW A, 1994, J CLIN INVEST, V93, P2526, DOI 10.1172/JCI117263; Genest J, 2000, CAN MED ASSOC J, V163, P37; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Heeschen C, 2000, J AM COLL CARDIOL, V35, P1535, DOI 10.1016/S0735-1097(00)00581-7; Herrick S, 1999, INT J BIOCHEM CELL B, V31, P741, DOI 10.1016/S1357-2725(99)00032-1; Kelly PJ, 2002, NEUROLOGY, V59, P529, DOI 10.1212/WNL.59.4.529; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Kluijtmans LAJ, 1999, AM J HUM GENET, V65, P59, DOI 10.1086/302439; Kraft HG, 1996, ARTERIOSCL THROM VAS, V16, P713, DOI 10.1161/01.ATV.16.6.713; Kushner I, 2002, ARCH INTERN MED, V162, P867, DOI 10.1001/archinte.162.8.867; LANGE HW, 2003, AM COLL CARD 52 ANN; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; Lee AJ, 1999, THROMB HAEMOSTASIS, V81, P553; LEVIN EG, 1994, ARTERIOSCLER THROMB, V14, P438, DOI 10.1161/01.ATV.14.3.438; Li XN, 1997, ARTERIOSCL THROM VAS, V17, P3215, DOI 10.1161/01.ATV.17.11.3215; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lippi G, 1998, CLIN CHEM LAB MED, V36, P5, DOI 10.1515/CCLM.1998.003; Lippi G, 2000, QJM-MON J ASSOC PHYS, V93, P75, DOI 10.1093/qjmed/93.2.75; Lloyd-Jones DM, 2003, NEW ENGL J MED, V348, P1059; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; Lowe HC, 2002, J AM COLL CARDIOL, V39, P183, DOI 10.1016/S0735-1097(01)01742-9; MacMahon M, 2000, NUTR METAB CARDIOVAS, V10, P195; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; Mangoni AA, 2002, AM J MED, V112, P556, DOI 10.1016/S0002-9343(02)01021-5; Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7; Marcovina SM, 2000, CLIN CHEM, V46, P1956; Maresca G, 1999, ARTERIOSCL THROM VAS, V19, P1368, DOI 10.1161/01.ATV.19.6.1368; MCCULLY KS, 1992, NUTR REV, V50, P7, DOI 10.1111/j.1753-4887.1992.tb02454.x; Meade T, 2002, BRIT MED J, V325, P1139, DOI 10.1136/bmj.325.7373.1139; MEADE TW, 1987, LANCET, V2, P986; Milazzo D, 1999, AM J CARDIOL, V84, P459, DOI 10.1016/S0002-9149(99)00333-1; Milionis HJ, 2000, J CLIN PATHOL, V53, P487, DOI 10.1136/jcp.53.7.487; Moller J, 2000, SCAND J CLIN LAB INV, V60, P491; Moons KGM, 1997, EPIDEMIOLOGY, V8, P12, DOI 10.1097/00001648-199701000-00002; Mosca L, 2002, NEW ENGL J MED, V347, P1615, DOI 10.1056/NEJMe020127; MUDD SH, 1985, AM J HUM GENET, V37, P1; Muir KW, 1999, STROKE, V30, P981, DOI 10.1161/01.STR.30.5.981; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Park R, 2002, CIRCULATION, V106, P2073, DOI 10.1161/01.CIR.0000033819.29662.09; Pasceri V, 2000, CIRCULATION, V102, P2165; Pasternak Richard C., 1999, American Journal of Medicine, V107, p31S; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Pillarisetti S, 1997, J CLIN INVEST, V100, P867, DOI 10.1172/JCI119602; Poon M, 1997, CIRCULATION, V96, P2514, DOI 10.1161/01.CIR.96.8.2514; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schnyder G, 2002, JAMA-J AM MED ASSOC, V288, P973, DOI 10.1001/jama.288.8.973; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; SMIEJA M, 2001, AM HEART ASS SCI SES; Solfrizzi V, 2002, AM J CARDIOL, V89, P825, DOI 10.1016/S0002-9149(02)02192-6; Spence JD, 2001, NEUROEPIDEMIOLOGY, V20, P16, DOI 10.1159/000054753; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Tanne D, 2001, AM J MED, V111, P457, DOI 10.1016/S0002-9343(01)00914-7; Tommasi S, 1999, AM J CARDIOL, V83, P1595, DOI 10.1016/S0002-9149(99)00162-9; Torzewski J, 1998, ARTERIOSCL THROM VAS, V18, P1386, DOI 10.1161/01.ATV.18.9.1386; Torzewski M, 2000, ARTERIOSCL THROM VAS, V20, P2094, DOI 10.1161/01.ATV.20.9.2094; van Exel E, 2002, STROKE, V33, P1135, DOI 10.1161/01.STR.0000014206.05597.9E; Verma S, 2002, CIRCULATION, V105, P1890, DOI 10.1161/01.CIR.0000015126.83143.B4; von Eckardstein A, 2001, J AM COLL CARDIOL, V37, P434, DOI 10.1016/S0735-1097(00)01126-8; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wallis EJ, 2001, J HYPERTENS, V19, P691, DOI 10.1097/00004872-200104000-00005; Walter DH, 2001, J AM COLL CARDIOL, V37, P839, DOI 10.1016/S0735-1097(00)01193-1; Walter DH, 2001, J AM COLL CARDIOL, V38, P2006, DOI 10.1016/S0735-1097(01)01662-X; Weintraub WS, 2000, EUR HEART J, V21, P958, DOI 10.1053/euhj.2000.2109; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Whicher JT, 1998, CLIN BIOCHEM, V31, P459, DOI 10.1016/S0009-9120(98)00035-6; WILKES HC, 1988, LANCET, V1, P307; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; World Health Organization, WORLD HLTH REP 2002; Yap S, 2000, SEMIN THROMB HEMOST, V26, P335, DOI 10.1055/s-2000-8100; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488; Zebrack JS, 2002, J AM COLL CARDIOL, V39, P632, DOI 10.1016/S0735-1097(01)01804-6; Zebrack JS, 2002, AM J CARDIOL, V89, P145, DOI 10.1016/S0002-9149(01)02190-7; Zwaka TP, 2001, CIRCULATION, V103, P1194	125	374	405	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					932	940		10.1001/jama.290.7.932	http://dx.doi.org/10.1001/jama.290.7.932			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928471	Bronze			2022-12-28	WOS:000184828800031
J	Conlon, M				Conlon, M			Appraisal: the catalyst of personal development	BRITISH MEDICAL JOURNAL			English	Article							CONSTRUCTIVE DIALOGUE; DOCTORS; MANAGERS; CARE	Appraisal of NHS consultants has been running for two years, and most general practitioners will have their first appraisal this year. If done properly, the process should enhance personal development and learning, but links with revalidation have led to fears about it being used only for assessment. The challenge is to produce a valued appraisal system that ultimately improves patient care	NHS Modernisat Agcy, NHS Clin Governance Support Team, GP Appraiser Training Programme, Leicester LE1 6NB, Leics, England		Conlon, M (corresponding author), NHS Modernisat Agcy, NHS Clin Governance Support Team, GP Appraiser Training Programme, Leicester LE1 6NB, Leics, England.							Davidoff F, 2002, BMJ-BRIT MED J, V324, P623, DOI 10.1136/bmj.324.7338.623; Davies HTO, 2003, BMJ-BRIT MED J, V326, P646, DOI 10.1136/bmj.326.7390.646; *DEP HLTH, APPR GEN PRACT GUID; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; *DEP HLTH, APPR NHS CONS; *DEP HLTH GEN MED, APPR REV; Department of Health, 1999, SUPP DOCT PROT PAT; DONALDSON L, 2002, APPRAISAL GEN PRACTI; Donaldson L., 2005, ORG MEMORY REPORT EX; Edwards N, 2003, BRIT MED J, V326, P609, DOI 10.1136/bmj.326.7390.609; Edwards N, 2003, BRIT MED J, V326, P116, DOI 10.1136/bmj.326.7381.116; General Medical Council, GUID GOOD MED PRACT; General Medical Council, 2003, LIC PRACT REV; Huby G, 2002, BMJ-BRIT MED J, V325, P140, DOI 10.1136/bmj.325.7356.140; Kmietowicz Z, 2001, BRIT MED J, V323, P887, DOI 10.1136/bmj.323.7318.887; Kolb D.A, 1984, EXPERIENTIAL LEARNIN; MARTIN D, APPRAISAL GPS; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; Wall D, 2002, BR J CLIN GOVERNANCE, V7, P294; West M, 2002, BRIT MED J, V325, P669, DOI 10.1136/bmj.325.7366.669; West MA, 2002, INT J HUM RESOUR MAN, V13, P1299, DOI 10.1080/09585190210156521	21	27	27	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					389	391		10.1136/bmj.327.7411.389	http://dx.doi.org/10.1136/bmj.327.7411.389			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919998	Green Published			2022-12-28	WOS:000184864200028
J	Lilly, RZ				Lilly, RZ			Extracts from "BestTreatments" - Bulimia nervosa	BRITISH MEDICAL JOURNAL			English	Review									BMJ Unified, London WC1H 9JR, England		Lilly, RZ (corresponding author), BMJ Unified, London WC1H 9JR, England.							WELCH SL, 1994, AM J PSYCHIAT, V151, P402	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					380	381		10.1136/bmj.327.7411.380	http://dx.doi.org/10.1136/bmj.327.7411.380			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919992	Green Published			2022-12-28	WOS:000184864200022
J	Tagliabue, E; Agresti, R; Carcangiu, ML; Ghirelli, C; Morelli, D; Campiglio, M; Martel, M; Giovanazzi, R; Greco, M; Balsari, A; Menard, S				Tagliabue, E; Agresti, R; Carcangiu, ML; Ghirelli, C; Morelli, D; Campiglio, M; Martel, M; Giovanazzi, R; Greco, M; Balsari, A; Menard, S			Role of HER2 in wound-induced breast carcinoma proliferation	LANCET			English	Article							GROWTH-FACTOR; TUMOR RECURRENCE; CELLS; CANCER; MASTECTOMY; RESECTION; ANTIBODY; IMMUNOSUPPRESSION; PROGRESSION; IRRADIATION	Objective: Clinical and experimental data have suggested that surgical removal of primary tumours promotes the growth of metastatic lesions. We assessed the effect of surgery on proliferation of breast carcinomas, in particular those overexpressing HER2 oncoprotein. Methods: Proliferation of breast carcinoma cells was assessed by MIB-1 immunohistochemistry in sections of primary breast carcinomas and in residual tumour found in re-excision specimens, and in in-vitro cell lines by colorimetric assay. Epidermal growth factor (EGF)-like growth factors were measured by displacement of radiolabelled EGF from its receptor. Cellular damage was measured in terms of creatine phosphokinase level. Downmodulation of HER2 was investigated by cytoplasmic expression of anti-HER2 antibody and by inhibition with anti-HER2 antibody trastuzumab. Findings: Residual breast carcinomas that had been surgically removed within 48 days after first surgery showed a significant increase in proliferation if they were HER2-positive. Wound drainage fluid and postsurgical serum samples from patients stimulated in-vitro growth of HER2-overexpressing breast carcinoma cells. Removal of HER2 from the cell membrane led to a striking reduction of the induced proliferation. The amount of EGF-like growth factors in post-surgical serum samples, as well as the extent of drainage-fluid-induced proliferation, directly correlated with the amount of surgical damage assessed by creatine phosphokinase levels (r=0.77, p=0.002 and r=0.69, p=0.009, respectively). Treatment of HER2-positive tumour cells with trastuzumab before adding the growth stimulus abolished drainage-fluid-induced proliferation. Interpretation: HER2 overexpression by breast carcinoma cells has a role in postsurgery stimulation of growth of breast carcinoma cells.	Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Gen Surg Breast Unit B, I-20133 Milan, Italy; Ist Nazl Tumori, Pathol Unit, I-20133 Milan, Italy; Ist Nazl Tumori, Med Lab Unit, I-20133 Milan, Italy; Univ Milan, Inst Pathol, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan	Menard, S (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	sylvie.menard@istitutotumori.mi.it	Tagliabue, Elda/B-9377-2017; Morelli, Daniele/I-4113-2017; balsari, andrea/M-5657-2016; menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019	Tagliabue, Elda/0000-0001-9877-2903; Morelli, Daniele/0000-0002-1823-3764; balsari, andrea/0000-0002-3250-2668; Agresti, Roberto/0000-0003-4700-1951				BAKER DG, 1989, SURGERY, V106, P525; BLOTNICK S, 1994, P NATL ACAD SCI USA, V91, P2890, DOI 10.1073/pnas.91.8.2890; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; COLE WH, 1985, J SURG ONCOL, V30, P139; Decker D, 1996, SURGERY, V119, P316, DOI 10.1016/S0039-6060(96)80118-8; DEMICHELI R, 1994, J NATL CANCER I, V86, P45; FISHER B, 1989, CANCER RES, V49, P1996; FISHER B, 1992, SEMIN SURG ONCOL, V8, P153; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Haffty BG, 2002, SEMIN RADIAT ONCOL, V12, P329, DOI 10.1053/srao.2002.35252; HANSBROUGH JF, 1984, AM J SURG, V148, P303, DOI 10.1016/0002-9610(84)90459-8; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hofer SOP, 1998, ARCH SURG-CHICAGO, V133, P383, DOI 10.1001/archsurg.133.4.383; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; IOZZO RV, 1995, LAB INVEST, V73, P157; KLAUKE R, 1993, EUR J CLIN CHEM CLIN, V31, P901; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Menard S, 2002, CLIN CANCER RES, V8, P520; MIZUTANI J, 1992, BRIT J CANCER, V65, P794, DOI 10.1038/bjc.1992.170; MORGENSTERN L, 1973, AM J SURG, V125, P29, DOI 10.1016/0002-9610(73)90005-6; PIZAO PE, 1992, BRIT J CANCER, V66, P660, DOI 10.1038/bjc.1992.333; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rowley DR, 1998, CANCER METAST REV, V17, P411, DOI 10.1023/A:1006129420005; Schindel DT, 1997, J PEDIATR SURG, V32, P995, DOI 10.1016/S0022-3468(97)90385-7; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; Tagliabue E, 2000, J BIOL CHEM, V275, P5388, DOI 10.1074/jbc.275.8.5388; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; WATSON DI, 1995, MED J AUSTRALIA, V163, P106, DOI 10.5694/j.1326-5377.1995.tb126131.x	32	119	122	2	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					527	533		10.1016/S0140-6736(03)14112-8	http://dx.doi.org/10.1016/S0140-6736(03)14112-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932384				2022-12-28	WOS:000184817600009
J	Kashefi, K; Lovley, DR				Kashefi, K; Lovley, DR			Extending the upper temperature limit for life	SCIENCE			English	Article							ELECTRON-ACCEPTOR; GEN. NOV.; FE(III)		Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.							Blochl E, 1997, EXTREMOPHILES, V1, P14; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; GOLD T, 1992, P NATL ACAD SCI USA, V89, P6045, DOI 10.1073/pnas.89.13.6045; Jannasch H.W., 1995, GEOPHYS MONOGR SER, V91, P273, DOI DOI 10.1029/GM091P0273; Kashefi K, 2002, APPL ENVIRON MICROB, V68, P1735, DOI 10.1128/AEM.68.4.1735-1742.2002; Kashefi K, 2002, INT J SYST EVOL MICR, V52, P719, DOI [10.1099/ijs.0.01953-0, 10.1099/00207713-52-3-719]; Lovley DR, 2000, ENVIRONMENTAL MICROBE-METAL INTERACTIONS, P3; Russell MJ, 2002, GEOCHEM NEWS, V113, P6; Vargas M, 1998, NATURE, V395, P65, DOI 10.1038/25720	9	442	488	8	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					934	934		10.1126/science.1086823	http://dx.doi.org/10.1126/science.1086823			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920290				2022-12-28	WOS:000184755900028
J	Alley, RB; Lawson, DE; Larson, GJ; Evenson, EB; Baker, GS				Alley, RB; Lawson, DE; Larson, GJ; Evenson, EB; Baker, GS			Stabilizing feedbacks in glacier-bed erosion	NATURE			English	Article							FREEZE-ON MECHANISM; RICH BASAL ICE; SEDIMENT; ALASKA	Glaciers often erode, transport and deposit sediment much more rapidly than nonglacial environments(1), with implications for the evolution of glaciated mountain belts and their associated sedimentary basins. But modelling such glacial processes is difficult, partly because stabilizing feedbacks similar to those operating in rivers(2,3) have not been identified for glacial landscapes. Here we combine new and existing data of glacier morphology and the processes governing glacier evolution from diverse settings to reveal such stabilizing feedbacks. We find that the long profiles of beds of highly erosive glaciers tend towards steady-state angles opposed to and slightly more than 50 per cent steeper than the overlying ice-air surface slopes, and that additional subglacial deepening must be enabled by non-glacial processes. Climatic or glaciological perturbations of the ice-air surface slope can have large transient effects on glaciofluvial sediment flux and apparent glacial erosion rate.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, EMS Environm Inst, University Pk, PA 16802 USA; Cold Reg Res & Engn Lab, Hanover, NH 03755 USA; Michigan State Univ, Dept Geol Sci, E Lansing, MI 48824 USA; Lehigh Univ, Dept Earth & Environm Sci, Bethlehem, PA 18015 USA; SUNY Buffalo, Dept Geol, Buffalo, NY 14260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; United States Department of Defense; United States Army; U.S. Army Corps of Engineers; U.S. Army Engineer Research & Development Center (ERDC); Cold Regions Research & Engineering Laboratory (CRREL); Michigan State University; Lehigh University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Alley, RB (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.	ralley@essc.psu.edu	Baker, Gregory S./AAG-8934-2021	Baker, Gregory S./0000-0003-4184-8000				Alley RB, 1998, J GLACIOL, V44, P563, DOI 10.3189/S0022143000002070; Alley RB, 1997, QUATERNARY SCI REV, V16, P1017, DOI 10.1016/S0277-3791(97)00034-6; Alley RB, 1999, GEOL SOC AM SPEC PAP, P1; ALLEY RB, IN PRESS ANN GLACIOL; ARCONE SA, 2000, 8 INT C GROUND PEN R, P377; Brocklehurst SH, 2002, GEOMORPHOLOGY, V42, P1, DOI 10.1016/S0169-555X(01)00069-1; Cuffey K, 1996, ANN GLACIOL, V22, P17, DOI 10.3189/1996AoG22-1-17-24; Easterbrook D.J., 1999, SURFACE PROCESSES LA; Evenson EB, 1999, GEOL S AM S, P23; HALL DK, 1995, PHYS GEOGR, V16, P27, DOI 10.1080/02723646.1995.10642541; Hallet B, 1996, ANN GLACIOL, V22, P1; Hallet B, 1996, GLOBAL PLANET CHANGE, V12, P213, DOI 10.1016/0921-8181(95)00021-6; Hooke R Le B, 1991, GEOL SOC AM BULL, V34, P228; HOOKE RL, 1994, J GLACIOL, V40, P140; Hunter LE, 1996, J GLACIOL, V42, P123, DOI 10.3189/S0022143000030586; IVERSON NR, 1991, J GLACIOL, V37, P27; Koppes MN, 2002, GEOLOGY, V30, P47, DOI 10.1130/0091-7613(2002)030<0047:IORGRO>2.0.CO;2; Lawson DE, 1998, J GLACIOL, V44, P547, DOI 10.3189/S0022143000002069; LAWSON DE, 1979, 799 CRREL US ARM; LAWSON DE, 1993, CRREL MONOGRAPH, V932; LINKER JS, 2000, GEOL SOC AM ABSTR, V32, pA329; LLIBOUTRY L, 1983, J GLACIOL, V29, P216, DOI 10.3189/S0022143000008273; MACKIN JH, 1948, GEOL SOC AM BULL, V59, P463; Montgomery DR, 2002, GEOLOGY, V30, P1047, DOI 10.1130/0091-7613(2002)030<1047:VFBFAG>2.0.CO;2; NOLAN M, 1995, J GLACIOL, V41, P541, DOI 10.3189/S0022143000034870; Pearce JT, 2003, GEOLOGY, V31, P7, DOI 10.1130/0091-7613(2003)031<0007:BCOGDS>2.0.CO;2; POWELL RD, 1990, GEOL SOC SPEC PUBL, V53, P53, DOI 10.1144/GSL.SP.1990.053.01.03; Roberts MJ, 2002, GEOLOGY, V30, P439, DOI 10.1130/0091-7613(2002)030<0439:GSII>2.0.CO;2; Rocthlisberger H, 1987, GLACIOFLUVIAL SEDIME, P207; Williams J.R., 1961, ALASKA ARCTIC, V14, P82, DOI [10.14430/ARCTIC3664, DOI 10.14430/ARCTIC3664]	30	135	136	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					758	760		10.1038/nature01839	http://dx.doi.org/10.1038/nature01839			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917679				2022-12-28	WOS:000184733900034
J	Sakaba, T; Neher, E				Sakaba, T; Neher, E			Direct modulation of synaptic vesicle priming by GABA(B) receptor activation at a glutamatergic synapse	NATURE			English	Article							PRESYNAPTIC CALCIUM CURRENT; TRANSMITTER RELEASE; BRAIN-STEM; G-PROTEINS; INHIBITION; CAMP; RAT; TRANSMISSION; CURRENTS; CALYX	Second messenger cascades involving G proteins(1,2) and calcium(3) are known to modulate neurotransmitter release(4,5). A prominent effect of such a cascade is the downmodulation of presynaptic calcium influx(6,7), which markedly reduces evoked neurotransmitter release(5,7,8). Here we show that G-protein-mediated signalling, such as through GABA (gamma-amino butyric acid) subtype B (GABA(B)) receptors, retards the recruitment of synaptic vesicles during sustained activity and after short-term depression. This retardation occurs through a lowering of cyclic AMP, which blocks the stimulatory effect of increased calcium concentration on vesicle recruitment. In this signalling pathway, cAMP (functioning through the cAMP-dependent guanine nucleotide exchange factor) and calcium/calmodulin cooperate to enhance vesicle priming. The differential modulation of the two forms of synaptic plasticity, presynaptic inhibition and calcium-dependent recovery from synaptic depression, is expected to have interesting consequences for the dynamic behaviour of neural networks.	Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany	Max Planck Society	Neher, E (corresponding author), Max Planck Inst Biophys Chem, Dept Membrane Biophys, D-37077 Gottingen, Germany.		Neher, Erwin/A-2109-2013	Sakaba, Takeshi/0000-0003-0688-7717				BARNESDAVIES M, 1995, J PHYSIOL-LONDON, V488, P387, DOI 10.1113/jphysiol.1995.sp020974; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Borst JGG, 1995, J PHYSIOL-LONDON, V489, P825, DOI 10.1113/jphysiol.1995.sp021095; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; Dittman JS, 1998, J NEUROSCI, V18, P6147; Dittman JS, 1996, J NEUROSCI, V16, P1623; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; FORSYTHE ID, 1994, J PHYSIOL-LONDON, V479, P381, DOI 10.1113/jphysiol.1994.sp020303; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; Isaacson JS, 1998, J NEUROPHYSIOL, V80, P1571, DOI 10.1152/jn.1998.80.3.1571; Kajikawa Y, 2001, P NATL ACAD SCI USA, V98, P8054, DOI 10.1073/pnas.141031298; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Sakaba T, 2003, J NEUROSCI, V23, P837; Sakaba T, 2001, NEURON, V32, P1119, DOI 10.1016/S0896-6273(01)00543-8; Sakaba T, 2001, P NATL ACAD SCI USA, V98, P331, DOI 10.1073/pnas.021541098; SCANZIANI M, 1992, NEURON, V9, P919, DOI 10.1016/0896-6273(92)90244-8; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SILINSKY EM, 1984, J PHYSIOL-LONDON, V346, P243, DOI 10.1113/jphysiol.1984.sp015019; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Stevens CF, 1998, NEURON, V21, P415, DOI 10.1016/S0896-6273(00)80550-4; Takahashi T, 2000, SCIENCE, V289, P460, DOI 10.1126/science.289.5478.460; Takahashi T, 1998, J NEUROSCI, V18, P3138; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; Xu XZS, 1998, J BIOL CHEM, V273, P31297, DOI 10.1074/jbc.273.47.31297; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	30	184	191	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					775	778		10.1038/nature01859	http://dx.doi.org/10.1038/nature01859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917685				2022-12-28	WOS:000184733900040
J	Trompouki, E; Hatzivassiliou, E; Tsichritzis, T; Farmer, H; Ashworth, A; Mosialos, G				Trompouki, E; Hatzivassiliou, E; Tsichritzis, T; Farmer, H; Ashworth, A; Mosialos, G			CYLD is a deubiquitinating enzyme that negatively regulates NF-kappa B activation by TNFR family members	NATURE			English	Article							EPSTEIN-BARR-VIRUS; RECEPTOR-ASSOCIATED FACTOR-2; TRANSFORMING PROTEIN LMP1; ECTODERMAL DYSPLASIA; MEMBRANE-PROTEIN; COMPLEX; KINASE; TRAF2; IKK; IDENTIFICATION	Familial cylindromatosis is an autosomal dominant predisposition to tumours of skin appendages called cylindromas. Familial cylindromatosis is caused by mutations in a gene encoding the CYLD protein of previously unknown function(1). Here we show that CYLD is a deubiquitinating enzyme that negatively regulates activation of the transcription factor NF-kappaB by specific tumour-necrosis factor receptors (TNFRs). Loss of the deubiquitinating activity of CYLD correlates with tumorigenesis. CYLD inhibits activation of NF-kappaB by the TNFR family members CD40, XEDAR and EDAR in a manner that depends on the deubiquitinating activity of CYLD. Downregulation of CYLD by RNA-mediated interference augments both basal and CD40-mediated activation of NF-kappaB. The inhibition of NF-kappaB activation by CYLD is mediated, at least in part, by the deubiquitination and inactivation of TNFR-associated factor 2 (TRAF2) and, to a lesser extent, TRAF6. These results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-kappaB that is required for appropriate cellular homeostasis of skin appendages.	Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, Vari 16672, Greece; Inst Canc Res, Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England	Alexander Fleming Biomedical Sciences Research Center; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Mosialos, G (corresponding author), Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, 34 Alexander Fleming St, Vari 16672, Greece.		Trompouki, Eirini/AAX-9539-2020	Trompouki, Eirini/0000-0002-7242-8810				Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hatzivassiliou E, 1997, BIOCHEMISTRY-US, V36, P9221, DOI 10.1021/bi963145k; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hu M, 2002, CELL, V111, P1041, DOI 10.1016/S0092-8674(02)01199-6; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; McKenna S, 2003, J BIOL CHEM, V278, P13151, DOI 10.1074/jbc.M212353200; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Nguyen LT, 1999, IMMUNITY, V11, P379, DOI 10.1016/S1074-7613(00)80113-2; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yan MH, 2002, CURR BIOL, V12, P409, DOI 10.1016/S0960-9822(02)00687-5; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	27	758	788	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					793	796		10.1038/nature01803	http://dx.doi.org/10.1038/nature01803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917689	Green Published			2022-12-28	WOS:000184733900044
J	Bais, HP; Vepachedu, R; Gilroy, S; Callaway, RM; Vivanco, JM				Bais, HP; Vepachedu, R; Gilroy, S; Callaway, RM; Vivanco, JM			Allelopathy and exotic plant invasion: From molecules and genes to species interactions	SCIENCE			English	Article							ROOT; NEIGHBORS	Here we present evidence that Centaurea maculosa (spotted knapweed), an invasive species in the western United States, displaces native plant species by exuding the phytotoxin (-)-catechin from its roots. Our results show inhibition of native species' growth and germination in field soils at natural concentrations of (-)- catechin. In susceptible species such as Arabidopsis thaliana, the allelo-chemical triggers a wave of reactive oxygen species (ROS) initiated at the root meristem, which leads to a Ca2+ signaling cascade triggering genome-wide changes in gene expression and, ultimately, death of the root system. Our results support a "novel weapons hypothesis" for invasive success.	Colorado State Univ, Dept Hort & Landscape Architecture, Cell & Mol Biol Program, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Hort & Landscape Architecture, Grad Degree Program Ecol, Ft Collins, CO 80523 USA; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA	Colorado State University; Colorado State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Montana System; University of Montana	Vivanco, JM (corresponding author), Colorado State Univ, Dept Hort & Landscape Architecture, Cell & Mol Biol Program, Ft Collins, CO 80523 USA.	jvivanco@lamar.colostate.edu	Rechsteiner, Cynthia/C-5894-2011	Gilroy, Simon/0000-0001-9597-6839				Bais HP, 2002, PLANT PHYSIOL, V128, P1173, DOI 10.1104/pp.011019; Bais HP, 2001, IN VITRO CELL DEV-PL, V37, P730; BAIS HP, UNPUB; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; Callaway RM, 2002, TRENDS ECOL EVOL, V17, P104, DOI 10.1016/S0169-5347(01)02438-7; Fasano JM, 2001, PLANT CELL, V13, P907, DOI 10.1105/tpc.13.4.907; Gheldof N, 2002, J AGR FOOD CHEM, V50, P5870, DOI 10.1021/jf0256135; Goslee SC, 2001, ECOL MODEL, V139, P31, DOI 10.1016/S0304-3800(01)00231-9; Grant JJ, 2000, PLANT PHYSIOL, V124, P21, DOI 10.1104/pp.124.1.21; Jones DL, 1998, PLANTA, V206, P378, DOI 10.1007/s004250050413; KEANE S, 2002, TRENDS ECOL EVOL, V17, P170; Kennedy TA, 2002, NATURE, V417, P636, DOI 10.1038/nature00776; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Ridenour WM, 2001, OECOLOGIA, V126, P444, DOI 10.1007/s004420000533	14	780	1000	11	626	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1377	1380		10.1126/science.1083245	http://dx.doi.org/10.1126/science.1083245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958360				2022-12-28	WOS:000185116400041
J	Kiers, ET; Rousseau, RA; West, SA; Denison, RF				Kiers, ET; Rousseau, RA; West, SA; Denison, RF			Host sanctions and the legume-rhizobium mutualism	NATURE			English	Article							NITROGENASE ACTIVITY; ROOT-NODULES; EVOLUTION; STABILITY; PERMEABILITY; COMPETITION	Explaining mutualistic cooperation between species remains one of the greatest problems for evolutionary biology(1-4). Why do symbionts provide costly services to a host, indirectly benefiting competitors sharing the same individual host? Host monitoring of symbiont performance and the imposition of sanctions on 'cheats' could stabilize mutualism(5,6). Here we show that soybeans penalize rhizobia that fail to fix N-2 inside their root nodules. We prevented a normally mutualistic rhizobium strain from cooperating (fixing N-2) by replacing air with an N-2-free atmosphere (Ar:O-2). A series of experiments at three spatial scales (whole plants, half root systems and individual nodules) demonstrated that forcing non-cooperation (analogous to cheating) decreased the reproductive success of rhizobia by about 50%. Non-invasive monitoring implicated decreased O-2 supply as a possible mechanism for sanctions against cheating rhizobia. More generally, such sanctions by one or both partners may be important in stabilizing a wide range of mutualistic symbioses.	Univ Calif Davis, Davis, CA 95616 USA; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	University of California System; University of California Davis; University of Edinburgh	Denison, RF (corresponding author), Univ Calif Davis, 1 Shields Ave, Davis, CA 95616 USA.	rfdenison@ucdavis.edu	Toby, Kiers/H-4819-2017; West, Stuart A/M-3608-2014	Toby, Kiers/0000-0002-0597-1653; West, Stuart A/0000-0003-2152-3153				AMARGER N, 1981, SOIL BIOL BIOCHEM, V13, P475, DOI 10.1016/0038-0717(81)90037-7; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Burdon JJ, 1999, J APPL ECOL, V36, P398, DOI 10.1046/j.1365-2664.1999.00409.x; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; DENISON RF, 1991, PLANT PHYSIOL, V96, P137, DOI 10.1104/pp.96.1.137; Denison RF, 2000, AM NAT, V156, P567, DOI 10.1086/316994; DENISON RF, 1995, PLANT PHYSIOL, V107, P1355, DOI 10.1104/pp.107.4.1355; Ferriere R, 2002, P ROY SOC B-BIOL SCI, V269, P773, DOI 10.1098/rspb.2001.1900; Frank, 1998, FDN SOCIAL EVOLUTION; FRANK SA, 1995, NATURE, V377, P520, DOI 10.1038/377520a0; HAHN M, 1986, FEMS MICROBIOL LETT, V33, P143; HARTWIG U, 1987, ANN BOT-LONDON, V59, P285, DOI 10.1093/oxfordjournals.aob.a087317; Herre EA, 1999, TRENDS ECOL EVOL, V14, P49, DOI 10.1016/S0169-5347(98)01529-8; KIJNE JW, 1975, PHYSIOL PLANT PATHOL, V7, P17, DOI 10.1016/0048-4059(75)90055-7; KING BJ, 1991, PLANT PHYSIOL, V96, P376, DOI 10.1104/pp.96.2.376; Layzell D. B., 1989, Applications of continuous and steady-state methods to root biology., P1; LAYZELL DB, 1979, PLANT PHYSIOL, V64, P888, DOI 10.1104/pp.64.5.888; Lodwig EM, 2003, NATURE, V422, P722, DOI 10.1038/nature01527; PELLMYR O, 1994, NATURE, V372, P257, DOI 10.1038/372257a0; RASCHE ME, 1989, PLANT PHYSIOL, V91, P663, DOI 10.1104/pp.91.2.663; Ratnieks FLW, 2001, ANN ZOOL FENN, V38, P201; SEN D, 1980, PLANT SCI LETT, V18, P315, DOI 10.1016/0304-4211(80)90122-4; SHEEHY JE, 1983, ANN BOT-LONDON, V52, P565, DOI 10.1093/oxfordjournals.aob.a086611; SINGLETON PW, 1987, PLANT PHYSIOL, V83, P552, DOI 10.1104/pp.83.3.552; SINGLETON PW, 1983, CROP SCI, V23, P69, DOI 10.2135/cropsci1983.0011183X002300010019x; SPRENT JI, 1985, P ROY SOC EDINB B, V85, P215, DOI 10.1017/S0269727000004036; UDVARDI MK, 1993, SYMBIOSIS, V14, P87; West SA, 2002, J EVOLUTION BIOL, V15, P830, DOI 10.1046/j.1420-9101.2002.00441.x; West SA, 2002, P ROY SOC B-BIOL SCI, V269, P685, DOI 10.1098/rspb.2001.1878; Yu DW, 2001, BIOL J LINN SOC, V72, P529, DOI [10.1006/bijl.2000.0514, 10.1111/j.1095-8312.2001.tb01336.x]	30	619	643	5	415	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					78	81		10.1038/nature01931	http://dx.doi.org/10.1038/nature01931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955144	Green Published			2022-12-28	WOS:000185089200041
J	Bibby, TS; Mary, I; Nield, J; Partensky, F; Barber, J				Bibby, TS; Mary, I; Nield, J; Partensky, F; Barber, J			Low-light-adapted Prochlorococcus species possess specific antennae for each photosystem	NATURE			English	Article							CYANOBACTERIA/; PROKARYOTE; RESOLUTION; COMPLEXES; PHYLOGENY; PROTEINS; GENES; RING	Prochlorococcus, the most abundant genus of photosynthetic organisms(1), owes its remarkably large depth distribution in the oceans to the occurrence of distinct genotypes adapted to either low- or high-light niches(2,3). The pcb genes, encoding the major chlorophyll-binding, light-harvesting antenna proteins in this genus(4), are present in multiple copies in low- light strains but as a single copy in high-light strains(5). The basis of this differentiation, however, has remained obscure. Here we show that the moderate low- light-adapted strain Prochlorococcus sp. MIT 9313 has one iron-stress-induced pcb gene encoding an antenna protein serving photosystem I (PSI)-comparable to isiA genes from cyanobacteria(6,7) -and a constitutively expressed pcb gene encoding a photosystem II (PSII) antenna protein. By comparison, the very low- light-adapted strain SS120 has seven pcb genes encoding constitutive PSI and PSII antennae, plus one PSI iron-regulated pcb gene, whereas the high-light-adapted strain MED4 has only a constitutive PSII antenna. Thus, it seems that the adaptation of Prochlorococcus to low light environments has triggered a multiplication and specialization of Pcb proteins comparable to that found for Cab proteins in plants and green algae(8).	Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, London SW7 2AZ, England; CNRS, Biol Stn, UMR 7127, F-29682 Roscoff, France; Univ Paris 06, F-29682 Roscoff, France	Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Barber, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wolfson Labs, Dept Biol Sci, Biochem Bldg,S Kensington Campus, London SW7 2AZ, England.		Partensky, Frédéric/AAH-1170-2021; Bibby, Thomas/C-9159-2014; Partensky, Frédéric/B-9194-2018; Nield, Jon/C-5892-2013	Partensky, Frédéric/0000-0003-1274-4050; Partensky, Frédéric/0000-0003-1274-4050; Nield, Jon/0000-0001-9983-0239; Bibby, Thomas/0000-0003-1743-473X				Bhaya D, 2000, J BACTERIOL, V182, P5692, DOI 10.1128/JB.182.20.5692-5699.2000; Bibby TS, 2001, NATURE, V413, P590, DOI 10.1038/35098153; Bibby TS, 2001, NATURE, V412, P743, DOI 10.1038/35089098; Boekema EJ, 2001, NATURE, V412, P745, DOI 10.1038/35089104; Garczarek L, 2001, PLANT MOL BIOL, V46, P683, DOI 10.1023/A:1011681726654; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; Hankamer B, 1997, EUR J BIOCHEM, V243, P422, DOI 10.1111/j.1432-1033.1997.0422a.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; MARY I, IN PRESS FEMS MICROB; Moore LR, 1999, LIMNOL OCEANOGR, V44, P628, DOI 10.4319/lo.1999.44.3.0628; Moore LR, 1998, NATURE, V393, P464, DOI 10.1038/30965; Partensky F, 1997, PHOTOSYNTH RES, V51, P209, DOI 10.1023/A:1005807408161; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; PARTENSKY F, IN PRESS ADV PHOTOSY; SIDLER W, 1994, MOL BIOL CYANOBACTER, V14, P139; Straus N.A., 1994, MOL BIOL CYANOBACTER, P731, DOI DOI 10.1007/978-94-011-0227-8_25; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004	20	127	156	2	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1051	1054		10.1038/nature01933	http://dx.doi.org/10.1038/nature01933			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944966				2022-12-28	WOS:000184984200042
J	Culley, AI; Lang, AS; Suttle, CA				Culley, AI; Lang, AS; Suttle, CA			High diversity of unknown picorna-like viruses in the sea	NATURE			English	Article							MARINE VIRUSES; RNA; POLYMERASES; EVOLUTION; TAXONOMY; MOTIFS	Picorna-like viruses are a loosely defined group of positive-sense single-stranded RNA viruses that are major pathogens of animals, plants and insects. They include viruses that are of enormous economic and public-health concern and are responsible for animal diseases (such as poliomyelitis(1)), plant diseases (such as sharka(2)) and insect diseases (such as sacbrood(3)). Viruses from the six divergent families (the Picornaviridae, Caliciviridae, Comoviridae, Sequiviridae, Dicistroviridae and Potyviridae) that comprise the picorna-like virus superfamily(4) have the following features in common: a genome with a protein attached to the(5)' end and no overlapping open reading frames, all the RNAs are translated into a polyprotein before processing, and a conserved RNA-dependent RNA polymerase (RdRp) protein. Analyses of RdRp sequences from these viruses produce phylogenies that are congruent with established picorna-like virus family assignments(5-7); hence, this gene is an excellent molecular marker for examining the diversity of picorna-like viruses in nature. Here we report, on the basis of analysis of RdRp sequences amplified from marine virus communities, that a diverse array of picorna-like viruses exists in the ocean. All of the sequences amplified were divergent from known picorna-like viruses, and fell within four monophyletic groups that probably belong to at least two new families. Moreover, we show that an isolate belonging to one of these groups is a lytic pathogen of Heterosigma akashiwo, a toxic-bloom-forming alga responsible for severe economic losses to the finfish aquaculture industry, suggesting that picorna-like viruses are important pathogens of marine phytoplankton.	Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z4, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Suttle, CA (corresponding author), Univ British Columbia, Dept Bot, 1461-6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	csuttle@eos.ubc.ca	suttle, c/N-1144-2019; Suttle, Curtis A/C-3150-2008	suttle, c/0000-0002-0372-0033; Suttle, Curtis A/0000-0002-0372-0033; Lang, Andrew/0000-0002-4510-7683				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 2001, FIELDS VIROLOGY; BAILEY L, 1964, VIROLOGY, V23, P425, DOI 10.1016/0042-6822(64)90266-1; BERNARD J, 1995, VET RES, V26, P341; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; Kingsley DH, 2002, APPL ENVIRON MICROB, V68, P3914, DOI 10.1128/AEM.68.8.3914-3918.2002; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Liljas L, 2002, ARCH VIROL, V147, P59, DOI 10.1007/s705-002-8303-1; Mann NH, 2003, FEMS MICROBIOL REV, V27, P17, DOI 10.1016/S0168-6445(03)00016-0; Mari J, 2002, J GEN VIROL, V83, P915, DOI 10.1099/0022-1317-83-4-915; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Short SM, 2002, APPL ENVIRON MICROB, V68, P1290, DOI 10.1128/AEM.68.3.1290-1296.2002; Smayda T.J., 1998, PHYSL ECOLOGY HARMFU, P113; SMITH AW, 1973, NATURE, V244, P108, DOI 10.1038/244108a0; Smith AW, 2000, VIRAL ECOLOGY, P447, DOI 10.1016/B978-012362675-2/50013-6; SUTTLE CA, 1991, APPL ENVIRON MICROB, V57, P721, DOI 10.1128/AEM.57.3.721-726.1991; Suttle CA, 2000, VIRAL ECOLOGY, P247, DOI 10.1016/B978-012362675-2/50007-0; SUTTLE CA, 1992, APPL ENVIRON MICROB, V58, P3721, DOI 10.1128/AEM.58.11.3721-3729.1992; Tai V, 2003, J PHYCOL, V39, P343, DOI 10.1046/j.1529-8817.2003.01162.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Van Bressem MF, 1999, DIS AQUAT ORGAN, V38, P53, DOI 10.3354/dao038053; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; Wilhelm SW, 1999, BIOSCIENCE, V49, P781, DOI 10.2307/1313569; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; Zanotto PMD, 1996, J VIROL, V70, P6083, DOI 10.1128/JVI.70.9.6083-6096.1996; [No title captured]	30	149	156	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1054	1057		10.1038/nature01886	http://dx.doi.org/10.1038/nature01886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944967				2022-12-28	WOS:000184984200043
J	Blumenthal, JA; Lett, HS; Babyak, MA; White, W; Smith, PK; Mark, DB; Jones, R; Mathew, JP; Newman, MF				Blumenthal, JA; Lett, HS; Babyak, MA; White, W; Smith, PK; Mark, DB; Jones, R; Mathew, JP; Newman, MF		NORG Investigators	Depression as a risk factor for mortality after coronary artery bypass surgery	LANCET			English	Article							MYOCARDIAL-INFARCTION; MAJOR DEPRESSION; SYMPTOMS; HEALTH	Background Studies that have shown clinical depression to be a risk factor for cardiac events after coronary artery bypass graft (CABG) surgery have had small sample sizes, short follow-up, and have not had adequate power to assess mortality. We sought to assess whether depression is associated with an increased risk of mortality. Methods We assessed 817 patients undergoing CABG at Duke University Medical Center between May, 1989, and May, 2001. Patients completed the Center for Epidemiological Studies-Depression (CES-D) scale before surgery, 6 months after CABG, and were followed-up for up to 12 years. Findings In 817 patients there were 122 deaths (15%) in a mean follow-up of 5.2 years. 310 patients (38%) met the criterion for depression (CES-D greater than or equal to16): 213 (26%) for mild depression (CES-D 16-26) and 97 (12%) for moderate to severe depression (CES-D greater than or equal to27). Survival analyses, controlling for age, sex, number of grafts, diabetes, smoking, left ventricular ejection fraction, and previous myocardial infarction, showed that patients with moderate to severe depression at baseline (adjusted hazard ratio [HR] 2.4, [95% CI 1.4-4.0]; p=0.001) and mild or moderate to severe depression that persisted from baseline to 6 months (adjusted HR 2.2, [1.2-4.2]; p=0.015) had higher rates of death than did those with no depression. Interpretation Despite advances in surgical and medical management of patients after CABG, depression is an important independent predictor of death after CABG and should be carefully monitored and treated if necessary.	Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University; Duke University	Blumenthal, JA (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA.	blume003@mc.duke.edu		Mathew, Joseph/0000-0002-3815-4131; Mark, Daniel/0000-0001-6340-8087	NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NHLBI NIH HHS [HL 59672] Funding Source: Medline; NIMH NIH HHS [MH49679] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049679] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHERN DK, 1990, AM J CARDIOL, V66, P59, DOI 10.1016/0002-9149(90)90736-K; Appels A, 2000, PSYCHOSOM MED, V62, P601, DOI 10.1097/00006842-200009000-00001; Baker RA, 2001, AUST NZ J SURG, V71, P139, DOI 10.1046/j.1440-1622.2001.02055.x; Barefoot JC, 2000, PSYCHOSOM MED, V62, P790, DOI 10.1097/00006842-200011000-00008; Barefoot JC, 1996, AM J CARDIOL, V78, P613, DOI 10.1016/S0002-9149(96)00380-3; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Bush DE, 2001, AM J CARDIOL, V88, P337, DOI 10.1016/S0002-9149(01)01675-7; CARNEY RM, 1988, PSYCHOSOM MED, V50, P627, DOI 10.1097/00006842-198811000-00009; Carney RM, 2001, CIRCULATION, V104, P2024, DOI 10.1161/hc4201.097834; Connerney I, 2001, LANCET, V358, P1766, DOI 10.1016/S0140-6736(01)06803-9; COX DR, 1972, J R STAT SOC B, V34, P187; Deedwania Prakash C., 1998, American Journal of Medicine, V105, p1S, DOI 10.1016/S0002-9343(98)00204-6; DiMatteo MR, 2000, ARCH INTERN MED, V160, P2101, DOI 10.1001/archinte.160.14.2101; Druss BG, 2000, JAMA-J AM MED ASSOC, V283, P506, DOI 10.1001/jama.283.4.506; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; Glassman AH, 2002, JAMA-J AM MED ASSOC, V288, P701, DOI 10.1001/jama.288.6.701; Green CA, 2000, AM J HEALTH PROMOT, V15, P29, DOI 10.4278/0890-1171-15.1.29; Harrell F.E., 2015, REGRESSION MODELING, DOI [10.1007/978-3-319-19425-7, DOI 10.1007/978-3-319-19425-7, 10.1007/978-1-4757-3462-1]; Jiang W, 2001, ARCH INTERN MED, V161, P1849, DOI 10.1001/archinte.161.15.1849; LADWIG KH, 1994, LANCET, V343, P20, DOI 10.1016/S0140-6736(94)90877-X; Lane D, 2001, PSYCHOSOM MED, V63, P221, DOI 10.1097/00006842-200103000-00005; Lesperance F, 2002, CIRCULATION, V105, P1049, DOI 10.1161/hc0902.104707; Musselman DL, 1996, AM J PSYCHIAT, V153, P1313; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Saur C D, 2001, Am J Crit Care, V10, P4; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; STEPHENS T, 1988, PREV MED, V17, P35, DOI 10.1016/0091-7435(88)90070-9; VEITH RC, 1994, ARCH GEN PSYCHIAT, V51, P411	30	430	458	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					604	609		10.1016/S0140-6736(03)14190-6	http://dx.doi.org/10.1016/S0140-6736(03)14190-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944059				2022-12-28	WOS:000184904100008
J	Mossessova, E; Bickford, LC; Goldberg, J				Mossessova, E; Bickford, LC; Goldberg, J			SNARE selectivity of the COPII coat	CELL			English	Article							N-TERMINAL DOMAIN; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; TRANSPORT VESICLES; CRYSTAL-STRUCTURE; CARGO SELECTION; GOLGI-COMPLEX; YEAST; PROTEINS; ER	The COPII coat buds transport vesicles from the endoplasmic reticulum that incorporate cargo and SNARE molecules. Here, we show that recognition of the ER-Golgi SNAREs Bet1, Sed5, and Sec22 occurs through three binding sites on the Sec23/24 subcomplex of yeast COPII. The A site binds to the YNNSNPF motif of Sed5. The B site binds to Lxx-UM-E sequences present in both the Bet1 and Sed5 molecules, as well as to the DxE cargo-sorting signal. A third, spatially distinct site binds to Sec22. COPII selects the free v-SNARE form of Bet1 because the LxxLE sequence is sequestered in the four-helix bundle of the v-/t-SNARE complex. COPII favors Sed5 within the Sed5/Bos1/ Sec22 t-SNARE complex because t-SNARE assembly removes autoinhibitory contacts to expose the YNNSNPF motif. The COPII coat seems to be a specific conductor of the fusogenic forms of these SNAREs, suggesting how vesicle fusion specificity may be programmed during budding.	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bracher A, 2002, EMBO J, V21, P6114, DOI 10.1093/emboj/cdf608; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fiebig KM, 1999, NAT STRUCT BIOL, V6, P117; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Kiessling V, 2003, BIOPHYS J, V84, P408, DOI 10.1016/S0006-3495(03)74861-9; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Margittai M, 2003, BIOCHEMISTRY-US, V42, P4009, DOI 10.1021/bi027437z; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Munson M, 2000, NAT STRUCT BIOL, V7, P894; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Rowe T, 1998, SCIENCE, V279, P696, DOI 10.1126/science.279.5351.696; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thoma NH, 2000, BIOCHEMISTRY-US, V39, P12043, DOI 10.1021/bi000835m; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9	42	285	298	2	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					483	495		10.1016/S0092-8674(03)00608-1	http://dx.doi.org/10.1016/S0092-8674(03)00608-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941276	Bronze			2022-12-28	WOS:000184928800011
J	Crumpacker, CS; Gonzalez, RG; Makar, RS; Harris, NL				Crumpacker, CS; Gonzalez, RG; Makar, RS; Harris, NL			Case 26-2003: A 50-year-old Colombian man with fever and seizures - Encephalitis due to herpes simplex virus type 1 infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POLYMERASE CHAIN-REACTION; CEREBROSPINAL-FLUID; DIAGNOSIS; ACYCLOVIR; VIDARABINE		Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Radiol, Div Neuroradiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Crumpacker, CS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis, Boston, MA 02215 USA.							AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; COREY L, 2000, MANDELL DOUGLAS BENN, V2, P1564; Crumpacker CS, 2002, NAT MED, V8, P327, DOI 10.1038/nm0402-327; CRUMPACKER CS, 2001, FIELDS VIROLOGY, V1, P393; DORSKY DI, 1987, ANN INTERN MED, V107, P859, DOI 10.7326/0003-4819-107-6-859; ELION GB, 1977, P NATL ACAD SCI USA, V74, P5716, DOI 10.1073/pnas.74.12.5716; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Kerr A., 1955, SUBACUTE BACTERIAL E; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857; SKOLDENBERG B, 1984, LANCET, V2, P707; WHITLEY RJ, 1989, JAMA-J AM MED ASSOC, V262, P234, DOI 10.1001/jama.262.2.234; WHITLEY RJ, 1986, NEW ENGL J MED, V314, P144, DOI 10.1056/NEJM198601163140303; Whitley RJ, 1997, NEW ENGL J MED, V337, P1703; Wildemann B, 1997, NEUROLOGY, V48, P1341, DOI 10.1212/WNL.48.5.1341	14	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					789	796		10.1056/NEJMcpc030020	http://dx.doi.org/10.1056/NEJMcpc030020			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930932				2022-12-28	WOS:000184843300011
J	Thordarson, P; Bijsterveld, EJA; Rowan, AE; Nolte, RJM				Thordarson, P; Bijsterveld, EJA; Rowan, AE; Nolte, RJM			Epoxidation of polybutadiene by a topologically linked catalyst	NATURE			English	Article							DNA; ROTAXANE; METALLOPORPHYRINS; OXIDATION; MOTION	Nature has evolved complex enzyme architectures that facilitate the synthesis and manipulation of the biopolymers DNA and RNA, including enzymes capable of attaching to the biopolymer substrate and performing several rounds of catalysis before dissociating(1-5). Many of these 'processive' enzymes have a toroidal shape and completely enclose the biopolymer while moving along its chain, as exemplified by the DNA enzymes T4 DNA polymerase holoenzyme(6) and lambda-exonucleoase(7). The overall architecture of these systems resembles that of rotaxanes, in which a long molecule or polymer is threaded through a macrocycle. Here we describe a rotaxane that mimics the ability of processive enzymes to catalyse multiple rounds of reaction while the polymer substrate stays bound. The catalyst consists of a substrate binding cavity incorporating a manganese( III) porphyrin complex that oxidizes alkenes within the toroid cavity, provided a ligand has been attached to the outer face of the toroid to both activate the porphyrin complex and shield it from being able to oxidize alkenes outside the cavity. We find that when threaded onto a polybutadiene polymer strand, this catalyst epoxidizes the double bonds of the polymer, thereby acting as a simple analogue of the enzyme systems.	Univ Nijmegen, Dept Organ Chem, NSRIM, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen	Rowan, AE (corresponding author), Univ Nijmegen, Dept Organ Chem, NSRIM, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	rowan@sci.kun.nl	Thordarson, Pall/A-2138-2015; Nolte, Roeland/C-9930-2013; Rowan, Alan E/F-9702-2015	Thordarson, Pall/0000-0002-1200-8814; Nolte, Roeland/0000-0002-5612-7815; Rowan, Alan E/0000-0003-0728-3851				Ashton PR, 1998, J AM CHEM SOC, V120, P11190, DOI 10.1021/ja981889a; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; BISSELL RA, 1994, NATURE, V369, P133, DOI 10.1038/369133a0; Breyer WA, 2001, PROTEIN SCI, V10, P1699, DOI 10.1110/ps.10301; Brouwer AM, 2001, SCIENCE, V291, P2124, DOI 10.1126/science.1057886; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Davis AP, 1999, NATURE, V401, P120, DOI 10.1038/43576; Elemans JAAW, 2000, CHEM COMMUN, P2443, DOI 10.1039/b008567g; Elemans JAAW, 1999, J ORG CHEM, V64, P7009, DOI 10.1021/jo990112c; FARRINGT.JA, 1969, J CHEM SOC CHEM COMM, P259, DOI 10.1039/c29690000259; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HARADA A, 1992, NATURE, V356, P325, DOI 10.1038/356325a0; HOLLIS BW, 1990, P NATL ACAD SCI USA, V87, P6009, DOI 10.1073/pnas.87.16.6009; Jimenez MC, 2000, ANGEW CHEM INT EDIT, V39, P3284, DOI 10.1002/1521-3773(20000915)39:18<3284::AID-ANIE3284>3.0.CO;2-7; Kool ET, 1998, ACCOUNTS CHEM RES, V31, P502, DOI 10.1021/ar9602462; Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; LIN SM, 1993, NUCLEASES; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; Perkins TT, 2001, BIOPHYS J, V80, p349A; Rowan AE, 1998, CHEM COMMUN, P611, DOI 10.1039/a708373d; Sacco HC, 2001, J CHEM SOC PERK T 2, P181, DOI 10.1039/b006755p; Sauvage JP, 1998, ACCOUNTS CHEM RES, V31, P611, DOI 10.1021/ar960263r; Schalley CA, 2001, ACCOUNTS CHEM RES, V34, P465, DOI 10.1021/ar000179i; SHEN YX, 1994, J AM CHEM SOC, V116, P537, DOI 10.1021/ja00081a014; TORNARITIS MJ, 1992, POLYMER, V33, P1771, DOI 10.1016/0032-3861(92)91081-C; Trakselis MA, 2001, P NATL ACAD SCI USA, V98, P8368, DOI 10.1073/pnas.111006698; Tsuda Y, 1998, J MOL CATAL A-CHEM, V130, P285, DOI 10.1016/S1381-1169(97)00220-3	28	325	327	1	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					915	918		10.1038/nature01925	http://dx.doi.org/10.1038/nature01925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	713EH	12931181				2022-12-28	WOS:000184843600034
J	Ri-Li, G; Chase, PJ; Witkowski, S; Wyrick, BL; Stone, JA; Levine, BD; Babb, TG				Ri-Li, G; Chase, PJ; Witkowski, S; Wyrick, BL; Stone, JA; Levine, BD; Babb, TG			Obesity: Associations with acute mountain sickness	ANNALS OF INTERNAL MEDICINE			English	Article							RESEARCH ISSUES; HIGH-ALTITUDE; SLEEP-APNEA; EXERCISE	Background: Although few retrospective studies of high altitude have reported that obesity might be associated with the development of acute mountain sickness (AMS), this association has not been studied prospectively. Objective: To determine whether obesity is associated with the development of AMS. Design: Obese and nonobese men were compared at a simulated altitude of 3658 m (12000 ft). Setting: 24 hours in a hypobaric environmental chamber. Participants: 9 obese and 10 nonobese men. Measurements: Percentage body fat (by hydrostatic weighing), Lake Louise AMS score, and Sao(2) level (by pulse oximetry) were measured. Results: Average AMS scores increased more rapidly with time spent at simulated high altitudes for obese men than for nonobese men (P<0.001). The response of Sao(2) with exposure differed between nonobese and obese men. After 24 hours in the altitude chamber, seven obese men (78%) and four nonobese men (40%) had AMS scores of 4 or more. Conclusion: Obesity seems to be associated with the development of AMS, which may be partly related to greater nocturnal desaturation with altitude exposure.	Presbyterian Med Ctr, Inst Exercise & Environm Med, Dallas, TX 75231 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Qinghai Med Coll, Inst High Altitude Med, Xining, Qinghai, Peoples R China	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Qinghai University	Babb, TG (corresponding author), Presbyterian Med Ctr, Inst Exercise & Environm Med, 7232 Greenville Ave,Suite 435, Dallas, TX 75231 USA.		Chase, Paul/H-3462-2019	Chase, Paul/0000-0003-2127-0889				Ahmed Q, 1997, HUM PATHOL, V28, P264, DOI 10.1016/S0046-8177(97)90122-2; Becker HF, 1999, AM J RESP CRIT CARE, V159, P112, DOI 10.1164/ajrccm.159.1.9803037; Eichenberger U, 1996, AM J RESP CRIT CARE, V154, P1748, DOI 10.1164/ajrccm.154.6.8970365; Flegal KM, 1999, MED SCI SPORT EXER, V31, pS509, DOI 10.1097/00005768-199911001-00004; GE R, 1995, CHINESE J APPL PHYSL, V11, P205; GE RL, 1987, CHINESE J INT MED, V13, P115; GOLDSTEIN JL, 1992, EUR HEART J, V13, P34, DOI 10.1093/eurheartj/13.suppl_B.34; HACKETT PH, 2001, WILDERNESS MED, P1; Hill JO, 1999, MED SCI SPORT EXER, V31, pS515, DOI 10.1097/00005768-199911001-00005; HIRATA K, 1989, LANCET, V2, P1040; HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003; KAYSER B, 1991, J WILDERNESS MED, V2, P110, DOI 10.1580/0953-9859-2.2.110; LUPIHERRERA E, 1980, CHEST, V78, P553, DOI 10.1378/chest.78.4.553; Maggiorini M, 1998, AVIAT SPACE ENVIR MD, V69, P1186; PACY PJ, 1986, SPORTS MED, V3, P89, DOI 10.2165/00007256-198603020-00002; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; Sutton J., 1992, HYPOXIA MOUNTAIN MED; WEST JB, 1986, J APPL PHYSIOL, V61, P280, DOI 10.1152/jappl.1986.61.1.280; WHITE DP, 1985, MED CLIN N AM, V69, P1205, DOI 10.1016/S0025-7125(16)30983-X	19	72	79	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					253	257		10.7326/0003-4819-139-4-200308190-00007	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965980				2022-12-28	WOS:000184795600003
J	Christodoulides, DN; Lederer, F; Silberberg, Y				Christodoulides, DN; Lederer, F; Silberberg, Y			Discretizing light behaviour in linear and nonlinear waveguide lattices	NATURE			English	Review							OPTICAL BLOCH OSCILLATIONS; LOCALIZED MODES; SOLITONS; BEAM; EMISSION; ARRAYS; ENERGY	Light propagating in linear and nonlinear waveguide lattices exhibits behaviour characteristic of that encountered in discrete systems. The diffraction properties of these systems can be engineered, which opens up new possibilities for controlling the flow of light that would have been otherwise impossible in the bulk: these effects can be exploited to achieve diffraction- free propagation and minimize the power requirements for nonlinear processes. In two-dimensional networks of waveguides, self-localized states-or discrete solitons-can travel along 'wire-like' paths and can be routed to any destination port. Such possibilities may be useful for photonic switching architectures.	Univ Cent Florida, CREOL, Sch Opt, Orlando, FL 32816 USA; Univ Jena, D-07743 Jena, Germany; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel	State University System of Florida; University of Central Florida; Friedrich Schiller University of Jena; Weizmann Institute of Science	Christodoulides, DN (corresponding author), Univ Cent Florida, CREOL, Sch Opt, Orlando, FL 32816 USA.		SILBERBERG, YARON/K-1564-2012; Lederer, Falk/ABE-2796-2021					Ablowitz M. A., 1992, SOLITONS NONLINEAR E; Ablowitz MJ, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.254102; Aceves AB, 1996, PHYS REV E, V53, P1172, DOI 10.1103/PhysRevE.53.1172; Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; Ashcroft N.W, 1976, SOLID STATE PHYS; Bang O, 1996, OPT LETT, V21, P1105, DOI 10.1364/OL.21.001105; BenDahan M, 1996, PHYS REV LETT, V76, P4508, DOI 10.1103/PhysRevLett.76.4508; Bloch F, 1929, Z PHYS, V52, P555, DOI 10.1007/BF01339455; Cheo PL, 2001, IEEE PHOTONIC TECH L, V13, P439, DOI 10.1109/68.920744; Christodoulides DN, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.233901; Christodoulides DN, 2002, OPT LETT, V27, P568, DOI 10.1364/OL.27.000568; Christodoulides DN, 2001, OPT LETT, V26, P1876, DOI 10.1364/OL.26.001876; CHRISTODOULIDES DN, 1988, OPT LETT, V13, P794, DOI 10.1364/OL.13.000794; Darmanyan S, 1998, PHYS REV E, V57, P3520, DOI 10.1103/PhysRevE.57.3520; DAVYDOV AS, 1973, J THEOR BIOL, V38, P559, DOI 10.1016/0022-5193(73)90256-7; DAVYDOV AS, 1977, J THEOR BIOL, V66, P377, DOI 10.1016/0022-5193(77)90178-3; Efremidis NK, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.046602; Efremidis NK, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.026606; Eisenberg HS, 2000, PHYS REV LETT, V85, P1863, DOI 10.1103/PhysRevLett.85.1863; Eisenberg HS, 1998, PHYS REV LETT, V81, P3383, DOI 10.1103/PhysRevLett.81.3383; Eugenieva ED, 2001, OPT LETT, V26, P1978, DOI 10.1364/OL.26.001978; Fleischer JW, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.023902; Fleischer JW, 2003, NATURE, V422, P147, DOI 10.1038/nature01452; ILIEW R, 2002, P QUANT EL LAS SCI C; Joannopoulos JD, 1997, NATURE, V386, P143, DOI 10.1038/386143a0; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; JONES AL, 1965, J OPT SOC AM, V55, P261, DOI 10.1364/JOSA.55.000261; KIVSHAR YS, 1994, PHYS REV E, V50, P5020, DOI 10.1103/PhysRevE.50.5020; KIVSHAR YS, 1993, OPT LETT, V18, P1147, DOI 10.1364/OL.18.001147; Krolikowski W, 1996, J OPT SOC AM B, V13, P876, DOI 10.1364/JOSAB.13.000876; Lederer F., 2001, SPRINGER SERIES OPTI, P269; Malomed BA, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.026601; Mandelik D, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.053902; MEIER J, 2002, OSA TRENDS OPTICS PH, V80; Mingaleev SF, 2000, PHYS REV E, V62, P5777, DOI 10.1103/PhysRevE.62.5777; Morandotti R, 1999, PHYS REV LETT, V83, P4756, DOI 10.1103/PhysRevLett.83.4756; Morandotti R, 1999, PHYS REV LETT, V83, P2726, DOI 10.1103/PhysRevLett.83.2726; Morandotti R, 2001, PHYS REV LETT, V86, P3296, DOI 10.1103/PhysRevLett.86.3296; Pertsch T, 1999, PHYS REV LETT, V83, P4752, DOI 10.1103/PhysRevLett.83.4752; Pertsch T, 2003, OPT LETT, V28, P102, DOI 10.1364/OL.28.000102; Pertsch T, 2002, APPL PHYS LETT, V80, P3247, DOI 10.1063/1.1476720; Pertsch T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.093901; PERTSCH T, IN PRESS PHYS REV LE; PERTSCH T, 2002, OSA TRENDS OPTICS PH, V80; Peschel T, 1998, PHYS REV E, V57, P1127, DOI 10.1103/PhysRevE.57.1127; Peschel U, 1998, OPT LETT, V23, P1701, DOI 10.1364/OL.23.001701; Russell P, 2003, SCIENCE, V299, P358, DOI 10.1126/science.1079280; RUSSELL PS, 1986, APPL PHYS B-PHOTO, V39, P231, DOI 10.1007/BF00697490; SCOTT AC, 1983, PHYS LETT A, V98, P87, DOI 10.1016/0375-9601(83)90733-8; SIEVERS AJ, 1988, PHYS REV LETT, V61, P970, DOI 10.1103/PhysRevLett.61.970; SOMEKH S, 1973, APPL PHYS LETT, V22, P46, DOI 10.1063/1.1654468; Stegeman GI, 1999, SCIENCE, V286, P1518, DOI 10.1126/science.286.5444.1518; Sukhorukov AA, 2002, OPT LETT, V27, P2112, DOI 10.1364/OL.27.002112; Trombettoni A, 2001, PHYS REV LETT, V86, P2353, DOI 10.1103/PhysRevLett.86.2353; WASCHKE C, 1993, PHYS REV LETT, V70, P3319, DOI 10.1103/PhysRevLett.70.3319; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; Yariv A, 1999, OPT LETT, V24, P711, DOI 10.1364/OL.24.000711; Zener C., 1932, P ROY SOC LOND A MAT, V145, P523	58	1286	1306	10	261	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					817	823		10.1038/nature01936	http://dx.doi.org/10.1038/nature01936			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917695				2022-12-28	WOS:000184733900050
J	Guan, Y; Zheng, BJ; He, YQ; Liu, XL; Zhuang, ZX; Cheung, CL; Luo, SW; Li, PH; Zhang, LJ; Guan, YJ; Butt, KM; Wong, KL; Chan, KW; Lim, W; Shortridge, KF; Yuen, KY; Peiris, JSM; Poon, LLM				Guan, Y; Zheng, BJ; He, YQ; Liu, XL; Zhuang, ZX; Cheung, CL; Luo, SW; Li, PH; Zhang, LJ; Guan, YJ; Butt, KM; Wong, KL; Chan, KW; Lim, W; Shortridge, KF; Yuen, KY; Peiris, JSM; Poon, LLM			Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China	SCIENCE			English	Article							ACUTE RESPIRATORY SYNDROME	A novel coronavirus (SCoV) is the etiological agent of severe acute respiratory syndrome (SARS). SCoV-like viruses were isolated from Himalayan palm civets found in a live-animal market in Guangdong, China. Evidence of virus infection was also detected in other animals ( including a raccoon dog, Nyctereutes procyonoides) and in humans working at the same market. All the animal isolates retain a 29-nucleotide sequence that is not found in most human isolates. The detection of SCoV-like viruses in small, live wild mammals in a retail market indicates a route of interspecies transmission, although the natural reservoir is not known.	Univ Hong Kong, Dept Microbiol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; Ctr Dis Control & Prevent, Shenzhen, Guangdong Prov, Peoples R China; Univ Hong Kong, Dept Pathol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China; Dept Hlth, Govt Virus Unit, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Chinese Center for Disease Control & Prevention; University of Hong Kong	Guan, Y (corresponding author), Univ Hong Kong, Dept Microbiol, Queen Mary Hosp, Univ Pathol Bldg, Hong Kong, Hong Kong, Peoples R China.	yguan@hkucc.hku.hk	Poon, Leo/AAP-6887-2020; Poon, Leo Lit Man/C-4382-2009; Yuen, Kwok Yung/C-4465-2009; Cheung, Yiu Man/T-2708-2019	Poon, Leo Lit Man/0000-0002-9101-7953; 				Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; HOLMES KE, UNPUB; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; ZHONG NS, IN PRESS LANCET	8	1477	1591	31	338	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					276	278		10.1126/science.1087139	http://dx.doi.org/10.1126/science.1087139			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12958366	Green Submitted			2022-12-28	WOS:000185825900039
J	Fu, J; Gaetani, S; Oveisi, F; Lo Verme, J; Serrano, A; de Fonseca, FR; Rosengarth, A; Luecke, H; Di Giacomo, B; Tarzia, G; Piomelli, D				Fu, J; Gaetani, S; Oveisi, F; Lo Verme, J; Serrano, A; de Fonseca, FR; Rosengarth, A; Luecke, H; Di Giacomo, B; Tarzia, G; Piomelli, D			Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha	NATURE			English	Article							FATTY-ACIDS; GAMMA ACTIVATORS; GENE-EXPRESSION; NITRIC-OXIDE; MICE; RAT; EICOSANOIDS; TRANSPORT; LIGANDS; PROTEIN	Oleylethanolamide (OEA) is a naturally occurring lipid that regulates satiety and body weight(1,2). Although structurally related to the endogenous cannabinoid anandamide, OEA does not bind to cannabinoid receptors and its molecular targets have not been defined. Here we show that OEA binds with high affinity to the peroxisome-proliferator-activated receptor-alpha (PPAR-alpha), a nuclear receptor that regulates several aspects of lipid metabolism. Administration of OEA produces satiety and reduces body weight gain in wild-type mice, but not in mice deficient in PPAR-alpha. Two distinct PPAR-alpha agonists have similar effects that are also contingent on PPAR-alpha expression, whereas potent and selective agonists for PPAR-gamma and PPAR-beta/delta are ineffective. In the small intestine of wild-type but not PPAR-alpha-null mice, OEA regulates the expression of several PPAR-alpha target genes: it initiates the transcription of proteins involved in lipid metabolism and represses inducible nitric oxide synthase, an enzyme that may contribute to feeding stimulation. Our results, which show that OEA induces satiety by activating PPAR-alpha, identify an unexpected role for this nuclear receptor in regulating behaviour, and raise possibilities for the treatment of eating disorders.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Fdn Hosp Carlos Haya, Malaga, Spain; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Univ Urbino, Inst Med Chem, I-61029 Urbino, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Urbino	Piomelli, D (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.		Gaetani, Silvana/D-3455-2009; Fu, Jin/A-3510-2012; Luecke, Hartmut/F-4712-2012; DE FONSECA, FERNANDO RODRIGUEZ/E-9767-2012	Luecke, Hartmut/0000-0002-4938-0775; Serrano, Antonia/0000-0002-8017-9754				Akiyama TE, 2001, J BIOL CHEM, V276, P39088, DOI 10.1074/jbc.M107073200; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Best JD, 2001, EXPERT OPIN INV DRUG, V10, P1901; BROWN PJ, 2000, Patent No. 32; Butler A A, 2001, Trends Genet, V17, pS50, DOI 10.1016/S0168-9525(01)02481-7; CHANG AY, 1983, DIABETES, V32, P830, DOI 10.2337/diabetes.32.9.830; CHAO EYH, 2001, Patent No. 83; Chaput E, 2000, BIOCHEM BIOPH RES CO, V271, P445, DOI 10.1006/bbrc.2000.2647; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CLEARY MP, 1987, ATHEROSCLEROSIS, V66, P107, DOI 10.1016/0021-9150(87)90185-7; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; de Fonseca FR, 2001, NATURE, V414, P209, DOI 10.1038/35102582; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gaetani S, 2003, NEUROPSYCHOPHARMACOL, V28, P1311, DOI 10.1038/sj.npp.1300166; Giuffrida A, 2000, ANAL BIOCHEM, V280, P87, DOI 10.1006/abio.2000.4509; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Gregoire FM, 2002, AM J PHYSIOL-ENDOC M, V282, pE703, DOI 10.1152/ajpendo.00072.2001; Janero DR, 2001, NUTRITION, V17, P896, DOI 10.1016/S0899-9007(01)00647-5; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; STICKERKRONGRAD A, 1996, LIFE SCI, V58, pPL9; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g	30	838	906	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					90	93		10.1038/nature01921	http://dx.doi.org/10.1038/nature01921			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955147				2022-12-28	WOS:000185089200044
J	Landon, BE; Normand, SLT; Blumenthal, D; Daley, J				Landon, BE; Normand, SLT; Blumenthal, D; Daley, J			Physician clinical performance assessment - Prospects and barriers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; REPORT CARDS; EXAMINATION SCORES; QUALITY; ASSOCIATION; COMPETENCE; MEDICARE; SURGERY; RATINGS	The performance of physicians in their day-to-day clinical practices has become an area of intense public interest. Both patients and health care purchasers want more effective means of identifying excellent clinicians, and a variety of organizations are discussing and implementing plans for assessing the performance of individual clinicians. In this article, we review the current state of physician clinical performance assessment with a focus on its usefulness for competency assessment. We describe recommendations for a physician clinical performance assessment system for these purposes, and identify ways in which current methods of performance assessment fall short of these. We conclude that important technical barriers stand in the way of using physician clinical performance assessment for evaluating the competency of individual physicians. Overcoming these barriers will require considerable additional research and development. Even then, for some uses, physician clinical performance assessment at the individual physician level may be technically impossible to accomplish in a valid and fair way.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Massachusetts Gen Hosp, Partners Healthcare Syst, Inst Hlth Care, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; Partners Healthcare System	Landon, BE (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.			Normand, Sharon-Lise/0000-0001-7027-4769				American Medical Association, 2016, PHYS CONS PERF IMPR; [Anonymous], 2001, CROSSING QUALITY CHA, DOI DOI 10.17226/10027; Bentley J M, 1998, Jt Comm J Qual Improv, V24, P40; Chen J, 2003, HEALTH AFFAIR, V22, P243, DOI 10.1377/hlthaff.22.2.243; DiSalvo TG, 2001, AM J MED, V111, P297, DOI 10.1016/S0002-9343(01)00842-7; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; Ferris T G, 2000, Eff Clin Pract, V3, P40; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Institute of Medicine, 2001, ENV NAT HLTH CAR QUA; JOST TS, 1994, JAMA-J AM MED ASSOC, V271, P1508, DOI 10.1001/jama.271.19.1508; Krumholz HM, 2002, JAMA-J AM MED ASSOC, V287, P1277, DOI 10.1001/jama.287.10.1277; Landrum MB, 2000, HLTH SERVICES OUTCOM, V1, P23, DOI [10.1023/A:1010093701870, DOI 10.1023/A:1010093701870]; LANGSLEY DG, 1991, JAMA-J AM MED ASSOC, V266, P977, DOI 10.1001/jama.266.7.977; Mannion R, 2002, J EVAL CLIN PRACT, V8, P215, DOI 10.1046/j.1365-2753.2002.00331.x; *NAT COMM QUAL ASS, 1999, STAT MAN CAR QUAL; Normand SLT, 2002, STAT MED, V21, P331, DOI 10.1002/sim.1020; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; Palmer RH, 1996, MED CARE, V34, pSS52; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Petersen LA, 2001, CIRCULATION, V104, P2898, DOI 10.1161/hc4901.100524; RAMSEY PG, 1993, JAMA-J AM MED ASSOC, V269, P1655, DOI 10.1001/jama.269.13.1655; Schneider EC, 2001, MED CARE, V39, P1313, DOI 10.1097/00005650-200112000-00007; Shahian DM, 2001, ANN THORAC SURG, V72, P2155, DOI 10.1016/S0003-4975(01)03222-2; Smith MA, 1997, JAMA-J AM MED ASSOC, V278, P1573, DOI 10.1001/jama.278.19.1573; STEVENS RA, PROFESSIONAL COMPETE; STONE E, 2002, ACCESSING PHYSICIAN; Tamblyn R, 1998, JAMA-J AM MED ASSOC, V280, P989, DOI 10.1001/jama.280.11.989; Tamblyn R, 2002, JAMA-J AM MED ASSOC, V288, P3019, DOI 10.1001/jama.288.23.3019; *US GEN ACC OFF, 1994, EMPL URG HOSP BATTL; Zaslavsky AM, 2000, MED CARE, V38, P981, DOI 10.1097/00005650-200010000-00002	34	178	180	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1183	1189		10.1001/jama.290.9.1183	http://dx.doi.org/10.1001/jama.290.9.1183			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LK	12953001				2022-12-28	WOS:000185090400014
J	Patrick, DL; Curtis, JR; Engelberg, RA; Nielsen, E; McCown, E				Patrick, DL; Curtis, JR; Engelberg, RA; Nielsen, E; McCown, E			Measuring and improving the quality of dying and death	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				OF-LIFE CARE; END; PHYSICIANS; FAMILY; ILLNESS	Improving end-of-life experience is a major challenge to successful aging. Deaths that are reasonably free of discomfort, in accordance with patients' wishes, and within acceptable professional and ethical standards are high-quality deaths. The authors developed a 31-item measure of the quality of dying and death and applied it in a community sample and a sample of hospice enrollees. Scores on the Quality of Dying and Death Instrument and measures of perceived quality of care were collected from patients' loved ones after death. Higher overall after-death ratings of the quality of care received from all providers and from physicians were associated with higher-quality dying and death. How well patients' symptoms were controlled in the community study and how well wishes were followed and treatments were explained in the hospice study were associated with higher-quality dying. Major challenges to end-of-life research include recruiting representative population samples, given widespread reluctance of patients and loved ones to participate in research at the end of life; important variation in evaluations among different reporters after death; reluctance of loved ones to assign negative evaluations to dying experiences after death; and the highly individual and dynamic nature of dying experiences. Overcoming these challenges is of great importance in the search for the social, organizational, and individual determinants of high-quality dying in the U.S. cultural and health care context.	Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Patrick, DL (corresponding author), Univ Washington, Dept Hlth Serv, Box 357660,1959 NE Pacific St, Seattle, WA 98195 USA.	donald@u.washington.edu	Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	AHRQ HHS [R03 HS09540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS009540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; Curtis JR, 2001, J GEN INTERN MED, V16, P41; Desbiens NA, 2000, J AM GERIATR SOC, V48, pS183, DOI 10.1111/j.1532-5415.2000.tb03130.x; Field MJ, 1997, APPROACHING DEATH IM; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; Hinton J, 1996, SOC SCI MED, V43, P1229, DOI 10.1016/0277-9536(95)00437-8; *I MED, 2001, CROSS QUAL CHASM NEW, P300; KASSBARTELMES BL, 2003, AHRQ PUB; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lynn J, 1997, J AM GERIATR SOC, V45, P526; Patrick DL, 2001, J PAIN SYMPTOM MANAG, V22, P717, DOI 10.1016/S0885-3924(01)00333-5; Pierson CM, 2002, AIDS CARE, V14, P587, DOI 10.1080/0954012021000005416; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Stewart AL, 1999, J PAIN SYMPTOM MANAG, V17, P93, DOI 10.1016/S0885-3924(98)00131-6; Teno JM, 1999, J PAIN SYMPTOM MANAG, V17, P75, DOI 10.1016/S0885-3924(98)00134-1; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; Tulsky JA, 1998, ANN INTERN MED, V129, P441, DOI 10.7326/0003-4819-129-6-199809150-00003; RW JOHNSON FDN LAST	22	118	118	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			410	415		10.7326/0003-4819-139-5_Part_2-200309021-00006	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965967				2022-12-28	WOS:000185133800006
J	Askari, AT; Unzek, S; Popovic, ZB; Goldman, CK; Forudi, F; Kiedrowski, M; Rovner, A; Ellis, SG; Thomas, JD; DiCorleto, PE; Topol, EJ; Penn, MS				Askari, AT; Unzek, S; Popovic, ZB; Goldman, CK; Forudi, F; Kiedrowski, M; Rovner, A; Ellis, SG; Thomas, JD; DiCorleto, PE; Topol, EJ; Penn, MS			Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy	LANCET			English	Article							MYOCARDIAL-INFARCTION; PROGENITOR CELLS; HEART FUNCTION; TRANSPLANTATION; MOBILIZATION; SDF-1; NEOVASCULARIZATION; RECRUITMENT; MIGRATION; REQUIRES	Background Myocardial regeneration via stem-cell mobilisation at the time of myocardial infarction is known to occur, although the mechanism for stem-cell homing to infarcted tissue subsequently and whether this approach can be used for treatment of ischaemic cardiomyopathy are unknown. We investigated these issues in a Lewis rat model (ligation of the left anterior descending artery) of ischaemic cardiomyopathy. Methods We studied the effects of stem-cell mobilisation by use of granulocyte colony-stimulating factor (filgrastim) with or without transplantation of syngeneic cells. Shortening fraction and myocardial strain by tissue doppler imaging were quantified by echocardiography. Findings Stem-cell mobilisation with filgrastim alone did not lead to engraftment of bone-marrow-derived cells. Stromal-cell-derived factor 1 (SDF-1), required for stem-cell homing to bone marrow, was upregulated immediately after myocardial infarction and downregulated within 7 days. 8 weeks after myocardial infarction, transplantation into the peri-infarct zone of syngeneic cardiac fibroblasts stably transfected to express SDF-1 induced homing of CD117-positive stem cells to injured myocardium after filgrastim administration (control vs SDF-1-expressing cardiac fibroblasts mean 7.2 [SD 3.4] vs 33.2 [6.0] cells/mm(2), n=4 per group, p<0.02) resulting in greater left-ventricular mass (1.24 [0.29] vs 1.57 [0.27] g) and better cardiac function (shortening fraction 9.2 [4.9] vs 17.2 [4.2]%, n=8 per group, p<0.05). Interpretation These findings show that SDF-1 is sufficient to induce therapeutic stem-cell homing to injured myocardium and suggest a strategy for directed stem-cell engraftment into injured tissues. Our findings also indicate that therapeutic strategies focused on stem-cell mobilisation for regeneration of myocardial tissue must be initiated within days of myocardial infarction unless signalling for stem-cell homing is re-established.	Cleveland Clin Fdn, Dept Cardiovasc Med, Expt Anim Lab, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Stem Cell & Regenerat Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Penn, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, Expt Anim Lab, NC10, Cleveland, OH 44195 USA.	pennm@ccf.org		Topol, Eric/0000-0002-1478-4729; popovic, zoran/0000-0001-5692-2299				Askari AT, 2003, J EXP MED, V197, P615, DOI 10.1084/jem.20021426; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; Collins KA, 2001, AM J PHYSIOL-HEART C, V280, pH1954, DOI 10.1152/ajpheart.2001.280.5.H1954; Doitsidou M, 2002, CELL, V111, P647, DOI 10.1016/S0092-8674(02)01135-2; Etzion S, 2001, J MOL CELL CARDIOL, V33, P1321, DOI 10.1006/jmcc.2000.1391; FIRSTENBERG MS, 2000, CURR SURG, V57, P466, DOI DOI 10.1016/S0149-7944(00)00296-8; Greenberg NL, 2002, CIRCULATION, V105, P99, DOI 10.1161/hc0102.101396; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Liesveld JL, 2001, J HEMATOTH STEM CELL, V10, P643, DOI 10.1089/152581601753193850; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Penn MS, 2002, PROG CARDIOVASC DIS, V45, P21, DOI 10.1053/pcad.2002.123466; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; ROBBINS MA, 1998, MANAGEMENT END STAGE, P3; Sakai T, 1999, J THORAC CARDIOV SUR, V118, P715, DOI 10.1016/S0022-5223(99)70018-8; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; Topol EJ, 2001, LANCET, V357, P1905; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yong K, 1999, BRIT J HAEMATOL, V107, P441, DOI 10.1046/j.1365-2141.1999.01714.x; Yoo KJ, 2002, YONSEI MED J, V43, P296, DOI 10.3349/ymj.2002.43.3.296; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	30	1034	1138	0	70	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					697	703		10.1016/S0140-6736(03)14232-8	http://dx.doi.org/10.1016/S0140-6736(03)14232-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957092				2022-12-28	WOS:000185034800010
J	Franz, WM; Zaruba, M; Theiss, H; David, R				Franz, WM; Zaruba, M; Theiss, H; David, R			Stem-cell homing and tissue regeneration in ischaemic cardiomyopathy	LANCET			English	Editorial Material							BONE-MARROW; HEART; TRANSPLANTATION		Univ Munich, Dept Cardiol, Med Clin 1, D-81377 Munich, Germany	University of Munich	Franz, WM (corresponding author), Univ Munich, Dept Cardiol, Med Clin 1, Marchioninistr 15, D-81377 Munich, Germany.		Zaruba, Marc-Michael/AAI-8571-2020	Zaruba, Marc-Michael/0000-0003-1074-5463				Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; Kessler PD, 1999, ANNU REV PHYSIOL, V61, P219, DOI 10.1146/annurev.physiol.61.1.219; Kollet O, 2001, BLOOD, V97, P3283, DOI 10.1182/blood.V97.10.3283; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22	10	14	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					675	676		10.1016/S0140-6736(03)14240-7	http://dx.doi.org/10.1016/S0140-6736(03)14240-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957085				2022-12-28	WOS:000185034800003
J	Merceron-Saffon, N; Baceiredo, A; Gornitzka, H; Bertrand, G				Merceron-Saffon, N; Baceiredo, A; Gornitzka, H; Bertrand, G			Synthesis of carbenes through substitution reactions at a carbene center	SCIENCE			English	Article							STABLE CARBENES	An(amino)(phosphino) carbene can be transformed into(amino)(phosphonio) carbenes, which undergo nucleophilic intermolecular as well as intramolecular substitution reactions at the carbene center. A variety of carbenes can be synthesized starting from a single carbene precursor. The resulting gamut of electronic and steric effects possible should open the way not only to a detailed study of the mechanism, but also to the subsequent improvement of catalytic reactions that involve carbene-transition metal complexes.	Univ Toulouse 3, Lab Heterochim Fondamentale & Appl, UMR 5069, F-31062 Toulouse 04, France; Univ Calif Riverside, Dept Chem, CNRS, UMR 2282,Joint Res Chem Lab, Riverside, CA 92521 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of California System; University of California Riverside	Bertrand, G (corresponding author), Univ Toulouse 3, Lab Heterochim Fondamentale & Appl, UMR 5069, 118 Route Narbonne, F-31062 Toulouse 04, France.	gbertran@mail.ucr.edu						Alder RW, 1998, J AM CHEM SOC, V120, P11526, DOI 10.1021/ja9819312; Alder RW, 1996, ANGEW CHEM INT EDIT, V35, P1121, DOI 10.1002/anie.199611211; Arduengo AJ, 1999, ACCOUNTS CHEM RES, V32, P913, DOI 10.1021/ar980126p; BESTMANN HJ, 1986, CHEM BER-RECL, V119, P1331, DOI 10.1002/cber.19861190421; Bourissou D, 2000, CHEM REV, V100, P39, DOI 10.1021/cr940472u; Brinker U. H., 1994, ADV CARBENE CHEM, V1; Brinker U. H., 1998, ADV CARBENE CHEM, V2; Crabtree RH, 1999, CHEM COMMUN, P1611, DOI 10.1039/a901022j; Herrmann WA, 2002, ANGEW CHEM INT EDIT, V41, P1290, DOI 10.1002/1521-3773(20020415)41:8<1290::AID-ANIE1290>3.0.CO;2-Y; Huang JK, 1999, ORGANOMETALLICS, V18, P2370, DOI 10.1021/om990054l; HYNE J, 1950, J AM CHEM SOC, V72, P2438; Jafarpour L, 2001, ADV ORGANOMET CHEM, V46, P181; Jones M., 1975, CARBENES, VII; Merceon N, 2002, J AM CHEM SOC, V124, P6806, DOI 10.1021/ja026556z; Moss R. A., 1973, CARBENES, V1; RAMIREZ F, 1968, J ORG CHEM, V33, P3787, DOI 10.1021/jo01274a023; Tafipolsky M, 2002, J AM CHEM SOC, V124, P5865, DOI 10.1021/ja011761k; Tomioka H, 2002, J AM CHEM SOC, V124, P474, DOI 10.1021/ja010658s; Trnka TM, 2001, ACCOUNTS CHEM RES, V34, P18, DOI 10.1021/ar000114f; Weiss R, 1998, Z NATURFORSCH B, V53, P599	20	54	54	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1223	1225		10.1126/science.1086860	http://dx.doi.org/10.1126/science.1086860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	715ZC	12947194				2022-12-28	WOS:000185003500037
J	Tsuda, M; Sasaoka, Y; Kiso, M; Abe, K; Haraguchi, S; Kobayashi, S; Saga, Y				Tsuda, M; Sasaoka, Y; Kiso, M; Abe, K; Haraguchi, S; Kobayashi, S; Saga, Y			Conserved role of nanos proteins in germ cell development	SCIENCE			English	Article							DROSOPHILA; MOUSE; GENERATION; PUMILIO; EMBRYOS; GENES	In Drosophila, maternally supplied Nanos functions in the migration of primordial germ cells (PGCs) into the gonad; in mice, zygotic genes are involved instead. We report the cloning and the functional analyses of nanos2 and nanos3 in mice. These genes are differentially expressed in mouse PGCs. nanos2 is predominantly expressed in male germ cells, and the elimination of this gene results in a complete loss of spermatogonia. However, nanos3 is found in migrating PGCs, and the elimination of this factor results in the complete loss of germ cells in both sexes. Hence, although mice and flies differ in their mechanisms for germ cell specification, there seems to be conserved function for nanos proteins among invertebrates and vertebrates.	SOKENDAI, Natl Inst Genet, Div Mammalian Dev, Shizuoka 4118540, Japan; Japan Sci & Technol Corp, CREST, Minato Ku, Tokyo 1050011, Japan; RIKEN, Bioresource Ctr, Tsukuba, Ibaraki 3050074, Japan; Shiga Univ Med Sci, Dept Microbiol, Otsu, Shiga 5202192, Japan; Okazaki Natl Res Inst, Natl Inst Basic Biol, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan	Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Japan Science & Technology Agency (JST); RIKEN; Shiga University of Medical Science; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB)	Saga, Y (corresponding author), SOKENDAI, Natl Inst Genet, Div Mammalian Dev, Yata 1111, Shizuoka 4118540, Japan.	ysaga@lab.nig.ac.jp						Abe K, 1996, DEV BIOL, V180, P468, DOI 10.1006/dbio.1996.0320; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Forbes A, 1998, DEVELOPMENT, V125, P679; Haraguchi S, 2003, MECH DEVELOP, V120, P721, DOI 10.1016/S0925-4773(03)00043-1; Jaruzelska J, 2003, DEV GENES EVOL, V213, P120, DOI 10.1007/s00427-003-0303-2; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; Koprunner M, 2001, GENE DEV, V15, P2877; Lawson KA, 1999, GENE DEV, V13, P424, DOI 10.1101/gad.13.4.424; Mochizuki K, 2000, DEV GENES EVOL, V210, P591, DOI 10.1007/s004270000105; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; Pilon M, 1997, DEVELOPMENT, V124, P1771; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Subramaniam K, 1999, DEVELOPMENT, V126, P4861; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; Ying Y, 2000, MOL ENDOCRINOL, V14, P1053, DOI 10.1210/me.14.7.1053	15	439	473	1	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1239	1241		10.1126/science.1085222	http://dx.doi.org/10.1126/science.1085222			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947200				2022-12-28	WOS:000185003500043
J	Lee, PN; Callaerts, P; de Couet, HG; Martindale, MQ				Lee, PN; Callaerts, P; de Couet, HG; Martindale, MQ			Cephalopod Hox genes and the origin of morphological novelties	NATURE			English	Article							SQUID EUPRYMNA-SCOLOPES; B-LIKE GENE; EXPRESSION; EVOLUTION; SHELL; BRAIN; ORGAN	Cephalopods are a diverse group of highly derived molluscs, including nautiluses, squids, octopuses and cuttlefish. Evolution of the cephalopod body plan from a monoplacophoran-like ancestor(1) entailed the origin of several key morphological innovations contributing to their impressive evolutionary success(2). Recruitment of regulatory genes(3), or even pre-existing regulatory networks(4), may be a common genetic mechanism for generating new structures. Hox genes encode a family of transcriptional regulatory proteins with a highly conserved role in axial patterning in bilaterians(5); however, examples highlighting the importance of Hox gene recruitment for new developmental functions are also known(6,7). Here we examined developmental expression patterns for eight out of nine Hox genes(8) in the Hawaiian bobtail squid Euprymna scolopes, by whole-mount in situ hybridization. Our data show that Hox orthologues have been recruited multiple times and in many ways in the origin of new cephalopod structures. The manner in which these genes have been co-opted during cephalopod evolution provides insight to the nature of the molecular mechanisms driving morphological change in the Lophotrochozoa, a clade exhibiting the greatest diversity of body plans in the Metazoa.	Univ Hawaii Manoa, Dept Zool, Honolulu, HI 96822 USA; Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA; Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Hawaii System; University of Hawaii Manoa; University of Hawaii System; University of Houston System; University of Houston	de Couet, HG (corresponding author), Univ Hawaii Manoa, Dept Zool, 2538 McCarthy Mall, Honolulu, HI 96822 USA.		de Couet, Heinz/J-9522-2012; Callaerts, Patrick/I-8118-2013	de Couet, Heinz/0000-0002-0307-2881; Callaerts, Patrick/0000-0003-4530-4561				Averof M, 1997, NATURE, V388, P682, DOI 10.1038/41786; Brusca RC, 2003, INVERTEBRATES; Budelrnann B, 1995, NERVOUS SYSTEM INVER, P115; BURKE AC, 1995, DEVELOPMENT, V121, P333; Callaerts P, 2002, P NATL ACAD SCI USA, V99, P2088, DOI 10.1073/pnas.042683899; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Hartmann B, 2003, MECH DEVELOP, V120, P177, DOI 10.1016/S0925-4773(02)00456-2; HINMAN VF, IN PRESS EVOL DEV; HOLLAND CH, 1987, J GEOL SOC LONDON, V144, P1, DOI 10.1144/gsjgs.144.1.0001; House M., 1988, CEPHALOPODS PRESENT, P1; Keys DN, 1999, SCIENCE, V283, P532, DOI 10.1126/science.283.5401.532; Kulakova MA, 2002, MECH DEVELOP, V115, P177, DOI 10.1016/S0925-4773(02)00113-2; Lowe CJ, 1997, NATURE, V389, P718, DOI 10.1038/39580; MCFALLNGAI M, 1990, BIOL BULL, V179, P332, DOI 10.2307/1542325; Moshel SM, 1998, DEV GENES EVOL, V208, P135, DOI 10.1007/s004270050164; Nederbragt AJ, 2002, DEV BIOL, V246, P341, DOI 10.1006/dbio.2002.0653; Nogi T, 2001, DEV GROWTH DIFFER, V43, P177; RUNNEGAR B, 1974, SCIENCE, V186, P311, DOI 10.1126/science.186.4161.311; Seaver EC, 2001, DEV BIOL, V236, P195, DOI 10.1006/dbio.2001.0309; Shigeno S, 2001, J COMP NEUROL, V437, P449, DOI 10.1002/cne.1295; Shigeno S, 2001, ZOOL SCI, V18, P527, DOI 10.2108/zsj.18.527; SUNDERMANN G, 1990, ZOOMORPHOLOGY, V109, P343, DOI 10.1007/BF00803575; Telford MJ, 2000, CURR BIOL, V10, P349, DOI 10.1016/S0960-9822(00)00387-0; von Boletzky S, 1970, C. r. hebd. Seanc. Acad. Sci., Paris, V270D, P2182; VONBOLETSKY S, 1994, MCGRAWHILL YB SCI TE, P73; VONBOLETZKY S, 1988, CEPHALOPODS PRESENT, P167; Wanninger A, 2001, EVOL DEV, V3, P312, DOI 10.1046/j.1525-142X.2001.01034.x; YOUNG JZ, 1972, PHILOS T R SOC B, V263, P409, DOI 10.1098/rstb.1972.0005; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	30	137	139	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1061	1065		10.1038/nature01872	http://dx.doi.org/10.1038/nature01872			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944969				2022-12-28	WOS:000184984200045
J	Diederich, S				Diederich, S			Screening for early lung cancer with low-dose spiral computed tomography	LANCET			English	Editorial Material							ACTION PROJECT; PREVALENCE; CT		Marien Hosp, Acad Teaching Hosp, Dept Diagnost & Intervent Radiol, D-40479 Dusseldorf, Germany	Marien Hospital Dusseldorf; St. Marien Hospital	Diederich, S (corresponding author), Marien Hosp, Acad Teaching Hosp, Dept Diagnost & Intervent Radiol, D-40479 Dusseldorf, Germany.	s.diederich@marien-hospital.de						*AM CANC SOC, 2001, CANC FACTS FIG; Diederich S, 2002, RADIOLOGY, V222, P773, DOI 10.1148/radiol.2223010490; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Henschke CI, 2001, CANCER, V92, P153, DOI 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; KUBIK A, 1986, CANCER-AM CANCER SOC, V57, P2427, DOI 10.1002/1097-0142(19860615)57:12<2427::AID-CNCR2820571230>3.0.CO;2-M; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Sobue T, 2002, J CLIN ONCOL, V20, P911, DOI 10.1200/JCO.2002.20.4.911; Sone S, 2001, BRIT J CANCER, V84, P25, DOI 10.1054/bjoc.2000.1531; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006	16	15	15	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					588	589		10.1016/S0140-6736(03)14205-5	http://dx.doi.org/10.1016/S0140-6736(03)14205-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944053				2022-12-28	WOS:000184904100002
J	Douglas, KMJ; Gordon, C; Osman, H; Heaton, S; Skan, J; Situnayake, D; Bowman, SJ				Douglas, KMJ; Gordon, C; Osman, H; Heaton, S; Skan, J; Situnayake, D; Bowman, SJ			Lupus and zoster	LANCET			English	Editorial Material									Univ Hosp Birmingham, Dept Rheumatol, Birmingham B18 7QH, W Midlands, England; City Hosp, Dept Rheumatol, Birmingham B18 7QH, W Midlands, England	University of Birmingham; University of Birmingham	Douglas, KMJ (corresponding author), Univ Hosp Birmingham, Dept Rheumatol, Birmingham B18 7QH, W Midlands, England.		Situnayake, Rohan/GQZ-7644-2022	Gordon, Caroline/0000-0002-1244-6443				Fairley CK, 1996, J INFECT DIS, V174, pS314, DOI 10.1093/infdis/174.Supplement_3.S314; Gilliland WR, 2002, ANN RHEUM DIS, V61, P191, DOI 10.1136/ard.61.3.191; Hata A, 2002, NEW ENGL J MED, V347, P26, DOI 10.1056/NEJMoa013441; Ogilvie MM, 1998, J INFECTION, V36, P31, DOI 10.1016/S0163-4453(98)80153-9; ROWLAND P, 1995, J CLIN ONCOL, V13, P1697, DOI 10.1200/JCO.1995.13.7.1697	5	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					616	616		10.1016/S0140-6736(03)14192-X	http://dx.doi.org/10.1016/S0140-6736(03)14192-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944061				2022-12-28	WOS:000184904100010
J	Kaplan, CD; Laprade, L; Winston, F				Kaplan, CD; Laprade, L; Winston, F			Transcription elongation factors repress transcription initiation from cryptic sites	SCIENCE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CHROMATIN-STRUCTURE; CELL-CYCLE; IN-VIVO; SPT6; YEAST; GENES; DROSOPHILA; MUTATIONS	Previous studies have suggested that transcription elongation results in changes in chromatin structure. Here we present studies of Saccharomyces cerevisiae Spt6, a conserved protein implicated in both transcription elongation and chromatin structure. Our results show that, surprisingly, an spt6 mutant permits aberrant transcription initiation from within coding regions. Furthermore, transcribed chromatin in the spt6 mutant is hypersensitive to micrococcal nuclease, and this hypersensitivity is suppressed by mutational inactivation of RNA polymerase II. These results suggest that Spt6 plays a critical role in maintaining normal chromatin structure during transcription elongation, thereby repressing transcription initiation from cryptic promoters. Other elongation and chromatin factors, including Spt16 and histone H3, appear to contribute to this control.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Winston, F (corresponding author), Harvard Univ, Sch Med, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.	winston@rascal.med.harvard.edu	Kaplan, Craig/AAO-4500-2021	Kaplan, Craig/0000-0002-7518-695X	NIGMS NIH HHS [GM32967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032967, R37GM032967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, MOL CELL, V9, P451, DOI 10.1016/S1097-2765(02)00487-2; Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; CLARKADAMS CD, 1987, MOL CELL BIOL, V7, P679, DOI 10.1128/MCB.7.2.679; DENIS CL, 1984, GENETICS, V108, P833; DOLLARD C, 1994, MOL CELL BIOL, V14, P5223, DOI 10.1128/MCB.14.8.5223; Formosa T, 2002, GENETICS, V162, P1557; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 2002, BBA-GENE STRUCT EXPR, V1577, P276, DOI 10.1016/S0167-4781(02)00458-X; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; KAPLAN CD, UNPUB; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lindstrom DL, 2001, GENETICS, V159, P487; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NATSOULIS G, 1994, GENETICS, V136, P93; NEIGEBORN L, 1987, MOL CELL BIOL, V7, P672, DOI 10.1128/MCB.7.2.672; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NORRIS D, 1988, SCIENCE, V242, P759, DOI 10.1126/science.2847314; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; PRELICH G, 1993, GENETICS, V135, P665; SWANSON MS, 1992, GENETICS, V132, P325; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; Winkler M, 2000, J VIROL, V74, P8053, DOI 10.1128/JVI.74.17.8053-8064.2000; WINSTON F, 1984, GENETICS, V107, P179	32	444	452	3	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1096	1099		10.1126/science.1087374	http://dx.doi.org/10.1126/science.1087374			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934008				2022-12-28	WOS:000184872400040
J	Gale, EAM				Gale, EAM			Is there really an epidemic of type 2 diabetes?	LANCET			English	Editorial Material							MORTALITY		Southmead Gen Hosp, Med Sch Unit, Bristol BS10 5NB, Avon, England	Southmead Hospital	Gale, EAM (corresponding author), Southmead Gen Hosp, Med Sch Unit, Bristol BS10 5NB, Avon, England.							Diamond J, 2003, NATURE, V423, P599, DOI 10.1038/423599a; Dublin LI, 1951, FACTS LIFE BIRTH DEA; HARRIS MI, 1995, NIH PUBLICATION; Hudson R. P., 1983, DIS ITS CONTROL SHAP; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; Roper NA, 2001, BRIT MED J, V322, P1389, DOI 10.1136/bmj.322.7299.1389; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405	7	25	27	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					503	504		10.1016/S0140-6736(03)14148-7	http://dx.doi.org/10.1016/S0140-6736(03)14148-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932378				2022-12-28	WOS:000184817600003
J	Lowe, GDO; Sandercock, PAG; Rosendaal, FR				Lowe, GDO; Sandercock, PAG; Rosendaal, FR			Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?	LANCET			English	Editorial Material							RANDOMIZED DOUBLE-BLIND; HIP-REPLACEMENT SURGERY; POSTOPERATIVE FONDAPARINUX; THROMBOSIS PREVENTION; FRACTURE SURGERY; ENOXAPARIN; PENTASACCHARIDE; PROPHYLAXIS		Univ Glasgow, Royal Infirm, Dept Med, Glasgow G31 2ER, Lanark, Scotland; Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland; Leiden Univ, Med Ctr, Leiden Univ Hosp, Dept Clin Epidemiol, Leiden, Netherlands	Royal Infirmary of Edinburgh; University of Glasgow; University of Edinburgh; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Lowe, GDO (corresponding author), Univ Glasgow, Royal Infirm, Dept Med, Glasgow G31 2ER, Lanark, Scotland.		sandercock, peter/GQI-3167-2022; Rosendaal, Frits/Q-3842-2017	sandercock, peter/0000-0001-8484-0135; Rosendaal, Frits/0000-0003-2558-7496				Bauer KA, 2001, NEW ENGL J MED, V345, P1305, DOI 10.1056/NEJMoa011099; Bounameaux H, 2002, LANCET, V359, P1710, DOI 10.1016/S0140-6736(02)08660-9; Eriksson BI, 2003, ARCH INTERN MED, V163, P1337, DOI 10.1001/archinte.163.11.1337; Eriksson BI, 2001, NEW ENGL J MED, V345, P1298, DOI 10.1056/NEJMoa011100; Heit JA, 2002, ARCH INTERN MED, V162, P1806, DOI 10.1001/archinte.162.16.1806; Lassen MR, 2002, LANCET, V359, P1715, DOI 10.1016/S0140-6736(02)08652-X; Murashige N, 2002, NEW ENGL J MED, V346, P940; SANOFISYNTHELAB, 2002, VENOUS THROMBOEMBOLI; *SCOTT INT GUID NE, 1933, SIGN PUBL, V62; Turpie AGG, 2002, ARCH INTERN MED, V162, P1833, DOI 10.1001/archinte.162.16.1833; Turpie AGG, 2002, LANCET, V359, P1721, DOI 10.1016/S0140-6736(02)08648-8; Turpie AGG, 2001, HAEMATOLOGICA, V86, P59; Vandenbroucke JP, 2002, LANCET, V360, P1605, DOI 10.1016/S0140-6736(02)11543-1; Vormfelde SV, 2002, LANCET, V360, P1701, DOI 10.1016/S0140-6736(02)11636-9	14	36	37	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					504	505		10.1016/S0140-6736(03)14149-9	http://dx.doi.org/10.1016/S0140-6736(03)14149-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932379				2022-12-28	WOS:000184817600004
J	Lo, B; Chou, V; Cedars, MI; Gates, E; Taylor, RN; Wagner, RM; Wolf, L; Yamamoto, KR				Lo, B; Chou, V; Cedars, MI; Gates, E; Taylor, RN; Wagner, RM; Wolf, L; Yamamoto, KR			Consent from donors for embryo and stem cell research	SCIENCE			English	Editorial Material							ATTITUDES		Univ Calif San Francisco, Program Med Eth, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Human Subjects Protect Program, Sch Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lo, B (corresponding author), Univ Calif San Francisco, Program Med Eth, Sch Med, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu		Wolf, Leslie/0000-0002-4660-8383				*ABCNEWS COM, 2001, PUBL BACKS STEM CELL; American Society for Reproductive Medicine, 2002, Fertil Steril, V77, pS2; *CAN I HLTH RES AD, 2002, HUM PLUR STEM CELL R; *CIHR, 2003, HUM STEM CELL RES OP; *COMM EUR COMM, 2003, REP HUM EMBR STEM CE; Ethics Comm, 2002, FERTIL STERIL, V78, P957; Feinberg J., 1988, HARMLESS WRONGDOING; *HL, 2002, REP SEL COMM STEM CE; *HUM FERT EMBR AUT, 2001, COD PRACT; Kalfoglou AL, 2000, FERTIL STERIL, V74, P660, DOI 10.1016/S0015-0282(00)01489-8; Kimbrell Andrew, 1997, HUMAN BODY SHOP CLON; McMahon CA, 2003, HUM REPROD, V18, P871, DOI 10.1093/humrep/deg167; *NAT BIOETH ADV CO, 1999, ETH ISS STEM CELL RE; National Bioethics Advisory Commission, 1999, RES INV HUM BIOL MAT; National Institute of Health, 1994, REP HUM EMBR RES PAN; *NY STAT TASK FORC, 1998, ASS REPR TECHN REC P; Radin Margaret J., 1996, CONTESTED COMMODITIE; Robertson JA., 1994, CHILDREN CHOICE FREE; *VA COMM U CTR PUB, 2002, VCU LIF SCI SURV; 2000, FED REG, V65, P51975	20	21	21	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2003	301	5635					921	921		10.1126/science.1087038	http://dx.doi.org/10.1126/science.1087038			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920284				2022-12-28	WOS:000184755900021
J	Abeysiri, P; Sivaprasad, S; Trew, D				Abeysiri, P; Sivaprasad, S; Trew, D			Clinical picture - Optic disc drusen	LANCET			English	Editorial Material									W Kent Eye Ctr, Farnborough, Kent, England		Abeysiri, P (corresponding author), W Kent Eye Ctr, Farnborough, Kent, England.			Sivaprasad, Sobha/0000-0001-8952-0659					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					468	468		10.1016/S0140-6736(03)14074-3	http://dx.doi.org/10.1016/S0140-6736(03)14074-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927436				2022-12-28	WOS:000184651100024
J	Pockley, AG				Pockley, AG			Heat shock proteins as regulators of the immune response	LANCET			English	Review							T-CELL RESPONSES; RECEPTOR-MEDIATED ENDOCYTOSIS; TYPE-16 E7-EXPRESSING TUMOR; JUVENILE CHRONIC ARTHRITIS; SMOOTH-MUSCLE CELLS; STRESS PROTEINS; MOLECULAR CHAPERONES; CUTTING EDGE; HUMAN HEAT-SHOCK-PROTEIN-60; MYCOBACTERIUM-TUBERCULOSIS	Until recently, heat shock proteins (also known as heat stress proteins) have mostly been regarded as intracellular molecules that mediate a range of essential housekeeping and cytoprotective functions. However, interest in their role as intercellular signalling molecules has been fuelled by the observations that these molecules can be released and re present in the extracellular environment under physiological conditions. They can elicit cytokine production by, and adhesion molecule expression of, a range of cell types, and they can deliver maturation signals and peptides to antigen presenting cells through receptor-mediated interactions. These functions suggest that heat shock proteins could be immunoregulatory agents with potent and widely-applicable therapeutic uses. Furthermore, the induction of self heat shock protein immune reactivity can attenuate autoimmunity and delay transplant rejection, and heat shock proteins derived from tumours and pathogens can elicit specific, protective immunity. This review will focus on this rapidly evolving area of heat shock protein biology.	Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Div Clin Sci N,Immunobiol Res Grp, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Pockley, AG (corresponding author), Univ Sheffield, No Gen Hosp, Ctr Clin Sci, Div Clin Sci N,Immunobiol Res Grp, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.	g.pockley@sheffield.ac.uk	Pockley, Alan G/I-4704-2015; Xia, Xianfeng/F-9169-2011	Pockley, Alan G/0000-0001-9593-6431; 	NHLBI NIH HHS [HL69726] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL069726] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KM, 2000, IMMUNOL LETT, V74, P35, DOI 10.1016/S0165-2478(00)00246-7; ANDERTON SM, 1995, J EXP MED, V181, P943, DOI 10.1084/jem.181.3.943; ANDERTON SM, 1996, STRESS PROTEINS MED, P73; Anthony LSD, 1999, VACCINE, V17, P373, DOI 10.1016/S0264-410X(98)00199-6; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Bassan M, 1998, NEUROSCI LETT, V250, P37, DOI 10.1016/S0304-3940(98)00428-5; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Berwin B, 2002, J IMMUNOL, V168, P4282, DOI 10.4049/jimmunol.168.9.4282; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Binder RJ, 2001, J IMMUNOL, V166, P4968, DOI 10.4049/jimmunol.166.8.4968; Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159; BLACHERE NE, 1993, J IMMUNOTHER, V14, P352, DOI 10.1097/00002371-199311000-00016; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Chandawarkar RY, 1999, J EXP MED, V189, P1437, DOI 10.1084/jem.189.9.1437; CHILD DF, 1993, J ROY SOC MED, V86, P217; CHILD DF, 1995, DIABETIC MED, V12, P595, DOI 10.1111/j.1464-5491.1995.tb00548.x; CHOUCHANE L, 1994, J INFECT DIS, V169, P253, DOI 10.1093/infdis/169.2.253; Chu NR, 2000, CELL STRESS CHAPERON, V5, P401, DOI 10.1379/1466-1268(2000)005<0401:IOAHPT>2.0.CO;2; Chu NR, 2000, CLIN EXP IMMUNOL, V121, P216, DOI 10.1046/j.1365-2249.2000.01293.x; Ciupitu AMT, 2002, CANCER IMMUNOL IMMUN, V51, P163, DOI 10.1007/s00262-002-0263-9; Ciupitu AMT, 1998, J EXP MED, V187, P685, DOI 10.1084/jem.187.5.685; COHEN IR, 1996, STRESS PROTEINS MED, P93; DEGRAEFFMEEDER ER, 1995, J CLIN INVEST, V95, P934, DOI 10.1172/JCI117801; DEGRAEFFMEEDER ER, 1991, LANCET, V337, P1368, DOI 10.1016/0140-6736(91)93057-G; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; FINCATO G, 1991, BLOOD, V77, P579; Galdiero M, 1997, INFECT IMMUN, V65, P699, DOI 10.1128/IAI.65.2.699-707.1997; Gaston JSH, 2002, CLIN EXP IMMUNOL, V127, P1, DOI 10.1046/j.1365-2249.2002.01759.x; GASTON JSH, 1990, J EXP MED, V171, P831, DOI 10.1084/jem.171.3.831; GEORGOPOULOS C, 1993, IMMUNOL TODAY, V14, P373, DOI 10.1016/0167-5699(93)90135-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569; Heikema A, 1997, IMMUNOL LETT, V57, P69, DOI 10.1016/S0165-2478(97)00048-5; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; Hoshino K, 1999, J IMMUNOL, V162, P3749; Janetzki S, 2000, INT J CANCER, V88, P232, DOI 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KAUFMANN SHE, 1990, IMMUNOL TODAY, V11, P129, DOI 10.1016/0167-5699(90)90050-J; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kingston AE, 1996, CLIN EXP IMMUNOL, V103, P77, DOI 10.1046/j.1365-2249.1996.929628.x; KIRBY AC, 1995, J CLIN INVEST, V96, P1185, DOI 10.1172/JCI118150; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Lamb J R, 1989, Int Immunol, V1, P191, DOI 10.1093/intimm/1.2.191; LATHANGUE NB, 1988, EXP CELL RES, V178, P169; Lewthwaite J, 2002, CELL STRESS CHAPERON, V7, P130, DOI 10.1379/1466-1268(2002)007<0130:RLCBNC>2.0.CO;2; Lewthwaite J, 2002, CIRCULATION, V106, P196, DOI 10.1161/01.CIR.0000021121.26290.2C; Lewthwaite JC, 2001, INFECT IMMUN, V69, P7349, DOI 10.1128/IAI.69.12.7349-7355.2001; Liao DF, 2000, J BIOL CHEM, V275, P189, DOI 10.1074/jbc.275.1.189; Macht LM, 2000, IMMUNOLOGY, V99, P208, DOI 10.1046/j.1365-2567.2000.00966.x; Mathew A, 2001, MOL CELL BIOL, V21, P7163, DOI 10.1128/MCB.21.21.7163-7171.2001; Meghji S, 1997, J EXP MED, V186, P1241, DOI 10.1084/jem.186.8.1241; Mizzen L, 1998, BIOTHERAPY, V10, P173, DOI 10.1007/BF02678295; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MUNK ME, 1989, J IMMUNOL, V143, P2844; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; Nollen EAA, 2002, J CELL SCI, V115, P2809; NOVER I, 1991, HEAT SHOCK RESPONSE; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Paul AGA, 2000, J IMMUNOL, V165, P7270, DOI 10.4049/jimmunol.165.12.7270; PEETERMANS WE, 1994, SCAND J IMMUNOL, V39, P613, DOI 10.1111/j.1365-3083.1994.tb03421.x; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Pockley AG, 2002, J HYPERTENS, V20, P1815, DOI 10.1097/00004872-200209000-00027; Pockley AG, 1999, CELL STRESS CHAPERON, V4, P29, DOI 10.1379/1466-1268(1999)004<0029:IOHHSP>2.3.CO;2; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Pockley AG, 2000, HYPERTENSION, V36, P303, DOI 10.1161/01.HYP.36.2.303; Ramage JM, 1999, J IMMUNOL, V162, P704; RANFORD JC, 2000, EXP REV MOL MED; Rea IM, 2001, EXP GERONTOL, V36, P341, DOI 10.1016/S0531-5565(00)00215-1; Reddi K, 1998, J BONE MINER RES, V13, P1260, DOI 10.1359/jbmr.1998.13.8.1260; RES PCM, 1988, LANCET, V2, P478, DOI 10.1016/S0140-6736(88)90123-7; RETZLAFF C, 1994, INFECT IMMUN, V62, P5689, DOI 10.1128/IAI.62.12.5689-5693.1994; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Robert J, 2001, EUR J IMMUNOL, V31, P186, DOI 10.1002/1521-4141(200101)31:1<186::AID-IMMU186>3.0.CO;2-D; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, EUR J IMMUNOL, V30, P2211, DOI 10.1002/1521-4141(2000)30:8<2211::AID-IMMU2211>3.0.CO;2-0; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728, DOI 10.1016/0952-7915(94)90076-0; STINISSEN P, 1995, J IMMUNOL, V154, P4883; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Suzue K, 1996, J IMMUNOL, V156, P873; Tanaka S, 1999, J IMMUNOL, V163, P5560; THOMPSON SJ, 1990, EUR J IMMUNOL, V20, P2479, DOI 10.1002/eji.1830201118; TISSIERES A, 1974, J MOL BIOL, V84, P389, DOI 10.1016/0022-2836(74)90447-1; TUN RYM, 1994, DIABETIC MED, V11, P66, DOI 10.1111/j.1464-5491.1994.tb00232.x; UDONO H, 1994, J IMMUNOL, V152, P5398; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; van Eden W, 2000, DRUG DISCOV TODAY, V5, P115, DOI 10.1016/S1359-6446(99)01464-6; van Eden W, 1998, IMMUNOL TODAY, V19, P303, DOI 10.1016/S0167-5699(98)01283-3; VANDENBROEK MF, 1989, J EXP MED, V170, P449, DOI 10.1084/jem.170.2.449; VanRoon J, 1996, FASEB J, V10, P1801; vanRoon JAG, 1997, J CLIN INVEST, V100, P459, DOI 10.1172/JCI119553; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang XY, 2001, J IMMUNOL, V166, P490, DOI 10.4049/jimmunol.166.1.490; WELCH WJ, 1993, SCI AM, V268, P56, DOI 10.1038/scientificamerican0593-56; Wendling U, 2000, J IMMUNOL, V164, P2711, DOI 10.4049/jimmunol.164.5.2711; Wright BH, 2000, HEART VESSELS, V15, P18, DOI 10.1007/s003800070043; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588; Xu QB, 2000, CIRCULATION, V102, P14, DOI 10.1161/01.CIR.102.1.14; Yoshida N, 2001, NATURE, V411, P44, DOI 10.1038/35075148; YOUNG D, 1993, PHILOS T ROY SOC B, V339, P363, DOI 10.1098/rstb.1993.0035; YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.immunol.8.1.401; ZUO J, 1994, MOL CELL BIOL, V14, P7447	119	527	566	3	47	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					469	476		10.1016/S0140-6736(03)14075-5	http://dx.doi.org/10.1016/S0140-6736(03)14075-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927437				2022-12-28	WOS:000184651100025
J	McTiernan, A; Kooperberg, C; White, E; Wilcox, S; Coates, R; Adams-Campbell, LL; Woods, N; Ockene, J				McTiernan, A; Kooperberg, C; White, E; Wilcox, S; Coates, R; Adams-Campbell, LL; Woods, N; Ockene, J			Recreational physical activity and the risk of breast cancer in postmenopausal women - The Women's Health Initiative cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-HEALTH; BODY-SIZE; NUTRITION; PREVENTION; EXERCISE; AGE	Context Women who are physically active have a decreased risk for breast cancer, but the types, amounts, and timing of activity needed are unknown. Objective To prospectively examine the association between current and past recreational physical activity and incidence of breast cancer in postmenopausal women. Design, Setting, and Patients Prospective cohort study in 74171 women aged 50 to 79 years who were recruited by 40 US clinical centers from 1993 through 1998. Main Outcome Measure Incident invasive and in situ breast cancer. Results We documented 1780 newly diagnosed cases of breast cancer over a mean follow-up of 4.7 years. Compared with less active women, women who engaged in regular strenuous physical activity at age 35 years had a 14% decreased risk of breast cancer (relative risk [RR], 0.86; 95% confidence interval [CI], 0.78-0.95). Similar but attenuated findings were observed for strenuous physical activity at ages 18 years and 50 years. An increasing total current physical activity score was associated with a reduced risk for breast cancer (P=.03 for trend). Women who engaged in the equivalent of 1.25 to 2.5 hours per week of brisk walking had an 18% decreased risk of breast cancer (RR, 0.82; 95% CI, 0.68-0.97) compared with inactive women. Slightly greater reduction in risk was observed for women who engaged in the equivalent of 10 hours or more per week of brisk walking. The effect of exercise was most pronounced in women in the lowest tertile of body mass index (BMI) (<24.1), but also was observed for women in the middle tertile of BMI (24.1-28.4). Conclusions These data suggest that increased physical activity is associated with reduced risk for breast cancer in postmenopausal women, longer duration provides most benefit, and that such activity need not be strenuous.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA; Univ S Carolina, Dept Exercise Sci, Norman J Arnold Sch Publ Hlth, Columbia, SC 29208 USA; Ctr Dis Control & Prevent, Div Canc Prevent & Control, NCCDPHP, Atlanta, GA USA; Howard Univ, Ctr Canc, Washington, DC 20059 USA; Univ Washington, Sch Nursing, Seattle, WA 98195 USA; Univ Massachusetts, Sch Med, Div Prevent & Behav Med, Worcester, MA USA	Fred Hutchinson Cancer Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Centers for Disease Control & Prevention - USA; Howard University; University of Washington; University of Washington Seattle; University of Massachusetts System; University of Massachusetts Worcester	McTiernan, A (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, POB 98109-1024,MP-900, Seattle, WA 98109 USA.	amctiern@fhcrc.org			WHI NIH HHS [N01-WH-4-2123, N01-WH-2-2110, N01-WH-3-2100, N01-WH-3-2111, N01-WH-4-2116] Funding Source: Medline; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH [N01WH042123, N01WH022110, N01WH042116, N01WH032111, N01WH032100] Funding Source: NIH RePORTER	WHI NIH HHS; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Breslow RA, 2001, CANCER EPIDEM BIOMAR, V10, P805; Byers T, 2002, CA-CANCER J CLIN, V52, P92, DOI 10.3322/canjclin.52.2.92; Carpenter CL, 1999, BRIT J CANCER, V80, P1852, DOI 10.1038/sj.bjc.6690610; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Coogan PF, 1997, CANCER CAUSE CONTROL, V8, P626, DOI 10.1023/A:1018402615206; COX DR, 1972, J R STAT SOC B, V34, P187; Dirx MJM, 2001, CANCER, V92, P1638, DOI 10.1002/1097-0142(20010915)92:6<1638::AID-CNCR1490>3.0.CO;2-Q; DORGAN JF, 1994, AM J EPIDEMIOL, V139, P662, DOI 10.1093/oxfordjournals.aje.a117056; Enger SM, 2000, CANCER EPIDEM BIOMAR, V9, P681; Fraser GE, 1997, ANN EPIDEMIOL, V7, P375, DOI 10.1016/S1047-2797(97)00042-2; Friedenreich CM, 2001, CANCER EPIDEM BIOMAR, V10, P287; LANGER RD, IN PRESS ANN EPIDEMI; Lee IM, 2001, CANCER CAUSE CONTROL, V12, P137, DOI 10.1023/A:1008948125076; Luoto R, 2000, EUR J EPIDEMIOL, V16, P973, DOI 10.1023/A:1010847311422; McTiernan A, 1998, CANCER CAUSE CONTROL, V9, P487, DOI 10.1023/A:1008853601471; McTiernan A, 1996, EPIDEMIOLOGY, V7, P598, DOI 10.1097/00001648-199611000-00006; Moore DB, 2000, EPIDEMIOLOGY, V11, P292, DOI 10.1097/00001648-200005000-00011; Moradi T, 2002, INT J CANCER, V100, P76, DOI 10.1002/ijc.10447; Morimoto LM, 2002, CANCER CAUSE CONTROL, V13, P741, DOI 10.1023/A:1020239211145; Patterson RE, 1999, ANN EPIDEMIOL, V9, P178, DOI 10.1016/S1047-2797(98)00055-6; Pukkala E, 1993, Eur J Cancer Prev, V2, P369, DOI 10.1097/00008469-199309000-00002; Rockhill B, 1999, ARCH INTERN MED, V159, P2290, DOI 10.1001/archinte.159.19.2290; Sesso HD, 1998, CANCER CAUSE CONTROL, V9, P433, DOI 10.1023/A:1008827903302; SIITERI PK, 1987, AM J CLIN NUTR, V45, P277, DOI 10.1093/ajcn/45.1.277; STEENLAND K, 1995, CANCER EPIDEM BIOMAR, V4, P807; Thompson PD, 2001, MED SCI SPORT EXER, V33, pS438, DOI 10.1097/00005768-200106001-00012; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; *US DEP HHS, 1992, NIH PUBL; *US DEP HHS, 1993, NIH PUBL; Vaino H, 2002, IARC HDB CANC PREVEN, V6; Verkasalo PK, 2001, CANCER CAUSE CONTROL, V12, P47, DOI 10.1023/A:1008929714862	33	399	406	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1331	1336		10.1001/jama.290.10.1331	http://dx.doi.org/10.1001/jama.290.10.1331			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966124	Bronze			2022-12-28	WOS:000185188600025
J	Ouyang, Z; Takats, Z; Blake, TA; Gologan, B; Guymon, AJ; Wiseman, JM; Oliver, JC; Davisson, VJ; Cooks, RG				Ouyang, Z; Takats, Z; Blake, TA; Gologan, B; Guymon, AJ; Wiseman, JM; Oliver, JC; Davisson, VJ; Cooks, RG			Preparing protein microarrays by soft-landing of mass-selected ions	SCIENCE			English	Article							POLYATOMIC IONS; FABRICATION; DEPOSITION	Intact, multiply protonated proteins of particular mass and charge were selected from ionized protein mixtures and gently landed at different positions on a surface to form a microarray. An array of cytochrome c, lysozyme, insulin, and apomyoglobin was generated, and the deposited proteins showed electrospray ionization mass spectra that matched those of the authentic compounds. Deposited lysozyme and trypsin retained their biological activity. Multiply charged ions of protein kinase A catalytic subunit and hexokinase were also soft-landed into glycerol-based liquid surfaces. These soft-landed kinases phosphorylated LRRASLG oligopeptide and D-fructose, respectively.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Cooks, RG (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	cooks@purdue.edu	Cooks, R Graham/G-1051-2015; Cockshutt, Naomi/AAJ-2721-2020	Cooks, R Graham/0000-0002-9581-9603; Blake, Thomas/0000-0001-8536-9998				Bromann K, 1996, SCIENCE, V274, P956, DOI 10.1126/science.274.5289.956; Feng BB, 1999, J AM CHEM SOC, V121, P8961, DOI 10.1021/ja9923888; FRANCHETTI V, 1977, INT J MASS SPECTROM, V23, P29, DOI 10.1016/0020-7381(77)80004-1; Fuerstenau SD, 2001, ANGEW CHEM INT EDIT, V40, P542, DOI 10.1002/1521-3773(20010202)40:3<541::AID-ANIE541>3.0.CO;2-K; Geiger RJ, 1999, INT J MASS SPECTROM, V182, P415, DOI 10.1016/S1387-3806(98)14262-8; Jones VW, 1998, ANAL CHEM, V70, P1233, DOI 10.1021/ac971125y; Laurell T, 1999, J MICROMECH MICROENG, V9, P369, DOI 10.1088/0960-1317/9/4/314; LEE JC, 1981, J BIOL CHEM, V256, P7193; Luo H, 1998, INT J MASS SPECTROM, V174, P193, DOI 10.1016/S0168-1176(97)00302-9; MacBeath G, 2000, SCIENCE, V289, P1760; Martin BD, 1998, LANGMUIR, V14, P3971, DOI 10.1021/la9713311; Miller SA, 1997, SCIENCE, V275, P1447, DOI 10.1126/science.275.5305.1447; Mooney JF, 1996, P NATL ACAD SCI USA, V93, P12287, DOI 10.1073/pnas.93.22.12287; Morozov VN, 1999, ANAL CHEM, V71, P3110, DOI 10.1021/ac981412h; Pan P, 2003, ANAL CHEM, V75, P1491, DOI 10.1021/ac020637w; Roda A, 2000, BIOTECHNIQUES, V28, P492, DOI 10.2144/00283st07; Rowe CA, 1999, ANAL CHEM, V71, P433, DOI 10.1021/ac980798t; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schwartz JC, 2002, J AM SOC MASS SPECTR, V13, P659, DOI 10.1016/S1044-0305(02)00384-7; Siuzdak G, 1999, J MASS SPECTROM, V34, P1087, DOI 10.1002/(SICI)1096-9888(199910)34:10<1087::AID-JMS872>3.0.CO;2-A; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4	21	219	226	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1351	1354		10.1126/science.1088776	http://dx.doi.org/10.1126/science.1088776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12920304				2022-12-28	WOS:000185116400032
J	Diehr, P; Patrick, DL				Diehr, P; Patrick, DL			Trajectories of health for older adults over time: Accounting fully for death	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				SELF-RATED HEALTH; PATTERNS; TRIAL; INDEX; LIFE	The process of healthy aging can best be described by plotting the trajectory of health-related variables over time. Unfortunately, graphs including data only from survivors may be misleading because they may confuse patterns of mortality with patterns of change in health. Two approaches for creating graphs that account for death in such situations are 1) to incorporate a category or value for death into the longitudinal health variable and 2) to measure time in years before death or some other event. The first approach has been applied to self-rated health (excellent to poor) and the 36-Item Short-Form Health Survey (SF-36). It allows for flexible and interpretable analyses and may be appropriate for other variables as well. The second approach also accounts fully for death, but the questions it can address are limited. Both approaches are useful and should be used at a minimum for supporting analyses in longitudinal studies in which persons die during observation.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Diehr, P (corresponding author), Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA.	pdiehr@u.washington.edu	Patrick, Donald/Y-2460-2019	Patrick, Donald/0000-0003-0756-0492	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085084, N01HC085081, N01HC015103, N01HC085082, N01HC085083, N01HC085085, N01HC035129, N01HC085080, N01HC085086, N01HC085079] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85081, N01-HC-85082, N01-HC-85080, N01-HC-85083, N01-HC-85079, N01-HC-85086, N01-HC-85084, N01-HC-35129, N01 HC-15103, N01-HC-85085] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOZZETTE SA, 1995, JAMA-J AM MED ASSOC, V273, P295, DOI 10.1001/jama.273.4.295; DIEHR P, 1995, MED CARE, V33, pAS164; Diehr P, 1998, J CLIN EPIDEMIOL, V51, P343, DOI 10.1016/S0895-4356(97)00298-9; Diehr P, 2002, J CLIN EPIDEMIOL, V55, P269, DOI 10.1016/S0895-4356(01)00462-0; Diehr P, 2001, QUAL LIFE RES, V10, P431, DOI 10.1023/A:1012566130639; Diehr P, 2001, MED CARE, V39, P670, DOI 10.1097/00005650-200107000-00004; Diehr P, 2001, J AM GERIATR SOC, V49, P36, DOI 10.1046/j.1532-5415.2001.49007.x; DIEHR P, 2003, IN PRESS MED CARE; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; JOHNSON LL, 2002, THESIS U WASHINGTON; KAPLAN RM, 1979, MED CARE, V17, P501, DOI 10.1097/00005650-197905000-00005; LONGSTRETH WT, 1993, NEUROLOGY, V43, P2534, DOI 10.1212/WNL.43.12.2534; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Shock N.W., 1984, NORMAL HUMAN AGING B	16	38	38	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			416	420		10.7326/0003-4819-139-5_Part_2-200309021-00007	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965968				2022-12-28	WOS:000185133800007
J	Durrington, P				Durrington, P			Dyslipidaemia	LANCET			English	Review							CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; CHOLESTERYL ESTER TRANSFER; APOLIPOPROTEIN-B REPLACE; TERM-FOLLOW-UP; FAMILIAL HYPERCHOLESTEROLEMIA; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; SERUM-CHOLESTEROL; RISK-FACTOR	The lowering of serum cholesterol is increasingly recognised as essential in the prevention of coronary heart disease and other atherosclerotic disease. The success of statin trials and the need to deploy these drugs effectively in the population has led increasingly to the identification of many people whose serum cholesterol, triglycerides, and HDL-cholesterol require clinical assessment, and frequently treatment. Lipid disorders are mainly straightforward, but some are complex or resistant to simple treatment strategies. I have reviewed the clinical manifestations of disordered lipid metabolism (dysilpidaemia) and its management.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England	University of Manchester	Durrington, P (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Oxford Rd, Manchester M13 9WL, Lancs, England.	pdurrington@man.ac.uk						*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, BMJ, V303, P893; Arca M, 2002, LANCET, V359, P841, DOI 10.1016/S0140-6736(02)07955-2; ASSMANN G, 1992, AM J CARDIOL, V70, P733, DOI 10.1016/0002-9149(92)90550-I; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Athyros VG, 2002, CURR MED RES OPIN, V18, P220, DOI 10.1185/030079902125000787; Austin MA, 2000, CIRCULATION, V101, P2777, DOI 10.1161/01.CIR.101.24.2777; AUSTIN MA, 1990, CIRCULATION, V82, P495, DOI 10.1161/01.CIR.82.2.495; BAGDADE JD, 1991, EUR J CLIN INVEST, V21, P161, DOI 10.1111/j.1365-2362.1991.tb01805.x; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Barter PJ, 2001, CURR OPIN LIPIDOL, V12, P377, DOI 10.1097/00041433-200108000-00002; Bhatnagar D, 1996, DIABETIC MED, V13, P139, DOI 10.1002/(SICI)1096-9136(199602)13:2<139::AID-DIA15>3.3.CO;2-3; BHATNAGAR D, 1995, LANCET, V345, P405; Bhatnagar D, 2000, BRIT MED J, V321, P1497, DOI 10.1136/bmj.321.7275.1497; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CHAIT A, 1993, AM J MED, V94, P350, DOI 10.1016/0002-9343(93)90144-E; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; de Graaf J, 1998, CURR OPIN LIPIDOL, V9, P189, DOI 10.1097/00041433-199806000-00002; de Jongh S, 2002, CIRCULATION, V106, P2231, DOI 10.1161/01.CIR.0000035247.42888.82; DEGRAAF J, 1991, ARTERIOSCLER THROMB, V11, P298, DOI 10.1161/01.ATV.11.2.298; DEJAGER S, 1993, J LIPID RES, V34, P295; DEMANT T, 1993, J LIPID RES, V34, P147; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; DOWSE G, 1993, BRIT MED J, V306, P532, DOI 10.1136/bmj.306.6877.532; Duell PB, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P897; Durrington PN, 1999, LANCET, V353, P278, DOI 10.1016/S0140-6736(98)04027-6; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; DURRINGTON PN, 1978, CLIN CHIM ACTA, V82, P151, DOI 10.1016/0009-8981(78)90038-4; DURRINGTON PN, 1981, ANN INTERN MED, V94, P211, DOI 10.7326/0003-4819-94-2-211; Durrington PN, 2002, CLIN CHEM, V48, P401; Durrington PN, 2001, LANCET, V357, P574, DOI 10.1016/S0140-6736(00)04075-7; Durrington PN, 2001, HEART, V85, P544, DOI 10.1136/heart.85.5.544; Durrington PN, 1998, ATHEROSCLEROSIS, V141, pS57, DOI 10.1016/S0021-9150(98)00219-6; DURRINGTON PN, 2000, BAILLIERES CLIN END, V13, P265; DURRINGTON PN, 1995, HYPERLIPIDAEMIA DIAG; DURRINGTON PN, 2003, YB DYSLIPIDAEMIA 200, P297; DURRINGTON PN, 1996, HYPERLIPIDAEMIA CHIL, P9; Egger M, 1999, ATHEROSCLEROSIS, V143, P275, DOI 10.1016/S0021-9150(98)00300-1; FARRER M, 1995, METABOLISM, V44, P1016, DOI 10.1016/0026-0495(95)90099-3; Forster LF, 2002, ATHEROSCLEROSIS, V164, P129, DOI 10.1016/S0021-9150(02)00052-7; Freeman DJ, 2001, CIRCULATION, V103, P357; Gagne C, 2002, CIRCULATION, V105, P2469, DOI 10.1161/01.CIR.0000018744.58460.62; GAGNE C, 1979, ATHEROSCLEROSIS, V34, P13, DOI 10.1016/0021-9150(79)90101-1; Goldbourt U, 1997, ARTERIOSCL THROM VAS, V17, P107, DOI 10.1161/01.ATV.17.1.107; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Gordon DJ, 2000, CHOLESTEROL-LOWERING THERAPY, P299; GRIFFIN BA, 1994, ATHEROSCLEROSIS, V106, P241, DOI 10.1016/0021-9150(94)90129-5; Griffin BA, 1999, CLIN SCI, V97, P269, DOI 10.1042/CS19990056; GRUNDY SM, 1987, BAILLIERE CLIN ENDOC, V1, P667, DOI 10.1016/S0950-351X(87)80028-9; Guerin M, 1996, ARTERIOSCL THROM VAS, V16, P763, DOI 10.1161/01.ATV.16.6.763; Guerin M, 2002, ATHEROSCLEROSIS, V163, P287, DOI 10.1016/S0021-9150(02)00037-0; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HAYDEN MR, 1992, MOL GENETICS CORONAR, P350; Heaney AP, 1999, J CLIN ENDOCR METAB, V84, P1203, DOI 10.1210/jc.84.4.1203; Heath KE, 2001, ATHEROSCLEROSIS, V154, P243, DOI 10.1016/S0021-9150(00)00647-X; Heath KE, 1999, ATHEROSCLEROSIS, V143, P41, DOI 10.1016/S0021-9150(98)00274-3; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HEIBERG A, 1977, BRIT MED J, V2, P493, DOI 10.1136/bmj.2.6085.493; HILL JS, 1991, ARTERIOSCLER THROMB, V11, P290, DOI 10.1161/01.ATV.11.2.290; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Humphries S, 1996, LANCET, V347, P1776; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JARRETT RJ, 1982, COMPLICATIONS DIABET, P179; Kajinami K, 1999, CURR OPIN LIPIDOL, V10, P401, DOI 10.1097/00041433-199910000-00004; KANE JP, 1995, METABOLIC MOL BASES, P1853; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1975, ATHEROSCLEROSIS, V22, P149, DOI 10.1016/0021-9150(75)90001-5; Kornerup K, 2002, ARTERIOSCL THROM VAS, V22, P1168, DOI 10.1161/01.ATV.0000022849.26083.FA; Lamarche B, 1997, CIRCULATION, V95, P69, DOI 10.1161/01.CIR.95.1.69; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEE AJ, 1993, BRIT HEART J, V69, P338; LEONARD JV, 1977, BRIT MED J, V1, P1566, DOI 10.1136/bmj.1.6076.1566; Lloyd J K, 1973, Clin Endocrinol Metab, V2, P127, DOI 10.1016/S0300-595X(73)80030-1; Londahl M, 2002, J INTERN MED, V251, P325, DOI 10.1046/j.1365-2796.2002.00959.x; MAHLEY RW, 1996, METABOLIC MOL BASES, P1953; Malmstrom R, 1997, DIABETOLOGIA, V40, P454, DOI 10.1007/s001250050700; MANN CJ, 1991, J CLIN INVEST, V88, P2059, DOI 10.1172/JCI115535; Mann JI, 1996, NEW ZEAL MED J, V109, P224; Marchioli R, 2002, CIRCULATION, V105, P1897, DOI 10.1161/01.CIR.0000014682.14181.F2; Marks D, 2003, ATHEROSCLEROSIS, V168, P1, DOI 10.1016/S0021-9150(02)00330-1; Marks D, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [10.3310/hta4290, DOI 10.3310/HTA4290]; MATSUMOTO T, 1994, DIABETES CARE, V17, P1062, DOI 10.2337/diacare.17.9.1062; MBEWU AD, 1991, ARTERIOSCLER THROMB, V11, P940, DOI 10.1161/01.ATV.11.4.940; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; Meade T, 2002, BRIT MED J, V325, P1139, DOI 10.1136/bmj.325.7373.1139; MIETTINEN TA, 1988, ARTERIOSCLEROSIS, V8, P163, DOI 10.1161/01.ATV.8.2.163; Miremadi S, 2002, CLIN CHEM, V48, P484; MITROPOULOS KA, 1992, ATHEROSCLEROSIS, V95, P119, DOI 10.1016/0021-9150(92)90015-9; MOORJANI S, 1986, METABOLISM, V35, P311, DOI 10.1016/0026-0495(86)90146-0; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; Myant N B, 1973, Clin Endocrinol Metab, V2, P81; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; MYANT NB, 1981, BIOL CHOLESTEROL REL, P689; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; Neil HAW, 1999, ATHEROSCLEROSIS, V142, P105; Newby LK, 2002, JAMA-J AM MED ASSOC, V287, P3087, DOI 10.1001/jama.287.23.3087; NIKKILA EA, 1973, LANCET, V1, P954; Norman D, 1999, J CLIN INVEST, V104, P619, DOI 10.1172/JCI6677; Okamoto H, 2000, NATURE, V406, P203, DOI 10.1038/35018119; Olsson AG, 2002, ANN MED, V34, P37, DOI 10.1080/078538902317338625; Oram JF, 2002, CURR OPIN LIPIDOL, V13, P373, DOI 10.1097/00041433-200208000-00004; Packard CJ, 1998, CIRCULATION, V97, P1440; PEDERSEN TR, 1994, LANCET, V344, P1383; PEKKANEN J, 1990, NEW ENGL J MED, V322, P1700, DOI 10.1056/NEJM199006143222403; PIMSTONE SN, 1998, ARTHEROSCLER THROMB, V18, P209; Rajamannan NM, 2002, CIRCULATION, V105, P2660, DOI 10.1161/01.CIR.0000017435.87463.72; Rallidis L, 1998, HEART, V80, P583, DOI 10.1136/hrt.80.6.583; REAVEN GM, 1993, J CLIN INVEST, V92, P141, DOI 10.1172/JCI116541; REAVEN GM, 1992, METABOLISM, V41, P16, DOI 10.1016/0026-0495(92)90088-R; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 2002, AM J CARDIOL, V90, P139, DOI 10.1016/S0002-9149(02)02436-0; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Schlesinger Z, 2000, CIRCULATION, V102, P21, DOI 10.1161/01.CIR.102.1.21; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; SHAPER AG, 1986, BRIT MED J, V293, P474, DOI 10.1136/bmj.293.6545.474; Shepherd J, 1996, LANCET, V348, P1339; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Sijbrands EJG, 2001, BMJ-BRIT MED J, V322, P1019, DOI 10.1136/bmj.322.7293.1019; SIMONS LA, 1986, AM J CARDIOL SG, V57, P5; SLACK J, 1969, LANCET, V2, P1380; Smilde TJ, 2001, LANCET, V357, P577, DOI 10.1016/S0140-6736(00)04053-8; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; SNIDERMAN AD, 1982, ANN INTERN MED, V97, P833, DOI 10.7326/0003-4819-97-6-833; Stangl MJ, 2000, CHIRURG, V71, P808, DOI 10.1007/s001040051140; Steyn K, 1996, HUM GENET, V98, P479, DOI 10.1007/s004390050243; STREJA D, 1978, ANN INTERN MED, V89, P871, DOI 10.7326/0003-4819-89-6-871; Sun XM, 1998, ATHEROSCLEROSIS, V136, P175, DOI 10.1016/S0021-9150(97)00181-0; TALMUD P, 1991, ATHEROSCLEROSIS, V89, P137, DOI 10.1016/0021-9150(91)90053-6; TAN KCB, 1995, ATHEROSCLEROSIS, V113, P273, DOI 10.1016/0021-9150(94)05454-Q; THELLE DS, 1983, BRIT HEART J, V49, P205, DOI 10.1136/hrt.49.3.205; THOMPSON GR, 1985, BMJ-BRIT MED J, V291, P1671, DOI 10.1136/bmj.291.6510.1671; THOMPSON GR, 1989, ARTERIOSCLEROSIS, V9, pI75; Thompson GR, 1999, CURR OPIN LIPIDOL, V10, P201, DOI 10.1097/00041433-199906000-00002; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Umans-Eckenhausen MAW, 2001, LANCET, V357, P165, DOI 10.1016/S0140-6736(00)03587-X; Wannamethee SG, 1998, J HUM HYPERTENS, V12, P735, DOI 10.1038/sj.jhh.1000714; WEST RJ, 1980, LANCET, V2, P873; WINOCOUR PH, 1991, ATHEROSCLEROSIS, V89, P49, DOI 10.1016/0021-9150(91)90006-O; WINOCOUR PH, 1987, BMJ-BRIT MED J, V294, P1648, DOI 10.1136/bmj.294.6588.1648; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wood D, 2000, BRIT MED J, V320, P705, DOI 10.1136/bmj.320.7236.705; Wood D, 1998, ATHEROSCLEROSIS, V140, P199, DOI 10.1016/S0021-9150(98)90209-X; Wood D, 1998, HEART, V80, pS1	156	269	282	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					717	731		10.1016/S0140-6736(03)14234-1	http://dx.doi.org/10.1016/S0140-6736(03)14234-1			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957096				2022-12-28	WOS:000185034800023
J	Holtzman, BK; Kohlstedt, DL; Zimmerman, ME; Heidelbach, F; Hiraga, T; Hustoft, J				Holtzman, BK; Kohlstedt, DL; Zimmerman, ME; Heidelbach, F; Hiraga, T; Hustoft, J			Melt segregation and strain partitioning: Implications for seismic anisotropy and mantle flow	SCIENCE			English	Article							PARTIALLY MOLTEN ROCKS; OLIVINE; SHEAR; BENEATH; DEFORMATION; ORIENTATION; WATER	One of the principal means of understanding upper mantle dynamics involves inferring mantle flow directions from seismic anisotropy under the assumption that the seismic fast direction (olivine a axis) parallels the regional flow direction. We demonstrate that (i) the presence of melt weakens the alignment of a axes and (ii) when melt segregates and forms networks of weak shear zones, strain partitions between weak and strong zones, resulting in an alignment of a axes 90degrees from the shear direction in three-dimensional deformation. This orientation of a axes provides a new means of interpreting mantle flow from seismic anisotropy in partially molten deforming regions of Earth.	Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA; Bayer Geoinst, D-95440 Bayreuth, Germany	University of Minnesota System; University of Minnesota Twin Cities; University of Bayreuth	Holtzman, BK (corresponding author), Univ Minnesota, Dept Geol & Geophys, Minneapolis, MN 55455 USA.	holtz007@umn.edu; dlkohl@umn.edu	Holtzman, Benjamin/E-8423-2010	Holtzman, Benjamin/0000-0002-6226-7689				ADAMS BL, 1993, METALL TRANS A, V24, P819, DOI 10.1007/BF02656503; Bjarnason IT, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000916; Bystricky M, 2000, SCIENCE, V290, P1564, DOI 10.1126/science.290.5496.1564; Daines MJ, 1997, J GEOPHYS RES-SOL EA, V102, P10257, DOI 10.1029/97JB00393; DURHAM WB, 1977, J GEOPHYS RES, V82, P5737, DOI 10.1029/JB082i036p05737; Gaherty JB, 2001, SCIENCE, V293, P1645, DOI 10.1126/science.1061565; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Holtzman BK, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000258; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; Koga K, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000378; Mainprice D, 1997, TECTONOPHYSICS, V279, P161, DOI 10.1016/S0040-1951(97)00122-4; MCKENZIE D, 1984, J PETROL, V25, P713, DOI 10.1093/petrology/25.3.713; NICOLAS A, 1987, FORMATION ANISOTROPY, V16; PATERSON MS, 1969, PHYSICS STRENGTH PLA, P377; Tommasi A, 1999, EARTH PLANET SC LETT, V168, P173, DOI 10.1016/S0012-821X(99)00046-1; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230; YANG XP, 1995, J GEOPHYS RES-SOL EA, V100, P18165, DOI 10.1029/95JB01425; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0; Zimmerman ME, 1999, GEOPHYS RES LETT, V26, P1505, DOI 10.1029/1999GL900259	19	400	413	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1227	1230		10.1126/science.1087132	http://dx.doi.org/10.1126/science.1087132			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947196				2022-12-28	WOS:000185003500039
J	Trembleau, L; Rebek, J				Trembleau, L; Rebek, J			Helical conformation of alkanes in a hydrophobic cavitand	SCIENCE			English	Article							MOLECULAR RECOGNITION; COMPLEXATION	Alkanes adopt extended conformations in solution that minimize steric interactions and maximize surface area. Folding can reduce the amount of hydrophobic surface exposed to solvent, but sterically unfavorable gauche interactions result. However, we found that the alkyl chains of two common surfactants in aqueous solution adopt helical conformations when bound within a synthetic receptor. The receptor recognizes the helical alkane better than the extended conformation, even though 2 to 3 kilocalories per mole of strain is introduced. The proper filling of space and burial of hydrophobic surface drive the molecular recognition between the receptor and the coiled alkane.	Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Rebek, J (corresponding author), Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jrebek@scripps.edu		Trembleau, Laurent/0000-0001-6376-9077	NIGMS NIH HHS [GM 27932] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027932, R01GM027932] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atwood JL, 2002, J AM CHEM SOC, V124, P10646, DOI 10.1021/ja027191l; Atwood JL, 2003, CHEM COMMUN, P940, DOI 10.1039/b301511d; ATWOOD JL, 1995, SUPRAMOL CHEM, V5, P105, DOI 10.1080/10610279508029481; BLOKZIJL W, 1993, ANGEW CHEM INT EDIT, V32, P1545, DOI 10.1002/anie.199315451; Casnati A, 2003, ACCOUNTS CHEM RES, V36, P246, DOI 10.1021/ar0200798; GOODLING K, 1994, J CHEM EDUC, V71, pA8, DOI 10.1021/ed071pA8; Haino T, 2000, CHEM-EUR J, V6, P3797, DOI 10.1002/1521-3765(20001016)6:20<3797::AID-CHEM3797>3.0.CO;2-1; Hof F, 2003, ANGEW CHEM INT EDIT, V42, P3150, DOI 10.1002/anie.200351174; LEHN JM, 1995, SUPRAMOL CHEM, V5, P97, DOI 10.1080/10610279508029480; MCDONALD DQ, 1992, TETRAHEDRON LETT, V33, P7743, DOI 10.1016/0040-4039(93)88034-G; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NISHIO M, 1998, CH PI INTERACTION; PETERSON BR, 1995, TETRAHEDRON, V51, P401, DOI 10.1016/0040-4020(94)00905-A; Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o; Rudkevich DM, 1998, J AM CHEM SOC, V120, P12216, DOI 10.1021/ja982970g; SCHNEIDER HJ, 1987, J ORG CHEM, V52, P1613, DOI 10.1021/jo00384a046; SONCINI P, 1992, J ORG CHEM, V57, P4608, DOI 10.1021/jo00043a015; STAFFORD RE, 1989, BIOCHEMISTRY-US, V28, P5113, DOI 10.1021/bi00438a031; TURRO NJ, 1978, J AM CHEM SOC, V100, P5951, DOI 10.1021/ja00486a062; VANSTAM J, 1994, J CHEM EDUC, V75, P93; [No title captured]	23	191	192	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1219	1220		10.1126/science.1086644	http://dx.doi.org/10.1126/science.1086644			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947192				2022-12-28	WOS:000185003500035
J	Fernandez-del Castillo, CF; Sahani, DV; Brugge, WR; Harris, NL; Warshaw, AL; Lauwers, GY; Carter, EL				Fernandez-del Castillo, CF; Sahani, DV; Brugge, WR; Harris, NL; Warshaw, AL; Lauwers, GY; Carter, EL			A man with recurrent epigastric pain and elevated amylase levels - Lymphoplasmacytic sclerosing pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AUTOIMMUNE-RELATED PANCREATITIS; INFLAMMATORY PSEUDOTUMOR; STEROID-THERAPY; NATURAL-HISTORY; CHOLANGITIS; CLASSIFICATION; MUTATIONS; FIBROSIS; VARIANT; GENE		Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Fernandez-del Castillo, CF (corresponding author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.		Castillo, Carlos Fenandez-del/AAO-2602-2020					AMMANN RW, 1987, PANCREAS, V2, P368, DOI 10.1097/00006676-198707000-00002; BARTHOLOMEW LG, 1963, NEW ENGL J MED, V269, P8, DOI 10.1056/NEJM196307042690102; CHARI ST, 1994, SCAND J GASTROENTERO, V29, P949, DOI 10.3109/00365529409094869; CLARK A, 1988, GASTROINTEST RADIOL, V13, P30, DOI 10.1007/BF01889019; Ectors N, 1997, GUT, V41, P263, DOI 10.1136/gut.41.2.263; Erkelens GW, 1999, LANCET, V354, P43, DOI 10.1016/S0140-6736(99)00603-0; Etemad B, 2001, GASTROENTEROLOGY, V120, P682, DOI 10.1053/gast.2001.22586; Hamano H, 2002, LANCET, V359, P1403, DOI 10.1016/S0140-6736(02)08359-9; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Horiuchi A, 2002, GASTROINTEST ENDOSC, V55, P494, DOI 10.1067/mge.2002.122653; Ito T, 1997, DIGEST DIS SCI, V42, P1458, DOI 10.1023/A:1018862626221; Kawa S, 2002, GASTROENTEROLOGY, V122, P1264, DOI 10.1053/gast.2002.33022; KAWAGUCHI K, 1991, HUM PATHOL, V22, P387, DOI 10.1016/0046-8177(91)90087-6; Kazumori H, 1998, INT J PANCREATOL, V24, P123; KinoOhsaki J, 1996, GASTROENTEROLOGY, V110, P1579, DOI 10.1053/gast.1996.v110.pm8613065; Kram MT, 2002, GASTROINTEST ENDOSC, V55, P588, DOI 10.1067/mge.2002.119603; Ohana M, 1998, AM J GASTROENTEROL, V93, P99; Okazaki K, 2000, GASTROENTEROLOGY, V118, P573, DOI 10.1016/S0016-5085(00)70264-2; Petter LM, 1998, MAYO CLIN PROC, V73, P447; RUTLEDGE PL, 1988, ARCH SURG-CHICAGO, V123, P597; SARLES H, 1961, AM J DIG DIS, V6, P688, DOI 10.1007/BF02232341; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Sugiyama M, 1998, ANN SURG, V228, P685, DOI 10.1097/00000658-199811000-00008; Tanaka S, 2000, LANCET, V356, P910, DOI 10.1016/S0140-6736(00)02684-2; TENNER SM, 1998, PANCREAS, V1, P331; Uchida K, 2000, AM J GASTROENTEROL, V95, P2788, DOI 10.1016/S0002-9270(00)01980-8; Witt H, 2000, NAT GENET, V25, P213, DOI 10.1038/76088; Wreesmann V, 2001, HISTOPATHOLOGY, V38, P105, DOI 10.1046/j.1365-2559.2001.01056.x; YOSHIDA K, 1995, DIGEST DIS SCI, V40, P1561, DOI 10.1007/BF02285209	29	17	20	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					893	901		10.1056/NEJMcpc030022	http://dx.doi.org/10.1056/NEJMcpc030022			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944576				2022-12-28	WOS:000184968400012
J	Eichinger, S; Minar, E; Bialonczyk, C; Hirschl, M; Quehenberger, P; Schneider, B; Weltermann, A; Wagner, O; Kyrle, PA				Eichinger, S; Minar, E; Bialonczyk, C; Hirschl, M; Quehenberger, P; Schneider, B; Weltermann, A; Wagner, O; Kyrle, PA			D-dimer levels and risk of recurrent venous thromboembolism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL ANTICOAGULANT-THERAPY; DEEP-VEIN THROMBOSIS; FACTOR-V-LEIDEN; PROTHROMBIN GENE; HETEROZYGOUS CARRIERS; FIRST EPISODE; MUTATION; THROMBOPHILIA	Context Widespread screening of patients with venous thromboembolism (VTE) for thrombophilic risk factors has become common clinical practice. Because of the increasing number of risk factors, assessing the risk of recurrence in an individual patient is intricate; therefore, a laboratory method that measures multifactorial thrombophilia is required. Objective To prospectively study the relationship between the risk of recurrent VTE and D-dimer, a global marker of coagulation activation and fibrinolysis. Design, Setting, and Participants Prospective cohort study of 610 patients older than 18 years who were treated with oral anticoagulants for at least 3 months with a first spontaneous VTE, in whom D-dimer levels were measured shortly after discontinuation of oral anticoagulation. The study was conducted at the Department of Internal Medicine I, University Hospital, Vienna, Austria. Patients entered the study at time of discontinuation of oral anticoagulants and were observed at 3-month intervals during the first year and every 6 months thereafter from July 1992 to October 2002. Main Outcome Measure Objectively documented symptomatic recurrent VTE. Results A total of 79 (13%) of 610 patients had recurrent VTE with a mean observation time of 38 months. Patients with recurrence had significantly higher D-dimer levels compared with those without recurrence (553 ng/mL vs 427 ng/mL, P=.01). Compared with patients with D-dimer levels of 750 ng/mL or higher, the relative risk (RR) of recurrence was 0.6 (95% confidence interval [CI], 0.3-1.4),0.6 (95% CI, 0.3-1.2), and 0.3 (95% CI, 0.1-0.6) in patients with D-dimer levels of 500 to 749 ng/mL, 250 to 499 ng/mL, and less than 250 ng/mL, respectively. The cumulative probability of recurrent VTE at 2 years was 3.7% (95% CI, 0.9%-6.5%) among patients with D-dimer levels of less than 250 ng/mL compared with 11.5% (95% CI, 8.0%-15.0%) among patients with higher levels (P=.001). Patients with D-dimer levels of less than 250 ng/mL had a 60% lower RR of recurrence compared with patients with higher levels (RR, 0.4; 95% CI, 0.2-0.8). Conclusion Patients with a first spontaneous VTE and a D-dimer level of less than 250 ng/mL after withdrawal of oral anticoagulation have a low risk of VTE recurrence.	Univ Vienna, Dept Internal Med 1, A-1090 Vienna, Austria; Univ Vienna, Ludwig Boltzmann Inst, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria; Univ Vienna, Clin Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; Univ Vienna, Inst Med Stat, A-1090 Vienna, Austria; Wilhelminenspital Stadt Wien, Vienna, Austria; Hanuschkrankenhaus, Vienna, Austria	University of Vienna; Ludwig Boltzmann Institute; University of Vienna; University of Vienna; University of Vienna; University of Vienna; Wilhelminenspital; WGKK - Hanusch Hospital	Eichinger, S (corresponding author), Univ Vienna, Dept Internal Med 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	sabine.eichinger@akh-wien.ac.at						Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Andreescu ACM, 2002, THROMB HAEMOSTASIS, V87, P47, DOI 10.1055/s-0037-1612942; Bauer KA, 2001, ANN INTERN MED, V135, P367, DOI 10.7326/0003-4819-135-5-200109040-00013; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Cushman M, 2003, BLOOD, V101, P1243, DOI 10.1182/blood-2002-05-1416; De Stefano V, 1999, NEW ENGL J MED, V341, P801, DOI 10.1056/NEJM199909093411104; De Stefano V, 2001, BRIT J HAEMATOL, V113, P630, DOI 10.1046/j.1365-2141.2001.02827.x; Eichinger S, 1999, THROMB HAEMOSTASIS, V81, P14; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Eichinger S, 2002, ARCH INTERN MED, V162, P2357, DOI 10.1001/archinte.162.20.2357; Hirsh J, 2002, BLOOD, V99, P3102, DOI 10.1182/blood.V99.9.3102; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702; Lindmarker P, 1999, THROMB HAEMOSTASIS, V81, P684; Mannucci PM, 2002, THROMB HAEMOSTASIS, V88, P1; Margaglione M, 1999, THROMB HAEMOSTASIS, V82, P1583; Martinelli I, 2001, THROMB HAEMOSTASIS, V86, P395; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; Pinede L, 2001, CIRCULATION, V103, P2453; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501	24	254	261	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1071	1074		10.1001/jama.290.8.1071	http://dx.doi.org/10.1001/jama.290.8.1071			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941680	Bronze			2022-12-28	WOS:000184958900026
J	Wang, TJ; Massaro, JM; Levy, D; Vasan, RS; Wolf, PA; D'Agostino, RB; Larson, MG; Kannel, WB; Benjamin, EJ				Wang, TJ; Massaro, JM; Levy, D; Vasan, RS; Wolf, PA; D'Agostino, RB; Larson, MG; Kannel, WB; Benjamin, EJ			A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community - The Framingham Heart Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; ISCHEMIC-STROKE; ANTICOAGULATION; MANAGEMENT; DISEASE; ASPIRIN; THROMBOEMBOLISM; PREVALENCE; VALIDATION; PREVENTION	Context Prior risk stratification schemes for atrial fibrillation (AF) have been based on randomized trial cohorts or Medicare administrative databases, have included patients with established AF, and have focused on stroke as the principal outcome. Objective To derive risk scores for stroke alone and stroke or death in community-based individuals with new-onset AF. Design, Setting, and Participants Prospective, community-based, observational cohort in Framingham, Mass. We identified 868 participants with new-onset AF, 705 of whom were not treated with warfarin at baseline. Risk scores for stroke (ischemic or hemorrhagic) and stroke or death were developed with censoring when warfarin initiation occurred during follow-up. Event rates were examined in low-risk individuals, as defined by the risk score and 4 previously published risk schemes. Main Outcome Measures Stroke and the combination of stroke or death. Results During a mean follow-up of 4.0 years free of warfarin use, stroke alone occurred in 83 participants and stroke or death occurred in 382 participants. A risk score for stroke was derived that included the following risk predictors: advancing age, female sex, increasing systolic blood pressure, prior stroke or transient ischemic attack, and diabetes. With the risk score, 14.3% of the cohort had a predicted 5-year stroke rate less than or equal to7.5% (average annual rate less than or equal to1.5%), and 30.6% of the cohort had a predicted 5-year stroke rate less than or equal to10% (average annual rate less than or equal to2%). Actual stroke rates in these low-risk groups were 1.1 and 1.5 per 100 person-years, respectively. Previous risk schemes classified 6.4% to 17.3% of subjects as low risk, with actual stroke rates of 0.9 to 2.3 per 100 person-years. A risk score for stroke or death is also presented. Conclusion These risk scores can be used to estimate the absolute risk of an adverse event in individuals with AF, which may be helpful in counseling patients and making treatment decisions.	Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Cardiol, Boston, MA 02215 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Epidemiol, Boston, MA 02215 USA; Boston Univ, Dept Math, Boston, MA 02215 USA; NHLBI, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Boston University	Benjamin, EJ (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	emelia@fram.nhlbi.nih.gov	Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABF-6873-2021; Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABB-2752-2021	Benjamin, Emelia/0000-0003-4076-2336; Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Larson, Martin/0000-0002-9631-1254; Massaro, Joseph/0000-0002-2682-4812; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL074077, K24HL004334] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23 HL074077-01, 1K24-HL-04334, N01-HC-25195] Funding Source: Medline; NINDS NIH HHS [5R01-NS-17950] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		*AM HEART ASS, 2002, HEART DIS STROK STAT; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Biblo LA, 2001, AM J CARDIOL, V87, P346, DOI 10.1016/S0002-9149(00)01374-6; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Evans A, 2001, ARCH INTERN MED, V161, P1443, DOI 10.1001/archinte.161.11.1443; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; Feinberg WM, 1999, J GEN INTERN MED, V14, P56, DOI 10.1046/j.1525-1497.1999.00281.x; Feinberg WM, 1999, THROMB HAEMOSTASIS, V82, P100, DOI 10.1055/s-0037-1614636; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Gerdts E, 2002, HYPERTENSION, V39, P739, DOI 10.1161/hy0302.105683; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1999, ANN INTERN MED, V131, P688, DOI 10.7326/0003-4819-131-9-199911020-00010; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Kalra L, 1999, STROKE, V30, P1218, DOI 10.1161/01.STR.30.6.1218; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; Kearon C, 1997, NEW ENGL J MED, V336, P1506, DOI 10.1056/NEJM199705223362107; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Morrow DA, 2000, CIRCULATION, V102, P2031, DOI 10.1161/01.CIR.102.17.2031; Nam BH, 2000, THESIS BOSTON U BOST; NOVELLO P, 1993, ITAL J NEUROL SCI, V14, P571, DOI 10.1007/BF02339217; ONUNDARSON PT, 1987, EUR HEART J, V8, P521; Pearce LA, 2000, AM J MED, V109, P45, DOI 10.1016/S0002-9343(00)00440-X; Seidl K, 1998, AM J CARDIOL, V82, P580, DOI 10.1016/S0002-9149(98)00419-6; *STROK PREV ATR FI, 1992, ANN INTERN MED, V116, P71; SULLIVAN LM, IN PRESS STAT MED; van Walraven C, 2003, ARCH INTERN MED, V163, P936, DOI 10.1001/archinte.163.8.936; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; Wood KA, 1997, AM J CARDIOL, V79, P1043, DOI 10.1016/S0002-9149(97)00044-1	44	585	614	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1049	1056		10.1001/jama.290.8.1049	http://dx.doi.org/10.1001/jama.290.8.1049			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941677	Bronze			2022-12-28	WOS:000184958900023
J	Eisenberg, M; Kobilo, T; Berman, DE; Dudai, Y				Eisenberg, M; Kobilo, T; Berman, DE; Dudai, Y			Stability of retrieved memory: Inverse correlation with trace dominance	SCIENCE			English	Article							PROTEIN-SYNTHESIS; RETROGRADE-AMNESIA; TASTE-AVERSION; EXTINCTION; RECONSOLIDATION	In memory consolidation, the memory trace stabilizes and becomes resistant to certain amnesic agents. The textbook account is that for any memorized item, consolidation starts and ends just once. However, evidence has accumulated that upon activation in retrieval, the trace may reconsolidate. Whereas some authors reported transient renewed susceptibility of retrieved memories to consolidation blockers, others could not detect it. Here, we report that in both conditioned taste aversion in the rat and fear conditioning in the medaka fish, the stability of retrieved memory is inversely correlated with the control of behavior by that memory. This result may explain some conflicting findings on reconsolidation of activated memories.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dudai, Y (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	yadin.dudai@weizmann.ac.il		Aizenberg, Mark/0000-0002-0010-0453				Anokhin KV, 2002, EUR J NEUROSCI, V15, P1759, DOI 10.1046/j.1460-9568.2002.02023.x; Bahar A, 2003, EUR J NEUROSCI, V17, P1527, DOI 10.1046/j.1460-9568.2003.02551.x; Berman DE, 2001, SCIENCE, V291, P2417, DOI 10.1126/science.1058165; Berman DE, 2003, LEARN MEMORY, V10, P16, DOI 10.1101/lm.53703; BOUTON ME, 1994, J EXP PSYCHOL-ANIM B, V20, P219, DOI 10.1037/0097-7403.20.3.219; Bures J, 1998, CONDITIONED TASTE AV; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Dudai Y, 2000, BRAIN, PERCEPTION, MEMORY, P149; Dudai Y., 2002, MEMORY KEYWORDS CONC; EISENBERG M, UNPUB; LEWIS DJ, 1979, PSYCHOL BULL, V86, P1054, DOI 10.1037/0033-2909.86.5.1054; Millin PM, 2001, NAT REV NEUROSCI, V2, P68, DOI 10.1038/35049075; MISANIN JR, 1968, SCIENCE, V160, P554, DOI 10.1126/science.160.3827.554; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Myers KM, 2002, NEURON, V36, P567, DOI 10.1016/S0896-6273(02)01064-4; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; Nader K, 2000, NATURE, V406, P722, DOI 10.1038/35021052; Pavlov I.P., 1927, CONDITIONED REFLEXES; Rescorla RA, 1996, Q J EXP PSYCHOL-B, V49, P245; Sara SJ, 2000, LEARN MEMORY, V7, P73, DOI 10.1101/lm.7.2.73; SAVAGE GE, 1968, CENTRAL NERVOUS SYST, P127; Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520; Vianna MRM, 2001, P NATL ACAD SCI USA, V98, P12251, DOI 10.1073/pnas.211433298; YAMAMOTO T, 1975, MEDAKA KILLIFISH BIO	24	415	425	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1102	1104		10.1126/science.1086881	http://dx.doi.org/10.1126/science.1086881			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	713RP	12934010				2022-12-28	WOS:000184872400042
J	Gebert, B; Fischer, W; Weiss, E; Hoffmann, R; Haas, R				Gebert, B; Fischer, W; Weiss, E; Hoffmann, R; Haas, R			Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation	SCIENCE			English	Article							GASTRIC EPITHELIAL-CELLS; PROTEIN; ABSENCE; TOXIN; GENE; CAGA; TRANSLOCATION; COLONIZATION; EXPRESSION; INFECTION	Helicobacter pylori (Hp) vacuolating cytotoxin VacA induces cellular vacuolation in epithelial cells. We found that VacA could efficiently block proliferation of T cells by inducing a G(1)/S cell cycle arrest. It interfered with the T cell receptor/interleukin-2 (IL-2) signaling pathway at the level of the Ca2+-calmodulin-dependent phosphatase calcineurin. Nuclear translocation of nuclear factor of activated T cells (NFAT), a transcription factor acting as a global regulator of immune response genes, was abrogated, resulting in downregulation of IL-2 transcription. VacA partially mimicked the activity of the immunosuppressive drug FK506 by possibly inducing a local immune suppression, explaining the extraordinary chronicity of Hp infections.	LMU Munchen, Max Von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany	University of Munich	Haas, R (corresponding author), LMU Munchen, Max Von Pettenkofer Inst Hyg & Med Microbiol, Munich, Germany.		Hoffmann, Reinhard/I-8748-2018	Hoffmann, Reinhard/0000-0003-1514-1183				ARNIEVA MR, 2003, SCIENCE, V300, P1430; ATHERTON JC, 1995, J BIOL CHEM, V270, P17771, DOI 10.1074/jbc.270.30.17771; Blaser MJ, 1996, SCI AM, V274, P104, DOI 10.1038/scientificamerican0296-104; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Kim HP, 2002, EMBO J, V21, P3051, DOI 10.1093/emboj/cdf321; KNIPP U, 1994, FEMS IMMUNOL MED MIC, V8, P157, DOI 10.1111/j.1574-695X.1994.tb00438.x; Krauss-Etschmann S, 2003, CLIN DIAGN LAB IMMUN, V10, P22, DOI 10.1128/CDLI.10.1.22-29.2003; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; Lucas B, 2001, INFECT IMMUN, V69, P1714, DOI 10.1128/IAI.69.3.1714-1721.2001; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Molinari M, 1998, J EXP MED, V187, P135, DOI 10.1084/jem.187.1.135; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Odenbreit S, 2001, CELL MICROBIOL, V3, P21, DOI 10.1046/j.1462-5822.2001.00088.x; RYFFEL B, 1995, IMMUNOPHARMACOLOGY, V30, P199, DOI 10.1016/0162-3109(95)00023-M; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Shirin H, 1999, CANCER RES, V59, P2277; Whitehouse CA, 1998, INFECT IMMUN, V66, P1934, DOI 10.1128/IAI.66.5.1934-1940.1998; Yoshida T, 1999, J IMMUNOL, V163, P3295	25	407	427	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1099	1102		10.1126/science.1086871	http://dx.doi.org/10.1126/science.1086871			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934009				2022-12-28	WOS:000184872400041
J	Wyse, R				Wyse, R			Astronomy - Galactic encounters	SCIENCE			English	Editorial Material							MERGING HISTORY; MILKY-WAY; HALO; GALAXY		Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA	Johns Hopkins University	Wyse, R (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.	wyse@skysrv.pha.jhu.edu						Ferguson AMN, 2002, ASTRON J, V124, P1452, DOI 10.1086/342019; Gilmore G, 2002, ASTROPHYS J, V574, pL39, DOI 10.1086/342363; IBATA RA, 1994, NATURE, V370, P194, DOI 10.1038/370194a0; Ibata RA, 2003, MON NOT R ASTRON SOC, V340, pL21, DOI 10.1046/j.1365-8711.2003.06545.x; Tolstoy E, 2003, ASTRON J, V125, P707, DOI 10.1086/345967; Unavane M, 1996, MON NOT R ASTRON SOC, V278, P727, DOI 10.1093/mnras/278.3.727; Wyse RFG, 1997, ANNU REV ASTRON ASTR, V35, P637, DOI 10.1146/annurev.astro.35.1.637; Wyse RFG, 2001, ASTR SOC P, V230, P71; Yanny B, 2000, ASTROPHYS J, V540, P825, DOI 10.1086/309386; Yanny B, 2003, ASTROPHYS J, V588, P824, DOI 10.1086/374220	10	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1055	1057		10.1126/science.1086836	http://dx.doi.org/10.1126/science.1086836			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12933998				2022-12-28	WOS:000184872400026
J	Kaiser, UB				Kaiser, UB			The pathogenesis of the ovarian hyperstimulation syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Kaiser, UB (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA.								0	62	63	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					729	732		10.1056/NEJMp038106	http://dx.doi.org/10.1056/NEJMp038106			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930924				2022-12-28	WOS:000184843300002
J	Horton, WA				Horton, WA			Skeletal development: insights from targeting the mouse genome	LANCET			English	Article							GROWTH-PLATE CHONDROCYTES; AUTOSOMAL SEX REVERSAL; TRANSGENIC MICE; INDIAN-HEDGEHOG; CRE RECOMBINASE; BONE-FORMATION; OSTEOBLAST DIFFERENTIATION; CAMPOMELIC DYSPLASIA; FACTOR RECEPTOR-3; COLLAGEN-II	Manipulation of the mouse genome through mis-expressing, knocking out, and introducing mutations into genes of interest has provided important insights into the genetic pathways responsible for human skeletal development. These pathways contribute to the sequential phases of skeletal morphogenesis that include patterning, condensation, and overt organogenesis of the membranous and endochondral embryonic skeletons and to subsequent linear growth. Disturbances in these pathways account for many developmental syndromes and disorders of the human skeleton. Recurrent themes include establishment of interlocking regulatory circuits involving growth factors, receptors, signalling pathways, and transcription factors that control cellular programmes such as migration, adhesion, proliferation, differentiation, and apoptosis, and use of common molecules for different purposes. Technical advances suggest that genetic engineering in mice will continue to be highly instructive in the field of skeletal biology.	Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97239 USA	Oregon Health & Science University	Horton, WA (corresponding author), Oregon Hlth & Sci Univ, Shriners Hosp Children, 3101 Sam Jackson Pk Rd, Portland, OR 97239 USA.	wah@shcc.org						Aszodi A, 1998, J CELL BIOL, V143, P1399, DOI 10.1083/jcb.143.5.1399; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bianco P, 1998, MATRIX BIOL, V17, P185, DOI 10.1016/S0945-053X(98)90057-9; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bradley A, 1996, NAT GENET, V14, P121, DOI 10.1038/ng1096-121; BRIGHTON CT, 1987, RHEUM DIS CLIN N AM, V13, P75; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BUCKWALTER JA, 1986, J BONE JOINT SURG AM, V68A, P243, DOI 10.2106/00004623-198668020-00010; Bunting M, 1999, GENE DEV, V13, P1524, DOI 10.1101/gad.13.12.1524; Capecchi MR, 2001, NAT MED, V7, P1086, DOI 10.1038/nm1001-1086; Cheah SS, 2000, METH MOL B, V136, P455; Chen L, 1999, J CLIN INVEST, V104, P1517, DOI 10.1172/JCI6690; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; Cronin CA, 2001, GENE DEV, V15, P1506, DOI 10.1101/gad.892001; D'Angelo M, 2001, J BONE MINER RES, V16, P2339, DOI 10.1359/jbmr.2001.16.12.2339; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Evans MJ, 2001, NAT MED, V7, P1081, DOI 10.1038/nm1001-1081; FLOYD WE, 1987, J BONE JOINT SURG AM, V69A, P185, DOI 10.2106/00004623-198769020-00004; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; GAROFALO S, 1991, P NATL ACAD SCI USA, V88, P9648, DOI 10.1073/pnas.88.21.9648; Garofalo S, 2000, METH MOL B, V137, P491; Garofalo S, 1999, J BONE MINER RES, V14, P1909, DOI 10.1359/jbmr.1999.14.11.1909; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Godwin AR, 1998, P NATL ACAD SCI USA, V95, P13042, DOI 10.1073/pnas.95.22.13042; GORDON JW, 1993, METHOD ENZYMOL, V225, P747; Hadjantonakis AK, 2001, HISTOCHEM CELL BIOL, V115, P49, DOI 10.1007/s004180000233; Hadjantonakis AK, 1999, METH MOL B, V97, P101, DOI 10.1385/1-59259-270-8:101; Hajihosseini MK, 2001, P NATL ACAD SCI USA, V98, P3855, DOI 10.1073/pnas.071586898; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; Hall BK, 1995, INT J DEV BIOL, V39, P881; Hall BK, 2001, J EXP ZOOL, V289, P153, DOI 10.1002/1097-010X(20010215)289:3<153::AID-JEZ1>3.0.CO;2-O; HALL BK, 1992, ANAT EMBRYOL, V186, P107; Hardouin SN, 2000, CLIN GENET, V57, P237, DOI 10.1034/j.1399-0004.2000.570401.x; Horton W. A., 2000, NELSON TXB PEDIAT, P2116; Horton W. A., 2002, EXTRACELLULAR MATRIX; Horton WA, 1996, ENDOCRIN METAB CLIN, V25, P683, DOI 10.1016/S0889-8529(05)70347-9; Huang WD, 2000, MOL CELL BIOL, V20, P4149, DOI 10.1128/MCB.20.11.4149-4158.2000; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Iwata T, 2000, HUM MOL GENET, V9, P1603, DOI 10.1093/hmg/9.11.1603; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; Karp SJ, 2000, DEVELOPMENT, V127, P543; Kaufman M.H., 1992, ATLAS MOUSE DEV; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lefebvre V, 2001, OSTEOARTHR CARTILAGE, V9, pS69, DOI 10.1053/joca.2001.0447; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; Lomri A, 1998, J CLIN INVEST, V101, P1310; Maddox BK, 1997, DEV DYNAM, V208, P170, DOI 10.1002/(SICI)1097-0177(199702)208:2<170::AID-AJA4>3.0.CO;2-F; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MELTON DW, 1994, BIOESSAYS, V16, P633, DOI 10.1002/bies.950160907; METSARANTA M, 1992, J CELL BIOL, V118, P203, DOI 10.1083/jcb.118.1.203; Minina E, 2001, DEVELOPMENT, V128, P4523; MORRIS NPO, 2002, EXTRACELLULAR MATRIX; Morriss-Kay GM, 2001, J ANAT, V199, P143; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; NAGY A, 2003, FLOXED GENES; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Naski MC, 1998, DEVELOPMENT, V125, P4977; Ogden J. A., 1988, BEHAVIOR GROWTH PLAT, P1; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526-968X(200002)26:2<145::AID-GENE14>3.0.CO;2-C; PALMITER RD, 1985, CELL, V41, P343, DOI 10.1016/S0092-8674(85)80004-0; Pedrozo HA, 1998, J CELL PHYSIOL, V177, P343, DOI 10.1002/(SICI)1097-4652(199811)177:2<343::AID-JCP16>3.0.CO;2-A; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; RIMOIN DL, 1997, EMERY RIMOINS PRINCI, P2279; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schipani E, 2001, GENE DEV, V15, P2865; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Uhthoff H. K., 1988, BEHAV GROWTH PLATE, P17; VANDENBERG P, 1991, P NATL ACAD SCI USA, V88, P7640, DOI 10.1073/pnas.88.17.7640; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Whitelaw E, 2000, METH MOL B, V158, P351; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; Willoughby DA, 2000, J BIOL CHEM, V275, P759, DOI 10.1074/jbc.275.2.759; Zelzer E, 2001, MECH DEVELOP, V106, P97, DOI 10.1016/S0925-4773(01)00428-2	96	49	49	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					560	569		10.1016/S0140-6736(03)14119-0	http://dx.doi.org/10.1016/S0140-6736(03)14119-0			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932391				2022-12-28	WOS:000184817600025
J	Spigel, DR				Spigel, DR			HER2 and surgery: more questions to answer	LANCET			English	Editorial Material							METASTATIC BREAST-CANCER; ONCOGENE AMPLIFICATION; PROGRESSION; TRASTUZUMAB		Sarah Cannon Canc Ctr, Nashville, TN 37203 USA	Sarah Cannon Research Institute	Spigel, DR (corresponding author), Sarah Cannon Canc Ctr, Nashville, TN 37203 USA.							BERNS EMJJ, 1995, GENE, V159, P11, DOI 10.1016/0378-1119(94)00534-Y; Burstein HJ, 2003, J CLIN ONCOL, V21, P46, DOI 10.1200/JCO.2003.03.124; Carlomagno C, 1996, J CLIN ONCOL, V14, P2702, DOI 10.1200/JCO.1996.14.10.2702; Hofer SOP, 1998, ARCH SURG-CHICAGO, V133, P383, DOI 10.1001/archsurg.133.4.383; MARTINSGREEN M, 1994, CANCER RES, V54, P4334; Rowley DR, 1998, CANCER METAST REV, V17, P411, DOI 10.1023/A:1006129420005; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SIEWEKE MH, 1994, CRIT REV ONCOGENESIS, V5, P297, DOI 10.1615/CritRevOncog.v5.i2-3.90; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Zemzoum I, 2003, J CLIN ONCOL, V21, P1022, DOI 10.1200/JCO.2003.04.170	13	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					502	503		10.1016/S0140-6736(03)14147-5	http://dx.doi.org/10.1016/S0140-6736(03)14147-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932377				2022-12-28	WOS:000184817600002
J	Tsuda, M; Shigemoto-Mogami, Y; Koizumi, S; Mizokoshi, A; Kohsaka, S; Salter, MW; Inoue, K				Tsuda, M; Shigemoto-Mogami, Y; Koizumi, S; Mizokoshi, A; Kohsaka, S; Salter, MW; Inoue, K			P2X(4) receptors induced in spinal microglia gate tactile allodynia after nerve injury	NATURE			English	Article							DORSAL HORN NEURONS; ATP P-2X RECEPTORS; SYNAPTIC TRANSMISSION; BRAIN; CORD; RAT; PAIN; INVOLVEMENT; CYTOKINES; RELEASE	Pain after nerve damage is an expression of pathological operation of the nervous system 1,2, one hallmark of which is tactile allodynia-pain hypersensitivity evoked by innocuous stimuli. Effective therapy for this pain is lacking, and the underlying mechanisms are poorly understood. Here we report that pharmacological blockade of spinal P2X(4) receptors (P2X(4)Rs)(3-7), a subtype of ionotropic ATP receptor(8), reversed tactile allodynia caused by peripheral nerve injury without affecting acute pain behaviours in naive animals. After nerve injury, P2X(4)R expression increased strikingly in the ipsilateral spinal cord, and P2X(4)Rs were induced in hyperactive microglia but not in neurons or astrocytes. Intraspinal administration of P2X(4)R antisense oligodeoxynucleotide decreased the induction of P2X(4)Rs and suppressed tactile allodynia after nerve injury. Conversely, intraspinal administration of microglia in which P2X(4)Rs had been induced and stimulated, produced tactile allodynia in naive rats. Taken together, our results demonstrate that activation of P2X(4)Rs in hyperactive microglia is necessary for tactile allodynia after nerve injury and is sufficient to produce tactile allodynia in normal animals. Thus, blocking P2X(4)Rs in microglia might be a new therapeutic strategy for pain induced by nerve injury.	Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, Tokyo 1588501, Japan; Hosp Sick Children, Programme Brain & Behav, Toronto, ON M5G 1X8, Canada; Natl Inst Hlth Sci, Div Pharmacol, Setagaya Ku, Tokyo 1588501, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, Fukuoka 8128582, Japan; Natl Inst Neurosci, Dept Neurochem, Tokyo 1878502, Japan	National Institute of Health Sciences - Japan; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); National Institute of Health Sciences - Japan; Kyushu University; National Center for Neurology & Psychiatry - Japan	Inoue, K (corresponding author), Natl Inst Hlth Sci, Div Biosignaling, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.		Tsuda, Makoto/AAE-7256-2020; Koizumi, Schuichi/E-8568-2010	Koizumi, Schuichi/0000-0001-6184-3106				Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Bardoni R, 1997, J NEUROSCI, V17, P5297; BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Fam SR, 2000, J NEUROSCI, V20, P2800; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Honore P, 2000, NEUROSCIENCE, V98, P585, DOI 10.1016/S0306-4522(00)00110-X; Inoue K, 2002, GLIA, V40, P156, DOI 10.1002/glia.10150; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Khakh BS, 2001, PHARMACOL REV, V53, P107; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; Li P, 1998, J NEUROPHYSIOL, V80, P3356, DOI 10.1152/jn.1998.80.6.3356; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; Nakatsuka T, 2001, J NEUROSCI, V21, P6522, DOI 10.1523/JNEUROSCI.21-17-06522.2001; SAWYNOK J, 1993, BRAIN RES, V610, P32, DOI 10.1016/0006-8993(93)91213-C; Seguela P, 1996, J NEUROSCI, V16, P448; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Tsuda M, 1999, BRIT J PHARMACOL, V128, P1497, DOI 10.1038/sj.bjp.0702960; Tsuda M, 1999, BRIT J PHARMACOL, V127, P449, DOI 10.1038/sj.bjp.0702582; Virginio C, 1998, MOL PHARMACOL, V53, P969; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang CZ, 1996, BIOCHEM BIOPH RES CO, V220, P196, DOI 10.1006/bbrc.1996.0380; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Zheng JH, 2000, NEUROSCI LETT, V278, P41, DOI 10.1016/S0304-3940(99)00896-4	28	1132	1243	5	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					778	783		10.1038/nature01786	http://dx.doi.org/10.1038/nature01786			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917686				2022-12-28	WOS:000184733900041
J	Vukusic, P; Sambles, JR				Vukusic, P; Sambles, JR			Photonic structures in biology	NATURE			English	Review							COLOR; LIGHT; BUTTERFLIES	Millions of years before we began to manipulate the flow of light using synthetic structures, biological systems were using nanometre-scale architectures to produce striking optical effects. An astonishing variety of natural photonic structures exists: a species of Brittlestar uses photonic elements composed of calcite to collect light, Morphobutterflies use multiple layers of cuticle and air to produce their striking blue colour and some insects use arrays of elements, known as nipple arrays, to reduce reflectivity in their compound eyes. Natural photonic structures are providing inspiration for technological applications.	Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England	University of Exeter	Vukusic, P (corresponding author), Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England.	P.Vukusic@ex.ac.uk	Sambles, John Roy/X-8675-2019	SAMBLES, John/0000-0003-2721-0692	Biotechnology and Biological Sciences Research Council [JF16983] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		AGOSTON GA, 1987, COLOUR THEORY ITS AP; Aizenberg J, 2001, NATURE, V412, P819, DOI 10.1038/35090573; Argyros A, 2002, MICRON, V33, P483, DOI 10.1016/S0968-4328(01)00044-0; BONE RA, 1985, APPL OPTICS, V24, P1408, DOI 10.1364/AO.24.001408; CHAN CT, 1991, EUROPHYS LETT, V16, P563, DOI 10.1209/0295-5075/16/6/009; DENTON E, 1971, SCI AM, V224, P64, DOI 10.1038/scientificamerican0171-64; GHIRADELLA H, 1991, APPL OPTICS, V30, P3492, DOI 10.1364/AO.30.003492; Gralak B, 2001, OPT EXPRESS, V9, P567, DOI 10.1364/OE.9.000567; HINTON HE, 1969, J INSECT PHYSIOL, V15, P549, DOI 10.1016/0022-1910(69)90253-4; Kaiser N., 2003, OPTICAL INTERFERENCE; Kinoshita S, 2002, P ROY SOC B-BIOL SCI, V269, P1417, DOI 10.1098/rspb.2002.2019; Knight JC, 2002, SCIENCE, V296, P276, DOI 10.1126/science.1070033; Land MF., 2001, ANIMAL EYES; Lawrence C, 2002, APPL OPTICS, V41, P437, DOI 10.1364/AO.41.000437; LEE DW, 1991, NATURE, V349, P260, DOI 10.1038/349260a0; Lee DW, 1997, AM SCI, V85, P56; McMillan WO, 2002, TRENDS ECOL EVOL, V17, P125, DOI 10.1016/S0169-5347(01)02427-2; NEVILLE AC, 1969, BIOL REV, V44, P531, DOI 10.1111/j.1469-185X.1969.tb00611.x; Parker AR, 1998, P ROY SOC B-BIOL SCI, V265, P811, DOI 10.1098/rspb.1998.0364; Parker AR, 2001, NATURE, V409, P36, DOI 10.1038/35051168; PARKER AR, 1998, EUR OPT SOC TOP M, V18, P27; Prum RO, 2003, J EXP BIOL, V206, P2409, DOI 10.1242/jeb.00431; Sanders J. V., 1971, MINERAL REC, V2, P261; Sweeney A, 2003, NATURE, V423, P31, DOI 10.1038/423031a; Vukusic P, 2000, NATURE, V404, P457, DOI 10.1038/35006561; Vukusic P, 2001, PROC SPIE, V4438, P85, DOI 10.1117/12.451481; Vukusic P, 2003, SPRINGER SERIES OPTI, V88, P1; Vukusic P, 1999, P ROY SOC B-BIOL SCI, V266, P1403, DOI 10.1098/rspb.1999.0794; Vukusic P, 2001, NATURE, V410, P36, DOI 10.1038/35065161; Wehner R, 2001, J EXP BIOL, V204, P2589; Yoshida A, 1997, ZOOL SCI, V14, P737, DOI 10.2108/zsj.14.737	31	1414	1455	36	648	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					852	855		10.1038/nature01941	http://dx.doi.org/10.1038/nature01941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917700				2022-12-28	WOS:000184733900055
J	Palatnik, JF; Allen, E; Wu, XL; Schommer, C; Schwab, R; Carrington, JC; Weigel, D				Palatnik, JF; Allen, E; Wu, XL; Schommer, C; Schwab, R; Carrington, JC; Weigel, D			Control of leaf morphogenesis by microRNAs	NATURE			English	Article							VIRAL SUPPRESSOR; DICER HOMOLOG; C-ELEGANS; RNA; ARABIDOPSIS; GENE; DROSOPHILA; PLANTS; EMBRYO; PREDICTION	Plants with altered microRNA metabolism have pleiotropic developmental defects, but direct evidence for microRNAs regulating specific aspects of plant morphogenesis has been lacking. In a genetic screen, we identified the JAW locus, which produces a microRNA that can guide messenger RNA cleavage of several TCP genes controlling leaf development. MicroRNA-guided cleavage of TCP4 mRNA is necessary to prevent aberrant activity of the TCP4 gene expressed from its native promoter. In addition, overexpression of wild-type and microRNA-resistant TCP variants demonstrates that mRNA cleavage is largely sufficient to restrict TCP function to its normal domain of activity. TCP genes with microRNA target sequences are found in a wide range of species, indicating that microRNA-mediated control of leaf morphogenesis is conserved in plants with very different leaf forms.	Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Bot & Plant Pathol, Corvallis, OR 97331 USA	Max Planck Society; Salk Institute; Oregon State University; Oregon State University	Weigel, D (corresponding author), Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany.		Weigel, Detlef/GSJ-0799-2022; Carrington, James C/A-4656-2012; Weigel, Detlef/AAR-3312-2021; Schommer, Carla/AAV-7958-2021; Weigel, Detlef/C-1418-2008; Schwab, Rebecca/I-9352-2012	Weigel, Detlef/0000-0002-2114-7963; Carrington, James C/0000-0003-3572-129X; Weigel, Detlef/0000-0002-2114-7963; Schwab, Rebecca/0000-0001-9933-9669; Allen, Edwards/0000-0002-8318-6319; Palatnik, Javier/0000-0001-7996-5224				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; CHEN X, 2003, SCIENCE         0731; Citerne HL, 2003, PLANT PHYSIOL, V131, P1042, DOI 10.1104/pp.102.016311; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Golden TA, 2002, PLANT PHYSIOL, V130, P808, DOI 10.1104/pp.003491; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kawasaki H, 2003, NATURE, V423, P838, DOI 10.1038/nature01730; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; Nath U, 2003, SCIENCE, V299, P1404, DOI 10.1126/science.1079354; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Plasterk RHA, 2002, SCIENCE, V296, P1263, DOI 10.1126/science.1072148; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rozas J, 1999, BIOINFORMATICS, V15, P174, DOI 10.1093/bioinformatics/15.2.174; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; SWOFFORD DL, 1993, GEN PHYSL, V102, pA9; Tang GL, 2003, GENE DEV, V17, P49, DOI 10.1101/gad.1048103; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; Weigel D., 2002, ARABIDOPSIS LAB MANU; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xie ZX, 2003, CURR BIOL, V13, P784, DOI 10.1016/S0960-9822(03)00281-1; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	40	1291	1490	21	278	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 18	2003	425	6955					257	263		10.1038/nature01958	http://dx.doi.org/10.1038/nature01958			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722JA	12931144				2022-12-28	WOS:000185370900035
J	Garg, AX; Suri, RS; Barrowman, N; Rehman, F; Matsell, D; Rosas-Arellano, MP; Salvadori, M; Haynes, RB; Clark, WF				Garg, AX; Suri, RS; Barrowman, N; Rehman, F; Matsell, D; Rosas-Arellano, MP; Salvadori, M; Haynes, RB; Clark, WF			Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome - A systematic review, meta-analysis, and meta-regression	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GLOMERULAR-FILTRATION RATE; ESCHERICHIA-COLI; FOLLOW-UP; CONTROLLED TRIAL; FUNCTIONAL RESERVE; CLINICAL-FEATURES; PLASMA INFUSION; CHILDREN; CHILDHOOD; EXPERIENCE	Context The long-term renal prognosis of patients with diarrhea-associated hemolytic uremic syndrome (HUS) remains controversial. Objectives To quantify the long-term renal prognosis of patients with diarrhea-associated HUS and to identify reasons for different estimates provided in the literature. Data Sources We searched MEDLINE and Experta. Medica (EMBASE) bibliographic, databases and conference proceedings, and we contacted experts until February 2003. We also searched the Institute for Scientific Information index and reference lists of all studies that fulfilled our eligibility criteria. The search strategy included the terms he, molytic-uremic syndrome, purpura, thrombotic thrombocytopenic, Escherichia coli O157, longitudinal studies, kidney diseases, hypertension, and proteinuria Study Selection Any study that followed up 10 or more patients with primary diarrhea-associated HUS for at least 1 year for renal sequelae. Data Extraction Two authors independently abstracted data on study and patient characteristics, renal measures, outcomes, and prognostic features. Disagreements were resolved by a third author or by consensus. Data Synthesis Forty-nine studies of 3476 patients with a mean follow-up of 4.4 years (range, 1-22 years at last follow-up) from 18 countries, 1950 to 2001, were summarized. At the time of recruitment, patients were aged 1 month to 18 years. In the different studies, death or permanent end-stage renal disease (ESRD) ranged from 0% to 30%, with a pooled incidence of 12% (95% confidence interval [CI], 10%-15%). A glomerular filtration rate lower than 80 mL/min per 1.73 m(2), hypertension, or proteinuria was extremely variable and ranged from 0% to 64%, with a pooled incidence of 25% (95% CI, 20%-30%). A higher severity of acute illness was strongly associated with worse long-term prognosis. Studies with a higher proportion of patients with central nervous system symptoms (coma, seizures, or stroke) had a higher proportion of patients who died or developed permanent ESRD at follow-up (explaining 44% of the between-study variability, P=.01). Studies with a greater proportion of patients lost to follow-up also described a worse prognosis (P=.001) because these patients were typically healthier than those followed up. One or more years after diarrhea-associated HUS, patients with a predicted creatinine clearance higher than 80 mL/min per 1.73 m(2), no overt proteinuria, and no hypertension appeared to have an excellent prognosis. Conclusions Death or ESRD occurs in about. 12% of patients with diarrhea-associated HUS, and 25% of survivors demonstrate long-term renal sequelae. Patients lost to follow-up contribute to worse estimates in some studies. The severity of acute illness, particularly central nervous system symptoms and the need for initial dialysis, is strongly associated with a worse long-term prognosis.	Univ Western Ontario, Div Adult & Pediat Nephrol, London, ON, Canada; Univ Western Ontario, Div Pediat Infect Dis, London, ON, Canada; Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada; Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada; Lawson Hlth Res Inst, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); McMaster University; McMaster University; Western University (University of Western Ontario); Western University (University of Western Ontario)	Garg, AX (corresponding author), London Hlth Sci Ctr, Walkerton Hlth Study, Div Nephrol, Westminster Campus,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	Amit.Garg@lhsc.on.ca	Clark, Bill/G-3287-2011; Barrowman, Nick/AAL-3166-2020; Suri, Rita S/G-3348-2011; Rehman, Faisal/GYA-3738-2022; Matsell, Douglas/ABI-7983-2020; Garg, Amit X/G-3295-2011	Barrowman, Nick/0000-0002-4704-9595; Suri, Rita S/0000-0002-0519-3927; Matsell, Douglas/0000-0003-4530-8554; Haynes, Robert Brian/0000-0002-1453-3196				Al-Eisa A, 2001, PEDIATR NEPHROL, V16, P1093, DOI 10.1007/s004670100036; ARMSTRONG GD, 1995, J INFECT DIS, V171, P1042, DOI 10.1093/infdis/171.4.1042; BALE JF, 1980, AM J DIS CHILD, V134, P869, DOI 10.1001/archpedi.1980.02130210053014; BELL BP, 1994, JAMA-J AM MED ASSOC, V272, P1349, DOI 10.1001/jama.272.17.1349; Blahova K, 2002, PEDIATR NEPHROL, V17, P400, DOI 10.1007/s00467-002-0836-z; Brandt JR, 1998, PEDIATR NEPHROL, V12, P222, DOI 10.1007/s004670050442; Brenner BM, 1996, KIDNEY INT, V49, P1774, DOI 10.1038/ki.1996.265; BRICHARD B, 1993, ACTA CLIN BELG, V48, P156, DOI 10.1080/17843286.1993.11718303; CAMPOS A, 1982, RADIOLOGY, V145, P811, DOI 10.1148/radiology.145.3.6755548; COAD NAG, 1991, CLIN NEPHROL, V35, P10; Cordero J, 1990, Rev Chil Pediatr, V61, P235; DEJONG M, 1988, NEPHROL DIAL TRANSPL, V3, P379, DOI 10.1093/oxfordjournals.ndt.a091684; DIEKMANN L, 1980, KLIN PADIATR, V192, P430, DOI 10.1055/s-2008-1035620; DOLISLAGER D, 1978, AM J DIS CHILD, V132, P55, DOI 10.1001/archpedi.1978.02120260057014; Donckerwolcke R A, 1973, Acta Paediatr Belg, V27, P284; DONCKERWOLCKE RA, 1979, PAEDIATRICIAN, V8, P378; FITZPATRICK MM, 1991, BMJ-BRIT MED J, V303, P489, DOI 10.1136/bmj.303.6801.489; Gagnadoux MF, 1996, CLIN NEPHROL, V46, P39; GIANANTONIO CA, 1968, J PEDIATR-US, V72, P757, DOI 10.1016/S0022-3476(68)80427-5; GILLOR A, 1986, NIEREN HOCHDRUCK, V15, P118; Gusmano R, 1987, Adv Exp Med Biol, V212, P199; GUYOT C, 1986, ARCH FR PEDIATR, V43, P253; HAYNES RB, 1994, J AM MED INFORM ASSN, V1, P447, DOI 10.1136/jamia.1994.95153434; Henning PH, 1998, MED J AUSTRALIA, V168, P552, DOI 10.5694/j.1326-5377.1998.tb139083.x; HUGHES DA, 1991, SCOT MED J, V36, P9, DOI 10.1177/003693309103600105; Huseman D, 1999, PEDIATR NEPHROL, V13, P672, DOI 10.1007/s004670050679; IMOBERDORF G, 1993, SCHWEIZ MED WSCHR, V123, P1439; JANSSEN F, 1974, ARCH FR PEDIATR, V31, P59; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; Kawamura N, 1999, PEDIATR INT, V41, P218, DOI 10.1046/j.1442-200X.1999.4121040.x; KELLES A, 1994, EUR J PEDIATR, V153, P38, DOI 10.1007/s004310050083; Litalien C, 1999, PEDIATR NEPHROL, V13, P840, DOI 10.1007/s004670050712; LOIRAT C, 1984, ARCH FR PEDIATR, V41, P15; LOIRAT C, 1988, PEDIATR NEPHROL, V2, P279, DOI 10.1007/BF00858677; Loirat C, 1993, Adv Nephrol Necker Hosp, V22, P141; MARTIN DL, 1990, NEW ENGL J MED, V323, P1161, DOI 10.1056/NEJM199010253231703; Matise I, 2001, J INFECT DIS, V183, P347, DOI 10.1086/317930; MCLEAN MM, 1966, ARCH DIS CHILD, V41, P76, DOI 10.1136/adc.41.215.76; Miyazaki S, 1994, Rinsho Ketsueki, V35, P341; Mizusawa Y, 1996, MED J AUSTRALIA, V165, P188, DOI 10.5694/j.1326-5377.1996.tb124922.x; Moghal NE, 1998, J PEDIATR-US, V133, P220, DOI 10.1016/S0022-3476(98)70223-9; MONNENS L, 1978, HELV PAEDIATR ACTA, V33, P321; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; OBRIEN JA, 1994, YALE J BIOL MED, V67, P1; Ogborn MR, 1998, PEDIATR NEPHROL, V12, P485, DOI 10.1007/s004670050493; OREGAN S, 1989, CLIN NEPHROL, V32, P217; ORR P, 1994, ARCTIC MED RES S2, V53, P630; PERELSTEIN EM, 1990, ARCH DIS CHILD, V65, P728, DOI 10.1136/adc.65.7.728; Perez N, 1998, PEDIATR NEPHROL, V12, P101, DOI 10.1007/s004670050413; RAMOS S, 2001, NASCER CRESCER, V10, P82; Ray PE, 2001, PEDIATR NEPHROL, V16, P823, DOI 10.1007/s004670100660; RIELLA MC, 1976, NEPHRON, V17, P188, DOI 10.1159/000180723; RIZZONI G, 1988, J PEDIATR-US, V112, P284, DOI 10.1016/S0022-3476(88)80071-4; Safdar N, 2002, JAMA-J AM MED ASSOC, V288, P996, DOI 10.1001/jama.288.8.996; Salvadori MI, 2002, J AM SOC NEPHROL, V13, p662A; SCHIEPPATI A, 1992, J AM SOC NEPHROL, V2, P1640; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; SHETH KJ, 1989, CHILD NEPHROL UROL, V9, P38; Siegler RL, 1996, J PEDIATR-US, V128, P505, DOI 10.1016/S0022-3476(96)70361-X; Small G, 1999, CLIN NEPHROL, V52, P352; SORRENTI LY, 1978, AM J DIS CHILD, V132, P59, DOI 10.1001/archpedi.1978.02120260061015; Spizzirri FD, 1997, PEDIATR NEPHROL, V11, P156, DOI 10.1007/s004670050248; TARR PI, 1989, AM J EPIDEMIOL, V129, P582, DOI 10.1093/oxfordjournals.aje.a115170; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Todd WTA, 2001, LANCET, V357, P1636, DOI 10.1016/S0140-6736(00)04859-5; TONSHOFF B, 1994, NEPHRON, V68, P63, DOI 10.1159/000188221; TUFRO A, 1991, PEDIATR NEPHROL, V5, P184, DOI 10.1007/BF01095948; VERMYLEN C, 1988, ACTA CLIN BELG, V43, P101; WendeFischer R, 1996, MONATSSCHR KINDERH, V144, P526; Wingen AM, 1997, LANCET, V349, P1117, DOI 10.1016/S0140-6736(96)09260-4; Yoshioka K, 1999, PEDIATR INT, V41, P223, DOI 10.1046/j.1442-200X.1999.4121039.x; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zhou XH, 1999, STAT MED, V18, P557, DOI 10.1002/(SICI)1097-0258(19990315)18:5<557::AID-SIM53>3.0.CO;2-F; Zurowska A, 2000, Pol Merkur Lekarski, V8, P234	74	308	330	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1360	1370		10.1001/jama.290.10.1360	http://dx.doi.org/10.1001/jama.290.10.1360			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966129				2022-12-28	WOS:000185188600030
J	Schirmer, EC; Florens, L; Guan, TL; Yates, JR; Gerace, L				Schirmer, EC; Florens, L; Guan, TL; Yates, JR; Gerace, L			Nuclear membrane proteins with potential disease links found by subtractive proteomics	SCIENCE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; PORE COMPLEX; IDENTIFICATION TECHNOLOGY; GENE; ENVELOPE; LAMINA	To comprehensively identify integral membrane proteins of the nuclear envelope (NE), we prepared separately NEs and organelles known to cofractionate with them from liver. Proteins detected by multidimensional protein identification technology in the cofractionating organelles were subtracted from the NE data set. In addition to all 13 known NE integral proteins, 67 uncharacterized open reading frames with predicted membrane-spanning regions were identified. All of the eight proteins tested targeted to the NE, indicating that there are substantially more integral proteins of the NE than previously thought. Furthermore, 23 of these mapped within chromosome regions linked to a variety of dystrophies.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Yates, JR (corresponding author), Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.			Schirmer, Eric/0000-0003-2635-1338; Florens, Laurence/0000-0002-9310-6650	NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM28521, F32 GM19085] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019085, R01GM028521] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; Dreger M, 2001, P NATL ACAD SCI USA, V98, P11943, DOI 10.1073/pnas.211201898; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; Goldman RD, 2002, GENE DEV, V16, P533, DOI 10.1101/gad.960502; Kitaguchi T, 2001, NEUROMUSCULAR DISORD, V11, P542, DOI 10.1016/S0960-8966(01)00207-3; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Santoni V, 2000, ELECTROPHORESIS, V21, P1054, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1054::AID-ELPS1054>3.3.CO;2-#; Satow R, 2002, BIOCHEM BIOPH RES CO, V295, P85, DOI 10.1016/S0006-291X(02)00641-1; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; Zhang QP, 2001, J CELL SCI, V114, P4485; [No title captured]	21	491	529	3	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1380	1382		10.1126/science.1088176	http://dx.doi.org/10.1126/science.1088176			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958361				2022-12-28	WOS:000185116400042
J	Gonzalez-Jose, RG; Gonzalez-Martin, AG; Hernandez, M; Pucciarelli, HM; Sardi, M; Rosales, A; Van der Molen, S				Gonzalez-Jose, RG; Gonzalez-Martin, AG; Hernandez, M; Pucciarelli, HM; Sardi, M; Rosales, A; Van der Molen, S			Craniometric evidence for Palaeoamerican survival in Baja California	NATURE			English	Article							CONTINENTAL MORPHOLOGICAL AFFINITIES; GENE FLOW; AMERICANS; SHAPE	A current issue on the settlement of the Americas refers to the lack of morphological affinities between early Holocene human remains (Palaeoamericans) and modern Amerindian groups, as well as the degree of contribution of the former to the gene pool of the latter(1-6). A different origin for Palaeoamericans and Amerindians is invoked to explain such a phenomenon(3). Under this hypothesis, the origin of Palaeoamericans must be traced back to a common ancestor for Palaeoamericans and Australians, which departed from somewhere in southern Asia and arrived in the Australian continent and the Americas around 40,000 and 12,000 years before present, respectively. Most modern Amerindians are believed to be part of a second, morphologically differentiated migration(3). Here we present evidence of a modern Amerindian group from the Baja California Peninsula in Mexico, showing clearer affinities with Palaeoamerican remains than with modern Amerindians. Climatic changes during the Middle Holocene probably generated the conditions for isolation from the continent, restricting the gene flow of the original group with northern populations, which resulted in the temporal continuity of the Palaeoamerican morphological pattern to the present.	Univ Barcelona, Fac Biol, Seccio Antropol, E-08028 Barcelona, Spain; Univ Autonoma Estado Hidalgo, Area Acad Hist & Antropol, Pachuca 42000, Mexico; Natl Univ La Plata, Fac Ciencias Nat & Museo, Museo La Plata, Dept Cient Antropol, RA-1900 La Plata, Argentina; Ctr INAH Baja California Sur, Inst Nacl Antropol & Hist, La Paz 23000, Mexico; Univ Autonoma Barcelona, Fac Ciencies, BAVE, Unitat Zool, E-08193 Barcelona, Spain	University of Barcelona; Universidad Autonoma del Estado de Hidalgo; National University of La Plata; Museo La Plata; Autonomous University of Barcelona	Gonzalez-Jose, RG (corresponding author), Univ Barcelona, Fac Biol, Seccio Antropol, Diagonal 645, E-08028 Barcelona, Spain.		Gonzalez-Martin, Antonio/A-5489-2015	Gonzalez-Martin, Antonio/0000-0003-0276-0778; Sardi, Marina L./0000-0003-3614-8341; Gonzalez-Jose, Rolando/0000-0002-8128-9381				Baker PA, 2001, SCIENCE, V291, P640, DOI 10.1126/science.291.5504.640; BOOKSTEIN FL, 1989, IEEE T PATTERN ANAL, V11, P567, DOI 10.1109/34.24792; Bradley R. S., 1999, PALEOCLIMATOLOGY REC; Dixon EJ, 2001, QUATERNARY SCI REV, V20, P277; Dryden IL, 1998, STAT SHAPE ANAL, DOI DOI 10.5555/1046920.1088707; Gonzalez-Jose R, 2001, AM J PHYS ANTHROPOL, V116, P154, DOI 10.1002/ajpa.1108; GONZALEZJOSE R, IN PRESS AM J PHYS A; GONZALEZJOSE R, UNPUB LATE PLEISTOCE; GOODALL C, 1991, J ROY STAT SOC B MET, V53, P285, DOI 10.1111/j.2517-6161.1991.tb01825.x; Grismer LL, 2000, P NATL ACAD SCI USA, V97, P14017, DOI 10.1073/pnas.260509697; Haberle S., 1997, P OCEAN DRILLING PRO, V155, P381, DOI DOI 10.2973/0DP.PR0C.SR.155.225.1997; HOWELLS WW, 1989, PAPERS HARVARD U; HOWELLS WW, 1973, PAPERS HARVARD U; Lahr M. M, 1996, EVOLUTION MODERN HUM; Neves WA, 1999, INTERCIENCIA, V24, P258; NEVES WA, 1991, J HUM EVOL, V21, P261, DOI 10.1016/0047-2484(91)90107-7; Neves WA, 1999, HOMO, V50, P263; Powell JF, 1999, YEARB PHYS ANTHROPOL, V42, P153; Relethford JH, 1997, HUM BIOL, V69, P443; RELETHFORD JH, 1994, AM J PHYS ANTHROPOL, V95, P249; Relethford JH, 2002, AM J PHYS ANTHROPOL, V118, P393, DOI 10.1002/ajpa.10079; RELETHFORD JH, 1990, HUM BIOL, V62, P5; Riddle BR, 2000, P NATL ACAD SCI USA, V97, P14438, DOI 10.1073/pnas.250413397; Rohlf FJ, 1999, J CLASSIF, V16, P197, DOI 10.1007/s003579900054; Rosales-Lopez A, 2000, ANTIGUA CALIFORNIA P; Sheets H.D., 2001, INTEGRATED MORPHOMET; SLICE DE, 1998, SOFTWARE MORPHOMETRI; Sparks CS, 2002, P NATL ACAD SCI USA, V99, P14636, DOI 10.1073/pnas.222389599; Willey G. R., 1966, INTRO AM ARCHAEOLOGY; WILLIAMSBLANGERO S, 1989, HUM BIOL, V61, P1	30	69	79	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					62	65		10.1038/nature01816	http://dx.doi.org/10.1038/nature01816			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	717LD	12955139				2022-12-28	WOS:000185089200036
J	Barzansky, B; Etzel, SI				Barzansky, B; Etzel, SI			Educational programs in US medical schools, 2002-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CURRICULUM	Context To better provide medical students with the knowledge, skills, attitudes, and values they will need as physicians, US medical schools continue to make ongoing changes to their staffing and curricula. Objective To review the status of US medical education in the 2002-2003 academic year, compared with 1997-1998. Data Sources The Liaison Committee on Medical Education (LCME) Annual Medical School Questionnaire, the Association of American Medical Colleges (AAMC) Databook, and the AAMC Data Warehouse: Applicant Matriculant File. Data evaluated included those on medical school faculty, applicants, and students; curriculum hours devoted to new multidisciplinary or nontraditional subject areas (eg, cultural diversity, evidence-based medicine, medical ethics, medical informatics); and methods used to evaluate student learning. Data Synthesis The number of full-time faculty members in the 126 LCME-accredited medical schools increased from 96773 in 1997-1998 to 109526 in 20022003 (+13.2%). The number of applicants entering decreased from 43016 in 19971998 to 33 625 in 2002-2003 (-21.8%). The number of enrollees remained virtually unchanged from 1997-1998 (66748) to 2002-2003 (66677). Most medical schools have incorporated new subject areas into their curricula, although time devoted to these areas varies across schools. Schools typically use written examinations (National Board of Medical Examiners subject tests and/or internally prepared examinations) to assess factual knowledge, and observations by faculty members and residents to assess clinical skills. Use of standardized methods (eg, an objective structured clinical examination [OSCE] to assess clinical skills is variable; 82 schools use a final third- or fourth-year comprehensive OSCE; 53 require a passing OSCE score for graduation. Conclusions While the number of applicants to US medical schools has continued to decline, student numbers are constant. The number of full-time faculty members has increased. Schools are incorporating new subject areas into their curricula, and the use of standardized methods of assessing clinical skills, while variable, is generally increasing.	Amer Med Assoc, Div Undergrad Med Educ Policy & Stand, Chicago, IL 60610 USA; Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA	American Medical Association; American Medical Association	Barzansky, B (corresponding author), Amer Med Assoc, Div Undergrad Med Educ Policy & Stand, 515 N State St, Chicago, IL 60610 USA.	barbara_barzansky@ama-assn.org						*AAMC, 2002, AAMC DAT WAR APPL MA; Alpert EJ, 1997, ACAD MED, V72, pS3; *ASS AM MED COLL, 2002, AAMC DAT; *ASS AM MED COLL, 1998, AAMC DAT; *ASS AM MED COLL, 2002, FUNCT STRUCT MED SCH; Barzansky B, 2002, JAMA-J AM MED ASSOC, V288, P1067, DOI 10.1001/jama.288.9.1067; Barzansky B, 1998, JAMA-J AM MED ASSOC, V280, P803, DOI 10.1001/jama.280.9.803; COLTON T, 1975, J MED EDUC, V50, P596; Conill AM, 2000, AM J MED SCI, V319, P306, DOI 10.1097/00000441-200005000-00007; DEITRICK JE, 1960, MED SCH US MIDCENTUR; Espino JU, 1998, J AM MED INFORM ASSN, P467; Felthous A R, 1987, Bull Am Acad Psychiatry Law, V15, P319; Hafferty FW, 1998, ACAD MED, V73, P403, DOI 10.1097/00001888-199804000-00013; Halpern R, 2001, ACAD MED, V76, P606, DOI 10.1097/00001888-200106000-00009; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784	15	82	89	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1190	1196		10.1001/jama.290.9.1190	http://dx.doi.org/10.1001/jama.290.9.1190			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953002				2022-12-28	WOS:000185090400015
J	Newton, DA; Grayson, AS				Newton, DA; Grayson, AS			Trends in career choice by US medical school graduates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SATISFACTION; WORKFORCE	Context Trends in career choice among specialties have varied greatly. Most notable is the recent decrease in the percentage of US medical student graduates choosing a primary care career, which has important implications for the US physician workforce. Objective To review temporal trends in career choice by graduates of allopathic US medical schools, focusing on US medical doctors entering residencies since 1987. Data Sources Three databases, the Association of American Medical Colleges Graduation Questionnaire (AAMC GQ), the National Resident Matching Program, and the national Graduate Medical Education census, were used to review temporal trends in the number of US medical doctors entering residencies in primary care, general or subspecialty surgical, and non-primary care and nonsurgical specialties from 1987 to 2002. Data Synthesis In 1987, 49.2% of all medical school graduates matched to one of the generalist residencies (internal medicine, pediatrics, or family medicine). The percentage of students matching to primary care specialties declined in the early 1990s, peaked at 53.2% in 1998, and declined to 44.2% in 2002. Concurrent with the latter decline, AAMC GQ data showed a decrease in medical student interest in primary care careers (35.6% in 1999 to 21.5% in 2002). The total percentage of US medical doctors matching to general or subspecialty surgical residencies remained stable at 11% to 12% from 1987 to 2002. During this same period, emergency medicine and plastic surgery increased as a match choice, while anesthesiology, pathology, and psychiatry were more variable over time. Conclusions Distribution of medical students' career choices among specialties varied considerably from 1987 to. 2002. The debate will continue regarding the appropriate specialty mix within the physician workforce.	E Carolina Univ, Brody Sch Med, Dept Pediat, Greenville, NC 27858 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	University of North Carolina; East Carolina University; New York Medical College	Newton, DA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Pediat, 3E-139 Brody Med Bldg, Greenville, NC 27858 USA.							ADAMS D, 2002, AM MED NEWS     0826, V45, P9; *AM MED ASS, 1998, JAMA-J AM MED ASSOC, V280, P836; *AM MED ASS, 1993, JAMA-J AM MED ASSOC, V270, P1116; *AM MED ASS, 2002, JAMA-J AM MED ASSOC, V288, P1151; *ASS AM MED COLL, 2003, MED SCH GRAD QUEST; Cooper RA, 2002, ACAD MED, V77, P761, DOI 10.1097/00001888-200208000-00002; CROWLEY A E, 1988, Journal of the American Medical Association, V260, P1093, DOI 10.1001/jama.260.8.1093; Guelich JM, 2002, J INVEST MED, V50, P412, DOI 10.1136/jim-50-06-01; Landon BE, 2003, JAMA-J AM MED ASSOC, V289, P442, DOI 10.1001/jama.289.4.442; Mayer RJ, 1996, J CLIN ONCOL, V14, P2612; *NAT RES MATCH PRO, 2003, NAT RES MATCH PROGR; Neumayer LA, 2002, ARCH SURG-CHICAGO, V137, P1262, DOI 10.1001/archsurg.137.11.1262; Richardson JD, 2002, ARCH SURG-CHICAGO, V137, P515, DOI 10.1001/archsurg.137.5.515; Rosenberg LE, 1999, J CLIN INVEST, V103, P1621, DOI 10.1172/JCI7304; Schroeder SA, 2002, ACAD MED, V77, P767, DOI 10.1097/00001888-200208000-00003; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wetterneck TB, 2002, ARCH INTERN MED, V162, P649, DOI 10.1001/archinte.162.6.649; Whitcomb ME, 2002, ACAD MED, V77, P759, DOI 10.1097/00001888-200208000-00001	18	168	172	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1179	1182		10.1001/jama.290.9.1179	http://dx.doi.org/10.1001/jama.290.9.1179			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953000	Bronze			2022-12-28	WOS:000185090400013
J	Sercombe, TB; Schaffer, GB				Sercombe, TB; Schaffer, GB			Rapid manufacturing of aluminum components	SCIENCE			English	Article							FREEFORM FABRICATION; SURFACE OXIDES; ALLOYS; ATMOSPHERE; PARTICLES	A manufacturing technique for the production of aluminum components is described. A resin-bonded part is formed by a rapid prototyping technique and then debound and infiltrated by a second aluminum alloy under a nitrogen atmosphere. During thermal processing, the aluminum reacts with the nitrogen and is partially transformed into a rigid aluminum nitride skeleton, which provides the structural rigidity during infiltration. The simplicity and rapidity of this process in comparison to conventional production routes, combined with the ability to fabricate complicated parts of almost any geometry and with high dimensional precision, provide an additional means to manufacture aluminum components.	Univ Queensland, Sch Engn, Div Mat, St Lucia, Qld 4072, Australia	University of Queensland	Sercombe, TB (corresponding author), Univ Queensland, Sch Engn, Div Mat, St Lucia, Qld 4072, Australia.		Sercombe, Tim/H-5799-2014	Sercombe, Tim/0000-0001-6663-8929				ANDERSON JE, 1998, C POWD MET AL LIGHT, P75; *ASM INT, 1993, ASM SPEC HDB; BRADLEY W, 1997, RAPID PROTOTYPING LA, P181; Calvert P, 1997, CHEM MATER, V9, P650, DOI 10.1021/cm9604726; Dalgarno K, 2001, RAPID PROTOTYPING J, V7, P173, DOI 10.1108/13552540110395600; GOETZEL CG, 1998, ASM HDB, V7, P541; HIGGINS PK, 1982, POWDER METALL INT, V14, P26; IACOCCA RG, 2000, ADV POWDER METALLURG; Kalpakjian S, 2001, MANUFACTURING ENG TE; KIM YW, 1985, JOM-J MIN MET MAT S, V37, P27, DOI 10.1007/BF03257675; Kondoh K, 2001, POWDER METALL, V44, P161, DOI 10.1179/003258901666310; Kondoh K, 2001, POWDER METALL, V44, P253, DOI 10.1179/003258901666428; LAKSHMINARAYAN U, 1995, ADV POWDER METALLURG; MARCUS P, 1993, SURF INTERFACE ANAL, V20, P923, DOI 10.1002/sia.740201108; MATHIEU HJ, 1985, J VAC SCI TECHNOL A, V3, P331, DOI 10.1116/1.573260; MUNIR ZA, 1981, POWDER METALL, V24, P177, DOI 10.1179/pom.1981.24.4.177; MUNIR ZA, 1979, J MATER SCI, V17, P2733; NIELSEN P, 1993, 1993 POWD MET WORLD, P58; Okumiya M, 2001, SURF COAT TECH, V142, P235, DOI 10.1016/S0257-8972(01)01151-3; OLEFJORD I, 1994, SURF INTERFACE ANAL, V21, P290, DOI 10.1002/sia.740210505; OLEFJORD I, 1986, C AL TECHN 86 11 13, P383; OZBILEN A, 1989, C PHYS CHEM POWD MET, P489; SCHAFFER G, 2000, ALUMINUM POWDER META; Schaffer GB, 2002, METALL MATER TRANS A, V33, P3279, DOI 10.1007/s11661-002-0314-z; SCHOLZ H, 1991, J MATER SCI, V26, P669, DOI 10.1007/BF00588302; Sercombe TB, 2003, MAT SCI ENG A-STRUCT, V341, P163, DOI 10.1016/S0921-5093(02)00207-1; Sercombe TB, 1999, J MATER SCI, V34, P4245, DOI 10.1023/A:1004602819393; Soundararajan R, 2001, J AM CERAM SOC, V84, P509, DOI 10.1111/j.1151-2916.2001.tb00691.x; Souvignier CW, 2001, J MATER RES, V16, P2613, DOI 10.1557/JMR.2001.0359; STHAPITANONDA P, 1957, J PHYS CHEM-US, V60, P1628, DOI 10.1021/j150546a008; Uzunsoy D, 2002, POWDER METALL, V45, P251, DOI 10.1179/003258902225002550; Wohlert M, 1996, PROCESSING AND FABRICATION OF ADVANCED MATERIALS V, P293; Woodford D.A., 1997, ASM HDB MAT SELECTIO, P573; [No title captured]	34	111	131	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1225	1227		10.1126/science.1086989	http://dx.doi.org/10.1126/science.1086989			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947195				2022-12-28	WOS:000185003500038
J	Serafini, M; Bugianesi, R; Maiani, G; Valtuena, S; De Santis, S; Crozier, A				Serafini, M; Bugianesi, R; Maiani, G; Valtuena, S; De Santis, S; Crozier, A			Plasma antioxidants from chocolate - Dark chocolate may offer its consumers health benefits the milk variety cannot match	NATURE			English	Editorial Material							CONSUMPTION		Natl Inst Food & Nutr Res, Human Nutr Unit, Antioxidant Res Lab, I-00178 Rome, Italy; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Plant Prod & Human Nutr Grp, Glasgow G12 8QQ, Lanark, Scotland	Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); University of Glasgow	Serafini, M (corresponding author), Natl Inst Food & Nutr Res, Human Nutr Unit, Antioxidant Res Lab, Via Ardeatina 546, I-00178 Rome, Italy.		Crozier, Alan/H-6642-2017; Serafini, Mauro/K-6498-2018	Crozier, Alan/0000-0001-7581-6782; Serafini, Mauro/0000-0003-0913-936X				BENZIE IFF, 1996, ANAL BIOCHEM, V239, P229; Charlton AJ, 2002, J AGR FOOD CHEM, V50, P1593, DOI 10.1021/jf010897z; Holt RR, 2002, JAMA-J AM MED ASSOC, V287, P2212, DOI 10.1001/jama.287.17.2212; Maiani G, 1997, J CHROMATOGR B, V692, P311, DOI 10.1016/S0378-4347(97)00009-1; Rein D, 2000, J NUTR, V130, p2109S, DOI 10.1093/jn/130.8.2109S; Serafini M, 1996, EUR J CLIN NUTR, V50, P28; Steinberg FM, 2003, J AM DIET ASSOC, V103, P215, DOI 10.1053/jada.2003.50028	7	347	359	1	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1013	1013		10.1038/4241013a	http://dx.doi.org/10.1038/4241013a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944955	Green Accepted, Bronze			2022-12-28	WOS:000184984200029
J	Lehmann, D; Tennant, MT; Silva, DT; McAullay, D; Lannigan, F; Coates, H; Stanley, FJ				Lehmann, D; Tennant, MT; Silva, DT; McAullay, D; Lannigan, F; Coates, H; Stanley, FJ			Benefits of swimming pools in two remote Aboriginal communities in Western Australia: intervention study	BRITISH MEDICAL JOURNAL			English	Article							OTITIS-MEDIA; CHILDHOOD; CHILDREN; RATES	Objective To determine the health impact of swimming pools built with the aim of improving quality of life and reducing high rates of pyoderma and otitis media. Design Intervention study assessing prevalence of ear disease and skin infections before and at six monthly intervals after opening of swimming pools. Setting Two remote Aboriginal communities in Western Australia. Participants 84 boys and 78 girls aged <17 years. Main outcome measures Changes in prevalence and severity of pyoderma and perforation of tympanic membranes with or without otorrhoea over 18 months after opening of pools. Results In community A, 61 children were seen before the pool was opened, and 41, 46, and 33 children were seen at the second, third, and fourth surveys. Equivalent figures for community B were 60, 35,39, and 45. Prevalence of pyoderma declined significantly from 62% to 18% in community A and from 70% to 20% in community B during the 18 months after the pools opened. Over the same period, prevalence of severe pyoderma fell from 30% to 15% in community A mid from 48% to 0% in community B. prevalence of perforations of the tympanic membrane fell front 32% in both communities to 13% in community A and 18% in community B. School attendance improved in community A. Conclusion Swimming pools in remote communities were associated with reduction in prevalence of pyoderma and tympanic membrane perforations, which could result in long term benefits through reduction in chronic disease burden and improved educational mid social outcomes.	Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6872, Australia; Princess Margaret Hosp Children, Subiaco, WA 6008, Australia	Telethon Kids Institute; University of Western Australia	Lehmann, D (corresponding author), Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, POB 855, Perth, WA 6872, Australia.		Coates, Harvey Larry Charles/AAR-2846-2020	McAullay, Daniel/0000-0002-0651-899X; Tennant, Marc/0000-0002-2553-9884				Barwick R S, 2000, MMWR CDC Surveill Summ, V49, P1; Carapetis JR, 1995, J PAEDIATR CHILD H, V31, P563, DOI 10.1111/j.1440-1754.1995.tb00886.x; Carapetis JR, 1997, PEDIATR INFECT DIS J, V16, P494, DOI 10.1097/00006454-199705000-00008; Carapetis JR, 1999, CLIN INFECT DIS, V28, P205, DOI 10.1086/515114; COUZOS S, 1999, ABORIGINAL PRIMARY H, P240; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; Goodfellow AM, 1999, EPIDEMIOL INFECT, V122, P67, DOI 10.1017/S0950268898001812; Hoy WE, 1998, KIDNEY INT, V54, P1296, DOI 10.1046/j.1523-1755.1998.00099.x; HUDSON HM, 1984, INT J EPIDEMIOL, V13, P73, DOI 10.1093/ije/13.1.73; HUNTER EM, 1992, MED J AUSTRALIA, V156, P575, DOI 10.5694/j.1326-5377.1992.tb121423.x; MACKELLAR A, 1995, MED J AUSTRALIA, V162, P238, DOI 10.5694/j.1326-5377.1995.tb139875.x; Morris PS, 1998, J PAEDIATR CHILD H, V34, P487, DOI 10.1046/j.1440-1754.1998.00299.x; *NSW HLTH DEP WORK, 1996, MED J AUST S, V164, pS1; Peart A, 2000, SWIMMING POOLS REMOT, P25; Silva DT, 1998, J PAEDIATR CHILD H, V34, P63, DOI 10.1046/j.1440-1754.1998.00156.x; *WHO, 1998, WHO CIB FDN WORKSH, P32	16	47	47	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					415	419		10.1136/bmj.327.7412.415	http://dx.doi.org/10.1136/bmj.327.7412.415			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715YY	12933727	Green Published, Bronze			2022-12-28	WOS:000185003100014
J	McDermott, R; Tulip, F; Schmidt, B; Sinha, A				McDermott, R; Tulip, F; Schmidt, B; Sinha, A			Sustaining better diabetes care in remote indigenous Australian communities	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Problem Inhabitants of Torres Strait Islands have the highest prevalence of diabetes in Australia and many preventable complications. In 1999, a one year randomised cluster trial showed improved diabetes care processes and reduced admissions to hospital when local indigenous health workers used registers, recall and reminder systems, and basic diabetes care plans, supported by a specialist outreach service. This study looked at whether those improvements were sustained two years after the end of the trial. Design Three year follow up clinical audit of 21 primary healthcare centres, and review of admissions to hospital in the previous 12 months. Background and setting Remote indigenous communities in far north east Australia, population about 9600, including 921 people with diabetes. Key measures for improvement Number of people on registers, care processes (regular measures of weight, blood pressure, haemoglobin A(1c), urinary protein concentration, and concentrations of serum lipids and creatinine), appropriate clinical interventions (drug treatment and vaccinations), and intermediate patient outcome measures (weight, blood pressure, and glycaemic control). Admissions to hospital. Strategies for change Audit and feedback to clinicians and managers; provision of clinical guidelines and a clear management structure; workshops and training. Effects of change The number of people on registers increased from 555 in 1999 to 921 in 2002. Most care processes and clinical interventions improved. The proportion of people with good glycaemic control (haemoglobin A(1c), less than or equal to 7%) increased from 18% to 25% in line with increased use of insulin (from 7% to 16%). The proportion of those with well controlled hypertension (<140/90) increased from 40% to 64%. The proportion admitted to hospital with a diabetes related condition fell from 25% to 20%. Mean weight increased from 87 kg to 91 kg. Lessons learnt In remote settings, appropriate management structures and clinical support for people with diabetes can lead to improvements in care processes, control of blood pressure, and preventable complications that result in admission to hospital. Control of weight and glycaemia are more difficult and requires more active community engagement. Priorities now include increasing the availability and affordability of good food, achieving weight loss, and increasing appropriate use of hypoglycaemic agents, including insulin.	Queensland Hlth, Trop Publ Hlth Unit, Cairns, Qld 4870, Australia; James Cook Univ N Queensland, Townsville, Qld 4811, Australia; Queensland Hlth, Cairns Diabet Ctr, Cairns, Qld 4870, Australia	Queensland Health; James Cook University; Queensland Health	McDermott, R (corresponding author), Queensland Hlth, Trop Publ Hlth Unit, Cairns, Qld 4870, Australia.	robyn_mcdermott@health.qld.gov.au	McDermott, Robyn A/C-5824-2008					Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P965; Leonard D, 1995, AUST J PUBLIC HEALTH, V19, P589; Leonard D, 2002, AUST NZ J PUBL HEAL, V26, P144, DOI 10.1111/j.1467-842X.2002.tb00907.x; McDermott RA, 2001, MED J AUSTRALIA, V174, P497, DOI 10.5694/j.1326-5377.2001.tb143397.x; *QUEENSL HLTH, 2002, CHRON DIS STRAT IMPL, V1, P76; *QUEENSL HLTH, 2000, HLTH FOOD ACC BASK; *TORR STRAIT NO PE, 1996, MER ZAG DIAB OUR WOR	7	63	66	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2003	327	7412					428	430		10.1136/bmj.327.7412.428	http://dx.doi.org/10.1136/bmj.327.7412.428			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933731	Green Published, Green Accepted			2022-12-28	WOS:000185003100021
J	Sucena, E; Delon, I; Jones, I; Payre, F; Stern, DL				Sucena, E; Delon, I; Jones, I; Payre, F; Stern, DL			Regulatory evolution of shavenbaby/ovo underlies multiple cases of morphological parallelism	NATURE			English	Article							WINGLESS; EPIDERMIS	Cases of convergent evolution that involve changes in the same developmental pathway, called parallelism, provide evidence that a limited number of developmental changes are available to evolve a particular phenotype(1). To our knowledge, in no case are the genetic changes underlying morphological convergence understood. However, morphological convergence is not generally assumed to imply developmental parallelism(2). Here we investigate a case of convergence of larval morphology in insects and show that the loss of particular trichomes, observed in one species of the Drosophila melanogaster species group, has independently evolved multiple times in the distantly related D. virilis species group(3). We present genetic and gene expression data showing that regulatory changes of the shavenbaby/ovo (svb/ovo) gene underlie all independent cases of this morphological convergence. Our results indicate that some developmental regulators might preferentially accumulate evolutionary changes and that morphological parallelism might therefore be more common than previously appreciated.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Ctr Dev Biol, F-31062 Toulouse 4, France; Vanguard High Sch, New York, NY 10021 USA	Princeton University	Stern, DL (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	dstern@princeton.edu	Sucena, Élio/ABF-6684-2020; Sucena, Élio/M-1753-2015	Sucena, Élio/0000-0001-8810-870X; Sucena, Élio/0000-0001-8810-870X; Stern, David/0000-0002-1847-6483; PAYRE, Francois/0000-0002-8144-6711	NIGMS NIH HHS [R01 GM063622] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1861, ORIGIN SPECIES MEANS; Bokor P, 1996, DEVELOPMENT, V122, P1083; DICKINSON WJ, 1993, EVOLUTION, V47, P1396, DOI [10.2307/2410155, 10.1111/j.1558-5646.1993.tb02162.x]; Endler J.A., 1986, Monographs in Population Biology, pviii; FFRENCHCONSTANT RH, 1994, INSECT BIOCHEM MOLEC, V24, P335, DOI 10.1016/0965-1748(94)90026-4; Hatini V, 2000, GENE DEV, V14, P1364; Hodin J, 2000, J EXP ZOOL, V288, P1; HSU TC, 1951, THESIS U TEXAS; KUHN DT, 1992, DROSOPHILA INFORMATI, V71, P218; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Spicer GS, 2002, ANN ENTOMOL SOC AM, V95, P156, DOI 10.1603/0013-8746(2002)095[0156:MPOTDV]2.0.CO;2; STEWART CB, 1987, COLD SPRING HARB SYM, V52, P891, DOI 10.1101/SQB.1987.052.01.097; Sucena E, 2000, P NATL ACAD SCI USA, V97, P4530, DOI 10.1073/pnas.97.9.4530; Throckmorton L.H., 1982, Genetics and Biology of Drosophila, V3b, P227; Wittkopp PJ, 2003, P NATL ACAD SCI USA, V100, P1808, DOI 10.1073/pnas.0336368100; Wittkopp PJ, 2002, CURR BIOL, V12, P1547, DOI 10.1016/S0960-9822(02)01113-2; Wray GA, 1998, CURR OPIN GENET DEV, V8, P675, DOI 10.1016/S0959-437X(98)80036-1	17	168	174	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					935	938		10.1038/nature01768	http://dx.doi.org/10.1038/nature01768			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931187				2022-12-28	WOS:000184843600040
J	de la Hoya, M; Fernandez, JM; Tosar, A; Godino, J; de Abajo, AS; Vidart, JA; Perez-Segura, P; Diaz-Rubio, E; Caldes, T				de la Hoya, M; Fernandez, JM; Tosar, A; Godino, J; de Abajo, AS; Vidart, JA; Perez-Segura, P; Diaz-Rubio, E; Caldes, T			Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-CHROMOSOME; INACTIVATION	Context Defects in X-chromosome inactivation distort sex ratio in mice. The BRCA1 gene is also involved in X-chromosome inactivation, suggesting the possibility that some sex-ratio distortion may be associated with BRCA1-related human cancer syndromes. Objective To determine whether BRCA1 mutations are associated with distortion of the sex ratio of births in families with breast cancer, ovarian cancer, or both. Design and Setting Analysis of germline mutations in participants from Spain who had been screened for BRCA between 1998 and 2002. Participants Sixty-eight families with at least 3 breast cancer cases or ovarian cancer cases, or both types of cancer in 2 generations (germline mutations: BRCA1, n = 17; BRCA2, n = 15; and BRCA unrelated, n = 36). An average of 4 relatives per family were tested for the corresponding BRCA mutation. Main Outcome Measure Male and female births registered in breast and/or ovarian pedigrees tested for the presence of BRCA1 and BRCA2 germline mutations. Results Of BRCA1-related breast and/or ovarian cancer pedigrees, there was a 2-fold excess of female births (218 female vs 109 male births). Of BRCA2-related or BRCA-unrelated breast and/or ovarian cancer pedigrees, there was not an excess of female births (1175 fernale/150 male and 344 female/315 male, respectively). Of 327 BRCA1 births, 218 (67%) were female births compared with 54% among BRCA2 pedigrees 0 75/327; P<.001) and 52% among BRCA-unrelated pedigrees (344/659; P<.001). Female births increased in the offspring of BRCA1 carriers compared with BRCA2 carriers (67% vs 52%; P=.004). Conclusion In these families with breast and/or ovarian cancer, mutations in BRCA1 but not BRCA2 were associated with a sex ratio skewed against male births.	Hosp Clin San Carlos, Mol Oncol Lab, Mol Oncol Unit, Madrid 28040, Spain; Hosp Clin San Carlos, Dept Gynecol, Madrid 28040, Spain; Hosp Clin San Carlos, Dept Clin Oncol, Madrid 28040, Spain	Hospital Clinico San Carlos; Hospital Clinico San Carlos; Hospital Clinico San Carlos	Caldes, T (corresponding author), Hosp Clin San Carlos, Mol Oncol Lab, Mol Oncol Unit, Martin Lagos S-N, Madrid 28040, Spain.		Godino, Javier/M-3753-2018; de la Hoya, MIguel/Z-2911-2019	Godino, Javier/0000-0002-5653-2722; de la Hoya, Miguel/0000-0002-8113-1410; Diaz-Rubio, Eduardo/0000-0003-2792-5348				Buller RE, 1999, JNCI-J NATL CANCER I, V91, P339, DOI 10.1093/jnci/91.4.339; de la Hoya M, 2002, INT J CANCER, V97, P466, DOI 10.1002/ijc.1627; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Lee JT, 2002, NAT GENET, V32, P195, DOI 10.1038/ng939; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	5	27	28	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					929	931		10.1001/jama.290.7.929	http://dx.doi.org/10.1001/jama.290.7.929			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928470	Bronze			2022-12-28	WOS:000184828800030
J	Treps, N; Grosse, N; Bowen, WP; Fabre, C; Bachor, HA; Lam, PK				Treps, N; Grosse, N; Bowen, WP; Fabre, C; Bachor, HA; Lam, PK			A quantum laser pointer	SCIENCE			English	Article								The measurement sensitivity of the pointing direction of a laser beam is ultimately limited by the quantum nature of light. To reduce this limit, we have experimentally produced a quantum laser pointer, a beam of light whose direction is measured with a precision greater than that possible for a usual laser beam. The laser pointer is generated by combining three different beams in three orthogonal transverse modes, two of them in a squeezed-vacuum state and one in an intense coherent. field. The result provides a demonstration of multichannel spatial squeezing, along with its application to the improvement of beam positioning sensitivity and, more generally, to imaging.	Australian Natl Univ, Australian Res Council, Ctr Excellence Quantum Atom Opt, Canberra, ACT 0200, Australia; Univ Paris 06, Lab Kastler Brossel, F-75252 Paris 05, France	Australian National University; UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; College de France; Ecole Normale Superieure (ENS); Centre National de la Recherche Scientifique (CNRS)	Treps, N (corresponding author), Australian Natl Univ, Australian Res Council, Ctr Excellence Quantum Atom Opt, Canberra, ACT 0200, Australia.	nicolas.treps@spectro.jussieu.fr	Quantum-Atom Optics, ARC CoE/B-9567-2009; Treps, Nicolas/AAM-3115-2021; Lam, Ping Koy/A-5276-2008; Treps, Nicolas/L-6621-2015; Bowen, Warwick P/A-7630-2010	Treps, Nicolas/0000-0002-1413-3715; Lam, Ping Koy/0000-0002-4421-601X; Treps, Nicolas/0000-0002-1413-3715; Bowen, Warwick P/0000-0001-8127-1715; Bachor, Hans/0000-0001-8866-9486				BACHOR HA, 1998, GUIDE EXPT QUANTUM O; BOCCARA AC, 1980, APPL PHYS LETT, V36, P130, DOI 10.1063/1.91395; Bowen WP, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.093601; Fabre C, 2000, OPT LETT, V25, P76, DOI 10.1364/OL.25.000076; Kolobov MI, 2000, PHYS REV LETT, V85, P3789, DOI 10.1103/PhysRevLett.85.3789; Kolobov MI, 1999, REV MOD PHYS, V71, P1539, DOI 10.1103/RevModPhys.71.1539; Lugiato LA, 2002, J OPT B-QUANTUM S O, V4, pS176, DOI 10.1088/1464-4266/4/3/312; Martinelli M, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.023808; Senden TJ, 2001, CURR OPIN COLLOID IN, V6, P95, DOI 10.1016/S1359-0294(01)00067-X; Sokolov IV, 2001, OPT COMMUN, V193, P175, DOI 10.1016/S0030-4018(01)01256-1; Treps N, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.203601	11	223	229	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 15	2003	301	5635					940	943		10.1126/science.1086489	http://dx.doi.org/10.1126/science.1086489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920292				2022-12-28	WOS:000184755900031
J	Knight, JC				Knight, JC			Photonic crystal fibres	NATURE			English	Review							OPTICAL-FIBER; ANOMALOUS-DISPERSION; GUIDANCE; BANDGAPS	Photonic crystal fibres have wavelength-scale morphological microstructure running down their length. This structure enables light to be controlled within the fibre in ways not previously possible or even imaginable. Our understanding of what an optical fibre is and what it does is changing because of the development of this new technology, and a broad range of applications based on these principles is being developed.	Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England	University of Bath	Knight, JC (corresponding author), Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England.	j.c.knight@bath.ac.uk	Knight, Jonathan/D-3879-2011	Knight, Jonathan/0000-0002-0802-8804				Allan DC, 2001, NATO SCI SER II-MATH, V563, P305; Benabid F, 2002, SCIENCE, V298, P399, DOI 10.1126/science.1076408; Benabid F, 2002, OPT EXPRESS, V10, P1195, DOI 10.1364/OE.10.001195; Birks TA, 1997, OPT LETT, V22, P961, DOI 10.1364/OL.22.000961; BIRKS TA, 1995, ELECTRON LETT, V31, P1941, DOI 10.1049/el:19951306; Bouwmans G, 2003, OPT EXPRESS, V11, P1613, DOI 10.1364/OE.11.001613; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; Eggleton BJ, 2001, OPT EXPRESS, V9, P698, DOI 10.1364/OE.9.000698; Engeness TD, 2003, OPT EXPRESS, V11, P1175, DOI 10.1364/OE.11.001175; Ferrando A, 2000, OPT LETT, V25, P790, DOI 10.1364/OL.25.000790; Jasapara J., 2002, Optical Fiber Communications Conference. (OFC). Postconference Technical Digest (IEEE Cat. No.02CH37339), P519, DOI 10.1109/OFC.2002.1036527; Johnson SG, 2001, OPT EXPRESS, V9, P748, DOI 10.1364/OE.9.000748; KAISER P, 1974, AT&T TECH J, V53, P1021, DOI 10.1002/j.1538-7305.1974.tb02780.x; Katagiri T, 2002, APPL OPTICS, V41, P7603, DOI 10.1364/AO.41.007603; Knight JC, 2000, IEEE PHOTONIC TECH L, V12, P807, DOI 10.1109/68.853507; Knight JC, 1998, SCIENCE, V282, P1476, DOI 10.1126/science.282.5393.1476; Knight JC, 1998, ELECTRON LETT, V34, P1347, DOI 10.1049/el:19980965; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Kumar VVRK, 2002, OPT EXPRESS, V10, P1520, DOI 10.1364/OE.10.001520; Limpert J, 2003, OPT EXPRESS, V11, P818, DOI 10.1364/OE.11.000818; Liu X, 2001, OPT LETT, V26, P358, DOI 10.1364/OL.26.000358; MacPherson WN, 2001, OPT COMMUN, V193, P97, DOI 10.1016/S0030-4018(01)01260-3; MARCATILI EAJ, 1964, AT&T TECH J, V43, P1783, DOI 10.1002/j.1538-7305.1964.tb04108.x; MIYAGI M, 1984, J LIGHTWAVE TECHNOL, V2, P116, DOI 10.1109/JLT.1984.1073590; MONRO TM, 2002, OFC 2002; MULLER D, 2003, P CLEO 2003; Myaing MT, 2003, OPT LETT, V28, P1224, DOI 10.1364/OL.28.001224; Ortigosa-Blanch A, 2000, OPT LETT, V25, P1325, DOI 10.1364/OL.25.001325; OUZOUNOV DG, 2003, CLEO 2003; Povazay B, 2002, OPT LETT, V27, P1800, DOI 10.1364/OL.27.001800; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; Reeves WH, 2002, OPT EXPRESS, V10, P609, DOI 10.1364/OE.10.000609; Russell P, 2003, SCIENCE, V299, P358, DOI 10.1126/science.1079280; TAJIMA K, 2003, OFC 2003; Temelkuran B, 2002, NATURE, V420, P650, DOI 10.1038/nature01275; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; van Eijkelenborg MA, 2001, OPT EXPRESS, V9, P319, DOI 10.1364/OE.9.000319; VENKATARAM N, 2002, P 28 EUR C OPT COMMU; YEH P, 1978, J OPT SOC AM, V68, P1196, DOI 10.1364/JOSA.68.001196	39	1393	1470	16	420	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					847	851		10.1038/nature01940	http://dx.doi.org/10.1038/nature01940			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917699				2022-12-28	WOS:000184733900054
J	Chen, LS; Lee, L; Kudlow, BA; Dos Santos, HG; Sletvold, O; Shafeghati, Y; Botha, EG; Garg, A; Hanson, NB; Martin, GM; Mian, IS; Kennedy, BK; Oshima, J				Chen, LS; Lee, L; Kudlow, BA; Dos Santos, HG; Sletvold, O; Shafeghati, Y; Botha, EG; Garg, A; Hanson, NB; Martin, GM; Mian, IS; Kennedy, BK; Oshima, J			LMNA mutations in atypical Werner's syndrome	LANCET			English	Article							HUTCHINSON-GILFORD PROGERIA; ENCODING LAMIN A/C; FAMILIAL PARTIAL LIPODYSTROPHY; DREIFUSS MUSCULAR-DYSTROPHY; MISSENSE MUTATIONS; NUCLEAR-ENVELOPE; GENE-EXPRESSION; ORGANIZATION; DISEASE; PROTEIN	Background Werner's syndrome is a progeroid syndrome caused by mutations at the WRN helicase locus. Some features of this disorder are also present in laminopathies caused by mutant LMNA encoding nuclear lamin A/C. Because of this similarity, we sequenced LMNA in individuals with atypical Werner's syndrome (wild-type WRN). Methods Of 129 index patients referred to our international registry for molecular diagnosis of Werner's syndrome, 26 (20%) had wildtype WRN coding regions and were categorised as having atypical Werner's syndrome on the basis of molecular criteria. We sequenced all exons of LMNA in these individuals. Mutations were confirmed at the mRNA level by RT-PCR sequencing. In one patient in whom an LMNA mutation was detected and fibroblasts were available, we established nuclear morphology and subnuclear localisation. Findings In four (15%) of 26 patients with atypical Werner's syndrome, we noted heterozygosity for novel missense mutations in LMNA, specifically A57P, R133L (in two people), and L140R. The mutations altered relatively conserved residues within lamin A/C. Fibroblasts from the patient with the L140R mutation had a substantially enhanced proportion of nuclei with altered morphology and mislocalised lamins. Individuals with atypical Werner's syndrome with mutations in LMNA had a more severe phenotype than did those with the disorder due to mutant WRN. Interpretation Our findings indicate that Werner's syndrome is molecularly heterogeneous, and a subset of the disorder can be judged a laminopathy.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Hosp Santa Maria, Med Genet Serv, Lisbon, Portugal; Norwegian Univ Sci & Technol, St Olav Hosp, Dept Neurosci, Sect Geriatr, N-7034 Trondheim, Norway; Univ Welf Sci & Rehabil, Tehran, Iran; Emory Univ, Sch Med, Atlanta, GA USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidade de Lisboa; Hospital Santa Maria; Norwegian University of Science & Technology (NTNU); Emory University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Oshima, J (corresponding author), Univ Washington, Dept Pathol, Box 357470,HSB K-543,1959 NE Pacific Ave, Seattle, WA 98195 USA.			Kennedy, Brian/0000-0002-5754-1874				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bonne G, 2000, ANN NEUROL, V48, P170, DOI 10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; BRIDGER JM, 1993, J CELL SCI, V104, P297; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brown CA, 2001, AM J MED GENET, V102, P359, DOI 10.1002/ajmg.1463; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cao H, 2000, HUM MOL GENET, V9, P109, DOI 10.1093/hmg/9.1.109; Cao HN, 2003, J HUM GENET, V48, P271, DOI 10.1007/s10038-003-0025-3; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Garg A, 2002, AM J MED, V112, P549, DOI 10.1016/S0002-9343(02)01070-7; GOTO M, 1985, ADV EXP MED BIOL, V190, P245; Hegele RA, 2000, PHYSIOL GENOMICS, V3, P39, DOI 10.1152/physiolgenomics.2000.3.1.39; Hughey R, 1996, COMPUT APPL BIOSCI, V12, P95; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; IMURA H, 1985, WERNERS SYNDROME AGI, P171; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; LIN F, 1993, J BIOL CHEM, V268, P16321; Muchir A, 2000, HUM MOL GENET, V9, P1453, DOI 10.1093/hmg/9.9.1453; NAKURA J, 1994, GENOMICS, V23, P600, DOI 10.1006/geno.1994.1548; Novelli G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Speckman RA, 2000, AM J HUM GENET, V66, P1192, DOI 10.1086/302836; Strelkov SV, 2002, EMBO J, V21, P1255, DOI 10.1093/emboj/21.6.1255; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	30	302	329	2	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					440	445		10.1016/S0140-6736(03)14069-X	http://dx.doi.org/10.1016/S0140-6736(03)14069-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927431				2022-12-28	WOS:000184651100011
J	Collard, HR; Gruber, MP; Weinberger, SE; Saint, S				Collard, HR; Gruber, MP; Weinberger, SE; Saint, S			Anatomy of a diagnosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AORTOPULMONARY FISTULA; HEMOPTYSIS; AORTA; MANAGEMENT; TREE		Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Dept Vet Affairs, Hlth Serv Res & Dev Field Program, Ann Arbor, MI USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan	Collard, HR (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Box C-272, Denver, CO 80262 USA.	hal.collard@uchsc.edu	Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		DEMETER SL, 1980, ANGIOLOGY, V31, P431, DOI 10.1177/000331978003100607; FAVRE JP, 1994, SURGERY, V115, P264; GRAEBER GM, 1980, ANN THORAC SURG, V29, P555, DOI 10.1016/S0003-4975(10)61706-7; HIGASHIKAWA M, 1992, AM J ROENTGENOL, V159, P673, DOI 10.2214/ajr.159.3.1503047; Hirshberg B, 1997, CHEST, V112, P440, DOI 10.1378/chest.112.2.440; JOHNSON D, 1867, LANCET, V1, P44; JOHNSTON H, 1989, ARCH INTERN MED, V149, P1666, DOI 10.1001/archinte.149.7.1666; Killen DA, 2000, SOUTH MED J, V93, P195; MACINTOSH EL, 1991, ANN THORAC SURG, V51, P515, DOI 10.1016/0003-4975(91)90888-W; MILLER JP, 1994, CHEST, V105, P1249, DOI 10.1378/chest.105.4.1249; PAGE D, 1867, LANCET, V1, P43; POSNIAK HV, 1989, SEMIN ROENTGENOL, V24, P7, DOI 10.1016/0037-198X(89)90050-3; SANTIAGO S, 1991, ARCH INTERN MED, V151, P2449, DOI 10.1001/archinte.151.12.2449	13	5	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					987	992		10.1056/NEJMcps030546	http://dx.doi.org/10.1056/NEJMcps030546			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954748				2022-12-28	WOS:000185081400012
J	Squires, K; Pozniak, AL; Pierone, G; Steinhart, CR; Berger, D; Bellos, NC; Becker, SL; Wulfsohn, M; Miller, MD; Toole, JJ; Coakley, DF; Cheng, A				Squires, K; Pozniak, AL; Pierone, G; Steinhart, CR; Berger, D; Bellos, NC; Becker, SL; Wulfsohn, M; Miller, MD; Toole, JJ; Coakley, DF; Cheng, A		Study 907 Team	Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection a randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							ANTIRETROVIRAL-EXPERIENCED PATIENTS; IMMUNODEFICIENCY-VIRUS-INFECTION; ADEFOVIR DIPIVOXIL; DOUBLE-BLIND; THERAPY; PMPA; BIS(ISOPROPYLOXYMETHYLCARBONYL)PMPA; LAMIVUDINE; DIDANOSINE; RESERVOIR	Background: Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. Objective: To describe the efficacy and safety of tenofovir disoproxil fumarate (tenofovir DF) compared with placebo in patients with detectable viral replication despite current antiretroviral therapy. Design: Randomized, double-blind, placebo-controlled study through 24 weeks. After 24 weeks, all patients received open-label tenofovir DF for the remainder of the 48-week study. Setting: 75 North American, European, and Australian HIV clinics. Patients: 552 HIV-1-infected adults who were receiving antiretroviral therapy and had stable HIV-1 RNA levels ranging from 400 to 10 000 copies/mL. Measurements: Change in HIV-1 RNA level (time-weighted average from baseline through week 24); proportion of patients with grade 3 or 4 laboratory abnormalities and adverse events; and genotypic HIV-1 resistance testing in a separate substudy at baseline, week 24, and week 48. Results: A statistically significant decrease in HIV-1 RNA level through week 24 (the primary end point) was observed in the tenofovir DF group versus the placebo group (-0.61 log(10) copies/mL vs. -0.03 log(10) copies/mL, respectively [P < 0.001]; difference, -0.58 log(10) copies/mL [95% Cl, -0.68 to -0.49 log(10) copies/mL]). In a virologic substudy, 94% of 253 patients had plasma isolates expressing reverse transcriptase mutations associated with nucleoside resistance mutations at baseline. Through week 24, the incidence of clinical adverse events was similar between patients receiving placebo and those receiving tenofovir DF (14% vs. 13%). No evidence of tenofovir DF-related toxicity was seen through week 48. Conclusion: in treatment-experienced patients with suboptimal viral suppression, tenofovir DF significantly reduced HIV-1 RNA level and had a safety profile similar to that of placebo.	Univ So Calif, Keck Sch Med, Los Angeles, CA USA; Chelsea & Westminster Hosp, London, England; Treasure Coast Infect Dis, Miami, FL USA; Florida Caribbean AIDS Educ Training Ctr, Miami, FL USA; Northstar Med Ctr, Chicago, IL USA; SW Infect Dis, Dallas, TX USA; Pacific Horizon Med Grp, San Francisco, CA USA; Gilead Sci Inc, Foster City, CA 94404 USA	University of Southern California; Imperial College London; Gilead Sciences	Cheng, A (corresponding author), 333 Lakeside Dr, Foster City, CA 94404 USA.							BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332; Berrey MM, 2001, J INFECT DIS, V183, P1466, DOI 10.1086/320189; *BHIVA, 2001, HIV MED, V2, P276; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHL M, 7 C RETR OPP INF SAN; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Haubrich RH, 1999, AIDS, V13, P1099, DOI 10.1097/00002030-199906180-00014; Kahn J, 1999, JAMA-J AM MED ASSOC, V282, P2305, DOI 10.1001/jama.282.24.2305; Katlama C, 2000, AIDS, V14, P781, DOI 10.1097/00002030-200005050-00003; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Maggiolo F, 2001, ANTIVIR THER, V6, P249; Margot NA, 2003, JAIDS-J ACQ IMM DEF, V33, P15, DOI 10.1097/00126334-200305010-00003; Margot NA, 2002, AIDS, V16, P1227, DOI 10.1097/00002030-200206140-00004; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P612, DOI 10.1128/AAC.42.3.612; Schooley RT, 2002, AIDS, V16, P1257, DOI 10.1097/00002030-200206140-00008; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; Skowron G, 2002, J INFECT DIS, V186, P1028, DOI 10.1086/343740; Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P1484, DOI 10.1128/AAC.42.6.1484; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; Wainberg MA, 1999, ANTIVIR THER, V4, P87; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Ying C, 2000, J VIRAL HEPATITIS, V7, P161; [No title captured]	28	159	166	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				313	320		10.7326/0003-4819-139-5_Part_1-200309020-00006	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965939				2022-12-28	WOS:000185037500001
J	Sudan, M				Sudan, M			Quick and dirty refereeing?	SCIENCE			English	Editorial Material							CODES		MIT, CSAIL, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sudan, M (corresponding author), MIT, CSAIL, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	madhu@mit.edu						Ben-Sasson E., 2003, P 35 ANN ACM S THEOR, P612; Dinur I, 2002, ANN IEEE SYMP FOUND, P33, DOI 10.1109/SFCS.2002.1181880; Garey Johnson, 1979, COMPUTERS INTRACTABI; Goldreich O, 2002, ANN IEEE SYMP FOUND, P13, DOI 10.1109/SFCS.2002.1181878; Guruswami V, 1999, IEEE T INFORM THEORY, V45, P1757, DOI 10.1109/18.782097; Hastad J, 2001, J ACM, V48, P798, DOI 10.1145/502090.502098; Spielman DA, 1996, IEEE T INFORM THEORY, V42, P1723, DOI 10.1109/18.556668; SUDAN M, 2000, NOTES PCPS; Szpiro G, 2003, NATURE, V424, P12, DOI 10.1038/424012a	9	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1191	1192		10.1126/science.1086262	http://dx.doi.org/10.1126/science.1086262			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947187				2022-12-28	WOS:000185003500028
J	Birck, R; Krzossok, S; Markowetz, F; Schnulle, P; van der Woude, FJ; Braun, C				Birck, R; Krzossok, S; Markowetz, F; Schnulle, P; van der Woude, FJ; Braun, C			Acetylcysteine for prevention of contrast nephropathy: meta-analysis	LANCET			English	Article							ACUTE-RENAL-FAILURE; N-ACETYLCYSTEINE; RISK-FACTORS; INSUFFICIENCY; INTERVENTION; QUALITY; TRIALS; SALINE; DETERIORATION; PUBLICATION	Background Contrast nephropathy is associated with increased in-hospital morbidity and mortality and leads to extension of hospital stay in patients with chronic renal insufficiency. Acetylcysteine seems to be a safe and inexpensive way to reduce contrast nephropathy. We aimed to assess the efficacy of acetylcysteine to prevent contrast nephropathy after administration of radiocontrast media in patients with chronic renal insufficiency. Methods We did a meta-analysis of randomised controlled trials comparing acetylcysteine and hydration with hydration alone for preventing contrast nephropathy in patients with chronic renal insufficiency. The trials were identified through a combined search of the BIOSIS+/RRM, MEDLINE, Web of Science, Current Contents Medizin, and The Cochrane Library Databases. We used incidence of contrast nephropathy 48 h after administration of radiocontrast media as an outcome measure. Findings Seven trials including 805 patients were eligible according to our inclusion criteria and were analysed. Overall incidence of contrast nephropathy varied between 8% and 28%. Since significant heterogeneity was indicated by the Q statistics (p=0.016) we used a random-effects model to combine the data. Compared with periprocedural hydration alone, administration of acetylcysteine and hydration significantly reduced the relative risk of contrast nephropathy by 56% (0.435 [95% CI 0.215-0.879], p=0.02) in patients with chronic renal insufficiency. Meta-regression revealed no significant relation between the relative risk of contrast nephropathy and the volume of radiocontrast media administered or the degree of chronic renal insufficiency before the procedure. Interpretation Compared with periprocedural hydration alone, acetylcysteine with hydration significantly reduces the risk of contrast nephropathy in patients with chronic renal insufficiency. The relative risk of contrast nephropathy was not related to the amount of radiocontrast media given or to the degree of chronic renal insufficiency before the procedure.	Univ Hosp Mannheim, Dept Med 5, D-68135 Mannheim, Germany; Max Planck Inst Mol Genet, Berlin, Germany	Ruprecht Karls University Heidelberg; Max Planck Society	Birck, R (corresponding author), Univ Hosp Mannheim, Dept Med 5, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.	rainer.birck@med5.ma.uni-heidelberg.de	Markowetz, Florian/H-6883-2019; Braun, Claude/AAQ-7883-2020	Markowetz, Florian/0000-0002-2784-5308; 				Adamian MG, 2002, J AM COLL CARDIOL, V39, p1A; Allaqaband S, 2002, CATHETER CARDIO INTE, V57, P279, DOI 10.1002/ccd.10323; Bader BD, 2002, J AM SOC NEPHROL, V13, p447A; BAKRIS GL, 1990, AM J PHYSIOL, V258, pF115, DOI 10.1152/ajprenal.1990.258.1.F115; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Briguori C, 2002, J AM COLL CARDIOL, V40, P298, DOI 10.1016/S0735-1097(02)01958-7; Conti CR, 2003, CLIN CARDIOL, V26, P53, DOI 10.1002/clc.4960260202; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diaz-Sandoval LJ, 2002, AM J CARDIOL, V89, P356, DOI 10.1016/S0002-9149(01)02243-3; Durham JD, 2002, KIDNEY INT, V62, P2202, DOI 10.1046/j.1523-1755.2002.00673.x; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Furukawa TA, 2002, INT J EPIDEMIOL, V31, P72, DOI 10.1093/ije/31.1.72; Gruberg L, 2000, J AM COLL CARDIOL, V36, P1542, DOI 10.1016/S0735-1097(00)00917-7; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kay J, 2003, JAMA-J AM MED ASSOC, V289, P553, DOI 10.1001/jama.289.5.553; Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MOUHAYAR EN, 2002, J AM COLL CARDIOL S, V39, pA5; Murphy SW, 2000, J AM SOC NEPHROL, V11, P177, DOI 10.1681/ASN.V111177; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; RICH MW, 1990, ARCH INTERN MED, V150, P1237, DOI 10.1001/archinte.150.6.1237; Rihal CS, 2002, CIRCULATION, V105, P2259, DOI 10.1161/01.CIR.0000016043.87291.33; Safirstein R, 2000, NEW ENGL J MED, V343, P210, DOI 10.1056/NEJM200007203430311; Shyu KG, 2002, J AM COLL CARDIOL, V40, P1383, DOI 10.1016/S0735-1097(02)02308-2; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Sterne J, 2001, SYSTEMATIC REV HLTH; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304; Tepel M., 2001, Nephrology Dialysis Transplantation, V16, pA53; Tepel M, 2002, CURR OPIN NEPHROL HY, V11, P503, DOI 10.1097/00041552-200209000-00005; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; Trivedi HS, 2003, NEPHRON CLIN PRACT, V93, pC29, DOI 10.1159/000066641; Vallero A, 2002, G Ital Nefrol, V19, P529; van der Giet Markus, 2001, Journal of the American Society of Nephrology, V12, p849A; YOSHIOKA T, 1992, KIDNEY INT, V41, P1008, DOI 10.1038/ki.1992.153	40	326	345	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					598	603		10.1016/S0140-6736(03)14189-X	http://dx.doi.org/10.1016/S0140-6736(03)14189-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944058				2022-12-28	WOS:000184904100007
J	Bloomfield, A; Logan, R				Bloomfield, A; Logan, R			Quality improvement perspective and healthcare funding decisions	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Minist Hlth, Natl Screening Unit, Wellington, New Zealand; Natl Hlth Comm, Wellington, New Zealand		Bloomfield, A (corresponding author), Minist Hlth, Natl Screening Unit, POB 5013, Wellington, New Zealand.	ashley_bloomfield@moh.govt.nz						Ajwani S., 2003, DECADES DISPARITY ET; *AUSTR COUNC SAF Q, 2000, SAF 1 REP AUSTR HLTH; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P293, DOI 10.1093/phr/118.4.293; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; DUFFY AP, 2001, REPORT MINISTERIAL I; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Ham C, 2000, GLOBAL CHALLENGE HLT; *HLTH DIS COMM, 1998, CANT HLTH LTD REP HL; *HLTH FUND AUTH, 1998, SHALL WE PRIOR HLTH; HONIGSBAUM F, 1995, PRIORITY SETTING PRO; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; *NAT HLTH COMM, 2002, SAF SYST SUPP SAF CA; *NAT HLTH COMM, 1997, BEST HLTH, V3; National Advisory Committee on Health and Disability (National Health Committee), 1998, SOC CULT EC DET HLTH; *PHARM MAN AG, 2002, ANN REV YEAR END JUN; Upton S., 1991, YOUR HLTH PUBLIC HLT	16	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2003	327	7412					439	443		10.1136/bmj.327.7412.439	http://dx.doi.org/10.1136/bmj.327.7412.439			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715YY	12933735	Green Published			2022-12-28	WOS:000185003100025
J	McPherson, KM; Harwood, M; McNaughton, HK				McPherson, KM; Harwood, M; McNaughton, HK			Ethnicity, equity, and quality: lessons from New Zealand	BRITISH MEDICAL JOURNAL			English	Article									Wellington Sch Med & Hlth Sci, Wellington, New Zealand; Med Res Inst New Zealand, Wellington, New Zealand	University of Otago; Medical Research Institute Of New Zealand	McPherson, KM (corresponding author), Univ Southampton, Sch Hlth Profess & Rehabil Sci, Southampton SO17 1BJ, Hants, England.		McNaughton, Harry/AAC-6556-2020	Harwood, Matire/0000-0003-1240-5139; McPherson, Kathryn/0000-0003-1240-8882; McPherson, Kath/0000-0003-0487-8497				[Anonymous], 2001 CENS POP DWELL; Brinded PMJ, 2001, AUST NZ J PSYCHIAT, V35, P166, DOI 10.1046/j.1440-1614.2001.00885.x; Duric M., 1998, WHAIORA MAORI HLTH D; Kani Kingi T, 2000, HUA ORANGA MAORI MEA; McNaughton H, 2002, NEW ZEAL MED J, V115, P98; McPherson KM, 2001, DISABIL REHABIL, V23, P706; *MIN HLTH NZ, 2002, RED IN HLTH; Ramsden I., 2003, NURSING PRAXIS NZ, V8, P4; Reid P, 2000, Pac Health Dialog, V7, P38; SPORIE A, 2003, NZ MED J, V115, P127	10	14	15	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					443	444		10.1136/bmj.327.7412.443	http://dx.doi.org/10.1136/bmj.327.7412.443			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933736	Green Published			2022-12-28	WOS:000185003100026
J	Charlesworth, B				Charlesworth, B			Sex determination in the honeybee	CELL			English	Editorial Material								Sex determination in honeybees involves a multi-allelic locus, such that homozygotes develop as males and heterozygotes as females. In this issue of Cell, Beye and colleagues (2003) report the cloning of the sex-determining gene, csd. It codes for an SR protein, and different alleles have very different amino-acid sequences. Inactivating csd leads to development as a male.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Ashworth Labs, Edinburgh EH9 2BR, Midlothian, Scotland	University of Edinburgh	Charlesworth, B (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Ashworth Labs, Edinburgh EH9 2BR, Midlothian, Scotland.							Beye M, 2003, CELL, V114, P419, DOI 10.1016/S0092-8674(03)00606-8; Bull J.J., 1983, EVOLUTION SEX DETERM; Casselton LA, 2002, HEREDITY, V88, P142, DOI 10.1038/sj.hdy.6800035; Charlesworth D, 2002, CURR BIOL, V12, pR424, DOI 10.1016/S0960-9822(02)00915-6; Dobson SL, 1998, GENETICS, V149, P233; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990	6	7	12	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					397	398		10.1016/S0092-8674(03)00610-X	http://dx.doi.org/10.1016/S0092-8674(03)00610-X			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941267	Bronze			2022-12-28	WOS:000184928800002
J	Alexander, GC; Casalino, LP; Meltzer, DO				Alexander, GC; Casalino, LP; Meltzer, DO			Patient-physician communication about out-of-pocket costs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCRIPTION DRUGS; MEDICARE BENEFICIARIES; CARE; PAYMENT; OUTCOMES	Context Out-of-pocket costs account for approximately one fifth of health care expenditures and are increasing. Previous research suggests that these costs are associated with medication nonadherence and considerable economic burden among some patients. Little is known about patient-physician communication regarding these costs. Objective To identify patients' and physicians' beliefs and practices regarding discussions of out-of-pocket costs. Design, Setting, and Participants Cross-sectional paired surveys of 133 general internists and 484 of their outpatients, aged 18 years or older, in 3 academic and 18 community-general medicine practices in the Chicago,metropolitan area, March - November 2002. Main Outcome Measures Patient and physician beliefs regarding discussions of out-of-pocket costs, frequency and predictors of discussions, and physician recognition of patient burden from out-of-pocket costs. Results Sixty-three percent of patients reported a desire to talk with their physician about their out-of-pocket costs, and 79% of physicians believed that patients in general want to discuss these costs. By contrast, only 35% of physicians and 15% of patients reported ever having discussed the study patient's out-of-pocket costs. Multivariate analysis indicated that discussions were significantly more likely to occur with patients burdened by their out-of-pocket costs (prevalence ratio [PR], 2.55; 95% confidence intervals [CI], 1.62-3.76) and with those patients seen in a community practice (PR, 5.19; Cl, 1.86-8.93). Among patients burdened by out-of-pocket costs, physicians were substantially more likely to recognize this burden when a prior-discussion regarding out-of-pocket costs had taken place (80% vs 51%). Conclusions Among respondents, both patients and physicians believed that discussions of out-of-pocket costs were important, yet these discussions occurred infrequently. Physician communication with patients about out-of-pocket costs may be an important yet neglected aspect of current clinical practice. Further research should identify the prevalence of this problem in broader populations, investigate its causes, and evaluate the impact of enhanced communication about out-of-pocket costs on patient satisfaction, utilization of care, and outcomes.	Univ Chicago, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA; Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA; Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago, Harris Sch Publ Policy, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Alexander, GC (corresponding author), Univ Chicago, Robert Wood Johnson Clin Scholars Program, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.		Casalino, Lawrence/ABE-1245-2020; Meltzer, David/C-2926-2009	Casalino, Lawrence/0000-0002-7927-7859; Meltzer, David/0000-0003-2790-7393				Aday LA, 1996, DESIGNING CONDUCTING; *AM ASS RET PERS, 2002, NY TIMES        0426, pA14; Bell RA, 2001, ARCH INTERN MED, V161, P1977, DOI 10.1001/archinte.161.16.1977; Donelan K, 1999, HEALTH AFFAIR, V18, P206, DOI 10.1377/hlthaff.18.3.206; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; GREENHOUSE S, 2003, NY TIMES        0115, pA14; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V273, P1223, DOI 10.1001/jama.273.15.1223; Iglehart JK, 2001, NEW ENGL J MED, V344, P1010, DOI 10.1056/NEJM200103293441311; JACOB J, 2002, AM MED NEWS     0107, P19; LAGNADO L, 1998, WALL STREET J   1117, pA1; LEIBOWITZ A, 1985, SOC SCI MED, V21, P1063, DOI 10.1016/0277-9536(85)90161-3; Levinson W, 2000, JAMA-J AM MED ASSOC, V284, P1021, DOI 10.1001/jama.284.8.1021; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; *MED EXP PAN SURV, 2000, DISTR HEALTHC EXP 19; Rector TS, 2000, JAMA-J AM MED ASSOC, V283, P2163, DOI 10.1001/jama.283.16.2163; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Roter D L, 1994, JAMA, V271, P80, DOI 10.1001/jama.271.1.80; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STAPLETON S, 2002, AM MED NEWS     0506, P42; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; TONER R, 2002, NY TIMES        0219, pA1; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	25	280	281	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					953	958		10.1001/jama.290.7.953	http://dx.doi.org/10.1001/jama.290.7.953			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712ZE	12928475	Bronze			2022-12-28	WOS:000184828800035
J	Mechanic, D				Mechanic, D			Physician discontent - Challenges and opportunities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVING PRIMARY-CARE; GENERAL-PRACTITIONERS; NURSE-PRACTITIONERS; CHRONIC ILLNESS; UNITED-STATES; HEALTH-CARE; PATIENT; TIME; SATISFACTION; OUTCOMES	Most physicians continue to report overall career satisfaction, but increased public and patient expectations and administrative and regulatory controls contribute to perceptions of increased time pressures and erosion of autonomy. Increasingly, knowledgeable patients armed with information from the media, as well as guidelines developed by health plans, government, specialty societies, professional organizations, and advocacy groups, confront physicians with a bewildering array of new expectations and demands. Although physicians are spending more time with patients than in earlier periods they feel themselves on a treadmill. Strategies to ease pressures include increased use and enhanced scope of nonphysician clinicians, adoption of information technology and disease management programs to reduce errors and to increase efficiency and quality, and thoughtful practice design. Use of such strategies, combined with leadership and a clear sense of direction, can empower physicians, provide them with expanded knowledge and expert systems, and relieve some practice burdens and frustrations.	Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Mechanic, D (corresponding author), Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, 30 Coll Ave, New Brunswick, NJ 08901 USA.							Benson T, 2002, BRIT MED J, V325, P1086, DOI 10.1136/bmj.325.7372.1086; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; Campion EW, 2001, NEW ENGL J MED, V344, P223, DOI 10.1056/NEJM200101183440311; Chambers D W, 2001, J Dent Educ, V65, P1430; CHRISTIANSON JB, 2003, 611 COMM FUND; *CTR STUD HLTH SYS, 2002, CTS ONL CTS PHYS SUR; FINDLAY SD, 2001, PRESCRIPTION DRUGS M; FORD L, 1992, CHARTING NURSING FUT, P287; Ford LC, 1982, NURSING 1980S CRISES, P231; Grumbach K, 1999, NEW ENGL J MED, V341, P2008, DOI 10.1056/NEJM199912233412611; Hadley Jack, 2002, Int J Health Care Finance Econ, V2, P37, DOI 10.1023/A:1015397413797; HIBBARD JH, 1987, MED CARE, V25, P1019, DOI 10.1097/00005650-198711000-00001; Hirsch Roland L, 1990, NATL SURVEY LAWYERS; Inglehart R., 1997, WHY PEOPLE DONT TRUS, P217; Institute of Medicine, 2001, CROSSING QUALITY CHA; *KAIS FAM FDN, 2001, UND EFF DIR CONS PRE; *KAIS FAM FDN, 2002, NAT SURV PHYS 2; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; Kassirer JP, 1998, NEW ENGL J MED, V339, P1543, DOI 10.1056/NEJM199811193392109; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KOHNL T, 2000, ERR IS HUMAN BUILDIN; Landon BE, 2003, JAMA-J AM MED ASSOC, V289, P442, DOI 10.1001/jama.289.4.442; Leigh JP, 2002, ARCH INTERN MED, V162, P1577, DOI 10.1001/archinte.162.14.1577; LEWIS CE, 1967, NEW ENGL J MED, V277, P1236, DOI 10.1056/NEJM196712072772305; MCKINLY JB, 1990, CORPORATE TRANSFOR 1; Mechanic D, 1972, Med Care, V10, P402, DOI 10.1097/00005650-197209000-00004; MECHANIC D, 1975, MED CARE, V13, P189, DOI 10.1097/00005650-197503000-00001; Mechanic D, 1998, J HEALTH POLIT POLIC, V23, P661; Mechanic D, 2001, BRIT MED J, V323, P266, DOI 10.1136/bmj.323.7307.266; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; MECHANIC RE, 2002, DIS MANAGEMENT PROMI; Millenson ML, 2003, HEALTH AFFAIR, V22, P103, DOI 10.1377/hlthaff.22.2.103; Millenson ML., 1997, DEMANDING MED EXCELL; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; PRATT L, 1957, AM J PUBLIC HEALTH N, V47, P1277, DOI 10.2105/AJPH.47.10.1277; REED MC, 2003, PHYSICIANS CARE MANA; ROBINSON JC, 1999, CORPORATE PRACTICE M; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; ROTER DL, 1992, DOCTORS TALKING PATI, P27; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SPRATLEY E, 2000, REGISTERED NURSE POP, P38; St Peter RF, 1999, NEW ENGL J MED, V341, P1980, DOI 10.1056/NEJM199912233412606; Starr P, 1982, SOCIAL TRANSFORMATIO; TU HT, 2003, SEEKING HLTH CARE IN; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048; Weeks WB, 2003, ARCH INTERN MED, V163, P944, DOI 10.1001/archinte.163.8.944; Williams ES, 2002, HEALTH SERV RES, V37, P121; Williams RS, 2003, SCIENCE, V300, P549, DOI 10.1126/science.300.5619.549; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; 2002, S SPONS AC I U PENNS	52	158	160	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					941	946		10.1001/jama.290.7.941	http://dx.doi.org/10.1001/jama.290.7.941			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712ZE	12928472				2022-12-28	WOS:000184828800032
J	Sung, JJY; Chan, FKL; Lau, JYW; Yung, MY; Leung, WK; Wu, JCY; Ng, EKW; Chung, SCS				Sung, JJY; Chan, FKL; Lau, JYW; Yung, MY; Leung, WK; Wu, JCY; Ng, EKW; Chung, SCS			The effect of endoscopic therapy in patients receiving omeprazole for bleeding ulcers with nonbleeding visible vessels or adherent clots - A randomized comparison	ANNALS OF INTERNAL MEDICINE			English	Article							PEPTIC-ULCERS; HEMORRHAGE; STIGMATA	Background: The optimal treatment of ulcers with nonbleeding visible vessels and adherent clots is unclear. Objective: To compare intravenous omeprazole infusion plus endoscopic therapy with intravenous omeprazole infusion alone for prevention of recurrent bleeding from ulcers with nonbleeding visible vessels or adherent clots. Design: Single-blind randomized study with blinded evaluation of study end points. Setting: An endoscopy center in a university hospital in Hong Kong. Patients: 156 persons with upper gastrointestinal bleeding and ulcers showing nonbleeding visible vessels or adherent clots. Intervention: Combination of endoscopic therapy and omeprazole infusion versus sham endoscopic therapy and omeprazole infusion. Measurements: Recurrent ulcer bleeding before discharge and within 30 days. Results: 78 patients were recruited in each group. Ulcer bleeding recurred before discharge in seven patients who received intravenous omeprazole alone (9%) and no patients who received combined therapy (difference, 9 percentage points [95% CI, 1.7 to 17.6 percentage points]; P=0.01). The probability of recurrent bleeding within 30 days was 11.6% (9 patients) in the omeprazole-alone group and 1.1% (1 patient) in the combined therapy group (difference, 10.5 percentage points [CI, 1.7 to 19.8 percentage points]; P=0.009). Patients in the combined therapy group required less transfusion (difference in median units of blood transfused, 1 unit [CI, 0 to 2 units]; P=0.02). One patient in the combined therapy group had surgery for ulcer perforation. Four patients receiving omeprazole alone (5.1%) and two patients receiving combined therapy (2.6%) died within 30 days. Conclusion: The combination of endoscopic therapy and omeprazole infusion is superior to omeprazole infusion alone for preventing recurrent bleeding from ulcers with nonbleeding visible vessels and adherent clots.	Chinese Univ Hong Kong, Prince Wales Hosp, Endoscopy Ctr, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Sung, JJY (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Endoscopy Ctr, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.	joesung@cuhk.edu.hk	Sung, Joseph J. Y./R-3203-2018; Lau, James Y. W./O-2612-2016; Wu, Justin/N-6916-2015; Leung, Wai Keung/B-8140-2011; Ng, Enders Kwok Wai/E-8276-2016; Chan, Francis K. L./F-4851-2010; Lee, Yeong Yeh/G-2470-2010	Sung, Joseph J. Y./0000-0003-3125-5199; Lau, James Y. W./0000-0003-0122-4068; Leung, Wai Keung/0000-0002-5993-1059; Chan, Francis K. L./0000-0001-7388-2436; Lee, Yeong Yeh/0000-0002-6486-7717				BLEAU BL, 1997, GASTROINTEST ENDOSC, V45, pAB87; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; Javid G, 2001, AM J MED, V111, P280, DOI 10.1016/S0002-9343(01)00812-9; JENSEN D, 1995, GASTROINTEST ENDOSC, V41, pA279; Jensen DM, 2002, GASTROENTEROLOGY, V123, P407, DOI 10.1053/gast.2002.34782; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; LAINE L, 1994, GASTROINTEST ENDOSC, V40, P411, DOI 10.1016/S0016-5107(94)70202-0; Laine L, 1996, GASTROINTEST ENDOSC, V43, P107, DOI 10.1016/S0016-5107(06)80109-4; Laine L, 2002, GASTROENTEROLOGY, V123, P632, DOI 10.1053/gast.2002.35133; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; Lau JYW, 2000, NEW ENGL J MED, V343, P310, DOI 10.1056/NEJM200008033430501; Lau JYW, 1998, ENDOSCOPY, V30, P513, DOI 10.1055/s-2007-1001336; Lau JYW, 1997, GASTROINTEST ENDOSC, V46, P33, DOI 10.1016/S0016-5107(97)70206-2; Lin HJ, 1996, GASTROINTEST ENDOSC, V43, P470	15	106	110	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					237	243		10.7326/0003-4819-139-4-200308190-00005	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965978				2022-12-28	WOS:000184795600001
J	Walsh, KP				Walsh, KP			ABC of interventional cardiology - Interventional paediatric cardiology	BRITISH MEDICAL JOURNAL			English	Review							OCCLUDER		Our Ladys Hosp Sick Children, Dublin, Ireland	Our Ladys Children Hospital Crumlin	Walsh, KP (corresponding author), Our Ladys Hosp Sick Children, Dublin, Ireland.							KAN JS, 1982, NEW ENGL J MED, V307, P540, DOI 10.1056/NEJM198208263070907; Masura J, 1998, J AM COLL CARDIOL, V31, P878, DOI 10.1016/S0735-1097(98)00013-8; MORRISON WL, 2002, PRACTICAL INTERVENTI, P362; WAIGHT DJ, 2002, PRACTICAL INTERVENTI, P390; Walsh KP, 2000, CARDIOL YOUNG, V10, P493	5	4	4	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					385	388		10.1136/bmj.327.7411.385	http://dx.doi.org/10.1136/bmj.327.7411.385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919997	Green Published			2022-12-28	WOS:000184864200027
J	Buchner, DA; Trudeau, M; Meisler, MH				Buchner, DA; Trudeau, M; Meisler, MH			SCNM1, a putative RNA splicing factor that modifies disease severity in mice	SCIENCE			English	Article							SODIUM-CHANNEL SCN8A; MOUSE; MUTATION; GENES; IDENTIFICATION; NA(V)1.6; PROTEINS; ALLELES; ABSENCE; SNRNP	The severity of many inherited disorders is influenced by genetic background. We describe a modifier interaction in C57BL/6J mice that converts a chronic movement disorder into a lethal neurological disease. The primary mutation (med(J)) changes a splice donor site of the sodium channel gene Scn8a (Na(v) 1.6). The modifier mutation is characteristic of strain C57BL/6J and introduces a nonsense codon into sodium channel modifier 1 (SCNM1), a zinc finger protein and a putative splice factor. An internally deleted SCNM1 protein is also predicted as a result of exon skipping associated with disruption of a consensus exonic splicing enhancer. The effect of the modifier mutation is to reduce the abundance of correctly spliced sodium channel transcripts below the threshold for survival. Our finding that genetic variation in a putative RNA splicing factor influences disease susceptibility in mice raises the possibility that a similar mechanism modifies the severity of human inherited disorders.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Meisler, MH (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.	meislerm@umich.edu		Buchner, David/0000-0003-3920-4871	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [T32HG000040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024872, T32GM007544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000011] Funding Source: NIH RePORTER; NHGRI NIH HHS [T32 HG00040] Funding Source: Medline; NIDCD NIH HHS [T32 DC00011] Funding Source: Medline; NIGMS NIH HHS [GM24872, T32 GM07544] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1931, INBORN FACTORS DIS E; Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; BUCHNER DA, IN PRESS GENOMICS; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; Caldwell JH, 2000, P NATL ACAD SCI USA, V97, P5616, DOI 10.1073/pnas.090034797; Cartegni L, 2002, NAT GENET, V30, P377, DOI 10.1038/ng854; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Clark TA, 2002, SCIENCE, V296, P907, DOI 10.1126/science.1069415; Cryns K, 2002, GENOME RES, V12, P613, DOI 10.1101/gr.218402; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Golling G, 2002, NAT GENET, V31, P135, DOI 10.1038/ng896; Haywood MEK, 2000, ARTHRITIS RHEUM, V43, P349, DOI 10.1002/1529-0131(200002)43:2<349::AID-ANR14>3.0.CO;2-M; Kearney JA, 2002, HUM MOL GENET, V11, P2765, DOI 10.1093/hmg/11.22.2765; Kohrman DC, 1996, J BIOL CHEM, V271, P17576, DOI 10.1074/jbc.271.29.17576; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Meisler MH, 2001, NEUROSCIENTIST, V7, P136, DOI 10.1177/107385840100700208; Miki R, 2001, P NATL ACAD SCI USA, V98, P2199, DOI 10.1073/pnas.041605498; Nadeau JH, 2003, CURR OPIN GENET DEV, V13, P290, DOI 10.1016/S0959-437X(03)00061-3; Nesic D, 2001, MOL CELL BIOL, V21, P6406, DOI 10.1128/MCB.21.19.6406-6417.2001; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Slavotinek A, 2003, HUM MOL GENET, V12, pR45, DOI 10.1093/hmg/ddg099; Sprunger LK, 1999, HUM MOL GENET, V8, P471, DOI 10.1093/hmg/8.3.471; Stoilov P, 2002, DNA CELL BIOL, V21, P803, DOI 10.1089/104454902320908450; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Tarantino LM, 1998, ALCOHOL CLIN EXP RES, V22, P1099	29	95	100	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					967	969		10.1126/science.1086187	http://dx.doi.org/10.1126/science.1086187			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920299				2022-12-28	WOS:000184755900040
J	Jackson, A				Jackson, A			Intense equatorial flux spots on the surface of the Earth's core	NATURE			English	Article							GEOMAGNETIC SECULAR VARIATION; FIELD; GEODYNAMO; MODEL; WAVES	A large number of high-accuracy vector measurements of the Earth's magnetic field have recently become available from the satellite Oersted, complementing previous vector data from the satellite Magsat, which operated in 1979/80. These data can be used to infer the morphology of the magnetic field at the surface of the fluid core(1), similar to2,900 km below the Earth's surface. Here I apply a new methodology to these data to calculate maps of the magnetic field at the core surface which show intense flux spots in equatorial regions. The intensity of these features is unusually large-some have intensities comparable to high-latitude flux patches near the poles, previously identified as the major component of the dynamo field(2). The tendency for pairing of some of these spots to the north and south of the geographical equator suggests they might be associated with the tops of equatorially symmetric columnar structures in the fluid, or their antisymmetric equivalents. The drift of the equatorial features may represent material flow or could represent wave motion; discrimination of these two effects based on future data could provide new information on the strength of the hidden toroidal magnetic field of the Earth.	Univ Leeds, Sch Earth Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Jackson, A (corresponding author), Univ Leeds, Sch Earth Sci, Leeds LS2 9JT, W Yorkshire, England.							Backus G, 1996, FDN GEOMAGNETISM; BACKUS GE, 1967, GEOPHYS J ROY ASTR S, V13, P247, DOI 10.1111/j.1365-246X.1967.tb02159.x; BAUMGARDNER JR, 1985, SIAM J NUMER ANAL, V22, P1107, DOI 10.1137/0722066; BLOXHAM J, 1985, NATURE, V317, P777, DOI 10.1038/317777a0; BONDI H, 1950, MON NOT R ASTRON SOC, V110, P607, DOI 10.1093/mnras/110.6.607; Buck B., 1991, MAXIMUM ENTROPY ACTI; Christensen U, 1999, GEOPHYS J INT, V138, P393, DOI 10.1046/j.1365-246X.1999.00886.x; CONSTABLE CG, 1993, GEOPHYS J INT, V113, P419, DOI 10.1111/j.1365-246X.1993.tb00897.x; GUBBINS D, 1993, NATURE, V365, P829, DOI 10.1038/365829a0; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; GULL SF, 1984, IEE PROC-F, V131, P646, DOI 10.1049/ip-f-1.1984.0099; GULL SF, 1990, MEMSYS5 USERS MANUAL; HIDE R, 1966, PHILOS TR R SOC S-A, V259, P615, DOI 10.1098/rsta.1966.0026; Holme R, 1996, PHYS EARTH PLANET IN, V98, P221, DOI 10.1016/S0031-9201(96)03189-5; Hulot G, 2002, NATURE, V416, P620, DOI 10.1038/416620a; Jackson A, 2000, PHILOS T ROY SOC A, V358, P957, DOI 10.1098/rsta.2000.0569; MALKUS WVR, 1967, J FLUID MECH, V28, P793, DOI 10.1017/S0022112067002447; Olsen N, 2000, GEOPHYS RES LETT, V27, P3607, DOI 10.1029/2000GL011930; PARKER RL, 1994, GEOPHYSICAQOL INVERS; Roberts PH, 2000, PHILOS T ROY SOC A, V358, P1109, DOI 10.1098/rsta.2000.0576; Tikhonov A., 1977, SOLUTIONS ILL POSED; ZHANG K, 1993, J FLUID MECH, V248, P203, DOI 10.1017/S0022112093000746	22	64	64	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					760	763		10.1038/nature01879	http://dx.doi.org/10.1038/nature01879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917680				2022-12-28	WOS:000184733900035
J	Bache, J; Knowles, P				Bache, J; Knowles, P			Uses of error - Expect the unexpected - twice!	LANCET			English	Editorial Material									Leighton Hosp, Dept Accid & Emergency, Crewe CW1 4QJ, Cheshire, England		Bache, J (corresponding author), Leighton Hosp, Dept Accid & Emergency, Crewe CW1 4QJ, Cheshire, England.								0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					432	432		10.1016/S0140-6736(03)14067-6	http://dx.doi.org/10.1016/S0140-6736(03)14067-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927429				2022-12-28	WOS:000184651100009
J	Chen, W; ten Berge, D; Brown, J; Ahn, S; Hu, LA; Miller, WE; Caron, MG; Barak, LS; Nusse, R; Lefkowitz, RJ				Chen, W; ten Berge, D; Brown, J; Ahn, S; Hu, LA; Miller, WE; Caron, MG; Barak, LS; Nusse, R; Lefkowitz, RJ			Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4	SCIENCE			English	Article							COUPLED RECEPTOR KINASES; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; PROTEINS; ACTIVATION; SIGNALS; ADAPTER	Wnt proteins, regulators of development in many organisms, bind to seven transmembrane-spanning (7TMS) receptors called frizzleds, thereby recruiting the cytoplasmic molecule dishevelled (Dvl) to the plasma membrane. Frizzled-mediated endocytosis of Wg (a Drosophila Wnt protein) and lysosomal degradation may regulate the formation of morphogen gradients. Endocytosis of Frizzled 4 (Fz4) in human embryonic kidney 293 cells was dependent on added Wnt5A protein and was accomplished by the multifunctional adaptor protein beta-arrestin 2 (betaarr2), which was recruited to Fz4 by binding to phosphorylated Dvl2. These findings provide a previously unrecognized mechanism for receptor recruitment of beta-arrestin and demonstrate that Dvl plays an important role in the endocytosis of frizzled, as well as in promoting signaling.	Stanford Univ, Sch Med, Beckman Ctr, Dept Dev Biol,Howard Hughes Med Inst, Stanford, CA 94305 USA; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA	Howard Hughes Medical Institute; Stanford University; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Nusse, R (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Dept Dev Biol,Howard Hughes Med Inst, Stanford, CA 94305 USA.		Lefkowitz, Robert/AAW-2649-2021; Berge, Derk ten/ABF-2591-2020; Berge, Derk ten/C-1967-2012	Berge, Derk ten/0000-0002-5863-0860; Chen, Wei/0000-0002-9934-4000	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037, HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	22	259	270	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1391	1394		10.1126/science.1082808	http://dx.doi.org/10.1126/science.1082808			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958364				2022-12-28	WOS:000185116400045
J	Fudala, PJ; Bridge, TP; Herbert, S; Williford, WO; Chiang, CN; Jones, K; Collins, J; Raisch, D; Casadonte, P; Goldsmith, RJ; Ling, W; Malkerneker, U; McNicholas, L; Renner, J; Stine, S; Tusel, D				Fudala, PJ; Bridge, TP; Herbert, S; Williford, WO; Chiang, CN; Jones, K; Collins, J; Raisch, D; Casadonte, P; Goldsmith, RJ; Ling, W; Malkerneker, U; McNicholas, L; Renner, J; Stine, S; Tusel, D		Buprenorphine Naloxone Collaborati	Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED CLINICAL-TRIAL; DRUG-ABUSE TREATMENT; OPIOID DEPENDENCE; INTRAVENOUS BUPRENORPHINE; CRIMINAL ACTIVITY; VOLUNTEERS; COMBINATIONS; PREVALENCE; METHADONE	Background: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone has been proposed, but its efficacy and safety have not been well studied. Methods: We conducted a multicenter, randomized, placebo-controlled trial involving 326 opiate-addicted persons who were assigned to office-based treatment with sublingual tablets consisting of buprenorphine (16 mg) in combination with naloxone (4 mg), buprenorphine alone (16 mg), or placebo given daily for four weeks. The primary outcome measures were the percentage of urine samples negative for opiates and the subjects' self-reported craving for opiates. Safety data were obtained on 461 opiate-addicted persons who participated in an open-label study of buprenorphine and naloxone (at daily doses of up to 24 mg and 6 mg, respectively) and another 11 persons who received this combination only during the trial. Results: The double-blind trial was terminated early because buprenorphine and naloxone in combination and buprenorphine alone were found to have greater efficacy than placebo. The proportion of urine samples that were negative for opiates was greater in the combined-treatment and buprenorphine groups (17.8 percent and 20.7 percent, respectively) than in the placebo group (5.8 percent, P<0.001 for both comparisons); the active-treatment groups also reported less opiate craving (P<0.001 for both comparisons with placebo). Rates of adverse events were similar in the active-treatment and placebo groups. During the open-label phase, the percentage of urine samples negative for opiates ranged from 35.2 percent to 67.4 percent. Results from the open-label follow-up study indicated that the combined treatment was safe and well tolerated. Conclusions: Buprenorphine and naloxone in combination and buprenorphine alone are safe and reduce the use of opiates and the craving for opiates among opiate-addicted persons who receive these medications in an office-based setting.	Univ Penn, Sch Med, Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; NIDA, Div Treatment Res & Dev, NIH, Bethesda, MD 20892 USA; VA Cooperat Studies Program, Coordinating Ctr, Perry Point, MD USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ New Mexico, VA Cooperat Studies Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM 87131 USA; NYU, Sch Med, New York Harbor Hlth Care Syst, VA Med Ctr, New York, NY USA; VA Med Ctr, Cincinnati, OH USA; VA Med Ctr, Los Angeles, CA USA; VA Med Ctr, Hines, IL USA; Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA; VA Med Ctr, West Haven, CT USA; Univ Calif San Francisco, VA Med Ctr, San Francisco, CA 94143 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University System of Maryland; University of Maryland Baltimore; University of New Mexico; New York University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; Boston University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; University of California System; University of California San Francisco	Fudala, PJ (corresponding author), VA Med Ctr, Psychiat Serv, Ward 7E 116-7E,Univ & Woodland Aves, Philadelphia, PA 19104 USA.			, Walter/0000-0003-0664-5099; Stine, Susan/0000-0001-5426-4448	NIDA NIH HHS [3Y01-DA-30011-04] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		American Psychiatric Association, 1994, DSM 4; Bates M, 1996, SCOT MED J, V41, P173, DOI 10.1177/003693309604100606; BROWN BS, 1989, AM J DRUG ALCOHOL AB, V15, P261, DOI 10.3109/00952998908993407; CHILDRESS AR, 1991, RES MONOGRAPH NAT I, V106, P167; Comer SD, 2002, J PHARMACOL EXP THER, V301, P266, DOI 10.1124/jpet.301.1.266; DEMETS DL, 1987, STAT MED, V6, P753, DOI 10.1002/sim.4780060706; FRENCH MT, 1993, AM J DRUG ALCOHOL AB, V19, P19, DOI 10.3109/00952999309002663; Fudala PJ, 1998, DRUG ALCOHOL DEPEN, V50, P1, DOI 10.1016/S0376-8716(98)00008-8; Harling R, 1998, BRIT MED J, V317, P431; Harris DS, 2000, DRUG ALCOHOL DEPEN, V61, P85, DOI 10.1016/S0376-8716(00)00126-5; HARTNOLL RL, 1994, ADDICTION, V89, P1377, DOI 10.1111/j.1360-0443.1994.tb03733.x; HUGHES PH, 1995, EPIDEMIOL REV, V17, P66, DOI 10.1093/oxfordjournals.epirev.a036186; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; JOHNSON RE, 1995, DRUG ALCOHOL DEPEN, V40, P17, DOI 10.1016/0376-8716(95)01186-2; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Kakko J, 2003, LANCET, V361, P662, DOI 10.1016/S0140-6736(03)12600-1; Knolle H, 1997, SUBST USE MISUSE, V32, P1349, DOI 10.3109/10826089709039382; Krook AL, 2002, ADDICTION, V97, P533, DOI 10.1046/j.1360-0443.2002.00090.x; LEANDER JD, 1987, NEUROPHARMACOLOGY, V26, P1445, DOI 10.1016/0028-3908(87)90112-2; Ling W, 1998, ADDICTION, V93, P475, DOI 10.1046/j.1360-0443.1998.9344753.x; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Mendelson J, 1999, PSYCHOPHARMACOLOGY, V141, P37, DOI 10.1007/s002130050804; Mendelson J, 1996, CLIN PHARMACOL THER, V60, P105, DOI 10.1016/S0009-9236(96)90173-3; Mendelson J, 2003, DRUG ALCOHOL DEPEN, V70, pS29, DOI 10.1016/S0376-8716(03)00057-7; Merrill J, 1999, J SUBST ABUSE TREAT, V17, P313, DOI 10.1016/S0740-5472(99)00012-4; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nath RP, 1999, J CLIN PHARMACOL, V39, P619, DOI 10.1177/00912709922008236; *OFF DRUG CONTR PO, 1997, WHAT AM US SPEND ILL; Pani PP, 2000, DRUG ALCOHOL DEPEN, V60, P39, DOI 10.1016/S0376-8716(99)00140-4; PICKWORTH WB, 1993, CLIN PHARMACOL THER, V53, P570, DOI 10.1038/clpt.1993.72; Strain EC, 1997, PSYCHOPHARMACOLOGY, V129, P329, DOI 10.1007/s002130050199; 2001, FED REG, V66, P4075	32	407	414	0	32	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					949	958		10.1056/NEJMoa022164	http://dx.doi.org/10.1056/NEJMoa022164			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717HJ	12954743	Bronze			2022-12-28	WOS:000185081400006
J	Landefeld, CS				Landefeld, CS			Improving health care for older persons	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				COMPREHENSIVE GERIATRIC ASSESSMENT; FUNCTIONAL DECLINE; RANDOMIZED-TRIAL; MULTICOMPONENT INTERVENTION; HOSPITALIZED-PATIENTS; PROSTATE-CANCER; OUTCOMES; HOME; ADMISSION; PROGRAM	Health care of the highest quality promotes successful aging. This paper examines the efforts that have been taken to improve the quality of health care, especially hospital care. Most of these efforts have evaluated conventional treatments of specific diseases; they are critical but underfunded and underused, and many practices persist without much evidence of efficacy. Fewer efforts have attempted to improve care for groups of persons in specific settings, such as the hospital. Three complementary approaches to improving comprehensive outcomes for hospitalized older persons-Geriatric Evaluation and Management, Acute Care for Elders, and the Elder Life Program-demonstrate what has been learned about improving care for older persons by redesigning microsystems of care. A research agenda for advancing successful aging should include specific actions to improve the quality of health care.	Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Landefeld, CS (corresponding author), Univ Calif San Francisco, Div Geriatr, Box 1265, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE ON AGING [K07AG000912] Funding Source: NIH RePORTER; NIA NIH HHS [K07 AG00912] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; Counsell SR, 2000, J AM GERIATR SOC, V48, P1572, DOI 10.1111/j.1532-5415.2000.tb03866.x; Covinsky KE, 1999, J AM GERIATR SOC, V47, P532, DOI 10.1111/j.1532-5415.1999.tb02566.x; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Covinsky KE, 1997, ANN INTERN MED, V126, P417, DOI 10.7326/0003-4819-126-6-199703150-00001; Elixhauser A, 2000, AHRQ PUBLICATION; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; Lindenberger EC, 2003, J AM GERIATR SOC, V51, P621, DOI 10.1034/j.1600-0579.2003.00205.x; REUBEN DB, 1995, NEW ENGL J MED, V332, P1345, DOI 10.1056/NEJM199505183322007; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; Sands LP, 2003, J GERONTOL A-BIOL, V58, P37; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Walsh PC, 2002, NEW ENGL J MED, V347, P839, DOI 10.1056/NEJMe020089	19	43	43	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			421	424		10.7326/0003-4819-139-5_Part_2-200309021-00008	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965969				2022-12-28	WOS:000185133800008
J	McHorney, CA				McHorney, CA			Ten recommendations for advancing patient-centered outcomes measurement for older persons	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				ITEM RESPONSE THEORY; BECK DEPRESSION INVENTORY; QUALITY-OF-LIFE; FUNCTIONAL DISABILITY; PAST ACCOMPLISHMENTS; SCALE; UNIDIMENSIONALITY; TESTS; BIAS; DIMENSIONALITY	The past 50 years have seen great progress in the measurement of patient-based outcomes for older populations. Most of the measures now used were created under the umbrella of a set of assumptions and procedures known as classical test theory. A recent alternative for health status assessment is item response theory. Item response theory is superior to classical test theory because it can eliminate test dependency and achieve more precise measurement through computerized adaptive testing. Computerized adaptive testing reduces test administration times and allows varied and precise estimates of ability. Several key challenges must be met before computerized adaptive testing becomes a productive reality. I discuss these challenges for the health assessment of older persons in the form of 10 "Ds": things we need to deliberate, debate, decide, and do.	Indiana Univ, Sch Med, Regenstrief Inst, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	McHorney, CA (corresponding author), Indiana Univ, Sch Med, Regenstrief Inst, RHC 6th Floor,1050 Wishard Blvd, Indianapolis, IN 46202 USA.	cmchorney@regenstrief.org						Azocar F, 2001, J CLIN PSYCHOL, V57, P355, DOI 10.1002/jclp.1017; Bowling A., 2001, MEASURING DIS REV DI; Christensen H, 1999, PSYCHOL MED, V29, P325, DOI 10.1017/S0033291798008150; DEAYALA RJ, 1989, EDUC PSYCHOL MEAS, V49, P789, DOI 10.1177/001316448904900403; DODD BG, 1989, APPL PSYCH MEAS, V13, P129, DOI 10.1177/014662168901300202; DODD BG, 1995, APPL PSYCH MEAS, V19, P5, DOI 10.1177/014662169501900103; DORANS N, 2000, COMPUTERIZED ADAPTIV; DRASGOW F, 1983, J APPL PSYCHOL, V68, P363, DOI 10.1037/0021-9010.68.3.363; Eggen TJHM, 2000, EDUC PSYCHOL MEAS, V60, P713, DOI 10.1177/00131640021970862; Fleishman JA, 2002, J GERONTOL B-PSYCHOL, V57, pS275, DOI 10.1093/geronb/57.5.S275; FRASER RSS, 1988, PESTIC SCI, V23, P267, DOI 10.1002/ps.2780230308; GIBBONS RD, 1985, J PSYCHIAT RES, V19, P43, DOI 10.1016/0022-3956(85)90067-6; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Grayson DA, 2000, J GERONTOL B-PSYCHOL, V55, pP273, DOI 10.1093/geronb/55.5.P273; GREEN BF, 1984, J EDUC MEAS, V21, P347, DOI 10.1111/j.1745-3984.1984.tb01039.x; Gulliksen H., 1950, THEORY MENTAL TESTS; HALEY SM, 1994, J CLIN EPIDEMIOL, V47, P671, DOI 10.1016/0895-4356(94)90215-1; HAMBLETON R, 1985, INTERN RESPONSE THEO; Hambleton R.K., 1993, ED MEASUREMENT, P147; Hambleton RK, 1997, EUR J PSYCHOL ASSESS, V13, P21, DOI 10.1027/1015-5759.13.1.21; Hambleton RK, 1993, EDUC MEAS-ISSUES PRA, V12, P38, DOI DOI 10.1111/J.1745-3992.1993.TB00543.X; HATTIE J, 1985, APPL PSYCH MEAS, V9, P139, DOI 10.1177/014662168500900204; Hazuda HP, 2002, PSYCHOSOM MED, V64, P520, DOI 10.1097/00006842-200205000-00017; Holland PW., 1993, DIFFERENTIAL ITEM FU, DOI DOI 10.4324/9780203357811; JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X; Jones RN, 2002, J GERONTOL B-PSYCHOL, V57, pP548, DOI 10.1093/geronb/57.6.P548; KELLER DM, 1993, J AGING HEALTH, V5, P306, DOI DOI 10.1177/089826439300500302; KEMPEN GIJM, 1995, J CLIN EPIDEMIOL, V48, P1299, DOI 10.1016/0895-4356(95)00043-7; Kim Y, 2002, PSYCHOL AGING, V17, P379, DOI 10.1037//0882-7974.17.3.379; Lemann Nicholas, 1999, BIG TEST SECRET HIST; Leplege A, 1997, JAMA-J AM MED ASSOC, V278, P47, DOI 10.1001/jama.278.1.47; Lorentz WJ, 2002, CAN J PSYCHIAT, V47, P723, DOI 10.1177/070674370204700803; McHorney CA, 1997, ANN INTERN MED, V127, P743, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00061; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; McHorney CA, 2002, ARCH PHYS MED REHAB, V83, P383, DOI 10.1053/apmr.2002.29610; McHorney CA, 1999, ANNU REV PUBL HEALTH, V20, P309, DOI 10.1146/annurev.publhealth.20.1.309; McHorney CA, 2000, MED CARE, V38, P43; Orlando M, 2000, PSYCHOL ASSESSMENT, V12, P354, DOI 10.1037//1040-3590.12.3.354; ROZNOWSKI M, 1991, APPL PSYCH MEAS, V15, P109, DOI 10.1177/014662169101500201; Schaeffer N. C., 1988, SOCIOL METHODOL, P271; SHAPIRO MF, 1994, HEALTH SERV RES, V28, P661; Spector WD, 1998, J GERONTOL B-PSYCHOL, V53, pS46, DOI 10.1093/geronb/53B.1.S46; STEINBERG L, 1994, J PERS SOC PSYCHOL, V66, P341, DOI 10.1037/0022-3514.66.2.341; Steinberg L., 1995, PERSONALITY RES METH, P161; STOMMEL M, 1993, PSYCHIAT RES, V49, P239, DOI 10.1016/0165-1781(93)90064-N; SUDMAN S., 1996, THINKING ANSWERS APP; *TASK FORC HDB PSY, 2000, HDB PSYCH MEAS; TERESI J, 2001, J MENTAL HLTH AGING, V7, P79; Teresi JA, 2000, RES AGING, V22, P738, DOI 10.1177/0164027500226007; TERESI JA, 1995, J CLIN EPIDEMIOL, V48, P473, DOI 10.1016/0895-4356(94)00159-N; TERESI JA, 1989, J GERONTOL, V44, pS196, DOI 10.1093/geronj/44.5.S196; WISE WL, 2000, PSICOLOGICA, V21, P135; WOOD R, 2003, TESTFACT; World Health Organization, 2021, WHO GUID HLTH WORKF; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	57	47	48	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			403	409		10.7326/0003-4819-139-5_Part_2-200309021-00005	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965966				2022-12-28	WOS:000185133800005
J	Weiner, M; Callahan, CM; Tierney, WM; Overhage, JM; Mamlin, B; Dexter, PR; McDonald, CJ				Weiner, M; Callahan, CM; Tierney, WM; Overhage, JM; Mamlin, B; Dexter, PR; McDonald, CJ			Using information technology to improve the health care of older adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				COMPUTER-BASED INTERVENTION; CONGESTIVE-HEART-FAILURE; PHYSICIAN ORDER ENTRY; MONITORING-SYSTEM; CONTROLLED TRIAL; MEDICAL INFORMATICS; PREVENTIVE CARE; INFORMING PHYSICIANS; PRACTICE GUIDELINES; RANDOMIZED TRIAL	The high burden of illness and frailty common among our growing population of older adults often results in fragmentation of care across providers and health care systems, increasing the complexity and costs of caring for these patients. Information technology offers one way to meet this challenge. Scientists at the Regenstrief Institute have more than a quarter-century of experience in using medical informatics to support clinicians in the day-to-day care of older adults. Their research has progressed through several evolutionary cycles, beginning with the acquisition of relevant data and moving to studies of the most efficient and effective mechanisms that bring information to bear at the time of clinical decision making. Information technology designed with the input of the end user has the greatest promise of changing provider behavior because it balances technological challenges with the cultural context of the practice environment. One topic of active research is information technology to support transitions of care among sites and providers. These transitions place older adults at increased risk for avoidable illness, death, and health care costs. Information systems that improve communication among providers during these transitions have the potential to improve safety and reduce costs.	Indiana Univ, Ctr Aging Res, Regenstrief Inst, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Weiner, M (corresponding author), Indiana Univ, Ctr Aging Res, Regenstrief Inst, 1050 Wishard Blvd,6th Floor, Indianapolis, IN 46202 USA.	mw@cogit.net	Tao, Youyou/D-2367-2014; Weiner, Michael/H-5342-2019; Weiner, Michael/M-5185-2013	Weiner, Michael/0000-0002-0877-4583; Weiner, Michael/0000-0002-0877-4583; Overhage, Joseph/0000-0003-0223-0195	NATIONAL LIBRARY OF MEDICINE [N01LM093542] Funding Source: NIH RePORTER; NLM NIH HHS [N01-LM-9-3542] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Ash JS, 1998, J AM MED INFORM ASSN, P235; Barnett GO, 2000, M D COMPUT, V17, P19; BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; Bates DW, 1999, AM J MED, V106, P144, DOI 10.1016/S0002-9343(98)00410-0; Bates DW, 2003, J AM MED INFORM ASSN, V10, P115, DOI 10.1197/jamia.M1074; Beers Mark H., 1992, Journal of Medical Systems, V16, P237, DOI 10.1007/BF00996359; Binstock RH, 1997, HEALTH SERV RES, V32, P715; Bratton RL, 2001, J TELEMED TELECARE, V7, P85, DOI 10.1258/1357633011937263; *CA HEALTHC FDN, 2003, SANT BARB COUNT CAR; Callahan CM, 1997, ANN INTERN MED, V126, P426, DOI 10.7326/0003-4819-126-6-199703150-00002; Callahan CM, 1998, J GEN INTERN MED, V13, P746, DOI 10.1046/j.1525-1497.1998.00226.x; Callahan CM, 1998, J AM GERIATR SOC, V46, P1371, DOI 10.1111/j.1532-5415.1998.tb06003.x; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; CALLAHAN CM, 1992, J GEN INTERN MED, V7, P26, DOI 10.1007/BF02599097; *CAR, 2003, SANT BARB COUNT CAR; Chan WM, 2001, J TELEMED TELECARE, V7, P38, DOI 10.1258/1357633011936129; CHEN A, 2000, PR0010 MATH POL RES; Chen P, 2003, AM J CLIN PATHOL, V119, P432, DOI 10.1309/A96XU9YKU298HB2R; CIMINO JJ, 1995, J AM MED INFORM ASSN, V2, P273, DOI 10.1136/jamia.1995.96073829; Clayton PD, 2003, METHOD INFORM MED, V42, P1; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; *CTR MED MED SERV, 2003, ACT PROM INT; *CTR MED MED SERV, 2003, SUPP STAND; *DEP HLTH HUM SERV, 2000, AT COMM VIT HLTH ST; *DEP HLTH HUM SERV, 2003, BUILD NAT HLTH INF I; DEVORE PA, 1995, AGING-CLIN EXP RES, V7, P194, DOI 10.1007/BF03324314; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Dexter PR, 1998, ANN INTERN MED, V128, P102, DOI 10.7326/0003-4819-128-2-199801150-00005; Doolan DF, 2003, J AM MED INFORM ASSN, V10, P94, DOI 10.1197/jamia.M1127; EAGLE KA, 1990, JAMA-J AM MED ASSOC, V264, P992, DOI 10.1001/jama.264.8.992; Field TS, 2001, ARCH INTERN MED, V161, P1629, DOI 10.1001/archinte.161.13.1629; Fisch M, 1999, J Palliat Med, V2, P403, DOI 10.1089/jpm.1999.2.403; FitzHenry F, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P250; FRIES JF, 1972, J AMER MED ASSOC, V222, P1536, DOI 10.1001/jama.222.12.1536; GARDNER RM, 1990, COMPUT BIOMED RES, V23, P514, DOI 10.1016/0010-4809(90)90038-E; Gardner RM, 1999, M D COMPUT, V16, P29; Gardner RM, 1999, INT J MED INFORM, V54, P169, DOI 10.1016/S1386-5056(99)00013-1; GEISSBUHLER A, 1996, SUPERHIGHWAY EXPLOIT, P689; Grannis SJ, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P305; Halamka JD, 1997, J AM MED INFORM ASSN, P349; HERSH WR, 1995, J AM SOC INFORM SCI, V46, P726; *HLTH LEV 7 INC, 2003, HL7 STAND CLIN DOC A; *HLTH LEV 7 INC, 2003, HLTH LEV 7; HUI E, 2002, TELEHEALTH PRACTICE, V7, P3; HUI E, 2002, TELEHEALTH PRACTICE, V7, P13; HULSE RK, 1976, AM J HOSP PHARM, V33, P1061, DOI 10.1093/ajhp/33.10.1061; *I MED, 1997, COMP BAS PAT REC ESS; Institute of Medicine, 2001, CROSSING QUALITY CHA; KRUSE W, 1992, J AM GERIATR SOC, V40, P1151, DOI 10.1111/j.1532-5415.1992.tb01806.x; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LITZELMAN DK, 1993, J GEN INTERN MED, V8, P311, DOI 10.1007/BF02600144; Mamlin J J, 1973, Med Care, V11, P449, DOI 10.1097/00005650-197309000-00010; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1977, AM J PUBLIC HEALTH, V67, P240, DOI 10.2105/AJPH.67.3.240; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MCDONALD CJ, 1986, WESTERN J MED, V145, P823; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; MCDONALD P, 1988, POPUL INDEX, V54, P225, DOI 10.2307/3643952; Murray MD, 1999, AM J HEALTH-SYST PH, V56, P225, DOI 10.1093/ajhp/56.3.225; Murray MD, 1998, J AM MED INFORM ASSN, V5, P546, DOI 10.1136/jamia.1998.0050546; Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2; National Electrical Manufacturers Association, 2003, DIG IM COMM MED DICO; Ohta S, 2002, J TELEMED TELECARE, V8, P151, DOI 10.1258/135763302320118997; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Overhage JM, 2002, ANN EMERG MED, V39, P14, DOI 10.1067/mem.2002.120794; Overhage JM, 2001, J AM MED INFORM ASSN, V8, P361, DOI 10.1136/jamia.2001.0080361; OVERHAGE JM, 1995, B MED LIBR ASSOC, V83, P48; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Poon EG, 2002, J AM MED INFORM ASSN, V9, P217, DOI 10.1197/jamia.M1009; *REG I, 2002, LOG OBS ID NAM COD L; Safran C, 1999, METHOD INFORM MED, V38, P308; SAFRAN C, 1990, M D COMPUT, V7, P144; Sanders DL, 2001, J AM MED INFORM ASSN, P583; Shojania KG, 1998, J AM MED INFORM ASSN, V5, P554, DOI 10.1136/jamia.1998.0050554; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Southon FCG, 1997, J AM MED INFORM ASSN, V4, P112, DOI 10.1136/jamia.1997.0040112; Stroupe KT, 2000, J AM GERIATR SOC, V48, P760, DOI 10.1111/j.1532-5415.2000.tb04750.x; Teich JM, 1999, INT J MED INFORM, V54, P197, DOI 10.1016/S1386-5056(99)00007-6; Tierney WM, 2001, INT J MED INFORM, V62, P1, DOI 10.1016/S1386-5056(01)00127-7; TIERNEY WM, 1987, ANN INTERN MED, V107, P569, DOI 10.7326/0003-4819-107-4-569; Tierney WM, 1996, J GEN INTERN MED, V11, P83, DOI 10.1007/BF02599583; TIERNEY WM, 1995, MED CARE, V33, P1, DOI 10.1097/00005650-199501000-00001; TIERNEY WM, 1990, NEW ENGL J MED, V322, P1499, DOI 10.1056/NEJM199005243222105; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001; Weiner M, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P874; Weiner M, 2001, J AM MED INFORM ASSN, P751; WHITINGOKEEFE QE, 1985, JAMA-J AM MED ASSOC, V254, P1185, DOI 10.1001/jama.254.9.1185; WILLIAMS ME, 1995, J AM GERIATR SOC, V43, P1047, DOI 10.1111/j.1532-5415.1995.tb05572.x; WILSON GA, 1982, AM J PUBLIC HEALTH, V72, P698, DOI 10.2105/AJPH.72.7.698; WIRTSCHAFTER D, 1979, ANN INTERN MED, V90, P396, DOI 10.7326/0003-4819-90-3-396; Wolinsky FD, 1997, MED CARE, V35, P1031, DOI 10.1097/00005650-199710000-00005; Wolinsky FD, 1997, J AM GERIATR SOC, V45, P558, DOI 10.1111/j.1532-5415.1997.tb03087.x; ZEMCOV A, 1984, J AM GERIATR SOC, V32, P801, DOI 10.1111/j.1532-5415.1984.tb06300.x; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	97	57	58	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			430	436		10.7326/0003-4819-139-5_Part_2-200309021-00010	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965971				2022-12-28	WOS:000185133800010
J	Benkovic, SJ; Hammes-Schiffer, S				Benkovic, SJ; Hammes-Schiffer, S			A perspective on enzyme catalysis	SCIENCE			English	Review							DIHYDROFOLATE-REDUCTASE CATALYSIS; MOLECULAR-DYNAMICS SIMULATIONS; PROTON-TRANSFER REACTIONS; PROTEIN DYNAMICS; ESCHERICHIA-COLI; HYDRIDE-TRANSFER; QUANTUM DYNAMICS; SUBSTRATE-SPECIFICITY; CONFORMATIONAL-CHANGE; BIOLOGICAL CATALYSIS	The seminal hypotheses proposed over the years for enzymatic catalysis are scrutinized. The historical record is explored from both biochemical and theoretical perspectives. Particular attention is given to the impact of molecular motions within the protein on the enzyme's catalytic properties. A case study for the enzyme dihydrofolate reductase provides evidence for coupled networks of predominantly conserved residues that influence the protein structure and motion. Such coupled networks have important implications for the origin and evolution of enzymes, as well as for protein engineering.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Benkovic, SJ (corresponding author), Penn State Univ, Dept Chem, 152 Davey Lab, University Pk, PA 16802 USA.		Hammes-Schiffer, Sharon/B-7325-2013		NIGMS NIH HHS [GM13306, GM56207, GM24129] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024129, R01GM024129, R37GM056207, R01GM056207] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal PK, 2002, J PHYS CHEM B, V106, P3283, DOI 10.1021/jp020190v; Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Alhambra C, 2000, J AM CHEM SOC, V122, P8197, DOI 10.1021/ja001476l; Alves R, 2002, J MOL BIOL, V320, P751, DOI 10.1016/S0022-2836(02)00546-6; ANDO K, 1995, J MOL LIQ, V64, P25, DOI 10.1016/0167-7322(95)92818-V; Antoniou D, 2002, EUR J BIOCHEM, V269, P3103, DOI 10.1046/j.1432-1033.2002.03021.x; Babbitt PC, 1997, J BIOL CHEM, V272, P30591, DOI 10.1074/jbc.272.49.30591; Bahar I, 1999, J MOL BIOL, V285, P1023, DOI 10.1006/jmbi.1998.2371; Barbara PF, 1996, J PHYS CHEM-US, V100, P13148, DOI 10.1021/jp9605663; Bell R P, 1980, TUNNELING EFFECT CHE; Billeter SR, 2001, J AM CHEM SOC, V123, P11262, DOI 10.1021/ja011384b; Billeter SR, 2001, J CHEM PHYS, V114, P6925, DOI 10.1063/1.1356441; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BORGIS D, 1993, CHEM PHYS, V170, P315, DOI 10.1016/0301-0104(93)85117-Q; Borgis D, 1996, J PHYS CHEM-US, V100, P1118, DOI 10.1021/jp9522324; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; Bruice TC, 2002, ACCOUNTS CHEM RES, V35, P139, DOI 10.1021/ar0001665; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; BRUICE TC, 1976, ANNU REV BIOCHEM, V45, P331, DOI 10.1146/annurev.bi.45.070176.001555; BRUNO WJ, 1992, BIOPHYS J, V63, P689, DOI 10.1016/S0006-3495(92)81654-5; Callender R, 2002, CURR OPIN STRUC BIOL, V12, P628, DOI 10.1016/S0959-440X(02)00370-6; Cannon WR, 1998, J BIOL CHEM, V273, P26257, DOI 10.1074/jbc.273.41.26257; Cannon WR, 1996, NAT STRUCT BIOL, V3, P821, DOI 10.1038/nsb1096-821; Caratzoulas S, 2001, J CHEM PHYS, V114, P2910, DOI 10.1063/1.1342817; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; CHANDLER D, 1986, J STAT PHYS, V42, P49, DOI 10.1007/BF01010840; Chandrasegaran S, 1999, BIOL CHEM, V380, P841, DOI 10.1515/BC.1999.103; CHARLTON PA, 1979, J CHEM SOC CHEM COMM, P922, DOI 10.1039/c39790000922; Chowdhury S, 2000, J AM CHEM SOC, V122, P5417, DOI 10.1021/ja994302g; Cui QA, 2002, J PHYS CHEM B, V106, P7927, DOI 10.1021/jp0205057; Daizadeh I, 1997, P NATL ACAD SCI USA, V94, P3703, DOI 10.1073/pnas.94.8.3703; Deu E, 2002, PROTEIN SCI, V11, P1062, DOI 10.1110/ps.0200902; DEWAR MJS, 1985, P NATL ACAD SCI USA, V82, P2225, DOI 10.1073/pnas.82.8.2225; Dunietz BD, 2000, J AM CHEM SOC, V122, P2828, DOI 10.1021/ja9920967; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; EPSTEIN DM, 1995, BIOCHEMISTRY-US, V34, P11037, DOI 10.1021/bi00035a009; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; FIERKE CA, 1987, BIOCHEMISTRY-US, V26, P4085, DOI 10.1021/bi00387a052; Fischer E., 1894, BERICHTE DTSCH CHEM, V27, P3189; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; Freire E, 2000, P NATL ACAD SCI USA, V97, P11680, DOI 10.1073/pnas.97.22.11680; Friedberg I, 2002, PROTEIN SCI, V11, P350, DOI 10.1110/ps.18602; Gandour R. D., 1978, TRANSITION STATES BI; Gao JL, 2003, CURR OPIN STRUC BIOL, V13, P184, DOI 10.1016/S0959-440X(03)00041-1; Gerlt JA, 1998, CURR OPIN CHEM BIOL, V2, P607, DOI 10.1016/S1367-5931(98)80091-4; GERTNER BJ, 1989, J CHEM PHYS, V90, P3537, DOI 10.1063/1.455864; Haldane JBS, 1930, ENZYMES; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; HAMMES GG, 1964, NATURE, V204, P342, DOI 10.1038/204342a0; HAMMES-SCHIFFER S, 1994, J CHEM PHYS, V101, P4657, DOI 10.1063/1.467455; Hammes-Schiffer S, 2002, BIOCHEMISTRY-US, V41, P13335, DOI 10.1021/bi0267137; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hornung E, 1999, P NATL ACAD SCI USA, V96, P4192, DOI 10.1073/pnas.96.7.4192; HWANG JK, 1991, J PHYS CHEM-US, V95, P8445, DOI 10.1021/j100175a009; JENCKS WP, 1972, CHEM REV, V72, P705, DOI 10.1021/cr60280a004; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Karplus M, 2000, J PHYS CHEM B, V104, P11, DOI 10.1021/jp993555t; KARPLUS M, 1992, FARADAY DISCUSS, V93, P239, DOI 10.1039/fd9929300239; Knapp MJ, 2002, J AM CHEM SOC, V124, P3865, DOI 10.1021/ja012205t; Knapp MJ, 2002, EUR J BIOCHEM, V269, P3113, DOI 10.1046/j.1432-1033.2002.03022.x; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; KOSHLAND DE, 1968, ANNU REV BIOCHEM, V37, P359, DOI 10.1146/annurev.bi.37.070168.002043; Kuznetsov AM, 1999, CAN J CHEM, V77, P1085, DOI 10.1139/cjc-77-5-6-1085; LIENHARD GE, 1966, J AM CHEM SOC, V88, P5642, DOI 10.1021/ja00975a052; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Lu DS, 1998, PROTEINS, V33, P119, DOI 10.1002/(SICI)1097-0134(19981001)33:1<119::AID-PROT11>3.0.CO;2-O; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; McCammon JA., 1987, DYNAMICS PROTEINS NU; Miller GP, 1998, CHEM BIOL, V5, pR105, DOI 10.1016/S1074-5521(98)90616-0; Minshull J, 1999, CURR OPIN CHEM BIOL, V3, P284, DOI 10.1016/S1367-5931(99)80044-1; Mirny LA, 1999, J MOL BIOL, V291, P177, DOI 10.1006/jmbi.1999.2911; Moore GL, 2003, P NATL ACAD SCI USA, V100, P5091, DOI 10.1073/pnas.0831190100; Murzin AG, 1996, CURR OPIN STRUC BIOL, V6, P386, DOI 10.1016/S0959-440X(96)80059-5; MURZIN AG, 1993, TRENDS BIOCHEM SCI, V18, P403, DOI 10.1016/0968-0004(93)90132-7; OLIVEIRA L, 1993, J COMPUT AID MOL DES, V7, P649, DOI 10.1007/BF00125323; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Pan H, 2000, P NATL ACAD SCI USA, V97, P12020, DOI 10.1073/pnas.220240297; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; PAULING L, 1948, NATURE, V161, P707, DOI 10.1038/161707a0; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; PERUTZ MF, 1992, FARADAY DISCUSS, V93, P1, DOI 10.1039/fd9929300001; PERUTZ MF, 1967, PROC R SOC SER B-BIO, V167, P448, DOI 10.1098/rspb.1967.0046; Piana S, 2002, J MOL BIOL, V319, P567, DOI 10.1016/S0022-2836(02)00301-7; Radkiewicz JL, 2000, J AM CHEM SOC, V122, P225, DOI 10.1021/ja9913838; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; Rajagopalan PTR, 2002, BIOCHEMISTRY-US, V41, P12618, DOI 10.1021/bi026369d; Rajagopalan PTR, 2002, P NATL ACAD SCI USA, V99, P13481, DOI 10.1073/pnas.172501499; Rod TH, 2003, P NATL ACAD SCI USA, V100, P6980, DOI 10.1073/pnas.1230801100; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; Shurki A, 2002, J AM CHEM SOC, V124, P4097, DOI 10.1021/ja012230z; Stroud RM, 2003, BIOCHEMISTRY-US, V42, P239, DOI 10.1021/bi020598i; Suarez D, 2002, BIOCHEMISTRY-US, V41, P6615, DOI 10.1021/bi0121860; Sutcliffe MJ, 2002, EUR J BIOCHEM, V269, P3096, DOI 10.1046/j.1432-1033.2002.03020.x; TANAKA K, 1976, CAN J CHEM, V54, P1643, DOI 10.1139/v76-234; THOMAS JM, 1994, ANGEW CHEM INT EDIT, V33, P913, DOI 10.1002/anie.199409131; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Truhlar DG, 2002, ACCOUNTS CHEM RES, V35, P341, DOI 10.1021/ar0100226; TSOU CL, 1993, SCIENCE, V262, P380, DOI 10.1126/science.8211158; Villa J, 2001, J PHYS CHEM B, V105, P7887, DOI 10.1021/jp011048h; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WARSHEL A, 1984, P NATL ACAD SCI-BIOL, V81, P444, DOI 10.1073/pnas.81.2.444; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; Watney JB, 2003, J AM CHEM SOC, V125, P3745, DOI 10.1021/ja028487u; WESTHEIMER FH, 1985, ADV PHYS ORG CHEM, V21, P1, DOI 10.1016/S0065-3160(08)60097-0; Wolfenden R, 1999, J AM CHEM SOC, V121, P7419, DOI 10.1021/ja991280p; Wolfenden R, 1998, J AM CHEM SOC, V120, P833, DOI 10.1021/ja9733604; Xie XS, 1999, J BIOL CHEM, V274, P15967, DOI 10.1074/jbc.274.23.15967; Young L, 1996, BIOCHEMISTRY-US, V35, P15129, DOI 10.1021/bi961875m; Zhong WY, 1998, ANAL BIOCHEM, V255, P66, DOI 10.1006/abio.1997.2471; Zhou HX, 1998, P NATL ACAD SCI USA, V95, P9280, DOI 10.1073/pnas.95.16.9280	112	906	926	10	470	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1196	1202		10.1126/science.1085515	http://dx.doi.org/10.1126/science.1085515			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947189				2022-12-28	WOS:000185003500030
J	Bloss, TA; Witze, ES; Rothman, JH				Bloss, TA; Witze, ES; Rothman, JH			Suppression of CED-3-independent apoptosis by mitochondrial beta NAC in Caenorhabditis elegans	NATURE			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; IDENTIFICATION	To ensure cell survival, it is essential that the ubiquitous proapoptotic machinery is kept quiescent. As death is irreversible, cells must continually integrate developmental information with regulatory inputs to control the switch between repressing and activating apoptosis. Inappropriate activation or suppression of apoptosis can lead to degenerative pathologies(1) or tumorigenesis(2), respectively. Here we report that Caenorhabditis elegans inhibitor of cell death-1 (ICD-1) is necessary and sufficient to prevent apoptosis. Loss of ICD-1 leads to inappropriate apoptosis in developing and differentiated cells in various tissues. Although this apoptosis requires CED-4, it occurs independently of CED-3-the caspase essential for developmental apoptosis(3) showing that these core pro-apoptotic proteins have separable roles. Overexpressing ICD-1 inhibits the apoptosis of cells that are normally programmed to die. ICD-1 is the beta-subunit of the nascent polypeptide-associated complex (bNAC) and contains a putative caspase-cleavage site and caspase recruitment domain. It localizes primarily to mitochondria, underscoring the role of mitochondria in coordinating apoptosis(4). Human bNAC is a caspase substrate that is rapidly eliminated in dying cells(5,6), suggesting that ICD-1 apoptosis-suppressing activity may be inactivated by caspases.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Rothman, JH (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.							Brockstedt E, 1999, J PROTEIN CHEM, V18, P225, DOI 10.1023/A:1020636308270; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Fukushige T, 1998, DEV BIOL, V198, P286, DOI 10.1016/S0012-1606(98)80006-7; HALL D, 1995, CAENORHABDITIS ELEGA, P396; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hersh BM, 2002, P NATL ACAD SCI USA, V99, P4355, DOI 10.1073/pnas.062065399; Hodgkin J, 1997, C ELEGANS, P881; Kamath C, 2001, MASSIVE COMP, V2, P1; Ledwich D, 2000, METHOD ENZYMOL, V322, P76; LEWIS JA, 1995, CAENORHABDITIS ELEGA, P4; Liu QA, 1999, ANN NY ACAD SCI, V887, P92, DOI 10.1111/j.1749-6632.1999.tb07925.x; Loo DT, 1998, METHOD CELL BIOL, V57, P251; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; MILLER DM, 1995, CAENORHABDITIS ELEGA, P365; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; Sambrook J., 2002, MOL CLONING LAB MANU; Seshagiri S, 1998, FEBS LETT, V428, P71, DOI 10.1016/S0014-5793(98)00493-1; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Thiede B, 2001, J BIOL CHEM, V276, P26044, DOI 10.1074/jbc.M101062200; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Xu KL, 2001, NEURON, V31, P957, DOI 10.1016/S0896-6273(01)00432-9; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	29	86	105	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1066	1071		10.1038/nature01920	http://dx.doi.org/10.1038/nature01920			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944970				2022-12-28	WOS:000184984200046
J	Friedrich, MJ				Friedrich, MJ			A novel program seeks to take clinical scientists off the endangered species list	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																		Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1019	1020		10.1001/jama.290.8.1019	http://dx.doi.org/10.1001/jama.290.8.1019			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941663				2022-12-28	WOS:000184958900005
J	Pastorino, U; Bellomi, M; Landoni, C; De Fiori, E; Arnaldi, P; Picchio, M; Pelosi, G; Boyle, P; Fazio, F				Pastorino, U; Bellomi, M; Landoni, C; De Fiori, E; Arnaldi, P; Picchio, M; Pelosi, G; Boyle, P; Fazio, F			Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results	LANCET			English	Article							HELICAL COMPUTED-TOMOGRAPHY; PULMONARY NODULES; DIAGNOSIS; MORTALITY; RESECTION; CARCINOMA; SURVIVAL; PROJECT	Background Low-dose spiral CT of the chest effectively detects early-stage lung cancer in high-risk individuals. The high rate of benign nodules and issues of making a differential diagnosis are critical factors that currently hamper introduction of large-scale screening programmes. We investigated the efficacy of repeated yearly spiral CT and selective use of positron emission tomography (PET) in a large cohort of high-risk volunteers. Methods We enrolled 1035 individuals aged 50 years or older who had smoked for 20 pack-years or more. All patients underwent annual low-dose CT, with or without PET, for 5 years. Lesions up to 5 mm were deemed non-suspicious and low-dose CT was repeated after 12 months (year 2). Findings By year 2, 22 cases of lung cancer had been diagnosed (11 at baseline, 11 at year 2). 440 lung lesions were identified in 298 (29%) participants, and 95 were recalled for high-resolution contrast CT. PET scans were positive in 18 of 20 of the indentified cancer cases. Six patients underwent surgical biopsy for benign disease because of false-positive results (6% of recalls, 22% of invasive procedures). Complete resection was achieved in 21 (95%) lung cancers, 17 (77%) were pathological stage I (100% at year 2), and the mean tumour size was 18 mm. There were no interval lung cancers in the 2.5 years of follow-up (average time on study from randomisation to last contact), although 19 individuals were diagnosed with another form of cancer (two deaths and 17 non-fatal admissions). Interpretation Combined use of low-dose spiral CT and selective PET effectively detects early lung cancer. Lesions up to 5 mm can be checked again at 12 months without major risks of progression.	Ist Nazl Tumori, Div Thorac Surg, I-20133 Milan, Italy; Univ Milan, Div Radiol, Milan, Italy; European Inst Oncol, Div Pathol, Milan, Italy; European Inst Oncol, Dept Epidemiol, Milan, Italy; Univ Milano Bicocca, Inst HS Raffaele, CNR, IBFM,Div Nucl Med, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; IRCCS European Institute of Oncology (IEO); IRCCS European Institute of Oncology (IEO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR); University of Milano-Bicocca	Pastorino, U (corresponding author), Ist Nazl Studio & Cura Tumori, Via G Venezian 1, I-20133 Milan, Italy.	Ugo.Pastorino@istitutotumori.mi.it	Boyle, Peter/A-4380-2014; Bellomi, Massimo/AAM-4352-2020; Picchio, Maria/K-4941-2016; Pastorino, Ugo/C-2712-2017; De Fiori, Elvio/AAR-6550-2020; Pelosi, Giuseppe/F-5073-2012	Boyle, Peter/0000-0001-6251-0610; Picchio, Maria/0000-0002-7532-6211; Pastorino, Ugo/0000-0001-9974-7902; LANDONI, CLAUDIO/0000-0002-9199-1553; Pelosi, Giuseppe/0000-0003-4725-4692				Bach PB, 2001, NEW ENGL J MED, V345, P181, DOI 10.1056/NEJM200107193450306; Bernard A, 1996, ANN THORAC SURG, V61, P202, DOI 10.1016/0003-4975(95)01014-9; Boyle P, 2003, ANN ONCOL, V14, P1312, DOI 10.1093/annonc/mdg353; Colby TV, 2002, CANCER, V95, P2361, DOI 10.1002/cncr.10930; Diederich S, 2003, EUR J RADIOL, V45, P2, DOI 10.1016/S0720-048X(02)00302-9; FONTANA RS, 1986, J OCCUP ENVIRON MED, V28, P746, DOI 10.1097/00043764-198608000-00038; Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914; Henschke CI, 1999, LANCET, V354, P99, DOI 10.1016/S0140-6736(99)06093-6; Hillman BJ, 2003, ACAD RADIOL, V10, P349, DOI 10.1016/S1076-6332(03)80115-0; *IARC, 1999, IARC MON, V1, P1; Johnson BE, 1998, JNCI-J NATL CANCER I, V90, P1335, DOI 10.1093/jnci/90.18.1335; Kaneko M, 1996, RADIOLOGY, V201, P798, DOI 10.1148/radiology.201.3.8939234; Kodama K, 2002, ANN THORAC SURG, V73, P386, DOI 10.1016/S0003-4975(01)03410-5; Levi F, 2003, ANN ONCOL, V14, P490, DOI 10.1093/annonc/mdg110; MACK MJ, 1993, ANN THORAC SURG, V56, P825, DOI 10.1016/0003-4975(93)90339-J; Mahadevia PJ, 2003, JAMA-J AM MED ASSOC, V289, P313, DOI 10.1001/jama.289.3.313; MELAMED MR, 1984, CHEST, V86, P44, DOI 10.1378/chest.86.1.44; Mulshine JL, 2002, THORAX, V57, P1071, DOI 10.1136/thorax.57.12.1071; Patz EF, 2000, CHEST, V117, P1568, DOI 10.1378/chest.117.6.1568; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; ROMANO PS, 1992, CHEST, V101, P1332, DOI 10.1378/chest.101.5.1332; Sobue T, 2002, J CLIN ONCOL, V20, P911, DOI 10.1200/JCO.2002.20.4.911; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Stanley RJ, 2001, AM J ROENTGENOL, V177, P989, DOI 10.2214/ajr.177.5.1770989; Swensen SJ, 2003, RADIOLOGY, V226, P756, DOI 10.1148/radiol.2263020036; Swensen SJ, 2003, BRIT MED J, V326, P894, DOI 10.1136/bmj.326.7395.894; Swensen SJ, 2002, AM J RESP CRIT CARE, V165, P508, DOI 10.1164/ajrccm.165.4.2107006; Swensen SJ, 2000, RADIOLOGY, V214, P73, DOI 10.1148/radiology.214.1.r00ja1473; TOCKMAN MS, 1986, CHEST, V89, pS324, DOI 10.1378/chest.89.4_Supplement.324S-a; Watanabe S, 2002, ANN THORAC SURG, V73, P1071, DOI 10.1016/S0003-4975(01)03623-2	30	351	371	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					593	597		10.1016/S0140-6736(03)14188-8	http://dx.doi.org/10.1016/S0140-6736(03)14188-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944057				2022-12-28	WOS:000184904100006
J	Wong, J; Krisch, M; Farber, DL; Occelli, F; Schwartz, AJ; Chiang, TC; Wall, M; Boro, C; Xu, RQ				Wong, J; Krisch, M; Farber, DL; Occelli, F; Schwartz, AJ; Chiang, TC; Wall, M; Boro, C; Xu, RQ			Phonon dispersions of fcc delta-plutonium-gallium by inelastic X-ray scattering	SCIENCE			English	Article							CRYSTAL STRUCTURE; DYNAMICS; LATTICE	We report an experimental determination of the phonon dispersion curves in a face-centered cubic (fcc) delta-plutonium-0.6 weight % gallium alloy. Several unusual features, including a large elastic anisotropy, a small-shear elastic modulus C', a Kohn-like anomaly in the T-1[011] branch, and a pronounced softening of the [111] transverse modes, are found. These features can be related to the phase transitions of plutonium and to strong coupling between the lattice structure and the 5f valence instabilities. Our results also provide a critical test for theoretical treatments of highly correlated 5f electron systems as exemplified by recent dynamical mean field theory calculations for delta-plutonium.	Lawrence Livermore Natl Lab, Livermore, CA 94551 USA; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; European Synchrotron Radiation Facility (ESRF); University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wong, J (corresponding author), Lawrence Livermore Natl Lab, POB 808, Livermore, CA 94551 USA.	wong10@llnl.gov	Krisch, Michael H/U-5662-2018; Xu, Ruqing/K-3586-2012; Farber, Daniel L/F-9237-2011; Chiang, Tai C/H-5528-2011	Krisch, Michael H/0000-0001-7423-1715; Xu, Ruqing/0000-0003-1037-0059; 				Born M., 1954, DYNAMICAL THEORY CRY; Burkel E, 2000, REP PROG PHYS, V63, P171, DOI 10.1088/0034-4885/63/2/203; Cooper N.G, 2000, LOS ALAMOS SCI, V26; d'Astuto M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.167002; Dai X, 2003, SCIENCE, V300, P953, DOI 10.1126/science.1083428; GSCHNEIDNER KA, 1962, J PHYS CHEM SOLIDS, V23, P1191, DOI 10.1016/0022-3697(62)90166-X; Heathman S, 2000, PHYS REV LETT, V85, P2961, DOI 10.1103/PhysRevLett.85.2961; HECKER S.S., 2000, LOS ALAMOS SCI, V26, P244; HECKER S.S., 2000, CHALLENGES PLUTONIUM, V26, P290; Jeanloz R, 2000, PHYS TODAY, V53, P44, DOI 10.1063/1.1341914; Lashley JC, 2001, SCRIPTA MATER, V44, P2815, DOI 10.1016/S1359-6462(01)00979-4; LEDBETTER HM, 1976, ACTA METALL MATER, V24, P891, DOI 10.1016/0001-6160(76)90037-7; Manley ME, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.052302; Orme J.T., 1976, PLUTONIUM 1975 OTHER, P761; REESE RA, 1973, PHYS REV B, V8, P1332, DOI 10.1103/PhysRevB.8.1332; Requardt H, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.214303; Savrasov SY, 2001, NATURE, V410, P793, DOI 10.1038/35071035; STASSIS C, 1979, PHYS REV B, V19, P5746, DOI 10.1103/PhysRevB.19.5746; STASSIS C, 1982, PHYS REV B, V26, P5426, DOI 10.1103/PhysRevB.26.5426; STASSIS C, 1982, PHYS REV B, V25, P6485, DOI 10.1103/PhysRevB.25.6485; STEDMAN R, 1966, PHYS REV, V145, P492, DOI 10.1103/PhysRev.145.492; ZACHARIASEN WH, 1955, ACTA CRYSTALLOGR, V8, P431, DOI 10.1107/S0365110X55001357; ZACHARIASEN WH, 1963, ACTA CRYSTALLOGR, V16, P777, DOI 10.1107/S0365110X63002012	23	143	144	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1078	1080		10.1126/science.1087179	http://dx.doi.org/10.1126/science.1087179			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934002				2022-12-28	WOS:000184872400034
J	Bourlat, SJ; Nielsen, C; Lockyer, AE; Littlewood, DTJ; Telford, MJ				Bourlat, SJ; Nielsen, C; Lockyer, AE; Littlewood, DTJ; Telford, MJ			Xenoturbella is a deuterostome that eats molluscs	NATURE			English	Article							PHYLUM UNCERTAIN; BOCKI; PLATYHELMINTHES; FLATWORMS; SEQUENCE; SUPPORT	Xenoturbella bocki, first described in 1949 (ref. 1), is a delicate, ciliated, marine worm with a simple body plan: it lacks a through gut, organized gonads, excretory structures and coelomic cavities. Its nervous system is a diffuse nerve net with no brain. Xenoturbella's affinities have long been obscure and it was initially linked to turbellarian flatworms(1). Subsequent authors considered it variously as related to hemichordates and echinoderms owing to similarities of nerve net and epidermal ultrastructure (2,3), to acoelomorph flatworms based on body plan and ciliary ultrastructure(4-6) (also shared by hemichordates(7)), or as among the most primitive of Bilateria(8). In 1997 two papers seemed to solve this uncertainty: molecular phylogenetic analyses(9) placed Xenoturbella within the bivalve molluscs, and eggs and larvae resembling those of bivalves were found within specimens of Xenoturbella(10,11). This molluscan origin implies that all bivalve characters are lost during a radical metamorphosis into the adult Xenoturbella. Here, using data from three genes, we show that the samples in these studies were contaminated by bivalve embryos eaten by Xenoturbella and that Xenoturbella is in fact a deuterostome related to hemichordates and echinoderms.	Univ Cambridge, Dept Zool, Museum Zool, Cambridge CB2 3EJ, England; Univ Copenhagen, Zool Museum, DK-2100 Copenhagen, Denmark; Nat Hist Museum, Dept Zool, London SW7 5BD, England	University of Cambridge; University of Copenhagen; Natural History Museum London	Telford, MJ (corresponding author), Univ Cambridge, Dept Zool, Museum Zool, Downing St, Cambridge CB2 3EJ, England.		Lockyer, Anne/AAO-4327-2021; Nielsen, Claus/A-4794-2013; Bourlat, Sarah/AAR-2251-2020; Telford, Maximilian J/B-7178-2008; Littlewood, Tim/B-5230-2008; Bourlat, Sarah/A-5232-2009	Telford, Maximilian J/0000-0002-3749-5620; Littlewood, Tim/0000-0002-2718-4001; Bourlat, Sarah/0000-0003-0218-0298; Nielsen, Claus/0000-0001-6898-7655; Lockyer, Anne/0000-0002-3498-2423				Castresana J, 1998, P NATL ACAD SCI USA, V95, P3703, DOI 10.1073/pnas.95.7.3703; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Ehlers U, 1997, ZOOMORPHOLOGY, V117, P71; FRANZEN A, 1987, ZOOL SCR, V16, P9, DOI 10.1111/j.1463-6409.1987.tb00046.x; Gee H., 1996, BACKBONE VIEWS ORIGI; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Israelsson O, 1999, P ROY SOC B-BIOL SCI, V266, P835, DOI 10.1098/rspb.1999.0713; Israelsson O, 1997, NATURE, V390, P32, DOI 10.1038/36246; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Lundin K, 1998, ZOOL SCR, V27, P263, DOI 10.1111/j.1463-6409.1998.tb00440.x; Lundin K, 2001, BELG J ZOOL, V131, P153; Maddison D. R., 2000, MACCLADE 4 ANAL PHYL; Noren M, 1997, NATURE, V390, P31, DOI 10.1038/36242; PARDOS F, 1988, ACTA ZOOL-STOCKHOLM, V69, P1, DOI 10.1111/j.1463-6395.1988.tb00895.x; PEDERSEN KJ, 1986, ACTA ZOOL-STOCKHOLM, V67, P103, DOI 10.1111/j.1463-6395.1986.tb00854.x; REISINGER ERICH, 1960, ZEITSCHR WISS ZOOL, V164, P188; Swofford DL, 1998, PHYLOGENETIC ANAL US; Telford MJ, 2003, P ROY SOC B-BIOL SCI, V270, P1077, DOI 10.1098/rspb.2003.2342; Telford MJ, 2000, P NATL ACAD SCI USA, V97, P11359, DOI 10.1073/pnas.97.21.11359; Westblad E., 1949, ARK ZOOL, V1, P3	21	128	131	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					925	928		10.1038/nature01851	http://dx.doi.org/10.1038/nature01851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931184				2022-12-28	WOS:000184843600037
J	Sugiura, R; Kita, A; Shimizu, Y; Shuntoh, H; Sio, SO; Kuno, T				Sugiura, R; Kita, A; Shimizu, Y; Shuntoh, H; Sio, SO; Kuno, T			Feedback regulation of MAPK signalling by an RNA-binding protein	NATURE			English	Article							FISSION YEAST; KH-DOMAIN; IN-VIVO; KINASE; PHOSPHATASE; PATHWAYS; ENCODES; STRESS; POMBE	Mitogen-activated protein kinases (MAPKs) are evolutionarily conserved enzymes that convert extracellular signals into various outputs such as cell growth, differentiation and cell death(1-4). MAPK phosphatases selectively inactivate MAPKs by dephosphorylating critical phosphothreonine and phosphotyrosine residues(5,6). The transcriptional induction of MAPK phosphatase expression by various stimuli, including MAPK activation, has been well documented as a negative-feedback mechanism of MAPK signalling(7,8). Here we show that Rnc1, a novel K-homology-type RNA-binding protein in fission yeast, binds and stabilizes Pmp1 messenger RNA(9), the MAPK phosphatase for Pmk1 (refs 10, 11). Rnc1 therefore acts as a negative regulator of Pmk1 signalling. Notably, Pmk1 phosphorylates Rnc1, causing enhancement of the RNA-binding activity of Rnc1. Thus, Rnc1 is a component of a new negative-feedback loop that regulates the Pmk1 pathway through its binding to Pmp1 mRNA. Our findings-the post-transcriptional mRNA stabilization of a MAPK phosphatase mediated by an RNA-binding protein-provide an additional regulatory mechanism for fine-tuning of MAPK signalling pathways.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom, Kobe, Hyogo 6500017, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6540142, Japan	Kobe University; Kobe University	Sugiura, R (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom, Kobe, Hyogo 6500017, Japan.							Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOHRER K, 1988, NUCLEIC ACIDS RES, V6, P9457; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Loewith R, 2000, J CELL SCI, V113, P153; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Toda T, 1996, MOL CELL BIOL, V16, P6752; YOSHIDA T, 1994, J CELL SCI, V107, P1725; ZaitsevskayaCarter T, 1997, EMBO J, V16, P1318, DOI 10.1093/emboj/16.6.1318	24	57	61	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					961	965		10.1038/nature01907	http://dx.doi.org/10.1038/nature01907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931193				2022-12-28	WOS:000184843600046
J	Kivimaki, M; Head, J; Ferrie, JE; Shipley, MJ; Vahtera, J; Marmot, MG				Kivimaki, M; Head, J; Ferrie, JE; Shipley, MJ; Vahtera, J; Marmot, MG			Sickness absence as a global measure of health: evidence from mortality in the Whitehall II prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							BRITISH CIVIL-SERVANTS; SELF-RATED HEALTH; MIDDLE-AGED MEN; SOCIAL SUPPORT; DEATH; DISABILITY	Objective To examine the association between sickness absence and mortality compared with associations between established health indicators and mortality. Design Prospective cohort study. Medical examination and questionnaire survey conducted in 1985-8; sickness absence records covered the period 1985-98. Setting 20 civil service departments in London. Participants 6895 male and 3413 female civil servants aged 35-55 years. Main outcome measure All cause mortality until the end of 1999. Results After adjustment for age and grade, men and women who had more than five medically certified absences (spells >7 days) per 10 years had a mortality 4.8 (95% confidence interval 3.3 to 6.9) and 2.7 (1.5 to 4.9) times greater than those with no such absence. Poor self rated health, presence of longstanding illness, and a measure of common clinical conditions comprising diabetes, diagnosed heart disease, abnormalities on electrocardiogram, hypertension, and respiratory illness were all associated with mortality-relative rates between 1.3 and 1.9. In a multivariate model including all the above health indicators and additional health risk factors, medically certified sickness absence remained a significant predictor of mortality. No linear association existed between self certified absence (spells 1-7 days) and mortality, but the findings suggest that a small amount of self certified absence is protective. Conclusion Evidence linking sickness absence to mortality indicates that routinely collected sickness absence data could be used as a global measure of health differentials between employees. However, such approaches should focus on medically certified (or long term) absences rather than self certified absences.	Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; UCL, Sch Med, Dept Epidemiol & Publ Hlth, Int Ctr Hlth & Soc, London WC1E 6BT, England	Finnish Institute of Occupational Health; University of London; University College London; UCL Medical School	Kivimaki, M (corresponding author), Finnish Inst Occupat Hlth, Topeliuksenkatu 41 aA, FIN-00250 Helsinki, Finland.	mika.kivimaki@ttl.fi	Head, Jenny/GYA-2625-2022; Marmot, M G/Y-3920-2019; Kivimaki, Mika/B-3607-2012; Vahtera, Jussi/J-3271-2013; Ferrie, Jane/AAZ-2009-2020	Marmot, M G/0000-0002-2431-6419; Kivimaki, Mika/0000-0002-4699-5627; Head, Jennifer/0000-0002-6054-0872	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013196, R37AG013196] Funding Source: NIH RePORTER; AHRQ HHS [HS06516] Funding Source: Medline; Medical Research Council [G0100222, G19/35, G8802774] Funding Source: Medline; NHLBI NIH HHS [HL36310] Funding Source: Medline; NIA NIH HHS [AG13196] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ferrie J E, 2001, J Occup Health Psychol, V6, P26, DOI 10.1037/1076-8998.6.1.26; FOLGER R, 1985, RES ORGAN BEHAV, V7, P129; HEINRICH J, 2002, ANN EPIDEMIOL, V12, P338; Heistaro S, 2001, J EPIDEMIOL COMMUN H, V55, P227, DOI 10.1136/jech.55.4.227; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Kivimaki M, 1998, PSYCHOL MED, V28, P903, DOI 10.1017/S003329179800659X; Kivimaki M, 2002, BMJ-BRIT MED J, V325, P357; KRISTENSEN TS, 1991, SOC SCI MED, V32, P15, DOI 10.1016/0277-9536(91)90122-S; Mansson NO, 2001, SCAND J PUBLIC HEALT, V29, P151, DOI 10.1177/14034948010290020201; MARMOT M, 1995, J EPIDEMIOL COMMUN H, V49, P124, DOI 10.1136/jech.49.2.124; MARMOT MG, 1993, ADDICTION, V88, P369, DOI 10.1111/j.1360-0443.1993.tb00824.x; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Miller TQ, 1996, PSYCHOL BULL, V119, P322, DOI 10.1037/0033-2909.119.2.322; NORTH F, 1993, BRIT MED J, V306, P361, DOI 10.1136/bmj.306.6874.361; North FM, 1996, AM J PUBLIC HEALTH, V86, P332, DOI 10.2105/AJPH.86.3.332; PRINS R, 1986, BRIT J IND MED, V43, P529; RAEL EGS, 1995, J EPIDEMIOL COMMUN H, V49, P474, DOI 10.1136/jech.49.5.474; ROSE G, 1977, LANCET, V1, P105; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Stansfeld S, 1999, INT J LAW PSYCHIAT, V22, P425, DOI 10.1016/S0160-2527(99)00019-9; Stansfeld SA, 1997, PSYCHOL MED, V27, P35, DOI 10.1017/S0033291796004254; TAYLOR PJ, 1976, BRIT J IND MED, V33, P230; Vahtera J, 1997, LANCET, V350, P1124, DOI 10.1016/S0140-6736(97)03216-9; VAHTERA J, IN PRESS J EPIDEMIOL	24	319	323	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					364	368		10.1136/bmj.327.7411.364	http://dx.doi.org/10.1136/bmj.327.7411.364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	713NJ	12919985	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000184864200015
J	KewalRamani, VN; Coffin, JM				KewalRamani, VN; Coffin, JM			Weapons of mutational destruction	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; VIRAL VIF PROTEIN; REVERSE TRANSCRIPTION; G->A HYPERMUTATION; HIV-1 VIRIONS; TYPE-1 VIF; SOR GENE; DNA; REPLICATION; INFECTION		NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA; Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts University	KewalRamani, VN (corresponding author), NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA.		KewalRamani, Vineet/V-5084-2019		NATIONAL CANCER INSTITUTE [ZIABC010487, Z01BC010487] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; Fouchier RAM, 1996, J VIROL, V70, P8263, DOI 10.1128/JVI.70.12.8263-8269.1996; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Gunther S, 1997, VIROLOGY, V235, P104, DOI 10.1006/viro.1997.8676; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Klarmann GJ, 2003, J BIOL CHEM, V278, P7902, DOI 10.1074/jbc.M207223200; Korth MJ, 2000, CURR TOP MICROBIOL, V242, P197; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Ochsenbauer C, 1997, J GEN VIROL, V78, P627, DOI 10.1099/0022-1317-78-3-627; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; SIMON JHM, 1995, J VIROL, V69, P4166, DOI 10.1128/JVI.69.7.4166-4172.1995; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Simon JHM, 1998, EMBO J, V17, P1259, DOI 10.1093/emboj/17.5.1259; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; Vartanian JP, 2002, J GEN VIROL, V83, P801, DOI 10.1099/0022-1317-83-4-801; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WAINHOBSON S, 1995, VIROLOGY, V209, P297, DOI 10.1006/viro.1995.1261; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	29	29	31	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					923	925		10.1126/science.1088965	http://dx.doi.org/10.1126/science.1088965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920286	Green Published			2022-12-28	WOS:000184755900023
J	Bala, ADS; Spitzer, MW; Takahashi, TT				Bala, ADS; Spitzer, MW; Takahashi, TT			Prediction of auditory spatial acuity from neural images on the owl's auditory space map	NATURE			English	Article							INTERAURAL TIME DIFFERENCE; SOUND-LOCALIZATION; SINGLE NEURONS; BARN OWL; PSYCHOPHYSICAL PERFORMANCE; PERCEPTUAL DECISION; RECEPTIVE-FIELDS; MACAQUE MONKEY; VISUAL-MOTION; DISCRIMINATION	The owl can discriminate changes in the location of sound sources as small as 3degrees and can aim its head to within 2degrees of a source(1,2). Atypical neuron in its midbrain space map has a spatial receptive field that spans 40degrees- a width that is many times the behavioural threshold(3). Here we have quantitatively examined the relationship between neuronal activity and perceptual acuity in the auditory space map in the barn owl midbrain. By analysing changes in firing rate resulting from small changes of stimulus azimuth, we show that most neurons can reliably signal changes in source location that are smaller than the behavioural threshold. Each source is represented in the space map by a focus of activity in a population of neurons. Displacement of the source causes the pattern of activity in this population to change. We show that this change predicts the owl's ability to detect a change in source location.	Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of Oregon	Bala, ADS (corresponding author), Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.		Bala, Avinash/B-7923-2013	Bala, Avinash/0000-0002-8531-5110				AHISSAR M, 1992, J NEUROPHYSIOL, V67, P203, DOI 10.1152/jn.1992.67.1.203; [Anonymous], 1998, NEURAL NETWORKS BRAI; Bala ADS, 2000, J COMP PHYSIOL A, V186, P425, DOI 10.1007/s003590050442; BALDI P, 1988, BIOL CYBERN, V59, P313, DOI 10.1007/BF00332921; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; Bell CC, 2001, CURR OPIN NEUROBIOL, V11, P481, DOI 10.1016/S0959-4388(00)00238-5; Britten KH, 1999, J NEUROSCI, V19, P5074; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; COLBURN HS, 1973, J ACOUST SOC AM, V54, P1458, DOI 10.1121/1.1914445; Eurich CW, 1997, BIOL CYBERN, V76, P357, DOI 10.1007/s004220050349; FAREL PB, 1976, J NEUROPHYSIOL, V39, P661, DOI 10.1152/jn.1976.39.4.661; Fitzpatrick DC, 1997, NATURE, V388, P871, DOI 10.1038/42246; FUJITA I, 1991, J NEUROSCI, V11, P722; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Gold JI, 2000, NATURE, V404, P390, DOI 10.1038/35006062; HALL JL, 1965, J ACOUST SOC AM, V37, P813; Kandel E R, 1976, Cold Spring Harb Symp Quant Biol, V40, P465; Keller CH, 1998, HEARING RES, V118, P13, DOI 10.1016/S0378-5955(98)00014-8; KNUDSEN EI, 1977, SCIENCE, V198, P1278, DOI 10.1126/science.929202; KNUDSEN EI, 1979, J COMP PHYSIOL, V133, P13, DOI 10.1007/BF00663106; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; O'Reilly RC, 2002, TRENDS COGN SCI, V6, P505, DOI 10.1016/S1364-6613(02)02005-3; Recanzone GH, 2000, J NEUROPHYSIOL, V83, P2723, DOI 10.1152/jn.2000.83.5.2723; ROLLS ET, 1989, EUR J NEUROSCI, V1, P53, DOI 10.1111/j.1460-9568.1989.tb00774.x; SAKITT B, 1973, NATURE, V241, P133, DOI 10.1038/241133a0; Shackleton TM, 2003, J NEUROSCI, V23, P716, DOI 10.1523/JNEUROSCI.23-02-00716.2003; Shadlen MN, 1996, J NEUROSCI, V16, P1486; Siebert WM., 1968, RECOGNIZING PATTERNS, V104, P602; SOKOLOV EN, 1963, ANNU REV PHYSIOL, V25, P545, DOI 10.1146/annurev.ph.25.030163.002553; ZOHARY E, 1994, NATURE, V370, P140, DOI 10.1038/370140a0	30	76	76	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					771	774		10.1038/nature01835	http://dx.doi.org/10.1038/nature01835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917684				2022-12-28	WOS:000184733900039
J	Banks, R; Selby, P				Banks, R; Selby, P			Clinical proteomics - insights into pathologies and benefits for patients	LANCET			English	Editorial Material							MASS-SPECTROMETRY; PROTEIN EXPRESSION; CANCER; TECHNOLOGIES; CELLS		St James Univ Hosp, Ctr Res UK Clin Ctr Leeds, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital	Banks, R (corresponding author), St James Univ Hosp, Ctr Res UK Clin Ctr Leeds, Leeds LS9 7TF, W Yorkshire, England.			Banks, Rosamonde/0000-0002-0042-8715				Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; Cazares LH, 2002, CLIN CANCER RES, V8, P2541; Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X; Paweletz CP, 2000, DRUG DEVELOP RES, V49, P34, DOI 10.1002/(SICI)1098-2299(200001)49:1<34::AID-DDR6>3.3.CO;2-N; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Petricoin EF, 2002, NAT GENET, V32, P474, DOI 10.1038/ng1029; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; von Eggeling F, 2000, BIOTECHNIQUES, V29, P1066; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wilkins MR, 1996, BIOTECHNOL GENET ENG, V13, P19, DOI 10.1080/02648725.1996.10647923; Xu BGJ, 2002, J AM SOC MASS SPECTR, V13, P1292, DOI 10.1016/S1044-0305(02)00644-X; Zhukov TA, 2003, LUNG CANCER, V40, P267, DOI 10.1016/S0169-5002(03)00082-5	13	18	18	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					415	416		10.1016/S0140-6736(03)14096-2	http://dx.doi.org/10.1016/S0140-6736(03)14096-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927423				2022-12-28	WOS:000184651100003
J	Becker, BJ				Becker, BJ			Celestial spectroscopy: Making reality fit the myth	SCIENCE			English	Editorial Material									Univ Calif Irvine, Dept Hist, Irvine, CA 92697 USA	University of California System; University of California Irvine	Becker, BJ (corresponding author), Univ Calif Irvine, Dept Hist, 200 Krieger Hall, Irvine, CA 92697 USA.							CLERKE A, 1887, POPULAR HIST ASTRONO, P180; COMTE A, 1864, COURS PHILOS POSITIV, V2, P6; De la Rue W, 1861, CHEM NEWS, V4, P130; Fraunhofer J., 1827, EDINBURGH J SCI, V7, P101; FRAUNHOFER J, 1828, EDINBURGH J SCI, V8, P7; Fraunhofer J., 1827, EDINBURGH J SCI, V7, P251; Huggins William, 1897, 19 CENTURY MONTHLY R, V41, P907; KIRCHHOFF G, 1860, PHILOS MAG, V21, P196; ROSCOE HE, 1860, COMMUNICATION   0224; SCHELLEN H, 1872, SPECTRUM ANAL ITS AP, P466	10	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1332	1333		10.1126/science.1085135	http://dx.doi.org/10.1126/science.1085135			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958346				2022-12-28	WOS:000185116400023
J	Clack, JA; Ahlberg, PE; Finney, SM; Alonso, PD; Robinson, J; Ketcham, RA				Clack, JA; Ahlberg, PE; Finney, SM; Alonso, PD; Robinson, J; Ketcham, RA			A uniquely specialized ear in a very early tetrapod	NATURE			English	Article							PHOLIDERPETON-SCUTIGERUM HUXLEY; EARLY EVOLUTION; COAL MEASURES; ACANTHOSTEGA; AMPHIBIANS; STAPES; FOSSIL	The Late Devonian genus Ichthyostega was for many decades the earliest known tetrapod, and the sole representative of a transitional form between a fish and a land vertebrate. However, despite being known since 1932 (ref. 1) from a large collection of specimens, its morphology remained enigmatic and not what was expected of a very primitive tetrapod(2). Its apparent specializations led it to be considered as a "blind offshoot"(3) or "side-branch"(4) off the tetrapod family tree, and recent cladistic analyses have disagreed about its exact phylogenetic position(5-8) within the tetrapod stem group. In particular, its braincase and ear region defied interpretation, such that conventional anatomical terms seemed inapplicable(4). Using new material collected in 1998 (ref. 9), preparation of earlier-collected material, and high-resolution computed tomography scanning, here we identify and interpret these problematic anatomical structures. They can now be seen to form part of a highly specialized ear, probably a hearing device for use in water. This represents a structurally and functionally unique modification of the tetrapod otic region, unlike anything seen in subsequent tetrapod evolution. The presence of deeply grooved gill bars as in its contemporary Acanthostega(10) suggest that Ichthyostega may have been more aquatically adapted than previously believed.	Univ Museum Zool, Cambridge CB2 3EJ, England; Nat Hist Museum, Dept Palaeontol, London SW7 5BD, England; Univ Texas, Dept Geol Sci, High Resolut Xray CT Facil, Austin, TX 78712 USA	University of Cambridge; Natural History Museum London; University of Texas System; University of Texas Austin	Clack, JA (corresponding author), Univ Museum Zool, Downing St, Cambridge CB2 3EJ, England.	j.a.clack@zoo.cam.ac.uk	Ketcham, Richard/B-5431-2011; Ahlberg, Per/E-8086-2013; Domínguez Alonso, Patricio/C-2679-2013	Ketcham, Richard/0000-0002-2748-0409; Ahlberg, Per/0000-0001-9054-2900				Ahlberg PE, 1998, T ROY SOC EDIN-EARTH, V89, P11, DOI 10.1017/S0263593300002340; Ahlberg PE, 1996, NATURE, V381, P61, DOI 10.1038/381061a0; BERNACSEK GM, 1981, CAN J EARTH SCI, V18, P150, DOI 10.1139/e81-012; CLACK JA, 1987, PHILOS T ROY SOC B, V318, P1, DOI 10.1098/rstb.1987.0082; Clack JA, 1998, ZOOL J LINN SOC-LOND, V122, P61, DOI 10.1006/zjls.1997.0114; CLACK JA, 1983, ZOOL J LINN SOC-LOND, V79, P121, DOI 10.1111/j.1096-3642.1983.tb01163.x; Clack JA, 2002, J NEUROBIOL, V53, P251, DOI 10.1002/neu.10129; Clack JA, 2002, NATURE, V418, P72, DOI 10.1038/nature00824; Clack JA, 2000, GEOL SOC SPEC PUBL, V180, P557, DOI 10.1144/GSL.SP.2000.180.01.29; COATES MI, 1991, NATURE, V352, P234, DOI 10.1038/352234a0; Dominguez P, 2002, NATURE, V417, P841, DOI 10.1038/nature00805; HETHERINGTON TE, 1982, J EXP BIOL, V98, P49; Jarvik E., 1952, Meddelelser om Gronland, V114, P1; Jarvik E., 1980, BASIC STRUCTURE EVOL, V1; Jarvik Erik, 1996, Fossils and Strata, V40, P1; Ketcham RA, 2001, COMPUT GEOSCI-UK, V27, P381, DOI 10.1016/S0098-3004(00)00116-3; Laurin M, 1998, ANN SCI NAT ZOOL, V19, P1, DOI 10.1016/S0003-4339(98)80132-9; Ruta M, 2003, BIOL REV, V78, P251, DOI 10.1017/S1464793102006103; Save-Soderbergh G., 1932, Medd Grenland, V94 T, P1; SMITHSON TR, 1982, ZOOL J LINN SOC-LOND, V74, P93, DOI 10.1111/j.1096-3642.1982.tb01142.x; SMITHSON TR, 1982, ZOOL J LINN SOC-LOND, V76, P29, DOI 10.1111/j.1096-3642.1982.tb01955.x; Yan HY, 2000, J COMP PHYSIOL A, V186, P435, DOI 10.1007/s003590050443	22	80	82	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					65	69		10.1038/nature01904	http://dx.doi.org/10.1038/nature01904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955140				2022-12-28	WOS:000185089200037
J	Ghosh, S; Rosenbaum, TF; Aeppli, G; Coppersmith, SN				Ghosh, S; Rosenbaum, TF; Aeppli, G; Coppersmith, SN			Entangled quantum state of magnetic dipoles	NATURE			English	Article							ANTI-FERROMAGNETIC CHAIN; ISING SPIN CHAINS; CRITICAL-BEHAVIOR; RELAXATION; TRANSITION; LIERF4; LIHOF4	Free magnetic moments usually manifest themselves in Curie laws, where weak external magnetic fields produce magnetizations that vary as the reciprocal of the temperature (1/T). For a variety of materials that do not display static magnetism, including doped semiconductors(1) and certain rare-earth intermetallics(2), the 1/T law is replaced by a power law T(-alpha) with alpha < 1. Here we show that a much simpler material system-namely, the insulating magnetic salt LiHo(x)Y(1-x)F(4)-can also display such a power law. Moreover, by comparing the results of numerical simulations of this system with susceptibility and specific-heat data(3), we show that both energy-level splitting and quantum entanglement are crucial to describing its behaviour. The second of these quantum mechanical effects-entanglement, where the wavefunction of a system with several degrees of freedom cannot be written as a product of wavefunctions for each degree of freedom-becomes visible for remarkably small tunnelling terms, and is activated well before tunnelling has visible effects on the spectrum. This finding is significant because it shows that entanglement, rather than energy-level redistribution, can underlie the magnetic behaviour of a simple insulating quantum spin system.	Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA; UCL, London Ctr Nanotechnol, London WC1E 6BT, England; UCL, Dept Phys & Astron, London WC1E 6BT, England; NEC Labs, Princeton, NJ 08540 USA; Univ Wisconsin, Dept Phys, Madison, WI 53706 USA	University of Chicago; University of Chicago; University of London; University College London; University of London; University College London; NEC Corporation; University of Wisconsin System; University of Wisconsin Madison	Rosenbaum, TF (corresponding author), Univ Chicago, James Franck Inst, 5640 S Ellis Ave, Chicago, IL 60637 USA.	t-rosenbaum@uchicago.edu	Coppersmith, Susan N/I-9685-2018	Coppersmith, Susan N/0000-0002-5630-4893				Arnesen MC, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.017901; BHATT RN, 1982, PHYS REV LETT, V48, P344, DOI 10.1103/PhysRevLett.48.344; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; DASGUPTA C, 1980, PHYS REV B, V22, P1305, DOI 10.1103/PhysRevB.22.1305; FISHER DS, 1992, PHYS REV LETT, V69, P534, DOI 10.1103/PhysRevLett.69.534; FISHER DS, 1995, PHYS REV B, V51, P6411, DOI 10.1103/PhysRevB.51.6411; Ghosh S, 2002, SCIENCE, V296, P2195, DOI 10.1126/science.1070731; Gunlycke D, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.042302; HANSEN PE, 1975, PHYS REV B, V12, P5315, DOI 10.1103/PhysRevB.12.5315; MA SK, 1979, PHYS REV LETT, V43, P1434, DOI 10.1103/PhysRevLett.43.1434; MAGARINO J, 1980, PHYS REV B, V21, P18, DOI 10.1103/PhysRevB.21.18; Osborne TJ, 2002, QUANTUM INF PROCESS, V1, P45, DOI 10.1023/A:1019601218492; Osterloh A, 2002, NATURE, V416, P608, DOI 10.1038/416608a; PAALANEN MA, 1985, PHYS REV LETT, V54, P1295, DOI 10.1103/PhysRevLett.54.1295; PHILLIPS P, 1988, PHYS REV B, V37, P10876, DOI 10.1103/PhysRevB.37.10876; REICH DH, 1987, PHYS REV LETT, V59, P1969, DOI 10.1103/PhysRevLett.59.1969; REICH DH, 1990, PHYS REV B, V42, P4631, DOI 10.1103/PhysRevB.42.4631; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; STEPHEN MJ, 1981, J PHYS C SOLID STATE, V14, P1665, DOI 10.1088/0022-3719/14/11/026; VANVLECK JH, 1978, REV MOD PHYS, V50, P181, DOI 10.1103/RevModPhys.50.181; WESTERBERG E, 1995, PHYS REV LETT, V75, P4302, DOI 10.1103/PhysRevLett.75.4302; Wootters WK, 1998, PHYS REV LETT, V80, P2245, DOI 10.1103/PhysRevLett.80.2245	22	281	287	2	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					48	51		10.1038/nature01888	http://dx.doi.org/10.1038/nature01888			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955135	Green Submitted			2022-12-28	WOS:000185089200032
J	Guerin, PJ; Brasher, C; Baron, E; Mic, D; Grimont, F; Ryan, M; Aavitsland, P; Legros, D				Guerin, PJ; Brasher, C; Baron, E; Mic, D; Grimont, F; Ryan, M; Aavitsland, P; Legros, D			Shigella dysenteriae serotype 1 in west Africa: intervention strategy for an outbreak in Sierra Leone	LANCET			English	Article							FLUOROQUINOLONES	In November 1999, a Medecins Sans Frontieres team based in the southeastern part of Sierra Leone reported an increased number of cases of bloody diarrhoea. Shigella dysenteriae serotype 1 (Sd1) was isolated in the early cases. A total of 4218 cases of dysentery were reported in Kenema district from December, 1999, to March, 2000. The overall attack rate was 7-5%. The attack rate was higher among children younger than 5 years than in the rest of the population (11.2% vs 6.8%; relative risk=1.6; 95% CI 1.5-1.8). The case fatality was 3.1%, also higher for children younger than 5 years (6.1% vs 2.1%; relative risk=2.9; 95% CI 2.1-4-1]). Among 583 patients regarded at increased risk of death who were treated with ciprofloxacin in isolation centres, case fatality was 0.9%. A 5-day ciprofloxacin regimen, targeted to the most severe cases of bloody diarrhoea, was highly effective. This is the first time a large outbreak caused by Sd1 has been reported in west Africa.	Epictr, F-75011 Paris, France; Norwegian Inst Publ Hlth, Div Infect Dis Control, Oslo, Norway; Med Sans Frontieres, Paris, France; Inst Pasteur, Ctr Natl Reference Escherichia Coli & Shigella, Paris, France; WHO, Global Alert & Response Team, Dept Surveillance & Response, Communicable Dis Cluster, CH-1211 Geneva, Switzerland; European Programme Intervent Epidemiol Training, Paris, France	Norwegian Institute of Public Health (NIPH); Doctors Without Borders; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; World Health Organization	Guerin, PJ (corresponding author), Epictr, F-75011 Paris, France.		Guerin, Philippe/AAH-8873-2021; Brasher, Chris/Y-4488-2019	Brasher, Chris/0000-0003-1037-3604; Guerin, Philippe/0000-0002-6008-2963				Bethell DB, 1996, ARCH DIS CHILD, V74, P44, DOI 10.1136/adc.74.1.44; Hooper DC, 2000, CLIN INFECT DIS, V31, pS24, DOI 10.1086/314056; KEUSCH GT, 1998, BACTERIAL INFECT HUM, P631; Legros D, 1999, TROP MED INT HEALTH, V4, P428, DOI 10.1046/j.1365-3156.1999.00413.x; RIES AA, 1994, J INFECT DIS, V169, P1035, DOI 10.1093/infdis/169.5.1035	5	35	38	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					705	706		10.1016/S0140-6736(03)14227-4	http://dx.doi.org/10.1016/S0140-6736(03)14227-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957094				2022-12-28	WOS:000185034800012
J	Ross, JR; Saunders, Y; Edmonds, PM; Patel, S; Broadley, KE; Johnston, SRD				Ross, JR; Saunders, Y; Edmonds, PM; Patel, S; Broadley, KE; Johnston, SRD			Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MECHANISMS; CLODRONATE; INHIBIT	Objective To review the evidence for the use of bisphosphonates to reduce skeletal morbidity in cancer patients with bone metastases. Data sources Electronic databases, scanning reference lists, and consultation with experts and pharmaceutical companies. Foreign language papers were included. Study selection Included trials were randomised controlled trials of patients with malignant disease and bone metastases who were treated with oral or intravenous bisphosphonate compared with another bisphosphonate, placebo, or standard care. All trials measured at least one outcome of skeletal morbidity. Results 95 articles were identified; 30 studies fulfilled inclusion criteria. In studies that lasted greater than or equal to6 months, compared with placebo bisphosphonates significantly reduced the odds ratio for fractures (vertebral 0.69, 95% confidence interval 0.57 to 0.84, P<0.0001; non-vertebral 0.65, 0.54 to 0.79, P<0.0001; combined 0.65, 0.55 to 0.78, P<0.0001), radiotherapy (0.67, 0.57 to 0.79, P<0.0001), and hypercalcaemia (0.54, 0.36 to 0.81, P=0.003) but not for orthopaedic surgery (0.70, 0.46 to 1.05, P=0.086) or spinal cord compression (0.71, 0.47 to 1.08, P=0.113). The reduction in orthopaedic surgery was significant in studies that lasted over a year (0.59, 0.39 to 0.88, P=0.009). Use of bisphosphonates significantly increased time to first skeletal related event but did not increase survival. Subanalyses showed that most evidence supports use of intravenous aminobisphosphonates. Conclusions In people with metastatic bone disease bisphosphonates significantly decrease skeletal morbidity, except for spinal cord compression and increased time to first skeletal related event. Treatment should start when bone metastases are diagnosed and continue until it is no longer clinically relevant.	Royal Marsden Hosp, Dept Palliat Med, London SW3 6JJ, England; Kings Coll London, Dept Palliat Care & Policy, London SE5 9RS, England; Inst Child Hlth, Systemat Reviews Training Unit, London WC1N 1EH, England; Royal Marsden Hosp, Dept Med, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; University of London; King's College London; University of London; University College London; Royal Marsden NHS Foundation Trust	Ross, JR (corresponding author), Royal Marsden Hosp, Dept Palliat Med, London SW3 6JJ, England.	joy.ross@talk21.com						Bishop HM, 1999, EUR J SURG ONCOL, V25, P4; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; DEARNALEY DP, 2001, J CLIN ONCOL ASCO, pA693; DJULBEGOVIC B, 2003, COCHRANE DB SYST REV; FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495-199141020-00009; Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80; FRANCIS MD, 1969, SCIENCE, V165, P1264, DOI 10.1126/science.165.3899.1264; GRILL V, 2001, REV ENDOCR METAB DIS, V1, P253; Healey John H., 2000, Cancer, V88, P2940, DOI 10.1002/1097-0142(20000615)88:12+<2940::AID-CNCR10>3.0.CO;2-W; Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158; MUNDY GR, 1990, CALCIUM HOMEOSTASIS, P100; PAVOAKIS N, 2003, COCHRANE DB SYST REV; Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080; Rogers MJ, 1999, BONE, V24, p73S, DOI 10.1016/S8756-3282(99)00070-8; ROSS JR, 2003, IN PRESS HLTH TECHNO; Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212; WONG R, 2003, COCHRANE DB SYST REV; YAKATAN GJ, 1982, CLIN PHARMACOL THER, V31, P402, DOI 10.1038/clpt.1982.51	21	145	160	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2003	327	7413					469	472		10.1136/bmj.327.7413.469	http://dx.doi.org/10.1136/bmj.327.7413.469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946966	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000185088900012
J	Shao, F; Golstein, C; Ade, J; Stoutemyer, M; Dixon, JE; Innes, RW				Shao, F; Golstein, C; Ade, J; Stoutemyer, M; Dixon, JE; Innes, RW			Cleavage of Arabidopsis PBS1 by a bacterial type III effector	SCIENCE			English	Article							DISEASE RESISTANCE GENE; RICE BLAST RESISTANCE; PSEUDOMONAS-SYRINGAE; AVIRULENCE GENE; YERSINIA EFFECTOR; PROTEINS; KINASE; RIN4; VIRULENCE; PROTEASE	Plant disease-resistance (R) proteins are thought to function as receptors for ligands produced directly or indirectly by pathogen avirulence (Avr) proteins. The biochemical functions of most Avr proteins are unknown, and the mechanisms by which they activate R proteins have not been determined. In Arabidopsis, resistance to Pseudomonas syringae strains expressing AvrPphB requires RPS5, a member of the class of R proteins that have a predicted nucleotide-binding site and leucine-rich repeats, and PBS1, a protein kinase. AvrPphB was found to proteolytically cleave PBS1, and this cleavage was required for RPS5-mediated resistance, which indicates that AvrPphB is detected indirectly via its enzymatic activity.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	Indiana University System; Indiana University Bloomington; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Innes, RW (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		Innes, Roger/A-5244-2010		NIDDK NIH HHS [DK18849] Funding Source: Medline; NIGMS NIH HHS [GM46451] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046451, R01GM046451] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold DL, 2001, MICROBIOL-SGM, V147, P1171, DOI 10.1099/00221287-147-5-1171; Axtell MJ, 2003, CELL, V112, P369, DOI 10.1016/S0092-8674(03)00036-9; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Deslandes L, 2003, P NATL ACAD SCI USA, V100, P8024, DOI 10.1073/pnas.1230660100; FLOR HH, 1955, PHYTOPATHOLOGY, V45, P680; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; Kjemtrup S, 2000, CURR OPIN MICROBIOL, V3, P73, DOI 10.1016/S1369-5274(99)00054-5; Kruger J, 2002, SCIENCE, V296, P744, DOI 10.1126/science.1069288; Mackey D, 2003, CELL, V112, P379, DOI 10.1016/S0092-8674(03)00040-0; Mackey D, 2002, CELL, V108, P743, DOI 10.1016/S0092-8674(02)00661-X; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Orbach MJ, 2000, PLANT CELL, V12, P2019, DOI 10.1105/tpc.12.11.2019; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Puri N, 1997, MOL PLANT MICROBE IN, V10, P247, DOI 10.1094/MPMI.1997.10.2.247; Rossi M, 1998, P NATL ACAD SCI USA, V95, P9750, DOI 10.1073/pnas.95.17.9750; Shao F, 2002, CELL, V109, P575, DOI 10.1016/S0092-8674(02)00766-3; SHAO F, UNPUB; Swiderski MR, 2001, PLANT J, V26, P101, DOI 10.1046/j.1365-313x.2001.01014.x; Tampakaki AP, 2002, MOL PLANT MICROBE IN, V15, P292, DOI 10.1094/MPMI.2002.15.3.292; Tornero P, 2002, PLANT CELL, V14, P1005, DOI 10.1105/tpc.001032; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; Warren RF, 1998, PLANT CELL, V10, P1439, DOI 10.1105/tpc.10.9.1439; Warren RF, 1999, GENETICS, V152, P401; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2	27	421	440	4	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1230	1233		10.1126/science.1085671	http://dx.doi.org/10.1126/science.1085671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947197				2022-12-28	WOS:000185003500040
J	Baglin, T; Luddington, R; Brown, K; Baglin, C				Baglin, T; Luddington, R; Brown, K; Baglin, C			Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study	LANCET			English	Article							ORAL ANTICOAGULANT-THERAPY; FACTOR-V-LEIDEN; THROMBOSIS; CARRIERS; EPISODE; HISTORY	Background Stratification for risk of recurrence after a first episode of venous thromboembolism (VTE) would affect the duration of anticoagulant therapy. We aimed to determine the incidence of recurrence of VTE in relation to clinical risk factors and standard laboratory testing for heritable thrombophilic defects. Methods We established a database to prospectively follow-up a cohort of unselected patients who had had a first episode of objectively proven VTE. We excluded patients with malignant disease and anti phospholipid syndrome. All patients were offered testing for heritable thrombophilia. Findings At 2 years, the cumulative recurrence rate in 570 patients was 11%. Incidence was lowest after surgery-related VTE (0%) and highest after unprecipitated VTE (19.4%) (p<0.001). 85% of patients were tested for heritable thrombophilic defects. Recurrence rates were not related to presence or absence of laboratory' evidence of heritable thrombophilia (hazard ratio 1.50 [95% CI 0.82-2.77]; p=0.187). In patients with a first event that was unprecipitated or was associated with a non-surgical trigger, recurrence rates did not differ in patients with or without thrombophilia (1.34 [0.73-2.46]; p=0.351). Interpretation In unselected patients who have had a first episode of VTE, testing for heritable thrombophilia does not allow prediction of recurrent VTE in the first 2 years after anticoagulant therapy is stopped. However, assessment of clinical risk factors associated with the first episode of VTE does predict risk of recurrence. Patients with postoperative VTE have a very low rate of recurrence.	Addenbrookes NHS Trust, Dept Haematol, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Baglin, C (corresponding author), Addenbrookes NHS Trust, Dept Haematol, Cambridge CB2 2QQ, England.	tpb20@cam.ac.uk						Baglin T, 2002, THROMB HAEMOSTASIS, V88, P700, DOI 10.1055/s-0037-1613286; BRIET E, 1994, BRIT J HAEMATOL, V87, P348, DOI 10.1111/j.1365-2141.1994.tb04920.x; *BRIT COMM STAND H, 1998, BRIT J HAEMATOL, V101, P374; Brown PO, 1998, MOL BIOL CELL, V9, p2A; Crowther MA, 2001, THROMB HAEMOSTASIS, V85, P390; Hansson PO, 2000, ARCH INTERN MED, V160, P769, DOI 10.1001/archinte.160.6.769; Hunt BJ, 2002, THROMB HAEMOSTASIS, V87, P918; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; LEE LH, 1994, J CLIN PATHOL, V47, P631, DOI 10.1136/jcp.47.7.631; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; Luddington R, 1999, THROMB RES, V96, P197, DOI 10.1016/S0049-3848(99)00096-1; Middeldorp S, 2001, ANN INTERN MED, V135, P322, DOI 10.7326/0003-4819-135-5-200109040-00008; PABINGER I, 1992, BLOOD COAGUL FIBRIN, V3, P547, DOI 10.1097/00001721-199210000-00005; Palareti G, 2002, THROMB HAEMOSTASIS, V87, P7; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simioni P, 2002, BLOOD, V99, P1938, DOI 10.1182/blood.V99.6.1938; THIAGARAJAN P, 1986, BLOOD, V68, P869; Walker ID, 2001, BRIT J HAEMATOL, V114, P512, DOI 10.1046/j.1365-2141.2001.02981.x	21	494	508	2	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					523	526		10.1016/S0140-6736(03)14111-6	http://dx.doi.org/10.1016/S0140-6736(03)14111-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932383				2022-12-28	WOS:000184817600008
J	Chowdhury, TA; Escudier, V				Chowdhury, TA; Escudier, V			Lesson of the week - Poor glycaemic control caused by insulin induced lipohypertrophy	BRITISH MEDICAL JOURNAL			English	Review							LIPOATROPHY		Royal London Hosp, Mile End Diabet Ctr, London E1 4DG, England	Barts Health NHS Trust; Royal London Hospital	Chowdhury, TA (corresponding author), Royal London Hosp, Mile End Diabet Ctr, London E1 4DG, England.							*DIAB UK, ANN REV CHECKLIST; Hauner H, 1996, EXP CLIN ENDOCR DIAB, V104, P106, DOI 10.1055/s-0029-1211431; MCNALLY PG, 1988, POSTGRAD MED J, V64, P850, DOI 10.1136/pgmj.64.757.850; Raile K, 2001, EXP CLIN ENDOCR DIAB, V109, P393, DOI 10.1055/s-2001-18991; Roper NA, 1998, DIABETIC MED, V15, P1063, DOI 10.1002/(SICI)1096-9136(1998120)15:12<1063::AID-DIA706>3.0.CO;2-V; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Wallace TM, 2000, QJM-MON J ASSOC PHYS, V93, P369, DOI 10.1093/qjmed/93.6.369; YOUNG RJ, 1984, DIABETES CARE, V7, P479, DOI 10.2337/diacare.7.5.479	8	64	65	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					383	384		10.1136/bmj.327.7411.383	http://dx.doi.org/10.1136/bmj.327.7411.383			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919996	Green Published			2022-12-28	WOS:000184864200026
J	Clarke, G; Leverington, D; Teller, J; Dyke, A				Clarke, G; Leverington, D; Teller, J; Dyke, A			Superlakes, megafloods, and abrupt climate change	SCIENCE			English	Editorial Material							LAURENTIDE ICE-SHEET; GLACIAL LAKE AGASSIZ; COLD EVENT; YR BP; DEGLACIATION; INSTABILITY; RECORD; EUROPE		Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Smithsonian Inst, Ctr Earth & Planetray Studies, Natl Air & Space Museum, Washington, DC 20560 USA; Univ Manitoba, Dept Geol Sci, Winnipeg, MB R3T 2N2, Canada; Geol Survey Canada, Terain Sci Div, Ottawa, ON K1A 0E8, Canada	University of British Columbia; Smithsonian Institution; University of Manitoba; Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Clarke, G (corresponding author), Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada.							Alley RB, 1997, GEOLOGY, V25, P483, DOI 10.1130/0091-7613(1997)025<0483:HCIAPW>2.3.CO;2; Baldini JUL, 2002, SCIENCE, V296, P2203, DOI 10.1126/science.1071776; Barber DC, 1999, NATURE, V400, P344, DOI 10.1038/22504; Broecker WS, 1988, PALEOCEANOGRAPHY, V3, P1, DOI 10.1029/PA003i001p00001; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; Clark PU, 2002, NATURE, V415, P863, DOI 10.1038/415863a; CLARKE GKC, IN PRESS J GLACIOL; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; JOSENHANS HW, 1990, MAR GEOL, V92, P1, DOI 10.1016/0025-3227(90)90024-E; Klitgaard-Kristensen D, 1998, J QUATERNARY SCI, V13, P165, DOI 10.1002/(SICI)1099-1417(199803/04)13:2<165::AID-JQS365>3.0.CO;2-#; Leverington DW, 2002, QUATERNARY RES, V57, P244, DOI 10.1006/qres.2001.2311; RENSSEN H, 2002, PALEOCEANOGRAPHY, V17; Teller JT, 2002, QUATERNARY SCI REV, V21, P879, DOI 10.1016/S0277-3791(01)00145-7; von Grafenstein U, 1998, CLIM DYNAM, V14, P73, DOI 10.1007/s003820050210	14	103	102	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					922	923		10.1126/science.1085921	http://dx.doi.org/10.1126/science.1085921			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920285				2022-12-28	WOS:000184755900022
J	Aylin, P; Best, N; Bottle, A; Marshall, C				Aylin, P; Best, N; Bottle, A; Marshall, C			Following Shipman: a pilot system for monitoring mortality rates in primary care	LANCET			English	Article							FALSE DISCOVERY RATE; STATISTICAL SURVEILLANCE; LEAGUE TABLES; PERFORMANCE; BRISTOL; HEALTH; SURGERY	As part of the investigations into the crimes of Harold Shipman, it has become clear that there is little monitoring of deaths in general practice. By use of data on annual deaths at family physician and practice level for five English health authorities for 1993-99, we investigate whether cumulative sum charts (a type of statistical process control chart) could be used to create a workable monitoring system. On such charts, thresholds for deaths can be set, which, if crossed, may indicate a potential problem. We chose thresholds based on empirical calculations of the probabilities of false and successful detection after allowing for multiple testing over physicians or practices. We also statistically adjusted the charts for extra-Poisson varition due to unmeasured case mix. Of 1009 family physicians, 33 (including Shipman) crossed the alarm threshold designed to detect a 2 SD increase in standardised mortality, with 97% successful detection and a 5% false-alarm rate. Poor data quality, plus factors such as the proportion of patients treated by these physicians in nursing homes or hospices are likely explanations for most of these additional alarms. If used appropriately, such charts represent a useful tool for monitoring deaths in primary care. However, improvement in data quality is essential.	Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London W2 1PF, England	Imperial College London	Aylin, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, St Marys Campus,Norfolk Pl, London W2 1PF, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011				Adab P, 2002, BRIT MED J, V324, P95, DOI 10.1136/bmj.324.7329.95; Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; AYLIN P, 2003, MONITORING MORTALITY; Baker R, 2003, BRIT MED J, V326, P274, DOI 10.1136/bmj.326.7383.274; BAKER R, 2001, H SHIPMANS CLIN PRAC; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Christiansen CL, 1997, ANN INTERN MED, V127, P764, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00065; CURNOW RN, 1999, 0361 WIT BRIST ROYAL; FRISEN M, 1992, STAT MED, V11, P1489, DOI 10.1002/sim.4780111107; Genovese C, 2002, J ROY STAT SOC B, V64, P499, DOI 10.1111/1467-9868.00347; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GOLDSTEIN H, 2000, J ROY STAT SOC A STA, V165, P222; LIE RT, 1993, STAT MED, V12, P13, DOI 10.1002/sim.4780120104; MARSHALL EC, IN PRESS J R STAT SO; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MILNER RG, 1981, SIMULTANEOUS STAT IN; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; Morton A P, 2001, J Qual Clin Pract, V21, P112, DOI 10.1046/j.1440-1762.2001.00423.x; *NHS, NHS STRAT TRAC SERV; *NHS, NHS PERF IND; PAGE ES, 1954, BIOMETRIKA, V41, P100, DOI 10.2307/2333009; Poloniecki J, 1998, BRIT MED J, V316, P1697, DOI 10.1136/bmj.316.7146.1697; Rossi G, 1999, STAT MED, V18, P2111, DOI 10.1002/(SICI)1097-0258(19990830)18:16<2111::AID-SIM171>3.3.CO;2-H; SMITH AFM, 1983, STATISTICIAN, V32, P46; Sonesson C, 2003, J R STAT SOC A STAT, V166, P5, DOI 10.1111/1467-985X.00256; Spiegelhalter D, 2003, INT J QUAL HEALTH C, V15, P7, DOI 10.1093/intqhc/15.1.7; Steiner S H, 2000, Biostatistics, V1, P441, DOI 10.1093/biostatistics/1.4.441; Vanbrackle L, 1999, STAT MED, V18, P3309, DOI 10.1002/(SICI)1097-0258(19991215)18:23&lt;3309::AID-SIM318&gt;3.0.CO;2-G; Whitehead J., 1983, DESIGN ANAL SEQUENTI; SHIPMAN INQUIRY INDE	30	57	58	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					485	491		10.1016/S0140-6736(03)14077-9	http://dx.doi.org/10.1016/S0140-6736(03)14077-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927439				2022-12-28	WOS:000184651100027
J	Donnai, D; Read, AP				Donnai, D; Read, AP			How clinicians add to knowledge of development	LANCET			English	Article							PRADER-WILLI; HIRSCHSPRUNG-DISEASE; IMPRINTING-MUTATION; MENTAL-RETARDATION; FACIAL FEATURES; COLLAGEN GENE; HUMAN HOMOLOG; ELASTIN GENE; ANGELMAN; MOUSE	Studies of human birth defects and developmental disorders have made major contributions to our understanding of development. Rare human syndromes have allowed identification of important developmental genes, and revealed mechanisms such as uniparental disomy and unstable trinucleotide repeats that were not suspected from animal studies. Some aspects of development, in particular cognitive development, can only be studied in human beings. Basic developmental mechanisms are very highly conserved across a very wide range of animals, making for a rich interplay between animal and human studies. Often, clinical studies identify a gene, or suggest a hypothesis, that can then be investigated in animals.	Univ Manchester, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England; Cent Manchester & Manchester Childrens Univ Hosp, St Marys Hosp, Reg Genet Serv, Manchester M13 0JH, Lancs, England	University of Manchester; University of Manchester	Donnai, D (corresponding author), Univ Manchester, Acad Unit Med Genet, Manchester M13 0JH, Lancs, England.	Dian.Donnai@cmmc.nhs.uk						Abdelhak S, 1997, NAT GENET, V15, P157, DOI 10.1038/ng0297-157; [Anonymous], OMIM ONLINE MENDELIA; ANTONARAKIS SE, 2002, PRINCIPLES PRACTICE, P86; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Berger P, 2002, NEUROGENETICS, V4, P1, DOI 10.1007/s10048-002-0130-z; Bond J, 2002, NAT GENET, V32, P316, DOI 10.1038/ng995; Brown KW, 1996, HUM MOL GENET, V5, P2027, DOI 10.1093/hmg/5.12.2027; Bucan M, 2002, NAT REV GENET, V3, P114, DOI 10.1038/nrg728; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; Byers PH, 2000, CLIN GENET, V58, P270, DOI 10.1034/j.1399-0004.2000.580404.x; BYERS PH, 1988, AM J HUM GENET, V42, P237; Cacheux V, 2001, HUM MOL GENET, V10, P1503, DOI 10.1093/hmg/10.14.1503; Carrasquillo MM, 2002, NAT GENET, V32, P237, DOI 10.1038/ng998; Cassidy SB, 2000, AM J MED GENET, V97, P136, DOI 10.1002/1096-8628(200022)97:2<136::AID-AJMG5>3.0.CO;2-V; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chi N, 2002, TRENDS GENET, V18, P41, DOI 10.1016/S0168-9525(01)02594-X; CHRISTIANO AM, 1995, J CLIN INVEST, V95, P1328, DOI 10.1172/JCI117783; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Conway SJ, 1997, CARDIOVASC RES, V36, P163, DOI 10.1016/S0008-6363(97)00172-7; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; Cushman LJ, 2001, MAMM GENOME, V12, P485, DOI 10.1007/s003350040002; Dattani MT, 1998, NAT GENET, V19, P125, DOI 10.1038/477; Donnai D, 2000, AM J MED GENET, V97, P164, DOI 10.1002/1096-8628(200022)97:2<164::AID-AJMG8>3.0.CO;2-F; DONNAI D, 2000, TXB PEDIAT DERMATOLO, P1237; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; Fisch GS, 2000, AM J MED GENET, V97, P109, DOI 10.1002/1096-8628(200022)97:2<109::AID-AJMG1>3.3.CO;2-3; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; GOODMAN FR, 2003, IN PRESS LANCET; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanel ML, 2001, CLIN GENET, V59, P156, DOI 10.1034/j.1399-0004.2001.590303.x; Kaariainen H, 2001, CLIN DYSMORPHOL, V10, P157; Kalousek DK, 1996, J MED GENET, V33, P529, DOI 10.1136/jmg.33.7.529; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leventer RJ, 2001, TRENDS NEUROSCI, V24, P489, DOI 10.1016/S0166-2236(00)01887-7; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Mowat DR, 1998, J MED GENET, V35, P617, DOI 10.1136/jmg.35.8.617; Munro CS, 1998, LANCET, V352, P704, DOI 10.1016/S0140-6736(05)60820-3; *MURD RES I, 2001, POSSUM PICT STAND SY; Netchine I, 2000, NAT GENET, V25, P182, DOI 10.1038/76041; Newbury DF, 2002, AM J HUM GENET, V70, P1318, DOI 10.1086/339931; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Ohta T, 1999, AM J HUM GENET, V64, P397, DOI 10.1086/302233; Oldridge M, 1997, HUM MOL GENET, V6, P137, DOI 10.1093/hmg/6.1.137; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; RAWLINGS DJ, 1994, IMMUNOL REV, V138, P105, DOI 10.1111/j.1600-065X.1994.tb00849.x; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rincon-Limas DE, 1999, P NATL ACAD SCI USA, V96, P2165, DOI 10.1073/pnas.96.5.2165; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Smahi A, 2000, NATURE, V405, P466; SPENCE JE, 1988, AM J HUM GENET, V42, P217; STEEL KP, 1992, NAT GENET, V2, P75, DOI 10.1038/ng0992-75; STEEL KP, 1989, DEVELOPMENT, V107, P453; Tassabehji M, 1998, HUM MOL GENET, V7, P1021, DOI 10.1093/hmg/7.6.1021; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1995, HUM MOL GENET, V4, P2131, DOI 10.1093/hmg/4.11.2131; van Heyningen V, 2002, HUM MOL GENET, V11, P1161, DOI 10.1093/hmg/11.10.1161; Vu TH, 1997, NAT GENET, V17, P12, DOI 10.1038/ng0997-12; Wayne S, 2001, HUM MOL GENET, V10, P195, DOI 10.1093/hmg/10.3.195; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wilkie AOM, 1997, HUM MOL GENET, V6, P1647, DOI 10.1093/hmg/6.10.1647; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; Winter RM, 2001, LONDON DYSMORPHOLOGY; Wu W, 1998, NAT GENET, V18, P147, DOI 10.1038/ng0298-147	68	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					477	484		10.1016/S0140-6736(03)14076-7	http://dx.doi.org/10.1016/S0140-6736(03)14076-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927438				2022-12-28	WOS:000184651100026
J	Lee, PJ; Lilburn, M; Wendel, U; Schadewaldt, P				Lee, PJ; Lilburn, M; Wendel, U; Schadewaldt, P			A woman with untreated galactosaemia	LANCET			English	Editorial Material									UCL Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, London WC1N 3BG, England; Univ Klinikum, Klin Allgemeine Padiatrie, Dusseldorf, Germany	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Lee, PJ (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Charles Dent Metab Unit, Queen Sq, London WC1N 3BG, England.	philip.lee@uclh.org						Lai K, 2000, BIOCHEM BIOPH RES CO, V271, P392, DOI 10.1006/bbrc.2000.2629; Rubio-Gozalbo ME, 2002, ARCH DIS CHILD, V87, P57, DOI 10.1136/adc.87.1.57; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; Walter JH, 1999, ARCH DIS CHILD, V80, P93, DOI 10.1136/adc.80.1.93	5	28	29	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					446	446		10.1016/S0140-6736(03)14070-6	http://dx.doi.org/10.1016/S0140-6736(03)14070-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927432				2022-12-28	WOS:000184651100012
J	Yanagisawa, K; Shyr, Y; Xu, BGJ; Massion, PP; Larsen, PH; White, BC; Roberts, JR; Edgerton, M; Gonzalez, A; Nadaf, S; Moore, JH; Caprioli, RM; Carbone, DP				Yanagisawa, K; Shyr, Y; Xu, BGJ; Massion, PP; Larsen, PH; White, BC; Roberts, JR; Edgerton, M; Gonzalez, A; Nadaf, S; Moore, JH; Caprioli, RM; Carbone, DP			Proteomic patterns of tumour subsets in non-small-cell lung cancer	LANCET			English	Article							IMAGING MASS-SPECTROMETRY; GENE-EXPRESSION; PROSTATE-CANCER; MESSENGER-RNA; BREAST-CANCER; PROTEINS; SERUM; SUMO; CLASSIFICATION; ADENOCARCINOMA	Background Proteomics-based approaches complement the genome initiatives and may be the next step in attempts to understand the biology of cancer. We used matrix-assisted laser desorption/ionisation mass spectrometry directly from 1-mm regions of single frozen tissue sections for profiling of protein expression from surgically resected tissues to classify lung tumours. Methods Proteomic spectra were obtained and aligned from 79 lung tumours and 14 normal lung tissues. We built a class-prediction model with the proteomic patterns in a training cohort of 42 lung tumours and eight normal lung samples, and assessed their statistical significance. We then applied this model to a blinded test cohort, including 37 lung tumours; and six normal lung samples, to estimate the misclassification rate. Findings We obtained more than 1600 protein peaks from histologically selected 1 mm diameter regions of single frozen sections from each tissue. Class-prediction models based on differentially expressed peaks enabled us to perfectly classify lung cancer histologies, distinguish primary tumours from metastases to the lung from other sites, and classify nodal involvement with 85% accuracy in the training cohort. This model nearly perfectly classified samples in the independent blinded test cohort. We also obtained a proteomic pattern comprised of 15 distinct mass spectrometry peaks that distinguished between patients with resected non-small-cell lung cancer who had poor prognosis (median survival 6 months, n=25) and those who had good prognosis (median survival 33 months, n=41, p<0.0001). Interpretation Proteomic patterns obtained directly from small amounts of fresh frozen lung-tumour tissue could be used to accurately classify and predict histological groups as well as nodal involvement and survival in resected non-small-cell lung cancer.	Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cardiovasc & Thorac Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Program Human Genet, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Carbone, DP (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol,Dept Med, 2200 Pierce Ave,685 Preston Res Bldg, Nashville, TN 37232 USA.		Moore, Jason H./AAV-9645-2021; Yanagisawa, Kiyoshi/I-7263-2014	Moore, Jason H./0000-0002-5015-1099; White, Bill/0000-0002-0684-5210	NCI NIH HHS [P50CA70907, CA 86243, 1P50CA90949] Funding Source: Medline; NIGMS NIH HHS [GM 58008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907, R33CA086243, P50CA090949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam BL, 2002, CANCER RES, V62, P3609; Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Caprioli RM, 1997, ANAL CHEM, V69, P4751, DOI 10.1021/ac970888i; Carbone DP, 1997, SEMIN ONCOL, V24, P388; Chaurand P, 2002, CURR OPIN CHEM BIOL, V6, P676, DOI 10.1016/S1367-5931(02)00370-8; Chaurand P, 2001, PROTEOMICS, V1, P1320, DOI 10.1002/1615-9861(200110)1:10<1320::AID-PROT1320>3.3.CO;2-7; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Junker K, 2000, J CANCER RES CLIN, V126, P361, DOI 10.1007/PL00008483; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MINNA JD, 2001, HARRISONS PRINCIPLES, P562; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; Paweletz CP, 2001, DIS MARKERS, V17, P301, DOI 10.1155/2001/674959; Petricoin EF, 2002, J NATL CANCER I, V94, P1576; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; SHYR Y, 2003, TUMOR PROTEOMIC PATT; SHYR Y, 2003, PRACTICAL APPROACH M; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; TUKEY JW, 1993, CONTROL CLIN TRIALS, V14, P266, DOI 10.1016/0197-2456(93)90225-3; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Wilkins MR, 1996, ELECTROPHORESIS, V17, P830, DOI 10.1002/elps.1150170504; Xu BGJ, 2002, J AM SOC MASS SPECTR, V13, P1292, DOI 10.1016/S1044-0305(02)00644-X	33	456	512	3	69	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					433	439		10.1016/S0140-6736(03)14068-8	http://dx.doi.org/10.1016/S0140-6736(03)14068-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927430				2022-12-28	WOS:000184651100010
J	Miller, MW; Williams, ES				Miller, MW; Williams, ES			Horizontal prion transmission in mule deer	NATURE			English	Editorial Material							CHRONIC WASTING DISEASE; ODOCOILEUS-HEMIONUS; SCRAPIE; SHEEP; EPIDEMIOLOGY		Wildlife Res Ctr, Colorado Div, Ft Collins, CO 80526 USA; Univ Wyoming, Dept Vet Sci, Laramie, WY 82070 USA	University of Wyoming	Miller, MW (corresponding author), Wildlife Res Ctr, Colorado Div, Ft Collins, CO 80526 USA.							HADLOW WJ, 1982, J INFECT DIS, V146, P657, DOI 10.1093/infdis/146.5.657; Hoinville LJ, 1996, REV SCI TECH OIE, V15, P827, DOI 10.20506/rst.15.3.959; Hourrigan J., 1979, Slow transmissible diseases of the nervous system. Volume 1., P331; MCFADYEAN J, 1918, J COMP PATHOL THER, V31, P102; Miller MW, 2000, J WILDLIFE DIS, V36, P676, DOI 10.7589/0090-3558-36.4.676; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Redman CA, 2002, EPIDEMIOL INFECT, V128, P513, DOI 10.1017/S0950268802007008; Sigurdson CJ, 1999, J GEN VIROL, V80, P2757, DOI 10.1099/0022-1317-80-10-2757; Spraker TR, 2002, VET PATHOL, V39, P110, DOI 10.1354/vp.39-1-110; Williams E.S., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P551; Williams ES, 2002, REV SCI TECH OIE, V21, P305, DOI 10.20506/rst.21.2.1340; Woolhouse MEJ, 1998, P ROY SOC B-BIOL SCI, V265, P1205, DOI 10.1098/rspb.1998.0421	12	221	225	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					35	36		10.1038/425035a	http://dx.doi.org/10.1038/425035a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955129				2022-12-28	WOS:000185089200026
J	Reijneveld, SA; Crone, MR; Verhulst, FC; Verloove-Vanhorick, SP				Reijneveld, SA; Crone, MR; Verhulst, FC; Verloove-Vanhorick, SP			The effect of a severe disaster on the mental health of adolescents: a controlled study	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NATURAL DISASTER; TRAUMA EXPOSURE; POPULATION; CHILDREN; DEPRESSION; SYMPTOMS; BEHAVIOR; ANXIETY; TEAMS	Background Disasters greatly affect the mental health of children and adolescents, but quantification of such effects is difficult. Using prospective predisaster and postdisaster data for affected and control populations, we aimed to assess the effects of a severe disaster on the mental health and substance use of adolescents. Methods In January, 2001, a fire in a cafe in Volendam, Netherlands, wounded 250 adolescents and killed 14. In the 15 months before the disaster, all grade 2 students (aged 12-15 years) from a school in Volendam (of whom 31 were in the cafe during the fire), and from two other schools, had been selected as controls for a study. 124 Volendam students and 830 from the other two schools had provided data for substance use, and completed the youth self-report (YSR) questionnaire about behavioural and emotional problems. 5 months after the disaster, we obtained follow-up data from 91 (response rate 73.4%) Volendam adolescents and 643 (77.5%) controls from the other two schools. The primary outcome measures were changes in score in YSR categories of total problems, alcohol misuse, smoking, and substance use. We compared changes in scores between groups using logistic regression. Findings Volendam adolescents had larger increases in clinical scores than controls for total problems (odds ratio 1.82, 95% CI 1.01-3.29, p=0.045) and excessive use of alcohol (4.57, 2.73-7.64, p<0.0001), but not for smoking or use of marijuana, MDMA (ecstasy), and sedatives. Increases in YSR scores were largest for being anxious or depressed (2.85, 1.23-6.61), incoherent thinking (2.16, 1.09-4.30), and aggressive behaviour (3.30, 1.30-8.36). Intention-to-treat analyses showed significantly larger for increases in rates of excessive drinking and YSR symptom subscales in Volendam adolescents than controls. Effects were mostly similar in victims and their classmates. Interpretation Mental health interventions after disasters should address anxiety, depression, thought problems, aggression, and alcohol abuse of directly affected adoloscents and their peer group.	TNO Prevent & Hlth, NL-2301 CE Leiden, Netherlands; Erasmus Univ, Med Ctr Rotterdam, Sophia Childrens Hosp, Rotterdam, Netherlands; Leiden Univ, Med Ctr, Dept Paediat, Leiden, Netherlands	Netherlands Organization Applied Science Research; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Reijneveld, SA (corresponding author), TNO Prevent & Hlth, POB 2215, NL-2301 CE Leiden, Netherlands.	SA.Reijneveld@pg.tno.nl	Crone, Mathilde/AAR-2923-2020	Reijneveld, Sijmen/0000-0002-1206-7523; Crone, Mathilde/0000-0003-1243-858X				Achenbach T. M., 1991, MANUAL SELF REPORT 1; APTEKAR L, 1990, INT J MENT HEALTH, V19, P77, DOI 10.1080/00207411.1990.11449164; Armitage P., 2002, STAT METHODS MED RES; Bolton D, 2000, J CHILD PSYCHOL PSYC, V41, P513, DOI 10.1111/1469-7610.00636; Boxma H, 2001, Ned Tijdschr Geneeskd, V145, P2321; Boyle MH, 1997, ARCH GEN PSYCHIAT, V54, P793; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; BROMET E, 1995, EPIDEMIOL REV, V17, P113, DOI 10.1093/oxfordjournals.epirev.a036166; BURKE JD, 1982, AM J PSYCHIAT, V139, P1010; *COMM INQ CAF FIR, 2001, CAF FIR FIN REP; Cuijpers P, 2002, ADDICT BEHAV, V27, P1009, DOI 10.1016/S0306-4603(02)00295-2; Del Boca FK, 2000, ADDICTION, V95, pS347; DURKIN MS, 1993, AM J PUBLIC HEALTH, V83, P1549, DOI 10.2105/AJPH.83.11.1549; FOXCROFT DR, 2003, COCHRANE LIB, V2; GIACONIA RM, 1995, J AM ACAD CHILD PSY, V34, P1369, DOI 10.1097/00004583-199510000-00023; Koenen KC, 2002, J NERV MENT DIS, V190, P209, DOI 10.1097/00005053-200204000-00001; Kremers SPJ, 2001, PREV MED, V33, P392, DOI 10.1006/pmed.2001.0904; Larkin M, 1998, LANCET, V352, P1606, DOI 10.1016/S0140-6736(05)61059-8; Last J.M., 2000, DICT EPIDEMIOLOGY, Vthird; MILGRAM RM, 1976, J PSYCHOL, V94, P107, DOI 10.1080/00223980.1976.9921403; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; NIMH, 1997, DIAGN INT SCHED CHIL; NOLENHOEKSEMA S, 1991, J PERS SOC PSYCHOL, V61, P115, DOI 10.1037/0022-3514.61.1.115; Pynoos RS, 1998, CHILD ADOL PSYCH CL, V7, P195, DOI 10.1016/S1056-4993(18)30268-2; Rebagliato M, 2002, J EPIDEMIOL COMMUN H, V56, P163, DOI 10.1136/jech.56.3.163; ROTHMAN KJ, 2001, MODERN EPIDEMIOLOGY; RUBONIS AV, 1991, PSYCHOL BULL, V109, P384, DOI 10.1037/0033-2909.109.3.384; Shaw JA, 2000, PSYCHIAT QUART, V71, P227, DOI 10.1023/A:1004630127000; Silberg J, 2001, BRIT J PSYCHIAT, V179, P116, DOI 10.1192/bjp.179.2.116; Stanton WR, 1996, ADDICTION, V91, P1705; Stein MB, 2002, AM J PSYCHIAT, V159, P1675, DOI 10.1176/appi.ajp.159.10.1675; Verhulst FC, 1997, MANUAL YSR; VOGEL JM, 1993, J CLIN CHILD PSYCHOL, V22, P464, DOI 10.1207/s15374424jccp2204_7; Weinberg NZ, 1998, J AM ACAD CHILD PSY, V37, P252, DOI 10.1097/00004583-199803000-00009; WEINBERG WA, 2002, CHILD ADOL PSYCH CL, P437; Yule W, 2001, J CLIN PSYCHIAT, V62, P23; Yule W, 2000, J CHILD PSYCHOL PSYC, V41, P503, DOI 10.1017/S0021963099005570	38	96	98	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					691	696		10.1016/S0140-6736(03)14231-6	http://dx.doi.org/10.1016/S0140-6736(03)14231-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	716NH	12957091				2022-12-28	WOS:000185034800009
J	Zhang, HZ; Gilbert, B; Huang, F; Banfield, JF				Zhang, HZ; Gilbert, B; Huang, F; Banfield, JF			Water-driven structure transformation in nanoparticles at room temperature	NATURE			English	Article							MOLECULAR-DYNAMICS SIMULATION; SEMICONDUCTOR NANOCRYSTALS; PHASE-STABILITY; AB-INITIO; SURFACE; RELAXATION	The thermodynamic behaviour of small particles differs from that of the bulk material by the free energy term gammaA-the product of the surface (or interfacial) free energy and the surface (or interfacial) area. When the surfaces of polymorphs of the same material possess different interfacial free energies, a change in phase stability can occur with decreasing particle size(1,2). Here we describe a nanoparticle system that undergoes structural changes in response to changes in the surface environment rather than particle size. ZnS nanoparticles (average diameter 3 nm) were synthesized in methanol and found to exhibit a reversible structural transformation accompanying methanol desorption, indicating that the particles readily adopt minimum energy structural configurations(3,4). The binding of water to the as-formed particles at room temperature leads to a dramatic structural modification, significantly reducing distortions of the surface and interior to generate a structure close to that of sphalerite (tetrahedrally coordinated cubic ZnS). These findings suggest a route for post-synthesis control of nanoparticle structure and the potential use of the nanoparticle structural state as an environmental sensor. Furthermore, the results imply that the structure and reactivity of nanoparticles at planetary surfaces, in interplanetary dust(5) and in the biosphere(6,7), will depend on both particle size and the nature of the surrounding molecules.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Banfield, JF (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	jill@eps.berkeley.edu	Gilbert, Benjamin/E-3182-2010; Huang, Feng/X-9404-2019	Huang, Feng/0000-0002-4623-2216; Zhang, Hengzhong/0000-0003-2322-2274; Banfield, Jill/0000-0001-8203-8771; Gilbert, Benjamin/0000-0003-0853-0826				Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506; Banfield J.F., 2001, REV MINERALOGY GEOCH, V44; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; de Leeuw NH, 1998, PHYS REV B, V58, P13901, DOI 10.1103/PhysRevB.58.13901; Desgreniers S, 2000, PHYS REV B, V61, P8726, DOI 10.1103/PhysRevB.61.8726; Eichkorn K, 1998, CHEM PHYS LETT, V288, P235, DOI 10.1016/S0009-2614(98)00306-6; FARGES J, 1986, J CHEM PHYS, V84, P3491, DOI 10.1063/1.450235; Franceschetti A, 1999, PHYS REV B, V60, P1819, DOI 10.1103/PhysRevB.60.1819; Guinier, 1963, XRAY DIFFRACTION CRY, DOI DOI 10.1002/bip.10163; Harris DJ, 2001, MOL PHYS, V99, P825, DOI 10.1080/00268970010015568; Head-Gordon T, 2002, CHEM REV, V102, P2651, DOI 10.1021/cr0006831; HERTL W, 1988, LANGMUIR, V4, P594, DOI 10.1021/la00081a018; Huang F, 2003, ABSTR PAP AM CHEM S, V225, pU513; HUANG F, UNPUB PHYS REV LETT; Jenkins R., 1996, INTRO XRAY POWDER DI; Labrenz M, 2000, SCIENCE, V290, P1744, DOI 10.1126/science.290.5497.1744; Leung K, 1999, J CHEM PHYS, V110, P11012, DOI 10.1063/1.479037; Li A, 2002, ASTROPHYS J, V564, P803, DOI 10.1086/324300; McGinley C, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.245308; McHale JM, 1997, SCIENCE, V277, P788, DOI 10.1126/science.277.5327.788; Meulenberg RW, 2000, ABSTR PAP AM CHEM S, V220, pU215; Muilu J, 1996, SURF SCI, V364, P439, DOI 10.1016/0039-6028(96)00633-4; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Rabani E, 2001, J CHEM PHYS, V115, P1493, DOI 10.1063/1.1380748; RAGHAVACHARI K, 1993, CHEM PHYS LETT, V206, P156, DOI 10.1016/0009-2614(93)85533-T; Rockenberger J, 1998, J CHEM PHYS, V108, P7807, DOI 10.1063/1.476216; ROSSETTI R, 1985, J CHEM PHYS, V82, P552, DOI 10.1063/1.448727; RUHL E, 1993, J CHEM PHYS, V98, P6820, DOI 10.1063/1.464773; Stevens JE, 1996, J CHEM PHYS, V105, P8754, DOI 10.1063/1.472735; STILLINGER FH, 1978, J CHEM PHYS, V68, P666, DOI 10.1063/1.435738; WANG YR, 1987, PHYS REV B, V36, P2763, DOI 10.1103/PhysRevB.36.2763; WRIGHT K, 1995, J MATER CHEM, V5, P2037, DOI 10.1039/jm9950502037; Zhang HZ, 1998, J MATER CHEM, V8, P2073, DOI 10.1039/a802619j	34	389	395	4	242	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1025	1029		10.1038/nature01845	http://dx.doi.org/10.1038/nature01845			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944961				2022-12-28	WOS:000184984200035
J	Gottfried, JA; O'Doherty, J; Dolan, RJ				Gottfried, JA; O'Doherty, J; Dolan, RJ			Encoding predictive reward value in human amygdala and orbitofrontal cortex	SCIENCE			English	Article							SENSORY-SPECIFIC SATIETY; PREFRONTAL CORTEX; ACTIVATION; LESIONS; REINFORCEMENT; MOTIVATION; RESPONSES; NEURONS; HUNGER; FMRI	Adaptive behavior is optimized in organisms that maintain flexible representations of the value of sensory-predictive cues. To identify central representations of predictive reward value in humans, we used reinforcer devaluation while measuring neural activity with functional magnetic resonance imaging. We presented two arbitrary visual stimuli, both before and after olfactory devaluation, in a paradigm of appetitive conditioning. In amygdala and orbitofrontal cortex, responses evoked by a predictive target stimulus were decreased after devaluation, whereas responses to the nondevalued stimulus were maintained. Thus, differential activity in amygdala and orbitofrontal cortex encodes the current value of reward representations accessible to predictive cues.	Wellcome Dept Imaging Neurosci, Funct Imaging Lab, London WC1N 3BG, England	University of London; University College London	Gottfried, JA (corresponding author), Wellcome Dept Imaging Neurosci, Funct Imaging Lab, 12 Queen Sq, London WC1N 3BG, England.		O'Doherty, John P/F-1204-2013	Dolan, Ray/0000-0001-9356-761X				Balleine BW, 2000, J NEUROSCI, V20, P8954; Baxter MG, 2000, J NEUROSCI, V20, P4311; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; Critchley HD, 1996, J NEUROPHYSIOL, V75, P1673, DOI 10.1152/jn.1996.75.4.1673; Critchley HD, 2002, NEURON, V33, P653, DOI 10.1016/S0896-6273(02)00588-3; Dayan P, 2002, NEURON, V36, P285, DOI 10.1016/S0896-6273(02)00963-7; Dickinson A., 2002, STEVENS HDB EXPT PSY, V3; Gallagher M, 1999, J NEUROSCI, V19, P6610; Gottfried JA, 2002, J NEUROSCI, V22, P10829; Gottfried JA, 2002, J NEUROSCI, V22, P10819; Hatfield T, 1996, J NEUROSCI, V16, P5256; Ikeda M, 2002, J NEUROL NEUROSUR PS, V73, P371, DOI 10.1136/jnnp.73.4.371; LaBar KS, 2001, BEHAV NEUROSCI, V115, P493, DOI 10.1037//0735-7044.115.2.493; LaBar KS, 1998, NEURON, V20, P937, DOI 10.1016/S0896-6273(00)80475-4; Malkova L, 1997, J NEUROSCI, V17, P6011; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; O'Doherty J, 2000, NEUROREPORT, V11, P893, DOI 10.1097/00001756-200003200-00046; O'Doherty JP, 2002, NEURON, V33, P815, DOI 10.1016/S0896-6273(02)00603-7; ROLLS BJ, 1981, PHYSIOL BEHAV, V27, P137, DOI 10.1016/0031-9384(81)90310-3; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P733, DOI 10.1152/jn.1995.74.2.733; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; Schultz W, 2000, CEREB CORTEX, V10, P272, DOI 10.1093/cercor/10.3.272; Small DM, 2001, BRAIN, V124, P1720, DOI 10.1093/brain/124.9.1720; Small DM, 1999, NEUROREPORT, V10, P7, DOI 10.1097/00001756-199901180-00002; TERZIAN H, 1955, NEUROLOGY, V5, P373, DOI 10.1212/WNL.5.6.373	28	840	847	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1104	1107		10.1126/science.1087919	http://dx.doi.org/10.1126/science.1087919			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934011	Green Submitted			2022-12-28	WOS:000184872400043
J	Harvey, KF; Pfleger, CM; Hariharan, IK				Harvey, KF; Pfleger, CM; Hariharan, IK			The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis	CELL			English	Article							PROTEIN-KINASE; REGULATING APOPTOSIS; TNF SUPERFAMILY; IMAGINAL DISC; JNK PATHWAY; DEGRADATION; REAPER; DIAP1; GENE; GRIM	Establishing and maintaining homeostasis is critical to the well-being of an organism and is determined by the balance of cell proliferation and death. Two genes that function together to regulate growth, proliferation, and apoptosis in Drosophila are warts (wts), encoding a serine/threonine kinase, and salvador (sav), encoding a WW domain containing Wts-interacting protein. However, the mechanisms by which sav and wts regulate growth and apoptosis are not well understood. Here, we describe mutations in hippo (hpo), which encodes a protein kinase most related to mammalian Mst1 and Mst2. Like wts and sav, hpo mutations result in increased tissue growth and impaired apoptosis characterized by elevated levels of the cell cycle regulator cyclin E and apoptosis inhibitor DIAP1. Hpo, Sav, and Wts interact physically and functionally, and regulate DIAP1 levels, likely by Hpo-mediated phosphorylation and subsequent degradation. Thus, Hpo links Sav and Wts to a key regulator of apoptosis.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Hariharan, IK (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.		Harvey, Kieran/AAD-5268-2022	Harvey, Kieran/0000-0001-7845-369X	NCI NIH HHS [CA95281] Funding Source: Medline; NIGMS NIH HHS [GM61672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA095281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger J, 2001, NAT GENET, V29, P475, DOI 10.1038/ng773; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lisi S, 2000, GENETICS, V154, P669; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Richardson H, 2002, J IMMUNOL METHODS, V265, P21, DOI 10.1016/S0022-1759(02)00068-6; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Suzanne M, 2001, DEV BIOL, V237, P282, DOI 10.1006/dbio.2001.0384; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P668; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	40	726	757	1	69	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					457	467		10.1016/S0092-8674(03)00557-9	http://dx.doi.org/10.1016/S0092-8674(03)00557-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941274	Bronze			2022-12-28	WOS:000184928800009
J	Chien, P; DePace, AH; Collins, SR; Weissman, JS				Chien, P; DePace, AH; Collins, SR; Weissman, JS			Generation of prion transmission barriers by mutational control of amyloid conformations	NATURE			English	Article							STRUCTURAL BASIS; SUP35 PROTEIN; IN-VITRO; YEAST; PSI+; DIVERSITY; DISEASES; STRAINS; VARIANT; PSI(+)	Self-propagating beta-sheet-rich protein aggregates are implicated in a wide range of protein-misfolding phenomena, including amyloid diseases and prion-based inheritance(1). Two properties have emerged as common features of amyloids. Amyloid formation is ubiquitous: many unrelated proteins form such aggregates and even a single polypeptide can misfold into multiple forms(2-6) - a process that is thought to underlie prion strain variation(7). Despite this promiscuity, amyloid propagation can be highly sequence specific: amyloid fibres often fail to catalyse the aggregation of other amyloidogenic proteins(8,9). In prions, this specificity leads to barriers that limit transmission between species(7,8,10-12). Using the yeast prion [PSI+](13), we show in vitro that point mutations in Sup35p, the protein determinant of [PSI+], alter the range of 'infectious' conformations, which in turn changes amyloid seeding specificity. We generate a new transmission barrier in vivo by using these mutations to specifically disfavour subsets of prion strains. The ability of mutations to alter the conformations of amyloid states without preventing amyloid formation altogether provides a general mechanism for the generation of prion transmission barriers and may help to explain how mutations alter toxicity in conformational diseases.	Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA.	jsw1@itsa.ucsf.edu		Collins, Sean/0000-0002-4276-5840; Weissman, Jonathan/0000-0003-2445-670X				Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Bartz JC, 2000, J VIROL, V74, P5542, DOI 10.1128/JVI.74.12.5542-5547.2000; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1996, GENETICS, V144, P1375; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; Kad NM, 2001, J MOL BIOL, V313, P559, DOI 10.1006/jmbi.2001.5071; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Mastrianni JA, 2001, NEUROLOGY, V57, P2198, DOI 10.1212/WNL.57.12.2198; Nakayashiki T, 2001, MOL CELL, V7, P1121, DOI 10.1016/S1097-2765(01)00259-3; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Post K, 2000, ARCH VIROL, P265; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	29	85	86	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					948	951		10.1038/nature01894	http://dx.doi.org/10.1038/nature01894			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931190				2022-12-28	WOS:000184843600043
J	Gompel, N; Carroll, SB				Gompel, N; Carroll, SB			Genetic mechanisms and constraints governing the evolution of correlated traits in drosophilid flies	NATURE			English	Article							CONVERGENT PHENOTYPES; ADULT ABDOMEN; MELANOGASTER; PHYLOGENY; PROTEINS; PATTERN; PANNIER	Some morphological traits differ greatly between related species, but it is not clear whether diversity evolves through changes in the same genes and whether similar, independent (that is, convergent) changes occur by the same mechanism(1,2). Pigmentation in fruitflies presents an attractive opportunity to explore these issues because pigmentation patterns are diverse, similar patterns have arisen in independent clades, and numerous genes governing their formation have been identified(3-5) in Drosophila melanogaster. Here we show that both evolutionary diversification and convergence can be due to evolution at the same locus, by comparing abdominal pigmentation and trichome patterns and the expression of Bric-a-brac2 (Bab2), which regulates both traits in D. melanogaster(3,6), in 13 species representing the major clades (7,8) of the subfamily Drosophilinae. Modifications of Bab2 expression are frequently correlated with diverse pigmentation and trichome patterns that evolved independently in multiple lineages. In a few species, Bab2 expression is not correlated with changes in pigmentation but is correlated with a conserved pattern of trichomes, indicating that this locus can be circumvented to evolve new patterns when a correlated trait is under different constraints.	Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, 1525 Linden Dr, Madison, WI 53706 USA.	sbcarrol@facstaff.wisc.edu		Gompel, Nicolas/0000-0003-3358-7963				Abzhanov A, 2000, DEVELOPMENT, V127, P2239; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; AYALA FJ, 1965, EVOLUTION, V19, P538, DOI 10.1111/j.1558-5646.1965.tb03329.x; BOCK IR, 1972, STUDIES GENETICS, P1, DOI DOI 10.1590/S0085-56262014000400004; Calleja M, 2000, DEVELOPMENT, V127, P3971; Couderc JL, 2002, DEVELOPMENT, V129, P2419; GRIMALDI DA, 1990, B AM MUS NAT HIST, P1; Kopp A, 2000, NATURE, V408, P553, DOI 10.1038/35046017; Kopp A, 1999, DEVELOPMENT, V126, P3495; Kopp A, 2003, GENETICS, V163, P771; Kopp A, 1997, DEVELOPMENT, V124, P3715; Kwiatowski J, 1999, MOL PHYLOGENET EVOL, V13, P319, DOI 10.1006/mpev.1999.0657; Lachaise D, 2000, P ROY SOC B-BIOL SCI, V267, P1487, DOI 10.1098/rspb.2000.1169; Llopart A, 2002, EVOLUTION, V56, P2262; Maddison D. R., 2000, MACCLADE 4 ANAL PHYL; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; Majerus M, 1998, MELANISM EVOLUTION A; Majerus M. E. N, 1994, LADYBIRDS; Remsen J, 2002, MOL PHYLOGENET EVOL, V24, P249, DOI 10.1016/S1055-7903(02)00226-9; Schutt C, 2000, DEVELOPMENT, V127, P667; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; Wittkopp PJ, 2003, P NATL ACAD SCI USA, V100, P1808, DOI 10.1073/pnas.0336368100; Wittkopp PJ, 2002, DEVELOPMENT, V129, P1849; Wray GA, 2002, BRAIN BEHAV EVOLUT, V59, P327, DOI 10.1159/000063566; Wulbeck C, 2002, DEVELOPMENT, V129, P3861	25	98	104	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					931	935		10.1038/nature01787	http://dx.doi.org/10.1038/nature01787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931186				2022-12-28	WOS:000184843600039
J	Singh, JA				Singh, JA			Military tribunals at Guantanamo Bay: dual loyalty conflicts	LANCET			English	Editorial Material									Univ Natal, Howard Coll Sch Law, ZA-4041 Durban, South Africa	University of Kwazulu Natal	Singh, JA (corresponding author), Univ Natal, Howard Coll Sch Law, ZA-4041 Durban, South Africa.							GRIFFITHS F, 2003, ASS PRESS WIRE  0603; HARRIS P, 2002, OBSERVER        1103; *PHR U CAP TOWHN H, 2003, DUAL LOYALT HUM RIGH; Priest Dana, 2002, WASH POST	4	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					573	573		10.1016/S0140-6736(03)14122-0	http://dx.doi.org/10.1016/S0140-6736(03)14122-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12938669				2022-12-28	WOS:000184817600028
J	Vandor, T				Vandor, T			Essence of being a doctor - Go back to basics	BRITISH MEDICAL JOURNAL			English	Letter																		Kmietowicz Z, 2003, BRIT MED J, V326, P1352	1	0	0	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					396	396		10.1136/bmj.327.7411.396-c	http://dx.doi.org/10.1136/bmj.327.7411.396-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12920013	Green Published			2022-12-28	WOS:000184864200045
J	Vestergaard, P; Mosekilde, L				Vestergaard, P; Mosekilde, L			Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; FOLLOW-UP; RISK; MORBIDITY; SURVIVAL; TRIAL; DEATH	Objectives To assess the effects of surgery compared with conservative treatment (no surgery) for primary hyperparathyroidism. Design Cohort study. Setting Nationwide Danish cohort. Participants 3213 patients, mean age 61 (SD 16) years, with a diagnosis of primary hyperparathyroidism between 1980 and 1999. 1934 (60%) underwent surgery and 1279 (40%) were treated conservatively. Main outcome measures Occurrence of fractures, osteoporosis, kidney or urinary tract stones, acute myocardial infarction, angina pectoris, cardiac arrhythmias, arterial hypertension, heart failure, stroke, acute pancreatitis, stomach or duodenal ulcers, muscle pain, malignant diseases, psychiatric disorders, and mortality. Results At diagnosis of primary hyperparathyroidism, patients who subsequently underwent surgery had a lower prevalence of previous fracture (odds ratio 0.64, 95% confidence interval 0.51 to 0.80), acute myocardial infarction (0.59, 0.42 to 0.83), stroke (0.57, 0.37 to 0.88), psychiatric disorders (0.54, 0.31 to 0.94), and painful muscle disorders (0.44, 0.26 to 0.76), whereas kidney stones (2.49, 1.93 to 3.23) and acute pancreatitis (2.77, 1.33 to 5.76) were more prevalent. After diagnosis, the risks of fractures (hazards ratio 0.69, 0.56 to 0.84) and gastric ulcers (0.59, 0.41 to 0.84) were lower in patients treated surgically than those treated conservatively. Events involving kidney or urinary tact stones were more prevalent in patients treated surgically than patients treated conservatively (1.87, 1.30 to 2.68). Mortality was lower in patients treated surgically (0.65, 0.57 to 0.73). Conclusions Patients treated surgically for primary hyperparathyroidism have a lower prevalence of fractures and gastric ulcers than patients treated conservatively. The type of treatment had no effect on the occurrence of cardiovascular events.	Aarhus Univ Hosp, Aarhus Kommune Hosp, Dept Endocrinol & Metab C, DK-8000 Aarhus, Denmark	Aarhus University	Vestergaard, P (corresponding author), Aarhus Kommune Hosp, Osteoporosis Clin, Tage Hansens Gade 2, DK-8000 Aarhus C, Denmark.	p-vest@post4.tele.dk						Andersen TF, 1999, DAN MED BULL, V46, P263; Bilezikian JP, 2002, J BONE MINER RES, V17, pN2; *CAN BUR STAT, 1998, STAT YB 1998; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christiansen P, 1999, BONE, V25, P589, DOI 10.1016/S8756-3282(99)00207-0; DANIELS J, 1983, AM J MED, V75, P17, DOI 10.1016/0002-9343(83)91162-2; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; Hedback G, 1998, EUR J CLIN INVEST, V28, P271; HEDBACK G, 1991, WORLD J SURG, V15, P399, DOI 10.1007/BF01658740; Jurgensen H J, 1984, Ugeskr Laeger, V146, P3303; Leifsson BG, 1996, J CLIN ENDOCR METAB, V81, P2149, DOI 10.1210/jc.81.6.2149; MADSEN M, 1990, Ugeskrift for Laeger, V152, P308; Mollerup CL, 2002, BMJ-BRIT MED J, V325, P807, DOI 10.1136/bmj.325.7368.807; Mosbech J, 1995, Ugeskr Laeger, V157, P3741; PALMER M, 1987, SURGERY, V102, P1; PALOYAN D, 1982, AM SURGEON, V48, P366; Rao D, 2000, J BONE MINER RES, V15, pS164; ROBERTS WC, 1981, AM J MED, V71, P371, DOI 10.1016/0002-9343(81)90163-7; SANCHO JJ, 1992, WORLD J SURG, V16, P732, DOI 10.1007/BF02067371; Soreide JA, 1997, SURGERY, V122, P1117, DOI 10.1016/S0039-6060(97)90216-6; Stefenelli T, 1997, SURGERY, V121, P157, DOI 10.1016/S0039-6060(97)90285-3; Talpos GB, 2000, SURGERY, V128, P1013, DOI 10.1067/msy.2000.110844; Vestergaard P, 2000, BRIT MED J, V321, P598, DOI 10.1136/bmj.321.7261.598; Wermers RA, 1997, ANN INTERN MED, V126, P433, DOI 10.7326/0003-4819-126-6-199703150-00003	24	103	107	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2003	327	7414					530	533		10.1136/bmj.327.7414.530	http://dx.doi.org/10.1136/bmj.327.7414.530			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958111	Green Published, Bronze			2022-12-28	WOS:000185283700016
J	Yewdell, JW				Yewdell, JW			Hide and seek in the peptidome	SCIENCE			English	Editorial Material							TRANSLATION; DEGRADATION; PROTEINS		NIAID, Viral Dis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, Bethesda, MD 20892 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000542, ZIAAI000542] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; Dantuma NP, 2002, CURR TOP MICROBIOL, V269, P23; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; Mayrand SM, 1998, IMMUNOL TODAY, V19, P551, DOI 10.1016/S0167-5699(98)01342-5; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schwab SR, 2003, SCIENCE, V301, P1367, DOI 10.1126/science.1085650; WHEATLEY DN, 1985, CELL BIOL INT REP, V9, P463, DOI 10.1016/0309-1651(85)90154-7; Yin Y, 2003, SCIENCE, V301, P1371, DOI 10.1126/science.1088902	9	29	30	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1334	1335		10.1126/science.1089553	http://dx.doi.org/10.1126/science.1089553			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958347				2022-12-28	WOS:000185116400024
J	Burke, W				Burke, W			Genomics as a probe for disease biology	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GENOTYPE-PHENOTYPE CORRELATION; CYSTIC-FIBROSIS; GENE POLYMORPHISM; ASTHMA; ASSOCIATION; DYSTROPHIN; MUTATIONS; SEVERITY; MEDICINE; PROTEIN		Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Burke, W (corresponding author), Univ Washington, Dept Med Hist & Eth, Box 357120,1959 NE Pacific,Rm A204, Seattle, WA 98195 USA.	wburke@u.washington.edu						Abbott A, 1999, NATURE, V402, P715, DOI 10.1038/45350; Ashley-Koch A, 2000, AM J EPIDEMIOL, V151, P839; Ayres J, 2001, J ROY SOC MED, V94, P115, DOI 10.1177/014107680109400304; Beggs AH, 1997, CIRCULATION, V95, P2344, DOI 10.1161/01.CIR.95.10.2344; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; BRITTON JR, 1989, BRIT MED J, V298, P483, DOI 10.1136/bmj.298.6672.483; BURKE W, 1992, CHEST, V102, P506, DOI 10.1378/chest.102.2.506; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; CAMPBELL PW, 1992, J PEDIATR-US, V120, P261, DOI 10.1016/S0022-3476(05)80438-X; Childs B, 2000, ANNU REV GENOM HUM G, V1, P1, DOI 10.1146/annurev.genom.1.1.1; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Cookson WOC, 2002, CHEST, V121, p7S, DOI 10.1378/chest.121.3_suppl.7S-a; Curtis JR, 1997, AM J RESP CRIT CARE, V155, P1921, DOI 10.1164/ajrccm.155.6.9196096; *CYST FIBR GEN PHE, 1993, NEW ENGL J MED, V329, P13086; DeBraekeleer M, 1997, HUM GENET, V101, P208, DOI 10.1007/s004390050616; Dipple KM, 2000, MOL GENET METAB, V71, P43, DOI 10.1006/mgme.2000.3052; Dork T, 1997, HUM GENET, V100, P365, DOI 10.1007/s004390050518; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; GAN KH, 1995, NEW ENGL J MED, V333, P95, DOI 10.1056/NEJM199507133330204; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Goodeve AC, 2000, THROMB HAEMOSTASIS, V83, P844; Guttmacher AE, 2002, NEW ENGL J MED, V347, P1512, DOI 10.1056/NEJMra012240; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Hakonarson H, 2001, CURR OPIN PEDIATR, V13, P267, DOI 10.1097/00008480-200106000-00010; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Khoury MJ, 1998, EPIDEMIOLOGY, V9, P350, DOI 10.1097/00001648-199805000-00023; Koppelman GH, 1999, CLIN EXP ALLERGY, V29, P1; KORF BR, 2003, DYSTROPHINOPATHIES I; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liggett SB, 1997, AM J RESP CRIT CARE, V156, pS156, DOI 10.1164/ajrccm.156.4.12tac-15; Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/oxfordjournals.aje.a000179; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Mekus F, 2003, HUM GENET, V112, P1, DOI 10.1007/s00439-002-0839-7; Mickle JE, 1998, CLIN CHEST MED, V19, P443, DOI 10.1016/S0272-5231(05)70092-7; Noone PG, 2001, RESP RES, V2, P328, DOI 10.1186/rr82; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P861, DOI 10.1164/ajrccm.165.7.2109096; Palmer LJ, 2001, RESP RES, V2, P102, DOI 10.1186/rr45; Patino CM, 2001, ALLERGY, V56, P279, DOI 10.1034/j.1398-9995.2001.00135.x; Postma DS, 1998, CLIN EXP ALLERGY, V28, P62; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Rozmahel R, 1996, NAT GENET, V13, P129, DOI 10.1038/ng0596-129a; Salvatore F, 2002, AM J MED GENET, V111, P88, DOI 10.1002/ajmg.10461; SANTIS G, 1990, LANCET, V336, P1081, DOI 10.1016/0140-6736(90)92566-Z; Shapiro SD, 2002, NEW ENGL J MED, V347, P936, DOI 10.1056/NEJMcibr022144; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; WANG Z, 2002, AM J RESP CRIT CARE, V166, P775; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404, DOI 10.1164/ajrccm.163.6.2001101; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Weiss ST, 2001, AM J RESP CRIT CARE, V164, P2014, DOI 10.1164/ajrccm.164.11.2110043b; Witkin SS, 2002, CLIN INFECT DIS, V34, P204, DOI 10.1086/338261; Zielenski J, 1999, NAT GENET, V22, P128, DOI 10.1038/9635; Zielenski J, 2000, RESPIRATION, V67, P117, DOI 10.1159/000029497	57	55	59	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					969	974		10.1056/NEJMra012479	http://dx.doi.org/10.1056/NEJMra012479			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954746	Bronze			2022-12-28	WOS:000185081400010
J	Rueness, EK; Stenseth, NC; O'Donoghue, M; Boutin, S; Ellegren, H; Jakobsen, KS				Rueness, EK; Stenseth, NC; O'Donoghue, M; Boutin, S; Ellegren, H; Jakobsen, KS			Ecological and genetic spatial structuring in the Canadian lynx	NATURE			English	Article							CLADISTIC-ANALYSIS; SNOWSHOE HARE; GEOGRAPHICAL-DISTRIBUTION; PHENOTYPIC ASSOCIATIONS; POPULATION-DYNAMICS; HAPLOTYPES; DISPERSAL; SPECIATION; PATTERNS; PROGRAM	The Canadian lynx, distributed all across the northern part of North America, is well known for its regular population cycles-cycles that have different underlying structures in different parts of Canada(1). Using both nuclear and mitochondrial DNA markers, we report here a close resemblance between the earlier observed spatial ecological structuring of the Canadian lynx(1) and its spatial genetic structuring. Specifically, we demonstrate that the Rocky Mountains represent a barrier to gene flow in western Canada, and, somewhat surprisingly, we detect the presence of a geographically invisible barrier south of Hudson Bay (coinciding with the separation between the ecological Continental and Atlantic regions(1)). No evidence for isolation in different glacial refugia within North America was found. We suggest that ecological factors underlying the spatial dynamic structuring also strongly influence the genetic structuring of the Canadian lynx.	Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, N-0315 Oslo, Norway; Yukon Dept Environm, Fish & Wildlife Branch, Mayo, YT Y0B 1M0, Canada; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Uppsala Univ, Dept Evolutionary Biol, SE-75236 Uppsala, Sweden	University of Oslo; University of Alberta; Uppsala University	Stenseth, NC (corresponding author), Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, POB 1031 Blindern, N-0315 Oslo, Norway.		Boutin, Stan A/A-2619-2014; Stenseth, Nils Chr./G-5212-2016	Boutin, Stan A/0000-0001-6317-038X; Stenseth, Nils Chr./0000-0002-1591-5399				Avise J.C., 2000, PHYLOGEOGRAPHY HIST; Burton C, 2002, MOL ECOL, V11, P1689, DOI 10.1046/j.1365-294X.2002.01566.x; Clement M, 2000, MOL ECOL, V9, P1657, DOI 10.1046/j.1365-294x.2000.01020.x; Dawson AG, 1992, ICE AGE EARTH LATE Q; Doebeli M, 2003, NATURE, V421, P259, DOI 10.1038/nature01274; Elton C, 1942, J ANIM ECOL, V11, P215, DOI 10.2307/1358; Fedorov VB, 2002, P ROY SOC B-BIOL SCI, V269, P2071, DOI 10.1098/rspb.2002.2126; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; JANCZEWSKI DN, 1995, MOL BIOL EVOL, V12, P690; Krebs C.J., 2001, ECOSYSTEM DYNAMICS B; KREBS CJ, 1995, SCIENCE, V269, P1112, DOI 10.1126/science.269.5227.1112; Kurten B., 1980, PLEISTOCENE MAMMALS; Menotti-Raymond M, 1999, GENOMICS, V57, P9, DOI 10.1006/geno.1999.5743; Mowat G, 1998, CAN FIELD NAT, V112, P32; Mowat Garth, 2000, P265; Poole KG, 1997, J WILDLIFE MANAGE, V61, P497, DOI 10.2307/3802607; Posada D, 2000, MOL ECOL, V9, P487, DOI 10.1046/j.1365-294x.2000.00887.x; Ranta E, 1997, ECOGRAPHY, V20, P454, DOI 10.1111/j.1600-0587.1997.tb00412.x; RAYMOND M, 1995, J HERED, V86, P248, DOI 10.1093/oxfordjournals.jhered.a111573; ROGERS AR, 1995, EVOLUTION, V49, P608, DOI 10.1111/j.1558-5646.1995.tb02297.x; Schneider S., 2000, ARLEQUIN SOFTWARE PO; Schwartz MK, 2002, NATURE, V415, P520, DOI 10.1038/415520a; Slough BG, 1996, J WILDLIFE MANAGE, V60, P946, DOI 10.2307/3802397; Stenseth NC, 1999, SCIENCE, V285, P1071, DOI 10.1126/science.285.5430.1071; Stenseth NC, 1997, P NATL ACAD SCI USA, V94, P5147, DOI 10.1073/pnas.94.10.5147; Stenseth NC, 1998, P NATL ACAD SCI USA, V95, P15430, DOI 10.1073/pnas.95.26.15430; TEMPLETON AR, 1995, GENETICS, V140, P767; TEMPLETON AR, 1992, GENETICS, V132, P619; TEMPLETON AR, 1993, GENETICS, V134, P659	30	91	97	2	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					69	72		10.1038/nature01942	http://dx.doi.org/10.1038/nature01942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955141				2022-12-28	WOS:000185089200038
J	Lilleyman, J				Lilleyman, J			Simple deliverable therapy needed for childhood leukaemia	LANCET			English	Editorial Material							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRIALS		Royal London Hosp, Queen Marys Sch Med & Dent, Barts & London, Dept Paediat Haematol & Oncol, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Lilleyman, J (corresponding author), Royal London Hosp, Queen Marys Sch Med & Dent, Barts & London, Dept Paediat Haematol & Oncol, London E1 1BB, England.							Campana D, 2003, BRIT J HAEMATOL, V121, P823, DOI 10.1046/j.1365-2141.2003.04393.x; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Greaves M, 2002, BRIT MED J, V324, P283, DOI 10.1136/bmj.324.7332.283; Hargrave DR, 2001, BRIT J HAEMATOL, V112, P293, DOI 10.1046/j.1365-2141.2001.02543.x; PETO J, 1986, LANCET, V1, P408; PINKEL D, 1971, J AMER MED ASSOC, V216, P648, DOI 10.1001/jama.216.4.648; PINKEL D, 1992, BRIT J CANCER, V65, P148, DOI 10.1038/bjc.1992.32; Silverman LB, 2003, CURR OPIN HEMATOL, V10, P290, DOI 10.1097/00062752-200307000-00007	8	19	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					676	677		10.1016/S0140-6736(03)14241-9	http://dx.doi.org/10.1016/S0140-6736(03)14241-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957086				2022-12-28	WOS:000185034800004
J	Opie, LH				Opie, LH			Errors: Incompetence, ineptitude or failure	LANCET			English	Editorial Material									Univ Cape Town, Fac Hlth Sci, Hatter Inst, ZA-7925 Observatory, South Africa	University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Fac Hlth Sci, Hatter Inst, ZA-7925 Observatory, South Africa.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					731	731		10.1016/S0140-6736(03)14235-3	http://dx.doi.org/10.1016/S0140-6736(03)14235-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957097				2022-12-28	WOS:000185034800024
J	Blackburn, GM; Williams, NH; Gamblin, SJ; Smerdon, SJ				Blackburn, GM; Williams, NH; Gamblin, SJ; Smerdon, SJ			Comment on "The pentacovalent phosphorus intermediate of a phosphoryl transfer reaction"	SCIENCE			English	Editorial Material									Univ Sheffield, Krebs Inst, Sheffield S3 7HF, S Yorkshire, England; Natl Inst Med Res, London NW7 1AA, England	University of Sheffield; MRC National Institute for Medical Research	Blackburn, GM (corresponding author), Univ Sheffield, Krebs Inst, Sheffield S3 7HF, S Yorkshire, England.	g.m.blackburn@shef.ac.uk; n.h.williams@shef.ac.uk; sgambli@nimr.mrc.ac.uk; ssmerdo@nimr.mrc.ac.uk		Smerdon, Stephen/0000-0001-5688-8465; Williams, Nicholas/0000-0002-4457-4220				Davies JE, 2001, ACTA CRYSTALLOGR E, V57, pO994, DOI 10.1107/S1600536801015951; Graham DL, 2002, CHEM BIOL, V9, P375, DOI 10.1016/S1074-5521(02)00112-6; HENGGE AC, 1998, COMPREHENSIVE BIOL C, V1, P517; Knowles J, 2003, SCIENCE, V299, P2002, DOI 10.1126/science.1084036; Lahiri SD, 2003, SCIENCE, V299, P2067, DOI 10.1126/science.1082710; LAYNE PP, 1975, J BIOL CHEM, V250, P966; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#	7	56	57	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947182				2022-12-28	WOS:000185003500021
J	Spath, GF; Lye, LF; Segawa, H; Sacks, DL; Turco, SJ; Beverley, SM				Spath, GF; Lye, LF; Segawa, H; Sacks, DL; Turco, SJ; Beverley, SM			Persistence without pathology in phosphoglycan-deficient Leishmania major	SCIENCE			English	Article							MURINE CUTANEOUS LEISHMANIASIS; LATENT LEISHMANIASIS; VIRULENCE FACTOR; LIPOPHOSPHOGLYCAN; MICE; PARASITES; HOST; PROMASTIGOTES; REACTIVATION; IMMUNITY	Leishmania infections involve an acute phase of replication within macrophages, typically associated with pathology. After recovery parasites persist for long periods, which can lead to severe disease upon reactivation. Unlike the role of host factors, parasite factors affecting persistence are poorly understood. Leishmania major lacking phosphoglycans (lpg2(-)) were unable to survive in sand flies and macrophages, but retained the ability to persist indefinitely in the mammalian host without inducing disease. The L. major lpg2(-) thus provides a platform for probing parasite factors implicated in persistence and its role in disease and immunity.	Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; NIAID, Parasit Dis Lab, Bethesda, MD 20892 USA	Washington University (WUSTL); University of Kentucky; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Beverley, SM (corresponding author), Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA.		Späth, Gerald/B-1393-2014	Spaeth, Gerald/0000-0002-0256-2029; Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI31078] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031078, ZIAAI000256, Z01AI000256] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AEBISCHER T, 1993, INFECT IMMUN, V61, P220, DOI 10.1128/IAI.61.1.220-226.1993; Alexander J, 1998, J IMMUNOL, V161, P6794; Alvar J, 1997, CLIN MICROBIOL REV, V10, P298, DOI 10.1128/CMR.10.2.298; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Bogdan C, 1998, INT J PARASITOL, V28, P121, DOI 10.1016/S0020-7519(97)00169-0; Bogdan C, 2000, J EXP MED, V191, P2121, DOI 10.1084/jem.191.12.2121; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; GREEN PJ, 1994, MOL BIOCHEM PARASIT, V66, P319, DOI 10.1016/0166-6851(94)90158-9; Ilg T, 1999, BIOCHEM SOC T, V27, P518; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; Ilgoutz SC, 2001, INT J PARASITOL, V31, P899, DOI 10.1016/S0020-7519(01)00197-7; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MOODY SF, 1993, J BIOL CHEM, V268, P18457; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Piedrafita D, 1999, EUR J IMMUNOL, V29, P235, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;235::AID-IMMU235&gt;3.0.CO;2-S; Rittig MG, 2000, PARASITOL TODAY, V16, P292, DOI 10.1016/S0169-4758(00)01692-6; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Spath GF, 2001, EXP PARASITOL, V99, P97, DOI 10.1006/expr.2001.4656; Stenger S, 1996, J EXP MED, V183, P1501, DOI 10.1084/jem.183.4.1501; TITUS RG, 1991, EUR J IMMUNOL, V21, P559, DOI 10.1002/eji.1830210305; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; UZONNA J, UNPUB; Uzonna JE, 2001, J IMMUNOL, V167, P6967, DOI 10.4049/jimmunol.167.12.6967	30	135	143	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1241	1243		10.1126/science.1087499	http://dx.doi.org/10.1126/science.1087499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947201				2022-12-28	WOS:000185003500044
J	Grossman, HB; Natale, RB; Tangen, CM; Speights, VO; Vogelzang, NJ; Trump, DL; White, RWD; Sarosdy, MF; Wood, DP; Raghavan, D; Crawford, ED				Grossman, HB; Natale, RB; Tangen, CM; Speights, VO; Vogelzang, NJ; Trump, DL; White, RWD; Sarosdy, MF; Wood, DP; Raghavan, D; Crawford, ED			Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSITIONAL-CELL-CARCINOMA; RADICAL CYSTECTOMY; PROGNOSTIC FACTORS; RANDOMIZED TRIAL; M-VAC; METHOTREXATE; DOXORUBICIN; VINBLASTINE; CISPLATIN; UROTHELIUM	BACKGROUND: Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases. We evaluated the ability of neoadjuvant chemotherapy to improve the outcome in patients with locally advanced bladder cancer who were treated with radical cystectomy. METHODS: Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be treated with radical cystectomy. They were stratified according to age (less than 65 years vs. 65 years or older) and stage (superficial muscle invasion vs. more extensive disease) and were randomly assigned to radical cystectomy alone or three cycles of methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy. RESULTS: We enrolled 317 patients over an 11-year period, 10 of whom were found to be ineligible; thus, 154 were assigned to receive surgery alone and 153 to receive combination therapy. According to an intention-to-treat analysis, the median survival among patients assigned to surgery alone was 46 months, as compared with 77 months among patients assigned to combination therapy (P=0.06 by a two-sided stratified log-rank test). In both groups, improved survival was associated with the absence of residual cancer in the cystectomy specimen. Significantly more patients in the combination-therapy group had no residual disease than patients in the cystectomy group (38 percent vs. 15 percent, P<0.001). CONCLUSIONS: As compared with radical cystectomy alone, the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA; SW Oncol Grp, Ctr Stat, Seattle, WA USA; Scott & White Mem Hosp & Clin, Temple, TX USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Univ Calif Davis, Sacramento, CA 95817 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; Wayne State Univ, Med Ctr, Detroit, MI 48202 USA; Univ So Calif, Sch Med, Los Angeles, CA USA; Univ Colorado, Denver, CO 80202 USA	University of Texas System; UTMD Anderson Cancer Center; Cedars Sinai Medical Center; Southwest Oncology Group; Scott & White Medical Center; University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio; Detroit Medical Center; Wayne State University; University of Southern California; University of Colorado System; University of Colorado Denver	Grossman, HB (corresponding author), SW Oncol Grp, Operat Off, SWOG 8710, 14980 Omicron Dr, San Antonio, TX 78245 USA.				NCI NIH HHS [CA35262, CA46441, CA35192, CA35090, CA32102, CA58415, CA58416, CA35281, CA35431, CA38926, CA42777, CA45377, CA45560, CA46113, CA46136, CA46282, CA46368, CA04920, CA14028, CA76447, CA63844, CA16385, CA20319, CA22433, CA58882, CA27057, CA58861, CA58686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA035090, U10CA046282, U10CA046136, U10CA046113, U10CA058861, U10CA058415, U10CA058686, U10CA014028, U10CA035431, U10CA032102, U10CA058882, U10CA022433, U10CA038926, U10CA035262, U10CA063844, U10CA020319, U10CA045560, U10CA016385, U10CA046368, U10CA058416, U10CA035281, U10CA027057, U10CA042777, U10CA045377, U10CA035192, U10CA076447, U10CA004920] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1999, Lancet, V354, P533; Bassi P, 1999, J UROLOGY, V161, P1494, DOI 10.1016/S0022-5347(05)68936-7; BEAHRS OH, 1992, MANUAL STAGING CANC, P195; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P144; Hall R, 2002, P AM SOC CLIN ONCOL, V21, p178A; Herr HW, 1998, J CLIN ONCOL, V16, P1298, DOI 10.1200/JCO.1998.16.4.1298; Lamm DL, 2000, J UROLOGY, V163, P1124, DOI 10.1016/S0022-5347(05)67707-5; LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066; LOEHRER PJ, 1993, J CLIN ONCOL, V11, P384; LOGOTHETIS CJ, 1990, J CLIN ONCOL, V8, P1050, DOI 10.1200/JCO.1990.8.6.1050; Millikan R, 2001, J CLIN ONCOL, V19, P4005, DOI 10.1200/JCO.2001.19.20.4005; Natale R B, 2000, Curr Oncol Rep, V2, P386, DOI 10.1007/s11912-000-0057-1; Negri E, 2001, EUR J CANCER PREV, V10, P7, DOI 10.1097/00008469-200102000-00002; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; SKINNER DG, 1984, J UROLOGY, V131, P1069, DOI 10.1016/S0022-5347(17)50809-5; Smith JA, 1997, J UROLOGY, V157, P805, DOI 10.1016/S0022-5347(01)65047-X; STERNBERG CN, 1989, CANCER, V64, P2448, DOI 10.1002/1097-0142(19891215)64:12<2448::AID-CNCR2820641209>3.0.CO;2-7; STERNBERG CN, 1985, J UROLOGY, V133, P403, DOI 10.1016/S0022-5347(17)48996-8; 1999, LANCET, V354, P1650	20	1787	1825	2	57	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					859	866		10.1056/NEJMoa022148	http://dx.doi.org/10.1056/NEJMoa022148			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944571				2022-12-28	WOS:000184968400006
J	Lenfant, C				Lenfant, C			Shattuck Lecture: Clinical research to clinical practice - Lost in translation?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Massachusetts-Medical-Society	MAY 03, 2003	BOSTON, MA	Massachusetts Med Soc			ACUTE MYOCARDIAL-INFARCTION; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; ACC/AHA GUIDELINES; AMERICAN-COLLEGE; DISEASE; RISK; MEDICATION; POLYMORPHISMS; POPULATION		NHLBI, NIH, Bethesda, MD 20892 USA; Dept Hlth & Human Serv, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Lenfant, C (corresponding author), NHLBI, NIH, 9000 Rockville Pike,Bldg 31,Room 5A52, Bethesda, MD 20892 USA.							[Anonymous], 1981, JAMA-J AM MED ASSOC, V246, P2073; Awtry EH, 2000, CIRCULATION, V101, P1206, DOI 10.1161/01.CIR.101.10.1206; Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Bloom BS, 1998, CLIN THER, V20, P671, DOI 10.1016/S0149-2918(98)80130-6; Califf RM, 2002, AM J CARDIOL, V89, P653, DOI 10.1016/S0002-9149(01)02335-9; Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393; Galuska DA, 1999, JAMA-J AM MED ASSOC, V282, P1576, DOI 10.1001/jama.282.16.1576; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Lee JY, 1996, AM J HYPERTENS, V9, P719, DOI 10.1016/0895-7061(96)00056-8; Morrison AC, 2001, STROKE, V32, P822, DOI 10.1161/01.STR.32.4.822; *NAT COMM QUAL, 2002, STAT HLTH CAR QUAL; *NAT COMM QUAL ASS, 1997, STAT MAN CAR QUAL; *NAT COMM QUAL ASS, 1999, STAT MAN CAR QUAL; *NAT REG MYOC INF, 2002, 4 NMRI NAT REG MYOC; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; Rees J, 2002, SCIENCE, V296, P698, DOI 10.1126/science.296.5568.698; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; Schneider EC, 2001, ANN INTERN MED, V135, P328, DOI 10.7326/0003-4819-135-5-200109040-00009; Schwartz K, 2003, NAT MED, V9, P493, DOI 10.1038/nm0503-493; Small KM, 2002, NEW ENGL J MED, V347, P1135, DOI 10.1056/NEJMoa020803; Stafford RS, 2003, J AM COLL CARDIOL, V41, P56, DOI 10.1016/S0735-1097(02)02670-0; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Turner ST, 2001, HYPERTENSION, V37, P739, DOI 10.1161/01.HYP.37.2.739; Wee CC, 1999, JAMA-J AM MED ASSOC, V282, P1583, DOI 10.1001/jama.282.16.1583; Willett WC, 2002, SCIENCE, V296, P695, DOI 10.1126/science.1071055; Wu KK, 2001, CIRCULATION, V103, P1386, DOI 10.1161/01.CIR.103.10.1386	29	607	628	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					868	874		10.1056/NEJMsa035507	http://dx.doi.org/10.1056/NEJMsa035507			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	715JM	12944573	Bronze			2022-12-28	WOS:000184968400009
J	Sullivan, MB; Waterbury, JB; Chisholm, SW				Sullivan, MB; Waterbury, JB; Chisholm, SW			Cyanophages infecting the oceanic cyanobacterium Prochlorococcus	NATURE			English	Article							MARINE SYNECHOCOCCUS; SARGASSO SEA; DIVERSITY; ABUNDANCE; BACTERIOPHAGE; ECOTYPES; ECOLOGY; VIRUSES; WH7803; PHAGES	Prochlorococcus is the numerically dominant phototroph in the tropical and subtropical oceans, accounting for half of the photosynthetic biomass in some areas(1,2). Here we report the isolation of cyanophages that infect Prochlorococcus, and show that although some are host-strain-specific, others cross-infect with closely related marine Synechococcus as well as between high-light-and low-light-adapted Prochlorococcus isolates, suggesting a mechanism for horizontal gene transfer. Highlight-adapted Prochlorococcus hosts yielded Podoviridae exclusively, which were extremely host-specific, whereas low-light-adapted Prochlorococcus and all strains of Synechococcus yielded primarily Myoviridae, which has a broad host range. Finally, both Prochlorococcus and Synechococcus strain-specific cyanophage titres were low (< 10(3) ml(-1)) in stratified oligotrophic waters even where total cyanobacterial abundances were high (> 10(5) cells ml(-1)). These low titres in areas of high total host cell abundance seem to be a feature of open ocean ecosystems. We hypothesize that gradients in cyanobacterial population diversity, growth rates, and/or the incidence of lysogeny underlie these trends.	MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; MIT, Woods Hole Oceanog Inst, Joint Program Biol Oceanog, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution; Massachusetts Institute of Technology (MIT); Woods Hole Oceanographic Institution	Chisholm, SW (corresponding author), MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA.		Sullivan, Matthew B/H-3256-2011	Sullivan, Matthew B/0000-0003-4040-9831; Chisholm, Sallie/0000-0003-1480-2445				Bohannan BJM, 2000, ECOL LETT, V3, P362, DOI 10.1046/j.1461-0248.2000.00161.x; Cavender-Bares KK, 2001, DEEP-SEA RES PT I, V48, P2373, DOI 10.1016/S0967-0637(01)00027-9; Fuller NJ, 2003, APPL ENVIRON MICROB, V69, P2430, DOI 10.1128/AEM.69.5.2430-2443.2003; Hendrix RW, 1999, P NATL ACAD SCI USA, V96, P2192, DOI 10.1073/pnas.96.5.2192; Liu HB, 1997, AQUAT MICROB ECOL, V12, P39, DOI 10.3354/ame012039; Lu J, 2001, APPL ENVIRON MICROB, V67, P3285, DOI 10.1128/AEM.67.7.3285-3290.2001; Mann EL, 2002, LIMNOL OCEANOGR, V47, P976, DOI 10.4319/lo.2002.47.4.0976; Moore LR, 1999, LIMNOL OCEANOGR, V44, P628, DOI 10.4319/lo.1999.44.3.0628; Moore LR, 1998, NATURE, V393, P464, DOI 10.1038/30965; Murphy FA, 1995, VIRUS TAXONOMY CLASS; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Rocap G, 2002, APPL ENVIRON MICROB, V68, P1180, DOI 10.1128/AEM.68.3.1180-1191.2002; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rohwer F, 2000, LIMNOL OCEANOGR, V45, P408, DOI 10.4319/lo.2000.45.2.0408; Scanlan DJ, 2002, FEMS MICROBIOL ECOL, V40, P1, DOI 10.1111/j.1574-6941.2002.tb00930.x; Steward GF, 1996, MAR ECOL PROG SER, V131, P287, DOI 10.3354/meps131287; Suttle C.A., 2000, ECOLOGY CYANOBACTERI, P563, DOI DOI 10.1007/0-306-46855-7_20; SUTTLE CA, 1994, APPL ENVIRON MICROB, V60, P3167, DOI 10.1128/AEM.60.9.3167-3174.1994; SUTTLE CA, 1993, MAR ECOL PROG SER, V92, P99, DOI 10.3354/meps092099; Thingstad TF, 2000, LIMNOL OCEANOGR, V45, P1320, DOI 10.4319/lo.2000.45.6.1320; Urbach E, 1998, LIMNOL OCEANOGR, V43, P1615, DOI 10.4319/lo.1998.43.7.1615; WATERBURY JB, 1993, APPL ENVIRON MICROB, V59, P3393, DOI 10.1128/AEM.59.10.3393-3399.1993; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71; Wichels A, 1998, APPL ENVIRON MICROB, V64, P4128; Wilson WH, 1996, J PHYCOL, V32, P506, DOI 10.1111/j.0022-3646.1996.00506.x; WILSON WH, 1993, APPL ENVIRON MICROB, V59, P3736, DOI 10.1128/AEM.59.11.3736-3743.1993; Woese CR, 2000, P NATL ACAD SCI USA, V97, P8392, DOI 10.1073/pnas.97.15.8392	29	384	412	3	103	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1047	1051		10.1038/nature01929	http://dx.doi.org/10.1038/nature01929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944965				2022-12-28	WOS:000184984200041
J	Aronow, WS				Aronow, WS			Might losartan reduce sudden cardiac death in diabetic patients with hypertension?	LANCET			English	Editorial Material							COMPLEX VENTRICULAR ARRHYTHMIAS; ACUTE MYOCARDIAL-INFARCTION; CHRONIC HEART-FAILURE; ATRIAL-FIBRILLATION; RANDOMIZED TRIAL; ELDERLY PATIENTS; MORTALITY; PROPRANOLOL; DISEASE; HYPERTROPHY		Westchester Cty Med Ctr, Dept Med, Div Cardiol & Geriatr, Valhalla, NY 10595 USA; New York Med Coll, Div Cardiol & Geriatr, Valhalla, NY 10595 USA	Westchester Medical Center; New York Medical College	Aronow, WS (corresponding author), Westchester Cty Med Ctr, Dept Med, Div Cardiol & Geriatr, Valhalla, NY 10595 USA.							Aronow WS, 1999, AM J CARDIOL, V84, P468, DOI 10.1016/S0002-9149(99)00336-7; ARONOW WS, 1994, AM J CARDIOL, V74, P267, DOI 10.1016/0002-9149(94)90369-7; ARONOW WS, 1988, AM J CARDIOL, V62, P1124, DOI 10.1016/0002-9149(88)90562-0; ARONOW WS, 1995, AM J CARDIOL, V75, P182, DOI 10.1016/S0002-9149(00)80074-0; ARONOW WS, 1994, AM J CARDIOL, V74, P819, DOI 10.1016/0002-9149(94)90445-6; ARONOW WS, 1994, AM J CARDIOL, V74, P613, DOI 10.1016/0002-9149(94)90755-2; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GUNDERSEN T, 1982, CIRCULATION, V66, P1179, DOI 10.1161/01.CIR.66.6.1179; HANSTEEN V, 1983, CIRCULATION, V67, P57; Hjalmarson A, 1999, LANCET, V353, P2001; KENNEDY HL, 1994, AM J CARDIOL, V74, P674, DOI 10.1016/0002-9149(94)90308-5; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; OLSSON G, 1992, EUR HEART J, V13, P28, DOI 10.1093/oxfordjournals.eurheartj.a060043; OLSSON G, 1991, AM J HYPERTENS, V4, P151, DOI 10.1093/ajh/4.2.151; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; WIKSTRAND J, 1992, EUR HEART J, V13, P111	20	29	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					591	592		10.1016/S0140-6736(03)14208-0	http://dx.doi.org/10.1016/S0140-6736(03)14208-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944056				2022-12-28	WOS:000184904100005
J	Taylor, A				Taylor, A			ABC of subfertility - Extent of the problem	BRITISH MEDICAL JOURNAL			English	Review							EUROPEAN MULTICENTER; INFERTILITY; SUBFECUNDITY		Guys & St Thomass Assisted Concept Unit, London, England		Taylor, A (corresponding author), Guys & St Thomass Assisted Concept Unit, London, England.							Balen A. H., 1997, INFERTILITY PRACTICE; Bolumar F, 1996, AM J EPIDEMIOL, V143, P578; Bolumar F, 2000, AM J EPIDEMIOL, V151, P1072, DOI 10.1093/oxfordjournals.aje.a010150; COLLINS JA, 1995, FERTIL STERIL, V64, P22, DOI 10.1016/s0015-0282(16)57650-x; Dunson DB, 2002, HUM REPROD, V17, P1399, DOI 10.1093/humrep/17.5.1399; FORMAN R, 1996, DRUG INDUCED INFERTI; SKAKKEBAEK NE, 1994, LANCET, V343, P1473, DOI 10.1016/S0140-6736(94)92586-0	7	68	70	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					434	436		10.1136/bmj.327.7412.434	http://dx.doi.org/10.1136/bmj.327.7412.434			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715YY	12933733	Green Published			2022-12-28	WOS:000185003100023
J	Bandfield, JL; Glotch, TD; Christensen, PR				Bandfield, JL; Glotch, TD; Christensen, PR			Spectroscopic identification of carbonate minerals in the martian dust	SCIENCE			English	Article							THERMAL EMISSION; MARS; SPECTROMETER; SOIL; SURFACES; SPECTRA; CLIMATE; CLAYS	Thermal infrared spectra of the martian surface indicate the presence of small concentrations (similar to2 to 5 weight %) of carbonates, specifically dominated by magnesite (MgCO3). The carbonates are widely distributed in the martian dust, and there is no indication of a concentrated source. The presence of small concentrations of carbonate minerals in the surface dust and in martian meteorites can sequester several bars of atmospheric carbon dioxide and may have been an important sink for a thicker carbon dioxide atmosphere in the martian past.	Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA	Arizona State University; Arizona State University-Tempe	Bandfield, JL (corresponding author), Arizona State Univ, Dept Geol Sci, Tempe, AZ 85287 USA.		Glotch, Timothy/B-6829-2008	Bandfield, Joshua/0000-0003-3571-3716				Bandfield JL, 2000, SCIENCE, V287, P1626, DOI 10.1126/science.287.5458.1626; Bandfield JL, 2003, ICARUS, V161, P47, DOI 10.1016/S0019-1035(02)00025-8; BANDFIELD JL, 2002, J GEOPHYS RES; BANIN A, 1979, J MOL EVOL, V14, P133, DOI 10.1007/BF01732373; BETTS BH, 1995, J GEOPHYS RES-PLANET, V100, P5285, DOI 10.1029/95JE00226; BLANEY DL, 1989, J GEOPHYS RES-SOLID, V94, P10159, DOI 10.1029/JB094iB08p10159; BOOTH MC, 1978, J GEOPHYS RES, V83, P1809, DOI 10.1029/JB083iB04p01809; CALVIN WM, 1994, J GEOPHYS RES-PLANET, V99, P14659, DOI 10.1029/94JE01090; Christensen PR, 2001, J GEOPHYS RES-PLANET, V106, P23823, DOI 10.1029/2000JE001370; Fanale F.P., 1992, MARS, P1135; FANALE FP, 1982, ICARUS, V50, P381, DOI 10.1016/0019-1035(82)90131-2; Farmer V. C., 1974, INFRARED SPECTRA MIN; Gaffey S.J., 1993, REMOTE GEOCHEMICAL A, P43; GOODING JL, 1978, ICARUS, V33, P483, DOI 10.1016/0019-1035(78)90186-0; GOODING JL, 1992, ICARUS, V99, P28, DOI 10.1016/0019-1035(92)90168-7; HUGUENIN RL, 1974, J GEOPHYS RES, V79, P3895, DOI 10.1029/JB079i026p03895; JAKOSKY BM, 1990, GEOPHYS RES LETT, V17, P985, DOI 10.1029/GL017i007p00985; KAHN R, 1985, ICARUS, V62, P175, DOI 10.1016/0019-1035(85)90116-2; Lane MD, 1997, J GEOPHYS RES-PLANET, V102, P25581, DOI 10.1029/97JE02046; Lellouch E, 2000, PLANET SPACE SCI, V48, P1393, DOI 10.1016/S0032-0633(00)00118-5; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P14595, DOI 10.1029/JB095iB09p14595; RUFF SW, 2002, EOS S, V83, P1059; RUFF SW, 2002, J GEOPHYS RES; Salisbury J.W., 1991, INFRARED 2 1 25 MUM; SALISBURY JW, 1989, J GEOPHYS RES-SOLID, V94, P9192, DOI 10.1029/JB094iB07p09192; SETTLE M, 1979, J GEOPHYS RES, V84, P8343, DOI 10.1029/JB084iB14p08343; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; Wagner C, 1996, ICARUS, V123, P256, DOI 10.1006/icar.1996.0156	29	256	262	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1084	1087		10.1126/science.1088054	http://dx.doi.org/10.1126/science.1088054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934004				2022-12-28	WOS:000184872400036
J	Wu, S; Huang, JB; Dong, JX; Pan, DJ				Wu, S; Huang, JB; Dong, JX; Pan, DJ			hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts	CELL			English	Article							TUMOR SUPPRESSORS; IMAGINAL DISC; CYCLIN-E; DROSOPHILA; GROWTH; SIZE; ACTIVATION; MOSAICS; DEATH; SHAPE	The coordination between cell proliferation and cell death is essential to maintain homeostasis within multicellular organisms. The mechanisms underlying this regulation are yet to be completely understood. Here, we report the identification of hippo (hpo) as a gene that regulates both cell proliferation and cell death in Drosophila. hpo encodes a Ste-20 family protein kinase that binds to and phosphorylates the tumor suppressor protein Salvador (Sav), which is known to interact with the Warts (Wts) protein kinase. Loss of hpo results in elevated transcription of the cell cycle regulator cyclin E and the cell-death inhibitor diap1, leading to increased proliferation and reduced apoptosis. Further, we show that hpo, sav, and wts define a pathway that regulates diap1 at the transcriptional level. A human homolog of hpo completely rescues the overgrowth phenotype of Drosophila hpo mutants, suggesting that hpo might play a conserved role for growth control in mammals.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Pan, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wu, Shian/0000-0003-4990-6594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062323] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62323] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen B, 1998, GENETICS, V149, P157; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hisaoka M, 2002, LAB INVEST, V82, P1427, DOI 10.1097/01.LAB.0000032381.68634.CA; Johnston LA, 2002, BIOESSAYS, V24, P54, DOI 10.1002/bies.10021; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Wolff Tanya, 1993, P1277; XU TA, 1995, DEVELOPMENT, V121, P1053; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	30	806	846	5	76	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					445	456		10.1016/S0092-8674(03)00549-X	http://dx.doi.org/10.1016/S0092-8674(03)00549-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941273	Bronze			2022-12-28	WOS:000184928800008
J	Jafar, TH; Stark, PC; Schmid, CH; Landa, M; Maschio, G; de Jong, PE; de Zeeuw, D; Shahinfar, S; Toto, R; Levey, AS				Jafar, TH; Stark, PC; Schmid, CH; Landa, M; Maschio, G; de Jong, PE; de Zeeuw, D; Shahinfar, S; Toto, R; Levey, AS		AIPRD Study Grp	Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC RENAL-DISEASE; CARDIOVASCULAR-DISEASE; HYPERTENSION; INSUFFICIENCY; NIFEDIPINE; ENALAPRIL; OUTCOMES; INJURY	Background: Angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure and urine protein excretion and slow the progression of chronic kidney disease. Purpose: To determine the levels of blood pressure and urine protein excretion associated with the lowest risk for progression of chronic kidney disease during anti hypertensive therapy with and without ACE inhibitors. Data Sources: 11 randomized, controlled trials comparing the efficacy of anti hypertensive regimens with or without ACE inhibitors for patients with predominantly nondiabetic kidney disease. Study Selection: MEDLINE database search for English-language studies published between 1977 and 1999. Data Extraction: Data on 1860 nondiabetic patients were pooled in a patient-level meta-analysis. Progression of kidney disease was defined as a doubling of baseline serum creatinine level or onset of kidney failure. Multivariable regression analysis was performed to assess the association of systolic and diastolic blood pressure and urine protein excretion with kidney disease progression at 22610 patient visits. Data Synthesis: Mean duration of follow-up was 2.2 years. Kidney disease progression was documented in 311 patients. Systolic blood pressure of 110 to 129 mm Hg and urine protein excretion less than 2.0 g/d were associated with the lowest risk for kidney disease progression. Angiotensin-converting enzyme inhibitors remained beneficial after adjustment for blood pressure and urine protein excretion (relative risk, 0.67 [95% CI, 0.53 to 0.84]). The increased risk for kidney progression at higher systolic blood pressure levels was greater in patients with urine protein excretion greater than 1.0 g/d (P<0.006). Conclusion: Although reverse causation cannot be excluded with certainty, a systolic blood pressure goal between 110 and 129 mm Hg may be beneficial in patients with urine protein excretion greater than 1.0 g/d. Systolic blood pressure less than 110 mm Hg may be associated with a higher risk for kidney disease progression.	Tufts Univ New England Med Ctr, Div Nephrol, Boston, MA 02111 USA; Aga Khan Univ, Karachi, Pakistan; Osped Civile, I-37126 Verona, Italy; Univ Groningen, Groningen, Netherlands; Merck Res Labs, West Point, PA USA; Univ Texas, SW Med Ctr, Dallas, TX USA	Tufts Medical Center; Aga Khan University; University of Groningen; Merck & Company; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Levey, AS (corresponding author), Tufts Univ New England Med Ctr, Div Nephrol, 750 Washington St,Box 391, Boston, MA 02111 USA.		Toto, Robert/AAQ-3336-2021; de Zeeuw, Dick/E-9080-2014; Schmid, Christopher H./J-2398-2014	de Zeeuw, Dick/0000-0003-3434-7777; Schmid, Christopher H./0000-0002-0855-5313	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010064] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053869] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN PK, 1993, SPRINGER SERIES STAT, P152; ANDERSON S, 1989, KIDNEY INT, V36, P526, DOI 10.1038/ki.1989.227; BANNISTER KM, 1995, CONTRIB NEPHROL, V111, P184; BANNISTER KM, 1995, CONTRIB NEPHROL, V111, P192; Basile DP, 2001, AM J PHYSIOL-RENAL, V281, pF887, DOI 10.1152/ajprenal.0050.2001; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Chaturvedi N, 2001, ANN INTERN MED, V134, P370, DOI 10.7326/0003-4819-134-5-200103060-00009; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cinotti GA, 2001, NEPHROL DIAL TRANSPL, V16, P961, DOI 10.1093/ndt/16.5.961; Coresh J, 2001, ARCH INTERN MED, V161, P1207, DOI 10.1001/archinte.161.9.1207; HAKIM RM, 1989, AM J KIDNEY DIS, V14, P396, DOI 10.1016/S0272-6386(89)80173-8; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; HANSSON L, 1999, J CLIN HYPERTENS GRE, V2, P136; Himmelmann Anders, 1995, Blood Pressure, V4, P85, DOI 10.3109/08037059509077575; Ihle BU, 1996, AM J KIDNEY DIS, V27, P489, DOI 10.1016/S0272-6386(96)90158-4; Jafar TH, 2001, KIDNEY INT, V60, P1131, DOI 10.1046/j.1523-1755.2001.0600031131.x; Jafar TH, 2001, ANN INTERN MED, V135, P73, DOI 10.7326/0003-4819-135-2-200107170-00007; Joint National Committee on Prevention Detection evaluation and treatment of high blood pressure, 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005; KAMPER AL, 1992, AM J HYPERTENS, V5, P423, DOI 10.1093/ajh/5.7.423; Kaplan N, 1998, LANCET, V351, P1748, DOI 10.1016/S0140-6736(98)22024-1; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Marin R, 2001, J HYPERTENS, V19, P1871, DOI 10.1097/00004872-200110000-00023; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; Mashiach E, 1998, NEPHRON, V80, P458, DOI 10.1159/000045220; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1999, LANCET, V354, P359, DOI 10.1016/S0140-6736(98)10363-X; Sarnak MJ, 2000, AM J KIDNEY DIS, V35, pS117, DOI 10.1016/S0272-6386(00)70239-3; Schmid CH, 2003, CONTROL CLIN TRIALS, V24, P324, DOI 10.1016/S0197-2456(02)00319-7; SIMONS JL, 1994, KIDNEY INT, V46, P396, DOI 10.1038/ki.1994.287; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; THERNEAU T, 1997, P 1 SEATTL S BIOST; *US REN DAT SYST, 2000, USRDS 2000 ANN DAT R; *US REN DAT SYST, 2002, USRDS 2002 ANN DAT R; vanEssen GG, 1997, KIDNEY INT, pS58; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Young JH, 2002, J AM SOC NEPHROL, V13, P2776, DOI 10.1097/01.ASN.0000031805.09178.37; Yusuf S, 2000, NEW ENGL J MED, V342, P145; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309	42	816	854	3	41	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					244	252		10.7326/0003-4819-139-4-200308190-00006	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00006			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965979				2022-12-28	WOS:000184795600002
J	Magira, EE; Gounaris, T; Pantelidaki, C; Sioula, E				Magira, EE; Gounaris, T; Pantelidaki, C; Sioula, E			Diarrhoea and ulcers	LANCET			English	Editorial Material							TUBERCULOSIS; ESOPHAGUS; RARE		Evangelismos Med Ctr, Dept Med, Athens, Greece; Evangelismos Med Ctr, Dept Pathol, Athens, Greece	Evangelismos Hospital; Evangelismos Hospital	Magira, EE (corresponding author), Evangelismos Med Ctr, Dept Med, Athens, Greece.		Magira, Eleni/AAF-8494-2019					Jain SK, 2002, AM J GASTROENTEROL, V97, P287, DOI 10.1111/j.1572-0241.2002.05456.x; Kaushik SP, 1996, J GASTROEN HEPATOL, V11, P532, DOI 10.1111/j.1440-1746.1996.tb01697.x; KNUTSON L, 1984, ACTA CHIR SCAND, V150, P345; LEOTTA SMG, 1995, J INTERN MED, V238, P77, DOI 10.1111/j.1365-2796.1995.tb00902.x; Wort SJ, 1997, LANCET, V349, P1072, DOI 10.1016/S0140-6736(05)62295-7	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					534	534		10.1016/S0140-6736(03)14114-1	http://dx.doi.org/10.1016/S0140-6736(03)14114-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932386				2022-12-28	WOS:000184817600011
J	Pardanani, A; Elliott, M; Reeder, T; Li, CY; Baxter, EJ; Cross, NCP; Tefferi, A				Pardanani, A; Elliott, M; Reeder, T; Li, CY; Baxter, EJ; Cross, NCP; Tefferi, A			Imatinib for systemic mast-cell disease	LANCET			English	Article							C-KIT; MUTATIONS; MASTOCYTOSIS; INHIBITOR	Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ton patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had Important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that Imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.	Mayo Clin, Div Hematol & Internal Med, Rochester, MN 55905 USA; Mayo Clin, Div Hematopathol, Rochester, MN USA; Salisbury Dist Hosp, Wessex Reg Genet Lab, Salisbury, Wilts, England	Mayo Clinic; Mayo Clinic; Salisbury District Hospital	Tefferi, A (corresponding author), Mayo Clin, Div Hematol & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Cross, Nicholas/B-4817-2009	Cross, Nicholas/0000-0001-5481-2555; Baxter, Elizabeth Joanna/0000-0002-5946-5238				FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Yavuz AS, 2002, BLOOD, V100, P661, DOI 10.1182/blood-2002-01-0203	5	207	214	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					535	537		10.1016/S0140-6736(03)14115-3	http://dx.doi.org/10.1016/S0140-6736(03)14115-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932387				2022-12-28	WOS:000184817600012
J	Davis, RJ				Davis, RJ			All that glitters is not Au-0	SCIENCE			English	Editorial Material							LOW-TEMPERATURE OXIDATION; CO OXIDATION; GOLD; CATALYSTS; CLUSTERS		Univ Virginia, Dept Chem Engn, Charlottesville, VA 22904 USA	University of Virginia	Davis, RJ (corresponding author), Univ Virginia, Dept Chem Engn, Charlottesville, VA 22904 USA.							Bond GC, 1999, CATAL REV, V41, P319, DOI 10.1081/CR-100101171; Boyen HG, 2002, SCIENCE, V297, P1533, DOI 10.1126/science.1076248; Costello CK, 2002, APPL CATAL A-GEN, V232, P159, DOI 10.1016/S0926-860X(02)00092-3; Fu Q, 2003, SCIENCE, V301, P935, DOI 10.1126/science.1085721; Guzman J, 2003, ANGEW CHEM INT EDIT, V42, P690, DOI 10.1002/anie.200390191; Guzman J, 2002, J PHYS CHEM B, V106, P7659, DOI 10.1021/jp020584m; HAMMER B, 1995, NATURE, V376, P238, DOI 10.1038/376238a0; HARUTA M, 1993, J CATAL, V144, P175, DOI 10.1006/jcat.1993.1322; HARUTA M, 1989, J CATAL, V115, P301, DOI 10.1016/0021-9517(89)90034-1; Li J, 2003, SCIENCE, V299, P864, DOI 10.1126/science.1079879; Lopez N, 2002, J AM CHEM SOC, V124, P11262, DOI 10.1021/ja026998a; Valden M, 1998, SCIENCE, V281, P1647, DOI 10.1126/science.281.5383.1647	12	111	115	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					926	927		10.1126/science.1088209	http://dx.doi.org/10.1126/science.1088209			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920287				2022-12-28	WOS:000184755900025
J	Kozlova, T; Thummel, CS				Kozlova, T; Thummel, CS			Essential roles for ecdysone signaling during Drosophila mid-embryonic development	SCIENCE			English	Article							GERM-BAND RETRACTION; RETINOID-X-RECEPTOR; MORPHOGENESIS; MELANOGASTER; ISOFORMS; TISSUE; METAMORPHOSIS; ULTRASPIRACLE; EMBRYOGENESIS; ECDYSTEROIDS	Although functions for the steroid hormone ecdysone during Drosophila metamorphosis have been well established, roles for the embryonic ecdysone pulse remain poorly understood. We show that the EcR-USP ecdysone receptor is first activated in the extraembryonic amnioserosa, implicating this tissue as a source of active ecdysteroids in the early embryo. Ecdysone signaling is required for germ band retraction and head involution, morphogenetic movements that shape the first instar larva. This mechanism for coordinating morphogenesis during Drosophila embryonic development parallels the role of ecdysone during metamorphosis. It also provides an intriguing parallel with the role of mammalian extraembryonic tissues as a critical source of steroid hormones during embryonic development.	Univ Utah, Sch Med, Dept Human Genet, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Kozlova, T (corresponding author), Univ S Florida, Dept Biol, 4202 E Fowler Ave, Tampa, FL 33620 USA.							Antoniewski C, 1996, MOL CELL BIOL, V16, P2977; Bender M, 1997, CELL, V91, P777, DOI 10.1016/S0092-8674(00)80466-3; BOWNES M, 1988, P NATL ACAD SCI USA, V85, P1554, DOI 10.1073/pnas.85.5.1554; Buszczak M, 1999, DEVELOPMENT, V126, P4581; Chavez VM, 2000, DEVELOPMENT, V127, P4115; Cherbas L, 2003, DEVELOPMENT, V130, P271, DOI 10.1242/dev.00205; CLIFFORD R, 1992, DEVELOPMENT, V115, P853; D'Avino PP, 2000, DEV BIOL, V220, P211, DOI 10.1006/dbio.2000.9650; Frank LH, 1996, DEVELOPMENT, V122, P1343; GAREN A, 1977, P NATL ACAD SCI USA, V74, P5099, DOI 10.1073/pnas.74.11.5099; Ghbeish N, 2001, P NATL ACAD SCI USA, V98, P3867, DOI 10.1073/pnas.061437798; Hoffmann J.A., 1985, P435; Kiehart DP, 2000, J CELL BIOL, V149, P471, DOI 10.1083/jcb.149.2.471; Kozlova T, 2002, DEVELOPMENT, V129, P1739; Lamka ML, 1999, DEV BIOL, V214, P102, DOI 10.1006/dbio.1999.9409; MAROY P, 1988, J INSECT PHYSIOL, V34, P633, DOI 10.1016/0022-1910(88)90071-6; ORO AE, 1992, DEVELOPMENT, V115, P449; PERRIMON N, 1985, GENETICS, V111, P23; Riddiford LM, 2001, VITAM HORM, V60, P1; ROOTE CE, 1995, DEV BIOL, V169, P322, DOI 10.1006/dbio.1995.1147; Schock F, 2003, GENE DEV, V17, P597, DOI 10.1101/gad.1068403; Schock F, 2002, DEV BIOL, V248, P29, DOI 10.1006/dbio.2002.0698; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; VONKALM L, 1995, BIOESSAYS, V17, P693, DOI 10.1002/bies.950170806; WARD RE, IN PRESS GENETICS; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; Yip MLR, 1997, DEVELOPMENT, V124, P2129	27	123	125	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 26	2003	301	5641					1911	1914		10.1126/science.1087419	http://dx.doi.org/10.1126/science.1087419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725GW	12958367				2022-12-28	WOS:000185536700052
J	Jakicic, JM; Marcus, BH; Gallagher, KI; Napolitano, M; Lang, W				Jakicic, JM; Marcus, BH; Gallagher, KI; Napolitano, M; Lang, W			Effect of exercise duration and intensity on weight loss in overweight, sedentary women - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL-ACTIVITY; CARDIORESPIRATORY FITNESS; BODY-COMPOSITION; ALL-CAUSE; MORTALITY; HEALTH	Context A higher duration and intensity of exercise may improve long-term weight loss. Objective To compare the effects of different durations and intensities of exercise on 12-month weight loss and cardiorespiratory fitness. Design, Setting, and Participants Randomized trial conducted from January 2000 through December 2001 involving 201 sedentary women (mean [SD] age, 37.0 [5.7] years; mean [SD] body mass index, 32.6 [4.2]) in a university-based weight control program. Intervention Participants were randomly assigned to 1 of 4 exercise groups (vigorous intensity/high duration; moderate intensity/high duration; moderate intensity/moderate duration; or vigorous intensity/moderate duration) based on estimated energy expenditure (1000 kcal/wk vs 2000 kcal/wk) and exercise intensity (moderate vs vigorous). All women were instructed to reduce intake of energy to between 1200 and 1500 kcal/d and dietary fat to between 20% and 30% of total energy intake. Main Outcome Measures Body weight, cardiorespiratory fitness, and exercise participation. Results After exclusions, 184 of 196 randomized participants completed 12 months of treatment (94%). in intention-to-treat analysis, mean (SD) weight loss following 12 months of treatment was statistically significant (P <.001) in all exercise groups (vigorous intensity/high duration=8.9 [7.3] kg; moderate intensity/high duration=8.2 [7.6] kg; moderate intensity/moderate duration=6.3 [5.6] kg; vigorous intensity/moderate duration=7.0 [6.4] kg), with no significant difference between groups. Mean (SD) cardiorespiratory fitness levels also increased significantly (P=.04) in all groups (vigorous intensity/high duration=22.0% [19.9%]; moderate intensity/high duration=14.9% [18.6%]; moderate intensity/moderate duration=13.5% [16.9%]; vigorous intensity/moderate duration=18.9% [16.9%]), with no difference between groups. Post hoc analysis revealed that percentage weight loss at 12 months was associated with the level of physical activity performed at 6 and 12 months. Women reporting less than 150 min/wk had a mean (SD) weight loss of 4.7% [6.0%]; inconsistent (other) pattern of physical activity, 7.0% [6.9%]; 150 min/wk or more, 9.5% [7.9%]; and 200 min/wk or more of exercise, 13.6% [7.8%]. Conclusions Significant weight loss and improved cardiorespiratory fitness were achieved through the combination of exercise and diet during 12 months, although no differences were found based on different exercise durations and intensities in this group of sedentary, overweight women.	Univ Pittsburgh, Phys Act & Weight Management Res Ctr, Pittsburgh, PA 15261 USA; Brown Med Sch, Ctr Behav & Prevent Med, Providence, RI USA; Miriam Hosp, Ctr Behav & Prevent Med, Providence, RI 02906 USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Wake Forest University	Jakicic, JM (corresponding author), Univ Pittsburgh, Phys Act & Weight Management Res Ctr, 140 Trees Hall, Pittsburgh, PA 15261 USA.	jjakicic@pitt.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064991] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64991] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American College of Sports Medicine, 2000, GUID EX TEST PRESCR; BARLOW CE, 1995, INT J OBESITY, V19, pS41; BLAIR SN, 1985, AM J EPIDEMIOL, V122, P794, DOI 10.1093/oxfordjournals.aje.a114163; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; Brill JB, 2002, INT J OBESITY, V26, P1484, DOI 10.1038/sj.ijo.0802133; DUNCAN JJ, 1991, JAMA-J AM MED ASSOC, V266, P3295, DOI 10.1001/jama.266.23.3295; Farrell SW, 2002, OBES RES, V10, P417, DOI 10.1038/oby.2002.58; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; GREDIAGIN MA, 1995, J AM DIET ASSOC, V95, P661, DOI 10.1016/S0002-8223(95)00181-6; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB; Jakicic JM, 1999, JAMA-J AM MED ASSOC, V282, P1554, DOI 10.1001/jama.282.16.1554; Jakicic JM, 2002, MED SCI SPORT EXER, V34, P1653, DOI 10.1097/00005768-200210000-00018; Lee CD, 1999, AM J CLIN NUTR, V69, P373; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; McGuire MT, 1999, J CONSULT CLIN PSYCH, V67, P177, DOI 10.1037/0022-006X.67.2.177; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Pronk N P, 1994, Obes Res, V2, P587; Schoeller DA, 1997, AM J CLIN NUTR, V66, P551, DOI 10.1093/ajcn/66.3.551; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; Wei M, 1999, JAMA-J AM MED ASSOC, V282, P1547, DOI 10.1001/jama.282.16.1547; 1998, OBES RES S2, V6, pS71	21	332	337	4	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1323	1330		10.1001/jama.290.10.1323	http://dx.doi.org/10.1001/jama.290.10.1323			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966123	Bronze			2022-12-28	WOS:000185188600024
J	Abernethy, AP; Currow, DC; Frith, P; Fazekas, BS; McHugh, A; Bui, C				Abernethy, AP; Currow, DC; Frith, P; Fazekas, BS; McHugh, A; Bui, C			Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS; LUNG-CANCER; CLINICAL-TRIAL; BREATHLESSNESS; DISEASE	Objective To determine the efficacy of oral morphine in relieving the sensation of breathlessness in patients in whom the underlying aetiology is maximally treated. Design Randomised, double blind, placebo controlled crossover study. Setting Four Outpatient clinics at a hospital in South Australia. Participants 48 participants who had not previously been treated with opioids (mean age 76, SD 5) with predominantly chronic obstructive pulmonary disease (42, 88%) were randomised to four days of 20 mg oral morphine with sustained release followed by four days of identically formulated placebo, or vice versa. Laxatives were provided as needed. Main outcome measures Dyspnoea in the morning and evening as shown on a 100 turn visual analogue scale, quality of sleep, wellbeing, performance on physical exertion, and side effects as measured at the end of the four day treatment period. Results 38 participants completed the study; three withdrew because of definite and two because of possible side effects of morphine (nausea, vomiting, and sedation). Participants reported significantly different dyspnoea scores when treated with morphine: an improvement of 6.6 mm (95% confidence interval 1.6 mm to 11.6 mm) in the morning and of 9.5 mm (3.0 mm to 16.1 mm) in the evening (P = 0.011 and P = 0.006, respectively). During the period in which they were taking morphine participants also reported better sleep (P = 0.039). More participants reported distressing constipation while taking morphine (9 upsilon 1, P = 0.021) in spite of using laxatives. All other side effects were not significantly worse with morphine, although the study was not powered to address side effects. Conclusions Sustained release, oral morphine at low dosage provides significant symptomatic improvement in refractory dyspnoea in the community setting.	Flinders Univ S Australia, Dept Palliat & Support Serv, Div Med, Bedford Pk, SA 5042, Australia; Repatriat Gen Hosp, So Adelaide Palliat Serv, Bedford Pk, SA 5042, Australia; Repatriat Gen Hosp, Dept Resp Med, Bedford Pk, SA 5042, Australia; Nepean Hosp, Dept Nucl Med, Kingswood, NSW 2747, Australia	Flinders University South Australia; Nepean Hospital	Currow, DC (corresponding author), Flinders Univ S Australia, Dept Palliat & Support Serv, Div Med, Bedford Pk, SA 5042, Australia.			Frith, Peter Anthony/0000-0003-3265-0131; Abernethy, Amy/0000-0001-6930-8722; Currow, David/0000-0003-1988-1250				Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; Bredin M, 1999, BMJ-BRIT MED J, V318, P901, DOI 10.1136/bmj.318.7188.901; BURDON JGW, 1994, EUR RESPIR J, V7, P1342, DOI 10.1183/09031936.94.07071342; Chua TP, 1997, J AM COLL CARDIOL, V29, P147, DOI 10.1016/S0735-1097(96)00446-9; HIGGINSON I, 1989, J ROY SOC MED, V82, P264, DOI 10.1177/014107688908200507; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Mashford ML, 2001, THERAPEUTIC GUIDELIN; Mazzocato C, 1999, ANN ONCOL, V10, P1511, DOI 10.1023/A:1008337624200; Morgan MDL, 2001, THORAX, V56, P827; O'Driscoll M, 1999, EUR J CANCER CARE, V8, P37; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; REUBEN DB, 1986, CHEST, V89, P234, DOI 10.1378/chest.89.2.234; Ripamonti C, 1999, SUPPORT CARE CANCER, V7, P233, DOI 10.1007/s005200050255; ROBIN ED, 1986, CHEST, V90, P888, DOI 10.1378/chest.90.6.888; Tanaka K, 2002, J PAIN SYMPTOM MANAG, V23, P490, DOI 10.1016/S0885-3924(02)00400-1	19	339	355	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					523	526		10.1136/bmj.327.7414.523	http://dx.doi.org/10.1136/bmj.327.7414.523			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958109	Bronze, Green Published			2022-12-28	WOS:000185283700014
J	Chen, W; Kirkbride, KC; How, T; Nelson, CD; Mo, JY; Frederick, JP; Wang, XF; Lefkowitz, RJ; Blobe, GC				Chen, W; Kirkbride, KC; How, T; Nelson, CD; Mo, JY; Frederick, JP; Wang, XF; Lefkowitz, RJ; Blobe, GC			beta-arrestin 2 mediates endocytosis of type III TGF-beta receptor and down-regulation of its signaling	SCIENCE			English	Article							GROWTH-FACTOR-BETA; PROTEIN-COUPLED RECEPTORS; INTERNALIZATION; ARRESTIN; EXPRESSION; MODULATION; TRANSDUCTION; MECHANISM; DISTINCT; KINASES	beta-Arrestins bind to activated seven transmembrane-spanning (7TMS) receptors (G protein-coupled receptors) after the receptors are phosphorylated by G protein-coupled receptor kinases (GRKs), thereby regulating their signaling and internalization. Here, we demonstrate an unexpected and analogous role of beta-arrestin 2 (betaarr2) for the single transmembrane-spanning type III transforming growth factor-beta (TGF-beta) receptor (TbetaRIII, also referred to as betaglycan). Binding of betaarr2 to TbetaRIII was also triggered by phosphorylation of the receptor on its cytoplasmic domain (likely at threonine 841). However, such phosphorylation was mediated by the type II TGF-beta receptor (TbetaRII), which is itself a kinase, rather than by a GRK. Association with betaarr2 led to internalization of both receptors and down-regulation of TGF-beta signaling. Thus, the regulatory actions of beta-arrestins are broader than previously appreciated, extending to the TGF-beta receptor family as well.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med & Pharmacol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Duke University	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Chen, Wei/0000-0002-9934-4000	NATIONAL CANCER INSTITUTE [R01CA075368, K22CA091816] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NCI NIH HHS [CA 91816, CA 75368] Funding Source: Medline; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Brown CB, 1999, SCIENCE, V283, P2080, DOI 10.1126/science.283.5410.2080; Chen W., UNPUB; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Deng XB, 1999, CELL GROWTH DIFFER, V10, P11; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Ehrlich M, 2001, J CELL SCI, V114, P1777; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Luttrell LM, 2002, J CELL SCI, V115, P455; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; SIPES NJ, 1990, MOL CARCINOGEN, V3, P12, DOI 10.1002/mc.2940030106; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Yao DY, 2002, MOL BIOL CELL, V13, P4001, DOI 10.1091/mbc.02-07-0104; Zwaagstra JC, 1999, EXP CELL RES, V252, P352, DOI 10.1006/excr.1999.4640; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	25	215	233	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1394	1397		10.1126/science.1083195	http://dx.doi.org/10.1126/science.1083195			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958365				2022-12-28	WOS:000185116400046
J	Fertig, HA				Fertig, HA			Spinning holes in semiconductors	SCIENCE			English	Editorial Material							SPINTRONICS		Univ Kentucky, Dept Phys & Astron, Lexington, KY 40506 USA	University of Kentucky	Fertig, HA (corresponding author), Univ Kentucky, Dept Phys & Astron, Lexington, KY 40506 USA.							DATTA S, 1990, APPL PHYS LETT, V56, P665, DOI 10.1063/1.102730; Fiederling R, 1999, NATURE, V402, P787, DOI 10.1038/45502; Flatte ME, 2001, APPL PHYS LETT, V78, P1273, DOI 10.1063/1.1348317; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Malajovich I, 2001, NATURE, V411, P770, DOI 10.1038/35081014; Murakami S, 2003, SCIENCE, V301, P1348, DOI 10.1126/science.1087128; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Streda P, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.256601; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389	9	5	5	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1335	1336		10.1126/science.1089800	http://dx.doi.org/10.1126/science.1089800			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958348				2022-12-28	WOS:000185116400025
J	Bercovici, D; Karato, S				Bercovici, D; Karato, S			Whole-mantle convection and the transition-zone water filter	NATURE			English	Article							EARTHS MANTLE; SILICATE MELTS; HIGH-PRESSURE; DEEP MANTLE; DENSITY; OLIVINE; PHASE; MODEL; GPA; SOLUBILITY	Because of their distinct chemical signatures, ocean-island and mid-ocean-ridge basalts are traditionally inferred to arise from separate, isolated reservoirs in the Earth's mantle. Such mantle reservoir models, however, typically satisfy geochemical constraints, but not geophysical observations. Here we propose an alternative hypothesis that, rather than being divided into isolated reservoirs, the mantle is filtered at the 410-km-deep discontinuity. We propose that, as the ascending ambient mantle (forced up by the downward flux of subducting slabs) rises out of the high-water-solubility transition zone (between the 660 km and 410 km discontinuities) into the low-solubility upper mantle above 410 km, it undergoes dehydration-induced partial melting that filters out incompatible elements. The filtered, dry and depleted solid phase continues to rise to become the source material for mid-ocean-ridge basalts. The wet, enriched melt residue may be denser than the surrounding solid and accordingly trapped at the 410 km boundary until slab entrainment returns it to the deeper mantle. The filter could be suppressed for both mantle plumes (which therefore generate wetter and more enriched ocean-island basalts) as well as the hotter Archaean mantle (thereby allowing for early production of enriched continental crust). We propose that the transition-zone water-filter model can explain many geochemical observations while avoiding the major pitfalls of invoking isolated mantle reservoirs.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University	Bercovici, D (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.		Bercovici, David/B-1676-2008	Bercovici, David/0000-0003-1993-0016				AHRENS TJ, 1989, NATURE, V342, P122, DOI 10.1038/342122a0; Albarede F, 1998, CHEM GEOL, V145, P413, DOI 10.1016/S0009-2541(97)00152-6; Allegre CJ, 1996, GEOPHYS RES LETT, V23, P3555, DOI 10.1029/96GL03373; Ballentine CJ, 2002, PHILOS T ROY SOC A, V360, P2611, DOI 10.1098/rsta.2002.1083; Boehler R, 1996, ANNU REV EARTH PL SC, V24, P15, DOI 10.1146/annurev.earth.24.1.15; Bolfan-Casanova N, 2000, EARTH PLANET SC LETT, V182, P209, DOI 10.1016/S0012-821X(00)00244-2; Burnham C. W., 1979, EVOLUTION IGNEOUS RO, P439, DOI DOI 10.2307/J.CTT13X1DKM.19; CARROLL MR, 1993, GEOCHIM COSMOCHIM AC, V57, P5039, DOI 10.1016/0016-7037(93)90606-W; Chakraborty S, 1999, SCIENCE, V283, P362, DOI 10.1126/science.283.5400.362; Chamorro EM, 2002, GEOCHIM COSMOCHIM AC, V66, P507, DOI 10.1016/S0016-7037(01)00784-0; Coltice N, 1999, EARTH PLANET SC LETT, V174, P125, DOI 10.1016/S0012-821X(99)00258-7; Davaille A, 1999, NATURE, V402, P756, DOI 10.1038/45461; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Fei Y., 1995, AGU REFERENCE SHELF, P29; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; Hamano Y., 1978, TERRESTRIAL RARE GAS, P155; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; HAURI EH, 1994, CHEM GEOL, V117, P149, DOI 10.1016/0009-2541(94)90126-0; Hofmann A.W., 1980, CARNEGIE I WASH YR B, V79, P477; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; INOUE T, 1994, PHYS EARTH PLANET IN, V85, P237, DOI 10.1016/0031-9201(94)90116-3; Kawamoto T, 1996, EARTH PLANET SC LETT, V142, P587, DOI 10.1016/0012-821X(96)00113-6; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KENNETT BLN, 1991, GEOPHYS J INT, V105, P429, DOI 10.1111/j.1365-246X.1991.tb06724.x; Kohlstedt DL, 1996, CONTRIB MINERAL PETR, V123, P345, DOI 10.1007/s004100050161; MACKWELL SJ, 1990, J GEOPHYS RES-SOLID, V95, P5079, DOI 10.1029/JB095iB04p05079; Masters G., 2000, EARTHS DEEP INTERIOR, V117, P63, DOI DOI 10.1029/GM117P0063; Murakami M, 2002, SCIENCE, V295, P1885, DOI 10.1126/science.1065998; Ochs FA, 1997, CONTRIB MINERAL PETR, V129, P155, DOI 10.1007/s004100050329; OHTANI E, 1995, CHEM GEOL, V120, P207, DOI 10.1016/0009-2541(94)00139-Y; Ohtani E, 2001, EARTH PLANET SC LETT, V193, P69, DOI 10.1016/S0012-821X(01)00505-2; Ohtani E, 2000, PHYS CHEM MINER, V27, P533, DOI 10.1007/s002690000097; ONIONS RK, 1983, NATURE, V306, P429, DOI 10.1038/306429a0; PITZER KS, 1994, J CHEM PHYS, V101, P3111, DOI 10.1063/1.467624; REVENAUGH J, 1994, NATURE, V369, P474, DOI 10.1038/369474a0; Richard G, 2002, EARTH PLANET SC LETT, V205, P37, DOI 10.1016/S0012-821X(02)01012-9; Richet P, 2000, CONTRIB MINERAL PETR, V138, P337, DOI 10.1007/s004100050567; RICHTER FM, 1985, EARTH PLANET SC LETT, V73, P350, DOI 10.1016/0012-821X(85)90083-4; Ringwood, 1975, COMPOSITION STRUCTUR; RINGWOOD AE, 1991, GEOCHIM COSMOCHIM AC, V55, P2083, DOI 10.1016/0016-7037(91)90090-R; Schubert G, 2001, MANTLE CONVECTION EA; SHAW DM, 1970, GEOCHIM COSMOCHIM AC, V34, P237, DOI 10.1016/0016-7037(70)90009-8; SILVER L, 1985, J GEOL, V93, P161, DOI 10.1086/628938; Sobolev AV, 1996, EARTH PLANET SC LETT, V137, P45, DOI 10.1016/0012-821X(95)00203-O; STOLPER E, 1981, J GEOPHYS RES, V86, P6261, DOI 10.1029/JB086iB07p06261; Suzuki A, 1998, PHYS EARTH PLANET IN, V107, P53, DOI 10.1016/S0031-9201(97)00123-4; TACKLEY P, 2002, GEOCHEM GEOPHYS GEOS, V3; Taylor S.R., 1985, CONTINENTAL CRUST IT; van Keken PE, 2002, ANNU REV EARTH PL SC, V30, P493, DOI 10.1146/annurev.earth.30.091201.141236; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; VINNIK L, 2002, GEOPHYS RES LETT, V29; Williams Q, 2001, ANNU REV EARTH PL SC, V29, P365, DOI 10.1146/annurev.earth.29.1.365; Xu YS, 1998, SCIENCE, V280, P1415, DOI 10.1126/science.280.5368.1415; YOUNG TE, 1993, PHYS CHEM MINER, V19, P409; Zhao YH, 2001, ACTA PETROL SIN, V17, P123	55	526	558	3	181	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					39	44		10.1038/nature01918	http://dx.doi.org/10.1038/nature01918			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955133				2022-12-28	WOS:000185089200030
J	McAlindon, T; Formica, M; Kabbara, K; LaValley, M; Lehmer, M				McAlindon, T; Formica, M; Kabbara, K; LaValley, M; Lehmer, M			Conducting clinical trials over the internet: feasibility study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; OSTEOARTHRITIS; KNEE; GLUCOSAMINE; MANAGEMENT; EFFICACY		Tufts Univ, New England Med Ctr, Div Rheumatol, Boston, MA 02111 USA; Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02118 USA	Tufts Medical Center; Tufts University; Boston University	McAlindon, T (corresponding author), Tufts Univ, New England Med Ctr, Div Rheumatol, Box 406,715 Washington St, Boston, MA 02111 USA.	tmcalindon@tufts-nemc.org	LaValley, Michael/AAA-2030-2020	Flynn, Peter/0000-0001-5633-7145; Kabbara, Karim/0000-0002-9699-3160; LaValley, Michael/0000-0002-8488-5170	NATIONAL LIBRARY OF MEDICINE [R01LM006856] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; ALTMAN RD, 1991, J RHEUMATOL, V18, P10; Baker KR, 2001, J RHEUMATOL, V28, P1655; Bellamy N, 1997, J RHEUMATOL, V24, P2413; Carey VJ, 1997, STAT MED, V16, P1667, DOI 10.1002/(SICI)1097-0258(19970815)16:15<1667::AID-SIM602>3.3.CO;2-G; CIBERE J, 2002, ARTHRITIS RHEUM S, V9, pS1549; Edworthy SM, 1999, LUPUS, V8, P596, DOI 10.1191/096120399680411434; Fransen M, 2001, J RHEUMATOL, V28, P156; Hughes R, 2002, RHEUMATOLOGY, V41, P279, DOI 10.1093/rheumatology/41.3.279; Kelly MA, 1997, INT J MED INFORM, V47, P91, DOI 10.1016/S1386-5056(97)00091-9; Marks R, 2001, CLIN CARDIOL, V24, P17; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; McKenna F, 2001, SCAND J RHEUMATOL, V30, P11; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Murray GD, 2000, STAT METHODS MED RES, V9, P17, DOI 10.1191/096228000670253839; Pelletier JP, 2000, ARTHRITIS RHEUM-US, V43, P2339, DOI 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P; Rindone JP, 2000, WESTERN J MED, V172, P91, DOI 10.1136/ewjm.172.2.91; Theiler R, 2002, OSTEOARTHR CARTILAGE, V10, P479, DOI 10.1053/joca.2002.0807	18	63	63	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2003	327	7413					484	487		10.1136/bmj.327.7413.484	http://dx.doi.org/10.1136/bmj.327.7413.484			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946971	Green Published, Bronze			2022-12-28	WOS:000185088900019
J	Cheng, YF; Wong, RSM; Soo, YOY; Chui, CH; Lau, FY; Chan, NPH; Wong, WS; Cheng, G				Cheng, YF; Wong, RSM; Soo, YOY; Chui, CH; Lau, FY; Chan, NPH; Wong, WS; Cheng, G			Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADULTS; THERAPY; MANAGEMENT; CHILDREN; TRIAL; ITP	BACKGROUND: The role of high-dose dexamethasone in the treatment of immune thrombocytopenic purpura in adults is controversial. We assessed the effectiveness of high-dose dexamethasone as initial treatment in a series of consecutive adults with immune thrombocytopenic purpura. METHODS: Consecutive patients with newly diagnosed immune thrombocytopenic purpura and a platelet count of less than 20,000 per cubic millimeter or a platelet count of less than 50,000 per cubic millimeter and clinically significant bleeding were enrolled between January 1997 and December 2000. Oral dexamethasone at a dose of 40 mg per day for four consecutive days was the initial treatment. A response was defined as an increase in the platelet count of at least 30,000 per cubic millimeter and a platelet count of more than 50,000 per cubic millimeter by day 10 after the initiation of treatment. A sustained response was defined as a platelet count of more than 50,000 per cubic millimeter six months after the initial treatment. RESULTS: Of 157 consecutive patients, 125 were eligible. The mean (+/-SD) platelet count before treatment was 12,200+/-11,300 per cubic millimeter. A good initial response to high-dose dexamethasone occurred in 106 of the 125 patients (85 percent): the platelet count increased by at least 20,000 per cubic millimeter by the third day of treatment, and the mean platelet count was 101,400+/-53,200 per cubic millimeter (range, 50,000 to 260,000 per cubic millimeter) one week after the initiation of treatment. Among the 106 patients with a response, 53 (50 percent) had a sustained response; the other 53 (50 percent) had a relapse within six months, most of them (94 percent) within the first three months. A platelet count of less than 90,000 per cubic millimeter on day 10 was associated with a high risk of relapse. The treatment was well tolerated. CONCLUSIONS: A four-day course of high-dose dexamethasone is effective initial therapy for adults with immune thrombocytopenic purpura.	Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Hong Kong Polytechnic University	Cheng, G (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Ngan Shing St, Shatin, Hong Kong, Peoples R China.	gcheng@cuhk.edu.hk	Wong, Raymond S. M./H-9644-2016	Wong, Raymond S. M./0000-0002-9011-4268				ANDERSEN JC, 1994, NEW ENGL J MED, V331, P283; ANDERSEN JC, 1994, NEW ENGL J MED, V330, P1560, DOI 10.1056/NEJM199406023302203; Apostolidis J, 2001, BLOOD, V98, P2875, DOI 10.1182/blood.V98.9.2875a; BELLUCCI S, 1988, BLOOD, V71, P1165; CAULIER MT, 1995, BRIT J HAEMATOL, V91, P477, DOI 10.1111/j.1365-2141.1995.tb05326.x; Demiroglu H, 1997, NEW ENGL J MED, V337, P425; George JN, 1996, BLOOD, V88, P3, DOI 10.1182/blood.V88.1.3.3; GEORGE JN, 1994, NEW ENGL J MED, V331, P1207, DOI 10.1056/NEJM199411033311807; George JN, 2002, BLOOD REV, V16, P37, DOI 10.1054/blre.2001.0179; Khouri I, 2002, NEW ENGL J MED, V347, P449; MAZZUCCONI MG, 1985, HAEMATOLOGICA, V70, P329; McMillan R, 1997, ANN INTERN MED, V126, P307, DOI 10.7326/0003-4819-126-4-199702150-00007; MCVERRY BA, 1985, BRIT J HAEMATOL, V59, P203, DOI 10.1111/j.1365-2141.1985.tb02985.x; Pamuk GE, 2002, ANN HEMATOL, V81, P436, DOI 10.1007/s00277-002-0488-x; PIZZUTO J, 1984, BLOOD, V64, P1179; Portielje JEA, 2001, BLOOD, V97, P2549, DOI 10.1182/blood.V97.9.2549; Schiavotto C, 1996, BRIT J HAEMATOL, V93, P491; STASI R, 1995, AM J MED, V98, P436, DOI 10.1016/S0002-9343(99)80342-8; Stasi R, 2000, BLOOD CELL MOL DIS, V26, P582, DOI 10.1006/bcmd.2000.0336; Wali YA, 2002, PEDIATR HEMAT ONCOL, V19, P329, DOI 10.1080/08880010290057345; Warner M, 1997, AM J HEMATOL, V54, P267, DOI 10.1002/(SICI)1096-8652(199704)54:4<267::AID-AJH1>3.0.CO;2-T	21	214	240	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					831	836		10.1056/NEJMoa030254	http://dx.doi.org/10.1056/NEJMoa030254			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944568				2022-12-28	WOS:000184968400003
J	Nishimoto, S; Kawane, K; Watanabe-Fukunaga, R; Fukuyama, H; Ohsawa, Y; Uchiyama, Y; Hashida, N; Ohguro, N; Tano, Y; Morimoto, T; Fukuda, Y; Nagata, S				Nishimoto, S; Kawane, K; Watanabe-Fukunaga, R; Fukuyama, H; Ohsawa, Y; Uchiyama, Y; Hashida, N; Ohguro, N; Tano, Y; Morimoto, T; Fukuda, Y; Nagata, S			Nuclear cataract caused by a lack of DNA degradation in the mouse eye lens	NATURE			English	Article							DIFFERENTIATION; APOPTOSIS; DEOXYRIBONUCLEASE; EXPRESSION; DENUCLEATION; TRANSMISSION; PROTEINS; CELLS; ALPHA	The eye lens is composed of fibre cells, which develop from the epithelial cells on the anterior surface of the lens(1-3). Differentiation into a lens fibre cell is accompanied by changes in cell shape, the expression of crystallins(4) and the degradation of cellular organelles(5,6). The loss of organelles is believed to ensure the transparency of the lens, but the molecular mechanism behind this process is not known. Here we show that DLAD ('DNase II-like acid DNase'(7), also called DNase IIbeta(8)) is expressed in human and murine lens cells, and that mice deficient in the DLAD gene are incapable of degrading DNA during lens cell differentiation-the undigested DNA accumulates in the fibre cells. The DLAD(-/-) mice develop cataracts of the nucleus lentis, and their response to light on electroretinograms is severely reduced. These results indicate that DLAD is responsible for the degradation of nuclear DNA during lens cell differentiation, and that if DNA is left undigested in the lens, it causes cataracts of the nucleus lentis, blocking the light path.	Osaka Univ, Sch Med, Dept Genet, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Cell Biol & Neurosci, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Ophthalmol, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Physiol & Biosignaling, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Integrated Biol Labs, Genet Lab, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Nagata, S (corresponding author), Trans Gen Inc, Prod Dept, Kumamoto 8612202, Japan.		Fukuyama, Hidehiro/AAY-6256-2021; Fukuyama, Hidehiro/N-5276-2018; , nhashida/ABI-4299-2020; Nagata, Shigekazu/AAG-3203-2019	Fukuyama, Hidehiro/0000-0002-6457-0630; Fukuyama, Hidehiro/0000-0002-6457-0630; Nagata, Shigekazu/0000-0001-9758-8426; Kawane, Kohki/0000-0003-1125-9483				Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; Bassnett S, 2002, EXP EYE RES, V74, P1, DOI 10.1006/exer.2001.1111; Bernardi G., 1971, HYDROLYSIS, P271; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Ezaki J, 1996, J NEUROCHEM, V67, P1677, DOI 10.1046/j.1471-4159.1996.67041677.x; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; GRAINGER RM, 1992, EYE, V6, P117, DOI 10.1038/eye.1992.26; IMOTO Y, IN PRESS JPN J OPHTH; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Krieser RJ, 2002, CELL DEATH DIFFER, V9, P956, DOI 10.1038/sj.cdd.4401056; Krieser RJ, 2001, GENE, V269, P205, DOI 10.1016/S0378-1119(01)00434-6; KUWABARA T, 1974, INVEST OPHTH VISUAL, V13, P973; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; MASU M, 1995, CELL, V80, P757, DOI 10.1016/0092-8674(95)90354-2; McAvoy JW, 1999, EYE, V13, P425, DOI 10.1038/eye.1999.117; McIlroy D, 2000, GENE DEV, V14, P549; Nagata S, 2003, CELL DEATH DIFFER, V10, P108, DOI 10.1038/sj.cdd.4401161; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Shiokawa D, 1999, NUCLEIC ACIDS RES, V27, P4083, DOI 10.1093/nar/27.20.4083; Torriglia A, 1998, MOL CELL BIOL, V18, P3612, DOI 10.1128/MCB.18.6.3612; VRENSEN GFJM, 1991, EXP EYE RES, V52, P647, DOI 10.1016/0014-4835(91)90017-9; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; Wride MA, 1998, EXP EYE RES, V66, P371, DOI 10.1006/exer.1997.0440	29	153	159	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1071	1074		10.1038/nature01895	http://dx.doi.org/10.1038/nature01895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944971				2022-12-28	WOS:000184984200047
J	Goodman, FR				Goodman, FR			Congenital abnormalities of body patterning: embryology revisited	LANCET			English	Review							BASAL-CELL CARCINOMA; FOOT-GENITAL SYNDROME; SONIC-HEDGEHOG GENE; DIGEORGE-SYNDROME REGION; CARDIO-FACIAL SYNDROME; ACUTE MYELOID-LEUKEMIA; BONE-MARROW CELLS; HOMEOBOX GENES; HOX GENES; LIMB DEVELOPMENT	Many of the developmental mechanisms and molecular pathways that underlie fundamental features of body patterning are shared by all vertebrates, and some have even been conserved across evolution from invertebrates to vertebrates. Defects in such processes are a common cause of congenital malformation syndromes, and rapid progress is being made in elucidating their embryological and genetic basis. Here, I focus on three examples, each of which has been the subject of recent advances, and which together illustrate many of the most interesting and important aspects of these disorders. The first example is the development of the pharyngeal apparatus and its perturbation in DiGeorge's syndrome; the second is the induction and differentiation of the forebrain and its perturbation in holoprosencephaly; and the third is the role played by the human HOX genes in congenital malformations.	Inst Child Hlth, Mol Med Unit, London WC1N 1EH, England	University of London; University College London	Goodman, FR (corresponding author), Inst Child Hlth, Mol Med Unit, 30 Guilford St, London WC1N 1EH, England.	fgoodman@hgmp.mrc.ac.uk						Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907; Ahlgren SC, 1999, CURR BIOL, V9, P1304, DOI 10.1016/S0960-9822(00)80052-4; AKARSU AN, 1995, J MED GENET, V32, P435, DOI 10.1136/jmg.32.6.435; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Bale AE, 2002, ANNU REV GENOM HUM G, V3, P47, DOI 10.1146/annurev.genom.3.022502.103031; Belloni E, 1996, NAT GENET, V14, P353, DOI 10.1038/ng1196-353; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Bodmer R, 1998, DEV GENET, V22, P181, DOI 10.1002/(SICI)1520-6408(1998)22:3<181::AID-DVG1>3.0.CO;2-2; Brown LY, 2001, HUM MOL GENET, V10, P791, DOI 10.1093/hmg/10.8.791; Brown SA, 1998, NAT GENET, V20, P180, DOI 10.1038/2484; Bruneau S, 2001, DEV BIOL, V237, P345, DOI 10.1006/dbio.2001.0382; Burn J, 1999, J MED GENET, V36, P737, DOI 10.1136/jmg.36.10.737; BURN J, 1996, EMERY RIMOINS PRINCI, P774; Calvo R, 2000, P NATL ACAD SCI USA, V97, P12776, DOI 10.1073/pnas.97.23.12776; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; Carlson C, 1997, AM J HUM GENET, V61, P620, DOI 10.1086/515508; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115; COHEN MM, 1989, TERATOLOGY, V40, P211, DOI 10.1002/tera.1420400304; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dahmane N, 2001, DEVELOPMENT, V128, P5201; DEMYER W, 1964, PEDIATRICS, V34, P256; Devriendt K, 1999, AM J HUM GENET, V65, P249, DOI 10.1086/302452; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Epstein J A, 2001, Trends Genet, V17, pS13, DOI 10.1016/S0168-9525(01)02450-7; Farrell MJ, 2001, INT REV CYTOL, V202, P99, DOI 10.1016/S0074-7696(01)02004-6; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; FIREMAN P, 1965, J PEDIATR-US, V67, P907; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Fujimoto M, 1998, J HUM GENET, V43, P32, DOI 10.1007/s100380050033; Fujino T, 2002, BLOOD, V99, P1428, DOI 10.1182/blood.V99.4.1428; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Garg V, 2001, DEV BIOL, V235, P62, DOI 10.1006/dbio.2001.0283; GEHRING WJ, 1993, GENE, V135, P215, DOI 10.1016/0378-1119(93)90068-E; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gong W, 2001, J Med Genet, V38, pE45, DOI 10.1136/jmg.38.12.e45; Goodman FR, 2000, AM J HUM GENET, V67, P197, DOI 10.1086/302961; Goodman FR, 2002, AM J MED GENET, V112, P256, DOI 10.1002/ajmg.10776; Goodman FR, 1997, P NATL ACAD SCI USA, V94, P7458, DOI 10.1073/pnas.94.14.7458; Goodman FR, 2001, CLIN GENET, V59, P1, DOI 10.1034/j.1399-0004.2001.590101.x; GOODMAN FR, 2003, IN PRESS MOL BASIS I; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Graham A, 2001, J ANAT, V199, P133, DOI 10.1017/S0021878201008159; Graham A, 2001, BIOESSAYS, V23, P54, DOI 10.1002/1521-1878(200101)23:1<54::AID-BIES1007>3.0.CO;2-5; Gripp KW, 2000, NAT GENET, V25, P205, DOI 10.1038/76074; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; Herault Y, 1997, DEVELOPMENT, V124, P3493; Ho KS, 2002, CURR OPIN NEUROBIOL, V12, P57, DOI 10.1016/S0959-4388(02)00290-8; Hu D, 1999, DEVELOPMENT, V126, P4873; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Innis JW, 2002, TERATOLOGY, V65, P47, DOI 10.1002/tera.10021; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.3.CO;2-I; Kimonis VE, 1997, AM J MED GENET, V69, P299, DOI 10.1002/(SICI)1096-8628(19970331)69:3<299::AID-AJMG16>3.0.CO;2-M; Kondo T, 1997, NATURE, V390, P29, DOI 10.1038/36234; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kruger K, 1999, ARCH DERMATOL RES, V291, P253, DOI 10.1007/s004030050405; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; LARSEN WJ, 1998, ESSENTIALS HUMAN EMB, P36; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lindsay EA, 1999, NATURE, V401, P379, DOI 10.1038/43900; LISCHNER HW, 1972, J PEDIATR-US, V81, P1042, DOI 10.1016/S0022-3476(72)80575-4; Mark M, 1997, PEDIATR RES, V42, P421, DOI 10.1203/00006450-199710000-00001; Marlow F, 1998, DEV BIOL, V203, P382, DOI 10.1006/dbio.1998.9032; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Ming JE, 1998, CLIN GENET, V53, P155; MORGAN BA, 1994, DEVELOPMENT, P181; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; MUENKE M, 2001, METABOLIC MOL BASES, P6203; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Nagai T, 2000, P NATL ACAD SCI USA, V97, P1618, DOI 10.1073/pnas.97.4.1618; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; Nanni L, 1999, HUM MOL GENET, V8, P2479, DOI 10.1093/hmg/8.13.2479; Naora H, 2001, P NATL ACAD SCI USA, V98, P15209, DOI 10.1073/pnas.011503998; Naora H, 2001, P NATL ACAD SCI USA, V98, P4060, DOI 10.1073/pnas.071594398; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Panagopoulos L, 2003, GENE CHROMOSOME CANC, V36, P107, DOI 10.1002/gcc.10139; Paylor R, 2001, HUM MOL GENET, V10, P2645, DOI 10.1093/hmg/10.23.2645; Peichel CL, 1997, DEVELOPMENT, V124, P3481; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Rozovskaia T, 2001, ONCOGENE, V20, P874, DOI 10.1038/sj.onc.1204174; Ryan AK, 1997, J MED GENET, V34, P798, DOI 10.1136/jmg.34.10.798; Sampath K, 1998, NATURE, V395, P185, DOI 10.1038/26020; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SAYLI BS, 1995, J MED GENET, V32, P421, DOI 10.1136/jmg.32.6.421; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; Shaikh TH, 2000, HUM MOL GENET, V9, P489, DOI 10.1093/hmg/9.4.489; SHPRINTZEN RJ, 1978, CLEFT PALATE J, V15, P56; Smith J, 1999, TRENDS GENET, V15, P154, DOI 10.1016/S0168-9525(99)01693-5; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Taddei I, 2001, P NATL ACAD SCI USA, V98, P11428, DOI 10.1073/pnas.201127298; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Taketani T, 2002, CANCER RES, V62, P33; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thompson AA, 2000, NAT GENET, V26, P397, DOI 10.1038/82511; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tickle C, 2000, INT J DEV BIOL, V44, P101; van Oostveen JW, 1999, LEUKEMIA, V13, P1675, DOI 10.1038/sj.leu.2401562; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963; Vider BZ, 2000, BIOCHEM BIOPH RES CO, V272, P513, DOI 10.1006/bbrc.2000.2804; Wallis D, 2000, HUM MUTAT, V16, P99, DOI 10.1002/1098-1004(200008)16:2<99::AID-HUMU2>3.0.CO;2-0; Wallis DE, 1999, NAT GENET, V22, P196, DOI 10.1038/9718; Wawersik S, 2000, HUM MOL GENET, V9, P917, DOI 10.1093/hmg/9.6.917; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weiner HL, 2002, CANCER RES, V62, P6385; Wicking C, 1997, AM J HUM GENET, V60, P21; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	133	38	39	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					651	662		10.1016/S0140-6736(03)14187-6	http://dx.doi.org/10.1016/S0140-6736(03)14187-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944067				2022-12-28	WOS:000184904100027
J	Kellum, JA				Kellum, JA			A drug to prevent renal failure?	LANCET			English	Editorial Material							MORTALITY; EPIDEMIOLOGY; MULTICENTER; DOPAMINE		Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kellum, JA (corresponding author), Univ Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	Kellumja@ccm.upmc.edu	Kellum, John A/HCH-2944-2022; Kellum, John/AAP-3072-2020	Kellum, John A/0000-0003-1995-2653; Kellum, John/0000-0003-1995-2653				Bellomo R, 2000, LANCET, V356, P2139; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Chertow GM, 1998, AM J MED, V104, P343, DOI 10.1016/S0002-9343(98)00058-8; HOU SH, 1983, AM J MED, V74, P243, DOI 10.1016/0002-9343(83)90618-6; Kellum JA, 2002, CRIT CARE MED, V30, P2156, DOI 10.1097/00003246-200209000-00041; Kellum JA, 2001, CRIT CARE MED, V29, P1526, DOI 10.1097/00003246-200108000-00005; KELLUM JA, 2003, RIFLE CRITERIA ACUTE; Kellum John A, 2002, Curr Opin Crit Care, V8, P509, DOI 10.1097/00075198-200212000-00005; Kurnik BRC, 1998, AM J KIDNEY DIS, V31, P674, DOI 10.1053/ajkd.1998.v31.pm9531185; Levy EM, 1996, JAMA-J AM MED ASSOC, V275, P1489, DOI 10.1001/jama.275.19.1489; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Mehta RL, 2002, JAMA-J AM MED ASSOC, V288, P2547, DOI 10.1001/jama.288.20.2547; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Star RA, 1998, KIDNEY INT, V54, P1817, DOI 10.1046/j.1523-1755.1998.00210.x; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tepel M, 2000, NEW ENGL J MED, V343, P180, DOI 10.1056/NEJM200007203430304	19	6	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					589	590		10.1016/S0140-6736(03)14206-7	http://dx.doi.org/10.1016/S0140-6736(03)14206-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944054				2022-12-28	WOS:000184904100003
J	Matzke, M; Matzke, AJM				Matzke, M; Matzke, AJM			Molecular biology - RNAi extends its reach	SCIENCE			English	Editorial Material							DNA METHYLATION; FISSION YEAST; INTERFERENCE; MAINTENANCE		Austrian Acad Sci, Inst Mol Biol, A-5020 Salzburg, Austria	Austrian Academy of Sciences	Matzke, M (corresponding author), Austrian Acad Sci, Inst Mol Biol, Billrothstr 11, A-5020 Salzburg, Austria.		Matzke, Antonius/H-8698-2015; Matzke, Marjori/H-8689-2015					Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Denli AM, 2003, TRENDS BIOCHEM SCI, V28, P196, DOI 10.1016/S0968-0004(03)00058-6; Gendrel AV, 2002, SCIENCE, V297, P1871, DOI 10.1126/science.1074950; Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Pandey R, 2002, NUCLEIC ACIDS RES, V30, P5036, DOI 10.1093/nar/gkf660; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; Schauer SE, 2002, TRENDS PLANT SCI, V7, P487, DOI 10.1016/S1360-1385(02)02355-5; Schramke V, 2003, SCIENCE, V301, P1069, DOI 10.1126/science.1086870; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; Yao MC, 2003, SCIENCE, V300, P1581, DOI 10.1126/science.1084737; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	17	37	52	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1060	1061		10.1126/science.1089047	http://dx.doi.org/10.1126/science.1089047			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934001				2022-12-28	WOS:000184872400029
J	Miller, EA; Beilharz, TH; Malkus, PN; Lee, MCS; Hamamoto, S; Orci, L; Schekman, R				Miller, EA; Beilharz, TH; Malkus, PN; Lee, MCS; Hamamoto, S; Orci, L; Schekman, R			Multiple cargo binding sites on the COPII subunit Sec24p ensure capture of diverse membrane proteins into transport vesicles	CELL			English	Article							ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; SELECTIVE EXPORT; CYTOPLASMIC TAIL; STRUCTURAL BASIS; GOLGI-COMPLEX; ER EXPORT; COAT; YEAST; SIGNAL	We have characterized the mechanisms of cargo selection into ER-derived vesicles by the COPII subunit Sec24p. We identified a site on Sec24p that recognizes the v-SNARE Bet1p and show that packaging of a number of cargo molecules is disrupted when mutations are introduced at this site. Surprisingly, cargo proteins affected by these mutations did not share a single common sorting signal, nor were proteins sharing a putative class of signal affected to the same degree. We show that the same site is conserved as a cargo-interaction domain on the Sec24p homolog Lst1p, which only packages a subset of the cargoes recognized by Sec24p. Finally, we identified an additional mutation that defines another cargo binding domain on Sec24p, which specifically interacts with the SNARE Sec22p. Together, our data support a model whereby Sec24p proteins contain multiple independent cargo binding domains that allow for recognition of a diverse set of sorting signals.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Geneva, Sch Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of Geneva	Schekman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Beilharz, Traude/O-5457-2019; Beilharz, Traude/I-1438-2014	Beilharz, Traude/0000-0002-8942-9502; Beilharz, Traude/0000-0002-8942-9502; Miller, Elizabeth/0000-0002-1033-8369; Lee, Marcus/0000-0002-4973-0915				Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 2002, TRAFFIC, V3, P537, DOI 10.1034/j.1600-0854.2002.30804.x; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Belden WJ, 2001, J BIOL CHEM, V276, P43040, DOI 10.1074/jbc.M108113200; Belden WJ, 2001, SCIENCE, V294, P1528, DOI 10.1126/science.1065224; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; Kurihara T, 2000, MOL BIOL CELL, V11, P983, DOI 10.1091/mbc.11.3.983; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Muniz M, 2000, J CELL BIOL, V148, P925, DOI 10.1083/jcb.148.5.925; Nakamura N, 1998, MOL BIOL CELL, V9, P3493, DOI 10.1091/mbc.9.12.3493; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nufer O, 2002, J CELL SCI, V115, P619; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 2001, TRAFFIC, V2, P105, DOI 10.1034/j.1600-0854.2001.020205.x; Peng RW, 1999, P NATL ACAD SCI USA, V96, P3751, DOI 10.1073/pnas.96.7.3751; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Shimoni Y, 2000, J CELL BIOL, V151, P973, DOI 10.1083/jcb.151.5.973; SIKORSKI RS, 1989, GENETICS, V122, P19; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124	39	386	394	1	21	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					497	509		10.1016/S0092-8674(03)00609-3	http://dx.doi.org/10.1016/S0092-8674(03)00609-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941277	Bronze			2022-12-28	WOS:000184928800012
J	Speiser, PW; White, PC				Speiser, PW; White, PC			Congenital adrenal hyperplasia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							STEROID 21-HYDROXYLASE DEFICIENCY; BILATERAL LAPAROSCOPIC ADRENALECTOMY; PEDIATRIC-ENDOCRINE-SOCIETY; ADULT HEIGHT; DECONVOLUTION ANALYSIS; CONSENSUS STATEMENT; TESTICULAR-TUMORS; CYP21B GENES; MUTATIONS; DIAGNOSIS		Schneider Childrens Hosp, Dept Pediat, N Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY 11042 USA; NYU Med Ctr, New York, NY 10016 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; New York University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Speiser, PW (corresponding author), Schneider Childrens Hosp, Dept Pediat, N Shore Long Isl Jewish Hlth Syst, 269-01 76th Ave, New Hyde Pk, NY 11042 USA.	pspeiser@LIJ.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037867] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK37867] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen DB, 1997, J PEDIATR-US, V130, P128, DOI 10.1016/S0022-3476(97)70321-4; AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Balsamo A, 1996, PEDIATRICS, V98, P362; BARNES RB, 1994, J CLIN ENDOCR METAB, V79, P1328, DOI 10.1210/jcem.79.5.7962325; Berenbaum S, 2002, HORM RES, V58, P188; Berenbaum S, 2002, J CLIN ENDOCR METAB, V87, P4048, DOI 10.1210/jc.2002-020611; Boudi A, 2000, STEROIDS, V65, P103, DOI 10.1016/S0039-128X(99)00089-6; Cabrera MS, 2001, J CLIN ENDOCR METAB, V86, P3070, DOI 10.1210/jc.86.7.3070; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Chin DS, 1998, J CLIN ENDOCR METAB, V83, P1940, DOI 10.1210/jc.83.6.1940; Creighton SM, 2001, LANCET, V358, P124, DOI 10.1016/S0140-6736(01)05343-0; CUTFIELD WS, 1995, J PEDIATR-US, V126, P118, DOI 10.1016/S0022-3476(95)70513-9; Day DJ, 1996, HUM MOL GENET, V5, P2039, DOI 10.1093/hmg/5.12.2039; DAY DJ, 1995, GENOMICS, V29, P152, DOI 10.1006/geno.1995.1226; Deneux C, 2001, J CLIN ENDOCR METAB, V86, P207, DOI 10.1210/jc.86.1.207; Dipple KM, 2000, AM J HUM GENET, V66, P1729, DOI 10.1086/302938; Eugster EA, 2001, J PEDIATR-US, V138, P26, DOI 10.1067/mpd.2001.110527; FIET J, 1988, J CLIN ENDOCR METAB, V66, P659, DOI 10.1210/jcem-66-4-659; Fitness J, 1999, J CLIN ENDOCR METAB, V84, P960, DOI 10.1210/jc.84.3.960; FUKUSHIGE J, 1994, EUR J PEDIATR, V153, P284, DOI 10.1007/BF01954521; Gmyrek GA, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e28; Gruneiro-Papendieck L, 2001, HORM RES, V55, P271, DOI 10.1159/000050012; Gunther DF, 1997, J CLIN ENDOCR METAB, V82, P3324, DOI 10.1210/jc.82.10.3324; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; HIGASHI Y, 1991, J BIOCHEM-TOKYO, V109, P638, DOI 10.1093/oxfordjournals.jbchem.a123433; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; Hunt PJ, 2000, J CLIN ENDOCR METAB, V85, P4650, DOI 10.1210/jc.85.12.4650; Jaaskelainen J, 1997, PEDIATR RES, V41, P30; KERRIGAN JR, 1993, J CLIN ENDOCR METAB, V76, P1505, DOI 10.1210/jc.76.6.1505; Knochenhauer ES, 1997, J CLIN ENDOCR METAB, V82, P479, DOI 10.1210/jc.82.2.479; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; Lo JC, 2001, ENDOCRIN METAB CLIN, V30, P207, DOI 10.1016/S0889-8529(08)70027-6; Merke Deborah P., 2002, Annals of Internal Medicine, V136, P320; Merke DP, 2000, NEW ENGL J MED, V343, P1362, DOI 10.1056/NEJM200011093431903; Merke DP, 2000, J CLIN ENDOCR METAB, V85, P1114, DOI 10.1210/jc.85.3.1114; METZGER DL, 1993, J CLIN ENDOCR METAB, V77, P458, DOI 10.1210/jc.77.2.458; Meyer-Bahlburg HFL, 2001, ENDOCRIN METAB CLIN, V30, P155, DOI 10.1016/S0889-8529(08)70024-0; Meyers RL, 2000, J PEDIATR SURG, V35, P1586, DOI 10.1053/jpsu.2000.18321; Migeon CJ, 2001, ENDOCRIN METAB CLIN, V30, P193, DOI 10.1016/S0889-8529(08)70026-4; Mikami A., 1999, Southeast Asian Journal of Tropical Medicine and Public Health, V30, P100; Minutti C., 2001, Journal of Inherited Metabolic Disease, V24, P10; Moran C, 2000, AM J OBSTET GYNECOL, V183, P1468, DOI 10.1067/mob.2000.108020; MORNET E, 1991, AM J HUM GENET, V48, P79; MULAIKAL RM, 1987, NEW ENGL J MED, V316, P178, DOI 10.1056/NEJM198701223160402; Murphy H, 2001, HUM REPROD, V16, P263, DOI 10.1093/humrep/16.2.263; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; New MI, 2001, J CLIN ENDOCR METAB, V86, P5651, DOI 10.1210/jc.86.12.5651; Newnham JP, 2001, CLIN EXP PHARMACOL P, V28, P957, DOI 10.1046/j.1440-1681.2001.03559.x; Nordenstrom A, 1999, J CLIN ENDOCR METAB, V84, P1505, DOI 10.1210/jc.84.5.1505; Oelkers WKH, 1996, STEROIDS, V61, P166, DOI 10.1016/0039-128X(96)00007-4; OHKUBO S, 1992, Acta Paediatrica Japonica, V34, P126; OWERBACH D, 1990, MOL ENDOCRINOL, V4, P125, DOI 10.1210/mend-4-1-125; PANG S, 1990, NEW ENGL J MED, V322, P111, DOI 10.1056/NEJM199001113220207; PANG SY, 1992, J CLIN ENDOCR METAB, V75, P249, DOI 10.1210/jc.75.1.249; Premawardhana LDKE, 1997, CLIN ENDOCRINOL, V46, P327, DOI 10.1046/j.1365-2265.1997.1360962.x; Quintos JBQ, 2001, J CLIN ENDOCR METAB, V86, P1511, DOI 10.1210/jc.86.4.1511; Schnitzer JJ, 2001, ENDOCRIN METAB CLIN, V30, P137, DOI 10.1016/S0889-8529(08)70023-9; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; Seckl JR, 1997, JAMA-J AM MED ASSOC, V277, P1077, DOI 10.1001/jama.277.13.1077; SPEISER PW, 1987, J CLIN ENDOCR METAB, V64, P86, DOI 10.1210/jcem-64-1-86; SPEISER PW, 1985, AM J HUM GENET, V37, P650; SPEISER PW, 1992, J CLIN INVEST, V90, P584, DOI 10.1172/JCI115897; Speiser PW, 2001, J ENDOCRINOL INVEST, V24, P681, DOI 10.1007/BF03343913; SRIKANTH MS, 1992, J PEDIATR SURG, V27, P639, DOI 10.1016/0022-3468(92)90466-K; Stikkelbroeck NMML, 2001, J CLIN ENDOCR METAB, V86, P5721, DOI 10.1210/jc.86.12.5721; Tajima T, 1999, GENE THER, V6, P1898, DOI 10.1038/sj.gt.3301018; Tajima T, 1997, J CLIN ENDOCR METAB, V82, P2350, DOI 10.1210/jc.82.7.2350; Tajima T, 1998, ENDOCR J, V45, P493, DOI 10.1507/endocrj.45.493; Therrell BL, 1998, PEDIATRICS, V101, P583, DOI 10.1542/peds.101.4.583; Therrell BL, 2001, ENDOCRIN METAB CLIN, V30, P15, DOI 10.1016/S0889-8529(08)70017-3; TUSIELUNA MT, 1991, MOL ENDOCRINOL, V5, P685, DOI 10.1210/mend-5-5-685; TUSIELUNA MT, 1990, J BIOL CHEM, V265, P20916; TUSIELUNA MT, 1995, P NATL ACAD SCI USA, V92, P10796, DOI 10.1073/pnas.92.23.10796; URBAN MD, 1978, NEW ENGL J MED, V299, P1392, DOI 10.1056/NEJM197812212992505; VanWyk JJ, 1996, J CLIN ENDOCR METAB, V81, P3180, DOI 10.1210/jc.81.9.3180; Walker BR, 1997, J UROLOGY, V157, P1460, DOI 10.1016/S0022-5347(01)65023-7; Warinner SA, 2000, WORLD J SURG, V24, P1347, DOI 10.1007/s002680010223; WEDELL A, 1994, J CLIN ENDOCR METAB, V78, P1145, DOI 10.1210/jc.78.5.1145; White PC, 2000, ENDOCR REV, V21, P245, DOI 10.1210/er.21.3.245; WHITE PC, 1987, NEW ENGL J MED, V316, P1580, DOI 10.1056/NEJM198706183162506; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; Wilson JD, 1999, ENDOCR REV, V20, P726, DOI 10.1210/er.20.5.726; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2322, DOI 10.1210/jc.80.8.2322; YU ACM, 1995, ACTA PAEDIATR, V84, P899, DOI 10.1111/j.1651-2227.1995.tb13789.x; Zarkovic M, 1999, J CLIN ENDOCR METAB, V84, P3170, DOI 10.1210/jc.84.9.3170; 2003, CYTOCHROME P450 SUBF	88	572	615	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					776	788		10.1056/NEJMra021561	http://dx.doi.org/10.1056/NEJMra021561			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930931				2022-12-28	WOS:000184843300010
J	Vasseur, C; Rodien, P; Beau, I; Desroches, A; Gerard, C; de Poncheville, L; Chaplot, S; Savagner, F; Croue, A; Mathieu, E; Lahlou, N; Descamps, P; Misrahi, M				Vasseur, C; Rodien, P; Beau, I; Desroches, A; Gerard, C; de Poncheville, L; Chaplot, S; Savagner, F; Croue, A; Mathieu, E; Lahlou, N; Descamps, P; Misrahi, M			A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERREACTIO-LUTEINALIS; PATHOPHYSIOLOGY; PREGNANCY; ECTODOMAIN; PHENOTYPE; AFFINITY; BINDING; INHIBIN; WOMEN		CHU Angers, Serv Endocrinol, F-49033 Angers 01, France; CHU Angers, Serv Gynecol Obstet, F-49033 Angers 01, France; CHU Angers, INSERM, EMI Unite0018, F-49033 Angers 01, France; CHU Angers, Biochim Lab, F-49033 Angers 01, France; CHU Angers, Lab Anatomopathol, F-49033 Angers 01, France; CHU Angers, Lab Hormonol, F-49033 Angers 01, France; Hop Bicetre, INSERM, EMI Unite 120, Le Kremlin Bicetre, France; Hop St Vincent de Paul, Lab Hormonol, F-75674 Paris, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Rodien, P (corresponding author), CHU Angers, Serv Endocrinol, 4 Rue Larrey, F-49033 Angers 01, France.	parodien@chu-angers.fr	Rodien, Patrice/AAT-7909-2021; Beau, Isabelle/M-4423-2017; Castan, Agnes/AAS-2580-2021; Desroches-Castan, Agnes/AAA-4557-2019	Beau, Isabelle/0000-0002-3352-6813; Castan, Agnes/0000-0002-3301-9504; 				[Anonymous], 1999, IN VITRO FERTILIZATI; Beau I, 1998, J CLIN INVEST, V102, P1352, DOI 10.1172/JCI3795; Bidus MA, 2002, OBSTET GYNECOL, V99, P958, DOI 10.1016/S0029-7844(02)01983-X; Csapo Z, 1999, J REPROD MED, V44, P53; EdiOsagie ECO, 1997, BRIT J OBSTET GYNAEC, V104, P952, DOI 10.1111/j.1471-0528.1997.tb14359.x; Elchalal U, 1997, HUM REPROD, V12, P1129; FAUSER BCJM, 1995, HUM REPROD, V10, P826, DOI 10.1093/oxfordjournals.humrep.a136047; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; Lahlou N, 1999, HUM REPROD, V14, P1190, DOI 10.1093/humrep/14.5.1190; Ludwig M, 1998, HUM REPROD, V13, P2082, DOI 10.1093/humrep/13.8.2082; Misrahi M, 1997, J CLIN ENDOCR METAB, V82, P2159, DOI 10.1210/jcem.82.7.4039; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Petraglia F, 1997, J CLIN ENDOCR METAB, V82, P2991, DOI 10.1210/jc.82.9.2991; Quereda F, 1996, EUR J OBSTET GYN R B, V66, P71, DOI 10.1016/0301-2115(95)02371-2; QUINTANA J, 1993, MOL ENDOCRINOL, V7, P767, DOI 10.1210/me.7.6.767; Rodien P, 1998, NEW ENGL J MED, V339, P1823, DOI 10.1056/NEJM199812173392505; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Schnorr JA, 1996, AM J PERINAT, V13, P95, DOI 10.1055/s-2007-994300; SCULLY RE, 1998, ATLAS TUMOR PATHOL, V23, P429; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; WAJDA KJ, 1989, ARCH PATHOL LAB MED, V113, P921; Wang TH, 2002, J CLIN ENDOCR METAB, V87, P3300, DOI 10.1210/jc.87.7.3300; WHITE CA, 1965, AM J OBSTET GYNECOL, V92, P973, DOI 10.1016/0002-9378(65)90731-3	25	144	158	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					753	759		10.1056/NEJMoa030065	http://dx.doi.org/10.1056/NEJMoa030065			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930927				2022-12-28	WOS:000184843300005
J	Iwashita, T; Kruger, GM; Pardal, R; Kiel, MJ; Morrison, SJ				Iwashita, T; Kruger, GM; Pardal, R; Kiel, MJ; Morrison, SJ			Hirschsprung disease is linked to defects in neural crest stem cell function	SCIENCE			English	Article							ENTERIC NERVOUS-SYSTEM; MICE LACKING GDNF; TYROSINE KINASE; SELF-RENEWAL; IN-VITRO; C-RET; KIDNEY; DIFFERENTIATION; GFR-ALPHA-1; EXPRESSION	Genes associated with Hirschsprung disease, a failure to form enteric ganglia in the hindgut, were highly up-regulated in gut neural crest stem cells relative to whole-fetus RNA. One of these genes, the glial cell line-derived neurotrophic factor (GDNF) receptor Ret, was necessary for neural crest stem cell migration in the gut. GDNF promoted the migration of neural crest stem cells in culture but did not affect their survival or proliferation. Gene expression pro. ling, combined with reverse genetics and analyses of stem cell function, suggests that Hirschsprung disease is caused by defects in neural crest stem cell function.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Morrison, SJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Morrison, Sean/ABD-5326-2021; Crane, Genevieve M/AAK-9224-2020; Pardal, Ricardo/C-4370-2015; IBIS, FISIOPATOLOGIA/O-9510-2015	Crane, Genevieve M/0000-0001-9274-0214; Pardal, Ricardo/0000-0003-1085-0714; Morrison, Sean/0000-0003-1587-8329	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R21HD040760] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557, P30AR048310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, P30DK020572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040750] Funding Source: NIH RePORTER; NCI NIH HHS [CA46592] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557, P30 AR48310] Funding Source: Medline; NICHD NIH HHS [R21 HD40760-02] Funding Source: Medline; NIDDK NIH HHS [DK58771, NIH5P60-DK20572] Funding Source: Medline; NINDS NIH HHS [R01 NS040750, R01 NS40750-01, R01 NS040750-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0; Chalazonitis A, 1998, DEV BIOL, V204, P385, DOI 10.1006/dbio.1998.9090; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Eketjall S, 2002, HUM MOL GENET, V11, P325, DOI 10.1093/hmg/11.3.325; Enomoto H, 1998, NEURON, V21, P317, DOI 10.1016/S0896-6273(00)80541-3; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Heuckeroth RO, 1998, DEV BIOL, V200, P116, DOI 10.1006/dbio.1998.8955; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Morrison SJ, 2000, J NEUROSCI, V20, P7370; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Newgreen D, 2002, PEDIATR DEVEL PATHOL, V5, P224, DOI 10.1007/s10024-001-0142-y; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Shinohara T, 1999, P NATL ACAD SCI USA, V96, P5504, DOI 10.1073/pnas.96.10.5504; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tani H, 2000, P NATL ACAD SCI USA, V97, P10960, DOI 10.1073/pnas.97.20.10960; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Young HM, 2001, DEV BIOL, V229, P503, DOI 10.1006/dbio.2000.0100	37	162	174	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					972	976		10.1126/science.1085649	http://dx.doi.org/10.1126/science.1085649			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920301	Green Accepted			2022-12-28	WOS:000184755900042
J	Beich, A; Thorsen, T; Rollnick, S				Beich, A; Thorsen, T; Rollnick, S			Screening in brief intervention trials targeting excessive drinkers in general practice: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; BRIEF PHYSICIAN ADVICE; PRIMARY HEALTH-CARE; BRIEF ALCOHOL INTERVENTION; BENEFIT-COST-ANALYSIS; HAZARDOUS DRINKERS; HEAVY DRINKERS; LONG-TERM; DRINKING; PRACTITIONERS	Objective To determine the effectiveness of programmes of screening in general practice for excessive alcohol use and providing brief interventions. Design Systematic review and meta-analysis of randomised controlled trials that used screening as a precursor to brief intervention. Setting General practice. Main outcome measures Number needed to treat, proportion of patients positive on screening, proportion given brief interventions, and effect of screening. Results The eight studies included for meta-analysis all used health questionnaires for screening, and the brief interventions included feedback, information, and advice. The studies contained several sources of bias that might lead to overestimates of the effects of intervention. External validity was compromised because typically three out of four people identified by screening as excessive users of alcohol did not qualify for the intervention after a secondary assessment. Overall, in 1000 screened patients, 90 screened positive and required further assessment, after which 25 qualified for brief intervention; after one year 2.6 (95% confidence interval 1.7 to 3.4) reported they drank less than the maximum recommended level. Conclusions Although even brief advice can reduce excessive drinking, screening in general practice does not seem to be an effective precursor to brief interventions targeting excessive alcohol use. This meta-analysis raises questions about the feasibility of screening in general practice for excessive use of alcohol.	Univ Copenhagen, Panum Inst, Cent Res Unit, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Panum Inst, Dept Gen Practice, DK-2200 Copenhagen, Denmark; Cardiff Univ, Llanedeyrn Hlth Ctr, Dept Gen Practice, Commun Skills Unit, Cardiff CF23 9PN, S Glam, Wales	University of Copenhagen; University of Copenhagen; Cardiff University		a.beich@gpract.ku.dk						Aalto M, 2000, ALCOHOL CLIN EXP RES, V24, P1680, DOI 10.1097/00000374-200011000-00010; Aalto M, 2001, ALCOHOL ALCOHOLISM, V36, P224, DOI 10.1093/alcalc/36.3.224; Altman D.G., 2000, STAT CONFIDENCE, Vsecond; ANDERSON P, 1992, BRIT J ADDICT, V87, P891; Anderson P, 2002, ADDICTION, V97, P619, DOI 10.1046/j.1360-0443.2002.00136.x; Babor T., 2001, BRIEF INTERVENTION H; Babor TF, 2000, ADDICTION, V95, P677, DOI 10.1046/j.1360-0443.2000.9556773.x; Beich A, 2002, BRIT MED J, V325, P870, DOI 10.1136/bmj.325.7369.870; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; Burge SK, 1997, ADDICTION, V92, P1705, DOI 10.1111/j.1360-0443.1997.tb02891.x; CLARKE M, 2002, COCHRANE REV HDB 4 1; *COCHR COLL, 2002, REV MAN REV MAN VERS; Cordoba R, 1998, FAM PRACT, V15, P562, DOI 10.1093/fampra/15.6.562; Edwards AGK, 1997, ADDICTION, V92, P1699, DOI 10.1111/j.1360-0443.1997.tb02890.x; *EFF HLTH CAR RES, 1993, EFFECTIVE HLTH CARE, V7, P1; Egger M, 1997, BMJ-BRIT MED J, V315, P1533, DOI 10.1136/bmj.315.7121.1533; Egger M, 2001, SYSTEMATIC REV HLTH; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Fleming MF, 2002, ALCOHOL CLIN EXP RES, V26, P36, DOI 10.1111/j.1530-0277.2002.tb02429.x; Fleming MF, 1999, J FAM PRACTICE, V48, P378; Fleming MF, 2000, MED CARE, V38, P7, DOI 10.1097/00005650-200001000-00003; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Gomel MK, 1998, SOC SCI MED, V47, P203, DOI 10.1016/S0277-9536(98)00063-X; Hansen LJ, 1999, FAM PRACT, V16, P551, DOI 10.1093/fampra/16.6.551; HAYNES B, 2001, EBM, P6; Healy P., 1993, ACCOUNT HORIZ, V7, P1; HEATHER N, 1987, J ROY COLL GEN PRACT, V37, P358; Heather N, 2002, ADDICTION, V97, P293, DOI 10.1046/j.1360-0443.2002.0105a.x; KAHAN M, 1995, CAN MED ASSOC J, V152, P851; Kaner EFS, 1999, BRIT J GEN PRACT, V49, P699; Lock CA, 1999, BRIT J GEN PRACT, V49, P695; Maisto SA, 2001, J STUD ALCOHOL, V62, P605, DOI 10.15288/jsa.2001.62.605; Manwell LB, 2000, ALCOHOL CLIN EXP RES, V24, P1517, DOI 10.1097/00000374-200010000-00009; McIntosh MC, 1997, CAN FAM PHYSICIAN, V43, P1959; Medical Research Council (MRC), 2000, FRAM DEV EV RCTS COM; Moyer A, 2002, ADDICTION, V97, P279, DOI 10.1046/j.1360-0443.2002.00018.x; Ockene JK, 1999, ARCH INTERN MED, V159, P2198, DOI 10.1001/archinte.159.18.2198; Poikolainen K, 1999, PREV MED, V28, P503, DOI 10.1006/pmed.1999.0467; Rembold CM, 1998, BMJ-BRIT MED J, V317, P307, DOI 10.1136/bmj.317.7154.307; RICHMOND R, 1995, ADDICTION, V90, P119, DOI 10.1046/j.1360-0443.1995.90111915.x; ROMELSJO A, 1989, BRIT J ADDICT, V84, P1319; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Scott E, 1991, Drug Alcohol Rev, V10, P313; Senft RA, 1997, AM J PREV MED, V13, P464, DOI 10.1016/S0749-3797(18)30143-0; SEPPA K, 1992, Scandinavian Journal of Primary Health Care, V10, P217, DOI 10.3109/02813439209014064; Smeeth L, 1999, BMJ-BRIT MED J, V318, P1548, DOI 10.1136/bmj.318.7197.1548; Tomson Y, 1998, SCAND J PRIM HEALTH, V16, P188; WALLACE P, 1988, BRIT MED J, V297, P663, DOI 10.1136/bmj.297.6649.663; Wilk AI, 1997, J GEN INTERN MED, V12, P274; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	50	158	159	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2003	327	7414					536	540A		10.1136/bmj.327.7414.536	http://dx.doi.org/10.1136/bmj.327.7414.536			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	720WW	12958114	Green Submitted, Bronze, Green Published, Green Accepted			2022-12-28	WOS:000185283700019
J	Hasegawa, Y; Loidl, R; Badurek, G; Baron, M; Rauch, H				Hasegawa, Y; Loidl, R; Badurek, G; Baron, M; Rauch, H			Violation of a Bell-like inequality in single-neutron interferometry	NATURE			English	Article							HIDDEN-VARIABLE THEORIES; QUANTUM-MECHANICS; THEOREMS	Non-local correlations between spatially separated systems have been extensively discussed in the context of the Einstein, Podolsky and Rosen (EPR) paradox(1) and Bell's inequalities(2). Many proposals and experiments designed to test hidden variable theories and the violation of Bell's inequalities have been reported(3-7); usually, these involve correlated photons, although recently an experiment was performed with Be-9(+) ions(8). Nevertheless, it is of considerable interest to show that such correlations (arising from quantum mechanical entanglement) are not simply a peculiarity of photons. Here we measure correlations between two degrees of freedom (comprising spatial and spin components) of single neutrons; this removes the need for a source of entangled neutron pairs, which would present a considerable technical challenge. A Bell-like inequality is introduced to clarify the correlations that can arise between observables of otherwise independent degrees of freedom. We demonstrate the violation of this Bell-like inequality: our measured value is 2.051 +/- 0.019, clearly above the value of 2 predicted by classical hidden variable theories(9-12).	Osterreich Univ, Atominst, A-1020 Vienna, Austria; Inst Max Von Laue Paul Langevin, F-38042 Grenoble 9, France	Institut Laue-Langevin (ILL)	Hasegawa, Y (corresponding author), Osterreich Univ, Atominst, Stadionallee 2, A-1020 Vienna, Austria.							ASPECT A, 1982, PHYS REV LETT, V49, P91, DOI 10.1103/PhysRevLett.49.91; Aspect A., 1984, Wave Particle Dualism. A Tribute to Louis de Broglie on his 90th Birthday. Proceedings of an International Symposium, P377; Basu S, 2001, PHYS LETT A, V279, P281, DOI 10.1016/S0375-9601(00)00747-7; BELL JS, 1966, REV MOD PHYS, V38, P447, DOI 10.1103/RevModPhys.38.447; Bell JS., 1964, PHYS, V1, P195, DOI [10.1103/PhysicsPhysiqueFizika.1.195, 10.1103/Physics-PhysiqueFizika.1.195, DOI 10.1103/PHYSICSPHYSIQUEFIZIKA.1.195]; BELL JS, 1989, THEMES CONT PHYSICS, V2, P1; Bertlmann R. A., 2002, QUANTUM UNSPEAKABLE; CLAUSER JF, 1978, REP PROG PHYS, V41, P1881, DOI 10.1088/0034-4885/41/12/002; Einstein A, 1935, PHYS REV, V47, P0777, DOI 10.1103/PhysRev.47.777; Englert BG, 1999, Z NATURFORSCH A, V54, P11; FREEDMAN SJ, 1972, PHYS REV LETT, V28, P938, DOI 10.1103/PhysRevLett.28.938; KOCH JM, 1987, AUST FOREST RES, V17, P59; Kroupa G, 2000, NUCL INSTRUM METH A, V440, P604, DOI 10.1016/S0168-9002(99)01049-9; MANN A, 1996, DILEMMA EINSTEIN, V12; MERMIN ND, 1993, REV MOD PHYS, V65, P803, DOI 10.1103/RevModPhys.65.803; Michler M, 2000, PHYS REV LETT, V84, P5457, DOI 10.1103/PhysRevLett.84.5457; OU ZY, 1988, PHYS REV LETT, V61, P50, DOI 10.1103/PhysRevLett.61.50; RAUCH H, 1978, Z PHYS B CON MAT, V29, P281, DOI 10.1007/BF01321193; Rauch H., 2000, NEUTRON INTERFEROMET; Rowe MA, 2001, NATURE, V409, P791, DOI 10.1038/35057215; ROY SM, 1993, PHYS REV A, V48, P3379, DOI 10.1103/PhysRevA.48.3379; Sakurai J. J., 1994, MODERN QUANTUM MECH, P203; Tittel W, 1998, PHYS REV LETT, V81, P3563, DOI 10.1103/PhysRevLett.81.3563; Weihs G, 1998, PHYS REV LETT, V81, P5039, DOI 10.1103/PhysRevLett.81.5039; [No title captured]	27	207	207	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					45	48		10.1038/nature01881	http://dx.doi.org/10.1038/nature01881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955134				2022-12-28	WOS:000185089200031
J	Theise, ND; Wilmut, I				Theise, ND; Wilmut, I			Flexible arrangement	NATURE			English	Editorial Material									Beth Israel Med Ctr, Div Digest Dis, New York, NY 10003 USA; Roslin Inst, Roslin Bioctr, Roslin EH25 9PS, Midlothian, Scotland	Harvard University; Beth Israel Deaconess Medical Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Theise, ND (corresponding author), Beth Israel Med Ctr, Div Digest Dis, New York, NY 10003 USA.							Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Cavaleri F, 2003, CELL, V113, P551, DOI 10.1016/S0092-8674(03)00394-5; Theise ND, 2002, LEUKEMIA, V16, P542, DOI 10.1038/sj.leu.2402445; Wilmut I, 2002, NATURE, V419, P583, DOI 10.1038/nature01079	4	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					21	21		10.1038/425021a	http://dx.doi.org/10.1038/425021a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955119	Bronze			2022-12-28	WOS:000185089200018
J	Yedidia, MJ; Gillespie, CC; Kachur, E; Schwartz, MD; Ockene, J; Chepaitis, AE; Snyder, CW; Lazare, A; Lipkin, M				Yedidia, MJ; Gillespie, CC; Kachur, E; Schwartz, MD; Ockene, J; Chepaitis, AE; Snyder, CW; Lazare, A; Lipkin, M			Effect of communications training on medical student performance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLOBAL RATINGS; PATIENT; PHYSICIAN; SKILLS; INFORMATION; CHECKLISTS; OUTCOMES; CARE	Context Although physicians' communication skills have been found to be related to clinical outcomes and patient satisfaction, teaching of communication skills has not been fully integrated into many medical school curricula or adequately evaluated with large-scale controlled trials. Objective To determine whether communications training for medical students improves specific competencies known to affect outcomes of care. Design and Setting A communications curriculum instituted in 2000-2001 at 3 US medical schools was evaluated with objective structured clinical examinations (OSCEs). The same OSCEs were administered to a comparison cohort of students in the year before the intervention. Participants One hundred thirty-eight randomly selected medical students (38% of eligible students) in the comparison cohort, tested at the beginning and end of their third year (1999-2000), and 155 students in the intervention cohort (42% of eligible students), tested at the beginning and end of their third year (2000-2001). Intervention Comprehensive communications curricula were developed at each school using an established educational model for teaching and practicing core communication skills and engaging students in self-reflection on their performance. Communications teaching was integrated with clinical material during the third year, required clerkships, and was supported by formal faculty development. Main Outcome Measures Standardized patients assessed student performance in OSCEs on 21 skills related to 5 key patient care tasks: relationship development and maintenance, patient assessment, education and counseling, negotiation and shared decision making, and organization and time management. Scores were calculated as percentage of maximum possible performance. Results Adjusting for baseline differences, students exposed to the intervention significantly outperformed those in the comparison cohort on the overall OSCE (65.4% vs 60.4%; 5.1% difference; 95% confidence interval [CI], 3.9%-6.3%; P<.001), relationship development and maintenance (5.3% difference; 95% CI, 3.8%-6.7%; P<.001), organization and time management (1.8% difference; 95% CI, 1.0%-2.7%; P<.001), and subsets of cases addressing patient assessment (6.7% difference; 95% CI, 5.9%-7.8%; P<.001) and negotiation and shared decision making (5.7% difference; 95% CI, 4.5%-6.9%; P<.001). Similar effects were found at each of the 3 schools, though they differed in magnitude. Conclusions Communications curricula using an established educational model significantly improved third-year students' overall communications competence as well as their skills in relationship building, organization and time management, patient assessment, and negotiation and shared decision making-tasks that are important to positive patient outcomes. Improvements were observed at each of the 3 schools despite adaptation of the intervention to the local curriculum and culture.	NYU, Robert F Wagner Grad Sch Publ Serv, Ctr Hlth & Publ Serv Res, New York, NY 10003 USA; NYU, Sch Med, New York, NY USA; Med Educ Dev, New York, NY USA; Univ Massachusetts, Sch Med, Worcester, MA USA; Case Western Reserve Univ, Sch Med, Cleveland, OH USA	New York University; New York University; University of Massachusetts System; University of Massachusetts Worcester; Case Western Reserve University	Yedidia, MJ (corresponding author), NYU, Robert F Wagner Grad Sch Publ Serv, Ctr Hlth & Publ Serv Res, 726 Broadway,5th Floor, New York, NY 10003 USA.	michael.yedidia@nyu.edu		Lipkin, Mack/0000-0001-9970-0725; Schwartz, Mark/0000-0002-7123-0060; Gillespie, Colleen/0000-0001-9096-3430				Aspegren K, 1999, MED TEACH, V21, P563, DOI 10.1080/01421599978979; *ASS AM MED COLL, 1999, 3 ASS AM MED COLL ME; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BERTAKIS KD, 1977, J FAM PRACTICE, V5, P217; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; Boon H, 1998, PATIENT EDUC COUNS, V35, P161, DOI 10.1016/S0738-3991(98)00063-9; BRODY DS, 1989, J GEN INTERN MED, V4, P506, DOI 10.1007/BF02599549; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; COHEN R, 1991, ACAD MED, V66, P545, DOI 10.1097/00001888-199109000-00012; Colliver JA, 1998, ACAD MED, V73, pS81, DOI 10.1097/00001888-199810000-00053; EISENTHAL S, 1979, ARCH GEN PSYCHIAT, V36, P393; Epstein RM, 2002, JAMA-J AM MED ASSOC, V287, P226, DOI 10.1001/jama.287.2.226; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Fallowfield L, 1998, J CLIN ONCOL, V16, P1961, DOI 10.1200/JCO.1998.16.5.1961; Floreck LM, 2001, ACAD MED, V76, pS93, DOI 10.1097/00001888-200110001-00031; Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358; Hodges B, 1999, ACAD MED, V74, P1129, DOI 10.1097/00001888-199910000-00017; Huitema B., 1980, ANAL COVARIANCE ALTE; Janicik Regina, 2002, Acad Med, V77, P460, DOI 10.1097/00001888-200205000-00033; KALET A, CURRICULUM MACY INIT; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Kaplan SH, 1996, ANN INTERN MED, V124, P497, DOI 10.7326/0003-4819-124-5-199603010-00007; Kraan HF, 1995, MED INTERVIEW CLIN C, P460; KUPST MJ, 1975, AM J ORTHOPSYCHIAT, V45, P420, DOI 10.1111/j.1939-0025.1975.tb02553.x; Lazare A., 1995, MED INTERVIEW CLIN C, P3; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Liaison Committee on Medical Education, 1998, FUNCT STRUCT MED SCH; Lipkin M, 1985, MED INTERVIEW CLIN C, P422; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; MAKOUL A, 2001, ACAD MED, V76, P390; MAXWELL SE, 1989, DESIGNING EXPT ANAL; NOVACK DH, 1993, JAMA-J AM MED ASSOC, V269, P2101, DOI 10.1001/jama.269.16.2101; Pedhazur EJ, 1991, MEASUREMENT DESIGN A; ROTER DL, 1987, J GEN INTERN MED, V2, P325, DOI 10.1007/BF02596168; ROWE MB, 1986, J TEACH EDUC, V37, P43, DOI 10.1177/002248718603700110; SCHULMAN BA, 1979, MED CARE, V17, P267, DOI 10.1097/00005650-197903000-00004; SILVERMAN J, 1998, SKILLS COMMUNICATING; Stewart M, 1995, PATIENT CTR MED TRAN; STEWART MA, 1997, IMPACT PATIENT CTR C; STILES WB, 1979, SOC SCI MED-MED SOC, V13, P335, DOI 10.1016/0271-7123(79)90055-5; Stone S, 2003, TEACH LEARN MED, V15, P7, DOI 10.1207/S15328015TLM1501_03; Swartz MH, 1999, ACAD MED, V74, P1028, DOI 10.1097/00001888-199909000-00018; Tuckett D., 1985, M EXPERTS APPROACH S; WASSERMAN RC, 1984, PEDIATRICS, V74, P1047; WEINBERGER M, 1981, SOC SCI MED-MED PSYC, V15, P239, DOI 10.1016/0271-5384(81)90019-3	45	291	304	0	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1157	1165		10.1001/jama.290.9.1157	http://dx.doi.org/10.1001/jama.290.9.1157			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LK	12952997	Bronze			2022-12-28	WOS:000185090400010
J	Chen, LH; Barnett, ED; Wilson, ME				Chen, LH; Barnett, ED; Wilson, ME			Preventing infectious diseases during and after international adoption	ANNALS OF INTERNAL MEDICINE			English	Review							HEPATITIS-B; IMMUNIZATION STATUS; CHILDREN; TRANSMISSION; HEALTH; TUBERCULOSIS; RESISTANCE; MEASLES	Families of internationally adopted children face risks associated with travel if they pick up their children overseas. Unlike other travelers, they also face risks because of close contact with a child with uncertain infection and vaccination status. Tuberculosis organisms, hepatitis A virus, hepatitis B virus, and measles virus have been transmitted from adopted children to family and community members. Intestinal parasites, Bordetella pertussis, and other infectious disease agents can also be transmitted. Some of these infections may be inapparent or may not manifest in adopted children until many years after the adoption. Increased attention to preventive measures for family members and early diagnosis of infectious diseases in adopted children can reduce transmission of the organisms causing these infections. Those providing health care to families planning international adoption should know about standard pretravel advice, as well as the spectrum of possible infections in adopted children, so that they can protect the health of the travelers and family members and close friends who will welcome the new child into the home.	Mt Auburn Hosp, Cambridge, MA 02238 USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Med Ctr, Maxwell Finland Lab Infect Dis, Boston, MA 02118 USA	Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School; Boston Medical Center	Chen, LH (corresponding author), Mt Auburn Hosp, 330 Mt Auburn St, Cambridge, MA 02238 USA.	lchen@hms.harvard.edu	Chen, Lin/ADS-6751-2022	Barnett, Elizabeth/0000-0003-4822-5949; Chen, Lin/0000-0002-5684-8436				Albers LH, 1997, JAMA-J AM MED ASSOC, V278, P922, DOI 10.1001/jama.278.11.922; *AM AC PED COMM IN, 2000, 2000 RED BOOK REP CO; Barnett ED, 2002, CLIN INFECT DIS, V35, P403, DOI 10.1086/341772; BEZRUCHKA SA, 2003, TRAVEL TROPICAL MED, P112; Boulos Z, 2002, AVIAT SPACE ENVIR MD, V73, P953; *CDCP, 2003, HLT INF INT TRAV 200; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P366; Curtis AB, 1999, NEW ENGL J MED, V341, P1491, DOI 10.1056/NEJM199911113412002; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; FEDSON DS, 1999, VACCINES, P553; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; HERSHOW RC, 1987, PEDIATR INFECT DIS J, V6, P431, DOI 10.1097/00006454-198705000-00002; Hostetter Margaret K., 1998, Pediatric Research, V43, p147A; HOSTETTER MK, 1991, NEW ENGL J MED, V325, P479, DOI 10.1056/NEJM199108153250706; Jenista JA, 2000, PEDIATR ANN, V29, P208, DOI 10.3928/0090-4481-20000401-05; JENISTA JA, 1987, AM J DIS CHILD, V141, P298, DOI 10.1001/archpedi.1987.04460030076029; JOHNSON DE, 1992, JAMA-J AM MED ASSOC, V268, P3446, DOI 10.1001/jama.268.24.3446; JONG EC, 2003, TRAVEL TROPICAL MED; Khan K, 2002, NEW ENGL J MED, V347, P1850, DOI 10.1056/NEJMsa021099; Macariola DR, 2002, INFECT MED, V19, P13; Mahmoud AAF, 1996, CLIN INFECT DIS, V23, P949, DOI 10.1093/clinids/23.5.949; Miller LC, 1999, NEW ENGL J MED, V341, P1539, DOI 10.1056/NEJM199911113412009; Miller LC, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e76; Miller LC, 2001, PEDIATRICS, V108, P1050; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; RUDIN C, 1990, LANCET, V336, P1592, DOI 10.1016/0140-6736(90)93380-8; Ryan ET, 2000, NEW ENGL J MED, V342, P1716, DOI 10.1056/NEJM200006083422306; Saiman L, 2001, PEDIATRICS, V108, P608, DOI 10.1542/peds.108.3.608; Schulpen TWJ, 2001, LANCET, V358, P2131, DOI 10.1016/S0140-6736(01)07188-4; SMITH RP, 2002, BLACKWELLS PRIMARY C; SOKAL EM, 1995, ARCH DIS CHILD, V72, P191, DOI 10.1136/adc.72.2.191-a; Staat MA, 2002, PEDIATR INFECT DIS J, V21, P257, DOI 10.1097/00006454-200203000-00019; Staat Mary A., 2001, Pediatric Research, V49, p468A; *US DEP STAT, IMM VIS ISS ORPH COM; VERNON TM, 1976, JAMA-J AM MED ASSOC, V235, P2829, DOI 10.1001/jama.235.26.2829; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Wilson ME, 2001, CLIN INFECT DIS, V33, P1083, DOI 10.1086/323200; Zuber PLF, 1997, JAMA-J AM MED ASSOC, V278, P304, DOI 10.1001/jama.278.4.304; ZWIENER RJ, 1992, J PEDIATR-US, V121, P572, DOI 10.1016/S0022-3476(05)81147-3; 2002, MMWR MORB MORTAL WKL, V51, P394; 2002, MMWR MORB MORTAL WKL, V51, P1115	41	20	21	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				371	378		10.7326/0003-4819-139-5_Part_1-200309020-00013	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965946				2022-12-28	WOS:000185037500008
J	Chiovato, L; Latrofa, F; Braverman, LE; Pacini, F; Capezzone, M; Masserini, L; Grasso, L; Pinchera, A				Chiovato, L; Latrofa, F; Braverman, LE; Pacini, F; Capezzone, M; Masserini, L; Grasso, L; Pinchera, A			Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens	ANNALS OF INTERNAL MEDICINE			English	Article							GRAVES-DISEASE; ANTITHYROGLOBULIN ANTIBODIES; SURGICAL-TREATMENT; TSH RECEPTOR; AUTOANTIBODIES; THYROGLOBULIN; CARCINOMA; CANCER	Background: The development of antibodies to thyroid peroxidase, thyroglobulin, and thyroid-stimulating hormone (TSH) receptor is a main feature of autoimmune thyroid diseases. Objective: To investigate whether complete removal of thyroid antigens results in the abatement of humoral thyroid autoimmunity. Design: Retrospective chart review study of patients treated and monitored with a standard prospective protocol. Setting: University hospital in Pisa, Italy, between 1976 and 1994. Patients: 182 patients with differentiated thyroid carcinoma and serum antibodies to thyroid peroxidase, thyroglobulin, or TSH receptor due to coexistent clinical Hashimoto thyroiditis, Graves disease, or focal autoimmune thyroiditis. Intervention: Total thyroidectomy and radioiodine treatment to ablate residual or metastatic thyroid tissue. Regular follow-up with iodine-131 whole-body scanning and serum thyroglobulin measurement. Mean follow-up (+/-SD) was 10.1 +/- 4.1 years (range, 4 to 20 years). Measurements: Serum antibodies to thyroid peroxidase, thyroglobulin, and TSH receptor. Results: Thyroid peroxidase, thyroglobulin, and TSH-receptor antibodies progressively disappeared after the initial treatment. The median disappearance time was 6.3 years for thyroid peroxidase antibodies and 3.0 years for thyroglobulin antibodies. There was a statistically significant correlation between the disappearance of thyroid tissue and that of thyroid antibodies. The coexistence of Hashimoto thyroiditis or Graves disease with thyroid cancer did not modify the pattern of disappearance of thyroid antibody compared with patients with focal autoimmune thyroiditis. Conclusions: Complete ablation of thyroid tissue with its antigenic components results in the disappearance of antibodies to all major thyroid antigens, thus supporting the concept that continued antibody production depends on the persistence of autoantigen in the body.	Univ Pisa, Osped Cisanello, Dipartimento Endocrinol & Metab Ortopedia & Traum, I-56124 Pisa, Italy; Boston Univ, Sch Med, Boston, MA 02118 USA	University of Pisa; Boston University	Pinchera, A (corresponding author), Univ Pisa, Osped Cisanello, Dipartimento Endocrinol & Metab Ortopedia & Traum, Via Paradisa 2, I-56124 Pisa, Italy.	a.pinchera@endoc.med.unipi.it	Capezzone, Marco/AAD-1776-2022; Capezzone, Marco/AAA-3137-2022; Capezzone, Marco/AAL-2308-2020; Chiovato, Luca/K-6617-2016; chiovato, luca/AAC-9003-2019	Capezzone, Marco/0000-0001-8624-5831; Chiovato, Luca/0000-0001-7457-7353; MASSERINI, LUCIO/0000-0002-9661-9953; Latrofa, Francesco/0000-0003-0297-5904; Braverman, Lewis/0000-0003-1263-1099				DEBRUIN TWA, 1988, CLIN EXP IMMUNOL, V72, P481; Fatemi S., 2000, Endocrine Journal, V47, P108; HAYASHI Y, 1985, J CLIN ENDOCR METAB, V61, P1172, DOI 10.1210/jcem-61-6-1172; Larbre H, 2000, ANN ENDOCRINOL-PARIS, V61, P422; Marcocci C, 2000, THYROID, V8, P414; MARIOTTI S, 1984, J CLIN ENDOCR METAB, V58, P18, DOI 10.1210/jcem-58-1-18; MCLACHLAN SM, 1983, CLIN EXP IMMUNOL, V52, P620; Miccoli P, 1996, SURGERY, V120, P1020, DOI 10.1016/S0039-6060(96)80049-3; MORI Y, 1992, WORLD J SURG, V16, P647, DOI 10.1007/BF02067345; PACINI F, 1988, ACTA ENDOCRINOL-COP, V119, P373, DOI 10.1530/acta.0.1190373; Park Y. J., 2000, Endocrine Journal, V47, P108; PINCHERA A, 1969, J CLIN ENDOCR METAB, V29, P231, DOI 10.1210/jcem-29-2-231; Roeher HD, 1996, SURGERY, V120, P1024; RUBELLO D, 1992, J NUCL MED, V33, P1478; Spencer CA, 1998, J CLIN ENDOCR METAB, V83, P1121, DOI 10.1210/jc.83.4.1121; TENG CS, 1980, J CLIN ENDOCR METAB, V50, P1005, DOI 10.1210/jcem-50-6-1005; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WINSA B, 1995, EUR J ENDOCRINOL, V132, P406, DOI 10.1530/eje.0.1320406	18	226	241	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				346	351		10.7326/0003-4819-139-5_Part_1-200309020-00010	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00010			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965943				2022-12-28	WOS:000185037500005
J	Lerman, R				Lerman, R			Death rituals	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									William Beaumont Hosp, Imaging Ctr, Royal Oak, MI 48073 USA	Beaumont Health	Lerman, R (corresponding author), William Beaumont Hosp, Imaging Ctr, 3601 W 13 Mile Rd, Royal Oak, MI 48073 USA.	rlerman@beaumont.edu							0	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				384	384		10.7326/0003-4819-139-5_Part_1-200309020-00016	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965949				2022-12-28	WOS:000185037500011
J	Baird, G; Cass, H; Slonims, V				Baird, G; Cass, H; Slonims, V			Diagnosis of autism	BRITISH MEDICAL JOURNAL			English	Review							PERVASIVE DEVELOPMENTAL DISORDERS; SPECTRUM DISORDERS; EARLY RECOGNITION; CHILDREN; INTERVIEW; GENETICS		Guys & St Thomas NHS Trust, Newcomen Ctr, London SE1 9RT, England; Great Ormond St Hosp Children, London WC1N 3JH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Baird, G (corresponding author), Guys & St Thomas NHS Trust, Newcomen Ctr, London SE1 9RT, England.		Cass, Hilary/L-6780-2019	Cass, Hilary/0000-0001-8598-9134				[Anonymous], NHS IMM STAT ENGL 20; ATTWOOD T, 1988, ASPERGERS SYNDROME G; Baird G, 2000, J AM ACAD CHILD PSY, V39, P694, DOI 10.1097/00004583-200006000-00007; Baron -Cohen S., 1997, MINDBLINDNESS ESSAY; Baron-Cohen S., 1993, AUTISM FACTS; Bryson S. E., 2000, AUTISM, V4, P117, DOI [DOI 10.1177/1362361300004002002, 10.1177/1362361300004002002]; Charman T, 2002, J CHILD PSYCHOL PSYC, V43, P289, DOI 10.1111/1469-7610.00022; COCHRANE A, 1969, BRIT MED B, V27, P3; Emerson E, 2003, J INTELL DISABIL RES, V47, P51, DOI 10.1046/j.1365-2788.2003.00464.x; Filipek PA, 1999, J AUTISM DEV DISORD, V29, P439, DOI 10.1023/A:1021943802493; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Fombonne E, 2003, MOL PSYCHIATR, V8, P133, DOI 10.1038/sj.mp.4001266; Fombonne E, 2003, JAMA-J AM MED ASSOC, V289, P87, DOI 10.1001/jama.289.1.87; Fombonne E, 2001, PEDIATRICS, V107, P411, DOI 10.1542/peds.107.2.411; Frith U, 1991, AUTISM ASPERGERS SYN; Hall DMB, 2003, HLTH ALL CHILDREN; Howlin P, 1998, J CHILD PSYCHOL PSYC, V39, P307, DOI 10.1017/S0021963097002138; Howlin P, 2000, AUTISM, V4, P63, DOI [10.1177/1362361300004001005, DOI 10.1177/1362361300004001005]; Howlin P., 1997, AUTISM, V1, P135, DOI [DOI 10.1177/1362361397012003, 10.1177/1362361397012003]; Jackson L., 2002, FREAKS GEEKS ASPERGE; Le Couteur A, 2003, NATL AUTISM PLAN CHI; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; OSTERLING J, 1994, J AUTISM DEV DISORD, V24, P247, DOI 10.1007/BF02172225; Rapin I, 1999, BRAIN DEV-JPN, V21, P152, DOI 10.1016/S0387-7604(99)00009-1; Rutter M, 1998, J CHILD PSYCHOL PSYC, V39, P465, DOI 10.1017/S0021963098002236; Rutter M, 1999, J CHILD PSYCHOL PSYC, V40, P19, DOI 10.1111/1469-7610.00423; SHEILDS J, 2001, AUTISM INT J RES PRA, V5, P49; Simonoff E, 1998, J AUTISM DEV DISORD, V28, P447, DOI 10.1023/A:1026060623511; STONE WL, 1994, ARCH PEDIAT ADOL MED, V148, P174, DOI 10.1001/archpedi.1994.02170020060010; Stone WL, 1999, J CHILD PSYCHOL PSYC, V40, P219, DOI 10.1111/1469-7610.00435; Szatmari P, 2003, BRIT MED J, V326, P173, DOI 10.1136/bmj.326.7382.173; Szatmari P, 2000, CAN J PSYCHIAT, V45, P731, DOI 10.1177/070674370004500806; Veenstra-Vanderweele J, 2003, J AM ACAD CHILD PSY, V42, P116, DOI 10.1097/00004583-200301000-00018; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wing L, 2002, J CHILD PSYCHOL PSYC, V43, P307, DOI 10.1111/1469-7610.00023; Wing L, 1988, DIAGNOSIS ASSESSMENT; Wing L., 1988, ASPECTS AUTISM BIOL; Wing L., 2002, AUTISTIC SPECTRUM GU	39	116	120	0	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					488	493		10.1136/bmj.327.7413.488	http://dx.doi.org/10.1136/bmj.327.7413.488			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LA	12946972	Green Published			2022-12-28	WOS:000185088900020
J	Hall, JG				Hall, JG			Twinning	LANCET			English	Review							FETAL ORIGINS HYPOTHESIS; EARLY-PREGNANCY FAILURE; MONOZYGOTIC TWINS; MULTIPLE BIRTHS; X INACTIVATION; DISCORDANT; BREAST; PLACENTATION; SURVIVAL; FUSION	Twinning has fascinated human beings over the centuries. New technologies and large study groups have led to improved documentation of frequency and complications in twin pregnancies and long-term outcomes. Artificial reproductive technologies have led to a pronounced rise in numbers of dizygotic and monozygotic twins. Although spontaneous dizygotic twinning is clearly associated with increased concentration of follicle-stimulating hormone and ovulation of more than one egg, causes of monozygotic twinning remain illusive. Twin studies are used increasingly to study complex traits and disorders: however, caution is suggested, since twins might not be representative of a typical singleton pregnancy. Monozygotic twinning seems to represent an anomaly in itself, with an increased number of spontaneous abortions and structural congenital anomalies. Both monozygotic and dizygotic twins have growth rates that slow at 30 weeks in utero and might be programmed both developmentally and biochemically earlier in pregnancy to have different responses at birth and after birth compared with singletons.	British Columbia Childrens Hosp, Dept Pediat, Vancouver, BC V6H 3V4, Canada	BC Childrens Hospital; University of British Columbia	Hall, JG (corresponding author), British Columbia Childrens Hosp, Dept Pediat, 4480 Oak St,Room 2D19, Vancouver, BC V6H 3V4, Canada.	jhall@cw.bc.ca		Hall, Judith G./0000-0001-5062-491X				BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENIRSCHKE K, 1961, OBSTET GYNECOL, V18, P334; BENIRSCHKE K, 1973, NEW ENGL J MED, V288, P1276, DOI 10.1056/NEJM197306142882406; BENIRSCHKE K, 1973, NEW ENGL J MED, V288, P1329, DOI 10.1056/NEJM197306212882505; Bianchi DW, 2000, AM J MED GENET, V91, P22, DOI 10.1002/(SICI)1096-8628(20000306)91:1<22::AID-AJMG4>3.0.CO;2-3; BIEBER FR, 1981, SCIENCE, V213, P775, DOI 10.1126/science.7196086; Blickstein I, 2002, FETUS AS A PATIENT: THE EVOLVING CHALLENGE, P205; BOKLAGE CE, 1987, AM J MED GENET, V28, P67, DOI 10.1002/ajmg.1320280111; BOKLAGE CE, 1990, INT J FERTIL, V35, P75; BOLES DJ, 1987, AM J MED GENET, V28, P103, DOI 10.1002/ajmg.1320280115; Bomsel-Helmreich O, 1995, MULTIPLE PREGNANCY E, P25; Boomsma D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/nrg932; Burn J, 1988, TWINNING TWINS, P7; Busjahn A, 2000, NAT GENET, V26, P398, DOI 10.1038/82515; CAMERON AH, 1968, P ROY SOC MED, V61, P229, DOI 10.1177/003591576806100314; CAMERON AH, 1983, EUR J OBSTET GYN R B, V14, P347, DOI 10.1016/0028-2243(83)90011-4; CAMPBELL DM, 1974, J BIOSOC SCI, V6, P463, DOI 10.1017/S0021932000009883; Chitnis S, 1999, AM J HUM GENET, V65, P570, DOI 10.1086/302502; COHEN A, 2001, TWIN RES, V4, P175; CZEIZEL AE, 1994, NEW ENGL J MED, V330, P1687, DOI 10.1056/NEJM199406093302314; DEROM C, 1988, NEW ENGL J MED, V319, P119; EDWARDS J. H., 1966, J MED GEMET, V3, P117, DOI 10.1136/jmg.3.2.117; EDWARDS R G, 1986, Journal of In Vitro Fertilization and Embryo Transfer, V3, P114, DOI 10.1007/BF01139357; Ericson A, 2001, Twin Res, V4, P63, DOI 10.1375/twin.4.2.63; Eriksson A W, 2000, Twin Res, V3, P189, DOI 10.1375/twin.3.4.189; GALTON F, 1875, J ANTHR I, V12, P566; GARDNER MO, 1996, MULTIPLE PREGNANCY D, P99; GERICKE GS, 1986, S AFR MED J, V69, P111; GIRELA E, 1997, AM J MED GENET, V64, P205; Greene B, 2000, TRAFFIC, V1, P69, DOI 10.1034/j.1600-0854.2000.010110.x; Hall J. G, 2001, EMERY RIMOINS PRINCI, V1, P501; HALL JG, 1983, AM J MED GENET, V15, P591, DOI 10.1002/ajmg.1320150408; Hall JG, 1996, AM J MED GENET, V61, P202, DOI 10.1002/(SICI)1096-8628(19960122)61:3<202::AID-AJMG2>3.0.CO;2-W; Hall JG, 1996, CURR OPIN GENET DEV, V6, P343, DOI 10.1016/S0959-437X(96)80012-8; Hallmayer J, 2002, AM J HUM GENET, V71, P941, DOI 10.1086/342990; HARVEY MAS, 1977, J PEDIATR-US, V90, P246, DOI 10.1016/S0022-3476(77)80640-9; HAY S, 1970, American Journal of Human Genetics, V22, P662; HEALEY SC, 2000, TWIN RES, V4, P19; HILL AVS, 1985, LANCET, V2, P1394; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3; JAMES WH, 1980, ANN HUM BIOL, V7, P273, DOI 10.1080/03014468000004321; JAMES WH, 1971, NATURE, V232, P277, DOI 10.1038/232277a0; James WH, 2002, TWIN RES, V5, P309, DOI 10.1375/twin.5.4.309; JANUNIAUX E, 1988, OBSTET GYNECOL, V72, P577; KEET MP, 1986, PEDIATRICS, V77, P336; KEITH LG, 1995, MULTIPLE PREGNANCY E, P192; Kiely J L, 2001, Twin Res, V4, P131; Kim S, 2000, AM J MED GENET, V91, P204, DOI 10.1002/(SICI)1096-8628(20000320)91:3<204::AID-AJMG10>3.3.CO;2-W; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; Lambalk C B, 1998, Twin Res, V1, P154, DOI 10.1375/136905298320566302; LANDY HJ, 1986, AM J OBSTET GYNECOL, V155, P14, DOI 10.1016/0002-9378(86)90068-2; LEVI S, 1976, Journal of Clinical Ultrasound, V4, P3, DOI 10.1002/jcu.1870040104; Lewis CM, 1996, AM J MED GENET, V61, P237, DOI 10.1002/(SICI)1096-8628(19960122)61:3<237::AID-AJMG7>3.0.CO;2-R; Li Z, 2003, LANCET, V361, P380, DOI 10.1016/S0140-6736(03)12390-2; LITTLE J, 1988, TWINNING TWINS, P207; LIVINGSTON JE, 1980, TERATOLOGY, V21, P139, DOI 10.1002/tera.1420210202; LUBINSKY MS, 1991, LANCET, V337, P1288, DOI 10.1016/0140-6736(91)92956-3; Machin G A, 1993, Birth Defects Orig Artic Ser, V29, P141; Machin GA, 1996, AM J MED GENET, V61, P216, DOI 10.1002/(SICI)1096-8628(19960122)61:3<216::AID-AJMG5>3.0.CO;2-S; Machin GA.KeithLG, 1999, ATLAS MULTIPLE PREGN; Mathews F, 1999, LANCET, V353, P291, DOI 10.1016/S0140-6736(05)74937-0; McLaren A, 1995, GENET RES, V66, P195, DOI 10.1017/S0016672300034649; Meulemans WJ, 1996, AM J MED GENET, V61, P258, DOI 10.1002/(SICI)1096-8628(19960122)61:3<258::AID-AJMG10>3.0.CO;2-S; Monteiro J, 1998, AM J HUM GENET, V63, P339, DOI 10.1086/301978; Murphy M, 1997, LANCET, V349, P1398, DOI 10.1016/S0140-6736(05)63241-2; Myrianthopoulos N C, 1975, Birth Defects Orig Artic Ser, V11, P1; NYLANDER PPS, 1981, ACTA GENET MED GEMEL, V30, P189, DOI 10.1017/S0001566000007650; Nylander PPS, 1975, HUMAN MULTIPLE REPRO, P87; Opitz J.M., 1987, P 7 INT C HUM GEN, P382; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; PHELAND MC, 1993, HUMAN MALFORMATIONS, P1047; Phillips D I, 2001, Twin Res, V4, P327, DOI 10.1375/1369052012669; Puck JM, 1998, AM J HUM GENET, V63, P327, DOI 10.1086/301988; RICHARDS CS, 1990, AM J HUM GENET, V46, P672; ROBINSON HP, 1977, BRIT J OBSTET GYNAEC, V84, P22, DOI 10.1111/j.1471-0528.1977.tb12460.x; SAIER F, 1975, OBSTET GYNECOL, V45, P217; SCHINZEL AAGL, 1979, J PEDIATR-US, V95, P921, DOI 10.1016/S0022-3476(79)80278-4; Segal N L, 2000, Twin Res, V3, P58; SHAPIRO LR, 1978, TWIN RES BIOL EPIDEM, P61; Sills E S, 2000, Twin Res, V3, P217, DOI 10.1375/twin.3.4.217; Singh S, 2002, CLIN GENET, V62, P97, DOI 10.1034/j.1399-0004.2002.620201.x; Sommer IEC, 1999, LANCET, V354, P1445, DOI 10.1016/S0140-6736(99)04130-6; Spencer R, 2000, CLIN ANAT, V13, P97, DOI 10.1002/(SICI)1098-2353(2000)13:2<97::AID-CA5>3.3.CO;2-9; SPERBER GH, 1994, AM J MED GENET, V51, P41, DOI 10.1002/ajmg.1320510110; St Clair JB, 2002, TWIN RES, V5, P294, DOI 10.1375/13690520260186498; Steinman G, 2000, Twin Res, V3, P337; Stockard CR, 1921, AM J ANAT, V28, P115, DOI 10.1002/aja.1000280202; STORRS EE, 1968, P NATL ACAD SCI USA, V60, P910, DOI 10.1073/pnas.60.3.910; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170; Tong S, 2000, Twin Res, V3, P12, DOI 10.1375/136905200320565634; Tong S, 2002, NATURE, V416, P142, DOI 10.1038/416142a; UCHIDA IA, 1983, AM J HUM GENET, V35, P987; VANALLEN MI, 1983, SEMIN PERINATOL, V7, P285; vanDijk BA, 1996, AM J MED GENET, V61, P264, DOI 10.1002/(SICI)1096-8628(19960122)61:3<264::AID-AJMG11>3.0.CO;2-R; VARMA TR, 1979, BRIT J OBSTET GYNAEC, V86, P290, DOI 10.1111/j.1471-0528.1979.tb11258.x; Verkasalo PK, 1999, CANCER EPIDEM BIOMAR, V8, P271; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Weksberg R, 2002, HUM MOL GENET, V11, P1317, DOI 10.1093/hmg/11.11.1317; Werler MM, 1997, AM J MED GENET, V71, P93; Williams S, 1999, BRIT MED J, V318, P897, DOI 10.1136/bmj.318.7188.897	102	392	408	0	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					735	743		10.1016/S0140-6736(03)14237-7	http://dx.doi.org/10.1016/S0140-6736(03)14237-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957099				2022-12-28	WOS:000185034800026
J	Antin, JH				Antin, JH			A 41-year-old woman with chronic myelogenous leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHRONIC MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; TYROSINE KINASE INHIBITOR; CHRONIC GRANULOCYTIC-LEUKEMIA; CYTOGENETIC CLONAL EVOLUTION; IMATINIB MESYLATE THERAPY; POLYMERASE-CHAIN-REACTION; 1ST CHRONIC PHASE; BCR-ABL		Dana Farber Canc Inst, Dept Med Oncol, Stem Cell Transplantat Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Antin, JH (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Stem Cell Transplantat Program, 44 Binney St, Boston, MA 02115 USA.							ANTIN J, 2003, BLOOD PRINCIPLES PRA, P433; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Baccarani M, 2002, BLOOD, V99, P1527, DOI 10.1182/blood.V99.5.1527; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Branford S, 2003, BLOOD, V102, P276, DOI 10.1182/blood-2002-09-2896; Braziel RM, 2002, BLOOD, V100, P435, DOI 10.1182/blood.V100.2.435; Buchdunger E, 1996, CANCER RES, V56, P100; Bumm T, 2003, BLOOD, V101, P1941, DOI 10.1182/blood-2002-07-2053; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cortes JE, 2003, BLOOD, V101, P3794, DOI 10.1182/blood-2002-09-2790; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Elmaagacli AH, 2003, BLOOD, V101, P446, DOI 10.1182/blood-2002-05-1615; GARCIAMANERO G, 2003, BLOOD PRINCIPLES PRA, P433; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1998, JNCI-J NATL CANCER I, V90, P850, DOI 10.1093/jnci/90.11.850; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; Hehlmann R, 1997, BRIT J HAEMATOL, V97, P76, DOI 10.1046/j.1365-2141.1997.102652.x; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; HEYSSEL R, 1960, BLOOD, V15, P313, DOI 10.1182/blood.V15.3.313.313; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; HOROWITZ MM, 1990, BLOOD, V75, P555; Hughes T, 2002, BLOOD, V100, p93A; Hughes Timothy P., 1995, P1142; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kantarjian HM, 2003, CANCER-AM CANCER SOC, V97, P1033, DOI 10.1002/cncr.11223; Kantarjian HM, 2002, BLOOD, V100, P1590, DOI 10.1182/blood.V100.5.1590.h81702001590_1590_1595; Kluin-Nelemans JC, 1998, BLOOD, V91, P2713; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Lee SJ, 1998, BLOOD, V92, P4047, DOI 10.1182/blood.V92.11.4047.423a04_4047_4052; Lee SJ, 2001, BLOOD, V98, P3205, DOI 10.1182/blood.V98.12.3205; Levis M, 2002, BLOOD, V99, P3885, DOI 10.1182/blood.V99.11.3885; Majlis A, 1996, J CLIN ONCOL, V14, P196, DOI 10.1200/JCO.1996.14.1.196; *NAT CANC I SURV E, 1997, PUBL US DC ROM 1973; Neumann F, 2003, EUR J HAEMATOL, V70, P1, DOI 10.1034/j.1600-0609.2003.02811.x; Niederwieser D, 2003, BLOOD, V101, P1620, DOI 10.1182/blood-2002-05-1340; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; O'Farrell AM, 2003, BLOOD, V101, P3597, DOI 10.1182/blood-2002-07-2307; Or R, 2003, BLOOD, V101, P441, DOI 10.1182/blood-2002-02-0535; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; ROTH MS, 1990, TRANSPLANTATION, V49, P714, DOI 10.1097/00007890-199004000-00012; Roumiantsev S, 2002, P NATL ACAD SCI USA, V99, P10700, DOI 10.1073/pnas.162140299; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Savage DG, 1997, BRIT J HAEMATOL, V96, P111, DOI 10.1046/j.1365-2141.1997.d01-1982.x; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schoch C, 2002, LEUKEMIA, V16, P53, DOI 10.1038/sj.leu.2402329; Shimoni A, 2003, LEUKEMIA, V17, P290, DOI 10.1038/sj.leu.2402808; Silver RT, 1999, BLOOD, V94, P1517; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Socie G, 1999, NEW ENGL J MED, V341, P14, DOI 10.1056/NEJM199907013410103; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; TURA S, 1994, NEW ENGL J MED, V330, P820; Wadhwa J, 2002, BLOOD, V99, P2304, DOI 10.1182/blood.V99.7.2304; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; Weisdorf DJ, 2002, BLOOD, V99, P1971, DOI 10.1182/blood.V99.6.1971	66	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1083	1090		10.1001/jama.290.8.1083	http://dx.doi.org/10.1001/jama.290.8.1083			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941682				2022-12-28	WOS:000184958900028
J	Boutron, I; Tubach, F; Giraudeau, B; Ravaud, P				Boutron, I; Tubach, F; Giraudeau, B; Ravaud, P			Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED-TRIALS; TIDAL IRRIGATION; QUALITY; SURGERY; VOLUME; IMPACT	Context Randomized controlled trials have been developed essentially in the context of pharmacological treatments (ie, oral drugs; intra-articular injection; and topical, intramuscular, and intravenous treatments), but assessment of the effectiveness of non pharmacological treatments (ie, surgery, arthroscopy, joint lavage, rehabilitation, acupuncture, and education) presents specific issues. Objectives To compare the quality of articles of non pharmacological and pharmacological treatments of hip and knee osteoarthritis and to identify specific methodological issues related to assessment of nonpharmacological treatments. Design and Setting We searched MEDLINE and the Cochrane Central Register of Controlled Trials for articles of randomized controlled trials published between January 1, 1992, and February 28, 2002, in 28 general medical and specialty journals with high impact factors and assessing nonpharmacological and pharmacological treatments in patients with hip or knee osteoarthritis. Main Outcome Measures The quality of the methods reported in the selected articles was assessed by 2 independent reviewers using the Jadad scale, the Delphi list, and guidelines found in the Users' Guides to the Medical Literature. Investigators also used a checklist of items developed by the authors to analyze study characteristics. Results A total of 110 articles were included in the analysis; 50 (45.5%) assessed non pharmacological treatments and 60 (54.5%) assessed pharmacological treatments. Reports of non pharmacological treatments had a lower global quality score than did reports of pharmacological treatments as measured by the Jadad scale (mean [SD] score, 1.4 [1.3] vs 3.0 [1.3]) and the Delphi list (mean [SD] score, 5.2 [1.5] vs 7.5 [1.1]). Lack of reporting adequate random sequence generation and intention-to-treat analyses were found in both non pharmacological and pharmacological articles. Non pharmacological treatments were less often compared with a placebo than were pharmacological treatments (28.0% of articles Vs 71.7%). Compared with pharmacological articles, non pharmacological articles less often described blinding of patients (26.0% vs 96.7%), care providers (6.0% Vs 81.7%), and outcome assessors (68.0% vs 98.3%). Care providers' skill levels could influence treatment effect in 84.0% of non pharmacological articles vs 23.3% of pharmacological articles. Conclusions In this analysis of reports of hip and knee osteoarthritis therapy, nonpharmacological articles scored lower than pharmacological articles in terms of quality. Assessments of nonpharmacological treatments must take into consideration additional methodological issues.	Univ Paris 07, Fac Xavier Bichat,Grp Hosp Bichat Claude Bernard, Assistance Publ Hop Paris, Dept Epidemiol Biostat & Rech Clin, Paris, France; INSERM EMI 0357, Paris, France; INSERM CIC 202, Tours, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Boutron, I (corresponding author), Grp Hosp Bichat Claude Bernard, Dept Epidemiol Biostat & Rech Clin, 46 Rue Henri Huchard, F-75877 Paris 18, France.	isabelle.boutron@bch.ap-hop-paris.fr	ravaud, philippe/C-1694-2009; Giraudeau, Bruno/L-9003-2015	Giraudeau, Bruno/0000-0003-3031-8258; Ravaud, Philippe/0000-0001-8264-9206; Boutron, Isabelle/0000-0002-5263-6241				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Badley EM, 1995, ARTHRIT CARE RES, V8, P221, DOI 10.1002/art.1790080405; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Black N, 1996, BRIT MED J, V312, P1215; Bradley JD, 2002, ARTHRITIS RHEUM-US, V46, P100, DOI 10.1002/1529-0131(200201)46:1<100::AID-ART10037>3.0.CO;2-V; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; Feldon SE, 2003, CONTROL CLIN TRIALS, V24, P294, DOI 10.1016/S0197-2456(02)00303-3; GUYATT G, 2001, USERS GUIDES MED LIT, P58; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hill CL, 2002, J CLIN EPIDEMIOL, V55, P783, DOI 10.1016/S0895-4356(02)00440-7; Hill CL, 2002, ARTHRITIS RHEUM, V46, P779, DOI 10.1002/art.512; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; IKE RW, 1992, J RHEUMATOL, V19, P772; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JUSTICE AC, 1994, JAMA-J AM MED ASSOC, V272, P117, DOI 10.1001/jama.272.2.117; Kreder HJ, 1997, J BONE JOINT SURG AM, V79A, P485, DOI 10.2106/00004623-199704000-00003; LAVERNIA CJ, 1995, J ARTHROPLASTY, V10, P133, DOI 10.1016/S0883-5403(05)80119-6; Lee KP, 2002, JAMA-J AM MED ASSOC, V287, P2805, DOI 10.1001/jama.287.21.2805; Majeed AW, 1996, LANCET, V347, P989, DOI 10.1016/S0140-6736(96)90143-9; McCulloch P, 2002, BRIT MED J, V324, P1448, DOI 10.1136/bmj.324.7351.1448; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; Prescott RJ, 1999, HEALTH TECHNOL ASSES, V3, P1, DOI DOI 10.3310/hta3200; Ravaud P, 1999, ARTHRITIS RHEUM-US, V42, P475, DOI 10.1002/1529-0131(199904)42:3<475::AID-ANR12>3.0.CO;2-S; Ridgway PF, 2002, BRIT MED J, V325, P560, DOI 10.1136/bmj.325.7364.560; Roberts C, 1999, STAT MED, V18, P2605, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2605::AID-SIM237>3.0.CO;2-N; RUSSELL I, 1995, BRIT MED J, V311, P1243, DOI 10.1136/bmj.311.7015.1243; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; van Rooyen S, 1998, JAMA-J AM MED ASSOC, V280, P234, DOI 10.1001/jama.280.3.234; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Verhagen AP, 2002, INT J TECHNOL ASSESS, V18, P11	37	111	113	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1062	1070		10.1001/jama.290.8.1062	http://dx.doi.org/10.1001/jama.290.8.1062			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941679	Bronze			2022-12-28	WOS:000184958900025
J	Wagner, KD; Ambrosini, P; Rynn, M; Wohlberg, C; Yang, RY; Greenbaum, MS; Childress, A; Donnelly, C; Deas, D				Wagner, KD; Ambrosini, P; Rynn, M; Wohlberg, C; Yang, RY; Greenbaum, MS; Childress, A; Donnelly, C; Deas, D		Sertraline Pediat Depression Study	Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder - Two randomized controlled trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSESSIVE-COMPULSIVE DISORDER; SITE VARIABILITY; CHILDHOOD; FLUOXETINE; PAROXETINE; ANXIETY; ONSET; RISK; RELIABILITY; VALIDITY	Context The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents. Objective To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD. Design and Setting Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled a priori. Participants Three hundred seventy-six children and adolescents aged 6 to 17 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined MDD of at least moderate severity. Intervention Patients were randomly assigned to receive a flexible dosage (50-200 mg/d) of sertraline (n=189) or matching placebo tablets (n=187) for 10 weeks. Main Outcome Measures Change from baseline in the Children's Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events. Results Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P=.001; overall mean change, -22.84 vs -20.19, respectively; P=.007). Based on a 40% decrease in the adjusted CDRS-R total score at study end point, 69% of sertraline-treated patients compared with 59% of placebo patients were considered responders (P=.05). Sertraline treatment was generally well tolerated. Seventeen sertraline-treated patients (9%) and 5 placebo patients (3%) prematurely discontinued the study because of adverse events. Adverse events that occurred in at least 5% of sertraline-treated patients and with an incidence of at least twice that in placebo patients included diarrhea, vomiting, anorexia, and agitation. Conclusion The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD.	Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Div Child & Adolescent Psychiat, Galveston, TX 77555 USA; Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Pfizer Inc, New York, NY USA; Ingenium Clin Res, Libertyville, IL USA; Nevada Behav Hlth Inc, Las Vegas, NV USA; Dartmouth Coll Sch Med, Lebanon, NH USA; Med Univ S Carolina, Charleston, SC 29425 USA	University of Texas System; University of Texas Medical Branch Galveston; Drexel University; University of Pennsylvania; Pfizer; Dartmouth College; Medical University of South Carolina	Wagner, KD (corresponding author), Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Div Child & Adolescent Psychiat, 301 Univ Blvd, Galveston, TX 77555 USA.	kwagner@utmb.edu	Ambrosini, Paul/AAY-4175-2020					Alderman J, 1998, J AM ACAD CHILD PSY, V37, P386, DOI 10.1097/00004583-199804000-00016; Ambrosini PJ, 1999, J AM ACAD CHILD PSY, V38, P566, DOI 10.1097/00004583-199905000-00018; Ambrosini PJ, 2000, PSYCHIAT SERV, V51, P627, DOI 10.1176/appi.ps.51.5.627; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Amsterdam JD, 2002, PROG NEURO-PSYCHOPH, V26, P989, DOI 10.1016/S0278-5846(02)00219-1; APTER A, 1994, J AM ACAD CHILD PSY, V33, P342, DOI 10.1097/00004583-199403000-00007; Berndt ER, 2000, AM J PSYCHIAT, V157, P940, DOI 10.1176/appi.ajp.157.6.940; Birmaher B, 1998, J AM ACAD CHILD PSY, V37, P1234, DOI 10.1097/00004583-199811000-00029; Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1427, DOI 10.1097/00004583-199611000-00011; BLAZER DG, 1994, AM J PSYCHIAT, V151, P979; Boulos C, 1992, J Child Adolesc Psychopharmacol, V2, P103, DOI 10.1089/cap.1992.2.103; COLLE LM, 1994, J CHILD ADOL PSYCHOP, V4, P225, DOI 10.1089/cap.1994.4.225; Emslie GJ, 2002, J AM ACAD CHILD PSY, V41, P1205, DOI 10.1097/00004583-200210000-00010; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; EMSLIE GJ, 1995, J CHILD NEUROL, V10, pS42, DOI 10.1177/08830738950100S110; ENDICOTT J, 1993, PSYCHOPHARMACOL BULL, V29, P321; *FDA, 2003, T0341 FDA; Findling R, 1996, PSYCHOPHARMACOL BULL, V32, P446; Findling R L, 1999, Paediatr Drugs, V1, P161, DOI 10.2165/00128072-199901030-00002; GERSHON ES, 1987, ARCH GEN PSYCHIAT, V44, P314; Ghaziuddin N, 1995, DEPRESSION, V6, P287; Guy W, 1976, ECDEU ASSESSMENT MAN, DOI DOI 10.1037/E591322011-001; HAZELL P, 1995, BRIT MED J, V310, P897, DOI 10.1136/bmj.310.6984.897; Kastelic E A, 2000, Curr Psychiatry Rep, V2, P117, DOI 10.1007/s11920-000-0055-x; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Keller MB, 2001, J AM ACAD CHILD PSY, V40, P762, DOI 10.1097/00004583-200107000-00010; Kessler R C, 1998, Depress Anxiety, V7, P3, DOI 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F; KLERMAN GL, 1989, JAMA-J AM MED ASSOC, V261, P2229, DOI 10.1001/jama.261.15.2229; Kovacs M, 1996, J AM ACAD CHILD PSY, V35, P705, DOI 10.1097/00004583-199606000-00010; KOVACS M, 1984, ARCH GEN PSYCHIAT, V41, P643, DOI 10.1001/archpsyc.1984.01790180013001; KOVACS M, 1984, ARCH GEN PSYCHIAT, V41, P229; LEWINSOHN PM, 1994, J AM ACAD CHILD PSY, V33, P809, DOI 10.1097/00004583-199407000-00006; March JS, 1997, J AM ACAD CHILD PSY, V36, P554, DOI 10.1097/00004583-199704000-00019; MCCAULEY E, 1993, J AM ACAD CHILD PSY, V32, P714, DOI 10.1097/00004583-199307000-00003; McConville BJ, 1996, J CHILD ADOL PSYCHOP, V6, P41, DOI 10.1089/cap.1996.6.41; Nixon MK, 2001, J CHILD ADOL PSYCHOP, V11, P131, DOI 10.1089/104454601750284036; Ornstein S, 2000, J FAM PRACTICE, V49, P68; Pine DS, 1998, ARCH GEN PSYCHIAT, V55, P56, DOI 10.1001/archpsyc.55.1.56; POZNANSKI EO, 1985, PSYCHOPHARMACOL BULL, V21, P979; Poznanski EO, 1995, CHILDRENS DEPRESSION; RAO U, 1993, J AM ACAD CHILD PSY, V32, P21, DOI 10.1097/00004583-199301000-00004; ReySanchez F, 1997, J AM ACAD CHILD PSY, V36, P1443, DOI 10.1097/00004583-199710000-00027; RYNN M, 2003, 156 ANN M AM PSYCH A; SHAFFER D, 1983, ARCH GEN PSYCHIAT, V40, P1228; Small GW, 1996, INT J GERIATR PSYCH, V11, P1089, DOI 10.1002/(SICI)1099-1166(199612)11:12<1089::AID-GPS463>3.0.CO;2-F; TIERNEY E, 1995, J CHILD ADOL PSYCHOP, V5, P13, DOI 10.1089/cap.1995.5.13; Walsh BT, 2002, JAMA-J AM MED ASSOC, V287, P1840, DOI 10.1001/jama.287.14.1840; Weissman MM, 1999, ARCH GEN PSYCHIAT, V56, P794, DOI 10.1001/archpsyc.56.9.794; Weissman MM, 1999, JAMA-J AM MED ASSOC, V281, P1707, DOI 10.1001/jama.281.18.1707	49	302	312	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1033	1041		10.1001/jama.290.8.1033	http://dx.doi.org/10.1001/jama.290.8.1033			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715FA	12941675				2022-12-28	WOS:000184958900021
J	Awasthi, S; Bundy, DAP; Savioli, L				Awasthi, S; Bundy, DAP; Savioli, L			Helminthic infections	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INTESTINAL NEMATODE INFECTIONS; SOIL-TRANSMITTED HELMINTHIASIS; ASCARIS-LUMBRICOIDES; PREGNANCY; CHILDREN; SCHISTOSOMIASIS; PRAZIQUANTEL; PERFORMANCE; TRICHURIS; HOOKWORM		CSMMU, Upgraded King George Med Coll, Dept Paediat, Lucknow, Uttar Pradesh, India; World Bank, Human Dev Network, Washington, DC 20433 USA; WHO, Div Intestinal Parasites & Vector Control, CH-1211 Geneva, Switzerland	King George's Medical University; The World Bank; World Health Organization	Awasthi, S (corresponding author), C-29 Sector C,Chetan Vihar, Lucknow 226024, Uttar Pradesh, India.	sawasthi@sancharnet.in						Albonico M, 1999, ADV PARASIT, V42, P277, DOI 10.1016/S0065-308X(08)60151-7; ANDERSON RM, 1985, PARASITOLOGY, V90, P629, DOI 10.1017/S0031182000052288; Bradley M, 2001, T ROY SOC TROP MED H, V95, P72, DOI 10.1016/S0035-9203(01)90338-4; BUNDY DAP, 1995, T ROY SOC TROP MED H, V89, P521, DOI 10.1016/0035-9203(95)90093-4; Bundy DAP, 1998, BRIT MED BULL, V54, P421, DOI 10.1093/oxfordjournals.bmb.a011698; Bundy DAP, 1998, T ROY SOC TROP MED H, V92, P254; BUNDY DAP, 1989, ADV PARASIT, V28, P107; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; COOPER ES, 1988, PARASITOL TODAY, V4, P301, DOI 10.1016/0169-4758(88)90110-X; Crompton DWT, 2003, ACTA TROP, V86, P121, DOI 10.1016/S0001-706X(03)00027-5; de Silva NR, 1999, LANCET, V353, P1145, DOI 10.1016/S0140-6736(98)06308-9; Dickson R, 2000, BMJ-BRIT MED J, V320, P1697, DOI 10.1136/bmj.320.7251.1697; Engel J, 1977, Curr Dev Psychopharmacol, V4, P1; Hadidjaja P, 1998, AM J TROP MED HYG, V59, P791, DOI 10.4269/ajtmh.1998.59.791; Hall A, 1999, T ROY SOC TROP MED H, V93, P653, DOI 10.1016/S0035-9203(99)90087-1; Jukes MCH, 2002, TROP MED INT HEALTH, V7, P104, DOI 10.1046/j.1365-3156.2002.00843.x; KVALSVIG JD, 1991, ANN TROP MED PARASIT, V85, P551, DOI 10.1080/00034983.1991.11812608; Michael E, 2000, BRIT MED J, V321, P1224; MIGUEL F, 2001, W8481 NBER; Montresor A, 2003, ACTA TROP, V86, P223, DOI 10.1016/S0001-706X(03)00042-1; Montresor A, 2002, T ROY SOC TROP MED H, V96, P323, DOI 10.1016/S0035-9203(02)90111-2; Montresor A, 2001, T ROY SOC TROP MED H, V95, P542, DOI 10.1016/S0035-9203(01)90034-3; Montresor A., 2002, HELMINTH CONTROL SCH; POLLITT E, 1989, AM J CLIN NUTR, V50, P687, DOI 10.1093/ajcn/50.3.687; ROCHE M, 1966, AM J TROP MED HYG, V15, P1032, DOI 10.4269/ajtmh.1966.15.1032; Savioli L, 2000, BRIT MED J, V321, P1226; STEPHENSON LS, 1993, J NUTR, V123, P1036; STEPHENSON LS, 1987, IMPACT HELMINTH INFE; Torlesse H, 2000, LANCET, V356, P1083, DOI 10.1016/S0140-6736(00)02738-0; van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9; Warren K.S., 1993, DIS CONTROL PRIORITI, P131; Watkins WE, 1997, PSYCHOL BULL, V121, P171, DOI 10.1037/0033-2909.121.2.171; *WHO, 1996, WHOCDSCPCSIP991; *WORLD BANK, 2000, FRESH FOC RES EFF SC; World Bank, 1993, WORLD DEV REP INV HL	35	77	80	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2003	327	7412					431	433		10.1136/bmj.327.7412.431	http://dx.doi.org/10.1136/bmj.327.7412.431			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715YY	12933732	Green Published			2022-12-28	WOS:000185003100022
J	Thursby, JG; Thursby, MC				Thursby, JG; Thursby, MC			Intellectual property - University licensing and the Bayh-Dole Act	SCIENCE			English	Editorial Material							INVENTIONS; GROWTH		Georgia Inst Technol, Atlanta, GA 30332 USA; Emory Univ, Atlanta, GA 30306 USA	University System of Georgia; Georgia Institute of Technology; Emory University	Thursby, JG (corresponding author), Emory Univ, Atlanta, GA 30306 USA.							Agrawal A, 2002, MANAGE SCI, V48, P44, DOI 10.1287/mnsc.48.1.44.14279; *ASS U TECHN MAN, 2001, AUTM LIC SURV; Association of University Technology Managers, 1991, AUTM LIC SURV; Atkinson RC, 2003, SCIENCE, V301, P174, DOI 10.1126/science.1085553; Blumenthal D, 1997, JAMA-J AM MED ASSOC, V277, P1224, DOI 10.1001/jama.277.15.1224; Cohen W., 2000, PROTECTING THEIR INT, DOI [10.3386/w7552, DOI 10.3386/W7552]; Cohen WM, 2002, MANAGE SCI, V48, P1, DOI 10.1287/mnsc.48.1.1.14273; Colyvas J, 2002, MANAGE SCI, V48, P61, DOI 10.1287/mnsc.48.1.61.14272; Dechenaux E, 2003, 9735 NBER; Henry MR, 2002, SCIENCE, V297, P1279, DOI 10.1126/science.1070899; Jensen R, 2001, AM ECON REV, V91, P240, DOI 10.1257/aer.91.1.240; JENSEN R, IN PRESS INT J IND O; Louis K.S., 2001, J TECHNOL TRANSFER, V26, DOI [10.1023/A:1011106006976, DOI 10.1023/A:1011106006976]; Mowery DC, 2001, RES POLICY, V30, P99, DOI 10.1016/S0048-7333(99)00100-6; NASS S, 2003, LARGE SCALE BIOMEDIC, P168; PRESS E, 2000, ATLANTIC MONTHLY, V285, P39; RAI AK, 2003, LAW CONTEMP PROBL, V66, P288; THURSBY J, IN PRESS BUYING SELL; THURSBY J, UNPUB; Thursby JG, 2002, MANAGE SCI, V48, P90, DOI 10.1287/mnsc.48.1.90.14271; THURSBY JG, 2001, J TECHNOLOGY TRANSFE, V26, P59, DOI DOI 10.1023/A:1007884111883	21	93	96	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1052	1052		10.1126/science.1087473	http://dx.doi.org/10.1126/science.1087473			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12933996				2022-12-28	WOS:000184872400024
J	Wang, CT; Lu, JC; Bai, JH; Chang, PY; Martin, TFJ; Chapman, ER; Jackson, MB				Wang, CT; Lu, JC; Bai, JH; Chang, PY; Martin, TFJ; Chapman, ER; Jackson, MB			Different domains of synaptotagmin control the choice between kiss-and-run and full fusion	NATURE			English	Article							ADRENAL CHROMAFFIN CELLS; CA2+ BINDING; HIPPOCAMPAL SYNAPSES; PC12 CELLS; EXOCYTOSIS; IV; KINETICS; MECHANISM; SECRETION; SENSOR	Exocytosis-the release of the contents of a vesicle-proceeds by two mechanisms(1-6). Full fusion occurs when the vesicle and plasma membranes merge. Alternatively, in what is termed kiss-and-run, vesicles can release transmitter during transient contacts with the plasma membrane. Little is known at the molecular level about how the choice between these two pathways is regulated. Here we report amperometric recordings of catecholamine efflux through individual fusion pores. Transfection with synaptotagmin (Syt) IV increased the frequency and duration of kiss-and-run events, but left their amplitude unchanged. Endogenous Syt IV, induced by forskolin treatment, had a similar effect. Full fusion was inhibited by mutation of a Ca2+ ligand in the C(2)A domain of Syt I; kiss-and-run was inhibited by mutation of a homologous Ca2+ ligand in the C2B domain of Syt IV. The Ca2+ sensitivity for full fusion was 5-fold higher with Syt I than Syt IV, but for kiss-and-run the Ca2+ sensitivities differed by a factor of only two. Syt thus regulates the choice between full fusion and kiss-and-run, with Ca2+ binding to the C(2)A and C2B domains playing an important role in this choice.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Dept Comparat Biosci, Endocrinol Reprod Physiol Program, Madison, WI 53706 USA; Univ Wisconsin, Biophys Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jackson, MB (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.		Wang, Chih-Tien/GRE-8232-2022; Lu, Juu-Chin/ABB-3198-2020	Wang, Chih-Tien/0000-0001-7639-7508; Lu, Juu-Chin/0000-0001-8523-6992; Chapman, Edwin/0000-0001-9787-8140				Albillos A, 1997, NATURE, V389, P509, DOI 10.1038/39081; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; ALVAREZ DT, 1993, NATURE, V363, P554, DOI DOI 10.1038/363554A0; Bai JH, 2002, P NATL ACAD SCI USA, V99, P1665, DOI 10.1073/pnas.032541099; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; Chow Robert H., 1995, P245; COLQUHOUN D, 1982, PHILOS T ROY SOC B, V300, P1, DOI 10.1098/rstb.1982.0156; CORMACK B, 1994, CURRENT PROTOCOLS MO; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Eaton BA, 2000, J NEUROSCI, V20, P7334; Ferguson GD, 2001, MOL NEUROBIOL, V23, P173; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; JACKSON MB, 1992, METHOD ENZYMOL, V207, P729; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; Klyachko VA, 2002, NATURE, V418, P89, DOI 10.1038/nature00852; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schneider SW, 2001, J MEMBRANE BIOL, V181, P67; Schroeder TJ, 1996, BIOPHYS J, V70, P1061, DOI 10.1016/S0006-3495(96)79652-2; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang CT, 2001, SCIENCE, V294, P1111, DOI 10.1126/science.1064002	28	170	174	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					943	947		10.1038/nature01857	http://dx.doi.org/10.1038/nature01857			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931189				2022-12-28	WOS:000184843600042
J	Mokete, M; Palmer, AR; O'Flynn, KJ				Mokete, M; Palmer, AR; O'Flynn, KJ			10-minute consultation - High result in prostate specific antigen test	BRITISH MEDICAL JOURNAL			English	Article									Hope Hosp, Dept Urol, Manchester M6 8HD, Lancs, England; Boundary House Med Ctr, Manchester M33 2RH, Lancs, England		Mokete, M (corresponding author), Hope Hosp, Dept Urol, Manchester M6 8HD, Lancs, England.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					379	379		10.1136/bmj.327.7411.379	http://dx.doi.org/10.1136/bmj.327.7411.379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919991	Green Published, Bronze			2022-12-28	WOS:000184864200021
J	Harmon, LJ; Schulte, JA; Larson, A; Losos, JB				Harmon, LJ; Schulte, JA; Larson, A; Losos, JB			Tempo and mode of evolutionary radiation in iguanian lizards	SCIENCE			English	Article							PHYLOGENETIC-RELATIONSHIPS; MOLECULAR PHYLOGENIES; ANOLIS LIZARDS; DIVERSITY; PATTERNS; DIVERSIFICATION; DISPARITY; STATES	Identification of general properties of evolutionary radiations has been hindered by the lack of a general statistical and phylogenetic approach applicable across diverse taxa. We present a comparative analytical framework for examining phylogenetic patterns of diversification and morphological disparity with data from four iguanian-lizard taxa that exhibit substantially different patterns of evolution. Taxa whose diversification occurred disproportionately early in their evolutionary history partition more of their morphological disparity among, rather than within, subclades. This inverse relationship between timing of diversification and morphological disparity within subclades may be a general feature that transcends the historically contingent properties of different evolutionary radiations.	Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Harmon, LJ (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	harmon@biology.wustl.edu	Harmon, Luke/A-8225-2012	Harmon, Luke/0000-0002-4985-5750				Ciampaglio CN, 2001, PALEOBIOLOGY, V27, P695, DOI 10.1666/0094-8373(2001)027<0695:DCIMOP>2.0.CO;2; Conway-Morris S., 1998, CRUCIBLE CREATION; Cunningham CW, 1998, TRENDS ECOL EVOL, V13, P361, DOI 10.1016/S0169-5347(98)01382-2; Etheridge Richard, 1995, American Museum Novitates, V3142, P1; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; FOOTE M, 1993, PALEOBIOLOGY, V19, P185, DOI 10.1017/S0094837300015864; Fortey RA, 1996, BIOL J LINN SOC, V57, P13, DOI 10.1006/bijl.1995.0002; GARLAND T, 1993, SYST BIOL, V42, P265, DOI 10.2307/2992464; Givnish T.J., 1997, MOL EVOLUTION ADAPTI; Gould SJ, 2002, STRUCTURE EVOLUTIONA; Jackman TR, 1999, SYST BIOL, V48, P254, DOI 10.1080/106351599260283; LOSOS JB, 1994, ANNU REV ECOL SYST, V25, P467, DOI 10.1146/annurev.es.25.110194.002343; Losos JB, 2002, AM NAT, V160, P147, DOI 10.1086/341557; Melville J, 2001, J EXP ZOOL, V291, P339, DOI 10.1002/jez.1133; NEE S, 1992, P NATL ACAD SCI USA, V89, P8322, DOI 10.1073/pnas.89.17.8322; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Pianka E., 1986, ECOLOGY NATURAL HIST; Pybus OG, 2000, P ROY SOC B-BIOL SCI, V267, P2267, DOI 10.1098/rspb.2000.1278; Ruber L, 2001, J EVOLUTION BIOL, V14, P325, DOI 10.1046/j.1420-9101.2001.00269.x; Schluter D, 1997, EVOLUTION, V51, P1699, DOI 10.1111/j.1558-5646.1997.tb05095.x; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Schulte JA, 2000, BIOL J LINN SOC, V69, P75, DOI 10.1006/bijl.1999.0346; SCHULTE JA, 2001, THESIS WASHINGTON U; Simpson G. G., 1953, MAJOR FEATURES EVOLU, DOI DOI 10.7312/SIMP93764; SITES JW, 1992, B AM MUS NAT HIST, P1; SMITH DC, 1981, ECOLOGY, V62, P679, DOI 10.2307/1937736; Wagner PJ, 1995, PALEOBIOLOGY, V21, P410, DOI 10.1017/S0094837300013464; Wills M. A., 2001, FOSSILS PHYLOGENY FO, P55	28	505	519	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					961	964		10.1126/science.1084786	http://dx.doi.org/10.1126/science.1084786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920297				2022-12-28	WOS:000184755900038
J	Higgins, JPT; Thompson, SG; Deeks, JJ; Altman, DG				Higgins, JPT; Thompson, SG; Deeks, JJ; Altman, DG			Measuring inconsistency in meta-analyses	BRITISH MEDICAL JOURNAL			English	Article							TRIALS; HETEROGENEITY; RECOMMENDATIONS; PERFORMANCE; GUIDELINES; SELECTION; BIAS		Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; Canc Res UK, NHS Ctr Stat Med, Inst Hlth Sci, Oxford OX3 7LF, England	MRC Biostatistics Unit; University of Cambridge; Cancer Research UK; University of Oxford	Higgins, JPT (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.		ravegnini, gloria/K-1330-2016; Higgins, Julian PT/H-4008-2011; Deeks, Jon/AAV-5745-2020	ravegnini, gloria/0000-0002-7774-402X; Higgins, Julian PT/0000-0002-8323-2514; Deeks, Jon/0000-0002-8850-1971				Angelillo IF, 1999, B WORLD HEALTH ORGAN, V77, P906; Barbui C, 2003, COCHRANE DB SYST REV; Clarke M, 1998, LANCET, V351, P1451; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Deeks JJ, 2002, STAT MED, V21, P1575, DOI 10.1002/sim.1188; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; Egger M, 1997, BMJ-BRIT MED J, V315, P1371, DOI 10.1136/bmj.315.7119.1371; EGGER M, 1995, BMJ-BRIT MED J, V310, P752, DOI 10.1136/bmj.310.6982.752; Engels EA, 2000, STAT MED, V19, P1707, DOI 10.1002/1097-0258(20000715)19:13<1707::AID-SIM491>3.0.CO;2-P; FREEMAN PR, 1989, STAT MED, V8, P1421, DOI 10.1002/sim.4780081202; GUYATT G, 2002, USERS GUIDES MED LIT, P599; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; Hardy RJ, 1998, STAT MED, V17, P841, DOI 10.1002/(SICI)1097-0258(19980430)17:8<841::AID-SIM781>3.0.CO;2-D; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674; JEFFERSON TO, 2002, COCHRANE DB SYST REV; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Liberati A, 2001, WESTERN J MED, V174, P262, DOI 10.1136/ewjm.174.4.262; PAUL SR, 1992, STAT MED, V11, P159, DOI 10.1002/sim.4780110203; Petitti DB, 2001, STAT MED, V20, P3625, DOI 10.1002/sim.1091; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Sterne JAC, 2001, SYSTEMATIC REV HLTH, P347, DOI [DOI 10.1002/9780470693926.CH18, 10.1002/9780470693926.ch18]; Steyerberg EW, 1999, J CLIN EPIDEMIOL, V52, P935, DOI 10.1016/S0895-4356(99)00103-1	24	37767	38173	89	1026	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					557	560		10.1136/bmj.327.7414.557	http://dx.doi.org/10.1136/bmj.327.7414.557			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958120	Green Published, Green Accepted			2022-12-28	WOS:000185283700028
J	Kerrison, S; McNally, N; Pollock, AM				Kerrison, S; McNally, N; Pollock, AM			United Kingdom research governance strategy	BRITISH MEDICAL JOURNAL			English	Article							RESEARCH ETHICS COMMITTEES; NEED	The new research governance strategy marks a radical overhaul of the arrangements for medical research in the NHS and academic institutions with far reaching implications for all those taking part in research. The days of registrars and consultants singlehandedly doing research projects are over.	UCL Hosp NHS Trust, London NW1 2LT, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Kerrison, S (corresponding author), UCL Hosp NHS Trust, London NW1 2LT, England.	susan.kerrison@uclh.nhs.uk		pollock, allyson/0000-0002-7388-3110				Abraham J, 1999, SOC SCI MED, V48, P1655, DOI 10.1016/S0277-9536(99)00042-8; *ALZH SOC, QUAL RES DEM; Ashcroft R, 2001, BRIT MED J, V322, P1294, DOI 10.1136/bmj.322.7297.1294; Ayres I, 1992, RESPONSIVE REGULATIO, P21; *DEP HLTH, 2001, GOV ARR NHS RES ETH; *DEP HLTH, 2001, RES GOV FRAM HLTH SO; Department of Health, 2000, ION RAD MED EXP REG; Gelijns AC, 2002, JAMA-J AM MED ASSOC, V287, P72, DOI 10.1001/jama.287.1.72; Jacobson PD, 2001, J HEALTH POLIT POLIC, V26, P1165, DOI 10.1215/03616878-26-5-1165; McNally N, 2003, BRIT MED J, V327, P550, DOI 10.1136/bmj.327.7414.550; Moreno JD, 2001, HASTINGS CENT REP, V31, P9, DOI 10.2307/3527549; Morin K, 2002, JAMA-J AM MED ASSOC, V287, P78, DOI 10.1001/jama.287.1.78; POSTE G, 2001, HUMAN GENETIC DATABA; Savulescu J, 2002, J MED ETHICS, V28, P1, DOI 10.1136/jme.28.1.1; Walt G, 2002, BRIT MED J, V325, P432, DOI 10.1136/bmj.325.7361.432	15	14	14	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					553	556		10.1136/bmj.327.7414.553	http://dx.doi.org/10.1136/bmj.327.7414.553			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	720WW	12958119	Green Published			2022-12-28	WOS:000185283700024
J	Rao, J; Krol, A				Rao, J; Krol, A			The harlequin color change	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Alberta, Edmonton, AB T6G 2G3, Canada; Oregon Hlth & Sci Univ, Portland, OR 97239 USA	University of Alberta; Oregon Health & Science University	Rao, J (corresponding author), Univ Alberta, Edmonton, AB T6G 2G3, Canada.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					968	968		10.1056/NEJMicm020831	http://dx.doi.org/10.1056/NEJMicm020831			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954745				2022-12-28	WOS:000185081400008
J	Metzger, ML; Howard, SC; Fu, LGC; Pena, A; Stefan, R; Hancock, ML; Zhang, Z; Pui, CH; Wilimas, J; Ribeiro, RC				Metzger, ML; Howard, SC; Fu, LGC; Pena, A; Stefan, R; Hancock, ML; Zhang, Z; Pui, CH; Wilimas, J; Ribeiro, RC			Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries	LANCET			English	Article								The causes of treatment failure in childhood acute lymphoblastic leukaemia are thought to differ between resource-rich and resource-poor countries. We assessed the records of 168 patients treated for this disease in Honduras. Abandonment of treatment (n=38), the main cause of failure, was associated with prolonged travel time to the treatment facility (2-5 h: hazard ratio 3.1, 95% CI 1.2-8.1 vs >5 h: 3.7, 1.3-10.9) and age younger than 4.5 years (2.6, 1.1-6.3). 35 patients died of treatment-related effects. Outcome could be substantially improved by interventions that help to prevent abandonment of therapy (such as funding for transport, satellite clinics, and support groups), and by prompt treatment of infection.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Int Outreach Program, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA; Hosp Escuela Bloque Maternoinfantil, Dept Pediat Hematol Oncol, Tegucigalpa, Honduras	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Metzger, ML (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	monika.metzger@stjude.org	Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal B., 2003, CONTEMPORARY CLIN NE, P321; Eden T, 2002, BRIT J HAEMATOL, V118, P945, DOI 10.1046/j.1365-2141.2002.03670.x; NANDAKUMAR A, 1995, INT J CANCER, V63, P37, DOI 10.1002/ijc.2910630108; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Wilimas JA, 2003, MED PEDIATR ONCOL, V41, P136, DOI 10.1002/mpo.10242	5	137	144	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					706	708		10.1016/S0140-6736(03)14228-6	http://dx.doi.org/10.1016/S0140-6736(03)14228-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957095				2022-12-28	WOS:000185034800013
J	Kestler, A; Keyes, L				Kestler, A; Keyes, L			Uvular angioedema (Quincke's disease)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kestler, A (corresponding author), Univ Colorado, Hlth Sci Ctr, 4200 E 9th Ave, Denver, CO 80262 USA.								0	8	9	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					867	867		10.1056/NEJMicm020617	http://dx.doi.org/10.1056/NEJMicm020617			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944572				2022-12-28	WOS:000184968400007
J	Lindholm, LH; Dahlof, B; Edelman, JM; Ibsen, H; Borch-Johnsen, K; Olsen, MH; Snapinn, S; Wachtell, K				Lindholm, LH; Dahlof, B; Edelman, JM; Ibsen, H; Borch-Johnsen, K; Olsen, MH; Snapinn, S; Wachtell, K		LIFE Study Grp	Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study	LANCET			English	Article							HYPERTENSION	In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality-especially cardiovascular mortality-in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan. We postulated post hoc that losartan might have a better effect on sudden cardiac death than atenolol, and we aimed to test this hypothesis. 44 patients with diabetes died of sudden cardiac death; significantly fewer deaths arose in the losartan group (14) than in the atenolol group (30; p=0.027). In the losartan group, five (6%) of 86 patients with diabetes and atrial fibrillation during the trial died of sudden cardiac death compared with nine (2%) of 500 in those without atrial fibrillation. The respective figures for the atenolol group were 14 (13%) of 105 and 16 (3%) of 504. Our results suggest losartan affords better protection against cardiac death from arrhythmias for patients with diabetes mellitus than does atenolol. Importantly, our analyses were exploratory and require confirmation.	Umea Univ Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden; Sahlgrenska Univ Hosp Ostra, Gothenburg, Sweden; Merck Res Labs, W Point, PA USA; Glostrup Univ Hosp, Glostrup, Denmark; Steno Diabet Ctr, DK-2820 Gentofte, Denmark	Umea University; Sahlgrenska University Hospital; Merck & Company; University of Copenhagen; Steno Diabetes Center	Lindholm, LH (corresponding author), Umea Univ Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.		Olsen, Michael H/H-8176-2014	Olsen, Michael Hecht/0000-0003-2230-5780				DELLSPERGER KC, 1990, CIRCULATION, V82, P941, DOI 10.1161/01.CIR.82.3.941; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Reiter Michael J, 2002, Curr Cardiol Rep, V4, P426, DOI 10.1007/s11886-002-0043-3; Singh Nalini, 2002, Journal of Cardiovascular Pharmacology and Therapeutics, V7, P117, DOI 10.1177/107424840200700208; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088	5	70	77	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					619	620		10.1016/S0140-6736(03)14183-9	http://dx.doi.org/10.1016/S0140-6736(03)14183-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944063				2022-12-28	WOS:000184904100012
J	Bindschadler, RA; King, MA; Alley, RB; Anandakrishnan, S; Padman, L				Bindschadler, RA; King, MA; Alley, RB; Anandakrishnan, S; Padman, L			Tidally controlled stick-slip discharge of a West Antarctic ice stream	SCIENCE			English	Article							MASS-BALANCE; GLACIER; SEA; SPEED; SHELF; SHEAR	A major West Antarctic ice stream discharges by sudden and brief periods of very rapid motion paced by oceanic tidal oscillations of about 1 meter. Acceleration to speeds greater than 1 meter per hour and deceleration back to a stationary state occur in minutes or less. Slip propagates at approximately 88 meters per second, suggestive of a shear wave traveling within the subglacial till. A model of an episodically slipping friction-locked fault reproduces the observed quasi-periodic event timing, demonstrating an ice stream's ability to change speed rapidly and its extreme sensitivity to subglacial conditions and variations in sea level.	NASA, Goddard Space Flight Ctr, Ocean & Ice Branch, Greenbelt, MD 20771 USA; Newcastle Univ, Sch Civil Engn & Geosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, EMS Environm Inst, University Pk, PA 16802 USA; Earth & Space Res, Seattle, WA 98102 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Newcastle University - UK; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bindschadler, RA (corresponding author), NASA, Goddard Space Flight Ctr, Ocean & Ice Branch, Greenbelt, MD 20771 USA.	Robert.A.Bindschadler@nasa.gov	King, Matt/B-4622-2008; Padman, Laurence/AAH-3808-2021	King, Matt/0000-0001-5611-9498; Padman, Laurence/0000-0003-2010-642X				Alley R.B., 2001, W ANTARCTIC ICE SHEE, V77, P1, DOI [10.1029/AR077p0001, DOI 10.1029/AR077P0001]; Alley RB, 2000, GEOL SOC SPEC PUBL, V176, P171, DOI 10.1144/GSL.SP.2000.176.01.13; ALLEY RB, 1993, J GLACIOL, V39, P447, DOI 10.3189/S0022143000016336; ANANDAKRISHNAN S, 1994, ANN GLACIOL, V20, P183, DOI 10.3189/172756494794587276; Anandakrishnan S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016329; Anandakrishnan S, 1997, J GEOPHYS RES-SOL EA, V102, P15183, DOI 10.1029/97JB01073; Anderson J.B., 1992, ANTARCT RES SER, V57, P39, DOI DOI 10.1029/AR057P0039; Bentley CR, 1997, SCIENCE, V275, P1077, DOI 10.1126/science.275.5303.1077; BENTLEY CR, 1987, J GEOPHYS RES-SOLID, V92, P8843, DOI 10.1029/JB092iB09p08843; Bindschadler RA, 2003, ANN GLACIOL, V36, P263, DOI 10.3189/172756403781816284; Bindschadler RA, 2002, SCI AM, V287, P98, DOI 10.1038/scientificamerican1202-98; BLANKENSHIP DD, 1987, J GEOPHYS RES-SOLID, V92, P8903, DOI 10.1029/JB092iB09p08903; Chen G., 1998, THESIS MIT; Conway H, 1999, SCIENCE, V286, P280, DOI 10.1126/science.286.5438.280; Doake CSM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014606; Iverson NR, 1998, J GLACIOL, V44, P634, DOI 10.3189/S0022143000002136; Joughin I, 2002, SCIENCE, V295, P476, DOI 10.1126/science.1066875; Kamb B., 2001, ANTARCT RES SER, V77, DOI DOI 10.1029/AR077P0157; KELLOGG TB, 1987, J GEOPHYS RES-SOLID, V92, P8859, DOI 10.1029/JB092iB09p08859; King M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016182; MEIER MF, 1987, J GEOPHYS RES-SOLID, V92, P9051, DOI 10.1029/JB092iB09p09051; Moore PL, 2002, GEOLOGY, V30, P843, DOI 10.1130/0091-7613(2002)030<0843:SESOGM>2.0.CO;2; O'Neel S, 2001, J GLACIOL, V47, P567, DOI 10.3189/172756501781831855; Padman L, 2003, ANTARCT SCI, V15, P31, DOI 10.1017/S0954102003001032; Padman L, 2002, ANN GLACIOL, V34, P247, DOI 10.3189/172756402781817752; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Rignot E, 2002, ANN GLACIOL, V34, P189, DOI 10.3189/172756402781817950; Shepherd A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014183; WALTERS RA, 1987, J GEOPHYS RES-SOLID, V92, P8969, DOI 10.1029/JB092iB09p08969; Whillans I.M., 2001, ANTARCT RES SER, V77, P257, DOI DOI 10.1029/AR077P0257	30	184	186	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1087	1089		10.1126/science.1087231	http://dx.doi.org/10.1126/science.1087231			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934005	Green Published			2022-12-28	WOS:000184872400037
J	Rau, AV; Dunningham, JA; Burnett, K				Rau, AV; Dunningham, JA; Burnett, K			Measurement-induced relative-position localization through entanglement	SCIENCE			English	Article							QUANTUM; ATOMS; INTERFERENCE; PHASE	We consider the localization of a pair of particles in relative-position space. We show how a sequence of scattering interactions progressively entangles two particles, giving rise to a robust state of well-defined separation and thus providing a natural description of relative position. We use two thought experiments to describe the localization process. The first is an interferometer with recoiling mirrors. The second, and more general, case considers photons scattering from a pair of particles and the resulting emergence of a Young's interference pattern. The underlying framework of the localization process suggests a prominent role for entanglement and relative observables at the boundary between quantum and classical mechanics.	Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England	University of Oxford	Rau, AV (corresponding author), Univ Oxford, Dept Phys, Clarendon Lab, Parks Lab, Oxford OX1 3PU, England.							Barnett S. M., 1997, METHODS THEORETICAL; Cabrillo C, 1999, PHYS REV A, V59, P1025, DOI 10.1103/PhysRevA.59.1025; Dunningham JA, 1999, PHYS REV LETT, V82, P3729, DOI 10.1103/PhysRevLett.82.3729; EICHMANN U, 1993, PHYS REV LETT, V70, P2359, DOI 10.1103/PhysRevLett.70.2359; GHIRARDI GC, 1986, PHYS REV D, V34, P470, DOI 10.1103/PhysRevD.34.470; Giulini D., 1996, DECOHERENCE APPEARAN; Hariharan P., 1992, BASICS INTERFEROMETR; Holland M, 1996, PHYS REV LETT, V76, P3683, DOI 10.1103/PhysRevLett.76.3683; Javanainen J, 1996, PHYS REV LETT, V76, P161, DOI 10.1103/PhysRevLett.76.161; JOOS E, 1985, Z PHYS B CON MAT, V59, P223, DOI 10.1007/BF01725541; Schiff L.I., 1968, QUANTUM MECH; TAN SM, 1993, PHYS REV A, V47, P4663, DOI 10.1103/PhysRevA.47.4663; Tegmark M, 2001, SCI AM, V284, P68, DOI 10.1038/scientificamerican0201-68; Vedral V, 1997, PHYS REV LETT, V78, P2275, DOI 10.1103/PhysRevLett.78.2275; Zurek WH, 2003, REV MOD PHYS, V75, P715, DOI 10.1103/RevModPhys.75.715	16	30	32	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1081	1084		10.1126/science.1084867	http://dx.doi.org/10.1126/science.1084867			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934003				2022-12-28	WOS:000184872400035
J	Sorenson, MD; Sefc, KM; Payne, RB				Sorenson, MD; Sefc, KM; Payne, RB			Speciation by host switch in brood parasitic indigobirds	NATURE			English	Article							VIDUA-CHALYBEATA; SYMPATRIC SPECIATION; SPECIES ASSOCIATIONS; GENETIC-EVIDENCE; COMMON CUCKOO; SONG MIMICRY; FINCHES; ORIGIN; DIFFERENTIATION; COEVOLUTION	A growing body of empirical and theoretical work supports the plausibility of sympatric speciation(1-3), but there remain few examples in which all the essential components of the process are well understood. The African indigobirds Vidua spp. are host-specific brood parasites. Indigobird nestlings are reared along with host young, and mimic the mouth markings of their respective hosts(4-6). As adults, male indigobirds mimic host song(4-7), whereas females use these songs to choose both their mates and the nests they parasitize(8). These behavioural mechanisms promote the cohesion of indigobird populations associated with a given host species, and provide a mechanism for reproductive isolation after a new host is colonized. Here we show that all indigobird species are similar genetically, but are significantly differentiated in both mitochondrial haplotype and nuclear allele frequencies. These data support a model of recent sympatric speciation. In contrast to the cuckoo Cuculus canorus, in which only female lineages are faithful to specific hosts(9,10), host switches have led to speciation in indigobirds because both males and females imprint on their hosts(8,11).	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Michigan, Museum Zool, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA	Boston University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Sorenson, MD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.		Sorenson, Michael/D-8065-2011	Sorenson, Michael/0000-0001-5375-2917; Sefc, Kristina/0000-0001-8108-8339				[Anonymous], 2013, INS PESTS POT GLOB, DOI DOI 10.1016/B978-0-12-386895-4.00005-3; Avise J.C., 2000, PHYLOGEOGRAPHY HIST; Balloux F, 2002, MOL ECOL, V11, P155, DOI 10.1046/j.0962-1083.2001.01436.x; Berlocher SH, 2002, ANNU REV ENTOMOL, V47, P773, DOI 10.1146/annurev.ento.47.091201.145312; de Queiroz K, 1998, ENDLESS FORMS, P57; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Edwards SV, 2000, EVOLUTION, V54, P1839; Gibbs HL, 2000, NATURE, V407, P183, DOI 10.1038/35025058; Goodman SJ, 1997, MOL ECOL, V6, P881, DOI 10.1046/j.1365-294X.1997.00260.x; Hedrick PW, 1999, EVOLUTION, V53, P313, DOI [10.2307/2640768, 10.1111/j.1558-5646.1999.tb03767.x]; Klein NK, 1998, EVOLUTION, V52, P566, DOI 10.1111/j.1558-5646.1998.tb01655.x; LOTEM A, 1995, ANIM BEHAV, V49, P1185, DOI 10.1006/anbe.1995.0152; Marchetti K, 1998, SCIENCE, V282, P471, DOI 10.1126/science.282.5388.471; Nicolai J., 1964, Zeitschrift fuer Tierpsychologie, V21, P129; Payne R.B., 1982, Miscellaneous Publications Museum of Zoology University of Michigan, V162, P1; Payne R. B., 1973, ORNITHOL MONOGR, V11, P1; Payne RB, 2000, ANIM BEHAV, V59, P69, DOI 10.1006/anbe.1999.1283; Payne RB, 1998, ANIM BEHAV, V55, P1537, DOI 10.1006/anbe.1997.0701; Payne RB, 2002, IBIS, V144, P373, DOI 10.1046/j.1474-919X.2002.00065.x; Payne RB, 2001, ANIM BEHAV, V62, P473, DOI 10.1006/anbe.2001.1773; PAYNE RB, 1994, IBIS, V136, P291, DOI 10.1111/j.1474-919X.1994.tb01098.x; Payne Robert B., 1996, Bulletin of the African Bird Club, V3, P14; SANDERSON MJ, 2003, R8S VERSION 1 60 AN; Sefc KM, 2001, MOL ECOL NOTES, V1, P252, DOI 10.1046/j.1471-8278.2001.00095.x; SLATKIN M, 1987, SCIENCE, V236, P787, DOI 10.1126/science.3576198; Sorenson MD, 2002, INTEGR COMP BIOL, V42, P388, DOI 10.1093/icb/42.2.388; Sorenson MD, 2001, EVOLUTION, V55, P2550; SWOFFORD DL, 2002, PAUP PHYLOGENETIC AN; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7; [No title captured]	30	180	190	0	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					928	931		10.1038/nature01863	http://dx.doi.org/10.1038/nature01863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931185	Green Published			2022-12-28	WOS:000184843600038
J	Hay, P				Hay, P			Commentary: Putting the research into practice	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Adelaide, Royal Adelaide Hosp, Dept Psychiat, Adelaide, SA 5001, Australia	Royal Adelaide Hospital; University of Adelaide	Hay, P (corresponding author), Univ Adelaide, Royal Adelaide Hosp, Dept Psychiat, Adelaide, SA 5001, Australia.	phillipa.hay@adelaide.edu.au		Hay, Phillipa/0000-0003-0296-6856				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 2000, Am J Psychiatry, V157, P1; [Anonymous], 1992, Arch Gen Psychiatry, V49, P139; Cooper P. J., 1995, BULIMIA NERVOSA BING; Fairburn CG, 2003, LANCET, V361, P407, DOI 10.1016/S0140-6736(03)12378-1; Fairburn CG, 1996, AM J PSYCHIAT, V153, P386; Hay P, 2003, INT J EAT DISORDER, V33, P434, DOI 10.1002/eat.10162; Hay P. J., 1998, PRIMARY CARE COMMUN, V4, P95; HAY PJ, 2003, CLIN EVIDENCE, P1388	9	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 16	2003	327	7411					381	381		10.1136/bmj.327.7411.381	http://dx.doi.org/10.1136/bmj.327.7411.381			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919993	Green Published			2022-12-28	WOS:000184864200023
J	Chin, JW; Cropp, TA; Anderson, JC; Mukherji, M; Zhang, ZW; Schultz, PG				Chin, JW; Cropp, TA; Anderson, JC; Mukherji, M; Zhang, ZW; Schultz, PG			An expanded eukaryotic genetic code	SCIENCE			English	Article							SITE-SPECIFIC INCORPORATION; TRANSFER-RNA-SYNTHETASE; TYROSINE TRANSFER-RNA; UNNATURAL AMINO-ACIDS; PHOTO-CROSS-LINKING; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; PROTEIN-STRUCTURE; REVERSE 2-HYBRID; YEAST	We describe a general and rapid route for the addition of unnatural amino acids to the genetic code of Saccharomyces cerevisiae. Five amino acids have been incorporated into proteins efficiently and with high fidelity in response to the nonsense codon TAG. The side chains of these amino acids contain a keto group, which can be uniquely modified in vitro and in vivo with a wide range of chemical probes and reagents; a heavy atom-containing amino acid for structural studies; and photocrosslinkers for cellular studies of protein interactions. This methodology not only removes the constraints imposed by the genetic code on our ability to manipulate protein structure and function in yeast, it provides a gateway to the systematic expansion of the genetic codes of multicellular eukaryotes.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Biol Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Schultz, PG (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER DG, 1982, FEBS LETT, V150, P419, DOI 10.1016/0014-5793(82)80781-3; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Burke D., 2000, METHODS YEAST GENETI; Chin JW, 2003, CHEM BIOL, V10, P511, DOI 10.1016/S1074-5521(03)00123-6; Chin JW, 2002, P NATL ACAD SCI USA, V99, P11020, DOI 10.1073/pnas.172226299; Chin JW, 2002, J AM CHEM SOC, V124, P9026, DOI 10.1021/ja027007w; Chin JW, 2002, CHEMBIOCHEM, V3, P1135, DOI 10.1002/1439-7633(20021104)3:11<1135::AID-CBIC1135>3.0.CO;2-M; Corey E.J., 1995, LOGIC CHEM SYNTHESIS; CORNISH VW, 1995, ANGEW CHEM INT EDIT, V34, P621, DOI 10.1002/anie.199506211; Cornish VW, 1996, J AM CHEM SOC, V118, P8150, DOI 10.1021/ja961216x; Dawson PE, 2000, ANNU REV BIOCHEM, V69, P923, DOI 10.1146/annurev.biochem.69.1.923; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; Dougherty DA, 2000, CURR OPIN CHEM BIOL, V4, P645, DOI 10.1016/S1367-5931(00)00148-4; EDWARDS H, 1990, MOL CELL BIOL, V10, P1633, DOI 10.1128/MCB.10.4.1633; EDWARDS H, 1991, P NATL ACAD SCI USA, V88, P1153, DOI 10.1073/pnas.88.4.1153; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; Furter R, 1998, PROTEIN SCI, V7, P419; GOODMAN HM, 1968, NATURE, V217, P1019, DOI 10.1038/2171019a0; Hughes Timothy R, 2002, Funct Integr Genomics, V2, P199, DOI 10.1007/s10142-002-0059-1; JACKSON DY, 1994, SCIENCE, V266, P243, DOI 10.1126/science.7939659; Kirshenbaum K, 2002, CHEMBIOCHEM, V3, P235, DOI 10.1002/1439-7633(20020301)3:2/3<235::AID-CBIC235>3.0.CO;2-7; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; MENDEL D, 1995, ANNU REV BIOPH BIOM, V24, P435, DOI 10.1146/annurev.bb.24.060195.002251; Merrifield RB, 1976, SCIENCE, V232, P341, DOI DOI 10.1126/SCIENCE.3961484; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; Sakamoto K, 2002, NUCLEIC ACIDS RES, V30, P4692, DOI 10.1093/nar/gkf589; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; TREZEGUET V, 1991, MOL CELL BIOL, V11, P2744, DOI 10.1128/MCB.11.5.2744; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wang L, 2003, P NATL ACAD SCI USA, V100, P56, DOI 10.1073/pnas.0234824100; Wang L, 2002, CHEM COMMUN, P1, DOI 10.1039/b108185n; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; ZHANG Z, 2003, BIOCHEMISTRY-US, V42, pL375; Zhang ZW, 2002, ANGEW CHEM INT EDIT, V41, P2840, DOI 10.1002/1521-3773(20020802)41:15<2840::AID-ANIE2840>3.0.CO;2-#; [No title captured]	41	606	749	8	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					964	967		10.1126/science.1084772	http://dx.doi.org/10.1126/science.1084772			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920298				2022-12-28	WOS:000184755900039
J	Vahala, KJ				Vahala, KJ			Optical microcavities	NATURE			English	Review							CAVITY-QUANTUM ELECTRODYNAMICS; WHISPERING-GALLERY MODES; ADD-DROP FILTER; PHOTONIC CRYSTAL MICROCAVITIES; DISTRIBUTED BRAGG REFLECTORS; STIMULATED RAMAN-SCATTERING; MICROMETER-SIZE DROPLETS; SURFACE-EMITTING LASERS; SPONTANEOUS EMISSION; SINGLE PHOTONS	Optical microcavities confine light to small volumes by resonant recirculation. Devices based on optical microcavities are already indispensable for a wide range of applications and studies. For example, microcavities made of active III-V semiconductor materials control laser emission spectra to enable long-distance transmission of data over optical fibres; they also ensure narrow spot-size laser read/write beams in CD and DVD players. In quantum optical devices, microcavities can coax atoms or quantum dots to emit spontaneous photons in a desired direction or can provide an environment where dissipative mechanisms such as spontaneous emission are overcome so that quantum entanglement of radiation and matter is possible. Applications of these remarkable devices are as diverse as their geometrical and resonant properties.	CALTECH, Pasadena, CA 91125 USA	California Institute of Technology	Vahala, KJ (corresponding author), CALTECH, Mail Stop 128-95, Pasadena, CA 91125 USA.	vahala@caltech.edu	huihui, zhang/M-9283-2014					ALEXANDER SB, 1993, J LIGHTWAVE TECHNOL, V11, P714, DOI 10.1109/50.233236; An KW, 1997, PHYS REV A, V56, P1662, DOI 10.1103/PhysRevA.56.1662; Armani DK, 2003, NATURE, V421, P925, DOI 10.1038/nature01371; Barland S, 2002, NATURE, V419, P699, DOI 10.1038/nature01049; BASCHE T, 1992, PHYS REV LETT, V69, P1516, DOI 10.1103/PhysRevLett.69.1516; Bayer M, 2001, PHYS REV LETT, V86, P3168, DOI 10.1103/PhysRevLett.86.3168; Boroditsky M, 1999, J LIGHTWAVE TECHNOL, V17, P2096, DOI 10.1109/50.803000; BOUWINEESTER D, 2000, PHYSICS QUANTUM INFO; BRAGINSKY VB, 1989, PHYS LETT A, V137, P393, DOI 10.1016/0375-9601(89)90912-2; Brinkman WF, 2000, BELL LABS TECH J, V5, P150, DOI 10.1002/bltj.2212; Brunel C, 1999, PHYS REV LETT, V83, P2722, DOI 10.1103/PhysRevLett.83.2722; Buck JR, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.033806; Cai M, 2000, OPT LETT, V25, P1430, DOI 10.1364/OL.25.001430; Cai M, 2000, PHYS REV LETT, V85, P74, DOI 10.1103/PhysRevLett.85.74; Chang R.K., 1996, OPTICAL PROCESSES MI, VVolume 3; Chu ST, 1999, IEEE PHOTONIC TECH L, V11, P691, DOI 10.1109/68.766787; Cirac JI, 1998, PHYS SCRIPTA, VT76, P223, DOI 10.1238/Physica.Topical.076a00223; Coldren L.A., 1995, DIODE LASERS PHOTONI; Cooper MA, 2002, NAT REV DRUG DISCOV, V1, P515, DOI 10.1038/nrd838; Deppe DG, 1997, IEEE J SEL TOP QUANT, V3, P893, DOI 10.1109/2944.640643; Djordjev K, 2002, IEEE PHOTONIC TECH L, V14, P1115, DOI 10.1109/LPT.2002.1021987; Djordjev K, 2002, IEEE PHOTONIC TECH L, V14, P828, DOI 10.1109/LPT.2002.1003107; Doerr CR, 1999, IEEE PHOTONIC TECH L, V11, P1437, DOI 10.1109/68.803071; Gayral B, 1999, APPL PHYS LETT, V75, P1908, DOI 10.1063/1.124894; Gerard JM, 1998, PHYSICA E, V2, P804, DOI 10.1016/S1386-9477(98)00164-7; Gerard JM, 2001, PHYSICA E, V9, P131, DOI 10.1016/S1386-9477(00)00187-9; Gerard JM, 1999, J LIGHTWAVE TECHNOL, V17, P2089, DOI 10.1109/50.802999; Gerard JM, 1996, APPL PHYS LETT, V69, P449, DOI 10.1063/1.118135; Gerard JM, 1998, PHYS REV LETT, V81, P1110, DOI 10.1103/PhysRevLett.81.1110; Gorodetsky ML, 1996, OPT LETT, V21, P453, DOI 10.1364/OL.21.000453; Gorodetsky ML, 1999, J OPT SOC AM B, V16, P147, DOI 10.1364/JOSAB.16.000147; Graham LA, 1999, J APPL PHYS, V85, P3383, DOI 10.1063/1.369688; Grover R, 2002, J LIGHTWAVE TECHNOL, V20, P872; Grover R, 2001, OPT LETT, V26, P506, DOI 10.1364/OL.26.000506; Happ TD, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.041303; HAROCHE S, 1989, PHYS TODAY, V42, P24, DOI 10.1063/1.881201; Haroche S, 1998, PHYS SCRIPTA, VT76, P159, DOI 10.1238/Physica.Topical.076a00159; Hibino Y, 2001, NTT REVIEW, V13, P4; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; Hood CJ, 2001, PHYS REV A, V64, DOI 10.1103/PhysRevA.64.033804; Huffaker DL, 1996, IEEE PHOTONIC TECH L, V8, P974, DOI 10.1109/68.508708; Ilchenko VS, 1999, OPT LETT, V24, P723, DOI 10.1364/OL.24.000723; JEWELL JL, 1989, APPL PHYS LETT, V54, P1400, DOI 10.1063/1.100679; KAMINOW IP, 2002, OPTICAL FIBER TELECO, V4; Kewitsch AS, 1998, OPT LETT, V23, P106, DOI 10.1364/OL.23.000106; Khitrova G, 1999, REV MOD PHYS, V71, P1591, DOI 10.1103/RevModPhys.71.1591; Kimble HJ, 1998, PHYS SCRIPTA, VT76, P127, DOI 10.1238/Physica.Topical.076a00127; KIMBLE HJ, 1977, PHYS REV LETT, V39, P691, DOI 10.1103/PhysRevLett.39.691; Kiraz A, 2001, APPL PHYS LETT, V78, P3932, DOI 10.1063/1.1379987; Knight JC, 1997, OPT LETT, V22, P1129, DOI 10.1364/OL.22.001129; KNIGHT JC, 1995, OPT LETT, V20, P1515, DOI 10.1364/OL.20.001515; Krioukov E, 2002, OPT LETT, V27, P512, DOI 10.1364/OL.27.000512; Kuwada John Y., 1992, Current Opinion in Neurobiology, V2, P31, DOI 10.1016/0959-4388(92)90158-H; LefevreSeguin V, 1997, MAT SCI ENG B-SOLID, V48, P53, DOI 10.1016/S0921-5107(97)00080-9; LIN HB, 1992, J OPT SOC AM B, V9, P43, DOI 10.1364/JOSAB.9.000043; LIN HB, 1992, OPT LETT, V17, P828, DOI 10.1364/OL.17.000828; Little BE, 1997, J LIGHTWAVE TECHNOL, V15, P998, DOI 10.1109/50.588673; Little BE, 1998, IEEE PHOTONIC TECH L, V10, P816, DOI 10.1109/68.681495; Little BE, 1999, IEEE PHOTONIC TECH L, V11, P215, DOI 10.1109/68.740708; Lounis B, 2000, NATURE, V407, P491, DOI 10.1038/35035032; Mabuchi H, 2002, SCIENCE, V298, P1372, DOI 10.1126/science.1078446; Mabuchi H, 1996, OPT LETT, V21, P1393, DOI 10.1364/OL.21.001393; MACDOUGAL MH, 1995, IEEE PHOTONIC TECH L, V7, P229, DOI 10.1109/68.372729; Marazuela MD, 2002, ANAL BIOANAL CHEM, V372, P664, DOI 10.1007/s00216-002-1235-9; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; MCCALL SL, 1992, APPL PHYS LETT, V60, P289, DOI 10.1063/1.106688; Michler P, 2000, NATURE, V406, P968, DOI 10.1038/35023100; Michler P, 2001, PHYS STATUS SOLIDI B, V224, P797, DOI 10.1002/(SICI)1521-3951(200104)224:3<797::AID-PSSB797>3.0.CO;2-I; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; Offrein BJ, 1999, IEEE J SEL TOP QUANT, V5, P1400, DOI 10.1109/2944.806897; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Pelton M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233602; Pelton M, 2002, IEEE J QUANTUM ELECT, V38, P170, DOI 10.1109/3.980269; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; PR Berman, 1993, CAVITY QUANTUM ELECT; PURCELL EM, 1946, PHYS REV, V69, P681; QIAN SX, 1986, SCIENCE, V231, P486, DOI 10.1126/science.231.4737.486; QIAN SX, 1985, OPT LETT, V10, P499, DOI 10.1364/OL.10.000499; QIAN SX, 1986, PHYS REV LETT, V56, P926, DOI 10.1103/PhysRevLett.56.926; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Rayleigh  L., 1912, SCI PAPERS, V5, P617; Reese C, 2001, J VAC SCI TECHNOL B, V19, P2749, DOI 10.1116/1.1412893; REMPE G, 1995, APPL PHYS B-LASERS O, V60, P233, DOI 10.1007/BF01135867; REMPE G, 1992, OPT LETT, V17, P363, DOI 10.1364/OL.17.000363; Rex NB, 2001, IEEE PHOTONIC TECH L, V13, P1, DOI 10.1109/68.903201; RICE PR, 1994, PHYS REV A, V50, P4318, DOI 10.1103/PhysRevA.50.4318; Sandoghdar V, 1996, PHYS REV A, V54, pR1777, DOI 10.1103/PhysRevA.54.R1777; Santori C, 2001, PHYS REV LETT, V86, P1502, DOI 10.1103/PhysRevLett.86.1502; SERPENGUZEL A, 1995, OPT LETT, V20, P654, DOI 10.1364/OL.20.000654; Shimizu Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233001; Solomon GS, 2000, PHYS STATUS SOLIDI A, V178, P341, DOI 10.1002/1521-396X(200003)178:1<341::AID-PSSA341>3.0.CO;2-5; Soref RA, 1998, IEEE PHOTONIC TECH L, V10, P1121, DOI 10.1109/68.701522; Spillane SM, 2002, NATURE, V415, P621, DOI 10.1038/415621a; Srinivasan K, 2002, OPT EXPRESS, V10, P670, DOI 10.1364/OE.10.000670; SRINIVASAN K, IN PRESS APPL PHYS L; Stone AD, 2001, PHYS SCRIPTA, VT90, P248, DOI 10.1088/0031-8949/2001/T90/036; Suzuki S, 2002, J LIGHTWAVE TECHNOL, V20, P745, DOI 10.1109/50.996599; Taranenko VB, 2002, IEEE J SEL TOP QUANT, V8, P488, DOI 10.1109/JSTQE.2002.1016352; THOMPSON RJ, 1992, PHYS REV LETT, V68, P1132, DOI 10.1103/PhysRevLett.68.1132; Thompson RM, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.201302; Treussart F, 1998, EUR PHYS J D, V1, P235, DOI 10.1007/s100530050087; Treussart F, 1997, ANN TELECOMMUN, V52, P557; Vernooy DW, 1998, PHYS REV A, V57, pR2293, DOI 10.1103/PhysRevA.57.R2293; Vernooy DW, 1998, OPT LETT, V23, P247, DOI 10.1364/OL.23.000247; Vollmer F, 2002, APPL PHYS LETT, V80, P4057, DOI 10.1063/1.1482797; Vuckovic J, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023808; Vuckovic J, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.016608; Walther H, 1998, PHYS SCRIPTA, VT76, P138, DOI 10.1238/Physica.Topical.076a00138; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; YAMAMOTO Y, 1993, PHYS TODAY, V46, P66, DOI 10.1063/1.881356; Yamamoto Y., 2000, SEMICONDUCTOR CAVITY; Yanagase Y, 2002, J LIGHTWAVE TECHNOL, V20, P1525, DOI 10.1109/JLT.2002.800296; Yariv A, 2002, IEEE PHOTONIC TECH L, V14, P483, DOI 10.1109/68.992585; Yariv A., 1989, QUANTUM ELECT; Yuan ZL, 2002, SCIENCE, V295, P102, DOI 10.1126/science.1066790; ZHANG JZ, 1990, J OPT SOC AM B, V7, P108, DOI 10.1364/JOSAB.7.000108; Zwiller V, 2001, APPL PHYS LETT, V78, P2476, DOI 10.1063/1.1366367	120	3881	4006	101	2133	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					839	846		10.1038/nature01939	http://dx.doi.org/10.1038/nature01939			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917698				2022-12-28	WOS:000184733900053
J	Hart, RG				Hart, RG			Atrial fibrillation and stroke prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Hart, RG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Neurol, San Antonio, TX 78284 USA.							SODERSTROM N, 1948, ACTA MED SCAND, V217, P51	1	35	57	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1015	1016		10.1056/NEJMp038123	http://dx.doi.org/10.1056/NEJMp038123			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968083				2022-12-28	WOS:000185223100001
J	Wei, JN; Sung, FC; Lin, CC; Lin, RS; Chiang, CC; Chuang, LM				Wei, JN; Sung, FC; Lin, CC; Lin, RS; Chiang, CC; Chuang, LM			National surveillance for type 2 diabetes mellitus in Taiwanese children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY; ADOLESCENTS; PREVALENCE; OBESITY; RISK	Context Despite a disturbing trend of increasing prevalence of type 2 diabetes mellitus (DM) in childhood, little is known about the epidemiology of childhood type 2 DM, especially in the Taiwanese population. Objective To study the rate and risk factors for childhood type 2 DM based on a nationwide screening program in Taiwan. Design, Setting, and Participants Screening in 1999 for type 2 DM using urine and blood testing and confirmed by follow-up telephone survey among schoolchildren aged 6 to 18 years in Taiwan, followed by a nested case-control study conducted in 2002 comparing 137 children with type 2 DM with 1000 randomly selected children without diabetes chosen to represent the age and sex distribution of the whole student population. Main Outcome Measures Rate and identification of risk factors associated with childhood type 2 DM. Results The rate of newly identified diabetes was 9.0 per 100000 for boys and 15.3 per 100000 for girls. Follow-up at 3 years revealed that, of 253 children with newly diagnosed diabetes, 24 (9.5%) had type 1 DM, 137 (54.2%) had type 2 DM, and 22 (8.7%) had secondary diabetes. Compared with children aged 6 to 9 years, the odds ratios (ORs) and 95% confidence intervals (CIs) of type 2 DM increased to 6.59 (3.23-13.4) for those aged 13 to 15 years and to 4.59 (2.07-10.2) for those aged 16 to 18 years. The OR (95% CI) of type 2 DM in children with a body mass index in the 95th percentile or higher (obesity) was 18.8 (9.22-38.5) compared with those with a body mass index in less than the 50th percentile. Other factors significantly associated with type 2 DM were hypercholesterolemia (OR, 1.80; 95% CI, 1.04-3.23), blood pressure greater than the 85th percentile (OR, 1.70; 95% CI, 1.07-2.70), and positive family history of diabetes (OR, 3.95; 95% CI, 2.01-7.78). Conclusions Our mass screening program showed that type 2 DM is the leading cause of childhood DM in Taiwan. Obesity is a major risk factor for the development of type 2 DM in children.	Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Inst Environm Hlth, Taipei 10764, Taiwan; Natl Taiwan Univ, Coll Publ Hlth, Inst Prevent Med, Taipei 10764, Taiwan; Chinese Fdn Hlth, Taipei, Taiwan; Chia Nan Univ Pharm & Sci, Tainan, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Chia Nan University of Pharmacy & Science	Chuang, LM (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 100, Taiwan.	leeming@ha.mc.ntu.edu.tw	Chuang, Lee-Ming/AAF-3324-2019	CHUANG, LEE-MING/0000-0003-0978-2662				*AM DIAB ASS, 2003, DIABETES CARE S1, V26, pS21, DOI DOI 10.2337/DIACARE.26.2007.S21; ANDERSSON DKG, 1993, DIABETIC MED, V10, P167, DOI 10.1111/j.1464-5491.1993.tb00036.x; Berg AO, 2003, ANN INTERN MED, V138, P212, DOI 10.7326/0003-4819-138-3-200302040-00014; Bloomgarden ZT, 2000, DIABETES CARE, V23, P1584, DOI 10.2337/diacare.23.10.1584; Boyko EJ, 2000, DIABETES CARE, V23, P465, DOI 10.2337/diacare.23.4.465; Caprio S, 1999, ENDOCRIN METAB CLIN, V28, P731, DOI 10.1016/S0889-8529(05)70099-2; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Dabelea D, 1998, DIABETOLOGIA, V41, P904, DOI 10.1007/s001250051006; Dabelea D, 1999, ENDOCRIN METAB CLIN, V28, P709, DOI 10.1016/S0889-8529(05)70098-0; Dean H, 1998, CLIN PEDIATR, V37, P89, DOI 10.1177/000992289803700205; Fagot-Campagna A, 1999, CLIN CHIM ACTA, V286, P81, DOI 10.1016/S0009-8981(99)00095-9; Forum Health Promotion and Disease Prevention Committee, 2000, ASS CHILDR ANTHR ITS, P33; Friderichsen B, 1997, J PUBLIC HEALTH MED, V19, P55, DOI 10.1093/oxfordjournals.pubmed.a024588; Gavin JR, 1997, DIABETES CARE, V20, P1183; Goran MI, 2001, DIABETES, V50, P2444, DOI 10.2337/diabetes.50.11.2444; Harris SB, 1996, CAN FAM PHYSICIAN, V42, P869; Hosmer D. W., 1989, APPL LOGISTIC REGRES, P132; Jeruc J, 2000, WIEN KLIN WOCHENSCHR, V112, P702; KIDA K, 2003, TYPE 2 DIABETES CHIL; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; KITAGAWA T, 1994, DIABETES RES CLIN PR, V24, pS7, DOI 10.1016/0168-8227(94)90221-6; Kitagawa T, 1998, CLIN PEDIATR, V37, P111, DOI 10.1177/000992289803700208; Kwamura T, 1999, DIABETES, V48, pA168; Moran A, 1999, DIABETES, V48, P2039, DOI 10.2337/diabetes.48.10.2039; *NAT CHOL ED PROGR, 1992, PEDIATRICS, V89, P525; Neufeld ND, 1998, DIABETES CARE, V21, P80, DOI 10.2337/diacare.21.1.80; ORIT PH, 1996, J PEDIATR, V128, P608; OSULLIVAN JB, 1991, DIABETES, V40, P131, DOI 10.2337/diab.40.2.S131; PANDIT MK, 1993, ANN INTERN MED, V118, P529, DOI 10.7326/0003-4819-118-7-199304010-00008; Pihoker C, 1998, CLIN PEDIATR, V37, P97, DOI 10.1177/000992289803700206; Rosenbloom A, 2000, DIABETES CARE, V23, P381; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHINOZAKI T, 1999, JPN J PUBLIC HLTH, V46, P790; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; TAI TY, 1992, INT J EPIDEMIOL, V21, P511, DOI 10.1093/ije/21.3.511; van der Sande MAB, 1999, TROP MED INT HEALTH, V4, P506; Wei JN, 2003, DIABETES RES CLIN PR, V59, P201, DOI 10.1016/S0168-8227(02)00247-4; WILLI SM, 2000, CURR OPIN ENDOCRINOL, V7, P71; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x	40	155	168	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1345	1350		10.1001/jama.290.10.1345	http://dx.doi.org/10.1001/jama.290.10.1345			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966126	Bronze, Green Published			2022-12-28	WOS:000185188600027
J	Changela, A; Chen, K; Xue, Y; Holschen, J; Outten, CE; O'Halloran, TV; Mondragon, A				Changela, A; Chen, K; Xue, Y; Holschen, J; Outten, CE; O'Halloran, TV; Mondragon, A			Molecular basis of metal-ion selectivity and zeptomolar sensitivity by CueR	SCIENCE			English	Article							MERR METALLOREGULATORY PROTEIN; P-TYPE ATPASE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVATION; COPPER HOMEOSTASIS; RECEPTOR-SITE; OXIDASE; COPA; DNA	The earliest of a series of copper efflux genes in Escherichia coli are controlled by CueR, a member of the MerR family of transcriptional activators. Thermodynamic calibration of CueR reveals a zeptomolar (10(-21) molar) sensitivity to free Cu+, which is far less than one atom per cell. Atomic details of this extraordinary sensitivity and selectivity for +1 transition-metal ions are revealed by comparing the crystal structures of CueR and a Zn2+-sensing homolog, ZntR. An unusual buried metal-receptor site in CueR restricts the metal to a linear, two-coordinate geometry and uses helix-dipole and hydrogen-bonding interactions to enhance metal binding. This binding mode is rare among metalloproteins but well suited for an ultrasensitive genetic switch.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University; Northwestern University	O'Halloran, TV (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.		Johnson, Michael D. L./B-4352-2012; O'Halloran, Thomas/ABE-6125-2021; Outten, Caryn E./I-9433-2019	O'Halloran, Thomas/0000-0001-8732-5059; Outten, Caryn E./0000-0003-0335-6531	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK061868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038784, R29GM038784, R01GM051350, R01GM038784] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK61868] Funding Source: Medline; NIGMS NIH HHS [GM08382, GM51350, R01 GM051350, GM38784] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; Alderighi L, 1999, COORDIN CHEM REV, V184, P311, DOI 10.1016/S0010-8545(98)00260-4; CHEN K, IN PRESS J AM CHEM S; Corazza A, 1996, EUR J BIOCHEM, V236, P697, DOI 10.1111/j.1432-1033.1996.0697d.x; Demple B, 2002, METHOD ENZYMOL, V348, P355, DOI 10.1016/S0076-6879(02)48654-5; Finney LA, 2003, SCIENCE, V300, P931, DOI 10.1126/science.1085049; Godsey MH, 2001, J BIOL CHEM, V276, P47178, DOI 10.1074/jbc.M105819200; Grass G, 2001, BIOCHEM BIOPH RES CO, V286, P902, DOI 10.1006/bbrc.2001.5474; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; Hitomi Y, 2001, J AM CHEM SOC, V123, P8614, DOI 10.1021/ja016146v; Huffman DL, 2002, BIOCHEMISTRY-US, V41, P10046, DOI 10.1021/bi0259960; Khan S, 2002, BIOCHEM BIOPH RES CO, V299, P438, DOI 10.1016/S0006-291X(02)02660-8; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; MARTELL AE, 2001, NATL I STANDARDS TEC, V46; Noll M, 1998, J BIOL CHEM, V273, P21393, DOI 10.1074/jbc.273.33.21393; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN T, 1987, SCIENCE, V235, P211, DOI 10.1126/science.3798107; OSTERBERG R, 1979, J INORG BIOCHEM, V10, P341, DOI 10.1016/S0162-0134(00)80200-7; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Pesce A, 1997, J MOL BIOL, V274, P408, DOI 10.1006/jmbi.1997.1400; Petersen C, 2000, GENE, V261, P289, DOI 10.1016/S0378-1119(00)00509-6; RALSTON DM, 1990, P NATL ACAD SCI USA, V87, P3846, DOI 10.1073/pnas.87.10.3846; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; ROH JH, 1995, BIOCHEM BIOPH RES CO, V212, P1107, DOI 10.1006/bbrc.1995.2083; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2340, DOI 10.1021/bi00431a053; Stoyanov JV, 2003, J BIOL CHEM, V278, P1407, DOI 10.1074/jbc.C200580200; Stoyanov JV, 2001, MOL MICROBIOL, V39, P502, DOI 10.1046/j.1365-2958.2001.02264.x; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724; WRIGHT JG, 1990, J AM CHEM SOC, V112, P2434, DOI 10.1021/ja00162a062	35	493	508	4	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1383	1387		10.1126/science.1085950	http://dx.doi.org/10.1126/science.1085950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958362				2022-12-28	WOS:000185116400043
J	Lipman, EA; Schuler, B; Bakajin, O; Eaton, WA				Lipman, EA; Schuler, B; Bakajin, O; Eaton, WA			Single-molecule measurement of protein folding kinetics	SCIENCE			English	Article							RESONANCE ENERGY-TRANSFER; TRANSFER CONFOCAL MICROSCOPY; FLUORESCENCE SPECTROSCOPY; DYNAMICS; PEPTIDES; TIME	In order to investigate the behavior of single molecules under conditions far from equilibrium, we have coupled a microfabricated laminar-flow mixer to a confocal optical system. This combination enables time-resolved measurement of Forster resonance energy transfer after an abrupt change in solution conditions. Observations of a small protein show the evolution of the intramolecular distance distribution as folding progresses. This technique can expose subpopulations, such as unfolded protein under conditions favoring the native structure, that would be obscured in equilibrium experiments.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; Lawrence Livermore Natl Lab, Biosecur Nanosci Lab, Livermore, CA 94550 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Eaton, WA (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 5,Room 104, Bethesda, MD 20892 USA.		Schuler, Benjamin/E-7342-2011; Lipman, Everett/D-1696-2009; Bakajin, Olgica/A-9745-2008	Schuler, Benjamin/0000-0002-5970-4251; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK029010, ZIADK029010] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Deniz AA, 2000, P NATL ACAD SCI USA, V97, P5179, DOI 10.1073/pnas.090104997; Deniz AA, 1999, P NATL ACAD SCI USA, V96, P3670, DOI 10.1073/pnas.96.7.3670; DOI M, 1996, INTRO POLYM PHYSICS; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; Hagen SJ, 2000, J MOL BIOL, V301, P1019, DOI 10.1006/jmbi.2000.3969; Hagen SJ, 2001, J MOL BIOL, V305, P1161, DOI 10.1006/jmbi.2000.4366; Jia YW, 1999, CHEM PHYS, V247, P69, DOI 10.1016/S0301-0104(99)00127-5; Kauffmann E, 2001, P NATL ACAD SCI USA, V98, P6646, DOI 10.1073/pnas.101122898; Perl D, 1998, NAT STRUCT BIOL, V5, P229, DOI 10.1038/nsb0398-229; Pollack L, 1999, P NATL ACAD SCI USA, V96, P10115, DOI 10.1073/pnas.96.18.10115; Rhoades E, 2003, P NATL ACAD SCI USA, V100, P3197, DOI 10.1073/pnas.2628068100; Schuler B, 2003, NATURE, V421, P94, DOI 10.1038/nature01291; Schuler B, 2002, NATURE, V419, P743, DOI 10.1038/nature01060; Shastry MCR, 1998, NAT STRUCT BIOL, V5, P385, DOI 10.1038/nsb0598-385; Talaga DS, 2000, P NATL ACAD SCI USA, V97, P13021, DOI 10.1073/pnas.97.24.13021; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; Wassenberg D, 1999, J MOL BIOL, V289, P187, DOI 10.1006/jmbi.1999.2772; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Zhuang XW, 2002, SCIENCE, V296, P1473, DOI 10.1126/science.1069013; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	21	322	334	2	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1233	1235		10.1126/science.1085399	http://dx.doi.org/10.1126/science.1085399			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947198				2022-12-28	WOS:000185003500041
J	Jungnickel, MK; Sutton, KA; Florman, HM				Jungnickel, MK; Sutton, KA; Florman, HM			In the beginning: Lessons from fertilization in mice and worms	CELL			English	Review							MOUSE SPERM; EGG; BINDING; RECEPTORS; FUSION	Sexual reproduction proceeds by fertilization; formation of new individuals by the union of haploid gametes. Recent reports in Cell and in Developmental Cell may provide new insights as to how this process begins and is regulated.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Florman, HM (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	harvey.florman@umassmed.edu	Sutton, Keith/AAI-2185-2020					Ensslin MA, 2003, CELL, V114, P405, DOI 10.1016/S0092-8674(03)00643-3; Evans JP, 2002, NAT CELL BIOL, V4, pS57, DOI 10.1038/ncb-nm-fertilityS57; Fukami K, 2003, J CELL BIOL, V161, P79, DOI 10.1083/jcb.200210057; He ZY, 2003, DEV BIOL, V254, P226, DOI 10.1016/S0012-1606(02)00043-X; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; Shemer G, 2003, BIOESSAYS, V25, P672, DOI 10.1002/bies.10301; Singson A, 2001, DEV BIOL, V230, P101, DOI 10.1006/dbio.2000.0118; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Thaler CD, 1996, J BIOL CHEM, V271, P23289, DOI 10.1074/jbc.271.38.23289; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Xu XZS, 2003, CELL, V114, P285, DOI 10.1016/S0092-8674(03)00565-8	15	30	33	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					401	404		10.1016/S0092-8674(03)00648-2	http://dx.doi.org/10.1016/S0092-8674(03)00648-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941269	Bronze			2022-12-28	WOS:000184928800004
J	Als-Nielsen, B; Chen, WD; Gluud, C; Kjaergard, LL				Als-Nielsen, B; Chen, WD; Gluud, C; Kjaergard, LL			Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONFLICTS-OF-INTEREST; ACUTE STROKE TRIALS; CLINICAL-TRIALS; PHARMACEUTICAL-INDUSTRY; METHODOLOGIC QUALITY; SYSTEMATIC REVIEWS; PUBLICATION BIAS; OUTCOME MEASURES; END-POINTS	Context Previous studies indicate that industry-sponsored trials tend to draw pro-industry conclusions. Objective To explore whether the association between funding and conclusions in randomized drug trials reflects treatment effects or adverse events. Design Observational study of 370 randomized drug trials included in meta-analyses from Cochrane reviews selected from the Cochrane Library, May 2001. From a random sample of 167 Cochrane reviews, 25 contained eligible meta-analyses (assessed a binary outcome; pooled at least 5 full-paper trials of which at least 1 reported adequate and 1 reported inadequate allocation concealment). The primary binary outcome from each meta-analysis was considered the primary outcome for all trials included in each meta-analysis. The association between funding and conclusions was analyzed by logistic regression with adjustment for treatment effect, adverse events, and additional confounding factors (methodological quality, control intervention, sample size, publication year, and place of publication). Main Outcome Measure Conclusions in trials, classified into whether the experimental drug was recommended as the treatment of choice or not. Results The experimental drug was recommended as treatment of choice in 16% of trials funded by nonprofit organizations, 30% of trials not reporting funding, 35% of trials funded by both nonprofit and for-profit organizations, and 51% of trials funded by for-profit organizations (P<.001; &chi;(2) test). Logistic regression analyses indicated that funding, treatment effect, and double blinding were the only significant predictors of conclusions. Adjusted analyses showed that trials funded by for-profit organizations were significantly more likely to recommend the experimental drug as treatment of choice (odds ratio, 5.3; 95% confidence interval, 2.0-14.4) compared with trials funded by nonprofit organizations. This association did not appear to reflect treatment effect or adverse events. Conclusions Conclusions in trials funded by for-profit organizations may be more positive due to biased interpretation of trial results. Readers should carefully evaluate whether conclusions in randomized trials are supported by data.	Univ Copenhagen Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Als-Nielsen, B (corresponding author), Univ Copenhagen Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.		Gluud, Christian/AAY-1027-2021; Gluud, Christian/HGB-3191-2022; Gluud, Lise L/AAY-2120-2020	Gluud, Christian/0000-0002-8861-0799; Gluud, Lise L/0000-0002-9462-4468				ADAMS ME, 1992, MED CARE, V30, P231, DOI 10.1097/00005650-199203000-00005; ALDERSON P, 2001, COCHRANE LIB UPDATE; Altman D.G., 1991, PRACTICAL STAT MED R; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; BROCKLEHURST P, 2001, COCHRANE LIB UPDATE; CANDELISE L, 2001, COCHRANE LIB UPDATE; Clarke M, 2003, COCHRANE REV HDB; Clifford TJ, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-18; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COUCHOUD C, 2001, COCHRANE LIB UPDATE; Davidoff F, 2001, JAMA-J AM MED ASSOC, V286, P1232, DOI 10.1001/jama.286.10.1232; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DAVIES H, 2001, COCHRANE LIB UPDATE; DAYA S, 2001, COCHRANE LIB UPDATE; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Duncan PW, 2000, STROKE, V31, P1429, DOI 10.1161/01.STR.31.6.1429; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2003, Health Technol Assess, V7, P1; FEIGIN VL, 2001, COCHRANE LIB UPDATE; Freemantle N, 2001, BRIT MED J, V322, P989, DOI 10.1136/bmj.322.7292.989; FRENCH LM, 2001, COCHRANE LIB UPDATE; Friedberg M, 1999, JAMA-J AM MED ASSOC, V282, P1453, DOI 10.1001/jama.282.15.1453; GARNER P, 2001, COCHRANE LIB UPDATE; GIBBS S, 2001, COCHRANE LIB UPDATE; GILBERT JP, 1977, SCIENCE, V198, P684, DOI 10.1126/science.333585; GLUUD C, 2001, PORTAL HYPERTENSION, V3, P204; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Gotzsche PC, 1996, INT J TECHNOL ASSESS, V12, P238, DOI 10.1017/S0266462300009594; HENRY DA, 2001, COCHRANE LIB UPDATE; Horton R, 1997, LANCET, V350, P756, DOI 10.1016/S0140-6736(05)62564-0; HOSMER DW, 1989, APPL LOGISTIC REGRES; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; IOANNOU G, 2001, COCHRANE LIB UPDATE; Jacobs A, 2002, BRIT MED J, V325, P1420; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; KELLNER JD, 2001, COCHRANE LIB UPDATE; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kjaergard LL, 1999, HEPATOLOGY, V30, P1134, DOI 10.1002/hep.510300510; Kjaergard LL, 2002, BMJ-BRIT MED J, V325, P249, DOI 10.1136/bmj.325.7358.249; KJAERGARD LL, ASS COMEPTING INTERE; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; LIMA MS, 2001, COCHRANE LIB UPDATE; MARTINHIRSCH PL, 2001, COCHRANE LIB UPDATE; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; OLLIARO P, 2001, COCHRANE LIB UPDATE; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Roberts L, 1998, STROKE, V29, P986, DOI 10.1161/01.STR.29.5.986; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; ROOS YBW, 2001, COCHRANE LIB UPDATE; ROSSETTI L, 1993, ONLINE J CURR CLIN T; ROWE BH, 2001, COCHRANE LIB UPDATE; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SILAGY C, 2001, COCHRANE LIB UPDATE; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; SOO S, 2001, COCHRANE LIB UPDATE; Streiner DL., 1995, HLTH MEASUREMENT SCA, V2nd ed.; SUAREZALMAZOR ME, 2001, COCHRANE LIB UPDATE; TAN BP, 2001, COCHRANE LIB UPDATE; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; TINNION ON, 2001, COCHRANE LIB; WOODBAKER R, 2001, COCHRANE LIB UPDATE; Yaphe J, 2001, FAM PRACT, V18, P565, DOI 10.1093/fampra/18.6.565; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; Zhang B, 2001, J PEDIATR-US, V138, P76, DOI 10.1067/mpd.2001.110299; 2001, COCHRANE LIB; 2003, COCHRANE LIB	70	547	555	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					921	928		10.1001/jama.290.7.921	http://dx.doi.org/10.1001/jama.290.7.921			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928469	Bronze			2022-12-28	WOS:000184828800029
J	Ardeshna, KM; Smith, P; Norton, A; Hancock, BW; Hoskin, PJ; MacLennan, KA; Marcus, RE; Jelliffe, A; Hudson, GV; Linch, DC				Ardeshna, KM; Smith, P; Norton, A; Hancock, BW; Hoskin, PJ; MacLennan, KA; Marcus, RE; Jelliffe, A; Hudson, GV; Linch, DC		Brit Natl Lymphoma Invest	Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial	LANCET			English	Article							FOLLICULAR LYMPHOMAS; NATURAL-HISTORY; TRANSPLANTATION; LEUKEMIA; DISEASE	Background Neither chemotherapy with a single-alkylating agent nor aggressive combination chemotherapy cures advanced stage low-grade non-Hodgkin lymphomas, even when combined with radiotherapy. Our aim was to compare administration of immediate chlorambucil treatment with a policy of delaying chlorambucil until clinical progression necessitated its use, in asymptomatic patients with advanced-stage, low-grade non-Hodgkin lymphoma. Methods 309 patients with asymptomatic, advanced-stage, low-grade non-Hodgkin lymphomas were recruited from 44 UK centres between Feb 1, 1981, and July 31, 1990. 158 patients were randomised to receive immediate systemic therapy with oral chlorambucil 10 mg per day continuously. The remaining 151 were randomised to an initial policy of observation, with systemic therapy delayed until disease progression. In both groups, local radiotherapy to symptomatic nodes was allowed. Findings Median length of follow-up was 16 years. Overall survival or cause-specific survival did not differ between the two groups (median overall survival for oral chlorambucil 5.9 [range 0-17.8] years and for observation 6.7 [0.5-18.9] years, p=0.84; median cause-specific survival 9 [0-17.8] years and 9.1 [0.67-18.9] years, respectively p=0.44). In a multivariate analysis, age younger than 60 years, erythrocyte sedimentation rate (ESR) 20 mm/h or less, and stage III disease, conferred significant advantages in both overall survival (p<0.0001, 0.03, and 0.03, respectively) and cause-specific survival (p=0.002, 0.008, and 0.001, respectively). In the observation group, at 10 years' follow-up, 19 patients were alive and had not received chemotherapy. The actuarial chance of not needing chemotherapy (non-lymphoma deaths censored) at 10 years was 19% (40% if older than 70 years). Interpretation An initial policy of watchful waiting in patients with asymptomatic, advanced stage low-grade non-Hodgkin lymphoma is appropriate, especially in patients older than age 70 years.	CRC & UCL Canc Trials Ctr, British Natl Lymphoma Invest, London NW1 2DA, England	University of London; University College London	Ardeshna, KM (corresponding author), CRC & UCL Canc Trials Ctr, British Natl Lymphoma Invest, London NW1 2DA, England.	kirit.ardeshna@uclh.org						BENNETT MH, 1974, LANCET, V2, P405; Brice P, 1997, J CLIN ONCOL, V15, P1110, DOI 10.1200/JCO.1997.15.3.1110; Czuczman MS, 2002, SEMIN ONCOL, V29, P11, DOI 10.1053/sonc.2002.32748; HOLMES JA, 1988, BRIT J HAEMATOL, V69, P97, DOI 10.1111/j.1365-2141.1988.tb07609.x; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; Horning SJ, 2000, ANN ONCOL, V11, P23, DOI 10.1023/A:1008385202953; Hunault-Berger M, 2002, BLOOD, V100, P1141, DOI 10.1182/blood.V100.4.1141.h81602001141_1141_1152; Khouri IF, 2001, BLOOD, V98, P3595, DOI 10.1182/blood.V98.13.3595; Kimby E, 1994, Ann Oncol, V5 Suppl 2, P67; LEONARD RCF, 1991, ANN ONCOL, V2, P655, DOI 10.1093/oxfordjournals.annonc.a058044; LINCH D, 2001, ANTICANCER DRUGS S2, V12, P5; OBRIEN MER, 1991, Q J MED, V80, P651; Peterson BA, 2003, J CLIN ONCOL, V21, P5, DOI 10.1200/JCO.2003.05.128; PORTLOCK CS, 1979, ANN INTERN MED, V90, P10, DOI 10.7326/0003-4819-90-1-10; ROSENBERG SA, 1982, CANCER, V49, P2112; Solal-Celigny P, 2001, ANTI-CANCER DRUG, V12, pS11; Symmers D, 1938, ARCH PATHOL, V26, P603; van Besien K, 1998, BLOOD, V92, P1832; YOUNG RC, 1988, SEMIN HEMATOL, V25, P11	19	363	371	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					516	522		10.1016/S0140-6736(03)14110-4	http://dx.doi.org/10.1016/S0140-6736(03)14110-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932382				2022-12-28	WOS:000184817600007
J	Cooper, DKC				Cooper, DKC			Clinical xenotransplantion - how close are we?	LANCET			English	Review							NUCLEAR TRANSFER; ANTIBODIES; TRANSPLANTATION; REJECTION; BABOONS; PRIMATE; PIGS	Context Xenotransplantation with pig organs offers a medium-term solution to the shortage of organs available for clinical transplantation. The immunological barriers to xenotransplantation have been and remain formidable. In the early 1990s the identification of Galalpha1,3Gal (Gal) as the main target for human xenoreactive (anti pig) antibodies and the development of pigs transgenic for a human complement regulatory protein, decay accelerating factor (hDAF), were major advances. The presence of hDAF on the vascular endothelium of pig organs provided some protection against complement mediated hyperacute rejection. This protection, however, was short lived and until recently, the longest median time for organ survival that had been achieved (with combinations of biological and pharmacological immunosuppressants) in a series of pig-to-primate organ transplants was under a month. Starting point. Christopher McGregor and colleagues recently reported to the International Society of Heart and Lung Transplantation (J Heart Lung Transplant 2003: 22: S89) that, by combining the use of organs which express hDAF with the administration of a soluble Gal glycoconjugate and other immunosuppressive agents, the survival of pig hearts in baboons can be extended to a median of 76 days. McGregor is work suggests that immunological barriers to xenotransplantation are not insurmountable. Where next? The recent generation of pigs that do not express Gal epitopes (alpha1,3 galactosyltransferase gene-knockout pigs) might remove the need both for the expression of hDAF and the administration of a soluble Gal glycoconjugate. The absence of a natural antibody response will allow investigation of the cellular immune response and of any molecular incompatibilities between pig and <LF>primate that may be detrimental to graft survival. Furthermore, the absence of a humoral response may open the way for the induction of immunological tolerance (or unresponsiveness in the absence of exogenous immunosuppression) to a transplanted pig organ.	Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA	Harvard University; Massachusetts General Hospital	Cooper, DKC (corresponding author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bldg 149-9019,13th St, Boston, MA 02129 USA.	David.Cooper@tbrc.mgh.harvard.edu			PHS HHS [1PO1 A145897] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barth RN, 2003, TRANSPLANTATION, V75, P1615, DOI 10.1097/01.TP.0000064335.50622.20; Buhler L, 2003, XENOTRANSPLANTATION, V10, P88, DOI 10.1034/j.1399-3089.2003.01122.x; Buhler L, 2001, TRANSPLANTATION, V72, P1743, DOI 10.1097/00007890-200112150-00007; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; COOPER DKC, 1993, LANCET, V342, P682, DOI 10.1016/0140-6736(93)91791-J; Cowan PJ, 2002, AM J TRANSPLANT, V2, P520, DOI 10.1034/j.1600-6143.2002.20605.x; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; Diamond LE, 2002, TRANSPLANTATION, V73, P1780, DOI 10.1097/00007890-200206150-00014; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; GALILI U, 1995, TRANSPLANTATION, V59, P1549, DOI 10.1097/00007890-199506150-00008; GOOD AH, 1992, TRANSPL P, V24, P559; Ierino FL, 1998, TRANSPLANTATION, V66, P1439, DOI 10.1097/00007890-199812150-00006; Katopodis AG, 2002, J CLIN INVEST, V110, P1869, DOI 10.1172/JCI200216526; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; McGregor C. G., 2003, Journal of Heart and Lung Transplantation, V22, pS89, DOI 10.1016/S1053-2498(02)00723-4; Oldmixon BA, 2002, J VIROL, V76, P3045, DOI 10.1128/JVI.76.6.3045-3048.2002; PARKER W, 1994, J IMMUNOL, V153, P3791; Phelps CJ, 2003, SCIENCE, V299, P411, DOI 10.1126/science.1078942; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Sachs DH, 2001, ADV IMMUNOL, V79, P129, DOI 10.1016/S0065-2776(01)79004-9; Teranishi K, 2002, TRANSPLANTATION, V73, P129, DOI 10.1097/00007890-200201150-00024; YE Y, 1994, TRANSPLANTATION, V58, P330, DOI 10.1097/00007890-199408000-00014; Zhu A, 2002, XENOTRANSPLANTATION, V9, P376, DOI 10.1034/j.1399-3089.2002.02138.x	23	78	87	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					557	559		10.1016/S0140-6736(03)14118-9	http://dx.doi.org/10.1016/S0140-6736(03)14118-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932390				2022-12-28	WOS:000184817600024
J	Sowers, T; Alley, RB; Jubenville, J				Sowers, T; Alley, RB; Jubenville, J			Ice core records of atmospheric N2O covering the last 106,000 years	SCIENCE			English	Article							NITROUS-OXIDE; ISOTOPIC COMPOSITION; GLACIAL MAXIMUM; CARBON-CYCLE; TAYLOR DOME; ARABIAN SEA; CO2; GREENLAND; ANTARCTICA; HOLOCENE	Paleoatmospheric records of trace-gas concentrations recovered from ice cores provide important sources of information on many biogeochemical cycles involving carbon, nitrogen, and oxygen. Here, we present a 106,000-year record of atmospheric nitrous oxide (N2O) along with corresponding isotopic records spanning the last 30,000 years, which together suggest minimal changes in the ratio of marine to terrestrial N2O production. During the last glacial termination, both marine and oceanic N2O emissions increased by 40 +/- 8%. We speculate that our records do not support those hypotheses that invoke enhanced export production to explain low carbon dioxide values during glacial periods.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, EMS Environm Inst, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Sowers, T (corresponding author), Penn State Univ, Dept Geosci, University Pk, PA 16802 USA.							Altabet MA, 2002, NATURE, V415, P159, DOI 10.1038/415159a; Archer D, 2000, REV GEOPHYS, V38, P159, DOI 10.1029/1999RG000066; Bange HW, 1996, GLOBAL BIOGEOCHEM CY, V10, P197, DOI 10.1029/95GB03834; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; BENDER ML, 2000, AM GEOPHYSICAL UNION, V112, P149; BERGER A, 1991, QUATERNARY SCI REV, V10, P297, DOI 10.1016/0277-3791(91)90033-Q; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; BOUWMAN AF, 1993, GLOBAL BIOGEOCHEM CY, V7, P557, DOI 10.1029/93GB01186; BOUWMAN AF, 1995, J GEOPHYS RES-ATMOS, V100, P2785, DOI 10.1029/94JD02946; Brook EJ, 1996, SCIENCE, V273, P1087, DOI 10.1126/science.273.5278.1087; Brook EJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P559, DOI 10.1029/1999GB001182; BUTLER JH, 1989, J GEOPHYS RES-ATMOS, V94, P14865, DOI 10.1029/JD094iD12p14865; CHAPPELLAZ J, 1993, NATURE, V366, P443, DOI 10.1038/366443a0; CHAPPELLAZ JA, 1993, TELLUS B, V45, P228, DOI 10.1034/j.1600-0889.1993.t01-2-00002.x; CRUTZEN PJ, 1993, GEOPHYS RES LETT, V20, P1047, DOI 10.1029/93GL01423; Davidson E. A., 1991, Microbial production and consumption of greenhouse gases: methane, nitrogen oxides, and halomethanes., P219; DAVIDSON EA, 1993, BIOGEOCHEMISTRY OF GLOBAL CHANGE, P369; Dore JE, 1998, NATURE, V396, P63, DOI 10.1038/23921; Fluckiger J, 1999, SCIENCE, V285, P227, DOI 10.1126/science.285.5425.227; Fluckiger J, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001417; Goldstein B, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016418; Gow AJ, 1997, J GEOPHYS RES-OCEANS, V102, P26559, DOI 10.1029/97JC00165; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HOLTON JR, 1995, REV GEOPHYS, V33, P403, DOI 10.1029/95RG02097; Indermuhle A, 2000, GEOPHYS RES LETT, V27, P735, DOI 10.1029/1999GL010960; Indermuhle A, 1999, NATURE, V398, P121, DOI 10.1038/18158; JUBENVILLE J, 2000, THESIS PENNSYLVANIA; Kroeze C, 1999, GLOBAL BIOGEOCHEM CY, V13, P1, DOI 10.1029/1998GB900020; LEUENBERGER M, 1992, NATURE, V360, P449, DOI 10.1038/360449a0; MARTINERIE P, 1995, J GEOPHYS RES-ATMOS, V100, P14291, DOI 10.1029/95JD00826; MINSCHWANER K, 1993, J GEOPHYS RES-ATMOS, V98, P10543, DOI 10.1029/93JD00223; Minschwaner K, 1998, J GEOPHYS RES-ATMOS, V103, P23243, DOI 10.1029/98JD02116; NEVISON CD, 1995, J GEOPHYS RES-OCEANS, V100, P15809, DOI 10.1029/95JC00684; Potter CS, 1996, J GEOPHYS RES-ATMOS, V101, P1361, DOI 10.1029/95JD02028; Potter CS, 1998, GLOBAL BIOGEOCHEM CY, V12, P621, DOI 10.1029/98GB02425; Rahn T, 2000, GLOBAL BIOGEOCHEM CY, V14, P537, DOI 10.1029/1999GB900070; Seitzinger SP, 1998, GLOBAL BIOGEOCHEM CY, V12, P93, DOI 10.1029/97GB03657; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Smith HJ, 1999, NATURE, V400, P248, DOI 10.1038/22291; Sowers T, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001911; Sowers T, 2001, J GEOPHYS RES-ATMOS, V106, P31903, DOI 10.1029/2000JD900707; Sowers T, 2000, J GEOPHYS RES-ATMOS, V105, P29155, DOI 10.1029/2000JD900335; SOWERS T, 1989, J GEOPHYS RES-ATMOS, V94, P5137, DOI 10.1029/JD094iD04p05137; Suthhof A, 2001, GLOBAL BIOGEOCHEM CY, V15, P637, DOI 10.1029/2000GB001337; Trudinger CM, 1997, J GEOPHYS RES-ATMOS, V102, P6747, DOI 10.1029/96JD03382	45	100	101	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					945	948		10.1126/science.1085293	http://dx.doi.org/10.1126/science.1085293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920293				2022-12-28	WOS:000184755900033
J	Dore, JE; Lukas, R; Sadler, DW; Karl, DM				Dore, JE; Lukas, R; Sadler, DW; Karl, DM			Climate-driven changes to the atmospheric CO2 sink in the subtropical North Pacific Ocean	NATURE			English	Article							INORGANIC CARBON; ATLANTIC OCEAN; SEAWATER; GYRE; DISSOCIATION; VARIABILITY; EQUILIBRIUM; CONSTANTS; EXCHANGE; DIOXIDE	The oceans represent a significant sink for atmospheric carbon dioxide(1). Variability in the strength of this sink occurs on interannual timescales, as a result of regional and basin-scale changes in the physical and biological parameters that control the flux of this greenhouse gas into and out of the surface mixed layer(2,3). Here we analyse a 13-year time series of oceanic carbon dioxide measurements from station ALOHA in the subtropical North Pacific Ocean near Hawaii(4), and find a significant decrease in the strength of the carbon dioxide sink over the period 1989-2001. We show that much of this reduction in sink strength can be attributed to an increase in the partial pressure of surface ocean carbon dioxide caused by excess evaporation and the accompanying concentration of solutes in the water mass. Our results suggest that carbon dioxide uptake by ocean waters can be strongly influenced by changes in regional precipitation and evaporation patterns brought on by climate variability.	Univ Hawaii, Sch Ocean & Earth Sci & Technol, Dept Oceanog, Honolulu, HI 96822 USA	University of Hawaii System	Dore, JE (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, Dept Oceanog, 1000 Pope Rd, Honolulu, HI 96822 USA.		Lukas, Roger B/B-3715-2009; Karl, David/AFP-3837-2022	Karl, David/0000-0002-6660-6721				Bates NR, 2002, NATURE, V420, P489, DOI 10.1038/nature01253; Chavez FP, 2003, SCIENCE, V299, P217, DOI 10.1126/science.1075880; Dickson A.G., 2001, OCEANOGRAPHY, V14, P21; DICKSON AG, 1987, DEEP-SEA RES, V34, P1733, DOI 10.1016/0198-0149(87)90021-5; *DOE, 1994, HDB METH AN VAR PAR; Dore JE, 2002, LIMNOL OCEANOGR, V47, P1595, DOI 10.4319/lo.2002.47.6.1595; Gruber N, 2002, SCIENCE, V298, P2374, DOI 10.1126/science.1077077; Hoerling M, 2003, SCIENCE, V299, P691, DOI 10.1126/science.1079053; Houghton J.T., 1990, CLIMATE CHANGE IPCC; Ishii M, 2001, MAR CHEM, V75, P17, DOI 10.1016/S0304-4203(01)00023-8; Karl DM, 1996, DEEP-SEA RES PT II, V43, P129, DOI 10.1016/0967-0645(96)00005-7; Keeling CD., 2002, TRENDS COMPENDIUM DA; KEELING CD, 1993, NATO ASI SERIES, V115; Lee K, 2000, GEOPHYS RES LETT, V27, P229, DOI 10.1029/1999GL002345; Lewis E., 1998, ORNLCDIAC105 US DEP; Lueker TJ, 2000, MAR CHEM, V70, P105, DOI 10.1016/S0304-4203(00)00022-0; Lukas R, 2001, GEOPHYS RES LETT, V28, P3485, DOI 10.1029/2001GL013116; MERBACH C, 1973, LIMNOL OCEANOGR, V18, P897; Minobe S, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014447; SIEGENTHALER U, 1993, NATURE, V365, P119, DOI 10.1038/365119a0; TUPAS L, 1993, 9314 SOEST U HAW; WANNINKHOF R, 1992, J GEOPHYS RES-OCEANS, V97, P7373, DOI 10.1029/92JC00188; Waple AM, 2002, B AM METEOROL SOC, V83, pS1; WEISS RF, 1982, NATURE, V300, P511, DOI 10.1038/300511a0; WINN CD, 1994, GLOBAL BIOGEOCHEM CY, V8, P157, DOI 10.1029/94GB00387	25	114	121	5	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					754	757		10.1038/nature01885	http://dx.doi.org/10.1038/nature01885			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917678				2022-12-28	WOS:000184733900033
J	Spiegel, A				Spiegel, A			beta-arrestin - Not just for G protein-coupled receptors	SCIENCE			English	Editorial Material							TRANSDUCTION		NIDDKD, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Spiegel, A (corresponding author), NIDDKD, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Luttrell LM, 2002, J CELL SCI, V115, P455; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	8	14	15	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1338	1339		10.1126/science.1089552	http://dx.doi.org/10.1126/science.1089552			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958351				2022-12-28	WOS:000185116400028
J	Wardemann, H; Yurasov, S; Schaefer, A; Young, JW; Meffre, E; Nussenzweig, MC				Wardemann, H; Yurasov, S; Schaefer, A; Young, JW; Meffre, E; Nussenzweig, MC			Predominant autoantibody production by early human B cell precursors	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY; CHAIN GENE; ANTIBODY; EXPRESSION; REPERTOIRE; POLYREACTIVITY; LYMPHOCYTES; SELECTION; REGION; MICE	During B lymphocyte development, antibodies are assembled by random gene segment reassortment to produce a vast number of specificities. A potential disadvantage of this process is that some of the antibodies produced are self-reactive. We determined the prevalence of self-reactive antibody formation and its regulation in human B cells. A majority (55 to 75%) of all antibodies expressed by early immature B cells displayed self-reactivity, including poly-reactive and anti-nuclear specificities. Most of these autoantibodies were removed from the population at two discrete checkpoints during B cell development. Inefficient checkpoint regulation would lead to substantial increases in circulating autoantibodies.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Allogeneic Bone Marrow Transplant Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, Clin Immunol Serv, New York, NY 10021 USA; Cornell Univ, Hosp Special Surg, Weill Med Coll, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Meffre, E (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	meffree@hss.edu; nussen@mail.rockefeller.edu	Nussenzweig, Michel/AAE-7292-2019	Wardemann, Hedda/0000-0003-3921-5933; Young, James/0000-0002-0032-6559				Aguilera I, 2001, IMMUNOLOGY, V102, P273, DOI 10.1046/j.1365-2567.2001.01159.x; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; BARBAS SM, 1995, P NATL ACAD SCI USA, V92, P2529, DOI 10.1073/pnas.92.7.2529; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Billips LG, 1995, ANN NY ACAD SCI, V764, P1; CROUZIER R, 1995, J IMMUNOL, V154, P4526; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GUIGOU V, 1991, J IMMUNOL, V146, P1368; ICHIYOSHI Y, 1994, J EXP MED, V180, P885, DOI 10.1084/jem.180.3.885; King LB, 2000, IMMUNOL REV, V176, P86; KLEINFIELD R, 1986, NATURE, V322, P843, DOI 10.1038/322843a0; Klonowski KD, 1999, J IMMUNOL, V162, P1566; Landsteiner K, 1936, SPECIFICITY SEROLOGI; Leslie D, 2001, J CLIN INVEST, V108, P1417, DOI 10.1172/JCI14452; Martin F, 2000, IMMUNOL REV, V175, P70, DOI 10.1034/j.1600-065X.2000.017515.x; Meffre E, 2001, J CLIN INVEST, V108, P879, DOI 10.1172/JCI13051; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Ochsenbein AF, 1999, SCIENCE, V286, P2156, DOI 10.1126/science.286.5447.2156; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1986, NATURE, V322, P840, DOI 10.1038/322840a0; Retter MW, 1998, J EXP MED, V188, P1231, DOI 10.1084/jem.188.7.1231; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; SEIGNEURIN JM, 1988, BLOOD, V71, P581; Shiokawa S, 1999, J IMMUNOL, V162, P6060; Silverstein AM, 2001, NAT IMMUNOL, V2, P279, DOI 10.1038/86280; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287	34	1448	1516	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1374	1377		10.1126/science.1086907	http://dx.doi.org/10.1126/science.1086907			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12920303				2022-12-28	WOS:000185116400040
J	Ludwig, MG; Vanek, M; Guerini, D; Gasser, JA; Jones, CE; Junker, U; Hofstetter, H; Wolf, RM; Seuwen, K				Ludwig, MG; Vanek, M; Guerini, D; Gasser, JA; Jones, CE; Junker, U; Hofstetter, H; Wolf, RM; Seuwen, K			Proton-sensing G-protein-coupled receptors	NATURE			English	Article							MEDIATED BONE-RESORPTION; ACTIVATION; ACIDOSIS; TISSUE; SPHINGOSYLPHOSPHORYLCHOLINE; NOCICEPTION; RHODOPSIN; CHANNELS; PAIN; PH	Blood pH is maintained in a narrow range around pH 7.4 mainly through regulation of respiration and renal acid extrusion(1,2). The molecular mechanisms involved in pH homeostasis are not completely understood. Here we show that ovarian cancer G-protein-coupled receptor 1 (OGR1), previously described as a receptor for sphingosylphosphorylcholine 3, acts as a proton-sensing receptor stimulating inositol phosphate formation. The receptor is inactive at pH 7.8, and fully activated at pH 6.8-site-directed mutagenesis shows that histidines at the extracellular surface are involved in pH sensing. We find that GPR4, a close relative of OGR1, also responds to pH changes, but elicits cyclic AMP formation. It is known that the skeleton participates in pH homeostasis as a buffering organ, and that osteoblasts respond to pH changes in the physiological range(4), but the pH-sensing mechanism operating in these cells was hitherto not known. We detect expression of OGR1 in osteosarcoma cells and primary human osteoblast precursors, and show that these cells exhibit strong pH-dependent inositol phosphate formation. Immunohistochemistry on rat tissue sections confirms the presence of OGR1 in osteoblasts and osteocytes. We propose that OGR1 and GPR4 are proton-sensing receptors involved in pH homeostasis.	Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England	Novartis; Novartis	Seuwen, K (corresponding author), Novartis Inst Biomed Res, CH-4002 Basel, Switzerland.		Gasser, Juerg Andreas/AAT-5389-2020	Gasser, Juerg Andreas/0000-0002-0106-364X				AN SZ, 1995, FEBS LETT, V375, P121, DOI 10.1016/0014-5793(95)01196-L; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Brechter AB, 2002, REGUL PEPTIDES, V103, P39, DOI 10.1016/S0167-0115(01)00325-1; Bushinsky DA, 2001, EUR J NUTR, V40, P238, DOI 10.1007/s394-001-8351-5; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Feldman JL, 2003, ANNU REV NEUROSCI, V26, P239, DOI 10.1146/annurev.neuro.26.041002.131103; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; Heming TA, 2001, CLIN SCI, V101, P267, DOI 10.1042/CS20010139; Ishizaka H, 1999, CIRCULATION, V99, P558, DOI 10.1161/01.CIR.99.4.558; Krieger NS, 2000, AM J PHYSIOL-RENAL, V279, pF1077, DOI 10.1152/ajprenal.2000.279.6.F1077; Meghji S, 2001, AM J PHYSIOL-ENDOC M, V280, pE112, DOI 10.1152/ajpendo.2001.280.1.E112; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Sottile V, 2002, BONE, V30, P699, DOI 10.1016/S8756-3282(02)00674-9; Swenson E R, 2001, Respir Care, V46, P342; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	29	482	504	4	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					93	98		10.1038/nature01905	http://dx.doi.org/10.1038/nature01905			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955148				2022-12-28	WOS:000185089200045
J	Shelby, JP; Lim, DSW; Kuo, JS; Chiu, DT				Shelby, JP; Lim, DSW; Kuo, JS; Chiu, DT			High radial acceleration in microvortices	NATURE			English	Editorial Material							TOTAL ANALYSIS SYSTEMS		Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Shelby, JP (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.							Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t; Beebe DJ, 2002, ANNU REV BIOMED ENG, V4, P261, DOI 10.1146/annurev.bioeng.4.112601.125916; Ng JMK, 2002, ELECTROPHORESIS, V23, P3461, DOI 10.1002/1522-2683(200210)23:20<3461::AID-ELPS3461>3.0.CO;2-8; Reyes DR, 2002, ANAL CHEM, V74, P2623, DOI 10.1021/ac0202435; Shankar PN, 2000, ANNU REV FLUID MECH, V32, P93, DOI 10.1146/annurev.fluid.32.1.93; Shelby JP, 2003, ANAL CHEM, V75, P1387, DOI 10.1021/ac026275+; Thorsen T, 2002, SCIENCE, V298, P580, DOI 10.1126/science.1076996	7	64	70	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					38	38		10.1038/425038a	http://dx.doi.org/10.1038/425038a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955132	Bronze			2022-12-28	WOS:000185089200029
J	Stark, AM; Mehdorn, HM				Stark, AM; Mehdorn, HM			Chondroid clival chordoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Kiel, Med Ctr, D-24106 Kiel, Germany	University of Kiel	Stark, AM (corresponding author), Univ Kiel, Med Ctr, D-24106 Kiel, Germany.		Mehdorn, Maximilian/D-2495-2010						0	7	7	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					E10	E10		10.1056/ENEJMicm010745	http://dx.doi.org/10.1056/ENEJMicm010745			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954756				2022-12-28	WOS:000185081400009
J	Callahan, CM; McHorney, CA				Callahan, CM; McHorney, CA			Successful aging and the humility of perspective	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN						Indiana Univ, Ctr Aging Res, Regenstrief Inst, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Callahan, CM (corresponding author), Indiana Univ, Ctr Aging Res, Regenstrief Inst, Richard L Roudebush Vet Adm Med Ctr, 1050 Wishard Blvd,RG6, Indianapolis, IN 46202 USA.	ccallaha@iupui.edu						Evans R. G., 1994, WHY ARE SOME PEOPLE; Institute of Medicine (US) Committee on Assuring the Health of the Public in the 21st Century, 2002, FUT PUBL HLTH 21 CEN	2	11	12	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			389	390		10.7326/0003-4819-139-5_Part_2-200309021-00001	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00001			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965962				2022-12-28	WOS:000185133800001
J	Viljanen, M; Malmivaara, A; Uitti, J; Rinne, M; Palmroos, R; Laippala, P				Viljanen, M; Malmivaara, A; Uitti, J; Rinne, M; Palmroos, R; Laippala, P			Effectiveness of dynamic muscle training, relaxation training, or ordinary activity for chronic neck pain: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE	Objective To determine the effectiveness of dynamic muscle training and relaxation training for chronic neck pain. Design Randomised controlled trial. Setting Five occupational healthcare centres, Tampere, Finland. Participants 393 female office workers (mean age 45 years) with chronic non-specific neck pain randomly assigned to 12 weeks of dynamic muscle training (n=135) or relaxation training (n=128), plus one week of reinforcement training six months after baseline; or ordinary activity (control group; n=130). Main outcome measure Change in intensity of neck pain at three, six, and 12 months. Results No significant difference was found in neck pain between the groups at follow up. However, the range of motion for cervical rotation and lateral flexion increased more in the training groups than in the control group. Conclusions Dynamic muscle training and relaxation training do not lead to better improvements in neck pain compared with ordinary activity.	Tampere Reg Inst Occupat Hlth, FIN-33101 Tampere, Finland; Natl Res & Dev Ctr Welf & Hlth, Finnish Off Hlth Technol Assessment, Helsinki, Finland; Kekkonen Inst Hlth Promot Res, Tampere, Finland; Tampere Univ Hosp, Res Unit, Tampere, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland	Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital; Tampere University	Viljanen, M (corresponding author), Tampere Reg Inst Occupat Hlth, POB 486, FIN-33101 Tampere, Finland.		salimi, mehdi/D-1192-2009					ALTMAN DG, 1989, STATISTICS CONFIDENC, P20; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; DENNER I, 1992, RETEST RELIABILITY C; DYRSSEN T, 1989, LAKARTIDNINGEN, V86, P116; ELO AL, 1994, OCCUPATIONAL MED, P945; GROSS AR, 2000, COCHRANE LIB; HAGBERG M, 1987, BRIT J IND MED, V44, P602; HERTLING D, 1990, MANAGEMENT COMMON MU, P144; Kjellman GV, 1999, SCAND J REHABIL MED, V31, P139; LEVOSKA S, 1993, ARCH PHYS MED REHAB, V74, P425; MOSSTON M, 1994, TEACHING PHYSICAL ED; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; RINNE M, 1998, PATIENT ED COUNSE S1, V334, P69; SALOKANGAS RKR, 1995, ACTA PSYCHIAT SCAND, V92, P10, DOI 10.1111/j.1600-0447.1995.tb09536.x; Taimela S, 2000, SPINE, V25, P1021, DOI 10.1097/00007632-200004150-00018; TOIVANEN H, 1993, J OCCUP ENVIRON MED, V35, P1123, DOI 10.1097/00043764-199311000-00015; VANTULDER MW, 2000, NECK BACK PAIN	20	146	146	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					475	477		10.1136/bmj.327.7413.475	http://dx.doi.org/10.1136/bmj.327.7413.475			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946968	Green Published, Bronze			2022-12-28	WOS:000185088900014
J	Ensslin, MA; Shur, BD				Ensslin, MA; Shur, BD			Identification of mouse sperm SED1, a bimotif EGF repeat and discoidin-domain protein involved in sperm-egg binding	CELL			English	Article							COAGULATION-FACTOR-V; ZONA-PELLUCIDA; FACTOR-VIII; CRYSTAL-STRUCTURES; SURFACE; MICE; ZP3; CLONING; ADHESION; BETA-1,4-GALACTOSYLTRANSFERASE	We report the identification of SED1, a protein required for mouse sperm binding to the egg zona pellucida. SED1 is homologous to a small group of secreted cell-matrix adhesive proteins that contain Notch-like EGF repeats and discoidin/F5/8 type C domains. SED1 is expressed in spermatogenic cells and is secreted by the initial segment of the caput epididymis, resulting in SED1 localization on the sperm plasma membrane overlying the acrosome. SED1 binds specifically to the zona pellucida of unfertilized oocytes, but not to the zona of fertilized eggs. Recombinant SED1 and anti-SED1 antibodies competitively inhibit sperm-egg binding, as do truncated SED1 proteins containing a discoidin/C domain. SED1 null males are subfertile and their sperm are unable to bind to the egg coat in vitro. These studies illustrate that Notch-like EGF and discoidin/C domains, protein motifs that facilitate a variety of cellular interactions, participate in gamete recognition as well.	Emory Univ, Sch Med, Dept Cell Biol, Whitehead Inst Biomed Res, Atlanta, GA 30322 USA	Emory University; Massachusetts Institute of Technology (MIT); Whitehead Institute	Shur, BD (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Whitehead Inst Biomed Res, 615 Michael St,Room 405, Atlanta, GA 30322 USA.	barry@cellbio.emory.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023479] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andersen MH, 2000, BIOCHEMISTRY-US, V39, P6200, DOI 10.1021/bi992221r; Andersen MH, 1997, BIOCHEMISTRY-US, V36, P5441, DOI 10.1021/bi963119m; Aviles M, 1997, BIOL REPROD, V57, P1155, DOI 10.1095/biolreprod57.5.1155; Blazar M, 2001, MOL CELL BIOL, V21, P2570, DOI 10.1128/MCB.21.7.2570-2580.2001; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Couto JR, 1996, DNA CELL BIOL, V15, P281, DOI 10.1089/dna.1996.15.281; Ensslin M, 1998, BIOL REPROD, V58, P1057, DOI 10.1095/biolreprod58.4.1057; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; Fuentes-Prior P, 2002, CURR PROTEIN PEPT SC, V3, P313, DOI 10.2174/1389203023380639; Fusi FM, 1996, MOL HUM REPROD, V2, P169, DOI 10.1093/molehr/2.3.169; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; Haltiwanger RS, 2002, CURR OPIN STRUC BIOL, V12, P593, DOI 10.1016/S0959-440X(02)00371-8; JANSSEN PJ, 1994, J HISTOCHEM CYTOCHEM, V42, P1169, DOI 10.1177/42.8.8027537; Johnston DS, 1998, J BIOL CHEM, V273, P1888, DOI 10.1074/jbc.273.4.1888; Larson JL, 1999, MOL REPROD DEV, V52, P445, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;445::AID-MRD14&gt;3.0.CO;2-6; Lawrence N, 2000, DEVELOPMENT, V127, P3185; Lonhienne T, 2001, J MOL BIOL, V310, P291, DOI 10.1006/jmbi.2001.4774; Lu QX, 1997, DEVELOPMENT, V124, P4121; Macedo-Ribeiro S, 1999, NATURE, V402, P434, DOI 10.1038/46594; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NAGDAS SK, 1994, BIOL REPROD, V51, P262, DOI 10.1095/biolreprod51.2.262; Nayernia K, 2002, MOL CELL BIOL, V22, P3046, DOI 10.1128/MCB.22.9.3046-3052.2002; NELLES LP, 1976, ANAL BIOCHEM, V73, P522, DOI 10.1016/0003-2697(76)90202-5; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; Ogura K, 1996, BIOCHEM BIOPH RES CO, V225, P932, DOI 10.1006/bbrc.1996.1274; Oshima K, 2002, EUR J BIOCHEM, V269, P1209, DOI 10.1046/j.1432-1033.2002.02758.x; Pearse RV, 1997, P NATL ACAD SCI USA, V94, P7555, DOI 10.1073/pnas.94.14.7555; Penta K, 1999, J BIOL CHEM, V274, P11101, DOI 10.1074/jbc.274.16.11101; Pratt KP, 1999, NATURE, V402, P439, DOI 10.1038/46601; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Rankin TL, 2003, DEV CELL, V5, P33, DOI 10.1016/S1534-5807(03)00195-3; Rankin TL, 1998, DEVELOPMENT, V125, P2415; REITHERMAN RW, 1975, P NATL ACAD SCI USA, V72, P3541, DOI 10.1073/pnas.72.9.3541; ROBAIRE B, 1994, PHYSL REPROD, P999; Shi XD, 2001, DEVELOPMENT, V128, P645; Singson A, 1998, CELL, V93, P71, DOI 10.1016/S0092-8674(00)81147-2; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; Trubner M, 1997, ANDROLOGIA, V29, P253; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wolfer DP, 2002, TRENDS NEUROSCI, V25, P336, DOI 10.1016/S0166-2236(02)02192-6; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; YOUAKIM A, 1994, J CELL BIOL, V126, P1573, DOI 10.1083/jcb.126.6.1573	42	191	201	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 22	2003	114	4					405	417		10.1016/S0092-8674(03)00643-3	http://dx.doi.org/10.1016/S0092-8674(03)00643-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941270	Bronze			2022-12-28	WOS:000184928800005
J	Lander, GH				Lander, GH			Physics - Sensing electrons on the edge	SCIENCE			English	Editorial Material							PLUTONIUM		European Commiss Joint Res Ctr, Inst Transuranium Elements, D-76125 Karlsruhe, Germany	European Commission Joint Research Centre; EC JRC Institute for Transuranium Elements (ITU)	Lander, GH (corresponding author), European Commiss Joint Res Ctr, Inst Transuranium Elements, D-76125 Karlsruhe, Germany.	gerard.lander@cec.eu.int						Dai X, 2003, SCIENCE, V300, P953, DOI 10.1126/science.1083428; Hecker SS, 2001, MRS BULL, V26, P672, DOI 10.1557/mrs2001.176; LANDER GH, 1994, ADV PHYS, V43, P1, DOI 10.1080/00018739400101465; LEDBETTER HM, 1976, ACTA METALL MATER, V24, P891, DOI 10.1016/0001-6160(76)90037-7; Sarrao JL, 2002, NATURE, V420, P297, DOI 10.1038/nature01212; Wong J, 2003, SCIENCE, V301, P1078, DOI 10.1126/science.1087179	6	41	41	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1057	+		10.1126/science.1088510	http://dx.doi.org/10.1126/science.1088510			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12933999				2022-12-28	WOS:000184872400027
J	Eckstein-Ludwig, U; Webb, RJ; van Goethem, IDA; East, JM; Lee, AG; Kimura, M; O'Neill, PM; Bray, PG; Ward, SA; Krishna, S				Eckstein-Ludwig, U; Webb, RJ; van Goethem, IDA; East, JM; Lee, AG; Kimura, M; O'Neill, PM; Bray, PG; Ward, SA; Krishna, S			Artemisinins target the SERCA of Plasmodium falciparum	NATURE			English	Article							CALCIUM-PUMP; ANTIMALARIAL; DERIVATIVES; MALARIA; INVITRO; RESISTANCE; RETICULUM; QINGHAOSU; PARASITE; DRUGS	Artemisinins are extracted from sweet wormwood (Artemisia annua) and are the most potent antimalarials available(1), rapidly killing all asexual stages of Plasmodium falciparum(2). Artemisinins are sesquiterpene lactones widely used to treat multidrug-resistant malaria(1), a disease that annually claims 1 million lives. Despite extensive clinical and laboratory experience(3-5) their molecular target is not yet identified. Activated artemisinins form adducts with a variety of biological macromolecules, including haem, translationally controlled tumour protein (TCTP) and other higher-molecular-weight proteins(6). Here we show that artemisinins, but not quinine or chloroquine, inhibit the SERCA orthologue (PfATP6) of Plasmodium falciparum in Xenopus oocytes with similar potency to thapsigargin (another sesquiterpene lactone and highly specific SERCA inhibitor). As predicted, thapsigargin also antagonizes the parasiticidal activity of artemisinin. Desoxyartemisinin lacks an endoperoxide bridge and is ineffective both as an inhibitor of PfATP6 and as an antimalarial. Chelation of iron by desferrioxamine abrogates the antiparasitic activity of artemisinins and correspondingly attenuates inhibition of PfATP6. Imaging of parasites with BODIPY-thapsigargin labels the cytosolic compartment and is competed by artemisinin. Fluorescent artemisinin labels parasites similarly and irreversibly in an Fe2+-dependent manner. These data provide compelling evidence that artemisinins act by inhibiting PfATP6 outside the food vacuole after activation by iron.	St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England; Univ Southampton, Dept Biochem & Mol Biol, Southampton SO16 7PX, Hants, England; Osaka City Univ, Sch Med, Radioisotope Ctr, Abeno Ku, Osaka 5458585, Japan; Univ Liverpool, Robert Robinson Labs, Dept Chem, Liverpool L69 7ZD, Merseyside, England; Univ Liverpool, Liverpool Sch Trop Med, Mol & Biochem Parasitol Grp, Liverpool L3 5QA, Merseyside, England	St Georges University London; University of Southampton; Osaka Metropolitan University; University of Liverpool; Liverpool School of Tropical Medicine; University of Liverpool	Krishna, S (corresponding author), St George Hosp, Sch Med, Dept Cellular & Mol Med, Cranmer Terrace, London SW17 0RE, England.	s.krishna@sghms.ac.uk	Hua, QX/HGE-3640-2022; Ward, Steve/G-6003-2015	Ward, Steve/0000-0003-2331-3192; Krishna, Sanjeev/0000-0003-0066-0634				Akompong T, 1999, MOL BIOCHEM PARASIT, V101, P71, DOI 10.1016/S0166-6851(99)00056-0; ALLEN DG, 1985, NATURE, V316, P674, DOI 10.1038/316674a0; ASAWAMAHASAKDA W, 1994, ANTIMICROB AGENTS CH, V38, P1854, DOI 10.1128/AAC.38.8.1854; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Bhisutthibhan J, 1998, J BIOL CHEM, V273, P16192, DOI 10.1074/jbc.273.26.16192; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; East J M, 1994, Methods Mol Biol, V27, P87; ELLIS DS, 1985, ANN TROP MED PARASIT, V79, P367, DOI 10.1080/00034983.1985.11811933; GU HM, 1984, T ROY SOC TROP MED H, V78, P265, DOI 10.1016/0035-9203(84)90296-7; Hawley SR, 1998, ANTIMICROB AGENTS CH, V42, P682, DOI 10.1128/AAC.42.3.682; Haynes RK, 2003, ANTIMICROB AGENTS CH, V47, P1175, DOI 10.1128/AAC.47.3.1175.2003; Haynes RK, 2001, CURR OPIN INFECT DIS, V14, P719, DOI 10.1097/00001432-200112000-00010; HIEN TT, 1993, LANCET, V341, P603; Jefford CW, 2001, CURR MED CHEM, V8, P1803, DOI 10.2174/0929867013371608; Krishna S, 2001, J BIOL CHEM, V276, P10782, DOI 10.1074/jbc.M010554200; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; MESHNICK SR, 1993, ANTIMICROB AGENTS CH, V37, P1108, DOI 10.1128/AAC.37.5.1108; O'Neill PM, 2000, J ORG CHEM, V65, P1578, DOI 10.1021/jo991585m; Olliaro PL, 2001, TRENDS PARASITOL, V17, P122, DOI 10.1016/S1471-4922(00)01838-9; ONO T, 1991, Japanese Journal of Parasitology, V40, P587; Pandey AV, 1999, J BIOL CHEM, V274, P19383, DOI 10.1074/jbc.274.27.19383; Price RN, 1999, ANTIMICROB AGENTS CH, V43, P2943, DOI 10.1128/AAC.43.12.2943; Robert A, 2002, ACCOUNTS CHEM RES, V35, P167, DOI 10.1021/ar990164o; SCHATZMANN HJ, 1953, HELV PHYSIOL PHARM A, V11, P346; Simpson PB, 1997, BIOCHEM J, V325, P239, DOI 10.1042/bj3250239; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272	30	767	805	7	373	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					957	961		10.1038/nature01813	http://dx.doi.org/10.1038/nature01813			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931192				2022-12-28	WOS:000184843600045
J	Brennan, TA; Mello, MM				Brennan, TA; Mello, MM			Patient safety and medical malpractice: A case study	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE EVENTS; CLAIMS; CARE; LITIGATION; PERCEPTIONS; NEGLIGENCE; PHYSICIANS; DISCLOSURE; SEVERITY; INJURIES	The system of tort liability for medical malpractice is frequently criticized for poorly performing its theoretical functions of compensating injured patients, deterring negligence, and dispensing corrective justice. Working from an actual malpractice case involving serious injury but no apparent negligence, the authors explore these criticisms from the perspectives of both the plaintiff-patient and the defendant-physician. They then examine the tort system through the lens of patient safety and conclude that the tensions between the system and patient safety initiatives suggest a need to reexamine our attachment to adversarial dispute resolution in health care. They propose targeted reforms that could improve the functioning of the system and create incentives to improve safety and quality.	Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St,PBB4, Boston, MA 02115 USA.			Mello, Michelle/0000-0003-2877-4270				ABEL RL, 1990, UCLA LAW REV, V37, P785; ALBERT T, 2002, AM MED NEWS     1014, P5; BELL PA, 1984, SYRACUSE LAW REV, V35, P939; Bovbjerg RR, 1989, UC DAVIS LAW REV, V22, P499; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Brennan TA, 1996, NEW ENGL J MED, V335, P1963, DOI 10.1056/NEJM199612263352606; Calabresi G, 1970, COSTS ACCIDENTS LEGA; CLINES FS, 2002, NY TIMES        0613, pA24; CONN LT, 2000, ERR IS HUMAN BUILDIN; DANZON P, 1984, J LAW ECON, V27, P115, DOI 10.1086/467060; Dubay L, 1999, J HEALTH ECON, V18, P491, DOI 10.1016/S0167-6296(99)00004-1; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; FARBER HS, 1991, RAND J ECON, V22, P199, DOI 10.2307/2601017; FURROW BR, 2001, LAW HLTH CARE ORG FI; GORMAN T, 2002, LOS ANGELES TIM 0301, P1; *HARV MED PRACT ST, 1990, PAT DOCT LAW MED INJ; Hupert N, 1996, SOC SCI MED, V43, P1, DOI 10.1016/0277-9536(95)00314-2; Hyman DA, 2002, TEX LAW REV, V80, P1639; Institute of Medicine, 2001, CROSSING QUALITY CHA; *JOINT COMM ACCR H, FACTS PAT SAF; KINNEY ED, 1995, J HEALTH POLIT POLIC, V20, P99, DOI 10.1215/03616878-20-1-99; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lamb RM, 2003, HEALTH AFFAIR, V22, P73, DOI 10.1377/hlthaff.22.2.73; LAWTHERS AG, 1992, J HEALTH POLIT POLIC, V17, P463, DOI 10.1215/03616878-17-3-463; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; LOCALIO AR, 1993, JAMA-J AM MED ASSOC, V269, P366, DOI 10.1001/jama.269.3.366; LOCALIO AR, 1991, NEW ENGL J MED, V325, P245, DOI 10.1056/NEJM199107253250405; Mello MM, 2003, NEW ENGL J MED, V348, P2281, DOI 10.1056/NEJMp030064; Mello MM, 2002, TEX LAW REV, V80, P1595; Moore PJ, 2000, WESTERN J MED, V173, P244, DOI 10.1136/ewjm.173.4.244; *NAT AC STAT HLTH, 2002, STAT RESP PROBL MED; *OFF TECHN ASS, 1994, DEF MED MED MALP; Peterson L M, 1990, J Clin Ethics, V1, P207; SCHEUTZOW SO, 1992, J LAW HLTH, V7, P169; SCHWARTZ GT, 1994, UCLA LAW REV, V42, P377; Shavell S., 1987, EC ANAL ACCIDENT LAW; SLOAN FA, 1995, MED CARE, V33, P700, DOI 10.1097/00005650-199507000-00006; SLOAN FA, 1985, J HEALTH POLIT POLIC, V9, P629, DOI 10.1215/03616878-9-4-629; SLOAN FA, 1991, INSURING MED MALPRAC; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Studdert DM, 2000, MED CARE, V38, P250, DOI 10.1097/00005650-200003000-00002; Studdert DM, 2001, JAMA-J AM MED ASSOC, V286, P217, DOI 10.1001/jama.286.2.217; TARAGIN MI, 1992, ANN INTERN MED, V117, P780, DOI 10.7326/0003-4819-117-9-780; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; Thomas EJ, 2002, ANN INTERN MED, V136, P812, DOI 10.7326/0003-4819-136-11-200206040-00009; WEILER PC, 1991, MED MALPRACTICE TRIA; Weiler PC, 1993, MEASURE MALPRACTICE; Wu AW, 1999, ANN INTERN MED, V131, P970, DOI 10.7326/0003-4819-131-12-199912210-00012; Wu AW, 1997, J GEN INTERN MED, V12, P770, DOI 10.1046/j.1525-1497.1997.07163.x	49	30	30	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					267	273		10.7326/0003-4819-139-4-200308190-00009	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712JY	12965982				2022-12-28	WOS:000184795600005
J	Ng, SKC				Ng, SKC			Possible role of an animal vector in the SARS outbreak at Amoy Gardens	LANCET			English	Article							TRANSMISSION DYNAMICS; CORONAVIRUS; AGENT	A mass outbreak of severe acute respiratory syndrome (SARS) in the Amoy Gardens housing complex in Hong Kong at the end of March, 2003, affected more than 300 residents in less than a month, and has epidemiologists all over the world puzzled about the mode of transmission of this new disease, which until then was thought to be transmitted solely by respiratory droplets. The source of the outbreak was later traced to an individual with SARS who spent two nights at Amoy Gardens. Official explanations failed to account for the large number of residents infected over a wide area within a short time., A powerful environmental mechanism that efficiently amplified and distributed the causal agent must. have been at work to cause this outbreak. One such mechanism could be an animal vector, most probably roof rats, that was infected by the index patient and subsequently spread the disease to more than 150 households.	Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	Columbia University	Ng, SKC (corresponding author), Unit A-C,11-F,Power Ind Bldg,9-15 Wo Heung St, Shatin, Hong Kong, Peoples R China.	skcng@hotmail.com						BENITEZ MA, 2003, S CHINA MORNING 0528, pC1; Bradsher K, 2003, NY TIMES, pA1; *DEP HLTH HONG KIO, 1908, OUTBR SEV AC RESP SY; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Haijema BJ, 2003, J VIROL, V77, P4528, DOI 10.1128/JVI.77.8.4528-4538.2003; JACBOY RO, 1986, VIRAL MYCOPLASMAL IN, P625; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; *PROF PEST MAN ASS, 2003, ROOF BLACK SHIP RAT; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; *U AZ COOP EXT, 2003, ROOF RAT CONTR HOM O; WHO, 2003, 1 DAT STAB RES SARS; *WHO, 2003, COR NEV BEF SEEN  HU; 2003, MING PAO HONG K 0505, pA11; 2003, MING PAO HONG K 0508, pA4; 2003, S CHINA MORNING 0517; 2003, MING PAO HONG K 0411, pA2	20	66	72	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					570	572		10.1016/S0140-6736(03)14121-9	http://dx.doi.org/10.1016/S0140-6736(03)14121-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932393	Green Published, Bronze			2022-12-28	WOS:000184817600027
J	Dumoulin, M; Last, AM; Desmyter, A; Decanniere, K; Canet, D; Larsson, G; Spencer, A; Archer, DB; Sasse, J; Muyldermans, S; Wyns, L; Redfield, C; Matagne, A; Robinson, CV; Dobson, CM				Dumoulin, M; Last, AM; Desmyter, A; Decanniere, K; Canet, D; Larsson, G; Spencer, A; Archer, DB; Sasse, J; Muyldermans, S; Wyns, L; Redfield, C; Matagne, A; Robinson, CV; Dobson, CM			A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme	NATURE			English	Article							HEREDITARY RENAL AMYLOIDOSIS; ALZHEIMERS-DISEASE; PRION REPLICATION; TRANSTHYRETIN; AGGREGATION; STRATEGIES; VARIANTS; BINDING	Amyloid diseases are characterized by an aberrant assembly of a specific protein or protein fragment into fibrils and plaques that are deposited in various organs and tissues(1-3), often with serious pathological consequences. Non-neuropathic systemic amyloidosis (4-6) is associated with single point mutations in the gene coding for human lysozyme. Here we report that a single-domain fragment of a camelid antibody(7-9) raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant, D67H. Our structural studies reveal that the epitope includes neither the site of mutation nor most residues in the region of the protein structure that is destabilized by the mutation. Instead, the binding of the antibody fragment achieves its effect by restoring the structural cooperativity characteristic of the wild-type protein. This appears to occur at least in part through the transmission of long-range conformational effects to the interface between the two structural domains of the protein. Thus, reducing the ability of an amyloidogenic protein to form partly unfolded species can be an effective method of preventing its aggregation, suggesting approaches to the rational design of therapeutic agents directed against protein deposition diseases.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QH, England; Free Univ Brussels, Dept Ultrastruct, B-1050 Brussels, Belgium; Inst Food Res, Norwich NR4 7UA, Norfolk, England; Univ Nottingham, Sch Life & Environm Sci, Nottingham NG7 2RD, England; Cent Vet Res Lab, Dubai, U Arab Emirates; Univ Liege, Inst Chim B6, Ctr Ingn Prot, Enzymol Lab, B-4000 Liege, Sart Tilman, Belgium	University of Cambridge; University of Oxford; Universite Libre de Bruxelles; Vrije Universiteit Brussel; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia; University of Nottingham; University of Liege	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cmd44@cam.ac.uk	Muyldermans, Serge V/C-6418-2016; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; robinson, carol/0000-0001-7829-5505; Redfield, Christina/0000-0001-7297-7708; Matagne, Andre/0000-0001-6417-6791				Aguzzi A, 2001, NAT REV NEUROSCI, V2, P745, DOI 10.1038/35094590; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Branden C., 1999, INTRO PROTEIN STRUCT; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; Dobson CM, 2003, NAT REV DRUG DISCOV, V2, P154, DOI 10.1038/nrd1013; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; McCammon MG, 2002, STRUCTURE, V10, P851, DOI 10.1016/S0969-2126(02)00771-2; Morozova-Roche LA, 2000, J STRUCT BIOL, V130, P339, DOI 10.1006/jsbi.2000.4264; Muyldermans S, 2001, J Biotechnol, V74, P277; OHKUBO T, 1991, J BIOCHEM-TOKYO, V110, P1022, DOI 10.1093/oxfordjournals.jbchem.a123672; Pepys MB, 2002, NATURE, V417, P254, DOI 10.1038/417254a; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Spencer A, 1999, PROTEIN EXPRES PURIF, V16, P171, DOI 10.1006/prep.1999.1036; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; Valleix S, 2002, KIDNEY INT, V61, P907, DOI 10.1046/j.1523-1755.2002.00205.x; White AR, 2003, NATURE, V422, P80, DOI 10.1038/nature01457; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Yazaki M, 2003, KIDNEY INT, V63, P1652, DOI 10.1046/j.1523-1755.2003.00904.x	30	202	293	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					783	788		10.1038/nature01870	http://dx.doi.org/10.1038/nature01870			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917687	Green Published			2022-12-28	WOS:000184733900042
J	Kovalenko, A; Chable-Bessia, C; Cantarella, G; Israel, A; Wallach, D; Courtois, G				Kovalenko, A; Chable-Bessia, C; Cantarella, G; Israel, A; Wallach, D; Courtois, G			The tumour suppressor CYLD negatively regulates NF-kappa B signalling by deubiquitination	NATURE			English	Article							KINASE COMPLEX; INTERFERING RNAS; ACTIVATION; IKK; PATHWAYS; ENZYMES; SYSTEM; GAMMA; TRAF2; GENE	NF-kappaB transcription factors have key roles in inflammation, immune response, oncogenesis and protection against apoptosis (1,2). In most cells, these factors are kept inactive in the cytoplasm through association with IkappaB inhibitors. After stimulation by various reagents, IkappaB is phosphorylated by the IkappaB kinase (IKK) complex(3) and degraded by the proteasome, allowing NF-kappaB to translocate to the nucleus and activate its target genes. Here we report that CYLD, a tumour suppressor that is mutated in familial cylindromatosis(4), interacts with NEMO, the regulatory subunit of IKK5,6. CYLD also interacts directly with tumour-necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), an adaptor molecule involved in signalling by members of the family of TNF/ nerve growth factor receptors. CYLD has deubiquitinating activity that is directed towards non-K48-linked polyubiquitin chains, and negatively modulates TRAF-mediated activation of IKK, strengthening the notion that ubiquitination is involved in IKK activation by TRAFs and suggesting that CYLD functions in this process. Truncations of CYLD found in cylindromatosis result in reduced enzymatic activity, indicating a link between impaired deubiquitination of CYLD substrates and human pathophysiology.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Inst Pasteur, CNRS, URA 2582, Unite Biol Mol Express Gen, F-75015 Paris, France; Univ Catania, Dept Expt & Clin Pharmacol, Sch Med, I-95125 Catania, Italy	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Catania	Wallach, D (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Cantarella, Giuseppina/AHD-9609-2022	COURTOIS, Gilles/0000-0003-3117-9595				Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2	22	812	841	6	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					801	805		10.1038/nature01802	http://dx.doi.org/10.1038/nature01802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917691				2022-12-28	WOS:000184733900046
J	Cooper, DS				Cooper, DS			Hyperthyroidism	LANCET			English	Review							THYROID-STIMULATING ANTIBODY; HUMAN CHORIONIC-GONADOTROPIN; TOXIC NODULAR GOITER; GRAVES-DISEASE; ANTITHYROID DRUGS; HORMONE CONCENTRATIONS; CLINICAL-FEATURES; FOLLOW-UP; THYROTROPIN; RADIOIODINE	Hyperthyroidism is a pathological syndrome in which tissue is exposed to excessive amounts of circulating thyroid hormone. The most common cause of this syndrome is Graves' disease, followed by toxic multinodular goltre, and solitary hyperfunctioning nodules. Autoimmune postpartum and subacute thyroiditis, tumours, that secrete thyrotropin, and drug-induced thyroid dysfunction, are also important causes. The diagnosis of hyperthyroidism is generally straightforward, with raised serum thyroid hormones and suppressed serum thyrotropin in almost all cases. Appropriate treatment of hyperthyroidism relies on identification of the underlying cause. Antithyroid drugs, radioactive iodine, and surgery are the traditional treatments for the three common forms of hyperthyroidism. beta-adrenergic blocking agents are used in most patients for symptomatic relief, and might be the only treatment needed for thyroiditis, which is transient. The more unusual causes of hyperthyroidism, including struma ovarii, thyrotropin-secreting tumours, choriocarcinoma, and amiodarone-induced thyrotoxicosis are, more often than not, a challenge to diagnose and treat.	Johns Hopkins Univ, Sch Med, Sinai Hosp, Div Endocrinol, Baltimore, MD 21215 USA	Johns Hopkins University; Sinai Hospital of Baltimore	Cooper, DS (corresponding author), Johns Hopkins Univ, Sch Med, Sinai Hosp, Div Endocrinol, Baltimore, MD 21215 USA.	dcooper@lifebridgehealth.org						Allahabadia A, 2001, J CLIN ENDOCR METAB, V86, P3611, DOI 10.1210/jc.86.8.3611; Alsanea O, 2000, ENDOCRIN METAB CLIN, V29, P321, DOI 10.1016/S0889-8529(05)70134-1; Amino N, 1999, THYROID, V9, P705, DOI 10.1089/thy.1999.9.705; ARAB DM, 1995, J CLIN ENDOCR METAB, V80, P1083, DOI 10.1210/jc.80.4.1083; ASTWOOD EB, 1945, HARVEY LECT, V40, P195; BAEZA A, 1991, CLIN ENDOCRINOL, V35, P439, DOI 10.1111/j.1365-2265.1991.tb03562.x; Bahn RS, 2002, THYROID, V12, P193, DOI 10.1089/105072502753600124; Bartalena L, 1996, J CLIN ENDOCR METAB, V81, P2930, DOI 10.1210/jc.81.8.2930; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; Benker G, 1998, CLIN ENDOCRINOL, V49, P451, DOI 10.1046/j.1365-2265.1998.00554.x; Bogazzi F, 1999, J CLIN ENDOCR METAB, V84, P499, DOI 10.1210/jc.84.2.499; BURCH HB, 1993, ENDOCRIN METAB CLIN, V22, P263, DOI 10.1016/S0889-8529(18)30165-8; Burch HB, 1998, THYROID, V8, P871, DOI 10.1089/thy.1998.8.871; BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; Burman KD, 2001, CLIN G MED MANAG, P33; CARLSON HE, 1980, NEW ENGL J MED, V303, P795, DOI 10.1056/NEJM198010023031405; CHEN JJS, 1986, J CLIN ENDOCR METAB, V63, P102; COBLER JL, 1984, ARCH INTERN MED, V144, P1758, DOI 10.1001/archinte.144.9.1758; Cooper DS, 1998, ENDOCRIN METAB CLIN, V27, P225, DOI 10.1016/S0889-8529(05)70308-X; Cooper DS, 1999, ENDOCRINOLOGIST, V9, P457, DOI 10.1097/00019616-199911000-00008; Da Silva MRD, 2002, J CLIN ENDOCR METAB, V87, P4881, DOI 10.1210/jc.2002-020698; Daniels GH, 2001, J CLIN ENDOCR METAB, V86, P3, DOI 10.1210/jc.86.1.3; DAVIS LE, 1989, AM J OBSTET GYNECOL, V160, P63, DOI 10.1016/0002-9378(89)90088-4; Di Matola T, 2000, J CLIN ENDOCR METAB, V85, P4323, DOI 10.1210/jc.85.11.4323; DIAVCITRIN O, 2000, TERTAOLOGY, V65, P38; FIGGE J, 1994, AM J MED, V96, P229, DOI 10.1016/0002-9343(94)90147-3; GEFFNER DL, 1992, AM J MED, V93, P61, DOI 10.1016/0002-9343(92)90681-Z; GLINOER D, 1993, J ENDOCRINOL INVEST, V16, P881, DOI 10.1007/BF03348950; GOODWIN TM, 1992, J CLIN ENDOCR METAB, V75, P1333, DOI 10.1210/jc.75.5.1333; GREENWOOD RM, 1985, CLIN ENDOCRINOL, V22, P583, DOI 10.1111/j.1365-2265.1985.tb02993.x; Gunton JE, 2000, EUR J ENDOCRINOL, V142, P587, DOI 10.1530/eje.0.1420587; HAMBURGER JI, 1975, AM J MED, V58, P740, DOI 10.1016/0002-9343(75)90630-0; HARRIS B, 1992, BMJ-BRIT MED J, V305, P152, DOI 10.1136/bmj.305.6846.152; HEDLEY AJ, 1989, CLIN ENDOCRINOL, V31, P209, DOI 10.1111/j.1365-2265.1989.tb01244.x; Hershman JM, 1999, THYROID, V9, P653, DOI 10.1089/thy.1999.9.653; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Homsanit M, 2001, CLIN ENDOCRINOL, V54, P385, DOI 10.1046/j.1365-2265.2001.01239.x; Imseis RE, 1998, J CLIN ENDOCR METAB, V83, P685, DOI 10.1210/jc.83.2.685; Koga M, 1999, J CLIN ENDOCR METAB, V84, P2221, DOI 10.1210/jc.84.6.2221; Krassas GE, 2000, FERTIL STERIL, V74, P1063, DOI 10.1016/S0015-0282(00)01589-2; Lahey FH, 1931, NEW ENGL J MED, V204, P747, DOI 10.1056/NEJM193104092041501; Laurberg P, 2001, THYROID, V11, P457, DOI 10.1089/105072501300176417; Ljunggren JG, 1998, THYROID, V8, P653, DOI 10.1089/thy.1998.8.653; Mandel SR, 2001, J CLIN ENDOCR METAB, V86, P2354, DOI 10.1210/jc.86.6.2354; Masiukiewicz US, 1999, THYROID, V9, P647, DOI 10.1089/thy.1999.9.647; Masschalck B., 2000, Innovative Food Science and Emerging Technologies, V1, P39, DOI 10.1016/S1466-8564(99)00006-5; Matos-Santos A, 2001, CLIN ENDOCRINOL, V55, P15, DOI 10.1046/j.1365-2265.2001.01332.x; Maugendre D, 1999, CLIN ENDOCRINOL, V50, P127, DOI 10.1046/j.1365-2265.1999.00629.x; McIver B, 1996, NEW ENGL J MED, V334, P220, DOI 10.1056/NEJM199601253340403; Michelangeli V, 1998, THYROID, V8, P119, DOI 10.1089/thy.1998.8.119; Mitsiades N, 2001, TRENDS ENDOCRIN MET, V12, P384, DOI 10.1016/S1043-2760(01)00441-6; Momotani N, 1997, J CLIN ENDOCR METAB, V82, P3633, DOI 10.1210/jc.82.11.3633; NAGAI K, 1991, HORM RES, V35, P185, DOI 10.1159/000181900; NICHOLAS WC, 1995, SOUTH MED J, V88, P973, DOI 10.1097/00007611-199509000-00018; Nieuwlaat WA, 2001, J CLIN ENDOCR METAB, V86, P5330, DOI 10.1210/jc.86.11.5330; Page SR, 1996, CLIN ENDOCRINOL, V45, P511, DOI 10.1046/j.1365-2265.1996.00800.x; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; Rodien P, 1998, NEW ENGL J MED, V339, P1823, DOI 10.1056/NEJM199812173392505; Ron E, 1998, JAMA-J AM MED ASSOC, V280, P347, DOI 10.1001/jama.280.4.347; RONNOVJE.V, 1973, BMJ-BRIT MED J, V1, P41, DOI 10.1136/bmj.1.5844.41; Roti E, 2001, THYROID, V11, P493, DOI 10.1089/105072501300176453; Safer JD, 1999, J CLIN ENDOCR METAB, V84, P3099, DOI 10.1210/jc.84.9.3099; Sanno N, 2001, J NEURO-ONCOL, V54, P179, DOI 10.1023/A:1012917701756; SCHLEUSENER H, 1989, ACTA ENDOCRINOL-COP, V120, P689, DOI 10.1530/acta.0.1200689; Schwartz KM, 2002, J CLIN ENDOCR METAB, V87, P438, DOI 10.1210/jc.87.2.438; Shimizu T, 2002, THYROID, V12, P489, DOI 10.1089/105072502760143863; Siegel RD, 1998, ENDOCRIN METAB CLIN, V27, P151, DOI 10.1016/S0889-8529(05)70304-2; SOLOMON B, 1990, J CLIN ENDOCR METAB, V70, P1518, DOI 10.1210/jcem-70-6-1518; Sosa JA, 1998, ANN SURG, V228, P320, DOI 10.1097/00000658-199809000-00005; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; TAJIRI J, 1990, ARCH INTERN MED, V150, P621, DOI 10.1001/archinte.150.3.621; Tajiri J, 1997, THYROID, V7, P575, DOI 10.1089/thy.1997.7.575; TAKAMATSU J, 1984, ANN INTERN MED, V100, P372, DOI 10.7326/0003-4819-100-3-372; TAMAGNA EI, 1979, J NUCL MED, V20, P387; TENG CS, 1980, J CLIN ENDOCR METAB, V50, P144, DOI 10.1210/jcem-50-1-144; Tonacchera M, 2000, J CLIN ENDOCR METAB, V85, P2270, DOI 10.1210/jc.85.6.2270; Torring O, 1996, J CLIN ENDOCR METAB, V81, P2986, DOI 10.1210/jc.81.8.2986; Trivalle C, 1996, J AM GERIATR SOC, V44, P50, DOI 10.1111/j.1532-5415.1996.tb05637.x; TRZEPACZ PT, 1989, AM J MED, V87, P558; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; Vanhoenacker FM, 2001, EUR RADIOL, V11, P1058, DOI 10.1007/s003300000735; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577; Vestergaard P, 2002, THYROID, V12, P69, DOI 10.1089/105072502753451995; Vitti P, 1997, THYROID, V7, P369, DOI 10.1089/thy.1997.7.369; VOLPE R, 1993, THYROID, V3, P253, DOI 10.1089/thy.1993.3.253; Wartofsky L, 1991, Thyroid, V1, P129, DOI 10.1089/thy.1991.1.129; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707; WEHMANN RE, 1985, NEW ENGL J MED, V312, P546, DOI 10.1056/NEJM198502283120904; Wiersinga WM, 2001, J CLIN ENDOCR METAB, V86, P501, DOI 10.1210/jc.86.2.501; Williams KV, 1997, J CLIN ENDOCR METAB, V82, P1727, DOI 10.1210/jc.82.6.1727; WING DA, 1994, AM J OBSTET GYNECOL, V170, P90; Wong V, 2002, CLIN ENDOCRINOL, V56, P793, DOI 10.1046/j.1365-2265.2002.01553.x; YOUNG ET, 1988, Q J MED, V66, P175; ZAKARIJA M, 1983, J CLIN ENDOCR METAB, V57, P1036, DOI 10.1210/jcem-57-5-1036; Zimmermann-Belsing T, 2002, EUR J ENDOCRINOL, V146, P173, DOI 10.1530/eje.0.1460173; Zingrillo M, 2000, THYROID, V10, P985, DOI 10.1089/thy.2000.10.985	97	309	339	1	55	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					459	468		10.1016/S0140-6736(03)14073-1	http://dx.doi.org/10.1016/S0140-6736(03)14073-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927435				2022-12-28	WOS:000184651100023
J	Lagro-Janssen, T; Rosser, WW; van Wee, C				Lagro-Janssen, T; Rosser, WW; van Wee, C			Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces	LANCET			English	Editorial Material							HEALTHY POSTMENOPAUSAL WOMEN; ESTROGEN PLUS PROGESTIN; TRIAL; RISK		Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands; Queens Univ, Dept Family Med, Kingston, ON, Canada	Radboud University Nijmegen; Queens University - Canada	van Wee, C (corresponding author), Univ Med Ctr Nijmegen, Dept Gen Practice, NL-6500 HB Nijmegen, Netherlands.		Lagro, A.L.M./H-8066-2014; van Weel, Chris/D-4375-2009	van Weel, Chris/0000-0003-3653-4701				[Anonymous], 2003, LANCET, V361, P977; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; *DUTCH COLL GEN PR, 2003, PRACT GUID NHG PRACT; Gapstur SM, 1999, JAMA-J AM MED ASSOC, V281, P2091, DOI 10.1001/jama.281.22.2091; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sackett DL, 2002, CAN MED ASSOC J, V167, P363; van Weel C, 1999, LANCET, V353, P916, DOI 10.1016/S0140-6736(98)08024-6; VANWEEL C, IN PRESS ANN FAMILY; Wilson RA, 1966, FEMININE FOREVER	12	33	33	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					414	415		10.1016/S0140-6736(03)14095-0	http://dx.doi.org/10.1016/S0140-6736(03)14095-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927422				2022-12-28	WOS:000184651100002
J	Herbig, J; Kraemer, T; Mark, M; Weber, T; Chin, C; Nagerl, HC; Grimm, R				Herbig, J; Kraemer, T; Mark, M; Weber, T; Chin, C; Nagerl, HC; Grimm, R			Preparation of a pure molecular quantum gas	SCIENCE			English	Article							BOSE-EINSTEIN CONDENSATE; FESHBACH RESONANCES; NOBEL LECTURE; ATOMS; SCATTERING; CESIUM	An ultracold molecular quantum gas is created by application of a magnetic field sweep across a Feshbach resonance to a Bose-Einstein condensate of cesium atoms. The ability to separate the molecules from the atoms permits direct imaging of the pure molecular sample. Magnetic levitation enables study of the dynamics of the ensemble on extended time scales. We measured ultralow expansion energies in the range of a few nanokelvin for a sample of 3000 molecules. Our observations are consistent with the presence of a macroscopic molecular matter wave.	Univ Innsbruck, Inst Expt Phys, A-6020 Innsbruck, Austria	University of Innsbruck	Grimm, R (corresponding author), Univ Innsbruck, Inst Expt Phys, Technikerstr 25, A-6020 Innsbruck, Austria.	rudolf.grimm@uibk.ac.at	Grimm, Rudolf/D-2864-2009; Naegerl, Hanns-Christoph/E-7329-2010	Grimm, Rudolf/0000-0003-1085-5558; Naegerl, Hanns-Christoph/0000-0002-7789-4431; Herbig, Jens/0000-0003-1251-8029				Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Bethlem HL, 2000, NATURE, V406, P491, DOI 10.1038/35020030; Chin C, 2000, PHYS REV LETT, V85, P2717, DOI 10.1103/PhysRevLett.85.2717; Chin C, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.033201; Cornell EA, 2002, REV MOD PHYS, V74, P875, DOI 10.1142/S0217979202014681; Donley EA, 2002, NATURE, V417, P529, DOI 10.1038/417529a; Goral K, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.170406; Heinzen DJ, 2000, PHYS REV LETT, V84, P5029, DOI 10.1103/PhysRevLett.84.5029; Inouye S, 1998, NATURE, V392, P151, DOI 10.1038/32354; Jaksch D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.040402; JULIENNE PS, 2003, COMMUNICATION; Ketterle W, 2002, REV MOD PHYS, V74, P1131, DOI [10.1103/RevModPhys.74.1131, 10.1142/S0217979202014668]; Leo PJ, 2000, PHYS REV LETT, V85, P2721, DOI 10.1103/PhysRevLett.85.2721; Mies FH, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.022721; Regal CA, 2003, NATURE, V424, P47, DOI 10.1038/nature01738; SALOMON C, 2003, QUANT EL LAS SCI C B; Timmermans E, 1999, PHYS REP, V315, P199, DOI 10.1016/S0370-1573(99)00025-3; van Abeelen FA, 1999, PHYS REV LETT, V83, P1550, DOI 10.1103/PhysRevLett.83.1550; Vanhaecke N, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.063001; Vuletic V, 1999, PHYS REV LETT, V83, P943, DOI 10.1103/PhysRevLett.83.943; Weber T, 2003, SCIENCE, V299, P232, DOI 10.1126/science.1079699; WEBER T, IN PRESS PHYS REV LE; Weinstein JD, 1998, NATURE, V395, P148, DOI 10.1038/25949; Wynar R, 2000, SCIENCE, V287, P1016, DOI 10.1126/science.287.5455.1016; Yurovsky VA, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.043605; 2002, NATURE, V416, P205	27	341	346	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 12	2003	301	5639					1510	1513		10.1126/science.1088876	http://dx.doi.org/10.1126/science.1088876			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12934014				2022-12-28	WOS:000185255300042
J	Car, J; Sheikh, A				Car, J; Sheikh, A			10-minute consultation - Acute low back pain	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London SW7 2AZ, England; Univ Edinburgh, Div Commun Hlth Serv, GP Sect, Edinburgh EH10 5PF, Midlothian, Scotland	Imperial College London; University of Edinburgh	Car, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Hlth Care & Gen Practice, London SW7 2AZ, England.		Car, Josip/H-6755-2015	Car, Josip/0000-0001-8969-371X; Sheikh, Aziz/0000-0001-7022-3056					0	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					541	541		10.1136/bmj.327.7414.541	http://dx.doi.org/10.1136/bmj.327.7414.541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958115	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000185283700020
J	Kile, BT; Hentges, KE; Clark, AT; Nakamura, H; Salinger, AP; Liu, B; Box, N; Stockton, DW; Johnson, RL; Behringer, RR; Bradley, A; Justice, MJ				Kile, BT; Hentges, KE; Clark, AT; Nakamura, H; Salinger, AP; Liu, B; Box, N; Stockton, DW; Johnson, RL; Behringer, RR; Bradley, A; Justice, MJ			Functional genetic analysis of mouse chromosome 11	NATURE			English	Article							RENAL TUBULAR-ACIDOSIS; ETHYL-N-NITROSOUREA; TARGETED DISRUPTION; MEMBRANE SKELETON; MOUSE; MUTATIONS; BAND-3; MUTAGENESIS; GENOME; MICE	Now that the mouse and human genome sequences are complete, biologists need systematic approaches to determine the function of each gene(1,2). A powerful way to discover gene function is to determine the consequence of mutations in living organisms. Large-scale production of mouse mutations with the point mutagen N-ethyl-N-nitrosourea (ENU) is a key strategy for analysing the human genome because mouse mutants will reveal functions unique to mammals, and many may model human diseases(3). To examine genes conserved between human and mouse, we performed a recessive ENU mutagenesis screen that uses a balancer chromosome, inversion chromosome 11 (refs 4, 5). Initially identified in the fruitfly, balancer chromosomes are valuable genetic tools that allow the easy isolation of mutations on selected chromosomes(6). Here we show the isolation of 230 new recessive mouse mutations, 88 of which are on chromosome 11. This genetic strategy efficiently generates and maps mutations on a single chromosome, even as mutations throughout the genome are discovered. The mutations reveal new defects in haematopoiesis, craniofacial and cardiovascular development, and fertility.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Justice, MJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	mjustice@bcm.tmc.edu	Kile, Benjamin/GNP-3246-2022; Kile, Benjamin T/F-6593-2011; Box, Neil/F-3591-2010	Kile, Benjamin/0000-0002-8836-8947; Kile, Benjamin T/0000-0002-8836-8947; Box, Neil/0000-0002-3486-0346; Bradley, Allan/0000-0002-2349-8839; Hentges, Kathryn/0000-0001-8917-3765; Liu, Bin/0000-0002-9113-9694				Barrow JR, 1996, DEVELOPMENT, V122, P3817; BEHRINGER RR, 2003, BIOMEDNET; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Conway SJ, 2003, GENESIS, V35, P1, DOI 10.1002/gene.10152; Hentges K, 1999, DEVELOPMENT, V126, P1601; Herron BJ, 2002, NAT GENET, V30, P185, DOI 10.1038/ng812; HITOTSUMACHI S, 1985, P NATL ACAD SCI USA, V82, P6619, DOI 10.1073/pnas.82.19.6619; JAROLIM P, 1995, BLOOD, V85, P634, DOI 10.1182/blood.V85.3.634.bloodjournal853634; JUSTICE MJ, 1999, GENETICS TRANSGENICS, P185; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Karet FE, 1998, P NATL ACAD SCI USA, V95, P6337, DOI 10.1073/pnas.95.11.6337; Kasarskis A, 1998, P NATL ACAD SCI USA, V95, P7485, DOI 10.1073/pnas.95.13.7485; Kile BT, 2003, MAMM GENOME, V14, P81, DOI 10.1007/s00335-002-2160-0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Muller HJ, 1918, GENETICS, V3, P422; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Noveroske JK, 2002, GENESIS, V32, P218, DOI 10.1002/gene.10060; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; Probst FJ, 1998, SCIENCE, V280, P1444, DOI 10.1126/science.280.5368.1444; Rinchik EM, 1999, GENETICS, V152, P373; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHEDLOVSKY A, 1988, P NATL ACAD SCI USA, V85, P180, DOI 10.1073/pnas.85.1.180; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949	30	159	162	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					81	86		10.1038/nature01865	http://dx.doi.org/10.1038/nature01865			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955145				2022-12-28	WOS:000185089200042
J	Brotherton, SE; Rockey, PH; Etzel, SI				Brotherton, SE; Rockey, PH; Etzel, SI			US graduate medical education, 2002-2003	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context By selecting a specialty to train in, physicians entering graduate medical education (GME) training provide advance information about the future physician workforce. Objective To determine trends in the residency choices of medical school graduates entering GME training. Design, Setting, and Participants The American Medical Association and Association of American Medical Colleges jointly surveyed active programs as well as combined programs in academic year 2002-2003 about active, transferred, and graduated residents. In 2002 the survey was sent to 8064 program directors; 84.2% of them confirmed the status of all active residents and 82.6% completed the program survey. Main Outcome Measures In addition to overall trends, the specialty choices of graduates of osteopathic schools (DOs) and international medical graduates (IMGs). Also, where native US citizen resident physicians attended medical school if not in the United States, with a focus on Hispanic ethnicity and Spanish-language facility. Results The census counted 98258 resident physicians in GME programs in academic year 2002-2003, similar to 5 years ago and reversing a decline over the past few years. There were 23 443 residents in graduate year 1 (GY1) positions, for which prior GME training is not required, a slight increase from 2001-2002. The proportion of GY1 residents without prior GME increased slightly compared with 2001-2002 (92.3% to 93.3%). In 1996-1997, 624 DOS were GY1 residents without prior GME (2.9%); their numbers increased to 1312 (6.0%) in 2002-2003. The number of IMGs in GY1 positions without prior GME also increased over this period, from 5033 (23.5%) to 5623 (25.7%). Over the past 6 years the number of IMG and DO GY1 residents without prior GME in specialties such as general surgery, obstetrics and gynecology, and emergency medicine has increased disproportionately faster than the overall rate. Hispanic native US citizens are more likely to be IMGs than non-Hispanic native US citizens (9.6% vs 5.0%). One third of Hispanic native US citizen IMGs received their medical education in Spanish vs less than 3% of non-Hispanic native US citizen IMGs. Conclusions Nearly 25% of physicians in US allopathic training programs in 20022003 were IMGs, and the percentage of DOS continues to increase. The number of residents conversant in Spanish could serve a need for a large US minority population.	Amer Med Assoc, Div Grad Med Educ, Chicago, IL 60610 USA	American Medical Association	Brotherton, SE (corresponding author), Amer Med Assoc, Div Grad Med Educ, 515 N State St, Chicago, IL 60610 USA.							*AM MED ASS, 2003, GRAD MED ED DIR; *ASS AM MED COLL, 2003, SUPR COURT RUL SUPP; Brotherton SE, 2002, JAMA-J AM MED ASSOC, V288, P1073, DOI 10.1001/jama.288.9.1073; Cummings M, 2003, ACAD MED, V78, P22, DOI 10.1097/00001888-200301000-00006; HOBBS F, 2002, CENSUS 2000 SPECIAL; National Resident Matching Program, 2002, RES DAT 2002 MATCH; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; *NRMP, 1997, NRMP DAT; Obradovic Joyce L, 2002, J Am Osteopath Assoc, V102, P582; Sweet Susan, 2002, J Am Osteopath Assoc, V102, P576; *US CENS BUR, 2000, AB SPEAK ENGL 2000; Whelan GP, 2002, JAMA-J AM MED ASSOC, V288, P1079, DOI 10.1001/jama.288.9.1079; 1997, JAMA, V278, P775; 2002, J AM OSTEOPATH ASS, V102, P613	14	29	30	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1197	1202		10.1001/jama.290.9.1197	http://dx.doi.org/10.1001/jama.290.9.1197			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953003				2022-12-28	WOS:000185090400016
J	Smits, G; Olatunbosun, O; Delbaere, A; Pierson, R; Vassart, G; Costagliola, S				Smits, G; Olatunbosun, O; Delbaere, A; Pierson, R; Vassart, G; Costagliola, S			Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SYNDROME OHSS; PREGNANCY; PATHOPHYSIOLOGY; PURIFICATION; ACTIVATION; PHYSIOLOGY; AGONIST; DOMAIN		Free Univ Brussels, Fac Med, IRIBHM, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Serv Genet Med, B-1070 Brussels, Belgium; Free Univ Brussels, Hop Erasme, Fertil Clin, B-1070 Brussels, Belgium; Univ Saskatchewan, Coll Med, Dept Obstet Gynecol & Reprod Sci, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Coll Med, Reprod Biol Res Unit, Saskatoon, SK S7N 0W0, Canada	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Saskatchewan; University of Saskatchewan	Vassart, G (corresponding author), Free Univ Brussels, Fac Med, IRIBHM, 808 Rte Lennik, B-1070 Brussels, Belgium.		costagliola, sabine/D-4864-2012; Pierson, Roger/A-4395-2008	Smits, Guillaume/0000-0003-2845-6758; Pierson, Roger/0000-0003-4435-0515				Cornelis S, 2001, BIOCHEMISTRY-US, V40, P9860, DOI 10.1021/bi0107389; Costagliola S, 1998, J IMMUNOL, V160, P1458; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Delbaere A, 1997, FERTIL STERIL, V67, P1038, DOI 10.1016/S0015-0282(97)81436-7; Delvigne A, 2002, HUM REPROD UPDATE, V8, P559, DOI 10.1093/humupd/8.6.559; Elchalal U, 1997, HUM REPROD, V12, P1129; Furneaux EC, 2001, OBSTET GYNECOL SURV, V56, P775, DOI 10.1097/00006254-200112000-00004; Glinoer D, 1997, ENDOCR REV, V18, P404, DOI 10.1210/er.18.3.404; Golan A, 1989, Obstet Gynecol Surv, V44, P430, DOI 10.1097/00006254-198906000-00004; Gromoll J, 1996, J CLIN ENDOCR METAB, V81, P1367, DOI 10.1210/jc.81.4.1367; Gromoll J, 2000, METHODS, V21, P83, DOI 10.1006/meth.2000.0977; Levin ER, 1998, J CLIN INVEST, V102, P1978, DOI 10.1172/JCI4814; Ludwig M, 1998, HUM REPROD, V13, P2082, DOI 10.1093/humrep/13.8.2082; Mathur RS, 2000, FERTIL STERIL, V73, P901, DOI 10.1016/S0015-0282(00)00492-1; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Olatunbosun O. A., 1996, Clinical and Experimental Obstetrics and Gynecology, V23, P127; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Remy JJ, 2001, J BIOL CHEM, V276, P1681, DOI 10.1074/jbc.M005206200; Rodien P, 1998, NEW ENGL J MED, V339, P1823, DOI 10.1056/NEJM199812173392505; Schmidt A, 2001, J BIOL CHEM, V276, P23373, DOI 10.1074/jbc.M100057200; Schubert RL, 2003, ENDOCRINOLOGY, V144, P129, DOI 10.1210/en.2002-220829; Shenker A, 2002, RECEPTOR CHANNEL, V8, P3, DOI 10.1080/10606820290004958; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; WAJDA KJ, 1989, ARCH PATHOL LAB MED, V113, P921	25	174	186	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					760	766		10.1056/NEJMoa030064	http://dx.doi.org/10.1056/NEJMoa030064			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930928				2022-12-28	WOS:000184843300006
J	Howitz, KT; Bitterman, KJ; Cohen, HY; Lamming, DW; Lavu, S; Wood, JG; Zipkin, RE; Chung, P; Kisielewski, A; Zhang, LL; Scherer, B; Sinclair, DA				Howitz, KT; Bitterman, KJ; Cohen, HY; Lamming, DW; Lavu, S; Wood, JG; Zipkin, RE; Chung, P; Kisielewski, A; Zhang, LL; Scherer, B; Sinclair, DA			Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan	NATURE			English	Article							CALORIE RESTRICTION; TRANS-RESVERATROL; PROTEIN SIR2; YEAST SIR2; NAD; LONGEVITY; P53; DEACETYLASES; NICOTINAMIDE; INHIBITION	In diverse organisms, calorie restriction slows the pace of ageing and increases maximum lifespan. In the budding yeast Saccharomyces cerevisiae, calorie restriction extends lifespan by increasing the activity of Sir2 (ref. 1), a member of the conserved sirtuin family of NAD(+)-dependent protein deacetylases(2-6). Included in this family are SIR-2.1, a Caenorhabditis elegans enzyme that regulates lifespan(7), and SIRT1, a human deacetylase that promotes cell survival by negatively regulating the p53 tumour suppressor(8-10). Here we report the discovery of three classes of small molecules that activate sirtuins. We show that the potent activator resveratrol, a polyphenol found in red wine, lowers the Michaelis constant of SIRT1 for both the acetylated substrate and NAD(+), and increases cell survival by stimulating SIRT1-dependent deacetylation of p53. In yeast, resveratrol mimics calorie restriction by stimulating Sir2, increasing DNA stability and extending lifespan by 70%. We discuss possible evolutionary origins of this phenomenon and suggest new lines of research into the therapeutic use of sirtuin activators.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Lamming, Dudley/O-7191-2015	Lamming, Dudley/0000-0002-0079-4467; Sinclair, David/0000-0002-9936-436X; Cohen, Haim Y./0000-0002-6613-8710	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG027916, R01AG019719, R37AG028730, R13AG033466, R01AG019972, R01AG028730] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG019972, R01 AG028730, R13 AG033466, P01 AG027916, R37 AG028730, R01 AG019719] Funding Source: Medline; NIGMS NIH HHS [R01 GM068072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dong ZG, 2003, MUTAT RES-FUND MOL M, V523, P145, DOI 10.1016/S0027-5107(02)00330-5; Ferguson LR, 2001, MUTAT RES-FUND MOL M, V475, P89, DOI 10.1016/S0027-5107(01)00073-2; GLOSSMANN H, 1981, N-S ARCH PHARMACOL, V317, P100, DOI 10.1007/BF00506266; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jazwinski SM, 2000, ANN NY ACAD SCI, V908, P21; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Middleton E, 2000, PHARMACOL REV, V52, P673; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Pandey R, 2002, NUCLEIC ACIDS RES, V30, P5036, DOI 10.1093/nar/gkf660; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Stojanovic S, 2001, ARCH BIOCHEM BIOPHYS, V391, P79, DOI 10.1006/abbi.2001.2388; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X	30	2893	3078	17	505	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 11	2003	425	6954					191	196		10.1038/nature01960	http://dx.doi.org/10.1038/nature01960			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	719ZT	12939617				2022-12-28	WOS:000185236000046
J	Fujii, N; Graybiel, AM				Fujii, N; Graybiel, AM			Representation of action sequence boundaries by macaque prefrontal cortical neurons	SCIENCE			English	Article							BASAL GANGLIA; CORTEX; MOVEMENTS; SACCADES; MODEL	Complex biological systems such as human language and the genetic code are characterized by explicit markers at the beginning and end of functional sequences. We report here that macaque prefrontal cortical neurons exhibit phasic peaks of spike activity that occur at the beginning and endpoint of sequential oculomotor saccade performance and have the properties of dynamic start- and end-state encoders accompanying responses to sequential actions. Sequence bounding may thus reflect a general mechanism for encoding biological information.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, 45 Carleton St,E25-618, Cambridge, MA 02139 USA.			Graybiel, Ann/0000-0002-4326-7720	NATIONAL EYE INSTITUTE [R01EY012848] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY012848, EY12848] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Averbeck BB, 2002, P NATL ACAD SCI USA, V99, P13172, DOI 10.1073/pnas.162485599; Bair W, 2002, J NEUROSCI, V22, P3189, DOI 10.1523/JNEUROSCI.22-08-03189.2002; Beiser DG, 1998, J NEUROPHYSIOL, V79, P3168, DOI 10.1152/jn.1998.79.6.3168; Bor D, 2003, NEURON, V37, P361, DOI 10.1016/S0896-6273(02)01171-6; Braitenberg V, 1997, BEHAV BRAIN SCI, V20, P229, DOI 10.1017/S0140525X9700143X; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Curran T., 1995, PSYCHE, V2, P12; Dehaene S, 1997, P NATL ACAD SCI USA, V94, P13293, DOI 10.1073/pnas.94.24.13293; Dreher JC, 2002, EUR J NEUROSCI, V16, P1609, DOI 10.1046/j.1460-9568.2002.02212.x; Duffy CJ, 1997, EXP BRAIN RES, V114, P472, DOI 10.1007/PL00005656; FUJII N, 2001, SOC NEUR ABSTR, V27; Fuster J. M., 1999, MEMORY CEREBRAL CORT; Grafton ST, 1998, J NEUROSCI, V18, P9420; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; KROGH A, 1994, NUCLEIC ACIDS RES, V22, P4768, DOI 10.1093/nar/22.22.4768; Lashley K.S., 1951, PROBLEM SERIAL ORDER, V21; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; MAKHOUL J, 1995, P NATL ACAD SCI USA, V92, P9956, DOI 10.1073/pnas.92.22.9956; Miller EK, 2002, PHILOS T R SOC B, V357, P1123, DOI 10.1098/rstb.2002.1099; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; Schall JD, 2002, PHILOS T ROY SOC B, V357, P1073, DOI 10.1098/rstb.2002.1098; Tanji J, 2001, ANNU REV NEUROSCI, V24, P631, DOI 10.1146/annurev.neuro.24.1.631; Toni I, 1998, NEUROIMAGE, V8, P50, DOI 10.1006/nimg.1998.0349; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0; Zacks JM, 2001, NAT NEUROSCI, V4, P651, DOI 10.1038/88486	27	133	135	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1246	1249		10.1126/science.1086872	http://dx.doi.org/10.1126/science.1086872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947203				2022-12-28	WOS:000185003500046
J	Eisen, HJ; Tuzcu, EM; Dorent, R; Kobashigawa, J; Mancini, D; Valantine-von Kaeppler, HA; Starling, RC; Sorensen, K; Hummel, M; Lind, JM; Abeywickrama, KH; Bernhardt, P				Eisen, HJ; Tuzcu, EM; Dorent, R; Kobashigawa, J; Mancini, D; Valantine-von Kaeppler, HA; Starling, RC; Sorensen, K; Hummel, M; Lind, JM; Abeywickrama, KH; Bernhardt, P		RAD B253 Study Grp	Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SDZ RAD; INTRAVASCULAR ULTRASOUND; MYCOPHENOLATE-MOFETIL; RAPAMYCIN; DISEASE; PROGRESSION; CYCLOSPORINE; ANGIOGRAPHY; SIROLIMUS; DONOR	BACKGROUND: Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus with azathioprine in recipients of a first heart transplant. METHODS: A total of 634 patients were randomly assigned to receive 1.5 mg of everolimus per day (209 patients), 3.0 mg of everolimus per day (211 patients), or 1.0 to 3.0 mg of azathioprine per kilogram of body weight per day (214 patients), in combination with cyclosporine, corticosteroids, and statins. The primary efficacy end point was a composite of death, graft loss or retransplantation, loss to follow-up, biopsy-proved acute rejection of grade 3A, or rejection with hemodynamic compromise. RESULTS: At six months, the percentage of patients who had reached the primary efficacy end point was significantly smaller in the group given 3.0 mg of everolimus (27.0 percent, P<0.001) and the group given 1.5 mg of everolimus (36.4 percent, P=0.03) than in the azathioprine group (46.7 percent). Intravascular ultrasonography showed that the average increase in maximal intimal thickness 12 months after transplantation was significantly smaller in the two everolimus groups than in the azathioprine group. The incidence of vasculopathy was also significantly lower in the 1.5-mg group (35.7 percent, P=0.045) and the 3.0-mg group (30.4 percent, P=0.01) than in the azathioprine group (52.8 percent). The rates of cytomegalovirus infection were significantly lower in the 1.5-mg group (7.7 percent, P<0.001) and the 3.0-mg group (7.6 percent, P<0.001) than in the azathioprine group (21.5 percent). Rates of bacterial infection were significantly higher in the 3.0-mg group than in the azathioprine group. Serum creatinine levels were also significantly higher in the two everolimus groups than in the azathioprine group. CONCLUSIONS: Everolimus was more efficacious than azathioprine in reducing the severity and incidence of cardiac-allograft vasculopathy, suggesting that everolimus therapy may alleviate this serious problem.	Temple Univ, Sch Med, Cardiol Sect, Philadelphia, PA 19140 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Hop La Pitie Salpetriere, Paris, France; Univ Calif Los Angeles, Los Angeles, CA USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Skejby Univ Hosp, Aarhus, Denmark; Deutsch Herzzentrum Berlin, Berlin, Germany; Novartis Pharmaceut, Summit, NJ USA; Novartis Pharmaceut, Basel, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Cleveland Clinic Foundation; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Los Angeles; Columbia University; NewYork-Presbyterian Hospital; Stanford University; Aarhus University; German Heart Center Berlin; Novartis; Novartis	Eisen, HJ (corresponding author), Temple Univ, Sch Med, Cardiol Sect, 3401 N Broad St, Philadelphia, PA 19140 USA.	eisenh@tuhs.temple.edu		Kobashigawa, Jon/0000-0001-9308-3172				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; [Anonymous], 1996, BRIT MED J, V313, P1448; Avery RK, 2001, NEW ENGL J MED, V344, P1545, DOI 10.1056/NEJM200105173442010; AZUMA H, 1994, CURR OPIN IMMUNOL, V6, P770, DOI 10.1016/0952-7915(94)90083-3; Billingham M E, 1990, J Heart Transplant, V9, P587; Costanzo MR, 1998, J HEART LUNG TRANSPL, V17, P744; COSTANZONORDIN MR, 1992, J HEART LUNG TRANSPL, V11, pS90; *EUR AG EV MED PRO, 1997, NOT GUID GOOD CLIN P; Fang JC, 1998, AM HEART J, V135, P980, DOI 10.1016/S0002-8703(98)70062-6; Fang JC, 2002, LANCET, V359, P1108, DOI 10.1016/S0140-6736(02)08154-0; GRATTAN MT, 1989, JAMA-J AM MED ASSOC, V261, P3561, DOI 10.1001/jama.261.24.3561; GREGORY CR, 1995, TRANSPLANTATION, V59, P655, DOI 10.1097/00007890-199503150-00002; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Humar A, 1999, TRANSPLANTATION, V68, P1879, DOI 10.1097/00007890-199912270-00011; Jimenez J, 2001, J HEART LUNG TRANSPL, V20, P393, DOI 10.1016/S1053-2498(00)00249-7; Julius BK, 2000, TRANSPLANTATION, V69, P847; Kahan BD, 1999, TRANSPLANTATION, V68, P1526, DOI 10.1097/00007890-199911270-00016; Kapadia SR, 1998, CIRCULATION, V98, P2672, DOI 10.1161/01.CIR.98.24.2672; Kapadia SR, 1999, CURR OPIN CARDIOL, V14, P140, DOI 10.1097/00001573-199903000-00011; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KECK BM, 1999, CLIN TRANSPL, V13, P35; KIMBALL PM, 1991, TRANSPLANTATION, V51, P486, DOI 10.1097/00007890-199102000-00041; Kobashigawa J, 1998, TRANSPLANTATION, V66, P507, DOI 10.1097/00007890-199808270-00016; Kobashigawa JA, 1998, CURR OPIN CARDIOL, V13, P117, DOI 10.1097/00001573-199803000-00008; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Liang DH, 1996, J HEART LUNG TRANSPL, V15, P980; MEHRA MR, 1995, J HEART LUNG TRANSPL, V14, P632; MEISER BM, 1991, LANCET, V338, P1297, DOI 10.1016/0140-6736(91)92594-R; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; MORRIS PJ, 1994, KIDNEY TRANSPLANTATI, P233; Neumayer HH, 1999, BRIT J CLIN PHARMACO, V48, P694; RICKENBACHER PR, 1995, CIRCULATION, V92, P3445, DOI 10.1161/01.CIR.92.12.3445; Schuler W, 1997, TRANSPLANTATION, V64, P36, DOI 10.1097/00007890-199707150-00008; Schuurman HJ, 1999, TRANSPLANT P, V31, P1024, DOI 10.1016/S0041-1345(98)01885-5; Schuurman HJ, 1997, TRANSPLANTATION, V64, P32, DOI 10.1097/00007890-199707150-00007; SEHGAL SN, 1995, THER DRUG MONIT, V17, P660, DOI 10.1097/00007691-199512000-00019; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398; Young JB, 1999, CIRCULATION, V100, P458, DOI 10.1161/01.CIR.100.5.458	38	860	884	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					847	858		10.1056/NEJMoa022171	http://dx.doi.org/10.1056/NEJMoa022171			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944570				2022-12-28	WOS:000184968400005
J	Megens, M; Aizenberg, J				Megens, M; Aizenberg, J			Like-charged particles at liquid interfaces	NATURE			English	Editorial Material							ATTRACTION		Philips Res Labs, NL-5656 AA Eindhoven, Netherlands; Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Philips; Philips Research; Alcatel-Lucent; Lucent Technologies; AT&T	Megens, M (corresponding author), Philips Res Labs, POB 80000, NL-5656 AA Eindhoven, Netherlands.							Nikolaides MG, 2002, NATURE, V420, P299, DOI 10.1038/nature01113; Stamou D, 2000, PHYS REV E, V62, P5263, DOI 10.1103/PhysRevE.62.5263	2	65	65	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1014	1014		10.1038/4241014a	http://dx.doi.org/10.1038/4241014a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944956				2022-12-28	WOS:000184984200030
J	Theobald, JA; Oxtoby, NS; Phillips, MA; Champness, NR; Beton, PH				Theobald, JA; Oxtoby, NS; Phillips, MA; Champness, NR; Beton, PH			Controlling molecular deposition and layer structure with supramolecular surface assemblies	NATURE			English	Article							SCANNING-TUNNELING-MICROSCOPY; TERMINATED SI(111); ORGANIC-MOLECULES; TRIMESIC ACID; NANOSTRUCTURES; ADSORPTION; MONOLAYER; SYSTEM; MODEL; C-60	Selective non-covalent interactions have been widely exploited in solution-based chemistry to direct the assembly of molecules into nanometre-sized functional structures such as capsules, switches and prototype machines(1-5). More recently, the concepts of supramolecular organization have also been applied to two-dimensional assemblies on surfaces(6,7) stabilized by hydrogen bonding(8-14), dipolar coupling(15-17) or metal co-ordination(18). Structures realized to date include isolated rows(8,13-15), clusters(9,10,18) and extended networks(10-12,17), as well as more complex multicomponent arrangements(16). Another approach to controlling surface structures uses adsorbed molecular monolayers to create preferential binding sites that accommodate individual target molecules(19,20). Here we combine these approaches, by using hydrogen bonding to guide the assembly of two types of molecules into a two-dimensional open honeycomb network that then controls and templates new surface phases formed by subsequently deposited fullerene molecules. We find that the open network acts as a two-dimensional array of large pores of sufficient capacity to accommodate several large guest molecules, with the network itself also serving as a template for the formation of a fullerene layer.	Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England; Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Champness, NR (corresponding author), Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England.	Neil.Champness@nottingham.ac.uk; Peter.Beton@nottingham.ac.uk	Beton, Peter/M-5303-2014; Champness, Neil/A-1342-2010	Beton, Peter/0000-0002-2120-8033; Champness, Neil/0000-0003-2970-1487; Phillips, Mick/0000-0003-3578-7301				Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Barth JV, 2000, ANGEW CHEM INT EDIT, V39, P1230, DOI 10.1002/(SICI)1521-3773(20000403)39:7<1230::AID-ANIE1230>3.0.CO;2-I; Berner S, 2001, CHEM PHYS LETT, V348, P175, DOI 10.1016/S0009-2614(01)01158-7; Bohringer M, 1999, ANGEW CHEM INT EDIT, V38, P821, DOI 10.1002/(SICI)1521-3773(19990315)38:6<821::AID-ANIE821>3.0.CO;2-A; Chen JS, 2002, J CERAM SOC JPN, V110, P18, DOI 10.2109/jcersj.110.18; Cuberes MT, 1997, SURF SCI, V371, pL231, DOI 10.1016/S0039-6028(96)01235-6; De Feyter S, 2003, CHEM SOC REV, V32, P139, DOI 10.1039/b206566p; de Wild M, 2002, CHEMPHYSCHEM, V3, P881, DOI 10.1002/1439-7641(20021018)3:10<881::AID-CPHC881>3.0.CO;2-P; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Dmitriev A, 2002, J PHYS CHEM B, V106, P6907, DOI 10.1021/jp014214u; Fujita M, 1999, NATURE, V400, P52, DOI 10.1038/21861; Furukawa M, 2000, SURF SCI, V445, P1, DOI 10.1016/S0039-6028(99)01007-9; Gimzewski JK, 1997, SURF SCI, V386, P101, DOI 10.1016/S0039-6028(97)00301-4; Griessl S, 2002, SINGLE MOL, V3, P25, DOI 10.1002/1438-5171(200204)3:1<25::AID-SIMO25>3.3.CO;2-B; Hecht S, 2003, ANGEW CHEM INT EDIT, V42, P24, DOI 10.1002/anie.200390045; KATAYAMA M, 1991, PHYS REV LETT, V66, P2762, DOI 10.1103/PhysRevLett.66.2762; Keeling DL, 2003, NANO LETT, V3, P9, DOI 10.1021/nl025821b; Lehn JM, 2002, P NATL ACAD SCI USA, V99, P4763, DOI 10.1073/pnas.072065599; Lin N, 2002, ANGEW CHEM INT EDIT, V41, P4779, DOI 10.1002/anie.200290046; Nakayama T, 1999, PHYS REV B, V59, P12627, DOI 10.1103/PhysRevB.59.12627; Paraschiv V, 2002, J AM CHEM SOC, V124, P7638, DOI 10.1021/ja012384e; Prins LJ, 2001, ANGEW CHEM INT EDIT, V40, P2382, DOI 10.1002/1521-3773(20010702)40:13<2382::AID-ANIE2382>3.0.CO;2-G; Reinhoudt DN, 2002, SCIENCE, V295, P2403, DOI 10.1126/science.1069197; Seeman NC, 2003, NATURE, V421, P427, DOI 10.1038/nature01406; TAKAHASHI T, 1991, SURF SCI, V242, P54, DOI 10.1016/0039-6028(91)90241-J; UDER B, 1995, Z PHYS B CON MAT, V97, P389, DOI 10.1007/BF01317220; Upward MD, 1999, SURF SCI, V441, P21, DOI 10.1016/S0039-6028(99)00778-5; Upward MD, 1997, PHYS REV B, V56, pR1704, DOI 10.1103/PhysRevB.56.R1704; WAN KJ, 1993, PHYS REV B, V47, P13700, DOI 10.1103/PhysRevB.47.13700; Yokoyama T, 2001, NATURE, V413, P619, DOI 10.1038/35098059	30	982	990	8	382	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1029	1031		10.1038/nature01915	http://dx.doi.org/10.1038/nature01915			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944962				2022-12-28	WOS:000184984200036
J	Spierings, E; Vermeulen, CJ; Vogt, MH; Doerner, LEE; Falkenburg, JHF; Mutis, T; Goulmy, E				Spierings, E; Vermeulen, CJ; Vogt, MH; Doerner, LEE; Falkenburg, JHF; Mutis, T; Goulmy, E			Identification of HLA class II-restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation	LANCET			English	Article							VERSUS-HOST-DISEASE; MINOR HISTOCOMPATIBILITY ANTIGENS; BONE-MARROW GRAFT; EFFECTOR MECHANISMS; DENDRITIC CELLS; GENE CODES; CD4(+) TH1; REJECTION; RECOGNITION; GENERATION	Background Stem-cell grafts between HLA-identical siblings are less likely to succeed when there is a sex mismatch. This lack of success can be interpreted as enhanced activity directed against minor histocompatibility antigens encoded by the Y chromosome (H-Y). So far, in man, only cytotoxic T lymphocytes (CTLs) specific for several minor histocompatibility antigens have been reported. We aimed to identify and clarify the role of MHC class II-restricted H-Y-specific T-helper cells in these transplant settings. Methods H-Y-specific MHC class II-restricted CD4+ T cells were isolated from blood of a female patient who rejected an HLA-identical male stem-cell transplant. By molecular cloning of H-Y genes and functional T-helper experiments, we elucidated antigen specificity and the functional properties of these H-Y-specific T-helper cells. Findings CD4+ T-helper cells recognise the Y gene-encoded peptide VIKVNDTVQI presented by HLA-DRbeta3*0301. These T-helper cells mature dendritic cells and enhance expansion of minor histocompatibility antigen-specific MHC class I-restricted CD8+ CTLs. Interpretation Characterisation of an MHC class II-restricted H-Y epitope that evoked CD4+ T-helper responses adds a novel cellular component to the alloimmune response against Y chromosome-encoded minor histocompatibility antigens. This component completes the H-Y-directed alloimmune response and aids understanding of the poorer outcome of sex-mismatched transplants.	Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Expt Haematol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Spierings, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, POB 9600, NL-2300 RC Leiden, Netherlands.		Spierings, Eric/AAU-5138-2021	Spierings, Eric/0000-0001-9441-1019				DEBUEGER M, 1992, EUR J IMMUNOL, V22, P875, DOI 10.1002/eji.1830220338; FABER LM, 1995, BLOOD, V86, P2821; GOULMY E, 1976, LANCET, V2, P1206; GOULMY E, 1977, NATURE, V266, P544, DOI 10.1038/266544a0; GOULMY E, 1979, J EXP MED, V149, P545, DOI 10.1084/jem.149.2.545; Goulmy E, 1996, CURR OPIN IMMUNOL, V8, P75, DOI 10.1016/S0952-7915(96)80108-7; Gratwohl A, 2001, Hematol J, V2, P363, DOI 10.1038/sj.thj.6200117; Lanzavecchia A, 1998, NATURE, V393, P413, DOI 10.1038/30845; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; MUTIS T, 1993, EUR J IMMUNOL, V23, P2189, DOI 10.1002/eji.1830230921; Pierce RA, 1999, J IMMUNOL, V163, P6360; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; ROOPENIAN DC, 1993, J IMMUNOL, V151, P4595; Scott D, 2000, IMMUNITY, V12, P711, DOI 10.1016/S1074-7613(00)80221-6; Spierings E, 2001, J IMMUNOL, V166, P5883, DOI 10.4049/jimmunol.166.10.5883; THEOBALD M, 1993, BLOOD, V82, P298, DOI 10.1182/blood.V82.1.298.bloodjournal821298; Urbano-Ispizua A, 2002, BLOOD, V100, P724, DOI 10.1182/blood-2001-11-0057; VANELS CACM, 1990, TRANSPLANTATION, V50, P67, DOI 10.1097/00007890-199007000-00012; VANELS CACM, 1990, TRANSPLANTATION, V50, P62, DOI 10.1097/00007890-199007000-00011; VANLEEUWEN A, 1979, J EXP MED, V150, P1075, DOI 10.1084/jem.150.5.1075; Vogt MHJ, 2000, BLOOD, V96, P3126, DOI 10.1182/blood.V96.9.3126.h8003126_3126_3132; Vogt MHJ, 2000, BLOOD, V95, P1100, DOI 10.1182/blood.V95.3.1100.003k42_1100_1105; Vogt MHJ, 2002, BLOOD, V99, P3027, DOI 10.1182/blood.V99.8.3027; VOOGT PJ, 1990, LANCET, V335, P131, DOI 10.1016/0140-6736(90)90003-N; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; Warren EH, 2000, J IMMUNOL, V164, P2807, DOI 10.4049/jimmunol.164.5.2807; Zelenika D, 1998, J IMMUNOL, V161, P1868; ZWAAN FE, 1989, BONE MARROW TRANS S2, V4, P8	28	95	101	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					610	615		10.1016/S0140-6736(03)14191-8	http://dx.doi.org/10.1016/S0140-6736(03)14191-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944060				2022-12-28	WOS:000184904100009
J	Barlowe, C				Barlowe, C			Molecular recognition of cargo by the COPII complex: A most accommodating coat	CELL			English	Editorial Material							EXPORT; ER	The molecular mechanism by which diverse cargo proteins are recognized and exported from the ER has been unclear. Two papers in this issue of Cell (Mosses-sova et al., 2003; Miller et al., 2003) add clarity by mapping multiple cargo recognition sites in the Sec24 subunit of the COPII coat complex and demonstrating roles for these sites in export of specific protein cargos from the ER.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Barlowe, C (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.							Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Otte S, 2002, EMBO J, V21, P6095, DOI 10.1093/emboj/cdf598; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3	8	21	21	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					395	397		10.1016/S0092-8674(03)00650-0	http://dx.doi.org/10.1016/S0092-8674(03)00650-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941266	Bronze			2022-12-28	WOS:000184928800001
J	Saunders, A; Werner, J; Andrulis, ED; Nakayama, T; Hirose, S; Reinberg, D; Lis, JT				Saunders, A; Werner, J; Andrulis, ED; Nakayama, T; Hirose, S; Reinberg, D; Lis, JT			Tracking FACT and the RNA polymerase II elongation complex through chromatin in vivo	SCIENCE			English	Article							HEAT-SHOCK GENES; TRANSCRIPTION ELONGATION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; REMODELING PROTEIN; DNASE-I; SPT5; NUCLEOSOME; PROMOTER; LOCALIZATION	RNA polymerase II (Pol II) transcription through nucleosomes is facilitated in vitro by the protein complex FACT (Facilitates Chromatin Transcription). Here we show that FACT is associated with actively transcribed Pol II genes on Drosophila polytene chromosomes. FACT displays kinetics of recruitment and of chromosome tracking in vivo similar to Pol II and elongation factors Spt5 and Spt6. Interestingly, FACT does not colocalize with Pol III-transcribed genes, which are known to undergo nucleosome transfer rather than disassembly in vitro. Our observations are consistent with FACT being restricted to transcription that involves nucleosome disassembly mechanisms.	Cornell Univ, Ithaca, NY 14850 USA; Natl Inst Genet, Dept Dev Genet, Mishima, Shizuoka 4118540, Japan; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Howard Hughes Med Inst, Piscataway, NJ 08854 USA	Cornell University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lis, JT (corresponding author), Cornell Univ, Biotechnol Bldg, Ithaca, NY 14850 USA.	jtl10@cornell.edu	Hirose, Susumu/I-8865-2019	Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, MOL CELL, V9, P451, DOI 10.1016/S1097-2765(02)00487-2; Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Armstrong JA, 2002, EMBO J, V21, P5245, DOI 10.1093/emboj/cdf517; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; BOEHM AK, IN PRESS MOL CELL BI; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; COSTLOW N, 1984, MOL CELL BIOL, V4, P1853, DOI 10.1128/MCB.4.9.1853; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; Formosa T, 2003, CURR TOP MICROBIOL, V274, P171; Formosa T, 2002, GENETICS, V162, P1557; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lindstrom DL, 2003, MOL CELL BIOL, V23, P1368, DOI 10.1128/MCB.23.4.1368-1378.2003; Lis J, 1998, COLD SPRING HARB SYM, V63, P347, DOI 10.1101/sqb.1998.63.347; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Pei Y, 2002, J BIOL CHEM, V277, P19639, DOI 10.1074/jbc.M200015200; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SCHWARTZ BE, IN PRESS METHODS ENZ; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; SIMON JA, 1985, CHROMOSOMA, V93, P26, DOI 10.1007/BF01259442; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; Takada S, 2000, CELL, V101, P459, DOI 10.1016/S0092-8674(00)80857-0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403	32	225	234	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1094	1096		10.1126/science.1085712	http://dx.doi.org/10.1126/science.1085712			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934007				2022-12-28	WOS:000184872400039
J	Xie, ZG; Sanada, K; Samuels, BA; Shih, H; Tsai, LH				Xie, ZG; Sanada, K; Samuels, BA; Shih, H; Tsai, LH			Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration	CELL			English	Article							FOCAL ADHESION KINASE; CENTRAL-NERVOUS-SYSTEM; ASPERGILLUS-NIDULANS; CYTOPLASMIC DYNEIN; TYROSINE KINASE; GENE-TRANSFER; CEREBRAL-CORTEX; P35/CDK5 KINASE; MICE LACKING; BRAIN	The serine/threonine kinase Cdk5 plays an essential role in neuronal positioning during corticogenesis, but the underlying mechanisms are unknown. In nonneuronal cells, the tyrosine kinase FAK is a major regulator of cell motility through focal adhesions. It is unclear whether FAK plays a role in brain development. Here, we show that FAK phosphorylation by Cdk5 at S732 is important for microtubule organization, nuclear movement, and neuronal migration. In cultured neurons, S732-phosphorylated FAK is enriched along a centrosome-associated microtubule fork that abuts the nucleus. Overexpression of the nonphosphorylatable mutant FAK S732A results in disorganization of the microtubule fork and impairment of nuclear movement in vitro, and neuronal positioning defects in vivo. These observations are reminiscent of what is seen in the Cdk5-deficient mice. Taken together, these results suggest that Cdk5 phosphorylation of FAK is critical for neuronal migration through regulation of a microtubule fork important for nuclear translocation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Program Neurosci, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Howard Hughes Medical Institute	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		SANADA, YOSHIKADO/G-5014-2014	Xie, Zhigang/0000-0002-7190-992X; Sanada, Kamon/0000-0002-0280-8957	NINDS NIH HHS [NS37007] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037007] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams NC, 2002, DEVELOPMENT, V129, P965; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; Anton ES, 1999, NEURON, V22, P277, DOI 10.1016/S0896-6273(00)81089-2; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; Bornens M, 1999, METHOD CELL BIOL, V61, P13; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Contestabile A, 2003, INT J DEV NEUROSCI, V21, P83, DOI 10.1016/S0736-5748(02)00126-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Fox JW, 1998, NEURON, V21, P1315, DOI 10.1016/S0896-6273(00)80651-0; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Graus-Porta D, 2001, NEURON, V31, P367, DOI 10.1016/S0896-6273(01)00374-9; Gupta A, 2002, NAT REV GENET, V3, P342, DOI 10.1038/nrg799; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hatten ME, 2002, SCIENCE, V297, P1660, DOI 10.1126/science.1074572; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Kesavapany S, 2001, EUR J NEUROSCI, V13, P241, DOI 10.1046/j.1460-9568.2001.01376.x; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Ko J, 2001, J NEUROSCI, V21, P6758; Kwon YT, 2000, CURR BIOL, V10, P363, DOI 10.1016/S0960-9822(00)00411-5; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; McEvilly RJ, 2002, SCIENCE, V295, P1528, DOI 10.1126/science.1067132; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0; Nadarajah B, 2002, NAT REV NEUROSCI, V3, P423, DOI 10.1038/nrn845; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patzke H, 2003, J NEUROSCI, V23, P2769; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Reiner O, 1998, INT J MOL MED, V1, P849; Reinsch S, 1998, J CELL SCI, V111, P2283; Renaudin A, 1999, J NEUROSCI RES, V55, P458, DOI 10.1002/(SICI)1097-4547(19990215)55:4<458::AID-JNR6>3.0.CO;2-D; RIVAS RJ, 1995, J NEUROSCI, V15, P981; Ross ME, 2001, ANNU REV NEUROSCI, V24, P1041, DOI 10.1146/annurev.neuro.24.1.1041; Saito T, 2001, DEV BIOL, V240, P237, DOI 10.1006/dbio.2001.0439; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Stevens GR, 1996, J NEUROSCI RES, V46, P445, DOI 10.1002/(SICI)1097-4547(19961115)46:4<445::AID-JNR6>3.3.CO;2-D; Sugitani Y, 2002, GENE DEV, V16, P1760, DOI 10.1101/gad.978002; Tabata H, 2001, NEUROSCIENCE, V103, P865, DOI 10.1016/S0306-4522(01)00016-1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Walsh CA, 2000, CURR OPIN GENET DEV, V10, P270, DOI 10.1016/S0959-437X(00)00076-9; Xiang X, 1999, CURR GENET, V35, P626, DOI 10.1007/s002940050461; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; Zheng C, 1996, SCIENCE, V272, P417, DOI 10.1126/science.272.5260.417	62	241	251	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					469	482		10.1016/S0092-8674(03)00605-6	http://dx.doi.org/10.1016/S0092-8674(03)00605-6			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941275	Bronze			2022-12-28	WOS:000184928800010
J	Choi, CH; Hiromura, M; Usheva, A				Choi, CH; Hiromura, M; Usheva, A			Transcription factor IIB acetylates itself to regulate transcription	NATURE			English	Article							RNA-POLYMERASE-II; PROTEIN; BINDING; AUTOACYLATION; ACYLATION; TFIIB	Acetylation is a well-known regulatory post-translational modification(1), but a biological function for acetylation in regulating basal transcription factors has not been reported. Here we show that the general transcription factor TFIIB, which is required for the initiation of eukaryotic polymerase II transcription(2), is acetylated. TFIIB is also an autoacetyltransferase, although it shares no sequence homology with any known acetyltransferases. In the absence of other enzymes, it binds acetyl-coenzyme A (acetyl-CoA), and catalyses the transfer of the acetyl group onto a specific lysine residue (K238). Both recombinant and cellular TFIIB can autoacetylate, markedly stabilizing the interaction between TFIIB and transcription factor TFIIF and activating transcription in vitro and in cells. A K238A mutant, which cannot be autoacetylated, does not show this activation of transcription. Our findings suggest that there is a regulatory pathway controlling acetylation of TFIIB, and they link acetyl-CoA with basal gene transcription.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Endocrinol Div, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Usheva, A (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Endocrinol Div, 99 Brookline Ave, Boston, MA 02215 USA.							BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fang SM, 1996, J BIOL CHEM, V271, P11703, DOI 10.1074/jbc.271.20.11703; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Luger K, 1999, METHOD ENZYMOL, V304, P3; MAYER RT, 1974, J CHROMATOGR, V90, P390, DOI 10.1016/S0021-9673(00)92549-4; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; YAMASHITA A, 1995, BIOCHEM J, V312, P301, DOI 10.1042/bj3120301; Yan Y, 2002, NAT STRUCT BIOL, V9, P862, DOI 10.1038/nsb849	18	41	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					965	969		10.1038/nature01899	http://dx.doi.org/10.1038/nature01899			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931194				2022-12-28	WOS:000184843600047
J	Shiralkar, S; Rennie, A; Snow, M; Galland, RB; Lewis, MH; Gower-Thomas, K				Shiralkar, S; Rennie, A; Snow, M; Galland, RB; Lewis, MH; Gower-Thomas, K			Doctors' knowledge of radiation exposure: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									Russells Hall Hosp, Dudley DY1 2HQ, W Midlands, England; Royal Berkshire Hosp, Reading RG1 5AN, Berks, England	Russells Hall Hospital; Royal Berkshire Hospital				snow, martyn/0000-0002-1366-109X				*ROYAL COLL RAD NA, 1990, DOC NAT RAD PROT BOA, V3; The Royal College of Radiologists, 1998, MAK BEST US DEP CLIN, V4th	2	226	232	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					371	372		10.1136/bmj.327.7411.371	http://dx.doi.org/10.1136/bmj.327.7411.371			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919987	Green Published, Bronze			2022-12-28	WOS:000184864200017
J	Nishimura, MT; Stein, M; Hou, BH; Vogel, JP; Edwards, H; Somerville, SC				Nishimura, MT; Stein, M; Hou, BH; Vogel, JP; Edwards, H; Somerville, SC			Loss of a callose synthase results in salicylic acid-dependent disease resistance	SCIENCE			English	Article							PERONOSPORA-PARASITICA; DEFENSE RESPONSES; ARABIDOPSIS; MUTANT	Plants attacked by pathogens rapidly deposit callose, a beta-1,3-glucan, at wound sites. Traditionally, this deposition is thought to reinforce the cell wall and is regarded as a defense response. Surprisingly, here we found that powdery mildew resistant 4 (pmr4), a mutant lacking pathogen-induced callose, became resistant to pathogens, rather than more susceptible. This resistance was due to mutation of a callose synthase, resulting in a loss of the induced callose response. Double-mutant analysis indicated that blocking the salicylic acid ( SA) defense signaling pathway was sufficient to restore susceptibility to pmr4 mutants. Thus, callose or callose synthase negatively regulates the SA pathway.	Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA; Western Illinois Univ, Dept Biol Sci, Macomb, IL 61455 USA	Carnegie Institution for Science; Western Illinois University	Somerville, SC (corresponding author), Carnegie Inst, Dept Plant Biol, Stanford, CA 94305 USA.		Vogel, John P/B-3176-2009; Bruening, Stefan/B-8505-2011	Stein, Monica/0000-0002-1926-4212; Nishimura, Marc Tad/0000-0003-4666-6900; Vogel, John/0000-0003-1786-2689				Aist J. R., 1991, The fungal spore and disease initiation in plants and animals., P321; AIST JR, 1976, ANNU REV PHYTOPATHOL, V14, P145, DOI 10.1146/annurev.py.14.090176.001045; Aviv DH, 2002, PLANT J, V29, P381, DOI 10.1046/j.0960-7412.2001.01225.x; Cano-Delgado A, 2003, PLANT J, V34, P351, DOI 10.1046/j.1365-313X.2003.01729.x; Donofrio NM, 2001, MOL PLANT MICROBE IN, V14, P439, DOI 10.1094/MPMI.2001.14.4.439; Ellis C, 2002, PLANT CELL, V14, P1557, DOI 10.1105/tpc.002022; GASPAR Y, COMMUNICATION; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Keen NT, 2000, ANNU REV PHYTOPATHOL, V38, P31, DOI 10.1146/annurev.phyto.38.1.31; Nawrath C, 2002, PLANT CELL, V14, P275, DOI 10.1105/tpc.010376; Nickle TC, 1998, PLANT J, V15, P321, DOI 10.1046/j.1365-313X.1998.00212.x; Ostergaard L, 2002, PLANT MOL BIOL, V49, P559, DOI 10.1023/A:1015558231400; RAAB TK, COMMUNICATION; Rairdan GJ, 2001, MOL PLANT MICROBE IN, V14, P1235, DOI 10.1094/MPMI.2001.14.10.1235; Spoel SH, 2003, PLANT CELL, V15, P760, DOI 10.1105/tpc.009159; STEIN MA, UNPUB; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vogel J, 2000, P NATL ACAD SCI USA, V97, P1897, DOI 10.1073/pnas.030531997; Wildermuth MC, 2001, NATURE, V414, P562, DOI 10.1038/35107108; Zhu YM, 2003, PLANT PHYSIOL, V132, P494, DOI 10.1104/pp.103.020420	21	487	514	1	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					969	972		10.1126/science.1086716	http://dx.doi.org/10.1126/science.1086716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920300				2022-12-28	WOS:000184755900041
J	Chiti, F; Stefani, M; Taddei, N; Ramponi, G; Dobson, CM				Chiti, F; Stefani, M; Taddei, N; Ramponi, G; Dobson, CM			Rationalization of the effects of mutations on peptide and protein aggregation rates	NATURE			English	Article							X-RAY-DIFFRACTION; TAU-PROTEIN; MISFOLDING DISEASES; ALZHEIMERS-DISEASE; INCLUSION-BODIES; ALPHA-SYNUCLEIN; FTDP-17 MUTANTS; AMYLOID FIBRILS; PRION PROTEIN; POLYMERIZATION	In order for any biological system to function effectively, it is essential to avoid the inherent tendency of proteins to aggregate and form potentially harmful deposits(1-4). In each of the various pathological conditions associated with protein deposition, such as Alzheimer's and Parkinson's diseases, a specific peptide or protein that is normally soluble is deposited as insoluble aggregates generally referred to as amyloid(2,3). It is clear that the aggregation process is generally initiated from partially or completely unfolded forms of the peptides and proteins associated with each disease. Here we show that the intrinsic effects of specific mutations on the rates of aggregation of unfolded polypeptide chains can be correlated to a remarkable extent with changes in simple physicochemical properties such as hydrophobicity, secondary structure propensity and charge. This approach allows the pathogenic effects of mutations associated with known familial forms of protein deposition diseases to be rationalized, and more generally enables prediction of the effects of mutations on the aggregation propensity of any polypeptide chain.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Cambridge; University of Florence	Dobson, CM (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.			Taddei, Niccolo/0000-0003-2513-1018; STEFANI, MASSIMO/0000-0002-4490-1922				Azriel R, 2001, J BIOL CHEM, V276, P34156, DOI 10.1074/jbc.M102883200; Barghorn S, 2000, BIOCHEMISTRY-US, V39, P11714, DOI 10.1021/bi000850r; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrio MM, 2002, J BIOTECHNOL, V96, P3, DOI 10.1016/S0168-1656(02)00032-9; Chiti F, 2002, P NATL ACAD SCI USA, V99, P16419, DOI 10.1073/pnas.212527999; Chiti F, 2002, NAT STRUCT BIOL, V9, P137, DOI 10.1038/nsb752; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Gamblin TC, 2003, BIOCHEMISTRY-US, V42, P2252, DOI 10.1021/bi0272510; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Li L, 2002, J BIOL CHEM, V277, P41390, DOI 10.1074/jbc.M206334200; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Miravalle L, 2000, J BIOL CHEM, V275, P27110; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Sakagashira S, 2000, AM J PATHOL, V157, P2101, DOI 10.1016/S0002-9440(10)64848-1; Salmona M, 1999, BIOCHEM J, V342, P207, DOI 10.1042/0264-6021:3420207; Street AG, 1999, P NATL ACAD SCI USA, V96, P9074, DOI 10.1073/pnas.96.16.9074; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Symmons MF, 1997, FEBS LETT, V412, P397, DOI 10.1016/S0014-5793(97)00809-0; Thompson AJ, 2001, BBA-PROTEIN STRUCT M, V1544, P242, DOI 10.1016/S0167-4838(00)00225-9; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200	30	883	905	0	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					805	808		10.1038/nature01891	http://dx.doi.org/10.1038/nature01891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917692				2022-12-28	WOS:000184733900047
J	Hamilton-Fairley, D; Taylor, A				Hamilton-Fairley, D; Taylor, A			ABC of subfertility - Anovulation	BRITISH MEDICAL JOURNAL			English	Article									Guys & St Thomass NHS Trust, London, England		Hamilton-Fairley, D (corresponding author), Guys & St Thomass NHS Trust, London, England.								0	45	47	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					546	549		10.1136/bmj.327.7414.546	http://dx.doi.org/10.1136/bmj.327.7414.546			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958117	Green Published			2022-12-28	WOS:000185283700022
J	Say, RE; Thomson, R				Say, RE; Thomson, R			The importance of patient preferences in treatment decisions - challenges for doctors	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CANCER-PATIENTS; GENERAL-PRACTITIONERS; RISK COMMUNICATION; CARE MANAGEMENT; BREAST-CANCER; INFORMATION; PARTICIPATION; CONSULTATION; PROBABILITY; INVOLVEMENT	The expectation that patients will become increasingly involved in making treatment decisions poses new challenges for doctors. This article discusses what these are and how doctors might, face them.	Med Sch Newcastle Upon Tyne, Sch Populat & Hlth Sci Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Thomson, R (corresponding author), Med Sch Newcastle Upon Tyne, Sch Populat & Hlth Sci Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	richard.thomson@newcastle.ac.uk						BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Bogardus ST, 1999, JAMA-J AM MED ASSOC, V281, P1037, DOI 10.1001/jama.281.11.1037; Bowling A, 2001, QUAL HEALTH CARE, V10, pI2; Butow PN, 1997, ANN ONCOL, V8, P857, DOI 10.1023/A:1008284006045; Calman KC, 1996, BRIT MED J, V313, P799; Charles C, 1998, SOCIOL HEALTH ILL, V20, P71, DOI 10.1111/1467-9566.00081; Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; Coulter A, 2002, BMJ-BRIT MED J, V324, P648, DOI 10.1136/bmj.324.7338.648; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; Deber RB, 1996, ARCH INTERN MED, V156, P1414, DOI 10.1001/archinte.156.13.1414; DEBER RB, 1994, CAN MED ASSOC J, V151, P423; *DEP HLTH, 2001, EXP PAT NEW APPR CHR, P12; Donabedian A, 1992, Qual Health Care, V1, P247, DOI 10.1136/qshc.1.4.247; Edwards A, 1997, BRIT J GEN PRACT, V47, P739; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Edwards A, 2001, QUAL HEALTH CARE, V10, pI9; Elwin G, 2001, LANCET, V358, P571, DOI 10.1016/S0140-6736(01)05709-9; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; Elwyn G, 1999, BRIT MED J, V319, P753, DOI 10.1136/bmj.319.7212.753; Elwyn Glyn, 1999, Health Expect, V2, P105, DOI 10.1046/j.1369-6513.1999.00045.x; ENDE J, 1989, J GEN INTERN MED, V4, P23, DOI 10.1007/BF02596485; FALLOWFIELD LJ, 1994, BRIT MED J, V309, P448, DOI 10.1136/bmj.309.6952.448; Freeman GK, 2002, BRIT MED J, V324, P880, DOI 10.1136/bmj.324.7342.880; Fuller R, 2001, AGE AGEING, V30, P473, DOI 10.1093/ageing/30.6.473; Gillespie R, 2002, CHANGING RELATIONSHI; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; Guadagnoli E, 1998, SOC SCI MED, V47, P329, DOI 10.1016/S0277-9536(98)00059-8; Haynes RB, 1996, LANCET, V348, P383; Iverson DC, 2001, PATIENT EDUC COUNS, V45, P83, DOI 10.1016/S0738-3991(01)00191-4; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Katz JN, 2001, JAMA-J AM MED ASSOC, V286, P1506, DOI 10.1001/jama.286.12.1506; Kenny Patricia, 1999, Health Expect, V2, P159, DOI 10.1046/j.1369-6513.1999.00050.x; Lelie A, 2000, PATIENT EDUC COUNS, V39, P81, DOI 10.1016/S0738-3991(99)00093-2; Lenert LA, 1998, MED DECIS MAKING, V18, P76, DOI 10.1177/0272989X9801800115; Little P, 2001, BRIT MED J, V323, P908, DOI 10.1136/bmj.323.7318.908; Lloyd AJ, 1999, LANCET, V353, P645, DOI 10.1016/S0140-6736(98)05670-0; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; Montgomery AA, 2001, QUAL HEALTH CARE, V10, pI39; Mouton C, 1997, ARCH FAM MED, V6, P342, DOI 10.1001/archfami.6.4.342; Protheroe J, 2000, BRIT MED J, V320, P1380, DOI 10.1136/bmj.320.7246.1380; *ROYAL PHARM SOC G, 1997, COMPL CONC SHAR GOAL; Sainio C, 2001, NURS ETHICS, V8, P97, DOI 10.1191/096973301677733388; Sculpher MJ, 1999, BRIT MED J, V319, P725, DOI 10.1136/bmj.319.7212.725; Shepperd S, 1999, BMJ-BRIT MED J, V319, P764, DOI 10.1136/bmj.319.7212.764; Stapleton H, 2002, BMJ-BRIT MED J, V324, P639, DOI 10.1136/bmj.324.7338.639; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; Thorne SE, 2001, PATIENT EDUC COUNS, V42, P81, DOI 10.1016/S0738-3991(00)00095-1; Towle A, 1999, BRIT MED J, V319, P766, DOI 10.1136/bmj.319.7212.766; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	51	270	272	1	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2003	327	7414					542	545		10.1136/bmj.327.7414.542	http://dx.doi.org/10.1136/bmj.327.7414.542			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	720WW	12958116	Green Published			2022-12-28	WOS:000185283700021
J	Schwab, SR; Li, KC; Kang, C; Shastri, N				Schwab, SR; Li, KC; Kang, C; Shastri, N			Constitutive display of cryptic translation products by MHC class I molecules	SCIENCE			English	Article							NEWLY SYNTHESIZED PROTEINS; DENDRITIC CELLS; DEGRADATION; INITIATION; ANTIGENS; PEPTIDES; GENERATION; GENE; H60	Major histocompatibility complex (MHC) class I molecules display tens of thousands of peptides on the cell surface, derived from virtually all endogenous proteins, for inspection by cytotoxic T cells (CTLs). We show that, in normal mouse cells, MHC I molecules present a peptide encoded in the 3' "untranslated" region. Despite its rarity, the peptide elicits CTL responses and induces self-tolerance, establishing that immune surveillance extends well beyond conventional polypeptides. Furthermore, translation of this cryptic peptide occurs by a previously unknown mechanism that decodes the CUG initiation codon as leucine rather than the canonical methionine.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Shastri, N (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Schwab, Susan/0000-0002-0834-0822				Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BOON T, 1989, IMMUNOGENETICS, V29, P75, DOI 10.1007/BF00395854; Choi EY, 2002, IMMUNITY, V17, P593, DOI 10.1016/S1074-7613(02)00428-4; Greenfield A, 1996, NAT GENET, V14, P474, DOI 10.1038/ng1296-474; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; Malarkannan S, 2000, IMMUNITY, V13, P333, DOI 10.1016/S1074-7613(00)00033-9; Malarkannan S, 1998, J IMMUNOL, V161, P3501; Malarkannan S, 1999, IMMUNITY, V10, P681, DOI 10.1016/S1074-7613(00)80067-9; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PEABODY DS, 1989, J BIOL CHEM, V264, P5031; PIRCHER H, 1989, EMBO J, V8, P719, DOI 10.1002/j.1460-2075.1989.tb03431.x; Rajbhandary Uttam L., 1995, P511; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Scott D, 2000, IMMUNITY, V12, P711, DOI 10.1016/S1074-7613(00)80221-6; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Yewdell J, 2002, MOL IMMUNOL, V39, P139, DOI 10.1016/S0161-5890(02)00097-4	19	93	95	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1367	1371		10.1126/science.1085650	http://dx.doi.org/10.1126/science.1085650			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958358				2022-12-28	WOS:000185116400038
J	Radovan, HA; Fortune, NA; Murphy, TP; Hannahs, ST; Palm, EC; Tozer, SW; Hall, D				Radovan, HA; Fortune, NA; Murphy, TP; Hannahs, ST; Palm, EC; Tozer, SW; Hall, D			Magnetic enhancement of superconductivity from electron spin domains	NATURE			English	Article							LARKIN-OVCHINNIKOV STATE; UNCONVENTIONAL SUPERCONDUCTIVITY; CRITICAL-FIELD; CECOIN5; HEAT; TEMPERATURE; PRESSURE	Since the discovery of superconductivity(1), there has been a drive to understand the mechanisms by which it occurs. The BCS (Bardeen-Cooper-Schrieffer) model successfully treats the electrons in conventional superconductors as pairs coupled by phonons (vibrational modes of oscillation) moving through the material(2), but there is as yet no accepted model for high-transition-temperature, organic or 'heavy fermion' superconductivity. Experiments that reveal unusual properties of those superconductors could therefore point the way to a deeper understanding of the underlying physics. In particular, the response of a material to a magnetic field can be revealing, because this usually reduces or quenches superconductivity. Here we report measurements of the heat capacity and magnetization that show that, for particular orientations of an external magnetic field, superconductivity in the heavy-fermion material CeCoIn5 is enhanced through the magnetic moments (spins) of individual electrons. This enhancement occurs by fundamentally altering how the superconducting state forms, resulting in regions of superconductivity alternating with walls of spin-polarized unpaired electrons; this configuration lowers the free energy and allows superconductivity to remain stable. The large magnetic susceptibility of this material leads to an unusually strong coupling of the field to the electron spins, which dominates over the coupling to the electron orbits.	Florida State Univ, NHMFL, Tallahassee, FL 32310 USA; Smith Coll, Dept Phys, Northampton, MA 01063 USA	State University System of Florida; Florida State University; Smith College	Radovan, HA (corresponding author), Florida State Univ, NHMFL, Tallahassee, FL 32310 USA.	radovan@magnet.fsu.edu	Hannahs, Scott/B-1274-2008; Fortune, Nathanael A./B-6914-2009	Hannahs, Scott/0000-0002-5840-7714; Fortune, Nathanael A./0000-0002-2704-9969				Agterberg DF, 2001, J PHYS-CONDENS MAT, V13, P9259, DOI 10.1088/0953-8984/13/41/315; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Bianchi A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.137002; BURKHARDT H, 1994, ANN PHYS-LEIPZIG, V3, P181, DOI 10.1002/andp.19945060305; Buzdin AI, 1996, EUROPHYS LETT, V35, P707, DOI 10.1209/epl/i1996-00152-9; Buzdin AI, 1996, PHYS LETT A, V218, P359, DOI 10.1016/0375-9601(96)00362-3; Fortune N, 2000, REV SCI INSTRUM, V71, P3825, DOI 10.1063/1.1310341; FULDE P, 1964, PHYS REV, V135, pA550, DOI 10.1103/PhysRev.135.A550; Hannahs ST, 2003, PHYSICA B, V329, P1586, DOI 10.1016/S0921-4526(02)02303-7; Hegger H, 2000, PHYS REV LETT, V84, P4986, DOI 10.1103/PhysRevLett.84.4986; Houzet M, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.184521; Ikeda S, 2001, J PHYS SOC JPN, V70, P2248, DOI 10.1143/JPSJ.70.2248; LARKIN AI, 1965, ZH EKSP TEOR FIZ, V20, P762; MAKI K, 1966, PHYS REV, V148, P362, DOI 10.1103/PhysRev.148.362; Matsuo S, 1998, J PHYS SOC JPN, V67, P280, DOI 10.1143/JPSJ.67.280; Mola MM, 2001, INT J MOD PHYS B, V15, P3353, DOI 10.1142/S0217979201007750; Monthoux P, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.054529; Movshovich R, 2001, PHYS REV LETT, V86, P5152, DOI 10.1103/PhysRevLett.86.5152; Murphy TP, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.100514; Nicklas M, 2001, J PHYS-CONDENS MAT, V13, pL905, DOI 10.1088/0953-8984/13/44/104; NORMAN MR, 1993, PHYS REV LETT, V71, P3391, DOI 10.1103/PhysRevLett.71.3391; Onnes H. K., 1911, COMMUN PHYS LAB U B, V120, P3; PAGLIONE J, 2002, UNPUB PHYS REV LETT; Petrovic C, 2001, J PHYS-CONDENS MAT, V13, pL337, DOI 10.1088/0953-8984/13/17/103; Sachdev S, 2000, SCIENCE, V288, P475, DOI 10.1126/science.288.5465.475; Shimahara H, 1997, J PHYS SOC JPN, V66, P3591, DOI 10.1143/JPSJ.66.3591; Tayama T, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.180504; WERTHAME.NR, 1966, PHYS REV, V147, P295, DOI 10.1103/PhysRev.147.295; Zieve RJ, 1996, PHYS REV B, V53, P11849, DOI 10.1103/PhysRevB.53.11849	30	370	370	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					51	55		10.1038/nature01842	http://dx.doi.org/10.1038/nature01842			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955136				2022-12-28	WOS:000185089200033
J	Cannuscio, C; Block, J; Kawachi, I				Cannuscio, C; Block, J; Kawachi, I			Social capital and successful aging: The role of senior housing	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				COMMUNITIES; AGE	Social capital is defined as the resources available to individuals and groups through social connections and social relations with others. Access to social capital enables older citizens to maintain productive, independent, and fulfilling lives. As the U.S. population ages, accompanied by a rise in the prevalence of seniors living alone, the availability of social capital within communities will become an important ingredient of successful aging. Recent evidence suggests that many traditional forms of social capital in communities-as represented by civic engagement in local associations and by the extent of voluntarism and social trust-are on the decline. If this observation in correct, there is no simple solution to rebuilding this lost social capital. Novel forms of senior housing, such as planned care developments and assisted-living facilities, may offer promising modes of delivery of social capital to the aging population. However, assisted living remains financially inaccessible for a large segment of the U.S. population, so investment in communities "aging in place" may be the key to delivering the health dividends of social capital.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Merck Res Labs, Blue Bell, PA USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Harvard University; Harvard T.H. Chan School of Public Health; Merck & Company; Tulane University	Kawachi, I (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.		Cannuscio, Carolyn/A-1123-2007					Blakely E.J., 1997, FORTRESS AM GATED CO; CINELLI D, 1999, AGING AUTONOMY ARCHI; CLARK WAV, 1990, RES AGING, V12, P430, DOI 10.1177/0164027590124004; EMRATH P, 1998, HOME EC, P10; FRY CL, 1977, HUM ORGAN, V36, P115, DOI 10.17730/humo.36.2.d10358241k26wv6r; HALL JA, 1999, IS AM BREAKING APART; HARNEY KR, 1996, LOS ANGELES TIM 1110, pK1; HARRIS JC, 1999, TIERRA GRANDE J REAL, V6, P1; HETZEL L, 2001, C2KBR0110 US CENS BU; Jacobzone S, 2000, HEALTH AFFAIR, V19, P213, DOI 10.1377/hlthaff.19.3.213; KANE RA, 1997, LONG TERM CARE PRINC; KAWACHI I, 2002, SOCIAL COSTS CONSUMP, P137; Kawachi I., 2000, SOCIAL EPIDEMIOLOGY, P174; Kenney G, 1998, HEALTH AFFAIR, V17, P201, DOI 10.1377/hlthaff.17.1.201; Klinenberg E., 2002, HEAT WAVE SOCIAL AUT; Putnam R. D., 2001, BOWLING ALONE COLLAP; PUTNAM RD, 1995, J DEMOCRACY, V0006; REGNIER V, 1997, SOC MECH MAINTAINING, P232; REGNIER V, 1995, ASSISTED LIVING AGED; Regnier V., 1994, ASSISTED LIVING HOUS; Schor J. B., 1991, OVERWORKED AM UNEXPE; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; Townshend IJ, 2002, ENVIRON PLANN B, V29, P371, DOI 10.1068/b2761t; Webster C, 2002, ENVIRON PLANN B, V29, P315, DOI 10.1068/b12926; WOLINSKY FD, 1997, SOC MECH MAINTAINING, P94; Wuthnow R., 1998, LOOSE CONNECTIONS	26	130	131	3	48	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			395	399		10.7326/0003-4819-139-5_Part_2-200309021-00003	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965964	Green Published			2022-12-28	WOS:000185133800003
J	Danial, NN; Gramm, CF; Scorrano, L; Zhang, CY; Krauss, S; Ranger, AM; Datta, SR; Greenberg, ME; Licklider, LJ; Lowell, BB; Gygi, SP; Korsmeyer, SJ				Danial, NN; Gramm, CF; Scorrano, L; Zhang, CY; Krauss, S; Ranger, AM; Datta, SR; Greenberg, ME; Licklider, LJ; Lowell, BB; Gygi, SP; Korsmeyer, SJ			BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis	NATURE			English	Article							ALDRICH-SYNDROME PROTEIN; GLUCOSE-HOMEOSTASIS; CELL-SURVIVAL; TOM COMPLEX; PHOSPHORYLATION; GROWTH; DEATH; GENE; BETA; CHROMATOGRAPHY	Glycolysis and apoptosis are considered major but independent pathways that are critical for cell survival(1-4). The activity of BAD, a pro-apoptotic BCL-2 family member, is regulated by phosphorylation in response to growth/survival factors(5-8). Here we undertook a proteomic analysis to assess whether BAD might also participate in mitochondrial physiology. In liver mitochondria, BAD resides in a functional holoenzyme complex together with protein kinase A(7) and protein phosphatase 1 (PP1) catalytic units(9), Wiskott-Aldrich family member WAVE-1 as an A kinase anchoring protein(10), and glucokinase (hexokinase IV)(11). BAD is required to assemble the complex in that Bad-deficient hepatocytes lack this complex, resulting in diminished mitochondria-based glucokinase activity and blunted mitochondrial respiration in response to glucose. Glucose deprivation results in dephosphorylation of BAD, and BAD-dependent cell death. Moreover, the phosphorylation status of BAD helps regulate glucokinase activity. Mice deficient for BAD or bearing a non-phosphorylatable BAD(3SA) mutant(12) display abnormal glucose homeostasis including profound defects in glucose tolerance. This combination of proteomics, genetics and physiology indicates an unanticipated role for BAD in integrating pathways of glucose metabolism and apoptosis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Neurobiol,Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Korsmeyer, SJ (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Howard Hughes Med Inst, 44 Binney St, Boston, MA 02115 USA.		Scorrano, Luca/A-6652-2008; Scorrano, Luca/K-3967-2019	Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928; Datta, Sandeep/0000-0002-8068-3862				Abdul KM, 2000, BIOCHEM BIOPH RES CO, V276, P1028, DOI 10.1006/bbrc.2000.3589; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BALI D, 1995, J BIOL CHEM, V270, P21464, DOI 10.1074/jbc.270.37.21464; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Garland JM, 1997, J BIOL CHEM, V272, P4680, DOI 10.1074/jbc.272.8.4680; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Krimmer T, 2001, J CELL BIOL, V152, P289, DOI 10.1083/jcb.152.2.289; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Niswender KD, 1997, J BIOL CHEM, V272, P22564, DOI 10.1074/jbc.272.36.22564; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	30	551	573	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					952	956		10.1038/nature01825	http://dx.doi.org/10.1038/nature01825			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931191				2022-12-28	WOS:000184843600044
J	Abrams, DI; Hilton, JF; Leiser, RJ; Shade, SB; Elbeik, TA; Aweeka, FT; Benowitz, NL; Bredt, BM; Kosel, B; Aberg, JA; Deeks, SG; Mitchell, TF; Mulligan, K; Bacchetti, P; McCune, JM; Schambelan, M				Abrams, DI; Hilton, JF; Leiser, RJ; Shade, SB; Elbeik, TA; Aweeka, FT; Benowitz, NL; Bredt, BM; Kosel, B; Aberg, JA; Deeks, SG; Mitchell, TF; Mulligan, K; Bacchetti, P; McCune, JM; Schambelan, M			Short-term effects of cannabinoids in patients with HIV-1 infection - A randomized, placebo-controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							RECEIVING CANCER-CHEMOTHERAPY; MARIJUANA SMOKERS; MEDICAL MARIJUANA; DELTA-9-TETRAHYDROCANNABINOL; METABOLISM; AIDS; RECEPTORS; WEIGHT; PHARMACOKINETICS; DRONABINOL	Background: Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid-protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways). Objective: To determine the short-term effects of smoked marijuana on the viral load in HIV-infected patients. Design: Randomized, placebo-controlled, 21-day intervention trial. Setting: The inpatient General Clinical Research Center at the San Francisco General Hospital, San Francisco, California. Participants: 67 patients with HIV-1 infection. Intervention: Participants were randomly assigned to a 3.95%-tetrahydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule three times daily before meals. Measurements: HIV RNA levels, CD4(+) and CD8(+) cell subsets, and pharmacokinetic analyses of the protease inhibitors. Results: 62 study participants were eligible for the primary end point (marijuana group, 20 patients; dronabinol group, 22 patients; and placebo group, 20 patients). Baseline HIV RNA level was less than 50 copies/mL for 36 participants (58%), and the median CD4(+) cell count was 340x10(9) cells/L. When adjusted for baseline variables, the estimated average effect versus placebo on change in log(10) viral load from baseline to day 21 was -0.07 (95% CI, -0.30 to 0.13) for marijuana and -0.04 (CI, -0.20 to 0.14) for dronabinol. The adjusted average changes in viral load in marijuana and dronabinol relative to placebo were -15% (CI, -50% to 34%) and -8% (CI, -37% to 37%), respectively. Neither CD4(+) nor CD8(+) cell counts appeared to be adversely affected by the cannabinoids. Conclusions: Smoked and oral cannabinoids did not seem to be unsafe in people with HIV infection with respect to HIV RNA levels, CD4(+) and CD8(+) cell counts, or protease inhibitor levels over a 21-day treatment.	Univ Calif San Francisco, Posit Hlth Program, San Francisco, CA 94110 USA	University of California System; University of California San Francisco	Abrams, DI (corresponding author), Univ Calif San Francisco, Posit Hlth Program, Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA.			Elbeik, Tarek/0000-0001-5983-0867	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH059037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011607] Funding Source: NIH RePORTER; NCRR NIH HHS [5-M01-RR00083] Funding Source: Medline; NIDA NIH HHS [1R01 DA/MH11607] Funding Source: Medline; NIMH NIH HHS [P30-MH59037] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abel EL, 1980, MARIJUANA 1 12000 YE; ABRAMS DI, 1995, NEW ENGL J MED, V333, P671; Abrams DI, 1998, J PSYCHOACTIVE DRUGS, V30, P163; Abrams DI, 2000, J ACQ IMMUN DEF SYND, V25, pS74, DOI 10.1097/00126334-200010001-00012; Acosta EP, 2000, CLIN INFECT DIS, V30, pS151, DOI 10.1086/313852; AGURELL S, 1986, PHARMACOL REV, V38, P21; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; BENOWITZ NL, 1980, CLIN PHARMACOL THER, V28, P115, DOI 10.1038/clpt.1980.139; BENOWITZ NL, 1977, CLIN PHARMACOL THER, V22, P259; BRAITSTEIN P, 2000, 13 INT AIDS C DURB S, P326; Bredt BM, 2002, J CLIN PHARMACOL, V42, p82S, DOI 10.1002/j.1552-4604.2002.tb06007.x; CHANG AE, 1979, ANN INTERN MED, V91, P819, DOI 10.7326/0003-4819-91-6-819; CHANG AE, 1981, CANCER, V47, P1746; CHILD CC, 1998, 12 WORLD AIDS C GEN, P1105; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; Efron B, 1993, INTRO BOOTSTRAP, P178; Felder CC, 1998, ANNU REV PHARMACOL, V38, P179, DOI 10.1146/annurev.pharmtox.38.1.179; FOLTIN RW, 1988, APPETITE, V11, P1, DOI 10.1016/S0195-6663(88)80017-5; FRIEDMAN H, 1995, ADV EXP MED BIOL, V373, P103; FRYTAK S, 1979, ANN INTERN MED, V91, P825, DOI 10.7326/0003-4819-91-6-825; GORTER R, 1992, AIDS, V6, P127, DOI 10.1097/00002030-199201000-00018; HOLLISTER LE, 1992, J PSYCHOACTIVE DRUGS, V24, P159, DOI 10.1080/02791072.1992.10471635; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; JOHNSON M, 1998, P 5 C RETR OPP INF C, P148; Joy JE, 1999, MARIJUANA MED ASSESS; Kane B, 2001, ANN INTERN MED, V134, P1159, DOI 10.7326/0003-4819-134-12-200106190-00035; Kosel BW, 2002, AIDS, V16, P543, DOI 10.1097/00002030-200203080-00005; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Lesaffre E, 1998, BIOMETRICS, V54, P570, DOI 10.2307/3109764; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; MULLIGAN K, 2001, P 8 C RETR OPP INF C, P238; NAHAS GG, 1974, SCIENCE, V183, P419, DOI 10.1126/science.183.4123.419; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Paxton WB, 1997, J INFECT DIS, V175, P247, DOI 10.1093/infdis/175.2.247; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Piscitelli SC, 2001, NEW ENGL J MED, V344, P984, DOI 10.1056/NEJM200103293441307; SALLAN SE, 1975, NEW ENGL J MED, V293, P795, DOI 10.1056/NEJM197510162931603; *US PHS, GUID US ANT AG HIV I; WALLACE JM, 1988, J PSYCHOACTIVE DRUGS, V20, P9, DOI 10.1080/02791072.1988.10524365; WATANABE K, 1995, BIOL PHARM BULL, V18, P1138; YAMAMOTO I, 1995, INT J BIOCHEM CELL B, V27, P741, DOI 10.1016/1357-2725(95)00043-O; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	43	139	145	1	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 19	2003	139	4					258	266		10.7326/0003-4819-139-4-200308190-00008	http://dx.doi.org/10.7326/0003-4819-139-4-200308190-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712JY	12965981				2022-12-28	WOS:000184795600004
J	Laiho, K; Belt, EA; Juvela, S; Paetau, A; Soini, I				Laiho, K; Belt, EA; Juvela, S; Paetau, A; Soini, I			Thigh pain due to intraspinal neurilemmoma	LANCET			English	Editorial Material									Rheumatism Fdn Hosp, FIN-18120 Heinola, Finland; Univ Helsinki, Cent Hosp, Dept Neurosurg, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00014 Helsinki, Finland	Rheumatism Foundation Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital	Laiho, K (corresponding author), Rheumatism Fdn Hosp, FIN-18120 Heinola, Finland.			Juvela, Seppo/0000-0003-4944-4983					0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					533	533		10.1016/S0140-6736(03)14113-X	http://dx.doi.org/10.1016/S0140-6736(03)14113-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932385				2022-12-28	WOS:000184817600010
J	Li, DK; Liu, LY; Douh, R				Li, DK; Liu, LY; Douh, R			Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							ASPIRIN	Objective To evaluate whether prenatal use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with increased risk of miscarriage. Design Population based cohort study. Prenatal use of NSAIDs, aspirin, and paracetamol (acetaminophen) ascertained by in-person interview. Setting Kaiser Permanente Medical Care Program, a healthcare delivery system, in the San Francisco area of the United States. Participants 1055 pregnant women recruited and interviewed immediately after their positive pregnancy test. Median gestational age at entry to the study was 40 days. Main outcome measures Pregnancy outcomes up to 20 weeks of gestation. Results 53 women (5%) reported prenatal NSAID use around conception or during pregnancy. After adjustment for potential confounders, prenatal NSAID use was associated with an 80% increased risk of miscarriage (adjusted hazard ratio 1.8 (95% confidence interval 1.0 to 3.2)). The association was stronger if the initial NSAID use was around the time of conception or if NSAID use lasted more than a week. Prenatal aspirin use was similarly associated with an increased risk of miscarriage. However, prenatal use of paracetamol, pharmacologically different from NSAIDs and aspirin, was not associated with increased risk of miscarriage regardless of timing and duration of use. Conclusion Prenatal use of NSAIDs and aspirin increased the risk of miscarriage. These findings need confirmation in studies designed specifically to examine the apparent association.	Kaiser Permanente, Kaiser Fdn Res Inst, Div Res, Oakland, CA 94612 USA	Kaiser Permanente	Li, DK (corresponding author), Kaiser Permanente, Kaiser Fdn Res Inst, Div Res, 2000 Broadway, Oakland, CA 94612 USA.							ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Brooks P., 1998, AM J MED, V104, p9S, DOI DOI 10.1016/S0002-9343(97)00204-0; DAWOOD MY, 1993, AM J OBSTET GYNECOL, V169, P1255; Hernandez-Diaz Sonia, 2001, American Journal of Medicine, V110, p20S; HERTZPICCIOTTO I, 1990, EPIDEMIOL REV, V12, P108, DOI 10.1093/oxfordjournals.epirev.a036049; Howards PP, 2002, AM J EPIDEMIOL, V155, ps35; Janssen NM, 2000, ARCH INTERN MED, V160, P610, DOI 10.1001/archinte.160.5.610; Li DK, 2002, EPIDEMIOLOGY, V13, P9, DOI 10.1097/00001648-200201000-00004; Nielsen GL, 2001, BRIT MED J, V322, P266, DOI 10.1136/bmj.322.7281.266; Setter S M, 2001, Home Care Provid, V6, P100, DOI 10.1067/mhc.2001.116262; STREISSGUTH AP, 1987, TERATOLOGY, V35, P211, DOI 10.1002/tera.1420350207; TM Therneau., 2000, MODELING SURVIVAL DA, DOI DOI 10.1007/978; vanderWeiden RMF, 1996, AM J OBSTET GYNECOL, V174, P1614, DOI 10.1016/S0002-9378(96)70616-6; vanderWeiden RMF, 1997, BRIT J RHEUMATOL, V36, P605; VANDERWEIDEN RMF, 1991, HUM REPROD, V6, P436, DOI 10.1093/oxfordjournals.humrep.a137354; WERLER MM, 1989, NEW ENGL J MED, V321, P1639, DOI 10.1056/NEJM198912143212404; [No title captured]	17	208	221	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					368	371		10.1136/bmj.327.7411.368	http://dx.doi.org/10.1136/bmj.327.7411.368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919986	Green Published, Bronze			2022-12-28	WOS:000184864200016
J	Keller, U				Keller, U			Recent developments in compact ultrafast lasers	NATURE			English	Review							MODE-LOCKED LASERS; X-RAY PULSES; SATURABLE-ABSORBER; PHASE-CONTROL; REPETITION RATES; CHIRPED MIRRORS; OPTICAL PULSES; FEMTOSECOND; GENERATION; DISPERSION	Ultrafast lasers, which generate optical pulses in the picosecond and femtosecond range, have progressed over the past decade from complicated and specialized laboratory systems to compact, reliable instruments. Semiconductor lasers for optical pumping and fast optical saturable absorbers, based on either semiconductor devices or the optical nonlinear Kerr effect, have dramatically improved these lasers and opened up new frontiers for applications with extremely short temporal resolution (much smaller than 10 fs), extremely high peak optical intensities (greater than 10 TW/cm(2)) and extremely fast pulse repetition rates (greater than 100 GHz).	ETH, Swiss Fed Inst Technol, Dept Phys, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Keller, U (corresponding author), ETH, Swiss Fed Inst Technol, Dept Phys, Zurich, Switzerland.	keller@phys.ethz.ch	Keller, Ursula/N-2437-2016	Keller, Ursula/0000-0002-1689-8041				Apolonski A, 2000, PHYS REV LETT, V85, P740, DOI 10.1103/PhysRevLett.85.740; Arahira S, 1996, IEEE J QUANTUM ELECT, V32, P1211, DOI 10.1109/3.517021; ASAKI MT, 1993, OPT LETT, V18, P977, DOI 10.1364/OL.18.000977; Baltuska A, 2003, NATURE, V421, P611, DOI 10.1038/nature01414; Bauer M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.025501; Boivin L, 1999, IEEE PHOTONIC TECH L, V11, P466, DOI 10.1109/68.752550; CERULLO G, 1994, OPT LETT, V19, P1040, DOI 10.1364/OL.19.001040; CERULLO G, 1994, OPT LETT, V19, P807, DOI 10.1364/OL.19.000807; CURLEY PF, 1993, OPT LETT, V18, P54, DOI 10.1364/OL.18.000054; DESOUZA EA, 1995, OPT LETT, V20, P1166, DOI 10.1364/OL.20.001166; DIELS JC, 1990, DYE LASER PRINCIPLES, P41; Drescher M, 2001, SCIENCE, V291, P1923, DOI 10.1126/science.1058561; Ell R, 2001, OPT LETT, V26, P373, DOI 10.1364/OL.26.000373; FERRAY M, 1988, J PHYS B-AT MOL OPT, V21, pL31, DOI 10.1088/0953-4075/21/3/001; FORK RL, 1987, OPT LETT, V12, P483, DOI 10.1364/OL.12.000483; FORK RL, 1984, OPT LETT, V9, P150, DOI 10.1364/OL.9.000150; Fujimoto JG, 2001, CR ACAD SCI IV-PHYS, V2, P1099, DOI 10.1016/S1296-2147(01)01257-4; Gallmann L, 2000, APPL PHYS B-LASERS O, V70, pS67, DOI 10.1007/s003400000307; Gallmann L, 1999, OPT LETT, V24, P1314, DOI 10.1364/OL.24.001314; GIBSON AF, 1974, APPL PHYS LETT, V24, P306, DOI 10.1063/1.1655194; GIESEN A, 1994, APPL PHYS B-LASERS O, V58, P365, DOI 10.1007/BF01081875; Hammer DX, 1996, IEEE J QUANTUM ELECT, V32, P670, DOI 10.1109/3.488842; Haring R, 2002, IEEE J QUANTUM ELECT, V38, P1268, DOI 10.1109/JQE.2002.802111; Hatziefremidis A, 1999, NUCL INSTRUM METH A, V431, P46, DOI 10.1016/S0168-9002(99)00271-5; Helbing FW, 2002, APPL PHYS B-LASERS O, V74, pS35, DOI 10.1007/s00340-002-0898-4; Holzwarth R, 2000, PHYS REV LETT, V85, P2264, DOI 10.1103/PhysRevLett.85.2264; Holzwarth R, 2001, IEEE J QUANTUM ELECT, V37, P1493, DOI 10.1109/3.970894; Honninger C, 1999, J OPT SOC AM B, V16, P46, DOI 10.1364/JOSAB.16.000046; Hoogland S, 2000, IEEE PHOTONIC TECH L, V12, P1135, DOI 10.1109/68.874213; HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169; Innerhofer E, 2003, OPT LETT, V28, P367, DOI 10.1364/OL.28.000367; IPPEN EP, 1980, APPL PHYS LETT, V37, P267, DOI 10.1063/1.91902; ISHIDA Y, 1990, ULTRAFAST PHENOMENA; ISLAM MN, 1989, IEEE J QUANTUM ELECT, V25, P2454, DOI 10.1109/3.40629; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; Juhasz T, 1999, IEEE J SEL TOP QUANT, V5, P902, DOI 10.1109/2944.796309; Kartner FX, 1997, OPT LETT, V22, P831, DOI 10.1364/OL.22.000831; Kartner FX, 1996, IEEE J SEL TOP QUANT, V2, P540, DOI 10.1109/2944.571754; KELLER U, 1992, OPT LETT, V17, P505, DOI 10.1364/OL.17.000505; Keller U, 1999, SEMICONDUCT SEMIMET, V59, P211; Keller U, 1996, IEEE J SEL TOP QUANT, V2, P435, DOI 10.1109/2944.571743; KELLER U, 1992, IEEE J QUANTUM ELECT, V28, P2123, DOI 10.1109/3.159521; KELLER U, 1991, OPT LETT, V16, P1022, DOI 10.1364/OL.16.001022; Krainer L, 2000, ELECTRON LETT, V36, P1846, DOI 10.1049/el:20001289; Krainer L, 1999, APPL PHYS B-LASERS O, V69, P245, DOI 10.1007/s003400050801; Krainer L, 2002, IEEE J QUANTUM ELECT, V38, P1331, DOI 10.1109/JQE.2002.802967; Krainer L, 2002, ELECTRON LETT, V38, P225, DOI 10.1049/el:20020055; Krishnamoorthy AV, 1996, IEEE J SEL TOP QUANT, V2, P55, DOI 10.1109/2944.541875; Lecomte S, 2002, OPT LETT, V27, P1714, DOI 10.1364/OL.27.001714; LEWENSTEIN M, 1994, PHYS REV A, V49, P2117, DOI 10.1103/PhysRevA.49.2117; Liu X, 1997, IEEE J QUANTUM ELECT, V33, P1706, DOI 10.1109/3.631270; Loesel FH, 1998, APPL PHYS B-LASERS O, V66, P121, DOI 10.1007/s003400050365; Loesel FH, 1996, IEEE J QUANTUM ELECT, V32, P1717, DOI 10.1109/3.538774; Maria A. J., 1966, APPL PHYS LETT, V8, P174; Matuschek N, 2000, APPL PHYS B-LASERS O, V71, P509, DOI 10.1007/s003400000426; Matuschek N, 1999, IEEE J QUANTUM ELECT, V35, P129, DOI 10.1109/3.740733; Miller DAB, 2000, IEEE J SEL TOP QUANT, V6, P1312, DOI 10.1109/2944.902184; Mollenauer LF, 2000, OPT LETT, V25, P704, DOI 10.1364/OL.25.000704; Mollenauer LF, 1998, IEEE J QUANTUM ELECT, V34, P2089, DOI 10.1109/3.726598; MOULTON PF, 1986, J OPT SOC AM B, V3, P125, DOI 10.1364/JOSAB.3.000125; MURNANE MM, 1991, SCIENCE, V251, P531, DOI 10.1126/science.251.4993.531; NEGUS DK, 1991, ADV SOLID STATE LASE, V10, P120; Nisoli M, 1997, OPT LETT, V22, P522, DOI 10.1364/OL.22.000522; Nolte S, 1997, J OPT SOC AM B, V14, P2716, DOI 10.1364/JOSAB.14.002716; Paschotta R, 2000, APPL PHYS B-LASERS O, V70, pS25, DOI 10.1007/s003400000269; Paschotta R, 2001, APPL PHYS B-LASERS O, V73, P653, DOI 10.1007/s003400100726; Paulus GG, 2001, NATURE, V414, P182, DOI 10.1038/35102520; RAMASWAMI R, 1998, MOR KAUF NETW, P1; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; SALIN F, 1991, OPT LETT, V16, P1674, DOI 10.1364/OL.16.001674; SCHENKEL B, IN PRESS OPT LETT; Schmidt O, 2002, APPL PHYS B-LASERS O, V74, P223, DOI 10.1007/s003400200803; Shah J., 1996, ULTRAFAST SPECTROSCO; SHANK CV, 1974, APPL PHYS LETT, V24, P373, DOI 10.1063/1.1655222; SHANK CV, 1988, ULTRASHORT LASER PUL, pCH2; Shirakawa A, 1999, APPL PHYS LETT, V74, P2268, DOI 10.1063/1.123820; Siders CW, 1999, SCIENCE, V286, P1340, DOI 10.1126/science.286.5443.1340; SPENCE DE, 1991, OPT LETT, V16, P42, DOI 10.1364/OL.16.000042; SPENCE DE, 1990, C LAS EL CLEO OSA IE; Spuhler GJ, 2003, ELECTRON LETT, V39, P778, DOI 10.1049/el:20030501; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507; Stenger J, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.021802; STINGL A, 1995, OPT LETT, V20, P602, DOI 10.1364/OL.20.000602; Sudmeyer T, 2001, OPT LETT, V26, P304, DOI 10.1364/OL.26.000304; SUDMEYER T, IN PRESS OPT LETT; Sutter DH, 1999, OPT LETT, V24, P631, DOI 10.1364/OL.24.000631; SZIPOCS R, 1994, OPT LETT, V19, P201, DOI 10.1364/OL.19.000201; Telle HR, 1999, APPL PHYS B-LASERS O, V69, P327, DOI 10.1007/s003400050813; Udem T, 2002, NATURE, V416, P233, DOI 10.1038/416233a; VALDMANIS JA, 1986, IEEE J QUANTUM ELECT, V22, P69, DOI 10.1109/JQE.1986.1072867; VALDMANIS JA, 1986, IEEE J QUANTUM ELECT, V22, P112, DOI 10.1109/JQE.1986.1072854; vonderLinde D, 1997, APPL SURF SCI, V109, P1, DOI 10.1016/S0169-4332(96)00611-3; WEINGARTEN KJ, 1988, IEEE J QUANTUM ELECT, V24, P198, DOI 10.1109/3.115; Xu L, 1996, OPT LETT, V21, P2008, DOI 10.1364/OL.21.002008; Zeller SC, 2003, APPL PHYS B-LASERS O, V76, P787, DOI 10.1007/s00340-003-1181-z; Zewail AH, 1996, J PHYS CHEM-US, V100, P12701, DOI 10.1021/jp960658s; Zewail AH, 2000, J PHYS CHEM A, V104, P5660, DOI 10.1021/jp001460h; ZHOU JP, 1994, OPT LETT, V19, P1149, DOI 10.1364/OL.19.001149	99	1598	1659	43	706	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					831	838		10.1038/nature01938	http://dx.doi.org/10.1038/nature01938			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917697				2022-12-28	WOS:000184733900052
J	Massad, LS				Massad, LS			For what?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1287	1287		10.1001/jama.290.10.1287	http://dx.doi.org/10.1001/jama.290.10.1287			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966105				2022-12-28	WOS:000185188600001
J	Trachtman, H; Cnaan, A; Christen, E; Gibbs, K; Zhao, SY; Acheson, DWK; Weiss, R; Kaskel, FJ; Spitzer, A; Hirschman, GH				Trachtman, H; Cnaan, A; Christen, E; Gibbs, K; Zhao, SY; Acheson, DWK; Weiss, R; Kaskel, FJ; Spitzer, A; Hirschman, GH		Investigators HUS-SYNSORB Pk Multic	Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESCHERICHIA-COLI O157-H7; MONOCLONAL-ANTIBODY TMA-15; INFECTIONS; EPIDEMIOLOGY; PATHOGENESIS; CHROMOSORB; PK	Context Diarrhea-associated hemolytic uremic syndrome (HUS) is the most common cause of acute renal failure in children. Most cases are caused by an intestinal infection with Shiga toxin-producing strains of Escherichia coli. Objective To determine if administration of an oral agent that binds Shiga toxin could diminish the severity of diarrhea-associated HUS in pediatric patients. Design, Setting, and Patients Multicenter, randomized, double-blind, placebo-controlled clinical trial of 145 children (96 experimental and 49 placebo) aged 6 months to 18 years with diarrhea-associated HUS conducted between July 27, 1997, and April 14, 2001, at 26 tertiary care pediatric nephrology centers in the United States and Canada. Trial included 2 phases, the hospital course for treatment of the acute illness and a 60-day outpatient follow-up period after discharge from the hospital. Intervention Patients were assigned to receive the binding agent, 500 mg/kg daily, or cornmeal placebo orally for 7 days in a 2:1 randomization scheme. Main Outcome Measures Combined frequency of death or serious extrarenal events and need for dialysis in the experimental vs placebo group. Results A total of 62 patients (43%) were male and 123 (85%) were white. The median age of the patients was 4.2 years. Most patients (59%) were transferred from other hospitals to participating sites. The severity of disease at the time of randomization was comparable in the 2 groups. The prevalence of death or serious extrarenal events was 18% and 20% in the experimental and placebo groups, respectively (P=.82). Dialysis was required in 42% of experimental and 39% of placebo groups (P=.86). Conclusions Oral therapy with a Shiga toxin-binding agent failed to diminish the severity of disease in pediatric patients with diarrhea-associated HUS.	N Shore Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Dept Pediat, Div Nephrol, New Hyde Pk, NY 11040 USA; Childrens Hosp Philadelphia, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; New York Med Coll, Dept Pediat, Valhalla, NY 10595 USA; Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA; NIDDKD, NIH, Kidney & Urol Program, Bethesda, MD 20892 USA	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University System of Maryland; University of Maryland Baltimore; New York Medical College; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Trachtman, H (corresponding author), N Shore Long Isl Jewish Med Ctr, Schneider Childrens Hosp, Dept Pediat, Div Nephrol, 269-0176th Ave,Room SCH365, New Hyde Pk, NY 11040 USA.	trachtma@lij.edu	Trachtman, Howard/GSE-2340-2022	Trachtman, Howard/0000-0001-7447-9489	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052147] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R01-DK52147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreoli SP, 2002, PEDIATR NEPHROL, V17, P293, DOI 10.1007/s00467-001-0783-0; ARMSTRONG GD, 1991, J INFECT DIS, V164, P1160, DOI 10.1093/infdis/164.6.1160; ARMSTRONG GD, 1995, J INFECT DIS, V171, P1042, DOI 10.1093/infdis/171.4.1042; Banatvala N, 2001, J INFECT DIS, V183, P1063, DOI 10.1086/319269; BERGSTEIN JM, 1992, NEW ENGL J MED, V327, P755, DOI 10.1056/NEJM199209103271102; Cornick NA, 2002, J INFECT DIS, V186, P57, DOI 10.1086/341295; DALTON RN, 1998, PEDIAT NEPHROLOGY, P354; Diez-Gonzalez F, 1998, SCIENCE, V281, P1666, DOI 10.1126/science.281.5383.1666; HULL AE, 1993, J CLIN MICROBIOL, V31, P1167, DOI 10.1128/JCM.31.5.1167-1172.1993; Kaplan BS, 1998, J AM SOC NEPHROL, V9, P1126; Karch H, 1999, DIAGN MICR INFEC DIS, V34, P229, DOI 10.1016/S0732-8893(99)00031-0; Kimura T, 2002, HYBRIDOMA HYBRIDOM, V21, P161, DOI 10.1089/153685902760173872; Kitov PI, 2000, NATURE, V403, P669, DOI 10.1038/35001095; LOPEZ EL, 1992, J PEDIATR-US, V120, P210, DOI 10.1016/S0022-3476(05)80429-9; Mead PS, 1998, LANCET, V352, P1207, DOI 10.1016/S0140-6736(98)01267-7; MEYERS KEC, 1998, PEDIAT NEPHROLOGY, P811; Mukherjee J, 2002, INFECT IMMUN, V70, P612, DOI 10.1128/IAI.70.2.612-619.2002; Nishikawa K, 2002, P NATL ACAD SCI USA, V99, P7669, DOI 10.1073/pnas.112058999; Paton AW, 2000, NAT MED, V6, P265, DOI 10.1038/73111; Ray PE, 2001, PEDIATR NEPHROL, V16, P823, DOI 10.1007/s004670100660; ROWE PC, 1991, J PEDIATR-US, V119, P218, DOI 10.1016/S0022-3476(05)80730-9; Schulman SL, 1996, PEDIATR NEPHROL, V10, P671, DOI 10.1007/s004670050187; SIEGLER RL, 1994, J PEDIATR-US, V125, P511, DOI 10.1016/S0022-3476(94)70001-X; Takeda T, 1999, MICROBIOL IMMUNOL, V43, P331, DOI 10.1111/j.1348-0421.1999.tb02413.x; te Loo DMWM, 2001, J AM SOC NEPHROL, V12, P800, DOI 10.1681/ASN.V124800; THAYER DW, 1993, APPL ENVIRON MICROB, V59, P1030, DOI 10.1128/AEM.59.4.1030-1034.1993; Trachtman Howard, 1999, Current Opinion in Pediatrics, V11, P162, DOI 10.1097/00008480-199904000-00011; Yamagami S, 2001, J INFECT DIS, V184, P738, DOI 10.1086/323082	28	131	140	1	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1337	1344		10.1001/jama.290.10.1337	http://dx.doi.org/10.1001/jama.290.10.1337			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966125				2022-12-28	WOS:000185188600026
J	Hartschuh, A; Pedrosa, HN; Novotny, L; Krauss, TD				Hartschuh, A; Pedrosa, HN; Novotny, L; Krauss, TD			Simultaneous fluorescence and Raman scattering from single carbon nanotubes	SCIENCE			English	Article							SPECTROSCOPY; MOLECULES; MODES	Single-molecule fluorescence spectroscopy was used to determine the electronic properties of individual single-walled carbon nanotubes. Carbon nanotube structure was determined simultaneously from Raman spectroscopy. Fluorescence spectra from individual nanotubes with identical structures have different emission energies and linewidths that likely arise from defects or the local environment. Unlike most other molecules studied to date, the fluorescence intensity or spectrum from a single nanotube unexpectedly did not fluctuate.	Univ Rochester, Inst Opt, Rochester, NY 14627 USA; Univ Rochester, Dept Chem, Rochester, NY 14627 USA; Univ Siegen, D-57068 Siegen, Germany	University of Rochester; University of Rochester; Universitat Siegen	Hartschuh, A (corresponding author), Univ Rochester, Inst Opt, Rochester, NY 14627 USA.		Krauss, Todd/GQA-6399-2022; Hartschuh, Achim/N-7136-2015	Krauss, Todd/0000-0002-4860-874X; 				Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Duesberg GS, 2000, PHYS REV LETT, V85, P5436, DOI 10.1103/PhysRevLett.85.5436; Hartschuh A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.095503; Hertel T, 2000, PHYS REV LETT, V84, P5002, DOI 10.1103/PhysRevLett.84.5002; Jiang KL, 2002, NATURE, V419, P801, DOI 10.1038/419801a; Jorio A, 2001, PHYS REV LETT, V86, P1118, DOI 10.1103/PhysRevLett.86.1118; Journet C, 1997, NATURE, V388, P756, DOI 10.1038/41972; Kane CL, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.207401; Lebedkin S, 2003, J PHYS CHEM B, V107, P1949, DOI 10.1021/jp027096z; Li ZM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127401; McEuen PL, 1999, PHYS REV LETT, V83, P5098, DOI 10.1103/PhysRevLett.83.5098; Misewich JA, 2003, SCIENCE, V300, P783, DOI 10.1126/science.1081294; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Rao AM, 1997, SCIENCE, V275, P187, DOI 10.1126/science.275.5297.187; Saito R., 1998, PHYS PROPERTIES CARB; Tombler TW, 2000, NATURE, V405, P769, DOI 10.1038/35015519; TRAUTMAN JK, 1994, NATURE, V369, P40, DOI 10.1038/369040a0; Woodside MT, 2002, SCIENCE, V296, P1098, DOI 10.1126/science.1069923; Zhao JL, 2002, NANO LETT, V2, P823, DOI 10.1021/nl025576w	21	341	345	5	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1354	1356		10.1126/science.1087118	http://dx.doi.org/10.1126/science.1087118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958353				2022-12-28	WOS:000185116400033
J	Kuroda, H; Maliga, P				Kuroda, H; Maliga, P			The plastid clpP1 protease gene is essential for plant development	NATURE			English	Article							ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; PHOTOSYSTEM-II; TOBACCO; TRANSFORMATION; GENOME; RNA; RECOMBINATION; CHLOROPLASTS; MUTAGENESIS	Plastids of higher plants are semi-autonomous cellular organelles that have their own genome and transcription-translation machinery(1). Examples of plastid functions are photosynthesis and biosynthesis of starch, amino acids, lipids and pigments(2). Plastid functions are encoded in similar to120 plastid genes(1) and similar to3,000 nuclear genes(2,3). Although many embryo and seedling lethal nuclear genes are required for chloroplast biogenesis(4-6), until now deletion of plastid genes either had no phenotypic consequence (8 genes), or caused a mutant phenotype but did not affect viability (13 genes)(7-10). Here we identify an essential plastid gene. By using the CRE-lox site-specific recombination system(11,12) we have deleted clpP1 (caseinolytic protease P1), one of the three genes (clpP1, ycf1 and ycf2) whose disruption had previously only been possible in a fraction of the 1,000-10,000 plastid genome copies in a cell(7,13). Loss of the clpP1 gene product, the ClpP1 protease subunit(14), results in ablation of the shoot system of tobacco plants, suggesting that ClpP1-mediated protein degradation is essential for shoot development.	Rutgers State Univ, Waksman Inst Microbiol, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Plant Biol, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Maliga, P (corresponding author), Rutgers State Univ, Waksman Inst Microbiol, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.							Adam Z, 2002, TRENDS PLANT SCI, V7, P451, DOI 10.1016/S1360-1385(02)02326-9; Bock Ralph, 2002, V63, P106; Budziszewski GJ, 2001, GENETICS, V159, P1765; Cahoon AB, 2003, PLANT CELL PHYSIOL, V44, P93, DOI 10.1093/pcp/pcg003; Corneille S, 2001, PLANT J, V27, P171, DOI 10.1046/j.1365-313x.2001.01068.x; CORNEILLE S, IN PRESS PLANT J; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Hager M, 2002, J BIOL CHEM, V277, P14031, DOI 10.1074/jbc.M112053200; Hajdukiewicz PTJ, 2001, PLANT J, V27, P161, DOI 10.1046/j.1365-313x.2001.01067.x; HAN CD, 1992, EMBO J, V11, P4037, DOI 10.1002/j.1460-2075.1992.tb05497.x; HESS WR, 1993, EMBO J, V12, P563, DOI 10.1002/j.1460-2075.1993.tb05688.x; Kuroda H, 2002, PLANT PHYSIOL, V129, P1600, DOI 10.1104/pp.004986; Leister D, 2003, TRENDS GENET, V19, P47, DOI 10.1016/S0168-9525(02)00003-3; Marechal Eric, 2002, Trends Plant Sci, V7, P99, DOI 10.1016/S1360-1385(02)02248-3; Martin W, 2002, P NATL ACAD SCI USA, V99, P12246, DOI 10.1073/pnas.182432999; McElver J, 2001, GENETICS, V159, P1751; Ow DW, 2002, PLANT MOL BIOL, V48, P183, DOI 10.1023/A:1013718106742; Peltier JB, 2001, J BIOL CHEM, V276, P16318, DOI 10.1074/jbc.M010503200; Shikanai T, 2001, PLANT CELL PHYSIOL, V42, P264, DOI 10.1093/pcp/pce031; Springer PS, 2000, PLANT CELL, V12, P1007, DOI 10.1105/tpc.12.7.1007; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; SUGIURA M, 1992, PLANT MOL BIOL, V19, P149, DOI 10.1007/BF00015612; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; Swiatek M, 2003, CURR GENET, V43, P45, DOI 10.1007/s00294-003-0369-4; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; WALBOT V, 1979, P NATL ACAD SCI USA, V76, P2760, DOI 10.1073/pnas.76.6.2760; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WOLFE KH, 1992, P NATL ACAD SCI USA, V89, P10648, DOI 10.1073/pnas.89.22.10648; Zhou YN, 2001, GENE DEV, V15, P627, DOI 10.1101/gad.864401; Zubko MK, 1998, PLANT J, V15, P265, DOI 10.1046/j.1365-313X.1998.00195.x	30	148	153	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					86	89		10.1038/nature01909	http://dx.doi.org/10.1038/nature01909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955146				2022-12-28	WOS:000185089200043
J	Sung, BJ; Hwang, KY; Jeon, YH; Lee, JI; Heo, YS; Kim, JH; Moon, J; Yoon, JM; Hyun, YL; Kim, E; Eum, SJ; Park, SY; Lee, JO; Lee, TG; Ro, S; Cho, JM				Sung, BJ; Hwang, KY; Jeon, YH; Lee, JI; Heo, YS; Kim, JH; Moon, J; Yoon, JM; Hyun, YL; Kim, E; Eum, SJ; Park, SY; Lee, JO; Lee, TG; Ro, S; Cho, JM			Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules	NATURE			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; CGMP-BINDING; INHIBITORS; MECHANISM; COMPLEX; PDE5	Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP(1-3). As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction(4-7). Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available(8,9). Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.	CrystalGenom Inc, Div Drug Discovery, Taejon 305390, South Korea; Yokohama City Univ, Prot Design Lab, Yokohama, Kanagawa 2300045, Japan; Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea	Yokohama City University; Korea Advanced Institute of Science & Technology (KAIST)	Ro, S (corresponding author), CrystalGenom Inc, Div Drug Discovery, Daedeok Biocommunity, Taejon 305390, South Korea.	sgro@crystalgenomics.com; jmcho@crystalgenomics.com	Lee, Jie-Oh/AAG-4302-2020; Jeon, Young Ho/F-4483-2011; Lee, Jie-Oh/C-1581-2011	Lee, Jie-Oh/0000-0001-6519-6049				BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; Corbin JD, 2002, INT J CLIN PRACT, V56, P453; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lee JY, 2002, J NANOPART RES, V4, P53, DOI 10.1023/A:1020107522135; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Orme M W, 2002, [No title captured], Patent No. [WO 0236593, 0236593]; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rotella DP, 2002, NAT REV DRUG DISCOV, V1, P674, DOI 10.1038/nrd893; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SEKHAR KR, 1996, PHOSPHODIESTERASE IN, P135; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Young JM, 2002, EXPERT OPIN INV DRUG, V11, P1487, DOI 10.1517/13543784.11.10.1487	23	207	222	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					98	102		10.1038/nature01914	http://dx.doi.org/10.1038/nature01914			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955149				2022-12-28	WOS:000185089200046
J	Velicer, GJ; Yu, YTN				Velicer, GJ; Yu, YTN			Evolution of novel cooperative swarming in the bacterium Myxococcus xanthus	NATURE			English	Article							CELL-INTERACTIONS; SOCIAL MOTILITY; GLIDING MOTILITY; GENE; MULTICELLULARITY; EXPRESSION; EXCITATION; COHESION; FIBRILS; SYSTEMS	Cooperation among individuals is necessary for evolutionary transitions to higher levels of biological organization(1-3). In such transitions, groups of individuals at one level (such as single cells) cooperate to form selective units at a higher level (such as multicellular organisms). Though the evolution of cooperation is difficult to observe directly in higher eukaryotes, microorganisms do offer such an opportunity(4). Here we report the evolution of novel cooperative behaviour in experimental lineages of the bacterium Myxococcus xanthus. Wild-type strains of M. xanthus exhibit socially dependent swarming across soft surfaces(5) by a mechanism known as 'S-motility' that requires the presence of extracellular type IV pili(6). In lineages of M. xanthus unable to make pili, a new mechanistic basis for cooperative swarming evolved. Evolved swarming is mediated, at least in part, by enhanced production of an extracellular fibril matrix that binds cells-and their evolutionary interests-together. Though costly to individuals, fibril production greatly enhanced population expansion in groups of interconnected cells. These results show that fundamental transitions to primitive cooperation can readily occur in bacteria.	Max Planck Inst Dev Biol, Dept Evolutionary Biol, D-72076 Tubingen, Germany; Max Planck Inst Dev Biol, Dept Prot Evolut, D-72076 Tubingen, Germany	Max Planck Society; Max Planck Society	Velicer, GJ (corresponding author), Max Planck Inst Dev Biol, Dept Evolutionary Biol, Spemannstr 35, D-72076 Tubingen, Germany.							ARNOLD JW, 1988, J BACTERIOL, V170, P5765, DOI 10.1128/jb.170.12.5765-5770.1988; BEHMLANDER RM, 1994, J BACTERIOL, V176, P6295, DOI 10.1128/jb.176.20.6295-6303.1994; BEHMLANDER RM, 1991, J BACTERIOL, V173, P7810, DOI 10.1128/jb.173.24.7810-7820.1991; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; Cramton SE, 2001, INFECT IMMUN, V69, P4079, DOI 10.1128/IAI.69.6.4079-4085.2001; Crespi BJ, 2001, TRENDS ECOL EVOL, V16, P178, DOI 10.1016/S0169-5347(01)02115-2; DANA JR, 1993, J BACTERIOL, V175, P3636, DOI 10.1128/jb.175.11.3636-3647.1993; HODGKIN J, 1979, MOL GEN GENET, V171, P177, DOI 10.1007/BF00270004; Kearns DB, 2001, TRENDS MICROBIOL, V9, P126, DOI 10.1016/S0966-842X(01)01948-5; Kearns DB, 2002, J BACTERIOL, V184, P1678, DOI 10.1128/JB.184.6.1678-1684.2002; Kearns DB, 2000, P NATL ACAD SCI USA, V97, P11505, DOI 10.1073/pnas.210448597; Krause J, 2002, LIVING GROUPS; Lancero H, 2002, J BACTERIOL, V184, P1462, DOI 10.1128/JB.184.5.1462-1465.2002; Michod RE, 2001, HEREDITY, V86, P1, DOI 10.1046/j.1365-2540.2001.00808.x; Pfeiffer T, 2003, P NATL ACAD SCI USA, V100, P1095, DOI 10.1073/pnas.0335420100; Queller DC, 2003, SCIENCE, V299, P105, DOI 10.1126/science.1077742; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; Rodriguez AM, 1999, J BACTERIOL, V181, P4381, DOI 10.1128/JB.181.14.4381-4390.1999; SHI WY, 1993, P NATL ACAD SCI USA, V90, P3378, DOI 10.1073/pnas.90.8.3378; SHIMKETS LJ, 1986, J BACTERIOL, V166, P842, DOI 10.1128/jb.166.3.842-848.1986; Shimkets LJ, 1999, ANNU REV MICROBIOL, V53, P525, DOI 10.1146/annurev.micro.53.1.525; Szathmary E, 1995, MAJOR TRANSITIONS EV; Velicer GJ, 1998, P NATL ACAD SCI USA, V95, P12376, DOI 10.1073/pnas.95.21.12376; Velicer GJ, 2003, TRENDS MICROBIOL, V11, P330, DOI 10.1016/S0966-842X(03)00152-5; Velicer GJ, 2002, J BACTERIOL, V184, P2719, DOI 10.1128/JB.184.10.2719-2727.2002; Wolgemuth C, 2002, CURR BIOL, V12, P369, DOI 10.1016/S0960-9822(02)00716-9; Wu SS, 1996, J BACTERIOL, V178, P5817, DOI 10.1128/jb.178.19.5817-5821.1996; WU SS, 1995, MOL MICROBIOL, V18, P547, DOI 10.1111/j.1365-2958.1995.mmi_18030547.x; Wu SS, 1997, J BACTERIOL, V179, P7748, DOI 10.1128/jb.179.24.7748-7758.1997	30	132	136	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 4	2003	425	6953					75	78		10.1038/nature01908	http://dx.doi.org/10.1038/nature01908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955143				2022-12-28	WOS:000185089200040
J	Ahn, CH; Triscone, JM; Mannhart, J				Ahn, CH; Triscone, JM; Mannhart, J			Electric field effect in correlated oxide systems	NATURE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; EFFECT TRANSISTOR; ELECTROSTATIC MODULATION; YBA2CU3O7-DELTA FILMS; INSULATOR TRANSITIONS; NORMAL-STATE; SILICON; HETEROSTRUCTURES; CROSSOVER; PHYSICS	Semiconducting field-effect transistors are the workhorses of the modern electronics era. Recently, application of the field-effect approach to compounds other than semiconductors has created opportunities to electrostatically modulate types of correlated electron behaviour-including high-temperature superconductivity and colossal magnetoresistance- and potentially tune the phase transitions in such systems. Here we provide an overview of the achievements in this field and discuss the opportunities brought by the field-effect approach.	Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA; Univ Geneva, Dept Condensed Matter Phys, CH-1211 Geneva 4, Switzerland; Univ Augsburg, Inst Phys, Ctr Elect Correlat & Magnetism, D-86135 Augsburg, Germany	Yale University; University of Geneva; University of Augsburg	Ahn, CH (corresponding author), Yale Univ, Dept Appl Phys, POB 208284, New Haven, CT 06520 USA.			Mannhart, Jochen/0000-0001-6331-2640				Abrahams E, 2001, REV MOD PHYS, V73, P251, DOI 10.1103/RevModPhys.73.251; Ahn CH, 1999, SCIENCE, V284, P1152, DOI 10.1126/science.284.5417.1152; Ahn CH, 1997, SCIENCE, V276, P1100, DOI 10.1126/science.276.5315.1100; Aidam R, 1999, PHYSICA C, V328, P21, DOI 10.1016/S0921-4534(99)00526-2; BEDNORZ JG, 1986, Z PHYS B CON MAT, V64, P189, DOI 10.1007/BF01303701; Boebinger GS, 1996, PHYS REV LETT, V77, P5417, DOI 10.1103/PhysRevLett.77.5417; CHRISTEN HM, 1994, PHYS REV B, V49, P12095, DOI 10.1103/PhysRevB.49.12095; Chu CW, 2002, PHYS SCRIPTA, VT102, P40, DOI 10.1238/Physica.Topical.102a00040; de Picciotto R, 2000, PHYS REV LETT, V85, P1730, DOI 10.1103/PhysRevLett.85.1730; EMERY VJ, 1995, PHYS REV LETT, V74, P3253, DOI 10.1103/PhysRevLett.74.3253; Gariglio S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.067002; GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248; Goldman AM, 1998, PHYS TODAY, V51, P39, DOI 10.1063/1.882069; Hebard A. F., 1987, Novel Superconductivity. Proceedings of the International Workshop on Novel Mechanisms of Superconductivity, P9; HONG X, IN PRESS SOLID STATE; Hubbard KJ, 1996, J MATER RES, V11, P2757, DOI 10.1557/JMR.1996.0350; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; Ivanov ZG, 1993, IEEE T APPL SUPERCON, V3, P2925, DOI 10.1109/77.234013; JEROME D, 1987, NATO ADV STUDY I B, V155; JOOSSE K, 1994, PHYSICA C, V224, P179, DOI 10.1016/0921-4534(94)90620-3; KRAVCHENKO SV, 1995, PHYS REV B, V51, P7038, DOI 10.1103/PhysRevB.51.7038; Levi BG, 2002, PHYS TODAY, V55, P14, DOI 10.1063/1.1522154; LEVY A, 1992, PHYS REV B, V46, P520, DOI 10.1103/PhysRevB.46.520; Lin A, 2001, APPL PHYS LETT, V78, P2034, DOI 10.1063/1.1358848; MANNHART J, 1993, APPL PHYS LETT, V62, P630, DOI 10.1063/1.108877; MANNHART J, 1991, Z PHYS B CON MAT, V83, P307, DOI 10.1007/BF01313398; Mannhart J, 1996, SUPERCOND SCI TECH, V9, P49, DOI 10.1088/0953-2048/9/2/001; Mathews S, 1997, SCIENCE, V276, P238, DOI 10.1126/science.276.5310.238; Mathur N, 2003, PHYS TODAY, V56, P25, DOI 10.1063/1.1554133; MATIJASEVIC VC, 1994, PHYSICA C, V235, P2097, DOI 10.1016/0921-4534(94)92269-1; Matthey D, 2002, PHYSICA C, V372, P583, DOI 10.1016/S0921-4534(02)00800-6; Mayer B, 1996, APPL PHYS LETT, V68, P3031, DOI 10.1063/1.115567; McKee RA, 1998, PHYS REV LETT, V81, P3014, DOI 10.1103/PhysRevLett.81.3014; Mott N.F., 1990, METAL INSULATOR TRAN; Newns DM, 1998, APPL PHYS LETT, V73, P780, DOI 10.1063/1.121999; Orenstein J, 2000, SCIENCE, V288, P468, DOI 10.1126/science.288.5465.468; Sachdev S., 1999, QUANTUM PHASE TRANSI; Schneider T, 1997, EUROPHYS LETT, V40, P79, DOI 10.1209/epl/i1997-00427-7; Shaw JM, 2001, IBM J RES DEV, V45, P3, DOI 10.1147/rd.451.0003; Stormer HL, 1999, REV MOD PHYS, V71, pS298, DOI 10.1103/RevModPhys.71.S298; Tanaka H, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.027204; Tokura Y., 2000, ADV CONDENSED MATTER, V2; UEMURA YJ, 1993, NATURE, V364, P605, DOI 10.1038/364605a0; UENO K, 2003, IN PRESS P M2S 2003; WATANABE Y, 1995, APPL PHYS LETT, V66, P1770, DOI 10.1063/1.113362; Wigner E, 1934, PHYS REV, V46, P1002, DOI 10.1103/PhysRev.46.1002; XI XX, 1992, PHYS REV LETT, V68, P1240, DOI 10.1103/PhysRevLett.68.1240; 2002, RESULTS INQUIRY VALI	49	564	573	5	263	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1015	1018		10.1038/nature01878	http://dx.doi.org/10.1038/nature01878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944958				2022-12-28	WOS:000184984200032
J	Foliaki, S; Pearce, N				Foliaki, S; Pearce, N			Prevention and control of diabetes in Pacific people	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LIFE-STYLE; DISEASE		Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand	Massey University	Foliaki, S (corresponding author), Massey Univ, Ctr Publ Hlth Res, Wellington Campus,Private Bag 756, Wellington, New Zealand.	s.foliaki@massey.ac.nz		, Sunia/0000-0002-3238-5940; Pearce, Neil/0000-0002-9938-7852				BENNET PH, 1984, 185 S PAC COMM; *DIAB PREV PROGR R, 2002, NEW ENGL J MED, V346, P1190; Ebrahim S, 2001, INT J EPIDEMIOL, V30, P201, DOI 10.1093/ije/30.2.201; Gilliland S., 1998, DIABETES SPECTRUM, V11, P166; Griffin JA, 2000, DIABETES EDUCATOR, V26, P681, DOI 10.1177/014572170002600416; Mau MK, 2001, DIABETES CARE, V24, P1770, DOI 10.2337/diacare.24.10.1770; McCarty Daniel J, 2001, EPIDEMIOLOGY DIABETE, P239; MCKINLAY RD, 1975, COMP POLIT, V8, P1, DOI 10.2307/421451; *MIN HLTH, 1999, ANN REP; Pearce N, 1996, AM J PUBLIC HEALTH, V86, P678, DOI 10.2105/AJPH.86.5.678; Pinkney J, 2002, BMJ-BRIT MED J, V325, P232, DOI 10.1136/bmj.325.7358.232; Prior I A, 1978, Adv Metab Disord, V9, P241; ROSE G, 2001, STRATEGY PREVENTIVE; Simmons D, 2000, NEW ZEAL MED J, V113, P364; SIMMONS D, 1994, NEW ZEAL MED J, V107, P197; Tunidau-Schultz J., 1997, Pacific Health Dialog, V4, P161; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; WILSON P, 1994, NEW ZEAL MED J, V107, P456; Zimmet P, 2000, J INTERN MED, V247, P301, DOI 10.1046/j.1365-2796.2000.00625.x; ZIMMET P, 2001, EPIDEMIOLOGY DIABETE, P41	20	18	18	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2003	327	7412					437	439		10.1136/bmj.327.7412.437	http://dx.doi.org/10.1136/bmj.327.7412.437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715YY	12933734	Green Accepted, Green Published			2022-12-28	WOS:000185003100024
J	Mercer, CH; Fenton, KA; Johnson, AM; Wellings, K; Macdowall, W; McManus, S; Nanchahal, K; Erens, B				Mercer, CH; Fenton, KA; Johnson, AM; Wellings, K; Macdowall, W; McManus, S; Nanchahal, K; Erens, B			Sexual function problems and help seeking behaviour in Britain: national probability sample survey	BRITISH MEDICAL JOURNAL			English	Article							ERECTILE DYSFUNCTION; PREVALENCE; QUESTIONNAIRE; POPULATION		UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Ctr Infect Dis Epidemiol, London WC1E 6AU, England; UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England; Hlth Protect Agcy, Ctr Communicable Dis Surveillance, HIV STI Div, London NW9 5EQ, England; Univ London London Sch Hyg & Trop Med, Ctr Sexual & Reprod Hlth Res, London WC1E 7HT, England; Natl Ctr Social Res, Hlth Res Grp, London EC1V 0AX, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; Health Protection Agency; University of London; London School of Hygiene & Tropical Medicine	Mercer, CH (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, Ctr Infect Dis Epidemiol, London WC1E 6AU, England.	cmercer@gum.ucl.ac.uk	McManus, Sally/S-4697-2019; McManus, Sally/HGD-4860-2022	McManus, Sally/0000-0003-2711-0819; Erens, Robert/0000-0002-3054-504X; Johnson, Anne/0000-0003-1330-7100; Macdowall, Wendy/0000-0001-5868-8336; Nanchahal, Kiran/0000-0001-8812-7628; Erens, Bob/0000-0002-4430-954X; Mercer, Catherine/0000-0002-4220-5034				Akkus E, 2002, EUR UROL, V41, P298, DOI 10.1016/S0302-2838(02)00027-1; CRENSHAW TL, 1996, SEXUAL PHARM DRUGS A; Daker-White G, 2002, ARCH SEX BEHAV, V31, P197, DOI 10.1023/A:1014743304566; Dunn KM, 1998, FAM PRACT, V15, P519, DOI 10.1093/fampra/15.6.519; ERENS B, 2001, NATL SURVEY SEXUAL A, V2; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Finkelhor D, 1991, VIOLENCE AM PUBLIC H, P79; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Humphery S, 2001, FAM PRACT, V18, P516, DOI 10.1093/fampra/18.5.516; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Kell P, 2001, INT J STD AIDS, V12, P395, DOI 10.1258/0956462011923183; Kinsey A, 1948, SEXUAL BEHAV HUMAN M, DOI 10.1037/t17515-000; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; MCCORMICK A, 1995, MORBIDITY STAT GEN P; MERCER CH, 2003, IN PRESS BMJ; Mirone V, 2002, EUR UROL, V41, P294, DOI 10.1016/S0302-2838(02)00005-2; Moreira ED, 2001, UROLOGY, V58, P583, DOI 10.1016/S0090-4295(01)01274-2; Moynihan R, 2003, BRIT MED J, V326, P45, DOI 10.1136/bmj.326.7379.45; PEACH C, 1998, ETHNICITY 1991 CENSU, V2, P206; REYNOLDS CF, 1988, PSYCHIAT RES, V24, P231, DOI 10.1016/0165-1781(88)90106-0; Simons JS, 2001, ARCH SEX BEHAV, V30, P177, DOI 10.1023/A:1002729318254; TAYLOR JF, 1994, ARCH SEX BEHAV, V23, P627, DOI 10.1007/BF01541816; Tiefer L, 2000, J SEX RES, V37, P273, DOI 10.1080/00224490009552048; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	26	262	264	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					426	427		10.1136/bmj.327.7412.426	http://dx.doi.org/10.1136/bmj.327.7412.426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933730	Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000185003100020
J	Fuller, W				Fuller, W			Who said 'helix'?	NATURE			English	Editorial Material							X-RAY DIFFRACTION; MOLECULAR CONFIGURATION; DEOXYRIBONUCLEIC ACID; FORM		Univ Keele, Sch Chem & Phys, Keele ST5 5BG, Staffs, England	Keele University	Fuller, W (corresponding author), Univ Keele, Sch Chem & Phys, Keele ST5 5BG, Staffs, England.							ASTBURY WT, 1947, SYM SOC EXP BIOL, V1, P66; FRANKLIN RE, 1953, ACTA CRYSTALLOGR, V6, P673, DOI 10.1107/S0365110X53001939; FULLER W, 1965, J MOL BIOL, V12, P60, DOI 10.1016/S0022-2836(65)80282-0; KLUG A, 1974, NATURE, V248, P787, DOI 10.1038/248787a0; KLUG A, 1968, NATURE, V219, P808, DOI 10.1038/219808a0; KLUG A, 1968, NATURE, V219, P1192, DOI 10.1038/2191192c0; KLUG A, 1968, NATURE, V219, P880, DOI 10.1038/219880b0; KLUG A, 1968, NATURE, V0219, P00843; KLUG A, 1968, NATURE, V219, P879; LANGRIDGE R, 1960, J MOL BIOL, V2, P38, DOI 10.1016/S0022-2836(60)80005-8; LANGRIDGE R, 1960, J MOL BIOL, V2, P19, DOI 10.1016/S0022-2836(60)80004-6; MADDOX B., 2002, R FRANKLIN DARK LADY; Olby R, 1974, PATH DOUBLE HELIX DI; STOKES AR, 1995, DNA GENESIS DISCOVER, P27; Watson J.D., 1968, DOUBLE HELIX PERSONA; WILSON HR, 1988, TRENDS BIOCHEM SCI, V13, P275, DOI 10.1016/0968-0004(88)90163-6	16	14	14	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					876	878		10.1038/424876a	http://dx.doi.org/10.1038/424876a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931159				2022-12-28	WOS:000184843600015
J	Lloyd-Williams, M; Dennis, M; Taylor, F; Baker, I				Lloyd-Williams, M; Dennis, M; Taylor, F; Baker, I			Is asking patients in palliative care, "Are you depressed?" appropriate? Prospective study	BRITISH MEDICAL JOURNAL			English	Article							SINGLE QUESTION; TERMINALLY ILL		Univ Liverpool, Sch Med, Dept Primary Care, Liverpool L69 3GB, Merseyside, England; Univ Leicester, Leicester Gen Hosp, Dept Psychiat, Leicester LE5 4PW, Leics, England; LOROS Hospice, Leicester LE3 9QE, Leics, England	University of Liverpool; University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester	Lloyd-Williams, M (corresponding author), Univ Liverpool, Sch Med, Dept Primary Care, Liverpool L69 3GB, Merseyside, England.							Chochinov HM, 1997, AM J PSYCHIAT, V154, P674; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; Lloyd-Williams M, 1999, PALLIATIVE MED, V13, P243, DOI 10.1191/026921699676753309; MAHONEY J, 1994, J AM GERIATR SOC, V42, P1006; Watkins C, 2001, BRIT MED J, V323, P1159, DOI 10.1136/bmj.323.7322.1159	5	54	54	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					372	373		10.1136/bmj.327.7411.372	http://dx.doi.org/10.1136/bmj.327.7411.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919988	Green Published, Bronze			2022-12-28	WOS:000184864200018
J	Abram, NJ; Gagan, MK; McCulloch, MT; Chappell, J; Hantoro, WS				Abram, NJ; Gagan, MK; McCulloch, MT; Chappell, J; Hantoro, WS			Coral reef death during the 1997 Indian Ocean dipole linked to Indonesian wildfires	SCIENCE			English	Article							WATER; IRON; PHYTOPLANKTON; PACIFIC; BIOMASS; FIRES; FRACTIONATION; LANTHANIDES; TEMPERATURE; ECOSYSTEMS	Geochemical anomalies and growth discontinuities in Porites corals from western Sumatra, Indonesia, record unanticipated reef mortality during anomalous Indian Ocean Dipole upwelling and a giant red tide in 1997. Sea surface temperature reconstructions show that although some past upwelling events have been stronger, there were no analogous episodes of coral mortality during the past 7000 years, indicating that the 1997 red tide was highly unusual. We show that iron fertilization by the 1997 Indonesian wild. res was sufficient to produce the extraordinary red tide, leading to reef death by asphyxiation. These findings highlight tropical wild. res as an escalating threat to coastal marine ecosystems.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Indonesian Inst Sci, Res & Dev Ctr Geotechnol, Bandung 40135, Indonesia	Australian National University; Indonesian Institute of Sciences	Abram, NJ (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.		McCulloch, Malcolm T/C-3651-2009; Gagan, Michael/L-5014-2018; Abram, Nerilie/AAT-5171-2021	McCulloch, Malcolm T/0000-0003-1538-1558; Gagan, Michael/0000-0002-8279-323X; Abram, Nerilie/0000-0003-1246-2344				Aronson RB, 2000, NATURE, V405, P36, DOI 10.1038/35011132; Bau M, 1997, MAR CHEM, V56, P123, DOI 10.1016/S0304-4203(96)00091-6; BEHRA P, 1990, NATURE, V344, P419, DOI 10.1038/344419a0; Bishop JKB, 2002, SCIENCE, V298, P817, DOI 10.1126/science.1074961; Byrne R.H., 1996, HANDB PHYSI, V23, P497; DARRIGO RD, 1994, TERR ATMOS OCIAN SCI, V5, P349; EATON P, 2001, FOREST FIRES REGIONA; Frogner P, 2001, GEOLOGY, V29, P487, DOI 10.1130/0091-7613(2001)029<0487:FPOVAI>2.0.CO;2; Gagan MK, 1998, SCIENCE, V279, P1014, DOI 10.1126/science.279.5353.1014; Gao Y, 2001, GEOPHYS RES LETT, V28, P29, DOI 10.1029/2000GL011926; GENIN A, 1995, NATURE, V377, P507, DOI 10.1038/377507a0; Gruber N, 1999, GLOBAL BIOGEOCHEM CY, V13, P307, DOI 10.1029/1999GB900019; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; INDRAWADI, 2000, 9 INT COR REEF S A, V16, P86; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Johnson KS, 2001, GEOPHYS RES LETT, V28, P1247, DOI 10.1029/2000GL012433; Joint I, 2000, J EXP MAR BIOL ECOL, V250, P233, DOI 10.1016/S0022-0981(00)00199-4; Kinkade C, 1997, DEEP-SEA RES PT I, V44, P581, DOI 10.1016/S0967-0637(97)00002-2; Koe LCC, 2001, ATMOS ENVIRON, V35, P2723, DOI 10.1016/S1352-2310(00)00395-2; Levine JS, 1999, GEOPHYS RES LETT, V26, P815, DOI 10.1029/1999GL900067; Maenhaut W, 2002, NUCL INSTRUM METH B, V189, P259, DOI 10.1016/S0168-583X(01)01054-0; Measures CI, 1999, DEEP-SEA RES PT II, V46, P1597, DOI 10.1016/S0967-0645(99)00037-5; Murtugudde RG, 1999, J GEOPHYS RES-OCEANS, V104, P18351, DOI 10.1029/1999JC900135; Nakajima T, 1999, GEOPHYS RES LETT, V26, P2421, DOI 10.1029/1999GL900208; Roberts CM, 2002, SCIENCE, V295, P1280, DOI 10.1126/science.1067728; Saji NH, 1999, NATURE, V401, P360, DOI 10.1038/43854; SHOLKOVITZ ER, 1994, GEOCHIM COSMOCHIM AC, V58, P1567, DOI 10.1016/0016-7037(94)90559-2; Siegert F, 2001, NATURE, V414, P437, DOI 10.1038/35106547; Sieh K, 1999, GEOPHYS RES LETT, V26, P3141, DOI 10.1029/1999GL005409; SIMPSON CJ, 1993, CORAL REEFS, V12, P185, DOI 10.1007/BF00334478; SUNDA WG, 1995, MAR CHEM, V50, P189, DOI 10.1016/0304-4203(95)00035-P; TOMASCIK T, 1997, ECOLOGY INDONESIAN S, V8, P1249; Walsh JJ, 2001, J GEOPHYS RES-OCEANS, V106, P11597, DOI 10.1029/1999JC000123; Webster PJ, 1999, NATURE, V401, P356, DOI 10.1038/43848; Wilkinson C, 2000, STATUS CORAL REEFS W; WYNDHAM TD, UNPUB; Yamasoe MA, 2000, ATMOS ENVIRON, V34, P1641, DOI 10.1016/S1352-2310(99)00329-5; Zachariasen J, 1999, J GEOPHYS RES-SOL EA, V104, P895, DOI 10.1029/1998JB900050	39	171	181	5	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					952	955		10.1126/science.1083841	http://dx.doi.org/10.1126/science.1083841			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920295				2022-12-28	WOS:000184755900035
J	Barnes, WL; Dereux, A; Ebbesen, TW				Barnes, WL; Dereux, A; Ebbesen, TW			Surface plasmon subwavelength optics	NATURE			English	Review							ENHANCED RAMAN-SCATTERING; PHOTONIC BAND-GAP; HOLE ARRAYS; 2ND-HARMONIC GENERATION; METALLIC NANOPARTICLES; GOLD NANOPARTICLES; LIGHT TRANSMISSION; LOCAL DETECTION; ENERGY GAPS; FILMS	Surface plasmons are waves that propagate along the surface of a conductor. By altering the structure of a metal's surface, the properties of surface plasmons- in particular their interaction with light-can be tailored, which offers the potential for developing new types of photonic device. This could lead to miniaturized photonic circuits with length scales that are much smaller than those currently achieved. Surface plasmons are being explored for their potential in subwavelength optics, data storage, light generation, microscopy and bio-photonics.	Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England; Univ Bourgogne, Phys Lab, F-21078 Dijon, France; Univ Strasbourg 1, ISIS, F-67083 Strasbourg, France	University of Exeter; Universite de Bourgogne; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Barnes, WL (corresponding author), Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England.		Dereux, Alain/K-8754-2016; Han, Kyuhee/B-6201-2009; Barnes, William L/J-7111-2013	Dereux, Alain/0000-0002-9009-114X; Barnes, William L/0000-0002-9474-5534				Altewischer E, 2002, NATURE, V418, P304, DOI 10.1038/nature00869; Andrew P, 1997, J MOD OPTIC, V44, P395, DOI 10.1080/09500349708241879; Baida FI, 2002, OPT COMMUN, V209, P17, DOI 10.1016/S0030-4018(02)01690-5; Barbara A, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.161403; Barnes WL, 1996, PHYS REV B, V54, P6227, DOI 10.1103/PhysRevB.54.6227; Barnes WL, 1997, J OPT SOC AM A, V14, P1654, DOI 10.1364/JOSAA.14.001654; Barnes WL, 1998, J MOD OPTIC, V45, P661, DOI 10.1080/09500349808230614; Bonod N, 2003, OPT EXPRESS, V11, P482, DOI 10.1364/OE.11.000482; Bozhevolnyi SI, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.186801; Bozhevolnyi SI, 2001, PHYS REV LETT, V86, P3008, DOI 10.1103/PhysRevLett.86.3008; Burstein E., 1974, POLARITONS, P1; COUTAZ JL, 1985, PHYS REV B, V32, P2227, DOI 10.1103/PhysRevB.32.2227; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; Darmanyan SA, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.035424; Degiron A, 2002, APPL PHYS LETT, V81, P4327, DOI 10.1063/1.1526162; Devaux E, 2000, PHYS REV B, V62, P10504, DOI 10.1103/PhysRevB.62.10504; Ditlbacher H, 2002, APPL PHYS LETT, V81, P1762, DOI 10.1063/1.1506018; Ditlbacher H, 2002, APPL PHYS LETT, V80, P404, DOI 10.1063/1.1435410; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; Felidj N, 2003, APPL PHYS LETT, V82, P3095, DOI 10.1063/1.1571979; Garcia-Vidal FJ, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.213901; Garcia-Vidal FJ, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.155412; GarciaVidal FJ, 1996, PHYS REV LETT, V77, P1163, DOI 10.1103/PhysRevLett.77.1163; Ghaemi HF, 1998, PHYS REV B, V58, P6779, DOI 10.1103/PhysRevB.58.6779; Gresillon S, 1999, PHYS REV LETT, V82, P4520, DOI 10.1103/PhysRevLett.82.4520; Haynes CL, 2001, J PHYS CHEM B, V105, P5599, DOI 10.1021/jp010657m; Hecht B, 1996, PHYS REV LETT, V77, P1889, DOI 10.1103/PhysRevLett.77.1889; Hermann C, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.235422; Hibbins AP, 2002, APPL PHYS LETT, V81, P4661, DOI 10.1063/1.1527704; Hobson PA, 2002, ADV MATER, V14, P1393, DOI 10.1002/1521-4095(20021002)14:19<1393::AID-ADMA1393>3.0.CO;2-B; Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9; Kitson SC, 1996, PHYS REV LETT, V77, P2670, DOI 10.1103/PhysRevLett.77.2670; Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667; Kneipp K, 2002, J PHYS-CONDENS MAT, V14, pR597, DOI 10.1088/0953-8984/14/18/202; Kottmann JP, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.235402; Kottmann JP, 2001, OPT LETT, V26, P1096, DOI 10.1364/OL.26.001096; Kreibig U., 1995, OPTICAL PROPERTIES M, P1, DOI [10.1007/978-3-662-09109-8_1, DOI 10.1007/978-3-662-09109-8_1]; Krenn JR, 1999, PHYS REV LETT, V82, P2590, DOI 10.1103/PhysRevLett.82.2590; KRETSCHM.E, 1968, Z NATURFORSCH PT A, VA 23, P2135, DOI 10.1515/zna-1968-1247; Krishnan A, 2001, OPT COMMUN, V200, P1, DOI 10.1016/S0030-4018(01)01558-9; Levi SA, 2002, CHEM-EUR J, V8, P3808, DOI 10.1002/1521-3765(20020816)8:16<3808::AID-CHEM3808>3.0.CO;2-6; LEZEC HJ, 2002, SCIENCE, V107, P1895; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; Martin-Moreno L, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.167401; Martin-Moreno L, 2001, PHYS REV LETT, V86, P1114, DOI 10.1103/PhysRevLett.86.1114; MORELAND J, 1982, PHYS REV B, V25, P2297, DOI 10.1103/PhysRevB.25.2297; Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102; Oldenburg SJ, 2002, ANAL BIOCHEM, V309, P109, DOI 10.1016/S0003-2697(02)00410-4; OTTO A, 1968, Z PHYS, V216, P398, DOI 10.1007/BF01391532; Pendry J, 1999, SCIENCE, V285, P1687, DOI 10.1126/science.285.5434.1687; POCKRAND I, 1980, CHEM PHYS LETT, V69, P499, DOI 10.1016/0009-2614(80)85113-X; Porto JA, 1999, PHYS REV LETT, V83, P2845, DOI 10.1103/PhysRevLett.83.2845; QUAIL JC, 1984, J APPL PHYS, V56, P2589, DOI 10.1063/1.334290; Raether H., 1988, SURFACE PLASMONS; Rechberger W, 2003, OPT COMMUN, V220, P137, DOI 10.1016/S0030-4018(03)01357-9; RITCHIE RH, 1957, PHYS REV, V106, P874, DOI 10.1103/PhysRev.106.874; RITCHIE RH, 1968, PHYS REV LETT, V21, P1530, DOI 10.1103/PhysRevLett.21.1530; Salomon L, 2001, PHYS REV LETT, V86, P1110, DOI 10.1103/PhysRevLett.86.1110; SAMBLES JR, 1991, CONTEMP PHYS, V32, P173, DOI 10.1080/00107519108211048; Schultz DA, 2003, CURR OPIN BIOTECH, V14, P13, DOI 10.1016/S0958-1669(02)00015-0; Silva TJ, 1996, REV SCI INSTRUM, V67, P715, DOI 10.1063/1.1146658; Smolyaninov II, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.187402; Sonnichsen C, 2000, APPL PHYS LETT, V77, P2949, DOI 10.1063/1.1323553; Tredicucci A, 2000, APPL PHYS LETT, V76, P2164, DOI 10.1063/1.126183; Tsang TYF, 1996, OPT LETT, V21, P245, DOI 10.1364/OL.21.000245; Vargas-Baca I, 2002, CAN J CHEM, V80, P1625, DOI 10.1139/V02-147; Vigoureux JM, 2001, OPT COMMUN, V198, P257, DOI 10.1016/S0030-4018(01)01522-X; WEBER WH, 1979, OPT LETT, V4, P236, DOI 10.1364/OL.4.000236; Weeber JC, 1999, PHYS REV B, V60, P9061, DOI 10.1103/PhysRevB.60.9061; Weeber JC, 1996, PHYS REV LETT, V77, P5332, DOI 10.1103/PhysRevLett.77.5332; Weeber JC, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.045411; Westphalen M, 2000, SOL ENERG MAT SOL C, V61, P97, DOI 10.1016/S0927-0248(99)00100-2; Wood RW, 1902, PHILOS MAG, V4, P396, DOI 10.1080/14786440209462857; Worthing PT, 2001, APPL PHYS LETT, V79, P3035, DOI 10.1063/1.1414294; 2001, APPL PHYS B, V73	75	9441	9770	156	4402	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					824	830		10.1038/nature01937	http://dx.doi.org/10.1038/nature01937			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917696				2022-12-28	WOS:000184733900051
J	O'Reilly, CM; Alin, SR; Plisnier, PD; Cohen, AS; McKee, BA				O'Reilly, CM; Alin, SR; Plisnier, PD; Cohen, AS; McKee, BA			Climate change decreases aquatic ecosystem productivity of Lake Tanganyika, Africa	NATURE			English	Article							ORGANIC-MATTER; ISOTOPIC COMPOSITION; WATER; INDICATORS; SEDIMENTS; CHEMISTRY; CARBON	Although the effects of climate warming on the chemical and physical properties of lakes have been documented(1), biotic and ecosystem-scale responses to climate change have been only estimated or predicted by manipulations and models(1). Here we present evidence that climate warming is diminishing productivity in Lake Tanganyika, East Africa. This lake has historically supported a highly productive pelagic fishery that currently provides 25-40% of the animal protein supply for the populations of the surrounding countries(2). In parallel with regional warming patterns since the beginning of the twentieth century, a rise in surface-water temperature has increased the stability of the water column. A regional decrease in wind velocity has contributed to reduced mixing, decreasing deep-water nutrient upwelling and entrainment into surface waters. Carbon isotope records in sediment cores suggest that primary productivity may have decreased by about 20%, implying a roughly 30% decrease in fish yields. Our study provides evidence that the impact of regional effects of global climate change on aquatic ecosystem functions and services can be larger than that of local anthropogenic activity or overfishing.	Univ Arizona, Dept Geosci, Tucson, AZ 85721 USA; Namur Univ, Dept Biol, B-5000 Namur, Belgium; Royal Museum Cent Africa, B-3080 Tervuren, Belgium; Tulane Univ, Dept Earth & Environm Sci, New Orleans, LA 70118 USA	University of Arizona; University of Namur; Royal Museum for Central Africa; Tulane University	O'Reilly, CM (corresponding author), Vassar Coll, Environm Sci Program, Poughkeepsie, NY 12603 USA.		Plisnier, Pierre-Denis/ABG-2933-2020; Alin, Simone/J-6836-2017	Alin, Simone/0000-0002-8283-1910				BEAUCHAMP R. S. A., 1939, INTERNAL REV GES HYDROBIOL U HYDROGR, V39, P316, DOI 10.1002/iroh.19390390303; BEAUCHAMP RSA, 1953, J ECOL, V41, P226, DOI 10.2307/2257037; Brenner M, 1999, J PALEOLIMNOL, V22, P205, DOI 10.1023/A:1008078222806; Coulter G. W., 1991, LAKE TANGANYIKA ITS; Craig H., 1974, LAKE TANGANYIKA GEOC; DEGENS ET, 1971, NATURWISSENSCHAFTEN, V58, P229, DOI 10.1007/BF00602986; DUBOIS J. T., 1958, HYDROBIOLOGIA, V10, P215, DOI 10.1007/BF00142188; EDMOND JM, 1993, LIMNOL OCEANOGR, V38, P725, DOI 10.4319/lo.1993.38.4.0725; Goddard L, 1999, J GEOPHYS RES-ATMOS, V104, P19099, DOI 10.1029/1999JD900326; HECKY RE, 1994, LIMNOL OCEANOGR, V39, P1476, DOI 10.4319/lo.1994.39.6.1476; Hodell DA, 1998, LIMNOL OCEANOGR, V43, P200, DOI 10.4319/lo.1998.43.2.0200; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hulme M, 2001, CLIM RES, V17, P145, DOI 10.3354/cr017145; IDSO SB, 1973, LIMNOL OCEANOGR, V18, P681, DOI 10.4319/lo.1973.18.4.0681; LEHMAN J. T., 1998, ENV CHANGE RESPONSE, P157; Mannini P., 1998, GEOGRAPHICAL DISTRIB; MARQUARDSEN H, 1916, MITTEILUNGEN DTSCH S, V29, P97; McKnight Diane, 1996, Limnology and Oceanography, V41, P815; MEYERS PA, 1993, ORG GEOCHEM, V20, P867, DOI 10.1016/0146-6380(93)90100-P; Molsa H, 1999, HYDROBIOLOGIA, V407, P1, DOI 10.1023/A:1003712708969; NIXON SW, 1988, LIMNOL OCEANOGR, V33, P1005, DOI 10.4319/lo.1988.33.4_part_2.1005; O'Reilly CM, 2002, LIMNOL OCEANOGR, V47, P306, DOI 10.4319/lo.2002.47.1.0306; PATTERSON G, 1995, FISHERY POTENTIAL PR, P1; Plisnier PD, 1999, HYDROBIOLOGIA, V407, P45, DOI 10.1023/A:1003762119873; Popp BN, 1998, GEOCHIM COSMOCHIM AC, V62, P69, DOI 10.1016/S0016-7037(97)00333-5; Shirakihara Kunio, 1992, African Study Monographs, V13, P57; TALBOT MR, 1992, EARTH PLANET SC LETT, V110, P23, DOI 10.1016/0012-821X(92)90036-U; van Zwieten PAM, 2002, FISH RES, V54, P329, DOI 10.1016/S0165-7836(01)00267-3; VANMEEL L, 1987, CONTRIBUTION LIMNOLO, V2; VANMEEL LIJ, 1987, CONTRIBUTION LIMNOLO, V1; VERBURG P, 1997, HYDRODYNAMICS LAKE T	31	439	478	14	252	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					766	768		10.1038/nature01833	http://dx.doi.org/10.1038/nature01833			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917682				2022-12-28	WOS:000184733900037
J	Scarabin, PY; Oger, E; Plu-Bureau, G				Scarabin, PY; Oger, E; Plu-Bureau, G		ESTHER Study Grp	Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; HORMONE REPLACEMENT; POSTMENOPAUSAL WOMEN; PULMONARY-EMBOLISM; COAGULATION; USERS; PHARMACOKINETICS; FIBRINOLYSIS; ESTRADIOL	Background Oral oestrogen-replacement therapy (ERT) activates blood coagulation and increases the risk of venous thromboembolism (VTE) in postmenopausal women. Transdermal ERT has little effect on haemostasis, but data assessing its effect on thrombotic process are scarce. We aimed to examine the effect of the route of oestrogen administration on VTE risk. Methods We did a multicentre hospital-based case-control study of postmenopausal women in France. During 1999-2002, we recruited 155 consecutive cases with a first documented episode of idiopathic VTE (92 with pulmonary embolisms and 63 with deep venous thrombosis), and 381 controls matched for centre, age, and time of recruitment. Findings Overall, 32 (21%) cases and 27 (7%) controls were current users of oral ERT, whereas 30 (19%) cases and 93 (24%) controls were current users of transdermal ERT. After adjustment for potential confounding variables, the odds ratio for VTE in current users of oral and transdermal ERT compared with non-users was 3.5 (95% CI 1.8-6.8) and 0.9 (0.5-1.6), respectively. Estimated risk for VTE in current users of oral ERT compared with transdermal ERT users was 4.0 (1.9-8.3). Interpretation- Oral but not transdermal ERT is associated with risk of VTE in postmenopausal women. These data suggest that transdermal ERT might be safer than oral ERT with respect to thrombotic risk.	INSERM, U258, F-94807 Villejuif, France; Hop Cavale Blanche, Dept Internal Med, Brest, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Brest; Universite de Bretagne Occidentale	Scarabin, PY (corresponding author), INSERM, U258, Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	scarabin@vjf.inserm.fr						Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; CONARD J, 1983, THROMB HAEMOSTASIS, V49, P252; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DELIGNIERES B, 1986, J CLIN ENDOCR METAB, V62, P536, DOI 10.1210/jcem-62-3-536; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hoibraaten E, 2001, BRIT J HAEMATOL, V115, P415, DOI 10.1046/j.1365-2141.2001.03111.x; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; JAMA, 1970, JAMA, V214, P1303, DOI DOI 10.1001/JAMA.1970.03180070069012; JICK H, 1978, AM J EPIDEMIOL, V107, P1; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Le Gal G, 2003, ATHEROSCLEROSIS, V166, P163, DOI 10.1016/S0021-9150(02)00325-8; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; Oger E, 1999, DRUG AGING, V14, P55, DOI 10.2165/00002512-199914010-00004; OGER E, 2003, IN PRESS ARTERIOSCLE; POWERS MS, 1985, AM J OBSTET GYNECOL, V152, P1099, DOI 10.1016/0002-9378(85)90569-1; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scarabin PY, 1997, ARTERIOSCL THROM VAS, V17, P3071, DOI 10.1161/01.ATV.17.11.3071; SCOTT RT, 1991, OBSTET GYNECOL, V77, P758; Seradour B, 1999, J MED SCREEN, V6, P99, DOI 10.1136/jms.6.2.99; Teede HJ, 2000, ARTERIOSCL THROM VAS, V20, P1404, DOI 10.1161/01.ATV.20.5.1404; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; 1990, JAMA, V263, P2753	24	502	515	2	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					428	432		10.1016/S0140-6736(03)14066-4	http://dx.doi.org/10.1016/S0140-6736(03)14066-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927428				2022-12-28	WOS:000184651100008
J	Murray, L; Watson, P; Johnston, B; Sloan, J; Mainie, IML; Gavin, A				Murray, L; Watson, P; Johnston, B; Sloan, J; Mainie, IML; Gavin, A			Risk of adenocarcinoma in Barrett's oesophagus: population based study	BRITISH MEDICAL JOURNAL			English	Article							CANCER-RISK; SURVEILLANCE		Queens Univ Belfast, Dept Epidemiol & Publ Hlth, No Ireland Canc Registry, Belfast BT12 6BJ, Antrim, North Ireland; Royal Hosp Trust, Belfast BT12 6BA, Antrim, North Ireland; Ulster Hosp, Belfast BT16 1RB, Antrim, North Ireland	Queens University Belfast	Murray, L (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, No Ireland Canc Registry, Belfast BT12 6BJ, Antrim, North Ireland.							Conio M, 2001, GUT, V48, P304, DOI 10.1136/gut.48.3.304; Gross CP, 1999, AM J GASTROENTEROL, V94, P3440, DOI 10.1111/j.1572-0241.1999.01606.x; Macdonald CE, 2000, BMJ-BRIT MED J, V321, P1252, DOI 10.1136/bmj.321.7271.1252; Provenzale D, 1999, AM J GASTROENTEROL, V94, P2043; Shaheen NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/gast.2000.9302	5	90	95	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					534	535		10.1136/bmj.327.7414.534	http://dx.doi.org/10.1136/bmj.327.7414.534			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958113	Green Published, Bronze			2022-12-28	WOS:000185283700018
J	Sirocko, F				Sirocko, F			What drove past teleconnections?	SCIENCE			English	Editorial Material							GREENLAND; CLIMATE; ATLANTIC; EVENTS		Johannes Gutenberg Univ Mainz, Inst Geosci, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Sirocko, F (corresponding author), Johannes Gutenberg Univ Mainz, Inst Geosci, D-55099 Mainz, Germany.	sirocko@uni-mainz.de						Behl RJ, 1996, NATURE, V379, P243, DOI 10.1038/379243a0; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Burns SJ, 2003, SCIENCE, V301, P1365, DOI 10.1126/science.1086227; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; JOHNSEN SJ, 1992, NATURE, V359, P311, DOI 10.1038/359311a0; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1	9	12	13	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1336	1337		10.1126/science.1088626	http://dx.doi.org/10.1126/science.1088626			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958349				2022-12-28	WOS:000185116400026
J	Cooper, RS				Cooper, RS			Gene-environment interactions and the etiology of common complex disease	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				AFRICAN-AMERICANS; HYPERTENSION; NIGERIANS; RISK; HERITABILITY; POPULATIONS; PREVALENCE; GENOTYPE; RACE	Genetic epidemiology has greatly expanded its scope as a result of major technological innovations in the past decade. Laboratory capacity to determine DNA variation and archival information on the human genome sequence are now readily available. A wide range of research projects have been launched on chronic disease and health problems of aging, on the assumption that a better understanding of mechanisms will improve treatment and prevention. In many instances, the actions of genes are known to be modified by environmental conditions, and considerable emphasis has now been placed on finding specific interactions between genes and the environment. Studies in agriculture and animals provide clear empirical evidence on the importance of this concept. Describing gene-environment interactions in studies of humans is still very challenging, however, given the difficulties in study design and measurement. Despite the theoretical value of characterizing both intrinsic and extrinsic components of the causal process in the development of disease, the argument can also be made that main effects of each component separately are much more important. For these reasons, gene-environment interactions are likely to remain a conceptual framework for health research rather than a practical goal for the foreseeable future.	Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA	Loyola University Chicago	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045508, R01HL047910, R37HL045508] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47910, HL 45508] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CLARE MJ, 1985, HEREDITY, V55, P19, DOI 10.1038/hdy.1985.67; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 1998, HYPERTENSION, V32, P813, DOI 10.1161/01.HYP.32.5.813; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Cooper RS, 1997, DIABETES CARE, V20, P343, DOI 10.2337/diacare.20.3.343; Cooper RS, 2000, HYPERTENSION, V35, P1141, DOI 10.1161/01.HYP.35.5.1141; COOPER RS, IN PRESS DISPARITIES; Evans RM, 2000, NEUROLOGY, V54, P240, DOI 10.1212/WNL.54.1.240; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Kardia S L, 2000, Curr Hypertens Rep, V2, P32; LEWONTIN R, 1997, HUMAN DIVERSITY; Luke A, 2001, INT J OBESITY, V25, P1034, DOI 10.1038/sj.ijo.0801650; LYNCH M, 1998, GENE X ENV INTERACTI, P567; Rotimi CN, 1997, GENET EPIDEMIOL, V14, P157, DOI 10.1002/(SICI)1098-2272(1997)14:2<157::AID-GEPI5>3.0.CO;2-4; Turner ST, 2001, HYPERTENSION, V37, P739, DOI 10.1161/01.HYP.37.2.739; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250	18	53	62	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			437	440		10.7326/0003-4819-139-5_Part_2-200309021-00011	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965972				2022-12-28	WOS:000185133800011
J	Jacobson, T; Liberati, S; Mattingly, D				Jacobson, T; Liberati, S; Mattingly, D			A strong astrophysical constraint on the violation of special relativity by quantum gravity	NATURE			English	Article							RADIATION; LIMITS; TESTS; SPEED; LIGHT	Special relativity asserts that physical phenomena appear the same to all unaccelerated observers. This is called Lorentz symmetry and relates long wavelengths to short ones: if the symmetry is exact it implies that space-time must look the same at all length scales. Several approaches to quantum gravity, however, suggest that there may be a microscopic structure of space-time that leads to a violation of Lorentz symmetry. This might arise because of the discreteness(1) or non-commutivity(2) of space-time, or through the action of extra dimensions(3). Here we determine a very strong constraint on a type of Lorentz violation that produces a maximum electron speed less than the speed of light. We use the observation of 100-MeV synchrotron radiation from the Crab nebula to improve the previous limit by a factor of 40 million, ruling out this type of Lorentz violation, and thereby providing an important constraint on theories of quantum gravity.	Univ Maryland, Dept Phys, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Jacobson, T (corresponding author), Univ Maryland, Dept Phys, College Pk, MD 20742 USA.	jacobson@physics.umd.edu	Liberati, Stefano/AAY-3319-2020	Liberati, Stefano/0000-0002-7632-7443				Aloisio R, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.053010; Amelino-Camelia G, 1998, NATURE, V393, P763, DOI 10.1038/31647; AMELINOCAMELIA G, 2002, IMPROVED LIMIT QUANT; AMELINOCAMELIA G, 2003, PROPOSAL 2ND GENERAT; Atoyan AM, 1996, MON NOT R ASTRON SOC, V278, P525, DOI 10.1093/mnras/278.2.525; Biller SD, 1999, PHYS REV LETT, V83, P2108, DOI 10.1103/PhysRevLett.83.2108; Burgess CP, 2002, J HIGH ENERGY PHYS; Carroll SM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.141601; Coleman S., 1999, Physical Review D, V59, p116008/1, DOI 10.1103/PhysRevD.59.116008; deJager OC, 1996, ASTROPHYS J, V457, P253, DOI 10.1086/176726; Gambini R, 1999, PHYS REV D, V59, DOI 10.1103/PhysRevD.59.124021; Gleiser RJ, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.083007; Gonzalez-Mestres L, 2001, AIP CONF PROC, V558, P874, DOI 10.1063/1.1370897; GonzalezMestres L, 1996, NUCL PHYS B, P131, DOI 10.1016/0920-5632(96)00227-7; Hillas AM, 1998, ASTROPHYS J, V503, P744, DOI 10.1086/306005; JACKSON JD, 1998, CLASSICAL ELECTRODYN, P671; Jacobson T, 2003, PHYS REV D, V67, DOI 10.1103/PhysRevD.67.124011; Jacobson T, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.081302; JACOBSON T, 2003, COMMENTS IMPROVED LI; Kaaret P, 1999, ASTRON ASTROPHYS, V345, pL32; Konopka TJ, 2002, NEW J PHYS, V4, DOI 10.1088/1367-2630/4/1/357; Myers RC, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.211601; NORRIS JP, 1999, B AM ASTRON SOC, V31, P717; PAVLOPOULOS TG, 1967, PHYS REV, V159, P1106, DOI 10.1103/PhysRev.159.1106; Schaefer BE, 1999, PHYS REV LETT, V82, P4964, DOI 10.1103/PhysRevLett.82.4964; Stecker FW, 2001, ASTROPART PHYS, V16, P97, DOI 10.1016/S0927-6505(01)00137-2; STECKER FW, 2003, TESTS QUANTUM GRAVIT	27	213	213	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1019	1021		10.1038/nature01882	http://dx.doi.org/10.1038/nature01882			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944959	Green Submitted			2022-12-28	WOS:000184984200033
J	Volkov, I; Banavar, JR; Hubbell, SP; Maritan, A				Volkov, I; Banavar, JR; Hubbell, SP; Maritan, A			Neutral theory and relative species abundance in ecology	NATURE			English	Article							SAMPLING THEORY	The theory of island biogeography(1) asserts that an island or a local community approaches an equilibrium species richness as a result of the interplay between the immigration of species from the much larger metacommunity source area and local extinction of species on the island (local community). Hubbell(2) generalized this neutral theory to explore the expected steady-state distribution of relative species abundance (RSA) in the local community under restricted immigration. Here we present a theoretical framework for the unified neutral theory of biodiversity(2) and an analytical solution for the distribution of the RSA both in the metacommunity (Fisher's log series) and in the local community, where there are fewer rare species. Rare species are more extinction-prone, and once they go locally extinct, they take longer to re-immigrate than do common species. Contrary to recent assertions(3), we show that the analytical solution provides a better fit, with fewer free parameters, to the RSA distribution of tree species on Barro Colorado Island, Panama(4), than the lognormal distribution(5,6).	Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Univ Georgia, Dept Plant Biol, Athens, GA 30602 USA; Smithsonian Trop Res Inst, Balboa, Panama; Scuola Int Super Studi Avanzati, SISSA, I-34014 Trieste, Italy; INFM, Trieste, Italy; Abdus Salam Int Ctr Theoret Phys, Trieste, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Georgia; University of Georgia; Smithsonian Institution; Smithsonian Tropical Research Institute; International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Abdus Salam International Centre for Theoretical Physics (ICTP)	Banavar, JR (corresponding author), Penn State Univ, Dept Phys, 104 Davey Lab, University Pk, PA 16802 USA.	banavar@psu.edu; shubbell@dogwood.botany.uga.edu	Volkov, Igor/GVT-6571-2022	Maritan, Amos/0000-0002-3535-7873				Bell G, 2001, SCIENCE, V293, P2413, DOI 10.1126/science.293.5539.2413; BOSWELL MT, 1979, STAT DISTRIBUTIONS E, P3; CARACO T, 1979, STATISTICAL DISTRIBU, P371; Chave J, 2002, AM NAT, V159, P1, DOI 10.1086/324112; Condit R, 2002, SCIENCE, V295, P666, DOI 10.1126/science.1066854; EWENS WJ, 1972, THEOR POPUL BIOL, V3, P87, DOI 10.1016/0040-5809(72)90035-4; Fisher RA, 1943, J ANIM ECOL, V12, P42, DOI 10.2307/1411; Hubbell Stephen P., 2001, V32, pi; KARLIN S, 1972, THEOR POPUL BIOL, V3, P113, DOI 10.1016/0040-5809(72)90036-6; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; Kimura M., 1983, NEUTRAL THEORY MOL E; Kimura M., 1971, THEORETICAL ASPECTS; MAC ARTHUR ROBERT H., 1967; MANOKARAN N, 1992, STAND TABLES SPECIES; May R.M., 1975, P81; McGill BJ, 2003, NATURE, V422, P881, DOI 10.1038/nature01583; McKane A, 2000, PHYS REV E, V62, P8466, DOI 10.1103/PhysRevE.62.8466; Morse P. M., 1953, METHODS THEORETICA 1; Press W., 1992, NUMERICAL RECIPES, V2nd; PRESTON FW, 1948, ECOLOGY, V29, P254, DOI 10.2307/1930989; Rao C. R., 1971, STATISTICAL ECOLOGY, V1, P131; Roughgarden J, 1986, COMMUNITY ECOL, P333; Sugihara G, 2003, P NATL ACAD SCI USA, V100, P5246, DOI 10.1073/pnas.0831096100; TILMAN D, 1988; van Kampen N.G., 2001, STOCHASTIC PROCESSES; WATTERSON GA, 1974, THEOR POPUL BIOL, V6, P217, DOI 10.1016/0040-5809(74)90025-2; Weiher E., 1999, ECOLOGICAL ASSEMBLY, DOI DOI 10.1017/CBO9780511542237	28	542	578	7	401	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 28	2003	424	6952					1035	1037		10.1038/nature01883	http://dx.doi.org/10.1038/nature01883			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944964	Green Submitted			2022-12-28	WOS:000184984200038
J	Zellner, C; Roorda, AK				Zellner, C; Roorda, AK			A bleeding Meckel's diverticulum	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									St Marys Hosp, San Francisco, CA 94117 USA		Zellner, C (corresponding author), St Marys Hosp, San Francisco, CA 94117 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					E9	E9		10.1056/ENEJMicm020554	http://dx.doi.org/10.1056/ENEJMicm020554			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944585				2022-12-28	WOS:000184968400008
J	Marin, D; Marktel, S; Szydlo, R; Klein, JP; Bua, M; Foot, N; Olavarria, E; Shepherd, P; Kanfer, E; Goldman, JM; Apperley, JF				Marin, D; Marktel, S; Szydlo, R; Klein, JP; Bua, M; Foot, N; Olavarria, E; Shepherd, P; Kanfer, E; Goldman, JM; Apperley, JF			Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa	LANCET			English	Article							TYROSINE KINASE; INHIBITOR	Until the recent introduction of Imatinib, interferon alfa was the standard treatment for patients in the chronic phase of chronic myeloid leukaemia. We compared survival of 143 such patients, who did not respond to interferon alfa and were treated with imatinib, with that of 246 historical controls who received conventional treatment. Patients on imatinib showed an overall survival advantage (relative risk 0.54, 95% CI 0.31-0.93). However, although patients on imatinib who achieved at least some degree of cytogenetic response after 6 months had better survival than controls (0.13, 0.05-0.39), those with no cytogenetic response to imatinib had significantly worse survival (1.69, 1.09-2.64). Our findings suggest that cytogenetic responders obtain benefit from imatinib but patients who show no cytogenetic response should be given alternative treatment without delay. We confirmed these results in a case-matched analysis.	Hammersmith Hosp, Dept Haematol, London W12 0NN, England; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Milwaukee, WI 53226 USA; Western Gen Hosp, Dept Haematol, Edinburgh EH4 2XU, Midlothian, Scotland	Imperial College London; Medical College of Wisconsin; University of Edinburgh	Goldman, JM (corresponding author), Hammersmith Hosp, Dept Haematol, London W12 0NN, England.		marktel, sarah/ABH-5549-2020; Szydlo, Richard/C-6678-2012	Szydlo, Richard/0000-0003-1102-8298; marktel, sarah/0000-0002-3768-4288				ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X	5	30	33	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					617	619		10.1016/S0140-6736(03)14182-7	http://dx.doi.org/10.1016/S0140-6736(03)14182-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944062				2022-12-28	WOS:000184904100011
J	Nazareth, I; Boynton, P; King, M				Nazareth, I; Boynton, P; King, M			Problems with sexual function in people attending London general practitioners: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ERECTILE DYSFUNCTION; PREVALENCE; QUESTIONNAIRE; BEHAVIOR	Objectives To assess sexual behaviour, prevalence of ICD-10 diagnosed sexual dysfunction, associations between sexual and psychological problems, and help seeking for sexual problems in people attending general practice; to assess predictors of ICD-10 diagnosis of sexual dysfunction. Design Cross sectional study. Setting 13 general practices in London. Participants 1065 women and 447 men attending general practices. Main outcome measure Prevalence and predictors of ICD-10 diagnoses of sexual dysfunction. Results 97 (22%, 95% confidence interval 18% to 25%) men mid 422 (40%, 37% to 43%) women received at least one ICD-10 diagnosis, but only 34% had an entry relating to sexual problems in their general practice notes. The most common problems were erectile failure and tack or loss of sexual desire in men mid lack or loss of sexual desire and failure of orgasmic response in women. Increasing age and being unemployed predicted sexual problems in women, and bisexual orientation, being non-white, and being unemployed were demographic predictors in men. No practice note factors predicted sexual problems in women, but high consulting rate predicted problems in men. The main clinical predictors were poor physical function and dissatisfaction with current sex life in both sexes and higher psychological morbidity in women. When all factors were considered, increasing age (odds ratio 1.01, 1.00 to 1.02), physical subscale score on the SF-12 (0.98, 0.97 to 0.99), sexual dissatisfaction (1.9, 1.5 to 2.4), and scoring over a 3/4 threshold score on the general health questionnaire (1.5, 1.1 to 1.9) independently predicted an ICD-10 sexual dysfunction diagnosis in women. Being bisexual (4.1, 1.3 to 12.8) was the only independent predictor of an ICD-10 diagnosis in men. Conclusions Sexual difficulties are common in people attending general practitioners, and many people are prepared to talk about them with their doctors.	UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Nazareth, I (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England.	i.nazareth@pcps.ucl.ac.uk	King, Michael B/D-7477-2011	King, Michael B/0000-0003-4715-7171; Nazareth, Irwin/0000-0003-2146-9628; Boynton, Petra/0000-0001-6699-2266				Akkus E, 2002, EUR UROL, V41, P298, DOI 10.1016/S0302-2838(02)00027-1; CRENSHAW TL, 1996, SEXUAL PHARM DRUGS A; Daker-White G, 2002, ARCH SEX BEHAV, V31, P197, DOI 10.1023/A:1014743304566; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Finkelhor D, 1991, VIOLENCE AM PUBLIC H, P79; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Humphery S, 2001, FAM PRACT, V18, P516, DOI 10.1093/fampra/18.5.516; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Kinsey A, 1948, SEXUAL BEHAV HUMAN M, DOI 10.1037/t17515-000; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; MCCORMICK A, 1995, MORBIDITY STAT GEN P; MERCER CH, 2003, IN PRESS BMJ; Mirone V, 2002, EUR UROL, V41, P294, DOI 10.1016/S0302-2838(02)00005-2; Moreira ED, 2001, UROLOGY, V58, P583, DOI 10.1016/S0090-4295(01)01274-2; Moynihan R, 2003, BRIT MED J, V326, P45, DOI 10.1136/bmj.326.7379.45; PEACH C, 1998, ETHNICITY 1991 CENSU, V2, P206; REYNOLDS CF, 1988, PSYCHIAT RES, V24, P231, DOI 10.1016/0165-1781(88)90106-0; TAYLOR JF, 1994, ARCH SEX BEHAV, V23, P627, DOI 10.1007/BF01541816; Tiefer L, 2000, J SEX RES, V37, P273, DOI 10.1080/00224490009552048; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	21	145	146	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 23	2003	327	7412					423	426		10.1136/bmj.327.7412.423	http://dx.doi.org/10.1136/bmj.327.7412.423			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715YY	12933729	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000185003100019
J	Tibi, R; Wiens, DA; Inoue, H				Tibi, R; Wiens, DA; Inoue, H			Remote triggering of deep earthquakes in the 2002 Tonga sequences	NATURE			English	Article							FAULT INTERACTION; DYNAMIC STRESS; MARCH 9; M-W; AFTERSHOCKS; LANDERS; JAPAN; KOBE	It is well established that an earthquake in the Earth's crust can trigger subsequent earthquakes, but such triggering has not been documented for deeper earthquakes. Models for shallow fault interactions suggest that static (permanent) stress changes can trigger nearby earthquakes, within a few fault lengths from the causative earthquake(1-3), whereas dynamic (transient) stresses carried by seismic waves may trigger earthquakes both nearby and at remote distances(4-8). Here we present a detailed analysis of the 19 August 2002 Tonga deep earthquake sequences and show evidence for both static and dynamic triggering. Seven minutes after a magnitude 7.6 earthquake occurred at a depth of 598 km, a magnitude 7.7 earthquake (664 km depth) occurred 300 km away, in a previously aseismic region. We found that nearby aftershocks of the first mainshock are preferentially located in regions where static stresses are predicted to have been enhanced by the mainshock. But the second mainshock and other triggered events are located at larger distances where static stress increases should be negligible, thus suggesting dynamic triggering. The origin times of the triggered events do not correspond to arrival times of the main seismic waves from the mainshocks and the dynamically triggered earthquakes frequently occur in aseismic regions below or adjacent to the seismic zone. We propose that these events are triggered by transient effects in regions near criticality, but where earthquakes have difficulty nucleating without external influences.	Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA; Natl Res Inst Earth Sci & Disaster Prevent, Tsukuba, Ibaraki 3050006, Japan	Washington University (WUSTL); National Research Institute for Earth Science & Disaster Resilience	Tibi, R (corresponding author), Washington Univ, Dept Earth & Planetary Sci, St Louis, MO 63130 USA.	tibi@seismo.wustl.edu	Wiens, Douglas A/J-9259-2016	Wiens, Douglas A/0000-0002-5169-4386				Belardinelli ME, 1999, J GEOPHYS RES-SOL EA, V104, P14925, DOI 10.1029/1999JB900094; Chen WP, 2001, SCIENCE, V292, P2475, DOI 10.1126/science.292.5526.2475; Cotton F, 1997, GEOPHYS J INT, V128, P676, DOI 10.1111/j.1365-246X.1997.tb05328.x; DZIEWONSKI AM, 1981, J GEOPHYS RES, V86, P2825, DOI 10.1029/JB086iB04p02825; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; Freed AM, 2001, NATURE, V411, P180, DOI 10.1038/35075548; FROHLICH C, 1989, ANNU REV EARTH PL SC, V17, P227, DOI 10.1146/annurev.ea.17.050189.001303; Gomberg J, 2001, NATURE, V411, P462, DOI 10.1038/35078053; Gomberg J, 1997, B SEISMOL SOC AM, V87, P294; GREEN HW, 1995, ANNU REV EARTH PL SC, V23, P169, DOI 10.1146/annurev.ea.23.050195.001125; Gudmundsson O, 1998, J GEOPHYS RES-SOL EA, V103, P7121, DOI 10.1029/97JB02488; HARRIS RA, 1993, J GEOPHYS RES-SOL EA, V98, P4461, DOI 10.1029/92JB02272; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; HILL DP, 1993, SCIENCE, V260, P1617, DOI 10.1126/science.260.5114.1617; HOBBS BE, 1988, J GEOPHYS RES-SOLID, V93, P10521, DOI 10.1029/JB093iB09p10521; HUDNUT KW, 1989, GEOPHYS RES LETT, V16, P199, DOI 10.1029/GL016i002p00199; Jaeger J. C., 1979, FUNDAMENTALS ROCK ME; JORDAN TH, 1981, B SEISMOL SOC AM, V71, P1105; Karato S, 2001, PHYS EARTH PLANET IN, V127, P83, DOI 10.1016/S0031-9201(01)00223-0; Kilb D, 2000, NATURE, V408, P570, DOI 10.1038/35046046; King GCP, 2001, ADV GEOPHYS, V44, P1, DOI 10.1016/S0065-2687(00)80006-0; KING GCP, 1994, B SEISMOL SOC AM, V84, P935; Kirby SH, 1996, REV GEOPHYS, V34, P261, DOI 10.1029/96RG01050; KISSLINGER C, 1976, ENG GEOL, V10, P85, DOI 10.1016/0013-7952(76)90014-4; McGuire JJ, 1997, J GEOPHYS RES-SOL EA, V102, P15163, DOI 10.1029/96JB03185; Nabelek J., 1984, THESIS MIT; OGAWA M, 1987, J GEOPHYS RES-SOLID, V92, P13801, DOI 10.1029/JB092iB13p13801; Pollitz FF, 1997, B SEISMOL SOC AM, V87, P1; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; Tibi R, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001948; TIBI R, 2000, STR0008 GEO FORSCH Z; Toda S, 1998, J GEOPHYS RES-SOL EA, V103, P24543, DOI 10.1029/98JB00765; VANDERHILST R, 1995, NATURE, V374, P154, DOI 10.1038/374154a0; Wiens DA, 2001, PHYS EARTH PLANET IN, V127, P145, DOI 10.1016/S0031-9201(01)00225-4; Wiens DA, 2000, J GEOPHYS RES-SOL EA, V105, P19067, DOI 10.1029/2000JB900097	35	55	60	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					921	925		10.1038/nature01903	http://dx.doi.org/10.1038/nature01903			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931183				2022-12-28	WOS:000184843600036
J	Young, TH; Tang, HS				Young, TH; Tang, HS			Calcified splenic cyst	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cardinal Tien Hosp, Taipei, Taiwan		Young, TH (corresponding author), Cardinal Tien Hosp, Taipei, Taiwan.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					E8	E8		10.1056/ENEJMicm030061	http://dx.doi.org/10.1056/ENEJMicm030061			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930943				2022-12-28	WOS:000184843300008
J	Gajalakshmi, V; Peto, R; Kanaka, TS; Jha, P				Gajalakshmi, V; Peto, R; Kanaka, TS; Jha, P			Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43 000 adult male deaths and 35 000 controls	LANCET			English	Article							MYOCARDIAL-INFARCTION; RISK-FACTORS; TOBACCO; CANCER; ALCOHOL	Background In India most adult deaths involve vascular disease, pulmonary tuberculosis, or other respiratory disease, and men have smoked cigarettes or bidis (which resemble small cigarettes) for several decades. The study objective was to assess age-specific mortality from smoking among men (since few women smoke) in urban and in rural India. Methods We did a case-control study of the smoking habits of 27 000 urban and 16 000 rural men who had died in the state of Tamil Nadu, southern India, from medical causes lie, any cause other than accident, homicide, or suicide), and of 20 000 urban and 15 000 rural male controls. The main analyses are of mortality at ages 25-69 years. Findings In the urban study area, the death rates from medical causes of ever smokers were double those of never smokers (standardised risk ratio at ages 25-69 years 2.1 [95% Cl 2.0-2.2]). The risks were substantial both for cigarette smoking (the main urban habit) and for bidi smoking. Of this excess mortality among smokers, a third involved respiratory disease, chiefly tuberculosis (4.5 [4.0-5.0], smoking-attributed fraction 61%), a third involved vascular disease (1.8 [1.7-1.9], smoking-attributed fraction 24%), 11% involved cancer (2.1 [1.9-2.4], smoking-attributed fraction 32%), chiefly of the respiratory or upper digestive tracts, and 14% involved alcoholism or cirrhosis (3.3 [2.9-3.8], not attributed to smoking). Among ever smokers, the absolute excess mortality from tuberculosis was substantial throughout the age range 25-69 years. (A separate survey of 250 000 men living in the urban study area found that ever smokers are three times as likely as never smokers to report a history of tuberculosis, corresponding to a higher rate of progression of chronic subclinical infection to clinical disease.) The proportional excesses of respiratory, vascular, and neoplastic mortality at ages 25-69 years among ever smokers in the urban study area were replicated, each with similarly narrow Cl for the risk ratio, in the rural study area (where bidi smoking predominated), and are taken to be largely or wholly causal. For urban and for rural death from medical causes at older ages (greater than or equal to70 years), the standardised risk ratio was 1.3. Interpretation Smoking, which increases the incidence of clinical tuberculosis, is a cause of half the male tuberculosis deaths in India, and of a quarter of all male deaths in middle age (plus smaller fractions of the deaths at other ages). At current death rates, about a quarter of cigarette or bidi smokers would be killed by tobacco at ages 25-69 years, those killed at these ages losing about 20 years of life expectancy. Overall, smoking currently causes about 700 000 deaths per year in India, chiefly from respiratory or vascular disease: about 550 000 men aged 25-69 years, about 110000 older men, and much smaller numbers of women (since few women smoke).	Epidemiol Res Ctr, Madras 600010, Tamil Nadu, India; Univ Oxford, Nuffield Dept Clin Med, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Nuffield Dept Clin Med, Epidemiol Studies Unit CTSU, Oxford, England; Univ Toronto, St Michaels Hosp, Ctr Global Hlth Res, Toronto, ON M5B 1W8, Canada	Indian Council of Medical Research (ICMR); ICMR - National Institute of Epidemiology (NIE); University of Oxford; University of Oxford; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto	Gajalakshmi, V (corresponding author), Epidemiol Res Ctr, New 37 Outer Circular Rd,KG Colony, Madras 600010, Tamil Nadu, India.			K T, Shenoy/0000-0002-2826-6869				[Anonymous], 2002, WORLD MORTALITY 2000; Banthia J. K., 2002, SAMPLE REGISTRATION; CHEN ZM, IN PRESS INT J CANC; Dikshit RP, 2000, INT J EPIDEMIOL, V29, P609, DOI 10.1093/ije/29.4.609; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Doll R, 1996, BRIT MED BULL, V52, P35, DOI 10.1093/oxfordjournals.bmb.a011531; Gajalakshmi CK, 1996, INT J EPIDEMIOL, V25, P1146, DOI 10.1093/ije/25.6.1146; Gajalakshmi CK, 1998, CANCER CAUSE CONTROL, V9, P131, DOI 10.1023/A:1008822008788; Gajalakshmi V., 2000, ASIAN PAC J CANC P S, V1, P199; GAJALAKSHMI V, IN PRESS INT J CANC; GAJALAKSHMI V, 2003, VERBAL AUTOPSY 48 00; Gupta P C, 1996, Tob Control, V5, P114, DOI 10.1136/tc.5.2.114; Gupta PC, 2000, B WORLD HEALTH ORGAN, V78, P877; *INT AG RES CANC, 2003, IARC MON EV CARC RIS, V83; International Agency for Research on Cancer, 1986, IARC MON EV CARC RIS, V38; JHA P, 2001, P ALL IND WORKSH CIV; Lam TH, 2001, BRIT MED J, V323, P361, DOI 10.1136/bmj.323.7309.361; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; LOWE CR, 1956, BMJ-BRIT MED J, V2, P1081, DOI 10.1136/bmj.2.5001.1081; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PARISH S, 1995, BMJ-BRIT MED J, V311, P471, DOI 10.1136/bmj.311.7003.471; *POP DIV UN DEP EC, 2001, WORLD POP PROSP 2000; RANI M, IN PRESS TOB CONTROL; *REG GEN IND, 1999, MED CERT CAUS DEATH; *REG GEN IND, 2001, IND ANN REP 1998 SER, V3; SANKARANARAYANAN R, 1990, INT J CANCER, V45, P879, DOI 10.1002/ijc.2910450517; SHAH J R, 1959, Indian J Med Sci, V13, P381; SHENOY KT, 2002, COUNTING DEAD INDIA; Sutherland I, 1976, Adv Tuberc Res, V19, P1; *US DEP HHS, 1989, US SURG GEN RED HLTH; *US DHEW, 1979, SMOK HLTH; *WHO, 1977, MAN INT CLASS DIS; *WHO, 2002, GLOBAL HLTH STAT; World Health Organization, 1997, TOB HLTH GLOB STAT R; ZARIDZE D, 1986, SCI PUBLICATION INT, V74; Znaor A, 2003, INT J CANCER, V105, P681, DOI 10.1002/ijc.11114; 2000, NATL FAMILY HLTH SUR, V2	37	307	319	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					507	515		10.1016/S0140-6736(03)14109-8	http://dx.doi.org/10.1016/S0140-6736(03)14109-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932381				2022-12-28	WOS:000184817600006
J	Grier, DG				Grier, DG			A revolution in optical manipulation	NATURE			English	Review							ORBITAL ANGULAR-MOMENTUM; COMPUTER-GENERATED HOLOGRAMS; LAGUERRE-GAUSSIAN MODES; GRADIENT LASER TRAP; COLLOIDAL INTERACTIONS; INDEX MICROPARTICLES; DIELECTRIC SPHERE; PATTERN-FORMATION; TWEEZER ARRAYS; LIGHT-BEAM	Optical tweezers use the forces exerted by a strongly focused beam of light to trap and move objects ranging in size from tens of nanometres to tens of micrometres. Since their introduction in 1986, the optical tweezer has become an important tool for research in the fields of biology, physical chemistry and soft condensed matter physics. Recent advances promise to take optical tweezers out of the laboratory and into the mainstream of manufacturing and diagnostics; they may even become consumer products. The next generation of single-beam optical traps offers revolutionary new opportunities for fundamental and applied research.	Univ Chicago, James Franck Inst, Dept Phys, Chicago, IL 60637 USA; Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Grier, DG (corresponding author), Univ Chicago, James Franck Inst, Dept Phys, 5640 S Ellis Ave, Chicago, IL 60637 USA.	grier@elbereth.uchicago.edu	Grier, David G/C-5761-2008	Grier, David G/0000-0002-4382-5139				Allen L, 1999, PROG OPTICS, V39, P291, DOI 10.1016/s0079-6638(08)70391-3; ALLEN L, 1992, PHYS REV A, V45, P8185, DOI 10.1103/PhysRevA.45.8185; Arlt J, 2000, OPT LETT, V25, P191, DOI 10.1364/OL.25.000191; Arlt J, 2001, OPT COMMUN, V197, P239, DOI 10.1016/S0030-4018(01)01479-1; ASHKIN A, 1992, BIOPHYS J, V61, P569, DOI 10.1016/S0006-3495(92)81860-X; ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Ashkin A, 1998, METHOD CELL BIOL, V55, P1; ASHKIN A, 1987, NATURE, V330, P608, DOI 10.1038/330608a0; Ashkin A, 2000, IEEE J SEL TOP QUANT, V6, P841, DOI 10.1109/2944.902132; BAYLES CJ, 1993, EXP MYCOL, V17, P191, DOI 10.1006/emyc.1993.1018; Bechinger C, 2001, PHYS REV LETT, V86, P930, DOI 10.1103/PhysRevLett.86.930; Berns MW, 1998, METHOD CELL BIOL, V55, P71; Brunner M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.248302; Bustamante C, 2000, CURR OPIN STRUC BIOL, V10, P279, DOI 10.1016/S0959-440X(00)00085-3; Chikkatur AP, 2002, SCIENCE, V296, P2193, DOI 10.1126/science.296.5576.2193; CHOWDHURY A, 1985, PHYS REV LETT, V55, P833, DOI 10.1103/PhysRevLett.55.833; Crocker JC, 1999, PHYS REV LETT, V82, P4352, DOI 10.1103/PhysRevLett.82.4352; Crocker JC, 1996, PHYS REV LETT, V77, P1897, DOI 10.1103/PhysRevLett.77.1897; CROCKER JC, 1994, PHYS REV LETT, V73, P352, DOI 10.1103/PhysRevLett.73.352; Curtis JE, 2003, OPT LETT, V28, P872, DOI 10.1364/OL.28.000872; Curtis JE, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133901; Curtis JE, 2002, OPT COMMUN, V207, P169, DOI 10.1016/S0030-4018(02)01524-9; Dufresne ER, 1998, REV SCI INSTRUM, V69, P1974, DOI 10.1063/1.1148883; Dufresne ER, 2001, REV SCI INSTRUM, V72, P1810, DOI 10.1063/1.1344176; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; Friese MEJ, 2001, APPL PHYS LETT, V78, P547, DOI 10.1063/1.1339995; Fuhr G, 1999, APPL PHYS A-MATER, V69, P611, DOI 10.1007/s003390051040; Gahagan KT, 1999, J OPT SOC AM B, V16, P533, DOI 10.1364/JOSAB.16.000533; Gahagan KT, 1996, OPT LETT, V21, P827, DOI 10.1364/OL.21.000827; Gahagan KT, 1998, J OPT SOC AM B, V15, P524, DOI 10.1364/JOSAB.15.000524; Galajda P, 2001, APPL PHYS LETT, V78, P249, DOI 10.1063/1.1339258; GHISLAIN LP, 1994, REV SCI INSTRUM, V65, P2762, DOI 10.1063/1.1144613; Gittes F, 1998, OPT LETT, V23, P7, DOI 10.1364/OL.23.000007; Gittes F, 1998, METHOD CELL BIOL, V55, P129; Gustavson TL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.020401; HE H, 1995, PHYS REV LETT, V75, P826, DOI 10.1103/PhysRevLett.75.826; Higurashi E, 2001, J MICROMECH MICROENG, V11, P140, DOI 10.1088/0960-1317/11/2/309; Higurashi E, 1999, PHYS REV E, V59, P3676, DOI 10.1103/PhysRevE.59.3676; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS; Kawata S, 2001, NATURE, V412, P697, DOI 10.1038/35089130; Ke PC, 1999, APPL OPTICS, V38, P160, DOI 10.1364/AO.38.000160; Korda PT, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.128301; Korda PT, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.024504; Koss BA, 2003, APPL PHYS LETT, V82, P3985, DOI 10.1063/1.1579859; Lachish-Zalait A, 2001, ADV FUNCT MATER, V11, P218, DOI 10.1002/1616-3028(200106)11:3<218::AID-ADFM218>3.0.CO;2-T; LADAVAC K, IN PRESS PHYS REV LE; Lee WM, 2002, ADV MATER, V14, P271, DOI 10.1002/1521-4095(20020219)14:4<271::AID-ADMA271>3.0.CO;2-Y; LIANG H, 1993, EXP CELL RES, V204, P110, DOI 10.1006/excr.1993.1015; Liesener J, 2000, OPT COMMUN, V185, P77, DOI 10.1016/S0030-4018(00)00990-1; Litvinov RI, 2002, P NATL ACAD SCI USA, V99, P7426, DOI 10.1073/pnas.112194999; LOUDIYI K, 1992, PHYSICA A, V184, P1, DOI 10.1016/0378-4371(92)90155-J; MacDonald MP, 2002, SCIENCE, V296, P1101, DOI 10.1126/science.1069571; Mangold K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.158302; McGloin D, 2003, OPT EXPRESS, V11, P158, DOI 10.1364/OE.11.000158; Mio C, 2001, FLUID PHASE EQUILIBR, V185, P157, DOI 10.1016/S0378-3812(01)00466-6; Mogensen PC, 2000, OPT COMMUN, V175, P75, DOI 10.1016/S0030-4018(00)00449-1; O'Neil AT, 2000, OPT COMMUN, V185, P139, DOI 10.1016/S0030-4018(00)00989-5; O'Neil AT, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.053601; O'Neil AT, 2001, OPT COMMUN, V193, P45, DOI 10.1016/S0030-4018(01)01198-1; Ohshima YN, 1997, PHYS REV LETT, V78, P3963, DOI 10.1103/PhysRevLett.78.3963; PADGETT MJ, 1995, OPT COMMUN, V121, P36, DOI 10.1016/0030-4018(95)00455-H; Paterson L, 2001, SCIENCE, V292, P912, DOI 10.1126/science.1058591; Pralle A, 1999, MICROSC RES TECHNIQ, V44, P378, DOI 10.1002/(SICI)1097-0029(19990301)44:5<378::AID-JEMT10>3.0.CO;2-Z; Reicherter M, 1999, OPT LETT, V24, P608, DOI 10.1364/OL.24.000608; Reimann P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3; Rodrigo PJ, 2002, OPT EXPRESS, V10, P1550, DOI 10.1364/OE.10.001550; Rohrbach A, 2002, APPL OPTICS, V41, P2494, DOI 10.1364/AO.41.002494; Rubinsztein-Dunlop H, 1998, ADV QUANTUM CHEM, V30, P469, DOI 10.1016/S0065-3276(08)60523-7; Sasaki K, 1997, J VAC SCI TECHNOL B, V15, P2786, DOI 10.1116/1.589728; SASAKI K, 1991, OPT LETT, V16, P1463, DOI 10.1364/OL.16.001463; Simpson NB, 1997, OPT LETT, V22, P52, DOI 10.1364/OL.22.000052; Simpson NB, 1998, J MOD OPTIC, V45, P1943, DOI 10.1080/09500349808231712; Simpson NB, 1996, J MOD OPTIC, V43, P2485, DOI 10.1080/09500349608230675; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; SVOBODA K, 1994, OPT LETT, V19, P930, DOI 10.1364/OL.19.000930; Taton TA, 2002, NATURE, V416, P685, DOI 10.1038/416685a; Terray A, 2002, APPL PHYS LETT, V81, P1555, DOI 10.1063/1.1503176; Terray A, 2002, SCIENCE, V296, P1841, DOI 10.1126/science.1072133; Verma R, 2000, MACROMOLECULES, V33, P177, DOI 10.1021/ma990362v; Verma R, 1998, PHYS REV LETT, V81, P4004, DOI 10.1103/PhysRevLett.81.4004; Wang GM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.050601; Wei X, 1998, BIOPHYS J, V74, pA378; Wright G, 1998, CURR OPIN OBSTET GYN, V10, P221, DOI 10.1097/00001703-199806000-00008; Yodh AG, 2001, PHILOS T ROY SOC A, V359, P921, DOI 10.1098/rsta.2000.0810	85	3803	3944	75	1710	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 14	2003	424	6950					810	816		10.1038/nature01935	http://dx.doi.org/10.1038/nature01935			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917694				2022-12-28	WOS:000184733900049
J	Hegele, RA				Hegele, RA			Drawing the line in progeria syndromes	LANCET			English	Editorial Material							HUTCHINSON-GILFORD PROGERIA; WERNER SYNDROME; DISEASE; LMNA		John P Robarts Res Inst, Blackburn Cardiovasc Genet Lab, London, ON N6A 5K8, Canada	Western University (University of Western Ontario)	Hegele, RA (corresponding author), John P Robarts Res Inst, Blackburn Cardiovasc Genet Lab, POB 5015, London, ON N6A 5K8, Canada.		Hegele, Robert/AAF-6482-2020; Hegele, Robert/G-3301-2011	Hegele, Robert/0000-0003-2861-5325; 				BROWN WT, 1985, ADV EXP MED BIOL, V190, P229; Burke B, 2002, NAT REV MOL CELL BIO, V3, P575, DOI 10.1038/nrm879; Cao HN, 2003, J HUM GENET, V48, P271, DOI 10.1007/s10038-003-0025-3; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Hegele RA, 2001, CIRCULATION, V103, P2225; IMURA H, 1985, ADV EXP MED BIOL, V190, P171; Novelli G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	11	14	16	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					416	417		10.1016/S0140-6736(03)14097-4	http://dx.doi.org/10.1016/S0140-6736(03)14097-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927424				2022-12-28	WOS:000184651100004
J	Nazin, GV; Qiu, XH; Ho, W				Nazin, GV; Qiu, XH; Ho, W			Visualization and spectroscopy of a metal-molecule-metal bridge	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPE; ELECTRON-TRANSPORT; SINGLE MOLECULES; CARBON NANOTUBES; CONDUCTANCE; JUNCTIONS; PHTHALOCYANINES; TRANSISTOR; RESISTANCE; DEVICES	Artificial nanostructures, each composed of a copper(II) phthalocyanine (CuPc) molecule bonded to two gold atomic chains with a controlled gap, were assembled on a NiAl(110) surface by manipulation of individual gold atoms and CuPc molecules with a scanning tunneling microscope. The electronic densities of states of these hybrid structures were measured by spatially resolved electronic spectroscopy and systematically tuned by varying the number of gold atoms in the chains one by one. The present approach provides structural images and electronic characterization of the metal-molecule-metal junction, thereby elucidating the nature of the contacts between the molecule and metal in this junction.	Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Ho, W (corresponding author), Univ Calif Irvine, Dept Phys & Astron, Irvine, CA 92697 USA.	wilsonho@uci.edu	Nazin, George/GQH-5396-2022					AVIRAM A, 1974, CHEM PHYS LETT, V29, P277, DOI 10.1016/0009-2614(74)85031-1; Avouris P, 2002, ACCOUNTS CHEM RES, V35, P1026, DOI 10.1021/ar010152e; Bartels L, 1997, PHYS REV LETT, V79, P697, DOI 10.1103/PhysRevLett.79.697; Beebe JM, 2002, J AM CHEM SOC, V124, P11268, DOI 10.1021/ja0268332; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cui XD, 2002, J PHYS CHEM B, V106, P8609, DOI 10.1021/jp0206065; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Dargel TK, 1999, MOL PHYS, V96, P583, DOI 10.1080/00268979909482995; Di Ventra M, 2000, PHYS REV LETT, V84, P979, DOI 10.1103/PhysRevLett.84.979; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Heath JR, 2003, PHYS TODAY, V56, P43, DOI 10.1063/1.1583533; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Kergueris C, 1999, PHYS REV B, V59, P12505, DOI 10.1103/PhysRevB.59.12505; Langlais VJ, 1999, PHYS REV LETT, V83, P2809, DOI 10.1103/PhysRevLett.83.2809; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Nilius N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.196103; Nilius N, 2002, SCIENCE, V297, P1853, DOI 10.1126/science.1075242; Nitzan A, 2003, SCIENCE, V300, P1384, DOI 10.1126/science.1081572; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; Reichert J, 2003, APPL PHYS LETT, V82, P4137, DOI 10.1063/1.1574844; Reichert J, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.176804; ROCCO MLM, 1990, J CHEM PHYS, V93, P6859, DOI 10.1063/1.458918; ROSA A, 1994, INORG CHEM, V33, P584, DOI 10.1021/ic00081a029; SCHAFFER AM, 1973, THEOR CHIM ACTA, V30, P9, DOI 10.1007/BF00527632; Stipe BC, 1999, REV SCI INSTRUM, V70, P137, DOI 10.1063/1.1149555; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Wallis TM, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.236802; Weber HB, 2002, CHEM PHYS, V281, P113, DOI 10.1016/S0301-0104(02)00343-9; Xue YQ, 2001, J CHEM PHYS, V115, P4292, DOI 10.1063/1.1391253; Yaliraki SN, 1999, J CHEM PHYS, V111, P6997, DOI 10.1063/1.480096	36	322	342	1	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 3	2003	302	5642					77	81		10.1126/science.1088971	http://dx.doi.org/10.1126/science.1088971			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	727UD	12958368				2022-12-28	WOS:000185678500037
J	Schadt, CW; Martin, AP; Lipson, DA; Schmidt, SK				Schadt, CW; Martin, AP; Lipson, DA; Schmidt, SK			Seasonal dynamics of previously unknown fungal lineages in tundra soils	SCIENCE			English	Article							ALPINE ECOSYSTEM; CO2 EFFLUX; DIVERSITY; EVOLUTION; NITROGEN; BUDGETS; WINTER; N2O	The finding that microbial communities are active under snow has changed the estimated global rates of biogeochemical processes beneath seasonal snow packs. We used microbiological and molecular techniques to elucidate the phylogenetic composition of undersnow microbial communities in Colorado, the United States. Here, we show that tundra soil microbial biomass reaches its annual peak under snow, and that fungi account for most of the biomass. Phylogenetic analysis of tundra soil fungi revealed a high diversity of fungi and three novel clades that constitute major new groups of fungi (divergent at the subphylum or class level). An abundance of previously unknown fungi that are active beneath the snow substantially broadens our understanding of both the diversity and biogeochemical functioning of fungi in cold environments.	Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; San Diego State Univ, Dept Biol, San Diego, CA 92182 USA	University of Colorado System; University of Colorado Boulder; California State University System; San Diego State University	Schmidt, SK (corresponding author), Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA.		Schadt, Christopher W./B-7143-2008; Schadt, Christopher/M-8746-2019; Schmidt, Steven K/G-2771-2010	Schadt, Christopher W./0000-0001-8759-2448; Schadt, Christopher/0000-0001-8759-2448; Schmidt, Steven K/0000-0002-9175-2085				Brooks PD, 1997, OECOLOGIA, V110, P403, DOI 10.1007/s004420050175; Brown J. H., 1998, BIOGEOGRAPHY; Eriksson OE., 2001, MYCONET, V7, P1; Fahnestock JT, 1999, GLOBAL BIOGEOCHEM CY, V13, P775, DOI 10.1029/1999GB900006; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; Jaeger CH, 1999, ECOLOGY, V80, P1883, DOI 10.1890/0012-9658(1999)080[1883:SPONBP]2.0.CO;2; Lipson DA, 2002, MICROB ECOL, V43, P307, DOI 10.1007/s00248-001-1057-x; Lipson DA, 1999, ECOLOGY, V80, P1623; LIPSON DA, UNPUB; MELILLO JM, 1995, GLOBAL BIOGEOCHEM CY, V9, P407; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; POST WM, 1982, NATURE, V298, P156, DOI 10.1038/298156a0; SCHADT CW, UNPUB; SCHMIDT SK, IN PRESS BIOGEOCHEMI; SOMMERFELD RA, 1993, NATURE, V361, P140, DOI 10.1038/361140a0; Vandenkoornhuyse P, 2002, SCIENCE, V295, P2051, DOI 10.1126/science.295.5562.2051; VILGALYS R, COMMUNICATION; Zimov SA, 1996, CLIMATIC CHANGE, V33, P111, DOI 10.1007/BF00140516	18	445	505	5	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1359	1361		10.1126/science.1086940	http://dx.doi.org/10.1126/science.1086940			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958355				2022-12-28	WOS:000185116400035
J	Schiotz, J; Jacobsen, KW				Schiotz, J; Jacobsen, KW			A maximum in the strength of nanocrystalline copper	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATION; GRAIN-SIZE; NANOSTRUCTURED METAL; PLASTIC-DEFORMATION; MECHANICAL-BEHAVIOR; NANOPHASE METALS; PETCH RELATION; THIN-FILMS; DISLOCATION; DEPENDENCE	We used molecular dynamics simulations with system sizes up to 100 million atoms to simulate plastic deformation of nanocrystalline copper. By varying the grain size between 5 and 50 nanometers, we show that the flow stress and thus the strength exhibit a maximum at a grain size of 10 to 15 nanometers. This maximum is because of a shift in the microscopic deformation mechanism from dislocation-mediated plasticity in the coarse-grained material to grain boundary sliding in the nanocrystalline region. The simulations allow us to observe the mechanisms behind the grain-size dependence of the strength of poly-crystalline metals.	Tech Univ Denmark, Dept Phys, CAMP, DK-2800 Lyngby, Denmark	Technical University of Denmark	Schiotz, J (corresponding author), Tech Univ Denmark, Dept Phys, CAMP, DK-2800 Lyngby, Denmark.		Schiøtz, Jakob/A-5692-2011; Jacobsen, Karsten Wedel/B-3602-2009	Schiøtz, Jakob/0000-0002-0670-8013; Jacobsen, Karsten Wedel/0000-0002-1121-2979				Agnew SR, 2000, MAT SCI ENG A-STRUCT, V285, P391, DOI 10.1016/S0921-5093(00)00669-9; Arzt E, 1998, ACTA MATER, V46, P5611, DOI 10.1016/S1359-6454(98)00231-6; ASHBY MF, 1970, PHILOS MAG, V21, P399, DOI 10.1080/14786437008238426; CARSLEY JE, 1995, NANOSTRUCT MATER, V5, P441, DOI 10.1016/0965-9773(95)00257-F; Chen MW, 2003, SCIENCE, V300, P1275, DOI 10.1126/science.1083727; CHOKSHI AH, 1989, SCRIPTA METALL MATER, V23, P1679, DOI 10.1016/0036-9748(89)90342-6; Conrad H, 2002, APPL PHYS LETT, V81, P2241, DOI 10.1063/1.1507353; HALL EO, 1951, P PHYS SOC LOND B, V64, P747, DOI 10.1088/0370-1301/64/9/303; HANSEN N, 1985, METALL TRANS A, V16, P2167, DOI 10.1007/BF02670417; Hugo RC, 2003, ACTA MATER, V51, P1937, DOI 10.1016/S1359-6454(02)00599-2; Jacobsen KW, 1996, SURF SCI, V366, P394, DOI 10.1016/0039-6028(96)00816-3; KE M, 1995, NANOSTRUCT MATER, V5, P689, DOI 10.1016/0965-9773(95)00281-I; Kumar KS, 2003, ACTA MATER, V51, P387, DOI 10.1016/S1359-6454(02)00421-4; LASALMONIE A, 1986, J MATER SCI, V21, P1837, DOI 10.1007/BF00547918; LI JCM, 1963, T METALL SOC AIME, V227, P239; NIEH TG, 1991, SCRIPTA METALL MATER, V25, P955, DOI 10.1016/0956-716X(91)90256-Z; PETCH NJ, 1953, J IRON STEEL I, V174, P25; Sanders PG, 1997, ACTA MATER, V45, P4019, DOI 10.1016/S1359-6454(97)00092-X; Schiotz J, 1999, PHYS REV B, V60, P11971, DOI 10.1103/PhysRevB.60.11971; Schiotz J, 1998, NATURE, V391, P561, DOI 10.1038/35328; Schuh CA, 2003, ACTA MATER, V51, P431, DOI 10.1016/S1359-6454(02)00427-5; THOMPSON AW, 1973, ACTA METALL MATER, V21, P1017, DOI 10.1016/0001-6160(73)90158-2; Van Swygenhoven H, 1999, PHYS REV B, V60, P22, DOI 10.1103/PhysRevB.60.22; Van Swygenhoven H, 2002, SCIENCE, V296, P66; Van Swygenhoven H, 2001, MAT SCI ENG A-STRUCT, V309, P440, DOI 10.1016/S0921-5093(00)01794-9; Wang YM, 2002, NATURE, V419, P912, DOI 10.1038/nature01133; Yamakov V, 2003, ACTA MATER, V51, P4135, DOI 10.1016/S1359-6454(03)00232-5; Yamakov V, 2002, NAT MATER, V1, P45, DOI 10.1038/nmat700; Yip S, 1998, NATURE, V391, P532, DOI 10.1038/35254; Youngdahl CJ, 2001, SCRIPTA MATER, V44, P1475, DOI 10.1016/S1359-6462(01)00712-6	30	1169	1215	18	472	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1357	1359		10.1126/science.1086636	http://dx.doi.org/10.1126/science.1086636			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958354				2022-12-28	WOS:000185116400034
J	Ojo, AO; Held, PJ; Port, FK; Wolfe, RA; Leichtman, AB; Young, EW; Arndorfer, J; Christensen, L; Merion, RM				Ojo, AO; Held, PJ; Port, FK; Wolfe, RA; Leichtman, AB; Young, EW; Arndorfer, J; Christensen, L; Merion, RM			Chronic renal failure after transplantation of a nonrenal organ	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLOSPORINE NEPHROTOXICITY; LIVER-TRANSPLANTATION; CARDIAC TRANSPLANTATION; HEART-TRANSPLANTATION; RISK-FACTORS; RECIPIENTS; TACROLIMUS; INSUFFICIENCY; IMPAIRMENT; SURVIVAL	Background: Transplantation of nonrenal organs is often complicated by chronic renal disease with multifactorial causes. We conducted a population-based cohort analysis to evaluate the incidence of chronic renal failure, risk factors for it, and the associated hazard of death in recipients of nonrenal transplants. Methods: Pretransplantation and post-transplantation clinical variables and data from a registry of patients with end-stage renal disease (ESRD) were linked in order to estimate the cumulative incidence of chronic renal failure (defined as a glomerular filtration rate of 29 ml per minute per 1.73 m(2) of body-surface area or less or the development of ESRD) and the associated risk of death among 69,321 persons who received nonrenal transplants in the United States between 1990 and 2000. Results: During a median follow-up of 36 months, chronic renal failure developed in 11,426 patients (16.5 percent). Of these patients, 3297 (28.9 percent) required maintenance dialysis or renal transplantation. The five-year risk of chronic renal failure varied according to the type of organ transplanted -- from 6.9 percent among recipients of heart-lung transplants to 21.3 percent among recipients of intestine transplants. Multivariate analysis indicated that an increased risk of chronic renal failure was associated with increasing age (relative risk per 10-year increment, 1.36; P<0.001), female sex (relative risk among male patients as compared with female patients, 0.74; P<0.001), pretransplantation hepatitis C infection (relative risk, 1.15; P<0.001), hypertension (relative risk, 1.18; P<0.001), diabetes mellitus (relative risk, 1.42; P<0.001), and postoperative acute renal failure (relative risk, 2.13; P<0.001). The occurrence of chronic renal failure significantly increased the risk of death (relative risk, 4.55; P<0.001). Treatment of ESRD with kidney transplantation was associated with a five-year risk of death that was significantly lower than that associated with dialysis (relative risk, 0.56; P=0.02). Conclusions: The five-year risk of chronic renal failure after transplantation of a nonrenal organ ranges from 7 to 21 percent, depending on the type of organ transplanted. The occurrence of chronic renal failure among patients with a nonrenal transplant is associated with an increase by a factor of more than four in the risk of death.	Univ Michigan, Sch Med, Div Nephrol, Sci Registry Transplant Recipients, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ojo, AO (corresponding author), Univ Michigan, Sch Med, Div Nephrol, Sci Registry Transplant Recipients, 3914 Taubman Ctr,Box 0364, Ann Arbor, MI 48109 USA.	aojo@umich.edu			NIDDK NIH HHS [K24 DK62234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK062234] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arend SM, 1997, NEPHROL DIAL TRANSPL, V12, P1672, DOI 10.1093/ndt/12.8.1672; Baid S, 2000, TRANSPLANTATION, V70, P255, DOI 10.1097/00007890-200007270-00001; Bennett WM, 1996, INT J CLIN PHARM TH, V34, P515; Bennett WM, 1996, KIDNEY INT, V50, P1089, DOI 10.1038/ki.1996.415; Brown RS, 1996, TRANSPLANTATION, V62, P1788, DOI 10.1097/00007890-199612270-00018; BRUNNER FP, 1988, NEPHROL DIAL TRANSPL, V3, P585, DOI 10.1093/oxfordjournals.ndt.a091710; Coopersmith CM, 2001, SURGERY, V130, P457, DOI 10.1067/msy.2001.115834; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; English RF, 2002, AM J TRANSPLANT, V2, P769, DOI 10.1034/j.1600-6143.2002.20811.x; Fisher NC, 1998, TRANSPLANTATION, V66, P59, DOI 10.1097/00007890-199807150-00010; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; Goldstein DJ, 1997, TRANSPLANTATION, V63, P664, DOI 10.1097/00007890-199703150-00009; GONWA TA, 1992, J HEART LUNG TRANSPL, V11, P926; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GREENBERG A, 1987, AM J KIDNEY DIS, V9, P12, DOI 10.1016/S0272-6386(87)80156-7; GREENBERG A, 1990, TRANSPLANTATION, V50, P589, DOI 10.1097/00007890-199010000-00012; Israni A, 2002, AM J KIDNEY DIS, V39, DOI 10.1053/ajkd.2002.31427; IWATSUKI S, 1984, TRANSPLANT P, V17, P191; Kasiske BL, 1998, AM J KIDNEY DIS, V32, pS142, DOI 10.1053/ajkd.1998.v32.pm9820472; KASISKE BL, 1993, MINER ELECTROL METAB, V19, P186; Khanna A, 2002, KIDNEY INT, V62, P2257, DOI 10.1046/j.1523-1755.2002.00668.x; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; MAUGER EA, 1995, STAT MED, V14, P1553, DOI 10.1002/sim.4780141406; MCCAULEY J, 1990, NEPHRON, V55, P121, DOI 10.1159/000185938; MCDIARMID SV, 1990, TRANSPLANTATION, V49, P81, DOI 10.1097/00007890-199001000-00018; Molmenti EP, 2001, TRANSPLANTATION, V71, P267, DOI 10.1097/00007890-200101270-00018; MYERS BD, 1986, KIDNEY INT, V30, P964, DOI 10.1038/ki.1986.280; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; *NAT I DIAB DIG KI, 2001, REN DAT SYST USRDS 2, P204; PATTISON JM, 1995, AM J KIDNEY DIS, V26, P643, DOI 10.1016/0272-6386(95)90602-9; PLATZ KP, 1994, TRANSPLANTATION, V58, P170, DOI 10.1097/00007890-199405820-00007; PORAYKO MK, 1995, TRANSPLANT P, V27, P1114; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; PUSCHETT JB, 1990, AM J NEPHROL, V10, P296, DOI 10.1159/000168123; RIMOLA A, 1987, GASTROENTEROLOGY, V93, P148, DOI 10.1016/0016-5085(87)90327-1; Ruilope LM, 2001, J AM COLL CARDIOL, V38, P1782, DOI 10.1016/S0735-1097(01)01627-8; SAKHUJA V, 1995, TRANSPL P, V27, P2728; Satchithananda DK, 2002, J HEART LUNG TRANSPL, V21, P651, DOI 10.1016/S1053-2498(01)00411-9; Sehgal AR, 1998, AM J KIDNEY DIS, V31, P593, DOI 10.1053/ajkd.1998.v31.pm9531174; SEHGAL V, 1995, AM J KIDNEY DIS, V26, P193, DOI 10.1016/0272-6386(95)90174-4; Shlipak MG, 2002, ANN INTERN MED, V137, P555, DOI 10.7326/0003-4819-137-7-200210010-00006; Trompeter R, 2002, PEDIATR NEPHROL, V17, P141, DOI 10.1007/s00467-001-0795-9; van Gelder T, 1998, NEPHROL DIAL TRANSPL, V13, P2322, DOI 10.1093/ndt/13.9.2322; VANBUREN DH, 1994, J AM SOC NEPHROL, V4, pS17; Waller JR, 2002, TRANSPLANT P, V34, P1587, DOI 10.1016/S0041-1345(02)03033-6; WASER M, 1993, J HEART LUNG TRANSPL, V12, P846; WHEATLEY HC, 1987, TRANSPLANTATION, V43, P641, DOI 10.1097/00007890-198705000-00007; Wilkinson AH, 1999, J AM SOC NEPHROL, V10, P1136; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; YOUNG EW, 1994, KIDNEY INT, V46, P1216, DOI 10.1038/ki.1994.387; ZALTZMAN JS, 1992, TRANSPLANTATION, V54, P875, DOI 10.1097/00007890-199211000-00021	51	1600	1645	1	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					931	940		10.1056/NEJMoa021744	http://dx.doi.org/10.1056/NEJMoa021744			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954741	Bronze			2022-12-28	WOS:000185081400004
J	Mattson, MP				Mattson, MP			Gene-diet interactions in brain aging and neurodegenerative disorders	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				AMYOTROPHIC-LATERAL-SCLEROSIS; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; EXPERIMENTAL-MODELS; HOMOCYSTEINE LEVELS; RESTRICTION; MICE; DAMAGE; DEGENERATION	While there are many examples of people who live for 100 years or more with little evidence of a decline in brain function, many others are not so fortunate and experience a neurodegenerative disorder, such as Alzheimer disease or Parkinson disease. Although an increasing number of genetic factors that may affect the risk for neurodegenerative disorders are being identified, emerging findings suggest that dietary factors play major roles in determining whether the brain ages successfully or experiences a neurodegenerative disorder. Dietary factors may interact with disease-causing or predisposing genes in molecular cascades that either promote or prevent the degeneration of neurons. Epidemiologic findings suggest that high-calorie diets and folic acid deficiency increase the risk for Alzheimer disease and Parkinson disease; studies of animal models of these disorders have shown that dietary restriction (reduced calorie intake or intermittent fasting) and dietary supplementation with folic acid can reduce neuronal damage and improve behavioral outcome. Animal studies have shown that the beneficial effects of dietary restriction on the brain result in part from increased production of neurotrophic factors and cytoprotective protein chaperones in neurons. By keeping homocysteine levels low, folic acid can protect cerebral vessels and prevent the accumulation of DNA damage in neurons caused by oxidative stress and facilitated by homocysteine. Although additional studies are required in humans, the emerging data suggest that high-calorie diets and elevated homocysteine levels may render the brain vulnerable to age-related neurodegenerative disorders, particularly in persons with a genetic predisposition to such disorders.	NIA, Neurosci Lab, Gerontol Res Ctr 4F01, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Mattson, MP (corresponding author), NIA, Neurosci Lab, Gerontol Res Ctr 4F01, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	Mattson, Mark P/F-6038-2012		NATIONAL INSTITUTE ON AGING [ZIAAG000314, ZIAAG000315, ZIAAG000312, Z01AG000315, Z01AG000312, Z01AG000314] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Brody JA, 2001, AGING-CLIN EXP RES, V13, P64, DOI 10.1007/BF03351527; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Cutler RG, 2002, ANN NEUROL, V52, P448, DOI 10.1002/ana.10312; Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x; Duan WZ, 1999, J NEUROSCI RES, V57, P195, DOI 10.1002/(SICI)1097-4547(19990715)57:2&lt;195::AID-JNR5&gt;3.0.CO;2-P; Duan WZ, 2001, J NEUROCHEM, V76, P619, DOI 10.1046/j.1471-4159.2001.00071.x; Frame LT, 1998, ENVIRON HEALTH PERSP, V106, P313; Gwinn-Hardy K, 2002, MOVEMENT DISORD, V17, P645, DOI 10.1002/mds.10173; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Kruman II, 2002, J NEUROSCI, V22, P1752, DOI 10.1523/JNEUROSCI.22-05-01752.2002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Kuhn W, 1998, EUR NEUROL, V40, P225, DOI 10.1159/000007984; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Logroscino G, 1996, ANN NEUROL, V39, P89, DOI 10.1002/ana.410390113; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Mattson M.P, 2002, DIET BRAIN CONNECTIO; Mattson MP, 1999, ANN NY ACAD SCI, V893, P154, DOI 10.1111/j.1749-6632.1999.tb07824.x; McCaddon A, 2001, DEMENT GERIATR COGN, V12, P309, DOI 10.1159/000051275; Pedersen WA, 1999, BRAIN RES, V833, P117, DOI 10.1016/S0006-8993(99)01471-7; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Seshadri S, 2002, NEW ENGL J MED, V346, P476, DOI 10.1056/NEJMoa011613; Tanzi RE, 2001, NEURON, V32, P181, DOI 10.1016/S0896-6273(01)00476-7; Ueland PM, 2001, TRENDS PHARMACOL SCI, V22, P195, DOI 10.1016/S0165-6147(00)01675-8; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2; Zhu HY, 1999, BRAIN RES, V842, P224, DOI 10.1016/S0006-8993(99)01827-2	28	107	114	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			441	444		10.7326/0003-4819-139-5_Part_2-200309021-00012	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965973				2022-12-28	WOS:000185133800012
J	Getz, L; Sigurdsson, JA; Hetlevik, I				Getz, L; Sigurdsson, JA; Hetlevik, I			Is opportunistic disease prevention in the consultation ethically justifiable?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK; CANCER; BENEFITS; MATTER	Medical resources are increasingly shifting from making patients better to preventing them from becoming ill. Genetic testing is likely to extend the list of conditions that can be screened for. Is it time to stop and consider whom we screen and how we approach it?	Landspitali Univ Hosp, Off Human Resources, IS-101 Reykjavik, Iceland; Univ Iceland, Solvangur Hlth Ctr, Dept Family Med, IS-220 Hafnarfjordur, Iceland; Norwegian Univ Sci & Technol, Dept Gen Practice & Community Med, N-7489 Trondheim, Norway	Landspitali National University Hospital; University of Iceland; Norwegian University of Science & Technology (NTNU)	Getz, L (corresponding author), Landspitali Univ Hosp, Off Human Resources, IS-101 Reykjavik, Iceland.	linngetz@med.is		Sigurdsson, Johann Agust/0000-0002-5646-6411				Ault A, 2003, LANCET, V362, P379, DOI 10.1016/S0140-6736(03)14063-9; Bracken Patrick., 2002, TRAUMA CULTURE MEANI; Edwards A, 2002, BMJ-BRIT MED J, V324, P827, DOI 10.1136/bmj.324.7341.827; Freeman AC, 2001, BRIT MED J, V323, P1100, DOI 10.1136/bmj.323.7321.1100; Getz L, 2003, SOC SCI MED, V56, P2045, DOI 10.1016/S0277-9536(02)00200-9; Getz L, 2003, SCAND J PRIM HEALTH, V21, P3, DOI 10.1080/02813430310000483; Haynes RB, 2002, BMJ-BRIT MED J, V324, P1350, DOI 10.1136/bmj.324.7350.1350; HETLEVIK I, 1999, THESIS TRONDHEIM; Hollingshead A.B., 2000, GROUP PROCESS INTERG, V3, P257, DOI [10.1177/1368430200033002, DOI 10.1177/1368430200033002]; Kirkengen A. L., 2001, INSCRIBED BODIES HLT; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Law MR, 2002, BMJ-BRIT MED J, V324, P1570, DOI 10.1136/bmj.324.7353.1570; Marteau TM, 2002, BRIT MED J, V325, P78, DOI 10.1136/bmj.325.7355.78; METCALFE D, 1986, J ROY COLL GEN PRACT, V36, P349; Misselbrook D, 2001, BRIT J GEN PRACT, V51, P276; Moynihan R, 2002, BRIT MED J, V324, P886, DOI 10.1136/bmj.324.7342.886; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sackett DL, 2002, CAN MED ASSOC J, V167, P363; SKOLBEKKEN JA, 1995, SOC SCI MED, V40, P291, DOI 10.1016/0277-9536(94)00262-R; SMITH R, 2003, BMJ             0426, P326; Stott N C, 1979, J R Coll Gen Pract, V29, P201; Swensen SJ, 2003, BRIT MED J, V326, P894, DOI 10.1136/bmj.326.7395.894; Tauber AI, 2001, HEALTH CARE ANAL, V9, P299, DOI 10.1023/A:1012901831835; WELSH HG, 2001, JAMA-J AM MED ASSOC, V285, P2776; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635	27	67	67	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 30	2003	327	7413					498	500		10.1136/bmj.327.7413.498	http://dx.doi.org/10.1136/bmj.327.7413.498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LA	12946974	Green Published			2022-12-28	WOS:000185088900022
J	Nurse, J; Woodcock, P; Ormsby, J				Nurse, J; Woodcock, P; Ormsby, J			Influence of environmental factors on mental health within prisons: focus group study	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; DISORDER; ISSUES	Objective To increase understanding of how the prison environment influences the mental health of prisoners and prison staff. Design Qualitative study with focus groups. Setting A local prison in southern England. Participants Prisoners and prison staff. Results Prisoners reported that long periods of isolation with little mental stimulus contributed to poor mental health and led to intense feelings of anger, frustration, and anxiety Prisoners said they misused drugs to relieve the long hours of tedium. Most focus groups identified negative relationships between staff and prisoners as an important issue affecting stress levels of staff and prisoners. Staff groups described a "circle of stress," whereby the prison culture, organisation, and staff shortages caused high staff stress levels, resulting in staff sickness, which in turn caused greater stress for remaining staff. Staff shortages also affected prisoners, who would be locked up for longer periods of time, the ensuing frustration would then be released on staff, aggravating the situation still further. Insufficient staff also affected control and monitoring of bullying and reduced the amount of time in which prisoners were able to maintain contact with their families. Conclusions Greater consideration should be given to understanding the wider environmental and organisational factors that contribute to poor mental health in prisons. This information can be used to inform prison policy makers and managers, and the primary care trusts who are beginning to work in partnership with prisons to improve the mental health of prisoners.	N & Mid Hampshire Hlth Author, Basingstoke, Hants, England		Nurse, J (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Keppel St, London WC1E 7HT, England.							Birmingham L, 1996, BRIT MED J, V313, P1521, DOI 10.1136/bmj.313.7071.1521; Brinberg D., 1985, VALIDITY RES PROCESS; Brooke D, 1996, BRIT MED J, V313, P1524, DOI 10.1136/bmj.313.7071.1524; BROWN GW, 1986, PSYCHOL MED, V16, P813, DOI 10.1017/S0033291700011831; Cote-Arsenault D, 1999, NURS RES, V48, P280; *DEP HLTH, PRIS HLTH; *DEP HLTH, 1998, OUR HLTH NAT; Department of Health, 1999, NAT SERV FRAM MENT H; Department of Health, 2001, MAK IT HAPP GUID DEL; Greenhalgh T, 2002, ENDOCRIN METAB CLIN, V31, P583, DOI 10.1016/S0889-8529(02)00009-9; GUNN J, 1991, BRIT MED J, V303, P338, DOI 10.1136/bmj.303.6798.338; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HM Chief Inspector of Prisons, 1999, SUIC IS EV CONC THEM; Lyth I.M., 1988, CONTAINING ANXIETY I; Morgan D.L, 1996, FOCUS GROUPS QUALITA; MORGAN DL, 1997, FOCUS GROUPS QUALITI; *NHS EX WORK GROUP, 1999, FUT ORG PRIS HLTH CA; NURSE J, 2000, M NEED DEV PRISON HL; *OFF NAT STAT, 1997, PSYCH MORB PRIS ENGL; *OFF POP CENS SURV, 1991, OPCS MORB STAT GEN P; Oppenheim A. N., 1992, QUESTIONNAIRE DESIGN; Reed J, 1997, J ADV NURS, V26, P765, DOI 10.1046/j.1365-2648.1997.00395.x; Sim J, 1998, J ADV NURS, V28, P345, DOI 10.1046/j.1365-2648.1998.00692.x; Vaughn Sharon, 1996, FOCUS GROUP INTERVIE; Whitelaw S, 2001, HEALTH PROMOT INT, V16, P339, DOI 10.1093/heapro/16.4.339; *WHO, 2000, WHO HLTH PRIS PROJ; HM PRISON ESTABLISHM	27	96	101	3	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					480	483		10.1136/bmj.327.7413.480	http://dx.doi.org/10.1136/bmj.327.7413.480			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LA	12946970	Bronze, Green Published			2022-12-28	WOS:000185088900016
J	Bystricky, M				Bystricky, M			Mantle flow revisited	SCIENCE			English	Editorial Material							LATTICE PREFERRED ORIENTATION; OLIVINE; STRAIN		ETH, Inst Geol, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bystricky, M (corresponding author), ETH, Inst Geol, Sonneggstr 5, CH-8092 Zurich, Switzerland.	misha@erdw.ethz.ch	Bystricky, Misha/A-8149-2010	Bystricky, Misha/0000-0002-7433-9758				Ben Ismail W, 1998, TECTONOPHYSICS, V296, P145; Bystricky M, 2000, SCIENCE, V290, P1564, DOI 10.1126/science.290.5496.1564; DURHAM WB, 1977, J GEOPHYS RES, V82, P5737, DOI 10.1029/JB082i036p05737; Frese K, 2003, CONTRIB MINERAL PETR, V145, P75, DOI 10.1007/s00410-002-0434-x; Holtzman BK, 2003, SCIENCE, V301, P1227, DOI 10.1126/science.1087132; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; Nicolas A., 1987, FORMATION ANISOTROPY, DOI DOI 10.1029/GD016P0111; Tommasi A, 2000, J GEOPHYS RES-SOL EA, V105, P7893, DOI 10.1029/1999JB900411; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0	9	1	1	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1190	1191		10.1126/science.1088835	http://dx.doi.org/10.1126/science.1088835			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947186				2022-12-28	WOS:000185003500027
J	Lowenberg, B; van Putten, W; Theobald, M; Gmur, J; Verdonck, L; Sonneveld, P; Fey, M; Schouten, H; de Greef, G; Ferrant, A; Kovacsovics, T; Gratwohl, A; Daenen, S; Huijgens, P; Boogaerts, M				Lowenberg, B; van Putten, W; Theobald, M; Gmur, J; Verdonck, L; Sonneveld, P; Fey, M; Schouten, H; de Greef, G; Ferrant, A; Kovacsovics, T; Gratwohl, A; Daenen, S; Huijgens, P; Boogaerts, M		HOVON Cooperative Grp; Swiss Grp Clin Canc Res	Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC GROWTH-FACTORS; ACUTE MYELOGENOUS LEUKEMIA; FACTOR GM-CSF; ACUTE MYELOBLASTIC-LEUKEMIA; DOSE ARA-C; CYTOSINE-ARABINOSIDE; INDUCTION CHEMOTHERAPY; EUROPEAN ORGANIZATION; ELDERLY PATIENTS; IN-VITRO	BACKGROUND Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). METHODS In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on disease-free survival was assessed in all patients and in cytogenetically distinct prognostic subgroups. RESULTS After induction chemotherapy, the rates of response were not significantly different in the two groups. After a median follow-up of 55 months, patients in complete remission after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than patients who did not receive G-CSF (42 percent vs. 33 percent at four years, P=0.02), owing to a reduced probability of relapse (relative risk, 0.77; 95 percent confidence interval, 0.61 to 0.99; P=0.04). G-CSF did not significantly improve overall survival (P=0.16). Although G-CSF did not improve the outcome in the subgroup with an unfavorable prognosis, the 72 percent of patients with standard-risk AML benefited from G-CSF therapy (overall survival at four years, 45 percent, as compared with 35 percent in the group that did not receive G-CSF [relative risk of death, 0.75; 95 percent confidence interval, 0.59 to 0.95; P=0.02]; disease-free survival, 45 percent vs. 33 percent [relative risk, 0.70]; 95 percent confidence interval, 0.55 to 0.90; P=0.006). CONCLUSIONS Sensitization of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML.	Erasmus Univ, Med Ctr, Dept Hematol, NL-3000 CA Rotterdam, Netherlands; Erasmus Univ, Med Ctr, HOVON Data Ctr, NL-3000 CA Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Stat, NL-3000 CA Rotterdam, Netherlands; Johannes Gutenberg Univ Mainz, Univ Hosp, Dept Hematol & Oncol, D-6500 Mainz, Germany; Hirslanden Klin Pk, Onkozentrum, Zurich, Switzerland; Univ Med Ctr, Dept Hematol, Utrecht, Netherlands; Univ Bern, Inst Med Oncol, Bern, Switzerland; Univ Bern, Inselspital, CH-3010 Bern, Switzerland; Univ Hosp, Dept Internal Oncol & Hematol, Maastricht, Netherlands; Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium; Univ Hosp, Div Hematol, Lausanne, Switzerland; Kantonsspital, Div Hematol, CH-4031 Basel, Switzerland; Univ Groningen, Univ Med Ctr Groningen, Univ Hosp, Dept Hematol, Groningen, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Hematol, Amsterdam, Netherlands; Catholic Univ Louvain, Hosp Gasthuisberg, Dept Hematol, B-3000 Louvain, Belgium	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Johannes Gutenberg University of Mainz; University Hospital Mainz; Utrecht University; Utrecht University Medical Center; University of Bern; University of Bern; Maastricht University; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Kantonsspital Aarau AG (KSA); University of Basel; University of Groningen; Vrije Universiteit Amsterdam; Universite Catholique Louvain	Lowenberg, B (corresponding author), Erasmus Univ, Med Ctr, Dept Hematol, POB 2040, NL-3000 CA Rotterdam, Netherlands.	b.lowenberg@erasmusmc.nl						Baer MR, 1996, BLOOD, V87, P1484, DOI 10.1182/blood.V87.4.1484.bloodjournal8741484; BHALLA K, 1991, BLOOD, V78, P2674; BHALLA K, 1988, LEUKEMIA, V2, P810; Bishop JF, 1996, BLOOD, V87, P1710, DOI 10.1182/blood.V87.5.1710.bloodjournal8751710; BOEKHORST PAWT, 1993, LEUKEMIA, V7, P1191; CANNISTRA SA, 1989, LEUKEMIA, V3, P328; CANNISTRA SA, 1991, LEUKEMIA, V5, P230; ESTEY E, 1992, BLOOD, V79, P2246; Estey EH, 1999, BLOOD, V93, P2478, DOI 10.1182/blood.V93.8.2478.408k04_2478_2484; FRENETTE PS, 1995, AM J HEMATOL, V49, P48, DOI 10.1002/ajh.2830490109; INATOMI Y, 1994, CANCER RES, V54, P455; LISTA P, 1988, BRIT J HAEMATOL, V70, P121, DOI 10.1111/j.1365-2141.1988.tb02444.x; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Lowenberg B, 1997, J CLIN ONCOL, V15, P3496; Lowenberg B, 2001, BEST PRACT RES CL HA, V14, P65, DOI 10.1053/beha.2000.0116; Lowenberg B, 1997, BLOOD, V90, P2952; LOWENBERG B, 1993, BLOOD, V81, P281; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Mitelman F, 1995, ICSN 1995 INT SYSTEM; MIYAUCHI J, 1989, BLOOD, V73, P1272; Mrozek K, 1997, SEMIN ONCOL, V24, P17; Ohno R, 1998, LEUKEMIA RES, V22, P1143, DOI 10.1016/S0145-2126(98)00117-9; OHNO R, 1994, BLOOD, V83, P2086; REUTER C, 1994, LEUKEMIA, V8, P217; Rossi HA, 2002, LEUKEMIA, V16, P310, DOI 10.1038/sj.leu.2402368; Schiffer CA, 1996, BLOOD, V88, P3675, DOI 10.1182/blood.V88.10.3675.bloodjournal88103675; TANAKA M, 1993, LEUKEMIA RES, V17, P585, DOI 10.1016/0145-2126(93)90089-4; TEBOEKHORST PAW, 1994, LEUKEMIA, V8, P1480; Terpstra W, 1997, LEUKEMIA, V11, P315, DOI 10.1038/sj.leu.2400561; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Witz F, 1998, BLOOD, V91, P2722; Zittoun R, 1996, J CLIN ONCOL, V14, P2150, DOI 10.1200/JCO.1996.14.7.2150	32	308	322	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					743	752		10.1056/NEJMoa025406	http://dx.doi.org/10.1056/NEJMoa025406			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930926	Green Published, Bronze			2022-12-28	WOS:000184843300004
J	Nurse, P				Nurse, P			Understanding cells	NATURE			English	Editorial Material									Canc Res UK, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Nurse, P (corresponding author), Canc Res UK, Cell Cycle Lab, Lincolns Inn Fields, London WC2A 3PX, England.							BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Bray D, 2002, P NATL ACAD SCI USA, V99, P7, DOI 10.1073/pnas.022641699; Guet CC, 2002, SCIENCE, V296, P1466, DOI 10.1126/science.1067407; Kauffman S.A., 1993, ORIGINS ORDER; NOVAK B, 1993, J CELL SCI, V106, P1153; Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6	6	44	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					883	883		10.1038/424883a	http://dx.doi.org/10.1038/424883a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931164	Bronze			2022-12-28	WOS:000184843600019
J	Woolhandler, S; Campbell, T; Himmelstein, DU				Woolhandler, S; Campbell, T; Himmelstein, DU			Costs of health care administration in the United States and Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOR-PROFIT HOSPITALS; QUALITY; REFORM; HMOS	BACKGROUND A decade ago, the administrative costs of health care in the United States greatly exceeded those in Canada. We investigated whether the ascendancy of computerization, managed care, and the adoption of more businesslike approaches to health care have decreased administrative costs. METHODS For the United States and Canada, we calculated the administrative costs of health insurers, employers' health benefit programs, hospitals, practitioners' offices, nursing homes, and home care agencies in 1999. We analyzed published data, surveys of physicians, employment data, and detailed cost reports filed by hospitals, nursing homes, and home care agencies. In calculating the administrative share of health care spending, we excluded retail pharmacy sales and a few other categories for which data on administrative costs were unavailable. We used census surveys to explore trends over time in administrative employment in health care settings. Costs are reported in U.S. dollars. RESULTS In 1999, health administration costs totaled at least $294.3 billion in the United States, or $1,059 per capita, as compared with $307 per capita in Canada. After exclusions, administration accounted for 31.0 percent of health care expenditures in the United States and 16.7 percent of health care expenditures in Canada. Canada's national health insurance program had overhead of 1.3 percent; the overhead among Canada's private insurers was higher than that in the United States (13.2 percent vs. 11.7 percent). Providers' administrative costs were far lower in Canada. Between 1969 and 1999, the share of the U.S. health care labor force accounted for by administrative workers grew from 18.2 percent to 27.3 percent. In Canada, it grew from 16.0 percent in 1971 to 19.1 percent in 1996. (Both nations' figures exclude insurance-industry personnel.) CONCLUSIONS The gap between U.S. and Canadian spending on health care administration has grown to $752 per capita. A large sum might be saved in the United States if administrative costs could be trimmed by implementing a Canadian-style health care system.	Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Canadian Inst Hlth Informat, Ottawa, ON, Canada	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Canadian Institute Health Information	Himmelstein, DU (corresponding author), 1493 Cambridge St, Cambridge, MA 02139 USA.							BALLINGER G, 2001, HOME CARE ESTIMATES; BLUMENTHAL D, 1993, NEW ENGL J MED, V329, P428, DOI 10.1056/NEJM199308053290612; BUSKE L, 1997, WHAT WE FOUND, P13; *CAN I HLTH INF, 2001, NAT HLTH EXP DAT NAT; *CAN LIF HLTH INS, 2002, SPEC STUD HLTH INS B; *CAN MED ASS, PHYS RES QUEST 2001; *CAN MED ASS, OV EXP; Congressional Budget Office, 1991, UN HLTH INS COV US M; Devereaux PJ, 2002, CAN MED ASSOC J, V166, P1399; *EC MURPH, 1993, WORK IM HLTH CAR; *FAULKN GRAY, 1999, FAULKN GRAYS HLTH DA; *GEN ACC OFF, 1991, GAOHRD9190; *GOV SASK, 2001, PUBL ACC 2000 01, V2, P96; GRAY BH, 1986, NEW ENGL J MED, V314, P1523, DOI 10.1056/NEJM198606053142335; Gray BH, 1986, PROFIT ENTERPRISE HL; Grembowski DE, 2000, HEALTH SERV RES, V35, P707; *HCIA SACHS, 2001, GUID NURS HOM IND 20; Heffler S, 2001, HEALTH AFFAIR, V20, P263; Heffler S, 2001, HEALTH AFFAIR, V20, P193, DOI 10.1377/hlthaff.20.2.193; Himmelstein DU, 1996, AM J PUBLIC HEALTH, V86, P172, DOI 10.2105/AJPH.86.2.172; Himmelstein DU, 1996, AM J PUBLIC HEALTH, V86, P790; Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159; Himmelstein DU, 2002, INT J HEALTH SERV, V32, P657, DOI 10.2190/JK74-14MB-YT5T-KUXQ; *HLTH INS ASS AM, 1999, SOURC BOOK HLTH INS; LATHROP JP, 2000, STRATEGY BUSINESS, P36; LATHROP P, 1998, STRATEGY MANAGEMENT, V13, P32; *LIB C C RES SERV, 1988, COST EFF EXT HLTH IN; *MIN FIN, 2001, PUBL ACC ONT 2000 01, V1, P4; MOORE JD, 1996, MOD HEALTHCARE, V26, P18; *OFF STAT HLTH PLA, 1999, LONG TERM CAR FIN DA; *ONT ASS COMM CAR, 2001, ADM COSTS COMM CAR A; *ORG EC COOP DEV, 2001, OECD HLTH DAT 2001; PATTISON RV, 1983, NEW ENGL J MED, V309, P347, DOI 10.1056/NEJM198308113090606; Pauly M, 1999, HEALTH AFFAIR, V18, P28, DOI 10.1377/hlthaff.18.6.28; Remler DK, 2000, INQUIRY-J HEALTH CAR, V37, P304; RIORDAN M, 2002, RW JOHNS FDN HLTH ET; RODWIN VG, 1992, PUBLIC HOSP SYSTEMS, P11; *SAS I, 1999, SAS SOFTW VERS 8 2; *SHERL CO, 2003, EXP BENCHM HLTH PLAN; Sloan FA, 2001, J HEALTH ECON, V20, P1, DOI 10.1016/S0167-6296(00)00066-7; *STAT CAN, 2002, 13604MIB STAT CAN; Taylor DH, 1999, NEW ENGL J MED, V340, P293, DOI 10.1056/NEJM199901283400408; THORPE KE, 1992, HEALTH AFFAIR, V11, P41, DOI 10.1377/hlthaff.11.2.41; WASSENAAR JD, 2001, PHYSICIAN SOCIOECONO; WATT JM, 1986, NEW ENGL J MED, V314, P89, DOI 10.1056/NEJM198601093140206; WOOLHANDLER S, 1994, NEW ENGL J MED, V331, P336, DOI 10.1056/NEJM199408043310520; Woolhandler S, 1997, NEW ENGL J MED, V337, P1783; Woolhandler S, 1997, NEW ENGL J MED, V336, P769, DOI 10.1056/NEJM199703133361106; WOOLHANDLER S, 1991, NEW ENGL J MED, V324, P1253, DOI 10.1056/NEJM199105023241805; WOOLHANDLER S, 1993, NEW ENGL J MED, V329, P400, DOI 10.1056/NEJM199308053290606; ZELMAN WA, 1994, HEALTH AFFAIR, V13, P9, DOI 10.1377/hlthaff.13.1.9; PROVIDER REIMBURSE 2; 2002, 1999 EMPLOYER SPONSO; 1991, AGING	54	382	383	1	34	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					768	775		10.1056/NEJMsa022033	http://dx.doi.org/10.1056/NEJMsa022033			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	713EE	12930930				2022-12-28	WOS:000184843300009
J	Khot, UN; Khot, MB; Bajzer, CT; Sapp, SK; Ohman, EM; Brener, SJ; Ellis, SG; Lincoff, AM; Topol, EJ				Khot, UN; Khot, MB; Bajzer, CT; Sapp, SK; Ohman, EM; Brener, SJ; Ellis, SG; Lincoff, AM; Topol, EJ			Prevalence of conventional risk factors in. patients with coronary heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; DIRECTIONAL ATHERECTOMY; ATHEROSCLEROSIS RISK; PRIMARY PREVENTION; DIABETES-MELLITUS; FOLLOW-UP; MORTALITY; STROKE	Context It is commonly suggested that more than 50% of patients with coronary heart disease (CHD) lack any of the conventional risk factors (cigarette smoking, diabetes, hyperlipidemia, and hypertension). This claim implies that other factors play a significant role in CHID and has led to considerable interest in nontraditional risk factors and genetic causes of CHD. Objective To determine the prevalence of the 4 conventional risk factors among patients with CHD. Design, Setting, and Patients In 2002-2003, we analyzed data for 122458 patients enrolled in 14 international randomized clinical trials of CHD conducted during the prior decade. Patients included 76716 with ST-elevation myocardial infarction, 35527 with unstable angina/non-ST-elevation myocardial infarction, and 10215 undergoing percutaneous coronary intervention. Main Outcome Measures Prevalence of each conventional risk factor and number of conventional risk factors present among patients with CHID, compared between men and women and by age at trial entry. Results Among patients with CHD, at least 1 of the 4 conventional risk factors was present in 84.6% of women and 80.6% of men. In younger patients (men : :55 years and women : 65 years) and most patients presenting either with unstable angina or for percutaneous coronary intervention, only 10% to 15% of patients lacked any of the 4 conventional risk factors. This pattern was largely independent of sex, geographic region, trial entry criteria, or prior CHD. Premature CHD was related to cigarette smoking in men and cigarette smoking and diabetes in women. Smoking decreased the age at the time of CHD event (at trial entry) by nearly 1 decade in all risk factor combinations. Conclusions In direct contrast with conventional,thinking, 80% to 90% of patients with CHID have conventional risk factors. Although research on nontraditional risk factors and genetic causes of heart disease is important, clinical medicine, public health policies, and research efforts should place significant emphasis on the 4 conventional risk factors and the lifestyle behaviors causing them to reduce the epidemic of CHD.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Univ N Carolina, Sch Med, Dept Med, Div Cardiol, Chapel Hill, NC USA	Cleveland Clinic Foundation; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Khot, UN (corresponding author), Indiana Heart Phys, 112 N 17th Ave,Suite 300, Beech Grove, IN 46107 USA.	khot@cvresearch.net	Manoj, Deepa/AAE-7083-2021	Topol, Eric/0000-0002-1478-4729				ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BOWLIN SJ, 1993, J CLIN EPIDEMIOL, V46, P561, DOI 10.1016/0895-4356(93)90129-O; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; Dobs AS, 1999, AM J EPIDEMIOL, V150, P1055, DOI 10.1093/oxfordjournals.aje.a009929; Fager G, 1997, ARTERIOSCL THROM VAS, V17, P3527, DOI 10.1161/01.ATV.17.12.3527; Franse LV, 2001, DIABETES CARE, V24, P2065, DOI 10.2337/diacare.24.12.2065; Futterman L G, 1998, Am J Crit Care, V7, P240; Grundy SM, 1998, CIRCULATION, V97, P1876, DOI 10.1161/01.CIR.97.18.1876; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Harrington RA, 2002, CIRCULATION, V105, P316; Hennekens CH, 1998, CIRCULATION, V97, P1095, DOI 10.1161/01.CIR.97.11.1095; HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; Hyman DJ, 2001, NEW ENGL J MED, V345, P479, DOI 10.1056/NEJMoa010273; Hyman DJ, 2000, ARCH INTERN MED, V160, P2281, DOI 10.1001/archinte.160.15.2281; JEFFREY S, INTER HEART LARGEST; Jha P, 1996, J AM COLL CARDIOL, V27, P1335, DOI 10.1016/0735-1097(96)00018-6; Jomini V, 2002, J AM COLL CARDIOL, V40, P676, DOI 10.1016/S0735-1097(02)02017-X; Kannel WB, 1998, AM HEART J, V136, P205, DOI 10.1053/hj.1998.v136.90226; Kannel William B, 2002, Am J Geriatr Cardiol, V11, P101, DOI 10.1111/j.1076-7460.2002.00995.x; Keil U, 1998, EUR HEART J, V19, P1197, DOI 10.1053/euhj.1998.1089; KNOPP RH, 2002, TXB CARDIOVASCULAR M, P175; Lefkowitz RJ, 2001, JAMA-J AM MED ASSOC, V285, P581, DOI 10.1001/jama.285.5.581; Levi F, 2002, HEART, V88, P119, DOI 10.1136/heart.88.2.119; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Magnus P, 2001, ARCH INTERN MED, V161, P2657, DOI 10.1001/archinte.161.22.2657; McKechnie RS, 2002, ACC CURR J REV, V11, P32; NIETO FJ, 1995, ARCH INTERN MED, V155, P677, DOI 10.1001/archinte.155.7.677; Norhammar A, 2002, LANCET, V359, P2140, DOI 10.1016/S0140-6736(02)09089-X; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Prasad A, 2002, CIRCULATION, V106, P184, DOI 10.1161/01.CIR.0000021125.83697.21; Prevention CfDCa, 2000, BEH RISK FACT SURV S; ROBINSON K, 2002, TXB CARDIOVASCULAR M, P200; Simoons ML, 1997, LANCET, V349, P1429; Simoons ML, 2001, LANCET, V357, P1915; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stamler J, 1999, JAMA-J AM MED ASSOC, V282, P2012, DOI 10.1001/jama.282.21.2012; Tavazzi L, 1999, AM HEART J, V138, pS48, DOI 10.1016/S0002-8703(99)70320-0; Tcheng JE, 1997, LANCET, V349, P1422; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1996, NEW ENGL J MED, V335, P775; TOPOL EJ, 1993, NEW ENGL J MED, V329, P221, DOI 10.1056/NEJM199307223290401; Topol EJ, 2001, LANCET, V357, P1905; *US DEP HHS, 1990, DHHS PUBL CDC; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186	55	974	1039	2	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2003	290	7					898	904		10.1001/jama.290.7.898	http://dx.doi.org/10.1001/jama.290.7.898			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712ZE	12928466				2022-12-28	WOS:000184828800026
J	English, DR; Burton, RC; del Mar, CB; Donovan, RJ; Ireland, PD; Emery, G				English, DR; Burton, RC; del Mar, CB; Donovan, RJ; Ireland, PD; Emery, G			Evaluation of aid to diagnosis of pigmented skin lesions in general practice: controlled trial randomised by practice	BRITISH MEDICAL JOURNAL			English	Article							MALIGNANT-MELANOMA; DYSPLASTIC NEVI	Objectives To determine whether an aid to the diagnosis of pigmented skin lesions reduces the ratio of benign lesions to melanomas excised in general practice. Design Controlled trial randomiscd by practice. Setting General practices in Perth, Western Australia. Participants 468 general practitioners in 223 practices. Interventions Intervention practices were given an algorithm and instant camera to assist with the diagnosis of pigmented skin lesions. All practices were given national guidelines on managing melanoma. Main outcome measures Ratio of benign pigmented lesions to melanomas excised. Analyses conducted with and without inclusion of seborrhoeic keratoses. Results At baseline the ratios of benign to malignant lesions were lower in the intervention group than in the control group. During the trial period the ratios were higher in the intervention group (19:1 v 17:1 without seborrhoeic keratoses and 29:1 v 26:1 with seborrhoeic keratoses). After adjustment for patients' age, sex, and socioeconomic status, the ratio was 1.02 times higher (95% confidence interval 0.68 to 1.51, P=0.94) in the intervention group when seborrhoeic keratoses were not included and 1.03 times higher (0.71 to 1.50, P=0.88) when seborrhoeic keratoses were included. General practitioners in the intervention group were less likely than those in the control group to excise the most recent pigmented skin lesion they managed (22% v 48%, P<0.001) and to refer the patient to a specialist (16% v 27%, P=0.06). Conclusions Provision of the algorithm and camera did not decrease the ratio of benign pigmented skin lesions to melanomas excised by general practitioners.	Canc Council Victoria, Carlton, Vic 3053, Australia; Natl Canc Control Initiat, Carlton, Vic 3053, Australia; Univ Queensland, Sch Med, Herston, Qld 4006, Australia; Curtin Univ Technol, Ctr Behav Res Canc Control, Bentley, WA 6102, Australia; Hollywood Private Hosp, Perth Cent Coastal Div Gen Practice, Nedlands, WA 6009, Australia	Cancer Council Victoria; University of Queensland; Curtin University; University of Western Australia	English, DR (corresponding author), Canc Council Victoria, Carlton, Vic 3053, Australia.		English, Dallas/AAH-5005-2019; Del Mar, Chris B/B-1136-2008	English, Dallas/0000-0001-7828-8188; Del Mar, Chris B/0000-0003-3821-8163				[Anonymous], 1996 CENSUS POPULATI; *AUSTR CANC NETW, 1997, GUID MAN CUT MAL MEL; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Burton RC, 1998, J MED SCREEN, V5, P156, DOI 10.1136/jms.5.3.156; BURTON RC, 1993, INT J CANCER, V55, P765, DOI 10.1002/ijc.2910550512; DECOSTE SD, 1993, ARCH DERMATOL, V129, P57, DOI 10.1001/archderm.129.1.57; DELMAR C, 1994, AUST J PUBLIC HEALTH, V18, P221; DELMAR CB, 1995, BRIT MED J, V310, P492, DOI 10.1136/bmj.310.6978.492; Kanzler MH, 2001, J AM ACAD DERMATOL, V45, P260, DOI 10.1067/mjd.2001.116239; Kelly JW, 1997, MED J AUSTRALIA, V167, P191, DOI 10.5694/j.1326-5377.1997.tb138843.x; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; Marks R, 1997, J AM ACAD DERMATOL, V36, P721, DOI 10.1016/S0190-9622(97)80324-6; RIVERS JK, 1990, CANCER, V65, P1232, DOI 10.1002/1097-0142(19900301)65:5<1232::AID-CNCR2820650533>3.0.CO;2-8; SHAW HM, 1985, PATHOLOGY, V17, P271, DOI 10.3109/00313028509063766; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x	16	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					375	378B		10.1136/bmj.327.7411.375	http://dx.doi.org/10.1136/bmj.327.7411.375			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919990	Green Published, Bronze			2022-12-28	WOS:000184864200020
J	Lawrie, N; Van Damme, W				Lawrie, N; Van Damme, W			The importance of refugee-host relations: Guinea 1990-2003	LANCET			English	Editorial Material									Inst Trop Med, B-2000 Antwerp, Belgium; One World Act, London, England	Institute of Tropical Medicine (ITM)	Van Damme, W (corresponding author), Inst Trop Med, B-2000 Antwerp, Belgium.		Van Damme, Wim/F-7404-2011	Van Damme, Wim/0000-0002-6344-3007				*HUM RIGHTS WATCH, 2001, GUIN REF STILL RISK, P13; *RAD NETH, TATT WELC MAT REF BU; *UN ENV PROGR, ENV IMP REF GUIN; *UN OCHA, 2003, COMM HUM CAP GUIN 20; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8	5	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					575	575		10.1016/S0140-6736(03)14124-4	http://dx.doi.org/10.1016/S0140-6736(03)14124-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12938671				2022-12-28	WOS:000184817600030
J	Yoshida, S				Yoshida, S			A lethal complication of central venous catheterisation	LANCET			English	Editorial Material									Muroran City Gen Hosp, Dept Radiol, Muroran, Hokkaido 0518512, Japan		Yoshida, S (corresponding author), Muroran City Gen Hosp, Dept Radiol, Yamate Chou 3-8-1, Muroran, Hokkaido 0518512, Japan.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					569	569		10.1016/S0140-6736(03)14120-7	http://dx.doi.org/10.1016/S0140-6736(03)14120-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932392				2022-12-28	WOS:000184817600026
J	Pahnke, K; Zahn, R; Elderfield, H; Schulz, M				Pahnke, K; Zahn, R; Elderfield, H; Schulz, M			340,000-year centennial-scale marine record of Southern Hemisphere climatic oscillation	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; LAST GLACIAL PERIOD; NEW-ZEALAND; NORTH-ATLANTIC; ICE-CORE; SOUTHWEST PACIFIC; FIELD INTENSITY; WATER MASSES; CHATHAM RISE; SW PACIFIC	In order to investigate rapid climatic changes at mid-southern latitudes, we have developed centennial-scale paleoceanographic records from the southwest Pacific that enable detailed comparison with Antarctic ice core records. These records suggest close coupling of mid-southern latitudes with Antarctic climate during deglacial and interglacial periods. Glacial sections display higher variability than is seen in Antarctic ice cores, which implies climatic decoupling between mid- and high southern latitudes due to enhanced circum-Antarctic circulation. Structural and temporal similarity with the Greenland ice core record is evident in glacial sections and suggests a degree of interhemispheric synchroneity not predicted from bipolar ice core correlations.	Cardiff Univ, Sch Earth Ocean & Planetary Sci, Cardiff CF10 3YE, S Glam, Wales; Univ Barcelona, Inst Catalana Rec & Estudis Avancats, E-08028 Barcelona, Spain; Univ Barcelona, Fac Geol, Grp Rec Consolidat Geociencies Marines, Dept Estratig Paleontol & Geociencias Marines, E-08028 Barcelona, Spain; Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England; Univ Bremen, Dept Geosci, D-28334 Bremen, Germany; Univ Bremen, DFG Res Ctr Ocean Margins, D-28334 Bremen, Germany	Cardiff University; ICREA; University of Barcelona; University of Barcelona; University of Cambridge; University of Bremen; German Research Foundation (DFG); University of Bremen	Pahnke, K (corresponding author), Cardiff Univ, Sch Earth Ocean & Planetary Sci, Park Pl, Cardiff CF10 3YE, S Glam, Wales.		Schulz, Michael/P-7276-2016	Schulz, Michael/0000-0001-6500-2697; Pahnke, Katharina/0000-0001-9114-8411	ICREA Funding Source: Custom	ICREA(ICREA)		Bard E, 1997, NATURE, V385, P707, DOI 10.1038/385707a0; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Borowski D, 2002, J PHYS OCEANOGR, V32, P2520, DOI 10.1175/1520-0485-32.9.2520; Bowler JM, 2003, NATURE, V421, P837, DOI 10.1038/nature01383; Brown SJ, 1996, PALEOCEANOGRAPHY, V11, P543, DOI 10.1029/96PA01491; Caillon N, 2003, SCIENCE, V299, P1728, DOI 10.1126/science.1078758; Carter L, 2002, MAR GEOL, V191, P19, DOI 10.1016/S0025-3227(02)00509-1; Carter L, 2000, PALAEOGEOGR PALAEOCL, V162, P333, DOI 10.1016/S0031-0182(00)00137-1; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; COX MD, 1989, J PHYS OCEANOGR, V19, P1730, DOI 10.1175/1520-0485(1989)019<1730:AIMOTW>2.0.CO;2; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Denton GH, 1999, GEOGR ANN A, V81A, P107, DOI 10.1111/j.0435-3676.1999.00055.x; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; HEATH RA, 1985, NEW ZEAL J MAR FRESH, V19, P79, DOI 10.1080/00288330.1985.9516077; HEUSSER LE, 1994, QUATERNARY SCI REV, V13, P273, DOI 10.1016/0277-3791(94)90030-2; Kanfoush SL, 2000, SCIENCE, V288, P1815, DOI 10.1126/science.288.5472.1815; King AL, 2001, DEEP-SEA RES PT I, V48, P1687, DOI 10.1016/S0967-0637(00)00106-0; Laj C, 2002, EARTH PLANET SC LETT, V200, P177, DOI 10.1016/S0012-821X(02)00618-0; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Mashiotta TA, 1999, EARTH PLANET SC LETT, V170, P417, DOI 10.1016/S0012-821X(99)00116-8; Mazaud A, 2002, EARTH PLANET SC LETT, V201, P159, DOI 10.1016/S0012-821X(02)00662-3; McManus JF, 1999, SCIENCE, V283, P971, DOI 10.1126/science.283.5404.971; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P135, DOI 10.1029/1999PA000415; Sachs JP, 1999, SCIENCE, V286, P756, DOI 10.1126/science.286.5440.756; Schmittner A, 2003, QUATERNARY SCI REV, V22, P659, DOI 10.1016/S0277-3791(02)00184-1; Schulz M, 1999, GEOPHYS RES LETT, V26, P3385, DOI 10.1029/1999GL006069; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; Sikes EL, 2000, NATURE, V405, P555, DOI 10.1038/35014581; SIKES EL, 2002, PALEOCEANOGRAPHY, V17; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Uddstrom MJ, 1999, J GEOPHYS RES-OCEANS, V104, P20729, DOI 10.1029/1999JC900167; Voelker AHL, 2000, RADIOCARBON, V42, P437, DOI 10.1017/S0033822200030368; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Weaver PPE, 1998, PALEOCEANOGRAPHY, V13, P70, DOI 10.1029/97PA02982; Wells P, 1997, MAR MICROPALEONTOL, V32, P341, DOI 10.1016/S0377-8398(97)00025-X; WILSON CJN, 1988, GEOL MAG, V125, P297, DOI 10.1017/S0016756800010232	39	241	254	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					948	952		10.1126/science.1084451	http://dx.doi.org/10.1126/science.1084451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920294				2022-12-28	WOS:000184755900034
J	Cannon, RO				Cannon, RO			Assessing risk in hypertrophic cardiomyopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NHLBI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cannon, RO (corresponding author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.								0	13	13	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1016	1018		10.1056/NEJMp038122	http://dx.doi.org/10.1056/NEJMp038122			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968084				2022-12-28	WOS:000185223100002
J	Higginson, IJ; Thompson, M				Higginson, IJ; Thompson, M			Children and young people who die from cancer: epidemiology and place of death in England (1995-9)	BRITISH MEDICAL JOURNAL			English	Article									Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Palliat Care & Policy, London SE5 9RJ, England	University of London; King's College London	Higginson, IJ (corresponding author), Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Palliat Care & Policy, London SE5 9RJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Bleyer WA, 2002, MED PEDIATR ONCOL, V38, P1, DOI 10.1002/mpo.1257; Edwards J, 2001, Int J Palliat Nurs, V7, P485; Feudtner C, 2002, PEDIATRICS, V109, P656, DOI 10.1542/peds.109.4.656; GOLDMAN A, 1990, ARCH DIS CHILD, V65, P641, DOI 10.1136/adc.65.6.641; Higginson IJ, 1998, PALLIATIVE MED, V12, P353, DOI 10.1191/026921698672530176	5	33	33	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2003	327	7413					478	479		10.1136/bmj.327.7413.478	http://dx.doi.org/10.1136/bmj.327.7413.478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LA	12946969	Green Published, Bronze			2022-12-28	WOS:000185088900015
J	Surman, OS; Hertl, M				Surman, OS; Hertl, M			Liver donation: donor safety comes first	LANCET			English	Editorial Material							TRANSPLANTATION		Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Transplantat Serv, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Surman, OS (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.							Allen TH, 1997, COMMUN RES, V24, P64, DOI 10.1177/009365097024001003; Beavers KL, 2003, LIVER TRANSPLANT, V9, P645, DOI 10.1053/jlts.2003.50123; Beavers KL, 2001, LIVER TRANSPLANT, V7, P943, DOI 10.1053/jlts.2001.28443; Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345; BUSUTTIL RW, 2003, P RUSSELL LECT TRANS; DELMONICO FL, IN PRESS TRANSPLANTA; Fukunishi I, 2001, PSYCHOSOMATICS, V42, P337, DOI 10.1176/appi.psy.42.4.337; Parascandola M, 2002, KENNEDY INST ETHIC J, V12, P245, DOI 10.1353/ken.2002.0018; SOBER E, 1998, EVOLUTION PSYCHOL UN; Veatch R. M., 2000, TRANSPLANTATION ETHI	10	27	28	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					674	675		10.1016/S0140-6736(03)14239-0	http://dx.doi.org/10.1016/S0140-6736(03)14239-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	716NH	12957084				2022-12-28	WOS:000185034800002
J	Jin, HJ; Kaplan, DL				Jin, HJ; Kaplan, DL			Mechanism of silk processing in insects and spiders	NATURE			English	Article							BOMBYX-MORI SILK; FIBROIN SOLUTION; SOLID-STATE; FIBERS; WATER; BIOMATERIALS; ORGANIZATION; SPECTROSCOPY; GENE; NMR	Silk spinning by insects and spiders leads to the formation of fibres that exhibit high strength and toughness(1). The lack of understanding of the protein processing in silk glands has prevented the recapitulation of these properties in vitro from reconstituted or genetically engineered silks. Here we report the identification of emulsion formation and micellar structures from aqueous solutions of reconstituted silkworm silk fibroin as a first step in the process to control water and protein-protein interactions. The sizes (100-200 nm diameter) of these structures could be predicted from hydrophobicity plots of silk protein primary sequence(2). These micelles subsequently aggregated into larger 'globules' and gel-like states as the concentration of silk fibroin increased, while maintaining solubility owing to the hydrophilic regions of the protein interspersed among the larger hydrophobic regions. Upon physical shearing or stretching structural transitions, increased birefringence and morphological alignment were demonstrated, indicating that this process mimics the behaviour of similar native silk proteins in vivo. Final morphological features of these silk materials are similar to those observed in native silkworm fibres.	Tufts Univ, Dept Biol & Chem Engn, Medford, MA 02155 USA; Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA	Tufts University; Tufts University	Kaplan, DL (corresponding author), Tufts Univ, Dept Biol & Chem Engn, Medford, MA 02155 USA.							Altman GH, 2003, BIOMATERIALS, V24, P401, DOI 10.1016/S0142-9612(02)00353-8; Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; ASAKURA T, 1985, MACROMOLECULES, V18, P1841, DOI 10.1021/ma00152a009; AUVRAY X, 1992, LANGMUIR, V8, P2671, DOI 10.1021/la00047a017; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; ISHIDA M, 1990, MACROMOLECULES, V23, P88, DOI 10.1021/ma00203a017; Jin HJ, 2002, BIOMACROMOLECULES, V3, P1233, DOI 10.1021/bm025581u; Knight DP, 2002, PHILOS T R SOC B, V357, P155, DOI 10.1098/rstb.2001.1030; Knight DP, 1999, P ROY SOC B-BIOL SCI, V266, P519, DOI 10.1098/rspb.1999.0667; Kwon KW, 2002, POLYMER, V43, P3353, DOI 10.1016/S0032-3861(02)00155-6; Lele AK, 2001, CHEM ENG SCI, V56, P5793, DOI 10.1016/S0009-2509(01)00288-3; MAGOSHI J, 1979, J POLYM SCI POL PHYS, V17, P515, DOI 10.1002/pol.1979.180170315; MALSTOM M, 1992, MACROMOLECULES, V25, P5440; MINOURA N, 1990, BIOMATERIALS, V11, P430, DOI 10.1016/0142-9612(90)90100-5; MITA K, 1994, J MOL EVOL, V38, P583; Ochi A, 2002, BIOMACROMOLECULES, V3, P1187, DOI 10.1021/bm020056g; Perez-Rigueiro J, 1998, J APPL POLYM SCI, V70, P2439, DOI 10.1002/(SICI)1097-4628(19981219)70:12<2439::AID-APP16>3.0.CO;2-J; Poza P, 2002, ENG FRACT MECH, V69, P1035, DOI 10.1016/S0013-7944(01)00120-5; Putthanarat S, 2000, POLYMER, V41, P7735, DOI 10.1016/S0032-3861(00)00036-7; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Seidel A, 2000, MACROMOLECULES, V33, P775, DOI 10.1021/ma990893j; Shen Y, 1998, MACROMOLECULES, V31, P8857, DOI 10.1021/ma980281j; Sofia S, 2001, J BIOMED MATER RES, V54, P139, DOI 10.1002/1097-4636(200101)54:1<139::AID-JBM17>3.0.CO;2-7; Tanaka T, 1998, POLYM INT, V45, P175, DOI 10.1002/(SICI)1097-0126(199802)45:2<175::AID-PI883>3.0.CO;2-K; Valluzzi R, 1999, J PHYS CHEM B, V103, P11382, DOI 10.1021/jp991363s; van Beek JD, 2002, P NATL ACAD SCI USA, V99, P10266, DOI 10.1073/pnas.152162299; Viney C, 1997, SUPRAMOL SCI, V4, P75, DOI 10.1016/S0968-5677(96)00059-4; Vollrath F, 2001, NATURE, V410, P541, DOI 10.1038/35069000; Wilson D, 2000, BIOPHYS J, V78, P2690, DOI 10.1016/S0006-3495(00)76813-5; Yamada H, 2001, MAT SCI ENG C-BIO S, V14, P41, DOI 10.1016/S0928-4931(01)00207-7; Zhou CZ, 2000, NUCLEIC ACIDS RES, V28, P2413, DOI 10.1093/nar/28.12.2413	31	1040	1104	41	776	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1057	1061		10.1038/nature01809	http://dx.doi.org/10.1038/nature01809			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944968				2022-12-28	WOS:000184984200044
J	Lawrence, J; Mayers, DL; Hullsiek, KH; Collins, G; Abrams, DI; Reisler, RB; Crane, LR; Schmetter, BS; Dionne, TJ; Saldanha, JM; Jones, MC; Baxter, JD				Lawrence, J; Mayers, DL; Hullsiek, KH; Collins, G; Abrams, DI; Reisler, RB; Crane, LR; Schmetter, BS; Dionne, TJ; Saldanha, JM; Jones, MC; Baxter, JD		064 Study Team Terry Beirn	Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIROLOGICAL FAILURE; THERAPY; MUTATIONS; HIV-1; EVOLUTION; IMPACT	BACKGROUND: We compared two strategies for treating patients infected with multidrug-resistant human immunodeficiency virus (HIV). METHODS: Patients with multidrug-resistant HIV and HIV RNA levels of more than 5000 copies per milliliter were randomly assigned to a four-month structured interruption of treatment followed by a change in antiretroviral regimen (treatment-interruption group) or to an immediate change in regimen (control group). Genotypic and phenotypic resistance testing was performed. Disease progression, death, and changes in genotypic resistance, CD4 cell counts, HIV RNA levels, and quality of life were assessed. RESULTS: After a median follow-up of 11.6 months, disease progression or death occurred in 22 of the 138 patients in the treatment-interruption group and in 12 of the 132 patients in the control group (P=0.01), with a hazard ratio of 2.57 (95 percent confidence interval, 1.2 to 5.5) for the treatment-interruption group. There were eight deaths in each group. In the treatment-interruption group, the mutant HIV populations completely or partially reverted to wild type by four months in 64.0 percent of patients. As compared with the control group, the treatment-interruption group had a mean CD4 cell count that was 85 cells per cubic millimeter lower from months 0 through 4 (P<0.001), 47 cells per cubic millimeter lower from months 5 through 8 (P<0.001), and 31 cells per cubic millimeter lower after eight months (P=0.11). The mean HIV RNA levels were 1.2 log copies per milliliter higher (on a base-10 scale) in the treatment-interruption group during months 0 through 4 (P<0.001), but they were not significantly different from those in the control group after month 4. The overall quality of life was similar in the two groups. CONCLUSIONS: In patients infected with multidrug-resistant HIV, structured interruption of treatment was associated with greater progression of disease and did not confer immunologic or virologic benefits or improve the overall quality of life.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, San Francisco, CA 94110 USA; Henry Ford Hosp, Detroit, MI 48202 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; NIAID, NIH, Div AIDS, Bethesda, MD 20892 USA; Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA; Social & Sci Syst, Silver Spring, MD USA; Washington Reg AIDS Program, Washington, DC USA; Denver Publ Hlth Dept, Denver, CO USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp, Dept Med, Camden, NJ 08103 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Wayne State University; Social & Scientific Systems; Denver Health Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lawrence, J (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Posit Hlth Program, 3180 18th St,Suite 305, San Francisco, CA 94110 USA.	jlawrence@php.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI042170, U01AI046362] Funding Source: NIH RePORTER; NIAID NIH HHS [5U01AI046362-03, 5U01AI042170-10] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Barbour JD, 2002, J VIROL, V76, P11104, DOI 10.1128/JVI.76.21.11104-11112.2002; Cohen CJ, 2002, AIDS, V16, P579, DOI 10.1097/00002030-200203080-00009; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2002, AIDS, V16, P201, DOI 10.1097/00002030-200201250-00009; Deeks SG, 2003, AIDS, V17, P361, DOI 10.1097/00002030-200302140-00010; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; DEEKS SG, 2000, 7 C RETR OPP INF SAN; Delaugerre C, 2001, AIDS, V15, P2189, DOI 10.1097/00002030-200111090-00016; Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001; Green LA, 1998, AIDS, V12, P1983, DOI 10.1097/00002030-199815000-00009; Izopet J, 2000, AIDS, V14, P2247, DOI 10.1097/00002030-200010200-00005; Kantor R, 2002, ANTIMICROB AGENTS CH, V46, P1086, DOI 10.1128/AAC.46.4.1086-1092.2002; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Katlama C, 2003, 10 C RETR OPP INF BO; LUNDGREN JD, 2002, 9 C RETR OPP INF SEA; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007; Ruiz L, 2002, ANTIVIR THER, V7, pS166; Tebas P, 2002, J INFECT DIS, V186, P1198; [U.S. Public Health Service (USPHS) Infectious Diseases Society of America (IDSA)], 1999, MMWR-MORBID MORTAL W, V48, p[1, 61]; Ware J. E., 2000, SF 12 SCORE SF 12 PH; Youle M, 2000, AIDS, V14, P1717, DOI 10.1097/00002030-200008180-00005	23	185	188	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					837	846		10.1056/NEJMoa035103	http://dx.doi.org/10.1056/NEJMoa035103			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944569				2022-12-28	WOS:000184968400004
J	Beye, M; Hasselmann, M; Fondrk, MK; Page, RE; Omholt, SW				Beye, M; Hasselmann, M; Fondrk, MK; Page, RE; Omholt, SW			The gene csd is the primary signal for sexual development in the honeybee and encodes an SR-type protein	CELL			English	Article							APIS-MELLIFERA; DROSOPHILA-MELANOGASTER; TRANSFORMER GENE; PREMESSENGER RNA; MUSCA-DOMESTICA; LOCUS REGION; SPLICE SITE; DIFFERENTIATION; EVOLUTION; GENOME	Haplodiploid organisms comprise about 20% of animals. Males develop from unfertilized eggs while females are derived from fertilized eggs. The underlying mechanisms of sex determination, however, appear to be diverse and are poorly understood. We have dissected the complementary sex determiner (csd) locus in the honeybee to understand its molecular basis. In this species, csd acts as the primary sex-determining signal with several alleles segregating in populations. Males are hemizygous and females are heterozygous at this locus; nonreproducing diploid males occur when the locus is homozygous. We have characterized csd by positional cloning and repression analysis. csd alleles are highly variable and no transcription differences were found between sexes. These results establish csd as a primary signal that governs sexual development by its allelic composition. Structural similarity of csd with tra genes of Dipteran insects suggests some functional relation of what would otherwise appear to be unrelated sex-determination mechanisms.	Univ Halle Wittenberg, Inst Zool, Biozentrum, D-06120 Halle Saale, Germany; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Agr Univ Norway, Dept Anim Sci, N-1432 As, Norway	Martin Luther University Halle Wittenberg; University of California System; University of California Davis; Norwegian University of Life Sciences	Beye, M (corresponding author), Univ Halle Wittenberg, Inst Zool, Biozentrum, Weinberg Weg 22, D-06120 Halle Saale, Germany.		Hasselmann, Martin/E-7681-2014; Hasselmann, Martin/ABB-6485-2021	Hasselmann, Martin/0000-0003-3305-4024				ADAMS J, 1977, GENETICS, V86, P583; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELL G, 1982, MASTERPIECE NATURE E; BELOTE JM, 1989, DEV GENET, V10, P143, DOI 10.1002/dvg.1020100304; Beye M, 1998, GENOMICS, V49, P317, DOI 10.1006/geno.1998.5253; Beye M, 1999, GENETICS, V153, P1701; Beye M, 2002, INSECT MOL BIOL, V11, P527, DOI 10.1046/j.1365-2583.2002.00361.x; BEYE M, 1994, NATURWISSENSCHAFTEN, V81, P460; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Bull J.J., 1983, EVOLUTION SEX DETERM; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; BUTLER B, 1986, EMBO J, V5, P3607, DOI 10.1002/j.1460-2075.1986.tb04689.x; Casselton LA, 2002, HEREDITY, V88, P142, DOI 10.1038/sj.hdy.6800035; Charlesworth D, 2002, CURR BIOL, V12, pR424, DOI 10.1016/S0960-9822(02)00915-6; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; COOK JM, 1993, HEREDITY, V71, P421, DOI 10.1038/hdy.1993.157; CROZIER RH, 1971, AM NAT, V105, P399, DOI 10.1086/282733; Dauwalder B, 1996, P NATL ACAD SCI USA, V93, P9004, DOI 10.1073/pnas.93.17.9004; Dauwalder B, 1998, EMBO J, V17, P6049, DOI 10.1093/emboj/17.20.6049; DRESCHER W, 1964, J HERED, V55, P90; Dubendorfer A, 2002, INT J DEV BIOL, V46, P75; DZIERZON A, 1845, EICHSTADTER BIENENZE, V1, P109; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hasselmann M, 2001, INSECT MOL BIOL, V10, P605, DOI 10.1046/j.0962-1075.2001.00300.x; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; HILFIKERKLEINER D, 1993, GENETICS, V134, P1187; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kennedy CF, 1998, MOL CELL BIOL, V18, P5425, DOI 10.1128/MCB.18.9.5425; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kristensen Niels P., 1995, Zoologische Beitraege, V36, P83; LAIDLAW HH, 1956, GENETICS, V41, P179; Laidlaw HH., 1997, QUEEN REARING BEE BR; Lasko P, 2000, J CELL BIOL, V150, pF51, DOI 10.1083/jcb.150.2.F51; MACKENSEN OTTO, 1955, JOUR HEREDITY, V46, P72; Maine EM, 2001, DEV BIOL, V239, P177, DOI 10.1006/dbio.2001.0394; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; Marin I, 1998, SCIENCE, V281, P1990, DOI 10.1126/science.281.5385.1990; McAllister BF, 2000, GENETICS, V154, P1711; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; Mount SM, 2000, J CELL BIOL, V150, pF37, DOI 10.1083/jcb.150.2.F37; OISHI K, 1993, GENETICA, V88, P119, DOI 10.1007/BF02424468; OMHOLT SW, 1995, APIDOLOGIE, V26, P297, DOI 10.1051/apido:19950404; Pane A, 2002, DEVELOPMENT, V129, P3715; PENG YSC, 1992, J INVERTEBR PATHOL, V60, P127, DOI 10.1016/0022-2011(92)90085-I; Sambrook J., 2002, MOL CLONING LAB MANU; Schutt C, 2000, DEVELOPMENT, V127, P667; Snodgrass R.E., 1956, ANATOMY HONEYBEE; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Staden R, 2000, Methods Mol Biol, V132, P115; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WALLDORF U, 1990, FEBS LETT, V267, P245, DOI 10.1016/0014-5793(90)80936-D; Whiting PW, 1943, GENETICS, V28, P365; WILKINS AS, 1995, BIOESSAYS, V17, P71, DOI 10.1002/bies.950170113; Willhoeft U, 1996, GENETICS, V144, P737; Wilson EB, 1905, SCIENCE, V22, P500, DOI 10.1126/science.22.564.500	63	364	399	3	73	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					419	429		10.1016/S0092-8674(03)00606-8	http://dx.doi.org/10.1016/S0092-8674(03)00606-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941271	Bronze			2022-12-28	WOS:000184928800006
J	Coull, JAM; Boudreau, D; Bachand, K; Prescott, SA; Nault, F; Sik, A; De Koninck, P; De Koninck, Y				Coull, JAM; Boudreau, D; Bachand, K; Prescott, SA; Nault, F; Sik, A; De Koninck, P; De Koninck, Y			Trans-synaptic shift in anion gradient in spinal lamina I neurons as a mechanism of neuropathic pain	NATURE			English	Article							CHRONIC CONSTRICTION INJURY; RAT SCIATIC-NERVE; DORSAL-HORN; SELECTIVE LOSS; GABA; MODEL; INHIBITION; EXCITATION; CORD; PHARMACOLOGY	Modern pain-control theory(1) predicts that a loss of inhibition (disinhibition) in the dorsal horn of the spinal cord is a crucial substrate for chronic pain syndromes(2). However, the nature of the mechanisms that underlie such disinhibition has remained controversial(3-6). Here we present evidence for a novel mechanism of disinhibition following peripheral nerve injury. It involves a trans-synaptic reduction in the expression of the potassium-chloride exporter KCC2, and the consequent disruption of anion homeostasis in neurons of lamina I of the superficial dorsal horn, one of the main spinal nociceptive output pathways(7). In our experiments, the resulting shift in the transmembrane anion gradient caused normally inhibitory anionic synaptic currents to be excitatory, substantially driving up the net excitability of lamina I neurons. Local blockade or knock-down of the spinal KCC2 exporter in intact rats markedly reduced the nociceptive threshold, confirming that the reported disruption of anion homeostasis in lamina I neurons was sufficient to cause neuropathic pain.	Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	Laval University; McGill University	De Koninck, Y (corresponding author), Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada.		De Koninck, Yves/C-2659-2008; Boudreau, Dominic/I-8144-2012	De Koninck, Yves/0000-0002-5779-9330; 				BERNANDER O, 1991, P NATL ACAD SCI USA, V88, P11569, DOI 10.1073/pnas.88.24.11569; Blomqvist A, 2000, J COMP NEUROL, V428, P1; CODERRE TJ, 1994, PAIN, V59, P345, DOI 10.1016/0304-3959(94)90020-5; CODERRE TJ, 1992, J NEUROSCI, V12, P3665; COOK AJ, 1987, NATURE, V325, P151, DOI 10.1038/325151a0; EBIHARA S, 1995, J PHYSIOL-LONDON, V484, P77, DOI 10.1113/jphysiol.1995.sp020649; Farber NB, 2002, MOL PSYCHIATR, V7, P726, DOI 10.1038/sj.mp.4001087; Ganguly K, 2001, CELL, V105, P521, DOI 10.1016/S0092-8674(01)00341-5; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Hwang JH, 1997, PAIN, V70, P15, DOI 10.1016/S0304-3959(96)03249-6; Keller AF, 2001, J NEUROSCI, V21, P7871, DOI 10.1523/JNEUROSCI.21-20-07871.2001; Kontinen VK, 2001, ANESTHESIOLOGY, V94, P333, DOI 10.1097/00000542-200102000-00024; LIGHT AR, 1992, INITIAL PROCESSING P; Malan TP, 2002, ANESTHESIOLOGY, V96, P1161, DOI 10.1097/00000542-200205000-00020; Martin TJ, 2001, J PHARMACOL EXP THER, V299, P811; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Mosconi T, 1996, PAIN, V64, P37, DOI 10.1016/0304-3959(95)00077-1; Nabekura J, 2002, J NEUROSCI, V22, P4412, DOI 10.1523/JNEUROSCI.22-11-04412.2002; Pitcher GM, 2000, EUR J NEUROSCI, V12, P2006, DOI 10.1046/j.1460-9568.2000.00087.x; Polgar E, 2003, PAIN, V104, P229, DOI 10.1016/S0304-3959(03)00011-3; Prescott SA, 2002, J PHYSIOL-LONDON, V539, P817, DOI 10.1113/jphysiol.2001.013437; Rabben T, 1999, J PHARMACOL EXP THER, V289, P1060; Rivera C, 1999, NATURE, V397, P251, DOI 10.1038/16697; Rudomin P, 1999, EXP BRAIN RES, V129, P1, DOI 10.1007/s002210050933; Serpell MG, 2002, PAIN, V99, P557, DOI 10.1016/S0304-3959(02)00255-5; Somers DL, 2002, NEUROSCI LETT, V323, P171, DOI 10.1016/S0304-3940(02)00157-X; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	30	770	809	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					938	942		10.1038/nature01868	http://dx.doi.org/10.1038/nature01868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931188				2022-12-28	WOS:000184843600041
J	Huber, C; Eisenreich, W; Hecht, S; Wachtershausher, G				Huber, C; Eisenreich, W; Hecht, S; Wachtershausher, G			A possible primordial peptide cycle	SCIENCE			English	Article							AMINO-ACIDS; ENZYMES; ORIGIN; LIFE	alpha-Amino acids can undergo peptide formation by activation with carbon monoxide (CO) under hot aqueous conditions in the presence of freshly coprecipitated colloidal (Fe,Ni)S. We now show that CO-driven peptide formation proceeds concomitantly with CO-driven, N-terminal peptide degradation by racemizing N-terminal hydantoin and urea derivatives to alpha-amino acids. This establishes a peptide cycle with closely related anabolic and catabolic segments. The hydantoin derivative is a purin-related heterocycle. The (Fe,Ni)S-dependent urea hydrolysis could have been the evolutionary precursor of the nickel-enzyme urease. The results support the theory of a chemoautotrophic origin of life with a CO-driven, (Fe,Ni)S-dependent primordial metabolism.	Tech Univ Munich, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Wachtershausher, G (corresponding author), Tech Univ Munich, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				Huber C, 1998, SCIENCE, V281, P670, DOI 10.1126/science.281.5377.670; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; Kricheldorf H. R., 1987, ALPHA AMINOACID N CA; Syldatk C, 1999, APPL MICROBIOL BIOT, V51, P293, DOI 10.1007/s002530051395; Taillades J, 1998, ORIGINS LIFE EVOL B, V28, P61, DOI 10.1023/A:1006566810636; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452	7	181	187	5	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					938	940		10.1126/science.1086501	http://dx.doi.org/10.1126/science.1086501			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920291				2022-12-28	WOS:000184755900030
J	Hughes, TP; Baird, AH; Bellwood, DR; Card, M; Connolly, SR; Folke, C; Grosberg, R; Hoegh-Guldberg, O; Jackson, JBC; Kleypas, J; Lough, JM; Marshall, P; Nystrom, M; Palumbi, SR; Pandolfi, JM; Rosen, B; Roughgarden, J				Hughes, TP; Baird, AH; Bellwood, DR; Card, M; Connolly, SR; Folke, C; Grosberg, R; Hoegh-Guldberg, O; Jackson, JBC; Kleypas, J; Lough, JM; Marshall, P; Nystrom, M; Palumbi, SR; Pandolfi, JM; Rosen, B; Roughgarden, J			Climate change, human impacts, and the resilience of coral reefs	SCIENCE			English	Review							GREAT-BARRIER-REEF; MARINE RESERVES; BIODIVERSITY; ECOSYSTEMS; EVOLUTION; FUTURE; PERSPECTIVES; DISTURBANCE; MORTALITY; DIVERSITY	The diversity, frequency, and scale of human impacts on coral reefs are increasing to the extent that reefs are threatened globally. Projected increases in carbon dioxide and temperature over the next 50 years exceed the conditions under which coral reefs have flourished over the past half-million years. However, reefs will change rather than disappear entirely, with some species already showing far greater tolerance to climate change and coral bleaching than others. International integration of management strategies that support reef resilience need to be vigorously implemented, and complemented by strong policy decisions to reduce the rate of global warming.	James Cook Univ, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia; Environm Protect Agcy, Old Quarantine Stn, Townsville, Qld 4810, Australia; Stockholm Univ, Dept Syst Ecol, SE-10691 Stockholm, Sweden; Univ Calif Davis, Ctr Populat Biol, Div Biol Sci, Sect Ecol & Evolut, Davis, CA 95616 USA; Univ Queensland, Ctr Marine Studies, St Lucia, Qld, Australia; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Smithsonian Trop Res Inst, Balboa, Panama; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Australian Inst Marine Sci, Townsville, Qld 4810, Australia; Great Barrier Reef Marine Pk Author, Townsville, Qld 4810, Australia; Stanford Univ, Hopkins Marine Stn, Dept Biol Sci, Pacific Grove, CA 93950 USA; Smithsonian Inst, Dept Paleobiol, Natl Museum Nat Hist, Washington, DC 20013 USA; Nat Hist Museum, Dept Zool, London SW7 5BD, England; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	James Cook University; Stockholm University; University of California System; University of California Davis; University of Queensland; University of California System; University of California San Diego; Scripps Institution of Oceanography; Smithsonian Institution; Smithsonian Tropical Research Institute; National Center Atmospheric Research (NCAR) - USA; Australian Institute of Marine Science; Stanford University; Smithsonian Institution; Smithsonian National Museum of Natural History; Natural History Museum London; Stanford University	Hughes, TP (corresponding author), James Cook Univ, Ctr Coral Reef Biodivers, Townsville, Qld 4811, Australia.		Hughes, Terry P/L-4721-2013; Pandolfi, John M/A-3121-2009; Hoegh-Guldberg, Ove/ABA-5420-2020; Lough, Janice M/L-1682-2013; Bellwood, David/E-2497-2011; Hoegh-Guldberg, Ove/H-6169-2011; Folke, Carl/Z-1545-2019; Connolly, Sean R./E-7773-2011; Baird, Andrew Hamilton/C-8449-2009	Hughes, Terry P/0000-0002-5257-5063; Pandolfi, John M/0000-0003-3047-6694; Hoegh-Guldberg, Ove/0000-0001-7510-6713; Lough, Janice M/0000-0002-3789-1009; Hoegh-Guldberg, Ove/0000-0001-7510-6713; Connolly, Sean R./0000-0003-1537-0859; Baird, Andrew Hamilton/0000-0001-8504-4077; Nystrom, Magnus/0000-0003-3608-2426; Folke, Carl/0000-0002-4050-3281				Ayre DJ, 2000, EVOLUTION, V54, P1590; Baird AH, 2002, MAR ECOL PROG SER, V237, P133, DOI 10.3354/meps237133; Baker AC, 2001, NATURE, V411, P765, DOI 10.1038/35081151; Bascompte J, 2002, AM NAT, V159, P128, DOI 10.1086/324793; Bellwood DR, 2003, ECOL LETT, V6, P281, DOI 10.1046/j.1461-0248.2003.00432.x; Bellwood DR, 2001, SCIENCE, V292, P1532, DOI 10.1126/science.1058635; Benzie JAH, 1999, AM ZOOL, V39, P131; Berkelmans R, 1999, CORAL REEFS, V18, P219, DOI 10.1007/s003380050186; Broecker WS, 2000, EARTH-SCI REV, V51, P137, DOI 10.1016/S0012-8252(00)00019-2; BUDDEMEIER RW, 1993, BIOSCIENCE, V43, P320, DOI 10.2307/1312064; Coles SL, 2003, ADV MAR BIOL, V46, P183, DOI 10.1016/S0065-2881(03)46004-5; COLES SL, 1991, CORAL REEFS, V9, P231, DOI 10.1007/BF00290427; Connell JH, 1997, ECOL MONOGR, V67, P461, DOI 10.1890/0012-9615(1997)067[0461:AYSOCA]2.0.CO;2; Douglas AE, 2003, MAR POLLUT BULL, V46, P385, DOI 10.1016/S0025-326X(03)00037-7; Etterson JR, 2001, SCIENCE, V294, P151, DOI 10.1126/science.1063656; GLYNN PW, 1993, CORAL REEFS, V12, P1, DOI 10.1007/BF00303779; Harvell CD, 2002, SCIENCE, V296, P2158, DOI 10.1126/science.1063699; Hastings A, 2003, ECOL APPL, V13, pS65; Hellberg ME, 2001, SCIENCE, V292, P1707, DOI 10.1126/science.1060102; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hughes TP, 2002, ECOL LETT, V5, P775, DOI 10.1046/j.1461-0248.2002.00383.x; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; Hughes TP, 1999, LIMNOL OCEANOGR, V44, P932, DOI 10.4319/lo.1999.44.3_part_2.0932; JACKSON JBC, 1992, AM ZOOL, V32, P719; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; Knowlton N, 2001, P NATL ACAD SCI USA, V98, P5419, DOI 10.1073/pnas.091092998; KNOWLTON N, IN PRESS AM NAT; Lessios HA, 2001, EVOLUTION, V55, P955, DOI 10.1554/0014-3820(2001)055[0955:PSASIT]2.0.CO;2; Loya Y, 2001, ECOL LETT, V4, P122, DOI 10.1046/j.1461-0248.2001.00203.x; Lubchenco J, 2003, ECOL APPL, V13, pS3; McClanahan TR, 2002, RESILIENCE BEHAV LAR; Moberg F, 1999, ECOL ECON, V29, P215, DOI 10.1016/S0921-8009(99)00009-9; *NOAA, HOTSP PROGR; Nystrom M, 2001, ECOSYSTEMS, V4, P406, DOI 10.1007/s10021-001-0019-y; Nystrom M, 2000, TRENDS ECOL EVOL, V15, P413, DOI 10.1016/S0169-5347(00)01948-0; Overpeck J, 2000, P NATL ACAD SCI USA, V97, P1335, DOI 10.1073/pnas.97.4.1335; Palumbi SR, 2003, ECOL APPL, V13, pS146; Pandolfi JM, 1996, PALEOBIOLOGY, V22, P152, DOI 10.1017/S0094837300016158; Pandolfi JM, 2003, SCIENCE, V301, P955, DOI 10.1126/science.1085706; Paulay G, 1996, AM MALACOL BULL, V12, P45; PLAYFORD P E, 1983, Journal of the Royal Society of Western Australia, V66, P10; POTTS DC, 1984, PALEOBIOLOGY, V10, P48, DOI 10.1017/S0094837300008010; Rosen B. R., 1984, GEOL J, V11, P201; Roughgarden J, 2001, ECOLOGY: ACHIEVEMENT AND CHALLENGE, P337; Roy K, 2001, ECOL LETT, V4, P366; Sadovy Yvonne J., 2002, P391, DOI 10.1016/B978-012615185-5/50023-2; Toller WW, 2001, BIOL BULL-US, V201, P360, DOI 10.2307/1543614; WATSON RT, 3 INT GOV PAN CLIM C; WILKINSON C, 2002, STATUS CORAL REEFS W	50	2541	2651	152	4345	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					929	933		10.1126/science.1085046	http://dx.doi.org/10.1126/science.1085046			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920289				2022-12-28	WOS:000184755900027
J	Nadeau, JH				Nadeau, JH			Modifying the message	SCIENCE			English	Editorial Material							MODIFIER GENES; MUTATION; DISEASE; HUMANS; SCN8A; MICE		Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University	Nadeau, JH (corresponding author), Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.							Bridges CB, 1919, J EXP ZOOL, V28, P337, DOI 10.1002/jez.1400280302; Buchner DA, 2003, SCIENCE, V301, P967, DOI 10.1126/science.1086187; BURGESS DL, 1995, NAT GENET, V10, P461, DOI 10.1038/ng0895-461; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; Garrod A.E., 1931, INBORN FACTORS DIS; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; GRUNEBERG H, 1950, PATHOLOGY DEV; Nadeau JH, 2003, CURR OPIN GENET DEV, V13, P290, DOI 10.1016/S0959-437X(03)00061-3; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Nissim-Rafinia M, 2002, TRENDS GENET, V18, P123, DOI 10.1016/S0168-9525(01)02619-1; Slavotinek A, 2003, HUM MOL GENET, V12, pR45, DOI 10.1093/hmg/ddg099; Sprunger LK, 1999, HUM MOL GENET, V8, P471, DOI 10.1093/hmg/8.3.471	12	9	10	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					927	928		10.1126/science.1088948	http://dx.doi.org/10.1126/science.1088948			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920288				2022-12-28	WOS:000184755900026
J	Pandolfi, JM; Bradbury, RH; Sala, E; Hughes, TP; Bjorndal, KA; Cooke, RG; McArdle, D; McClenachan, L; Newman, MJH; Paredes, G; Warner, RR; Jackson, JBC				Pandolfi, JM; Bradbury, RH; Sala, E; Hughes, TP; Bjorndal, KA; Cooke, RG; McArdle, D; McClenachan, L; Newman, MJH; Paredes, G; Warner, RR; Jackson, JBC			Global trajectories of the long-term decline of coral reef ecosystems	SCIENCE			English	Article							CLIMATE-CHANGE; BELIZE; DISEASES; ECOLOGY; FUTURE; SCALE	Degradation of coral reef ecosystems began centuries ago, but there is no global summary of the magnitude of change. We compiled records, extending back thousands of years, of the status and trends of seven major guilds of carnivores, herbivores, and architectural species from 14 regions. Large animals declined before small animals and architectural species, and Atlantic reefs declined before reefs in the Red Sea and Australia, but the trajectories of decline were markedly similar worldwide. All reefs were substantially degraded long before outbreaks of coral disease and bleaching. Regardless of these new threats, reefs will not survive without immediate protection from human exploitation over large spatial scales.	Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20013 USA; Australian Natl Univ, Ctr Resource & Environm Studies, Canberra, ACT 0200, Australia; Univ Calif San Diego, Scripps Inst Oceanog, Ctr Marine Biodivers & Conservat, La Jolla, CA 92093 USA; James Cook Univ, Ctr Coral Reef Biodivers, Sch Marine Biol, Townsville, Qld 4811, Australia; Univ Florida, Archie Carr Ctr Sea Turtle Res, Dept Zool, Gainesville, FL 32611 USA; Smithsonian Trop Res Inst, Ctr Trop Paleoecol & Archaeol, Balboa, Panama; Univ Calif Santa Barbara, Calif Sea Grant, Cooperat Extens, Santa Barbara, CA 93105 USA; Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; Australian National University; University of California System; University of California San Diego; Scripps Institution of Oceanography; James Cook University; State University System of Florida; University of Florida; Smithsonian Institution; Smithsonian Tropical Research Institute; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Pandolfi, JM (corresponding author), Natl Museum Nat Hist, Dept Paleobiol, MRC-121,POB 37012, Washington, DC 20013 USA.	pandolfi.john@nmnh.si.edu	Pandolfi, John M/A-3121-2009; Hughes, Terry P/L-4721-2013; Warner, Robert R./M-5342-2013	Pandolfi, John M/0000-0003-3047-6694; Hughes, Terry P/0000-0002-5257-5063; Warner, Robert R./0000-0002-3299-5685; Bjorndal, Karen/0000-0002-6286-1901; Bradbury, Roger/0000-0002-0940-3493				Aronson RB, 1998, CORAL REEFS, V17, P223, DOI 10.1007/s003380050122; Aronson RB, 2000, NATURE, V405, P36, DOI 10.1038/35011132; Aronson RB, 2002, ECOL MONOGR, V72, P233, DOI 10.1890/0012-9615(2002)072[0233:TESOST]2.0.CO;2; Brown BE, 1997, ADV MAR BIOL, V31, P221, DOI DOI 10.1016/S0065-2881(08)60224-2; Connell JH, 1997, ECOL MONOGR, V67, P461, DOI 10.1890/0012-9615(1997)067[0461:AYSOCA]2.0.CO;2; GOREAU TF, 1959, ECOLOGY, V40, P67, DOI 10.2307/1929924; Harvell CD, 1999, SCIENCE, V285, P1505, DOI 10.1126/science.285.5433.1505; Hoegh-Guldberg O, 1999, MAR FRESHWATER RES, V50, P839, DOI 10.1071/MF99078; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; HUGHES TP, 1994, SCIENCE, V265, P1547, DOI 10.1126/science.265.5178.1547; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jackson JBC, 2001, P NATL ACAD SCI USA, V98, P5411, DOI 10.1073/pnas.091092898; Knowlton N, 2001, P NATL ACAD SCI USA, V98, P5419, DOI 10.1073/pnas.091092998; LEWIS JB, 1984, CORAL REEFS, V3, P117, DOI 10.1007/BF00301955; McClanahan TR, 2002, SCOPE SER, V60, P111; Richardson LL, 1998, TRENDS ECOL EVOL, V13, P438, DOI 10.1016/S0169-5347(98)01460-8; ROGERS CS, 1990, MAR ECOL PROG SER, V62, P185, DOI 10.3354/meps062185; Wolanski E, 2003, AM SCI, V91, P44, DOI 10.1511/2003.11.843; [No title captured]	19	1372	1433	21	1006	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 15	2003	301	5635					955	958		10.1126/science.1085706	http://dx.doi.org/10.1126/science.1085706			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711RY	12920296				2022-12-28	WOS:000184755900036
J	Brummelkamp, TR; Nijman, SMB; Dirac, AMG; Bernards, R				Brummelkamp, TR; Nijman, SMB; Dirac, AMG; Bernards, R			Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappa B	NATURE			English	Article							NECROSIS-FACTOR; DEUBIQUITINATING ENZYMES; TNF; MECHANISMS; KINASE; CANCER	Protein modification by the conjugation of ubiquitin moieties-ubiquitination- plays a major part in many biological processes, including cell cycle and apoptosis(1). The enzymes that mediate ubiquitin-conjugation have been well-studied, but much less is known about the ubiquitin-specific proteases that mediate deubiquitination of cellular substrates(2,3). To study this gene family, we designed a collection of RNA interference vectors to suppress 50 human de-ubiquitinating enzymes, and used these vectors to identify de-ubiquitinating enzymes in cancer-relevant pathways. We report here that inhibition of one of these enzymes, the familial cylindromatosis tumour suppressor gene (CYLD)(4), having no known function, enhances activation of the transcription factor NF-kappaB. We show that CYLD binds to the NEMO (also known as IKKgamma) component of the IkappaB kinase (IKK) complex, and appears to regulate its activity through de-ubiquitination of TRAF2, as TRAF2 ubiquitination can be modulated by CYLD. Inhibition of CYLD increases resistance to apoptosis, suggesting a mechanism through which loss of CYLD contributes to oncogenesis. We show that this effect can be relieved by aspirin derivatives that inhibit NF-kappaB activity(5), which suggests a therapeutic intervention strategy to restore growth control in patients suffering from familial cylindromatosis.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	高, 雨莉/HGU-8187-2022	Bernards, Rene/0000-0001-8677-3423				Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Chung JY, 2002, J CELL SCI, V115, P679; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; HOLTMANN H, 1988, IMMUNOBIOLOGY, V177, P7, DOI 10.1016/S0171-2985(88)80087-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; VANBALKOM IDC, 1994, J MED GENET, V31, P321, DOI 10.1136/jmg.31.4.321; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	27	784	819	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 14	2003	424	6950					797	801		10.1038/nature01811	http://dx.doi.org/10.1038/nature01811			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	711HQ	12917690	Green Published			2022-12-28	WOS:000184733900045
J	Martinez, E; Arnaiz, JA; Podzamczer, D; Dalmau, D; Ribera, E; Domingo, P; Knobel, H; Riera, M; Pedrol, E; Force, L; Llibre, JM; Segura, F; Richart, C; Cortes, C; Javaloyas, M; Aranda, M; Cruceta, A; de Lazzari, E; Gatell, JM				Martinez, E; Arnaiz, JA; Podzamczer, D; Dalmau, D; Ribera, E; Domingo, P; Knobel, H; Riera, M; Pedrol, E; Force, L; Llibre, JM; Segura, F; Richart, C; Cortes, C; Javaloyas, M; Aranda, M; Cruceta, A; de Lazzari, E; Gatell, JM		NEFA Study Team	Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVERSE-TRANSCRIPTASE INHIBITOR; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; RANDOMIZED-TRIAL; EXPERIENCED PATIENTS; COMBINATION THERAPY; NAIVE PATIENTS; VIRAL LOAD; HIV-1; LIPODYSTROPHY	Background: We assessed the strategy of substituting nevirapine, efavirenz, or abacavir for a protease inhibitor in patients infected with human immunodeficiency virus type 1 (HIV-1) in whom virologic suppression had been achieved. Methods: We randomly assigned 460 adults who were taking two nucleoside reverse-transcriptase inhibitors and at least one protease inhibitor and whose plasma HIV-1 RNA levels had been less than 200 copies per milliliter for at least the previous six months to switch from the protease inhibitor to nevirapine (155 patients), efavirenz (156), or abacavir (149). The primary end point was death, progression to the acquired immunodeficiency syndrome, or an increase in HIV-1 RNA levels to 200 copies or more per milliliter. Results: At 12 months, the Kaplan-Meier estimates of the likelihood of reaching the end point were 10 percent in the nevirapine group, 6 percent in the efavirenz group, and 13 percent in the abacavir group (P=0.10 according to an intention-to-treat analysis). HIV-1 RNA could be amplified in 21 of the 29 patients in whom virologic failure developed during treatment with study medication (72 percent), and resistance mutations to the study medication and to at least one of the nucleoside reverse-transcriptase inhibitors in the regimen that failed were detected in all but 1 of the 21 patients. Twenty-three of the 29 patients with virologic failure during treatment with study medication had received prior suboptimal therapy with nucleoside reverse-transcriptase inhibitors. Fewer patients in the abacavir group (6 percent) than in the nevirapine group (17 percent) or the efavirenz group (17 percent) discontinued the study medication because of adverse events (P=0.01). The proportion of patients with fasting lipid levels warranting therapeutic intervention decreased significantly in the abacavir group, but the prevalence of clinical lipodystrophy did not change significantly in the three groups. Conclusions: When therapy was switched from a protease inhibitor to nevirapine, efavirenz, or abacavir in patients with virologic suppression, there was a trend toward a higher rate of virologic failure among those given abacavir.	Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Infect Dis Unit, E-08036 Barcelona, Spain; Bellvitge Hosp, Lhospitalet De Llobregat, Spain; Hosp Mutua Terrassa, Terrassa, Spain; Hosp Gen Valle Hebron, Barcelona, Spain; Hosp Santa Cruz & San Pablo, E-08025 Barcelona, Spain; Hosp del Mar, Barcelona, Spain; Hosp Son Dureta, Palma de Mallorca, Spain; Hosp Gen Granollers, Granollers, Spain; Hosp Mataro, Mataro, Spain; Hosp Sant Jaume, Calella, Spain; Hosp Parc Tauli, Sabadell, Spain; Univ Rovira & Virgili, Hosp Joan XXIII, Tarragona, Spain; Hosp Creu Roja, Lhospitalet De Llobregat, Spain; Hosp Viladecans, Viladecans, Spain; Hosp Terrassa, Terrassa, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Hospital Universitario Mutua Terrassa; Hospital Universitari Vall d'Hebron; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Universitat Rovira i Virgili; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Valdecans	Martinez, E (corresponding author), Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Infect Dis Unit, Villarroel 170, E-08036 Barcelona, Spain.		Knobel, Hernando/AAD-3582-2020; Leon, Agathe/K-9851-2015; Domingo, Pere/CAF-3577-2022; Gatell, Jose M/ABC-3607-2020; Knobel, Hernando/B-5223-2016; Domingo, Pere/AAP-7571-2021; RICHART, CRISTOBAL C/S-9158-2017	Knobel, Hernando/0000-0003-3186-6416; Leon, Agathe/0000-0002-1198-5090; Knobel, Hernando/0000-0003-3186-6416; Domingo, Pere/0000-0003-1138-5770; RICHART, CRISTOBAL C/0000-0003-0852-6739; Ribera, Esteban/0000-0002-3752-8808; De Lazzari, Elisa/0000-0003-2614-6545				AIDS Clinical Trials Group, 1992, TABL GRAD SEV AD ADV; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Barreiro P, 2000, AIDS, V14, P807, DOI 10.1097/00002030-200005050-00006; CASAGRANDE JT, 1978, BIOMETRICS, V34, P483, DOI 10.2307/2530613; Clumeck N, 2001, AIDS, V15, P1517, DOI 10.1097/00002030-200108170-00009; Dieleman JP, 1999, AIDS, V13, P1423, DOI 10.1097/00002030-199907300-00029; Dieleman JP, 2002, J INFECT DIS, V185, P1261, DOI 10.1086/340131; Drechsler H, 2002, CLIN INFECT DIS, V35, P1219, DOI 10.1086/343050; FISAC C, 2002, 14 INT AIDS C BARC S, pB7; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Henry K, 2000, ANN INTERN MED, V132, P306, DOI 10.7326/0003-4819-132-4-200002150-00009; Hirschel B, 2002, AIDS, V16, P381, DOI 10.1097/00002030-200202150-00009; Holmberg SD, 2002, LANCET, V360, P1747, DOI 10.1016/S0140-6736(02)11672-2; Knechten H, 2001, HIV Clin Trials, V2, P200; MAKUCH R, 1978, CANCER TREAT REP, V62, P1037; Martinez E, 2000, CLIN INFECT DIS, V31, P1266, DOI 10.1086/317426; Martinez E, 1999, AIDS, V13, P805, DOI 10.1097/00002030-199905070-00009; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; Masquelier B, 2001, J ACQ IMMUN DEF SYND, V28, P309, DOI 10.1097/00126334-200112010-00001; Matthews GV, 2002, AIDS, V16, P53, DOI 10.1097/00002030-200201040-00008; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Murphy R L, 2002, HIV Med, V3, P146, DOI 10.1046/j.1468-1293.2002.00102.x; Negredo E, 2002, CLIN INFECT DIS, V34, P504, DOI 10.1086/324629; Opravil M, 2002, J INFECT DIS, V185, P1251, DOI 10.1086/340312; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Penzak SR, 2000, SCAND J INFECT DIS, V32, P111; Phillips AN, 2001, AIDS, V15, P2385, DOI 10.1097/00002030-200112070-00006; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Podzamczer D, 2002, ANTIVIR THER, V7, P81; Pujol RM, 2000, J AM ACAD DERMATOL, V42, P193, DOI 10.1016/S0190-9622(00)90125-7; Raffi F, 2000, CLIN INFECT DIS, V31, P1274, DOI 10.1086/317424; Rey D, 2001, J ACQ IMMUN DEF SYND, V27, P459, DOI 10.1097/00126334-200108150-00006; Rubio R, 2002, ENFERM INFEC MICR CL, V20, P244, DOI 10.1016/S0213-005X(02)72804-8; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; SQUIRES KE, 2002, 42 INT C ANT AG CHEM, P11; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; VANLETH F, 2003, 10 C RETR OPP INF BO, P176; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	41	249	260	0	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1036	1046		10.1056/NEJMoa021589	http://dx.doi.org/10.1056/NEJMoa021589			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968087				2022-12-28	WOS:000185223100005
J	Askie, LM; Henderson-Smart, DJ; Irwig, L; Simpson, JM				Askie, LM; Henderson-Smart, DJ; Irwig, L; Simpson, JM			Oxygen-saturation targets and outcomes in extremely preterm infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BIRTH-WEIGHT INFANTS; CHRONIC LUNG-DISEASE; BRONCHOPULMONARY DYSPLASIA; PREMATURE-INFANTS; SUPPLEMENTAL OXYGEN; TEMPERAMENT; REQUIREMENT; RETINOPATHY; SURVIVORS; DISCHARGE	Background: Physiological studies have shown that chronic hypoxemia may occur in preterm infants who require supplemental oxygen for extended periods and that this hypoxemia may contribute to poor growth and development. Anecdotal reports and uncontrolled observational studies have suggested that a higher oxygen-saturation range may be beneficial in terms of growth and development. Methods: We conducted a multicenter, double-blind, randomized, controlled trial involving 358 infants born at less than 30 weeks of gestation who remained dependent on supplemental oxygen at 32 weeks of postmenstrual age. They were randomly assigned to a target functional oxygen-saturation range of either 91 to 94 percent (standard-saturation group) or 95 to 98 percent (high-saturation group); this target was maintained for the duration of supplemental-oxygen therapy. The primary outcomes were growth and neurodevelopmental measures at a corrected age of 12 months. Results: There were no significant differences between the groups in weight, length, or head circumference at a corrected age of 12 months. The frequency of major developmental abnormalities also did not differ significantly between the standard-saturation group and the high-saturation group (24 percent and 23 percent, respectively, P=0.85). There were six deaths due to pulmonary causes in the high-saturation group and one such death in the standard-saturation group (P=0.12). The high-saturation group received oxygen for a longer period after randomization (median, 40 days vs. 18 days; P<0.001) and had a significantly higher rate of dependence on supplemental oxygen at 36 weeks of postmenstrual age and a significantly higher frequency of home-based oxygen therapy. Conclusions: Targeting a higher oxygen-saturation range in extremely preterm infants who were dependent on supplemental oxygen conferred no significant benefit with respect to growth and development and resulted in an increased burden on health services.	Univ Sydney, Queen Elizabeth II Res Inst, Ctr Perinatal Hlth Serv Res, Sydney, NSW 2006, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Askie, LM (corresponding author), Univ Sydney, Queen Elizabeth II Res Inst, Ctr Perinatal Hlth Serv Res, Bldg DO2, Sydney, NSW 2006, Australia.	lisa.askie@perinatal.usyd.edu.au						Askie LM, 2001, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001077; Bowen JR, 1996, J PAEDIATR CHILD H, V32, P25, DOI 10.1111/j.1440-1754.1996.tb01536.x; CAREY WB, 1978, PEDIATRICS, V61, P735; CHYE JK, 1995, J PAEDIATR CHILD H, V31, P105, DOI 10.1111/j.1440-1754.1995.tb00756.x; *COMM PROF HOSP AC, 1986, INT CLASS DIS, V1; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Daniel A.E., 1983, POWER PRIVILEGE PRES; DOYLE LW, 1995, MED J AUSTRALIA, V163, P11, DOI 10.5694/j.1326-5377.1995.tb126079.x; Duc Gabriel, 1992, P178; Ellsbury DL, 2002, J PEDIATR-US, V140, P247, DOI 10.1067/mpd.2002.121933; FOSTER J, 2002, NEONAT PAEDIAT CHILD, V5, P5; Gregoire MC, 1998, PEDIATRICS, V101, P856, DOI 10.1542/peds.101.5.856; Griffiths R., 1996, GRIFFITHS MENTAL DEV; GROOTHUIS JR, 1987, AM J DIS CHILD, V141, P992, DOI 10.1001/archpedi.1987.04460090069028; Hack M, 2000, Semin Neonatol, V5, P89, DOI 10.1053/siny.1999.0001; HAMILL PVV, 1977, VITAL HLTH STAT SERI, V11; HARRIS MA, 1995, LANCET, V345, P831, DOI 10.1016/S0140-6736(95)92966-5; HUDAK BB, 1989, AM J DIS CHILD, V143, P357, DOI 10.1001/archpedi.1989.02150150115028; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; KITCHEN W, 1987, J PEDIATR-US, V111, P761, DOI 10.1016/S0022-3476(87)80264-0; McIntosh N, 2001, ARCH DIS CHILD-FETAL, V84, pF149, DOI 10.1136/fn.84.3.F149; *NEON INT CAR STUD, 1997, NSW PUBL HLTH B S, V2; Phelps DL, 2000, PEDIATRICS, V105, P295; *PSYCH ASS RES, 1995, PAR STRESS IND SHORT; *ROP INT COMM CLAS, 1984, PEDIATRICS, V74, P127; Saugstad OD, 2001, PEDIATRICS, V108, P1203, DOI 10.1542/peds.108.5.1203; SAUVE RS, 1985, PEDIATRICS, V76, P725; SEKAR KC, 1991, PEDIATR PULM, V10, P112, DOI 10.1002/ppul.1950100213; SEWELL J, 1988, AUST PAEDIATR J, V24, P343; SHENNAN AT, 1988, PEDIATRICS, V82, P527; SIGNORINI DF, 1993, STAT MED, V12, P2343, DOI 10.1002/sim.4780122410; Simakajornboon N, 2002, PEDIATRICS, V110, P884, DOI 10.1542/peds.110.5.884; SINGER L, 1992, PEDIATRICS, V90, P380; SKIDMORE MD, 1990, DEV MED CHILD NEUROL, V32, P325; Solis A, 2002, EUR J PEDIATR, V161, P428, DOI 10.1007/s00431-002-0991-z; STEIN REK, 1980, MED CARE, V18, P465, DOI 10.1097/00005650-198004000-00010; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; Tin W, 2002, PEDIATRICS, V110, P615, DOI 10.1542/peds.110.3.615; VOHR BR, 1991, DEV MED CHILD NEUROL, V33, P690; Weinberger B, 2002, TOXICOL APPL PHARM, V181, P60, DOI 10.1006/taap.2002.9387; WEINSTEIN MR, 1981, J PEDIATR-US, V99, P958, DOI 10.1016/S0022-3476(81)80032-7	41	329	345	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					959	967		10.1056/NEJMoa023080	http://dx.doi.org/10.1056/NEJMoa023080			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954744	Bronze			2022-12-28	WOS:000185081400007
J	Rainey, PB; Rainey, K				Rainey, PB; Rainey, K			Evolution of cooperation and conflict in experimental bacterial populations	NATURE			English	Article							COMPETITION; DIVERGENCE; DIVERSITY; ORIGIN	A fundamental problem in biology is the evolutionary transition from single cells to multicellular life forms(1-3). During this transition the unit of selection shifts from individual cells to groups of cooperating cells(1,3,4). Although there is much theory(5-15), there are few empirical studies(16). Here we describe an evolutionary transition that occurs in experimental populations of Pseudomonas fluorescens propagated in a spatially heterogeneous environment(17). Cooperating groups are formed by over-production of an adhesive polymer(18), which causes the interests of individuals to align with those of the group. The costs and benefits of cooperation, plus evolutionary susceptibility to defecting genotypes, were analysed to determine conformation to theory(1,3,12). Cooperation was costly to individuals, but beneficial to the group. Defecting genotypes evolved in populations founded by the cooperating type and were fitter in the presence of this type than in its absence. In the short term, defectors sabotaged the viability of the group; but these findings nevertheless show that transitions to higher orders of complexity are readily achievable, provide insights into the selective conditions, and facilitate experimental analysis of the evolution of individuality.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand	University of Oxford; University of Auckland	Rainey, PB (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	p.rainey@auckland.ac.nz	Rainey, Paul/A-3207-2008	Rainey, Paul/0000-0003-0879-5795				AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Bell G., 1985, ORIGIN EVOLUTION SEX, P221; Bonner JT., 2000, 1 SIGNALS EVOLUTION; Boraas ME, 1998, EVOL ECOL, V12, P153, DOI 10.1023/A:1006527528063; Buckling A, 2000, NATURE, V408, P961, DOI 10.1038/35050080; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; Dawkins Richard, 1976, SELFISH GENE; Ferriere R, 1996, AM NAT, V147, P692, DOI 10.1086/285875; Foster KR, 2002, P ROY SOC B-BIOL SCI, V269, P2357, DOI 10.1098/rspb.2002.2163; FRANK SA, 1995, NATURE, V377, P520, DOI 10.1038/377520a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; Kerszberg M, 1998, J THEOR BIOL, V193, P535, DOI 10.1006/jtbi.1998.0714; KOUFOPANOU V, 1993, P ROY SOC B-BIOL SCI, V254, P107, DOI 10.1098/rspb.1993.0134; LENSKI RE, 1991, AM NAT, V138, P1315, DOI 10.1086/285289; Maynard Smith J., 1988, EVOLUTIONARY PROGR, P219; Michod Richard E., 1999, DARWINIAN DYNAMICS E; Pfeiffer T, 2003, P NATL ACAD SCI USA, V100, P1095, DOI 10.1073/pnas.0335420100; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Queller DC, 2003, SCIENCE, V299, P105, DOI 10.1126/science.1077742; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Smith J, 2001, P ROY SOC B-BIOL SCI, V268, P61, DOI 10.1098/rspb.2000.1330; Sober E., 1998, OTHERS EVOLUTION PSY; Spiers AJ, 2002, GENETICS, V161, P33; Szathmary E, 1995, MAJOR TRANSITIONS EV; Velicer GJ, 2003, NATURE, V425, P75, DOI 10.1038/nature01908; Williams G. C., 1966, P307; WILSON DS, 1975, P NATL ACAD SCI USA, V72, P143, DOI 10.1073/pnas.72.1.143; Wolf JB, 2003, P NATL ACAD SCI USA, V100, P4655, DOI 10.1073/pnas.0635741100; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x	31	394	402	1	239	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 4	2003	425	6953					72	74		10.1038/nature01906	http://dx.doi.org/10.1038/nature01906			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717LD	12955142				2022-12-28	WOS:000185089200039
J	Perls, T; Terry, D				Perls, T; Terry, D			Understanding the determinants of exceptional longevity	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				HEART-DISEASE; IRON; CENTENARIANS; RISK; MECHANISMS; MORTALITY; GENETICS; PROFILE; LIFE	Centenarians represent an extreme of life expectancy. They achieve their exceptional longevity in part by lacking genetic variations linked to premature death. Pedigree studies have shown a substantial familial component in the ability to survive to extreme old age, and a recent study demonstrated a locus on chromosome 4 linked to exceptional longevity, indicating the likely existence of at least one longevity-enabling gene in humans. The children of centenarians have markedly reduced relative risks for age-related diseases, particularly heart disease, hypertension, and diabetes, and are a promising model for genetic and phenotypic studies of 1) aging slowly relative to the general population and 2) the delay of and perhaps escape from important age-related diseases. These studies and those of other mammals and lower organisms show great promise for the delineation of important environmental and genetic determinants of aging well.	Boston Univ, Med Ctr, Geriatr Sect, Boston, MA 02118 USA	Boston University	Perls, T (corresponding author), Boston Univ, Med Ctr, Geriatr Sect, 88 E Newton St, Boston, MA 02118 USA.	thperls@bu.edu		Terry, Dellara/0000-0002-1538-0216; Perls, Thomas/0000-0002-2492-4334	NIA NIH HHS [R01 AG18721] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018721] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barzilai N, 2001, J AM GERIATR SOC, V49, P76, DOI 10.1046/j.1532-5415.2001.49013.x; CUTLER RG, 1975, P NATL ACAD SCI USA, V72, P4664, DOI 10.1073/pnas.72.11.4664; DESANDREGIOVANN.A, 2003, SCIENCE         0417; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; EVERT J, IN PRESS J GERONTOLO; Fontaine KR, 2003, JAMA-J AM MED ASSOC, V289, P187, DOI 10.1001/jama.289.2.187; Fraser GE, 2001, ARCH INTERN MED, V161, P1645, DOI 10.1001/archinte.161.13.1645; Frett R., 1998, SCI AM PRESENTS, V9, P100; Hitt R, 1999, LANCET, V354, P652, DOI 10.1016/S0140-6736(99)01987-X; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; Klipstein-Grobusch K, 1999, AM J EPIDEMIOL, V149, P421, DOI 10.1093/oxfordjournals.aje.a009829; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Ljungquist B, 1998, J GERONTOL A-BIOL, V53, pM441, DOI 10.1093/gerona/53A.6.M441; Martin GM, 2002, MECH AGEING DEV, V123, P79, DOI 10.1016/S0047-6374(01)00404-3; Martin GM, 2002, MECH AGEING DEV, V123, P65, DOI 10.1016/S0047-6374(01)00335-9; McCarthy MI, 1998, GENET EPIDEMIOL, V15, P317, DOI 10.1002/(SICI)1098-2272(1998)15:4<317::AID-GEPI1>3.0.CO;2-#; Perls T, 2002, J AM GERIATR SOC, V50, P359, DOI 10.1046/j.1532-5415.2002.49283.x; PERLS T, 2000, J GERONTOL A-BIOL, V56, pM1; Perls TT, 2002, P NATL ACAD SCI USA, V99, P8442, DOI 10.1073/pnas.122587599; Puca AA, 2001, P NATL ACAD SCI USA, V98, P10505, DOI 10.1073/pnas.181337598; SALONEN JT, 1995, J INTERN MED, V237, P161, DOI 10.1111/j.1365-2796.1995.tb01156.x; Schachter F, 1998, AM J HUM GENET, V62, P1008, DOI 10.1086/301849; SCHACHTER F, 1994, NAT GENET, V6, P29, DOI 10.1038/ng0194-29; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SULLIVAN JL, 1981, LANCET, V1, P1293; TERRY DF, IN PRESS J GERONTOLO; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Wechsler H, 1998, JAMA-J AM MED ASSOC, V280, P1673, DOI 10.1001/jama.280.19.1673; Wei M, 1999, JAMA-J AM MED ASSOC, V282, P1547, DOI 10.1001/jama.282.16.1547; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	31	67	70	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			445	449		10.7326/0003-4819-139-5_Part_2-200309021-00013	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00013			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965974				2022-12-28	WOS:000185133800013
J	Oransky, I				Oransky, I			Gene therapy trial for Parkinson's disease begins	LANCET			English	News Item																			0	7	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 30	2003	362	9385					712	712		10.1016/S0140-6736(03)14247-X	http://dx.doi.org/10.1016/S0140-6736(03)14247-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957111				2022-12-28	WOS:000185034800017
J	Hamilton, SR; Bobrowicz, P; Bobrowicz, B; Davidson, RC; Li, HJ; Mitchell, T; Nett, JH; Rausch, S; Stadheim, TA; Wischnewski, H; Wildt, S; Gerngross, TU				Hamilton, SR; Bobrowicz, P; Bobrowicz, B; Davidson, RC; Li, HJ; Mitchell, T; Nett, JH; Rausch, S; Stadheim, TA; Wischnewski, H; Wildt, S; Gerngross, TU			Production of complex human glycoproteins in yeast	SCIENCE			English	Article							LINKED GLYCOSYLATION; PICHIA-PASTORIS; OLIGOSACCHARIDES; GOLGI	We report the humanization of the glycosylation pathway in the yeast Pichia pastoris to secrete a human glycoprotein with uniform complex N-glycosylation. The process involved eliminating endogenous yeast glycosylation pathways, while properly localizing five active eukaryotic proteins, including mannosidases I and II, N-acetylglucosaminyl transferases I and II, and uridine 5'-diphosphate (UDP)-N-acetylglucosamine transporter. Targeted localization of the enzymes enabled the generation of a synthetic in vivo glycosylation pathway, which produced the complex human N-glycan N-acetylglucosamine(2)-mannose(3)-N-acetylglucosamine(2) (GlcNAc(2)Man(3)GlcNAc(2)). The ability to generate human glycoproteins with homogeneous N-glycan structures in a fungal host is a step toward producing therapeutic glycoproteins and could become a tool for elucidating the structure-function relation of glycoproteins.	Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College	Gerngross, TU (corresponding author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R43GM066690] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R43GM66690-1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; Choi BK, 2003, P NATL ACAD SCI USA, V100, P5022, DOI 10.1073/pnas.0931263100; Cregg JM, 2000, MOL BIOTECHNOL, V16, P23, DOI 10.1385/MB:16:1:23; Dean N, 1999, BBA-GEN SUBJECTS, V1426, P309, DOI 10.1016/S0304-4165(98)00132-9; FOSTER JM, 1995, GENE, V154, P183, DOI 10.1016/0378-1119(94)00867-R; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200	7	283	404	4	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 29	2003	301	5637					1244	1246		10.1126/science.1088166	http://dx.doi.org/10.1126/science.1088166			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947202				2022-12-28	WOS:000185003500045
J	Rosen, T				Rosen, T			Update on genital lesions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HERPES-SIMPLEX-VIRUS; CLINICAL-DIAGNOSIS; VITILIGO; DISEASE; CREAM		Baylor Coll Med, Houston Vet Adm Med Ctr, Dermatol Serv, Houston, TX 77005 USA	Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Rosen, T (corresponding author), Baylor Coll Med, Houston Vet Adm Med Ctr, Dermatol Serv, 2815 Plumb, Houston, TX 77005 USA.	tedrosenmd@aol.com		Rosen, Ted/0000-0002-5946-5529				BLACK M, 2002, OBSTET GYNECOLOGIC D; Carlson JA, 1998, HUM PATHOL, V29, P932, DOI 10.1016/S0046-8177(98)90198-8; *CDCP, 2001, STD SURV 2001; CHAPEL TA, 1977, SEX TRANSM DIS, V4, P150, DOI 10.1097/00007435-197710000-00008; DANGOR Y, 1990, SEX TRANSM DIS, V17, P184, DOI 10.1097/00007435-199010000-00007; David N, 2002, INT J STD AIDS, V13, P573, DOI 10.1258/095646202760159729; DiCarlo RP, 1997, CLIN INFECT DIS, V25, P292, DOI 10.1086/514548; Edwards L, 1998, ARCH DERMATOL, V134, P25, DOI 10.1001/archderm.134.1.25; FISHER B, 1998, GENITAL SKIN DISORDE; Foster DC, 2002, OBSTET GYNECOL, V100, P145, DOI 10.1016/S0029-7844(02)02080-X; Garland SM, 2001, INT J STD AIDS, V12, P722, DOI 10.1258/0956462011924218; Hook EW, 2002, SEX TRANSM DIS, V29, P486, DOI 10.1097/00007435-200208000-00010; HUTCHINSON CM, 1994, ANN INTERN MED, V121, P94, DOI 10.7326/0003-4819-121-2-199407150-00003; Hwang L, 2000, ARCH DERMATOL, V136, P1560; Jones RW, 2001, BRIT J OBSTET GYNAEC, V108, P665, DOI 10.1111/j.1471-0528.2001.00134.x; Koutsky Laura, 1997, American Journal of Medicine, V102, P3; Leone PA, 2002, CLIN INFECT DIS, V34, P958, DOI 10.1086/339326; Liota  E, 2000, J Cutan Med Surg, V4, P76; Mehta NJ, 2000, SOUTHERN MED J, V93, P713; Mulekar SV, 2003, INT J DERMATOL, V42, P132, DOI 10.1046/j.1365-4362.2003.01628.x; Nasca MR, 1999, J AM ACAD DERMATOL, V41, P911, DOI 10.1016/S0190-9622(99)70245-8; Ozdemir M, 2002, INT J DERMATOL, V41, P135, DOI 10.1046/j.1365-4362.2002.01391.x; Pielop J, 2001, J AM ACAD DERMATOL, V44, P864, DOI 10.1067/mjd.2001.112923; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Rosen T, 1999, SEX TRANSM DIS, V26, P527, DOI 10.1097/00007435-199910000-00008; Rosen T, 1998, DERMATOL CLIN, V16, P673, DOI 10.1016/S0733-8635(05)70032-2; Tanghetti EA, 2003, CUTIS, V71, P158; Taylor P T Jr, 1995, Surg Oncol Clin N Am, V4, P121; Vaidhyanathan U, 2001, J CUTAN MED SURG, V5, P496, DOI 10.1007/s10227-001-0015-z; Wald A, 2002, J INFECT DIS, V186, pS34, DOI 10.1086/342969; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Wolf R, 2000, INT J DERMATOL, V39, P1, DOI 10.1046/j.1365-4362.2000.00721.x; Zampogna JC, 2002, J AM ACAD DERMATOL, V47, pS229, DOI 10.1067/mjd.2002.126584	33	14	14	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1001	1005		10.1001/jama.290.8.1001	http://dx.doi.org/10.1001/jama.290.8.1001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941660				2022-12-28	WOS:000184958900002
J	Stock, J				Stock, J			Geophysics - Hotspots come unstuck	SCIENCE			English	Editorial Material							HAWAIIAN HOTSPOT; PLATE CIRCUIT; MOTION; PACIFIC; PLUME; ATLANTIC		CALTECH, Seismo Lab, Pasadena, CA 91125 USA	California Institute of Technology	Stock, J (corresponding author), CALTECH, Seismo Lab, Pasadena, CA 91125 USA.	jstock@gps.caltech.edu	Stock, Joann Miriam/AAN-1526-2021	Stock, Joann Miriam/0000-0003-4816-7865				Davis AS, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000190; DePaolo DJ, 2003, SCIENCE, V300, P920, DOI 10.1126/science.1083623; DiVenere V, 1999, EARTH PLANET SC LETT, V170, P105, DOI 10.1016/S0012-821X(99)00096-5; Foulger GR, 2003, SCIENCE, V300, P921, DOI 10.1126/science.1083376; GORDON RG, 1980, J GEOPHYS RES, V85, P6534, DOI 10.1029/JB085iB11p06534; HARADA Y, 2000, AM GEOPHYS UNION GEO, V121, P327; Koppers AAP, 2001, EARTH PLANET SC LETT, V185, P237, DOI 10.1016/S0012-821X(00)00387-3; MOLNAR P, 1987, NATURE, V327, P587, DOI 10.1038/327587a0; MORGAN WJ, 1972, AM ASSOC PETR GEOL B, V56, P203; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; Raymond C. A., 2000, GEOPHYS MONOGR SER, V121, P359; Steinberger B, 1998, GEOPHYS J INT, V132, P412, DOI 10.1046/j.1365-246x.1998.00447.x; SUAREZ G, 1980, J GEOPHYS RES, V85, P5257, DOI 10.1029/JB085iB10p05257; Tarduno JA, 2003, SCIENCE, V301, P1064, DOI 10.1126/science.1086442; Tarduno JA, 1997, EARTH PLANET SC LETT, V153, P171, DOI 10.1016/S0012-821X(97)00169-6	15	6	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 22	2003	301	5636					1059	1060		10.1126/science.1089049	http://dx.doi.org/10.1126/science.1089049			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934000				2022-12-28	WOS:000184872400028
J	Stovring, H; Andersen, M; Beck-Nielsen, H; Green, A; Vach, W				Stovring, H; Andersen, M; Beck-Nielsen, H; Green, A; Vach, W			Rising prevalence of diabetes: Evidence from a Danish pharmaco-epidemiological database.	LANCET			English	Article								The prevalence of diabetes has Increased worldwide. We have undertaken an epidemiological analysis of drug-treated diabetes In a well defined community. We present estimates of prevalence, incidence, and mortality of patients with such diabetes during 1993-99, based on data for all 470 000 people living in the county of Fyn, Denmark. Although prevalence increased (odds ratio: female, 1.026 [95% CI 1.020-1.032]; male, 1.041 [1.036-1.047]), mortality in those treated declined (rate ratio: female, 0.976 [95% CI 0.952-1.001]; male, 0.966 [0.943-0.990]). We did not identify a clear trend for incidence. Future research into the causes of rising diabetes prevalence should take this fall in mortality into account to avoid incorrect conclusions about the relation between western lifestyle and the growing number of diabetics.	Univ So Denmark, Res Unit Gen Practice, DK-5000 Odense, Denmark; Aarhus Univ, Natl Ctr Registerbased Res, Aarhus, Denmark; Aarhus Univ, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; Univ So Denmark, Inst Publ Hlth, Odense, Denmark; Univ So Denmark, Dept Stat & Demog, Odense, Denmark; Odense Univ Hosp, Diabet Res Ctr, DK-5000 Odense, Denmark	University of Southern Denmark; Aarhus University; Aarhus University; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital	Stovring, H (corresponding author), Univ So Denmark, Res Unit Gen Practice, DK-5000 Odense, Denmark.		Støvring, Henrik/I-4683-2012; Støvring, Henrik/H-5754-2019; Vach, Werner/F-2512-2011; Andersen, Morten/H-3555-2011	Støvring, Henrik/0000-0002-5821-2351; Støvring, Henrik/0000-0002-5821-2351; Vach, Werner/0000-0003-1865-8399; Andersen, Morten/0000-0001-7029-2860				*DAN MED AG, 1998, ANT FORBR ANT 1994 1; HALLAS J, 1994, EUR J CLIN PHARMACOL, V47, P367; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; *WHO, 2001, ATC DDDS GUID ATC CL; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	5	74	77	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 16	2003	362	9383					537	538		10.1016/S0140-6736(03)14116-5	http://dx.doi.org/10.1016/S0140-6736(03)14116-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932388				2022-12-28	WOS:000184817600013
J	Tonks, A				Tonks, A			Commentary: Information for patients: What happens during cognitive behaviour therapy for bulimia	BRITISH MEDICAL JOURNAL			English	Editorial Material									BMJ Unified, London WC1H 9JR, England		Tonks, A (corresponding author), BMJ Unified, London WC1H 9JR, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 16	2003	327	7411					382	382		10.1136/bmj.327.7411.382	http://dx.doi.org/10.1136/bmj.327.7411.382			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713NJ	12919995	Green Published			2022-12-28	WOS:000184864200024
J	Eggebrecht, H; Mohlenkamp, S				Eggebrecht, H; Mohlenkamp, S			Myocardial bridging	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hosp Essen, D-45122 Essen, Germany	University of Duisburg Essen	Eggebrecht, H (corresponding author), Univ Hosp Essen, D-45122 Essen, Germany.		Möhlenkamp, Stefan/AGG-1320-2022						0	5	6	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2003	349	11					1047	1047		10.1056/NEJMicm020279	http://dx.doi.org/10.1056/NEJMicm020279			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719UH	12968088				2022-12-28	WOS:000185223100006
J	Clark, WF; Garg, AX; Blake, PG; Rock, GA; Heidenheim, AP; Sackett, DL				Clark, WF; Garg, AX; Blake, PG; Rock, GA; Heidenheim, AP; Sackett, DL			Effect of awareness of a randomized controlled trial on use of experimental therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; PLASMA-EXCHANGE	Context Use of experimental therapies during but outside of randomized controlled trials (RCTs) has not been studied. Objective To determine whether initiation of an RCT leads to increased use of the experimental therapy outside the trial. Design and Setting Data on national apheresis use during 3 Canadian RCTs for multiple sclerosis (1986-1988), thrombotic thrombocytopenic purpura (1982-1988), and myeloma cast nephropathy (1998-2000) were obtained from 19 major medical centers in Canada. The multiple sclerosis and myeloma cast nephropathy trials had data on apheresis use for 3 years prior to and during the trials, which permitted a time-series analysis to determine the impact of the RCTs on the use of apheresis. The ongoing myeloma cast nephropathy trial provided data on the number of patients inside and outside of the RCTs in trial and nontrial centers. initial and follow-up questionnaires were sent to 24 Canadian physicians in trial and nontrial centers to determine if they had noted an increase in apheresis activity during the trials and, if so, their explanation for it. Main Outcome Measure Change in number of patients undergoing apheresis for thrombotic thrombocytopenic purpura, multiple sclerosis, and myeloma cast nephropathy prior to and during the respective RCTs compared with all patients undergoing apheresis during the same periods. Results During all 3 RCTs, there were large increases in use of apheresis. The majority of the increased use of apheresis was outside of the trials: for multiple sclerosis, 30 of 49 patients per year (61% of increase); thrombotic thrombocytopenic purpura, 49 of 56 patients per year (72% of increase); and myeloma cast nephropathy, 60 of 72 patients per year (57% of increase). The myeloma cast nephropathy study noted that this increase occurred in both nontrial and trial centers. Among questionnaire respondents (n=22; 92% response rate), most physicians noted an increase in apheresis activity during the trials and attributed it to a "jumping-the-gun" phenomenon. Conclusions During 3 Canadian RCTs, apheresis increased, but most of the increase occurred outside the trials. This behavior during an RCT, in the absence of clear efficacy, can be termed jumping the gun.	Univ Western Ontario, London Hlth Sci Ctr, Div Nephrol, London, ON N6A 4G5, Canada; Canadian Apheresis Grp, Markdale, ON, Canada; Trout Res & Educ Ctr Irish Lake, Markdale, ON, Canada	London Health Sciences Centre; Western University (University of Western Ontario)	Clark, WF (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Div Nephrol, 800 Commissioners Rd E, London, ON N6A 4G5, Canada.		Blake, Peter/G-3279-2011; Clark, Bill/G-3287-2011; Garg, Amit X/G-3295-2011					Altman DG, 1996, BRIT MED J, V313, P570; ANGELL M, 1984, NEW ENGL J MED, V310, P1385, DOI 10.1056/NEJM198405243102111; [Anonymous], 1991, Lancet, V337, P441; Baxter C, 1998, BMJ-BRIT MED J, V317, P1134; BOISSEL JP, 1989, CONTROL CLIN TRIALS, V10, pS120; Clark WF, 1999, ANN INTERN MED, V131, P453, DOI 10.7326/0003-4819-131-6-199909210-00011; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; Jadad AR, 1998, JAMA-J AM MED ASSOC, V279, P319, DOI 10.1001/jama.279.4.319; Mamdani MM, 2001, CAN MED ASSOC J, V164, P1695; MARQUIS D, 1983, HASTINGS CENT REP, V13, P40, DOI 10.2307/3561721; Pickering WG, 1996, LANCET, V347, P379, DOI 10.1016/S0140-6736(96)90544-9; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; Sackett DL, 2000, CAN MED ASSOC J, V162, P1311; SCHAFER A, 1982, NEW ENGL J MED, V307, P721, DOI 10.1056/NEJM198209163071204; SILVERMAN WA, 1992, CONTROL CLIN TRIALS, V13, P100, DOI 10.1016/0197-2456(92)90016-S; *SPSS INC, 1994, SPSS TRENDS 6 1 INT, P137; Sue-A-Quan AK, 1999, CAN MED ASSOC J, V160, P1145; Tu JV, 1998, NEW ENGL J MED, V339, P1441, DOI 10.1056/NEJM199811123392006; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203	20	42	43	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1351	1355		10.1001/jama.290.10.1351	http://dx.doi.org/10.1001/jama.290.10.1351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966127				2022-12-28	WOS:000185188600028
J	Fitter, A				Fitter, A			Making allelopathy respectable	SCIENCE			English	Editorial Material									Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	University of York - UK	Fitter, A (corresponding author), Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England.							An M, 1996, RAPID COMMUN MASS SP, V10, P104; Bais HP, 2003, SCIENCE, V301, P1377, DOI 10.1126/science.1083245; Baker H. G., 1975, Annual Review of Ecology and Systematics, V5, P1, DOI 10.1146/annurev.es.05.110174.000245; Blossey B, 2001, BIODIVERS CONSERV, V10, P1787, DOI 10.1023/A:1012065703604; Harper J. L., 1975, Q REV BIOL, V50, P493; PERRINS J, 1992, BIOL CONSERV, V60, P47, DOI 10.1016/0006-3207(92)90798-R; PERRINS J, 1993, J BIOGEOGR, V20, P33, DOI 10.2307/2845737; Rice EL, 1974, ALLELOPATHY; Williamson M, 1999, ECOGRAPHY, V22, P5, DOI 10.1111/j.1600-0587.1999.tb00449.x; Williamson M., 1996, BIOL INVASIONS	10	99	131	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1337	1338		10.1126/science.1089291	http://dx.doi.org/10.1126/science.1089291			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958350				2022-12-28	WOS:000185116400027
J	Brogan, KV				Brogan, KV			James	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Cornell Univ, Joan & Sanford I Weill Med Coll, New York, NY 10021 USA	Cornell University	Brogan, KV (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, New York, NY 10021 USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1221	1222		10.1001/jama.290.9.1221	http://dx.doi.org/10.1001/jama.290.9.1221			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953010	Bronze			2022-12-28	WOS:000185090400023
J	Jiang, JR; Wang, HC; Chang, YC; Yang, PC				Jiang, JR; Wang, HC; Chang, YC; Yang, PC			Postural stridor	LANCET			English	Editorial Material									Far Eastern Mem Hosp, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Radiol, Taipei, Taiwan	Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Wang, HC (corresponding author), Far Eastern Mem Hosp, Taipei, Taiwan.	hcwang@ha.mc.ntu.edu.tw	Yang, Pan-Chyr/B-8808-2009	CHANG, YEUN-CHUNG/0000-0001-9984-5713; YANG, PAN-CHYR/0000-0001-6330-6048; Wang, Hao-Chien/0000-0002-7528-7494				Anders H, 1997, Eur J Med Res, V2, P488; Eliashar R, 2000, POSTGRAD MED J, V76, P187, DOI 10.1136/pmj.76.893.187; JAUREGUIL R, 1977, JAMA-J AM MED ASSOC, V283, P2163; Jennings A, 2001, ENDOCRIN METAB CLIN, V30, P401, DOI 10.1016/S0889-8529(05)70192-4; Louis PJ, 2002, ORAL SURG ORAL MED O, V93, P4, DOI 10.1067/moe.2002.119909	5	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					704	704		10.1016/S0140-6736(03)14233-X	http://dx.doi.org/10.1016/S0140-6736(03)14233-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957093				2022-12-28	WOS:000185034800011
J	Umeshita, K; Fujiwara, K; Kiyosawa, K; Makuuchi, M; Satomi, S; Sugimachi, K; Tanaka, K; Monden, M				Umeshita, K; Fujiwara, K; Kiyosawa, K; Makuuchi, M; Satomi, S; Sugimachi, K; Tanaka, K; Monden, M		Japanese Liver Transplantation Soc	Operative morbidity of living liver donors in Japan	LANCET			English	Article							TRANSPLANTATION; LOBE	Background Deaths of living liver donors have been reported in western countries, whereas the morbidity and mortality of such donors in Japan, one of the leading countries for living liver transplantation, have not been reported in detail. We aimed to review the operative morbidity and mortality of such donors in Japan. Methods 1853 donors of 1852 living liver transplants done in 46 liver transplant centres, and registered in the database of the Japanese Liver Transplantation Society, were assessed for eight donor-related factors of morbidity and mortality. Data for 1841 donors were analysed. Findings No perioperative mortality was recorded since inception of the liver transplantation programme in Japan from Nov 13, 1989, to April 11, 2002. 244 postoperative complications were reported in 228 (12%) donors. The frequency of complications was significantly higher in donors of the right liver lobe than in those involving the lateral segment, and left lobe graft (p<0.0001, and p<0.0001, respectively). Postoperative hospital stay was significantly longer in donors of the right lobe (mean 19.7 [SD 13.0]) than in those of the lateral segment (14.2 [7.6]), left lobe (14.0 [6.5]), and left lobe and caudate lobe (16.3 [12.1]). Re-operation related to donor hepatectomy was done in 23 donors. Interpretation By contrast with western countries, no perioperative mortality was recorded in living liver donors in Japan. However, a proportion of these donors developed serious complications. This morbidity should be reduced to maintain zero mortality in living liver donors.	Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Japanese Liver Transplantat Soc, Suita, Osaka 5650871, Japan; Saitama Med Sch, Dept Internal Med, Moroyama, Saitama, Japan; Shinshu Univ, Sch Med, Dept Internal Med 2, Nagano, Japan; Univ Tokyo, Grad Sch Med, Dept Surg, Div Transplantat, Tokyo, Japan; Univ Tokyo, Grad Sch Med, Dept Artificial Organ, Tokyo, Japan; Tohoku Univ, Sch Med, Dept Surg 2, Sendai, Miyagi 980, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Surg, Fukuoka 812, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Sci, Fukuoka 812, Japan; Kyoto Univ, Dept Transplantat Immunol, Kyoto, Japan	Osaka University; Saitama Medical University; Shinshu University; University of Tokyo; University of Tokyo; Tohoku University; Kyushu University; Kyushu University; Kyoto University	Monden, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Japanese Liver Transplantat Soc, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	monden@surg2.med.osaka-u.ac.jp	幕内, 雅敏 m/A-2140-2012					Brown RS, 2003, NEW ENGL J MED, V348, P818, DOI 10.1056/NEJMsa021345; HASHIKURA Y, 1994, LANCET, V343, P1233, DOI 10.1016/S0140-6736(94)92450-3; Japanese Liver Transplantation Society, 2002, JPN J TRANSPLANT, V37, P245; Klatsky AL, 2000, AM J CARDIOL, V85, P1334, DOI 10.1016/S0002-9149(00)00766-9; MALAGO M, 1994, TRANSPLANT P, V26, P3620; MARCOS A, 2000, LIVER TRANSPLANT, V6, P59; RAIA S, 1989, LANCET, V2, P497; Renz JF, 2000, LIVER TRANSPLANT, V6, pS73, DOI 10.1053/jlts.2000.18686; ROELSCH CE, 2000, LIVER TRANSPL S2, V6, P64; Sarasin FP, 2001, HEPATOLOGY, V33, P1073, DOI 10.1053/jhep.2001.23311; STRONG RW, 1990, NEW ENGL J MED, V322, P1505, DOI 10.1056/NEJM199005243222106; Surman OS, 2002, NEW ENGL J MED, V347, P618; Surman OS, 2002, PSYCHOSOMATICS, V43, P347, DOI 10.1176/appi.psy.43.5.347; Surman OS, 2002, NEW ENGL J MED, V346, P1038, DOI 10.1056/NEJM200204043461402; Trotter JF, 2002, NEW ENGL J MED, V346, P1074, DOI 10.1056/NEJMra011629; Vamvakas EC, 1996, TRANSFUSION, V36, P175, DOI 10.1046/j.1537-2995.1996.36296181932.x	16	224	229	3	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 30	2003	362	9385					687	690		10.1016/S0140-6736(03)14230-4	http://dx.doi.org/10.1016/S0140-6736(03)14230-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716NH	12957090				2022-12-28	WOS:000185034800008
J	Hirschel, B				Hirschel, B			Beware of drug holidays before HIV salvage therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hop Cantonal Univ Geneva, Div Infect Dis, Geneva, Switzerland	University of Geneva	Hirschel, B (corresponding author), Hop Cantonal Univ Geneva, Div Infect Dis, Geneva, Switzerland.							Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; MELLORS J, 2003, ANTIVIR THER, V8, pS150; Miller V, 2000, AIDS, V14, P2857, DOI 10.1097/00002030-200012220-00007	4	5	5	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					827	828		10.1056/NEJMp038111	http://dx.doi.org/10.1056/NEJMp038111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944566				2022-12-28	WOS:000184968400001
J	Zeitels, SM; Healy, GB				Zeitels, SM; Healy, GB			Medical progress: Laryngology and phonosurgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							VOCAL CORD PARALYSIS; DYE-LASER TREATMENT; ADDUCTOR SPASMODIC DYSPHONIA; LARYNGOTRACHEAL RECONSTRUCTION; MEDIALIZATION LARYNGOPLASTY; MICROLARYNGOSCOPIC SURGERY; LARYNGEAL PAPILLOMAS; CLINICAL EXPERIENCE; ARYTENOID ADDUCTION; GLOTTIC CANCER		Massachusetts Eye & Ear Infirm, Div Laryngol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA; Childrens Hosp, Dept Otolaryngol & Commun Disorders, Boston, MA 02115 USA	Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Zeitels, SM (corresponding author), Massachusetts Eye & Ear Infirm, Div Laryngol, 243 Charles St, Boston, MA 02114 USA.	smzeitels@meei.harvard.edu						ANDERSON R R, 1983, Lasers in Surgery and Medicine, V3, P211; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ARNOLD GE, 1961, ARCHIV OTOLARYNGOL, V73, P290; Berke GS, 1999, ANN OTO RHINOL LARYN, V108, P227, DOI 10.1177/000348949910800302; BLAKESLEE D, 1984, LARYNGOSCOPE, V94, P488, DOI 10.1288/00005537-198404000-00012; Blitzer A, 1998, LARYNGOSCOPE, V108, P1435, DOI 10.1097/00005537-199810000-00003; BLITZER A, 1988, LARYNGOSCOPE, V98, P636; Bouchayer M, 1991, PHONOSURGERY ASSESSM, V1991, P143; Bower CM, 1998, ANN OTO RHINOL LARYN, V107, P1001, DOI 10.1177/000348949810701201; BRONIATOWSKI M, 1988, LARYNGOSCOPE, V98, P1107; BRUNINGS W, 1912, DIRECT LARYNGOSCOPY, P116; CASTRO J, 1989, TIME            0911, P52; Chan RW, 2001, OTOLARYNG HEAD NECK, V124, P607, DOI 10.1067/mhn.2001.115906; COHEN JS, 1869, MED REC, V4, P244; COUREY MS, 1995, ANN OTO RHINOL LARYN, V104, P267, DOI 10.1177/000348949510400402; Czermak JN., 1858, WIEN MED WOCHENSCHR, V8, P196; DESANTO LW, 1976, CENT C LAR CANC, P146; Elsberg CA, 1910, ANN SURG, V52, P23, DOI 10.1097/00000658-191007000-00004; Ford CE, 1998, ARCH OTOLARYNGOL, V124, P476, DOI 10.1001/archotol.124.4.476; Franco RA, 2002, ANN OTO RHINOL LARYN, V111, P486, DOI 10.1177/000348940211100603; FRANKEL B, 1886, ARCH KLIN CHIR, V34, P281; GARCIA M., 1855, P R SOC LOND, V7, P399; GOLDFARB D, 1994, J VOICE, V8, P179, DOI 10.1016/S0892-1997(05)80310-8; Gray S, 1991, VOCAL FOLD PHYSL ACO, P21; Gray SD, 2000, ANN OTO RHINOL LARYN, V109, P77, DOI 10.1177/000348940010900115; Gray SD, 1999, LARYNGOSCOPE, V109, P845, DOI 10.1097/00005537-199906000-00001; GRAY SD, 1995, ANN OTO RHINOL LARYN, V104, P13, DOI 10.1177/000348949510400103; GRILLONE GA, 1994, LARYNGOSCOPE, V104, P30; Haxer MJ, 2001, J VOICE, V15, P231, DOI 10.1016/S0892-1997(01)00023-6; HIRANO M, 1985, ANN OTO RHINOL LARYN, V94, P232; Hochman I, 1999, ANN OTO RHINOL LARYN, V108, P10, DOI 10.1177/000348949910800102; Hooper FH., 1883, T AM LARYNGOL ASS, V5, P118; Hooper FH., 1886, T AM LARYNGOL ASS, V8, P22; ISSHIKI N, 1978, ARCH OTOLARYNGOL, V104, P555; ISSHIKI N, 1974, ACTA OTO-LARYNGOL, V78, P451, DOI 10.3109/00016487409126379; Jackson C., 1922, T AM LARYNGOL ASS, V44, P182; JAKO GJ, 1972, LARYNGOSCOPE, V82, P2204, DOI 10.1288/00005537-197212000-00009; Jelinek E., 1884, WIEN MED WOCHENSCHR, V34, P1334; Kambeyanda D, 1997, Assist Technol, V9, P95, DOI 10.1080/10400435.1997.10132301; KIRSTEIN A, 1897, AUTOSCOPY LARYNX TRA; Kirstein A, 1895, ARCH LARYNGOL RHINOL, V3, P156; KOJIMA H, 1991, ANN OTO RHINOL LARYN, V100, P15, DOI 10.1177/000348949110000103; KOUFMAN JA, 1986, LARYNGOSCOPE, V96, P726; KOUFMAN JA, 1991, LARYNGOSCOPE, V101, P1; Koufman JA, 2001, OTOLARYNG HEAD NECK, V124, P603, DOI 10.1067/mhn.2001.115856; LEHMAN JJ, 1988, OTOLARYNG HEAD NECK, V98, P121, DOI 10.1177/019459988809800205; LUDLOW CL, 1988, NEUROLOGY, V38, P1220, DOI 10.1212/WNL.38.8.1220; MACARTHUR C, 1994, ARCH OTOLARYNGOL, V120, P641; MACKENZIE M, 1880, DIS PHARYNX LARYNX T, P309; McCulloch TM, 1998, ANN OTO RHINOL LARYN, V107, P427, DOI 10.1177/000348949810700512; McMillan K, 1998, LARYNGOSCOPE, V108, P968, DOI 10.1097/00005537-199807000-00003; MONTGOMERY WW, 1993, ANN OTO RHINOL LARYN, V102, P571, DOI 10.1177/000348949310200801; MYERS EN, 1994, ANN OTO RHINOL LARYN, V103, P28, DOI 10.1177/000348949410300104; NETTERVILLE JL, 1993, ANN OTO RHINOL LARYN, V102, P413, DOI 10.1177/000348949310200602; Niklason LE, 2001, JAMA-J AM MED ASSOC, V285, P573, DOI 10.1001/jama.285.5.573; O'Dwyer J, 1886, NY MED REC, V29, P641; Oertel M., 1895, ARCH LARYNGOL RHINOL, V3, P1; Payr, 1915, DEUT MED WOCHENSCHR, V41, P1265; Remacle M, 1997, EUR ARCH OTO-RHINO-L, V254, P169, DOI 10.1007/BF00879268; Remacle M, 2001, EUR ARCH OTO-RHINO-L, V258, P267, DOI 10.1007/s004050100350; SATALOFF RT, 1995, J VOICE, V9, P198, DOI 10.1016/S0892-1997(05)80253-X; SCALCO A N, 1960, Ann Otol Rhinol Laryngol, V69, P1134; SCHRAMM VL, 1978, LARYNGOSCOPE, V88, P1268; SMITH ME, 1993, INT J PEDIATR OTORHI, V25, P173, DOI 10.1016/0165-5876(93)90051-4; SOLISCOHEN J, 1879, DIS THROAT GUIDE DIA, P636; STEINER W, 1993, AM J OTOLARYNG, V14, P116, DOI 10.1016/0196-0709(93)90050-H; Strome M, 2001, NEW ENGL J MED, V344, P1676, DOI 10.1056/NEJM200105313442204; STRONG MS, 1975, LARYNGOSCOPE, V85, P1286, DOI 10.1288/00005537-197508000-00003; STRONG MS, 1972, ANN OTO RHINOL LARYN, V81, P791, DOI 10.1177/000348947208100606; TURCK L, 1858, Z GESELLSCHAFT AERZT, V26, P401; VAUGHAN CW, 1982, NEW ENGL J MED, V307, P863, DOI 10.1056/NEJM198209303071405; VAUGHAN CW, 1978, LARYNGOSCOPE, V88, P1399; VAUGHAN CW, 1978, AM J SURG, V136, P490, DOI 10.1016/0002-9610(78)90267-2; von Leden H, 1963, REV PANAM OTORRINOLA, V1, P7; VONLEDEN H, 1961, ANN OTO RHINOL LARYN, V70, P881, DOI 10.1177/000348946107000319; VONLEDEN H, 1969, REV PANAM OTORRINOLA, V3, P137; VonsLeden H, 1991, PHONOSURGERY ASSESSM, P3; Winker MA, 2002, JAMA-J AM MED ASSOC, V287, P1326, DOI 10.1001/jama.287.10.1326; Woodson GE, 1998, ARCH OTOLARYNGOL, V124, P476; Zealear DL, 1996, ANN OTO RHINOL LARYN, V105, P689; Zeitels S.M., 2001, ATLAS PHONOMICROSURG; ZEITELS SM, 1995, LARYNGOSCOPE, V105, P1, DOI 10.1288/00005537-199503001-00001; Zeitels SM, 1998, ANN OTO RHINOL LARYN, V107, P2; Zeitels SM, 1999, ANN OTO RHINOL LARYN, V108, P1126, DOI 10.1177/000348949910801206; Zeitels SM, 2002, ANN OTO RHINOL LARYN, V111, P3, DOI 10.1177/0003489402111S1202; Zeitels SM, 2003, ANN OTO RHINOL LARYN, V112, P180, DOI 10.1177/000348940311200213; Zeitels SM, 2001, LARYNGOSCOPE, V111, P1862, DOI 10.1097/00005537-200110000-00036; Zeitels SM, 1997, HEAD NECK-J SCI SPEC, V19, P342, DOI 10.1002/(SICI)1097-0347(199707)19:4<342::AID-HED13>3.0.CO;2-B; Zeitels SM, 2002, ANN OTO RHINOL LARYN, V111, P21; Zeitels SM, 1996, AM J SURG, V172, P704, DOI 10.1016/S0002-9610(96)00295-4; Zeitels SM, 1996, LARYNGOSCOPE, V106, P545, DOI 10.1097/00005537-199605000-00006; ZEITELS SM, 2001, ATLAS PHONOMICROSURG, P219; Zeitels SM, 1993, OPERATIVE TECHNIQUES, V4, P218	93	57	62	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2003	349	9					882	892		10.1056/NEJMra035148	http://dx.doi.org/10.1056/NEJMra035148			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715JM	12944575				2022-12-28	WOS:000184968400011
J	Sox, CM; Cooper, WO; Koepsell, TD; DiGiuseppe, DL; Christakis, DA				Sox, CM; Cooper, WO; Koepsell, TD; DiGiuseppe, DL; Christakis, DA			Provision of pneumococcal prophylaxis for publicly insured children with sickle cell disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPROVING PRIMARY-CARE; PENICILLIN PROPHYLAXIS; ORAL PENICILLIN; PRESCRIPTION; SERVICES; URBAN	Context It is recommended that children younger than 5 years with sickle cell disease (SCD) take daily prophylactic antibiotics to prevent pneumococcal infections; however, how much prophylactic medication they actually are dispensed is unclear. Objectives To measure the amount of prophylactic antibiotics dispensed to young children with SCD and to investigate factors associated with increased delivery of medication. Design, Setting, and Patients Retrospective longitudinal study conducted January 1995 through December 1999 using Tennessee and Washington State Medicaid administrative claims and encounter data. Children (N=261) who had 1 inpatient or 2 outpatient claims or encounters listing an International Classification of Diseases, Ninth Revision, Clinical Modification code for SCD, were younger than 4 years at study entry (mean age, 1.4 years), and were continuously enrolled in Medicaid for a 1-year period. Main Outcome Measure Number of days during a 365-day period covered by prescription fills for a penicillin or macrolide antibiotic, or for trimethoprimsulfamethoxazole. Results In a 365-day period, patients were dispensed a mean of 148.4 (SD, 121.3; median, 114; interquartile range [IQR], 39-247) days of prophylactic medication. The total amount of medication dispensed varied widely: 10.3% of patients received none and 21.5% received more than 270 days of medication. In a 365-day period, a mean of 12.7 (SD, 10.5; range, 0-40) prophylactic prescriptions were filled per patient. The median prescription duration was 10 days. In a multivariate linear regression model adjusting for state, sex, age at study entry, inclusion year, residence in urban community, outpatient inclusion encounter, required prescription co-payment, and number of outpatient visits for nonpreventive care, each preventive visit was associated with 12.0 (95% confidence interval [CI], 2.3-21.7) additional days of prophylactic antibiotics, and each emergency department visit was associated with 10.0 (95% CI, 1.2-18.8) additional days. Conclusions Publicly insured children with SCD may receive inadequate antibiotic prophylaxis against pneumococcal infections, placing them at increased risk of morbidity and mortality; however, increased numbers of outpatient visits for preventive care are associated with improved provision of prophylactic antibiotics.	Univ Washington, Robert Wood Johnson Clin Scholars Program, Hlth Sci Ctr H220, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Inst Child Hlth, Seattle, WA USA; Vanderbilt Univ, Dept Pediat, Nashville, TN USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Vanderbilt University	Sox, CM (corresponding author), Univ Washington, Robert Wood Johnson Clin Scholars Program, Hlth Sci Ctr H220, Dept Pediat, Box 357183, Seattle, WA 98195 USA.	colinsox@u.washington.edu		Sox, Colin/0000-0002-0249-9656				Abramson JS, 2000, PEDIATRICS, V106, P367, DOI 10.1542/peds.106.2.367; Abramson JS, 2000, PEDIATRICS, V106, P362; Berkovitch M, 1998, BRIT J CLIN PHARMACO, V45, P605, DOI 10.1046/j.1365-2125.1998.00730.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; BUCHANAN GR, 1982, PEDIATRICS, V70, P926; Carson JL, 2000, PHARMACOEPIDEM DR S, P307; Christakis DA, 2001, AMBUL PEDIATR, V1, P99, DOI 10.1367/1539-4409(2001)001<0099:CAQOCF>2.0.CO;2; Cooper WO, 2002, AMBUL PEDIATR, V2, P375, DOI 10.1367/1539-4409(2002)002<0375:OCUACI>2.0.CO;2; Cooper WO, 2002, OBSTET GYNECOL, V100, P101, DOI 10.1016/S0029-7844(02)02001-X; Cooper WO, 2001, ARCH PEDIAT ADOL MED, V155, P1111, DOI 10.1001/archpedi.155.10.1111; *COUNC REG NETW GE, 1995, NAT NEWB SCREEN REP; CUMMINS D, 1991, BRIT MED J, V302, P989, DOI 10.1136/bmj.302.6783.989; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; GURWITZ JH, 1993, AM J PUBLIC HEALTH, V83, P711, DOI 10.2105/AJPH.83.5.711; Haque A, 2000, J RURAL HEALTH, V16, P43, DOI 10.1111/j.1748-0361.2000.tb00435.x; JOHNSON RE, 1991, J AM GERIATR SOC, V39, P1079, DOI 10.1111/j.1532-5415.1991.tb02872.x; Kuhlthau K, 2001, PEDIATRICS, V108, P906, DOI 10.1542/peds.108.4.906; Lane PA, 2002, PEDIATRICS, V109, P526; Li STT, 2003, ARCH PEDIAT ADOL MED, V157, P475, DOI 10.1001/archpedi.157.5.475; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; MILNE RIG, 1990, BRIT MED J, V300, P371, DOI 10.1136/bmj.300.6721.371; Morrill R, 1999, URBAN GEOGR, V20, P727, DOI 10.2747/0272-3638.20.8.727; OVERTURF GD, 1977, AM J DIS CHILD, V131, P784, DOI 10.1001/archpedi.1977.02120200066014; PEGELOW CH, 1991, J PEDIATR-US, V118, P736, DOI 10.1016/S0022-3476(05)80036-8; STEINER JF, 1988, MED CARE, V26, P814, DOI 10.1097/00005650-198808000-00007; Teach SJ, 1998, ARCH PEDIAT ADOL MED, V152, P274	28	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1057	1061		10.1001/jama.290.8.1057	http://dx.doi.org/10.1001/jama.290.8.1057			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715FA	12941678	Bronze			2022-12-28	WOS:000184958900024
J	Ahlberg, K; Ekman, T; Gaston-Johansson, F; Mock, V				Ahlberg, K; Ekman, T; Gaston-Johansson, F; Mock, V			Assessment and management of cancer-related fatigue in adults	LANCET			English	Review							QUALITY-OF-LIFE; PLACEBO-CONTROLLED TRIAL; PHASE-III TRIAL; BREAST-CANCER; DOUBLE-BLIND; RADIATION-THERAPY; LUNG-CANCER; MEGESTROL-ACETATE; PROSTATE-CANCER; EPOETIN-ALPHA	Fatigue is one of the most prevalent and distressing symptoms of cancer, and is a common side-effect of many of the treatments available for the management of malignant disease. We critically assess the evidence for cancer-related fatigue and its treatment in adults. Little is known about the cause and mechanisms of fatigue, and research into methods of alleviating the condition has focused on treatment for anaemia and behavioural interventions, such as exercise, both of which are effective in reducing fatigue. Although research into the condition has increased considerably in the past decade, important gaps in knowledge remain.	Sahlgrens Univ Hosp, Dept Oncol, SE-41345 Gothenburg, Sweden; Gothenburg Univ, Sahlgrenska Acad, Sch Hlth Caring Sci, Inst Nursing, Gothenburg, Sweden; Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; Johns Hopkins Univ Hosp, Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA	Sahlgrenska University Hospital; University of Gothenburg; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	Ahlberg, K (corresponding author), Sahlgrens Univ Hosp, Dept Oncol, SE-41345 Gothenburg, Sweden.	karin.ahlberg@vgregion.se						Agteresch HJ, 2000, J NATL CANCER I, V92, P321, DOI 10.1093/jnci/92.4.321; Akechi T, 1999, J PAIN SYMPTOM MANAG, V17, P42, DOI 10.1016/S0885-3924(98)00105-5; *AM COLL SPORTS ME, 1997, ACSMS EX MAN PERS CH; Anisman H, 1996, CAN MED ASSOC J, V155, P1075; Axdorph U, 2000, ANN ONCOL, V11, P1405, DOI 10.1023/A:1026551727795; Barrett-Lee PJ, 2000, BRIT J CANCER, V82, P93, DOI 10.1054/bjoc.1999.0883; Barsevick AM, 2002, CANCER NURS, V25, P333, DOI 10.1097/00002820-200210000-00001; BARSEVICK AM, 2002, ONCOL NURS FORUM, V29, P377; BEREK JS, 1991, AM J OBSTET GYNECOL, V164, P1038, DOI 10.1016/0002-9378(91)90582-C; Berger A M, 1999, Oncol Nurs Forum, V26, P1663; Berger A M, 1998, Oncol Nurs Forum, V25, P51; BERGER AM, 2002, ONCOL NURS FORUM, V29, P333; BLAY JY, 1992, CANCER RES, V52, P3317; Blesch K S, 1991, Oncol Nurs Forum, V18, P81; Bower JE, 2000, J CLIN ONCOL, V18, P743, DOI 10.1200/JCO.2000.18.4.743; Breitbart W, 2001, ARCH INTERN MED, V161, P411, DOI 10.1001/archinte.161.3.411; Broeckel JA, 1998, J CLIN ONCOL, V16, P1689, DOI 10.1200/JCO.1998.16.5.1689; Bruera E, 1989, J Pain Symptom Manage, V4, P59, DOI 10.1016/0885-3924(89)90023-7; BRUERA E, 1990, CANCER, V66, P1279, DOI 10.1002/1097-0142(19900915)66:6&lt;1279::AID-CNCR2820660630&gt;3.0.CO;2-R; BURISH TG, 1991, J CONSULT CLIN PSYCH, V59, P518, DOI 10.1037/0022-006X.59.4.518; Cella D, 1997, SEMIN HEMATOL, V34, P13; Cella D, 1998, SEMIN ONCOL, V25, P43; CIMPRICH B, 1993, CANCER NURS, V16, P83; Cimprich B, 2001, NURS RES, V50, P86, DOI 10.1097/00006199-200103000-00004; Cleeland CS, 1999, ONCOLOGY-NY, V13, P91; Courneya KS, 1999, ANN BEHAV MED, V21, P171, DOI 10.1007/BF02908298; Curt G A, 2000, Oncologist, V5, P353, DOI 10.1634/theoncologist.5-5-353; De Vita F, 2000, ONCOL REP, V7, P357; Demetri GD, 1998, J CLIN ONCOL, V16, P3412, DOI 10.1200/JCO.1998.16.10.3412; Dimeo F, 1998, MED SCI SPORT EXER, V30, P475, DOI 10.1097/00005768-199804000-00001; Dimeo FC, 1999, CANCER, V85, P2273, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2273::AID-CNCR24>3.0.CO;2-B; Dimeo FC, 1997, CANCER-AM CANCER SOC, V79, P1717; Escalante CP, 2001, CANCER-AM CANCER SOC, V92, P1708, DOI 10.1002/1097-0142(20010915)92:6+<1708::AID-CNCR1501>3.0.CO;2-F; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; Fawzy NW, 1995, CANCER NURS, V18, P427; Fayad L, 2001, BLOOD, V97, P256, DOI 10.1182/blood.V97.1.256; Ferraccioli G, 1996, J RHEUMATOL, V23, P1539; FORESTER B, 1985, AM J PSYCHIAT, V142, P22; Fossa SD, 2001, J CLIN ONCOL, V19, P62, DOI 10.1200/JCO.2001.19.1.62; Gabrilove JL, 2001, J CLIN ONCOL, V19, P2875, DOI 10.1200/JCO.2001.19.11.2875; Gaston-Johansson F, 1999, CANCER PRACT, V7, P240, DOI 10.1046/j.1523-5394.1999.75008.x; Gaston-Johansson F, 2000, CANCER NURS, V23, P277, DOI 10.1097/00002820-200008000-00004; Geinitz H, 2001, INT J RADIAT ONCOL, V51, P691, DOI 10.1016/S0360-3016(01)01657-1; Gelmon K, 1999, J CLIN ONCOL, V17, P3038, DOI 10.1200/JCO.1999.17.10.3038; Giannitrapani L, 2002, ANN NY ACAD SCI, V963, P46, DOI 10.1111/j.1749-6632.2002.tb04093.x; Given B, 2001, NURS RES, V50, P222, DOI 10.1097/00006199-200107000-00006; Given Barbara, 2002, Oncol Nurs Forum, V29, P949, DOI 10.1188/02.ONF.949-956; Given CW, 2001, J PAIN SYMPTOM MANAG, V21, P456, DOI 10.1016/S0885-3924(01)00284-6; Glaspy J, 1997, J CLIN ONCOL, V15, P1218, DOI 10.1200/JCO.1997.15.3.1218; Glaspy JA, 2002, BRIT J CANCER, V87, P268, DOI 10.1038/sj.bjc.6600465; Glaus A, 1996, Eur J Cancer Care (Engl), V5, P8, DOI 10.1111/j.1365-2354.1996.tb00247.x; Glaus A, 1998, FATIGUE PATIENTS CAN; GRAYDON JE, 1995, CANCER NURS, V18, P23; GREENBERG DB, 1993, J PAIN SYMPTOM MANAG, V8, P196, DOI 10.1016/0885-3924(93)90127-H; Groopman JE, 1999, JNCI-J NATL CANCER I, V91, P1616, DOI 10.1093/jnci/91.19.1616; Gutstein HB, 2001, CANCER-AM CANCER SOC, V92, P1678, DOI 10.1002/1097-0142(20010915)92:6+<1678::AID-CNCR1496>3.0.CO;2-R; Hadorn DC, 1996, J CLIN EPIDEMIOL, V49, P749, DOI 10.1016/0895-4356(96)00019-4; Harrison L, 2001, SEMIN ONCOL, V28, P54, DOI 10.1053/sonc.2001.25399; HEINZ L, 1998, SEMIN ONCOL       S7, V25, P2; Hickok JT, 1996, J PAIN SYMPTOM MANAG, V11, P370, DOI 10.1016/0885-3924(96)00008-5; Inui A, 1999, CANCER RES, V59, P4493; Jacobsen PB, 2002, J CLIN ONCOL, V20, P2851, DOI 10.1200/JCO.2002.08.301; Jacobsen PB, 1999, J PAIN SYMPTOM MANAG, V22, P277; Janda M, 2000, CANCER-AM CANCER SOC, V89, P1322, DOI 10.1002/1097-0142(20000915)89:6<1322::AID-CNCR18>3.0.CO;2-D; Jatoi A, 2002, J CLIN ONCOL, V20, P567, DOI 10.1200/JCO.20.2.567; Johnson JE, 1999, RES NURS HEALTH, V22, P435, DOI 10.1002/(SICI)1098-240X(199912)22:6<435::AID-NUR2>3.3.CO;2-H; JOHNSON JE, 1988, CANCER-AM CANCER SOC, V61, P46, DOI 10.1002/1097-0142(19880101)61:1<46::AID-CNCR2820610109>3.0.CO;2-2; Jones TH, 1998, SEMIN ONCOL, V25, P54; KENNEDY RL, 1991, J ENDOCRINOL, V129, P167, DOI 10.1677/joe.0.1290167; Knobel H, 2000, J PAIN SYMPTOM MANAG, V19, P446, DOI 10.1016/S0885-3924(00)00144-5; Kurzrock R, 2001, CANCER, V92, P1684, DOI 10.1002/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z; Lee K A, 2001, Annu Rev Nurs Res, V19, P249; Littlewood TJ, 2001, J CLIN ONCOL, V19, P2865, DOI 10.1200/JCO.2001.19.11.2865; LOGE JH, 1998, PROG PALLIAT CARE, V6, P43; Loprinzi CL, 1999, J CLIN ONCOL, V17, P3299, DOI 10.1200/JCO.1999.17.10.3299; LUNDHOLM K, 1994, CANCER RES, V54, P5602; MacVicar MG, 1986, CANC B, V38, P235; Magnusson K, 1999, EUR J CANCER CARE, V8, P224; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Maughan TS, 2002, LANCET, V359, P1555, DOI 10.1016/S0140-6736(02)08514-8; Meek PM, 2000, NURS RES, V49, P181, DOI 10.1097/00006199-200007000-00001; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Messias D K, 1997, Oncol Nurs Forum, V24, P43; Mock V, 2001, CANCER-AM CANCER SOC, V92, P1699, DOI 10.1002/1097-0142(20010915)92:6+<1699::AID-CNCR1500>3.0.CO;2-9; Mock V, 2000, ONCOLOGY-NY, V14, P151; Mock V, 1994, Oncol Nurs Forum, V21, P899; Mock V, 2001, CANCER PRACT, V9, P119, DOI 10.1046/j.1523-5394.2001.009003119.x; Mock V, 1997, Oncol Nurs Forum, V24, P991; Mock V., 2002, ONCOL NURS FORUM, V29, P338; Moss RB, 1999, J CLIN IMMUNOL, V19, P314, DOI 10.1023/A:1020595709352; MURAKAMI S, 1997, BREAST CANC, V25, P25; Nail L, 2002, ONCOL NURS FORUM, V29, P337; Nail Lilian M, 2002, Oncol Nurs Forum, V29, P537, DOI 10.1188/ONF.537-546; *NAT COMPR CANC NE, 2003, NAT COMPR CANC NETW; Okuyama T, 2001, J PAIN SYMPTOM MANAG, V22, P554, DOI 10.1016/S0885-3924(01)00305-0; Osterborg A, 2002, J CLIN ONCOL, V20, P2486, DOI 10.1200/JCO.2002.10.101; Pinto BM, 1999, PSYCHO-ONCOL, V8, P191, DOI 10.1002/(SICI)1099-1611(199905/06)8:3<191::AID-PON355>3.3.CO;2-K; Piper B, 1989, KEY ASPECTS COMFORT, P199; Piper B F, 1987, Oncol Nurs Forum, V14, P17; Piper B F, 1998, Oncol Nurs Forum, V25, P677; PIPER BF, 1997, INSTRUMENTS CLIN HLT, P482; POROCK D, 2000, J PALLIATIVE CARE, V19, P249; Portenoy R K, 1999, Oncologist, V4, P1; Preti HA, 1997, ANN INTERN MED, V127, P186, DOI 10.7326/0003-4819-127-3-199708010-00002; RICHARDSON A, 1994, J ADV NURS, V19, P782, DOI 10.1111/j.1365-2648.1994.tb01151.x; Rieger PT, 2001, CANCER-AM CANCER SOC, V92, P1733; RIZZO JD, 2002, J CLIN ONCOL, V20, P1; Robinson K D, 1992, Semin Oncol Nurs, V8, P17, DOI 10.1016/0749-2081(92)90050-D; Rozans M, 2002, J CLIN ONCOL, V20, P335, DOI 10.1200/JCO.20.1.335; SANDSTROM R, 1990, EUR J CANCER, V26, P811, DOI 10.1016/0277-5379(90)90158-P; SCHILLER JH, 1991, CANCER RES, V51, P1651; Schwartz A, 1999, J Nurs Meas, V7, P35; Schwartz A L, 1998, Oncol Nurs Forum, V25, P711; Schwartz AL, 2001, MED SCI SPORT EXER, V33, P718; Schwartz AL, 2000, CANCER PRACT, V8, P16, DOI 10.1046/j.1523-5394.2000.81003.x; Schwartz AL, 1999, QUAL LIFE RES, V8, P529, DOI 10.1023/A:1008978611274; SCHWARTZ AL, 2002, ONCOL NURS FORUM, V29, P1; Sitzia J, 1998, CANCER PRACT, V6, P13, DOI 10.1046/j.1523-5394.1998.1998006013.x; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; Stone P, 1999, BRIT J CANCER, V79, P1479, DOI 10.1038/sj.bjc.6690236; Stone P, 1998, EUR J CANCER, V34, P1670, DOI 10.1016/S0959-8049(98)00167-1; Stone P, 2000, ANN ONCOL, V11, P561, DOI 10.1023/A:1008331230608; Stone P, 2000, EUR J CANCER, V36, P1134, DOI 10.1016/S0959-8049(00)00084-8; SUTHERLAND HJ, 1988, CANCER NURS, V11, P303; Tempfer C, 1997, GYNECOL ONCOL, V66, P27, DOI 10.1006/gyno.1997.4726; Vansteenkiste J, 2002, J NATL CANCER I, V94, P1211; VITA FD, 2001, J INTERFERON CYTOKIN, V21, P45; Vogelzang NJ, 1997, SEMIN HEMATOL, V34, P4; Wang XS, 2001, CANCER-AM CANCER SOC, V92, P1725, DOI 10.1002/1097-0142(20010915)92:6+<1725::AID-CNCR1504>3.0.CO;2-D; Webster K, 1998, ONCOLOGY-NY, V12, P697; WEINSHENKER BG, 1992, NEUROLOGY, V42, P1468, DOI 10.1212/WNL.42.8.1468; WETZLER M, 1994, BLOOD, V84, P3142; Winningham M L, 1994, Oncol Nurs Forum, V21, P23; Yellen SB, 1997, J PAIN SYMPTOM MANAG, V13, P63, DOI 10.1016/S0885-3924(96)00274-6; YOUNGMCCAUGHAN S, 2002, ONCOL NURS FORUM, V29, P334; [No title captured]; 2002, NIH PANEL STATEMENT	138	362	378	2	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2003	362	9384					640	650		10.1016/S0140-6736(03)14186-4	http://dx.doi.org/10.1016/S0140-6736(03)14186-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	714GJ	12944066				2022-12-28	WOS:000184904100026
J	Mendez, J				Mendez, J			Cell proliferation without cyclin E-CDK2	CELL			English	Editorial Material							DNA-REPLICATION	In this issue of Cell, Geng et al. report that mice can undergo embryonic development without cyclins El and E2. Fibroblasts derived from the double knockout embryos proliferate normally in culture. However, E type cyclins seem essential for endoreplication and exit from quiescence.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Mendez, J (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Mendez, Juan/K-8001-2014	Mendez, Juan/0000-0002-3235-2559				Coverley D, 2002, NAT CELL BIOL, V4, P523, DOI 10.1038/ncb813; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; ORTEGA S, 2003, NAT GENET; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9	9	28	28	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					398	399		10.1016/S0092-8674(03)00649-4	http://dx.doi.org/10.1016/S0092-8674(03)00649-4			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941268	Bronze			2022-12-28	WOS:000184928800003
J	Sundar, VC; Yablon, AD; Grazul, JL; Ilan, M; Aizenberg, J				Sundar, VC; Yablon, AD; Grazul, JL; Ilan, M; Aizenberg, J			Fibre-optical features of a glass sponge - Some superior technological secrets have come to light from a deep-sea organism	NATURE			English	Editorial Material									Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; OFS, Murray Hill, NJ 07974 USA; Tel Aviv Univ, Dept Zool, IL-69978 Tel Aviv, Israel	Alcatel-Lucent; Lucent Technologies; AT&T; Furukawa Electric; Tel Aviv University	Sundar, VC (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Ilan, Micha/ABG-4106-2020	Ilan, Micha/0000-0002-4188-4573				Aizenberg J, 2001, NATURE, V412, P819, DOI 10.1038/35090573; CattaneoVietti R, 1996, NATURE, V383, P397, DOI 10.1038/383397b0; Cha JN, 2000, NATURE, V403, P289, DOI 10.1038/35002038; CLEGG WJ, 1990, NATURE, V347, P455, DOI 10.1038/347455a0; Kamat S, 2000, NATURE, V405, P1036, DOI 10.1038/35016535; Kroger N, 2002, SCIENCE, V298, P584, DOI 10.1126/science.1076221; Marcuse D., 1981, PRINCIPLES OPTICAL F; McPhedran RC, 2001, AUST J CHEM, V54, P241, DOI 10.1071/CH01054; Perry CC, 2000, J BIOL INORG CHEM, V5, P537, DOI 10.1007/s007750000130; Sarikaya M, 2001, J MATER RES, V16, P1420, DOI 10.1557/JMR.2001.0198; Simpson T., 1984, CELL BIOL SPONGES	11	215	230	8	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 21	2003	424	6951					899	900		10.1038/424899a	http://dx.doi.org/10.1038/424899a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931176				2022-12-28	WOS:000184843600029
J	Banks, E; Beral, V; Bull, D; Reeves, G; Austoker, J; English, R; Patnick, J; Peto, R; Vessey, M; Wallis, M; Abbott, S; Bailey, E; Baker, K; Balkwill, A; Barnes, I; Black, J; Brown, A; Cameron, B; Canfell, K; Cliff, A; Crossley, B; Couto, E; Davies, S; Ewart, D; Ewart, S; Ford, D; Gerrard, L; Goodill, A; Green, J; Gray, W; Hilton, E; Hogg, A; Hooley, J; Hurst, A; Kan, SW; Keene, C; Langston, N; Roddam, A; Saunders, P; Sherman, E; Simmonds, M; Spencer, E; Strange, H; Timadjer, A				Banks, E; Beral, V; Bull, D; Reeves, G; Austoker, J; English, R; Patnick, J; Peto, R; Vessey, M; Wallis, M; Abbott, S; Bailey, E; Baker, K; Balkwill, A; Barnes, I; Black, J; Brown, A; Cameron, B; Canfell, K; Cliff, A; Crossley, B; Couto, E; Davies, S; Ewart, D; Ewart, S; Ford, D; Gerrard, L; Goodill, A; Green, J; Gray, W; Hilton, E; Hogg, A; Hooley, J; Hurst, A; Kan, SW; Keene, C; Langston, N; Roddam, A; Saunders, P; Sherman, E; Simmonds, M; Spencer, E; Strange, H; Timadjer, A		Million Women Study Collaborators	Breast cancer and hormone-replacement therapy in the Million Women Study	LANCET			English	Article							ESTROGEN; PROGESTIN; RISK	Background Current use of hormone-replacement therapy (HRT) increases the incidence of breast cancer. The Million Women Study was set up to investigate the effects of specific types of HRT on incident and fatal breast cancer. Methods 1084 110 UK women aged 50-64 years were recruited into the Million Women Study between 1996 and 2001, provided information about their use of HRT and other personal details, and were followed up for cancer incidence and death. Findings Half the women had used HRT; 9364 incident invasive breast cancers and 637 breast cancer deaths were registered after an average of 2.6 and 4.1 years of follow-up, respectively. Current users of HRT at recruitment were more likely than never users to develop breast cancer (adjusted relative risk 1.66 [95% CI 1.58-1-75], p<0.0001) and die from it (1.22 [1.00-1.48], p=0.05). Past users of HRT were, however, not at an increased risk of incident or fatal disease (1.01 [0.94-1.09] and 1.05 [0.82-1.34], respectively). Incidence was significantly increased for current users of preparations containing oestrogen only (1.30 [1.21-1.40], p<0.0001), oestrogen-progestagen (2.00 [1.88-2.12], p<0.0001), and tibolone (1.45 [1.25-1.68], p<0.0001), but the magnitude of the associated risk was substantially greater for oestrogen-progestagen than for other types of HRT (p<0.0001). Results varied little between specific oestrogens and progestagens or their doses; or between continuous and sequential regimens. The relative risks were significantly increased separately for oral, transdermal, and implanted oestrogen-only formulations (1.32 [1.21-1.45]; 1.24 [1.11-1.39]; and 1.65 [1.26-2.16], respectively; all p<0.0001). In current users of each type of HRT the risk of breast cancer increased with increasing total duration of use. 10 years' use of HRT is estimated to result in five (95% CI 3-7) additional breast cancers per 1000 users of oestrogen-only preparations and 19 (15-23) additional cancers per 1000 users of oestrogen-progestagen combinations. Use of HRT by women aged 50-64 years in the UK over the past decade has resulted in an estimated 20 000 extra breast cancers, 15 000 associated with oestrogen-progestagen; the extra deaths cannot yet be reliably estimated. Interpretation Current use of HRT is associated with an increased risk of incident and fatal breast cancer; the effect is substantially greater for oestrogen-progestagen combinations than for other types of HRT.	Radcliffe Infirm, Canc Res UK, Epidemiol Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary	Beral, V (corresponding author), Radcliffe Infirm, Canc Res UK, Epidemiol Unit, Gibson Bldg,Woodstock Rd, Oxford OX2 6HE, England.		Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380				Abbott S, 2002, BJOG-INT J OBSTET GY, V109, P1319; Banks BA, 2001, SPACE TECHNOL PROC, V4, P1; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2001, J MED SCREEN, V8, P29, DOI 10.1136/jms.8.1.29; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 1999, J Epidemiol Biostat, V4, P191; BERQUIST L, 1989, NEW ENGL J MED, V32, P293; *BRIT MED ASS ROYA, 1999, BRIT NAT FORM; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Li CI, 2003, JAMA-J AM MED ASSOC, V289, P3254, DOI 10.1001/jama.289.24.3254; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Newcomb PA, 2003, CANCER CAUSE CONTROL, V14, P195, DOI 10.1023/A:1023066304473; *OFF NAT STAT, 2000, KEY HLTH STAT GEN PR; Parkin D., 2002, IARC PUBL, V8; Pike MC, 1997, J NATL CANCER I, V89, P1110, DOI 10.1093/jnci/89.15.1110; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; Weiderpass E, 1999, J NATL CANCER I, V91, P1131, DOI 10.1093/jnci/91.13.1131; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd	23	2280	2351	2	148	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2003	362	9382					419	427		10.1016/s0140-6736(03)14065-2	http://dx.doi.org/10.1016/s0140-6736(03)14065-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927427	Green Submitted			2022-12-28	WOS:000184651100007
J	Limpens, E; Franken, C; Smit, P; Willemse, J; Bisseling, T; Geurts, R				Limpens, E; Franken, C; Smit, P; Willemse, J; Bisseling, T; Geurts, R			LysM domain receptor kinases regulating rhizobial Nod factor-induced infection	SCIENCE			English	Article							MEDICAGO-TRUNCATULA CONTROLS; FACTOR-PERCEPTION; NODULATION FACTOR; MELILOTI; SIGNAL; SPECIFICITY; RESISTANCE; GENOMES; GENES; ENTRY	The rhizobial infection of legumes has the most stringent demand toward Nod factor structure of all host responses, and therefore a specific Nod factor entry receptor has been proposed. The SYM2 gene identfied in certain ecotypes of pea (Pisum sativum) is a good candidate for such an entry receptor. We exploited the close phylogenetic relationship of pea and the model legume Medicago truncatula to identify genes specifically involved in rhizobial infection. The SYM2 orthologous region of M. truncatula contains 15 putative receptor-like genes, of which 7 are LysM domain-containing receptor-like kinases (LYKs). Using reverse genetics in M. truncatula, we show that two LYK genes are specifically involved in infection thread formation. This, as well as the properties of the LysM domains, strongly suggests that they are Nod factor entry receptors.	Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, NL-6703 HA Wageningen, Netherlands	Wageningen University & Research	Bisseling, T (corresponding author), Univ Wageningen & Res Ctr, Dept Plant Sci, Mol Biol Lab, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.		Bisseling, Ton/A-2421-2013; Willemse, Joost/B-1861-2008; poinssot, benoit/B-2569-2009	Willemse, Joost/0000-0001-9312-6021; poinssot, benoit/0000-0001-5890-4318				Amon P, 1998, PLANT CELL, V10, P781; ARDOUREL M, 1994, PLANT CELL, V6, P1357, DOI 10.1105/tpc.6.10.1357; Bateman A, 2000, J MOL BIOL, V299, P1113, DOI 10.1006/jmbi.2000.3778; Ben Amor B, 2003, PLANT J, V34, P495, DOI 10.1046/j.1365-313X.2003.01743.x; Boisson-Dernier A, 2001, MOL PLANT MICROBE IN, V14, P695, DOI 10.1094/MPMI.2001.14.6.695; Catoira R, 2001, DEVELOPMENT, V128, P1507; Cheng HP, 1998, J BACTERIOL, V180, P5183, DOI 10.1128/JB.180.19.5183-5191.1998; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; Cullimore JV, 2001, TRENDS PLANT SCI, V6, P24, DOI 10.1016/S1360-1385(00)01810-0; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; FIRMIN JL, 1993, MOL MICROBIOL, V10, P351, DOI 10.1111/j.1365-2958.1993.tb01961.x; Gage DJ, 2002, J BACTERIOL, V184, P7042, DOI 10.1128/JB.184.24.7042-7046.2002; Geurts R, 1997, PLANT PHYSIOL, V115, P351, DOI 10.1104/pp.115.2.351; Geurts R, 2002, PLANT CELL, V14, pS239, DOI 10.1105/tpc.002451; GEURTS R, UNPUB; Gualtieri G, 2002, PLANT MOL BIOL, V50, P225, DOI 10.1023/A:1016085523752; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LIE TA, 1984, PLANT SOIL, V82, P415, DOI 10.1007/BF02184279; LIMPENS E, UNPUBLISHED; McCallum CM, 2000, PLANT PHYSIOL, V123, P439, DOI 10.1104/pp.123.2.439; Oldroyd GED, 2001, PLANT J, V28, P191, DOI 10.1046/j.1365-313X.2001.01149.x; Walker SA, 2000, MOL PLANT MICROBE IN, V13, P754, DOI 10.1094/MPMI.2000.13.7.754; Young ND, 2003, CURR OPIN PLANT BIOL, V6, P199, DOI 10.1016/S1369-5266(03)00006-2	23	537	580	7	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 24	2003	302	5645					630	633		10.1126/science.1090074	http://dx.doi.org/10.1126/science.1090074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	735MV	12947035				2022-12-28	WOS:000186119900055
J	Romanowsky, AJ; Douglas, NG; Arnaboldi, M; Kuijken, K; Merrifield, MR; Napolitano, NR; Capaccioli, M; Freeman, KC				Romanowsky, AJ; Douglas, NG; Arnaboldi, M; Kuijken, K; Merrifield, MR; Napolitano, NR; Capaccioli, M; Freeman, KC			A dearth of dark matter in ordinary elliptical galaxies	SCIENCE			English	Article							PLANETARY-NEBULAE; RADIAL-VELOCITIES; NGC-3379; HALO; PHOTOMETRY; DISTRIBUTIONS; KINEMATICS; ROTATION; DYNAMICS; PROFILES	The kinematics of the outer parts of three intermediate-luminosity elliptical galaxies were studied with the Planetary Nebula Spectrograph. The galaxies' velocity-dispersion profiles were found to decline with the radius, and dynamical modeling of the data indicates the presence of little if any dark matter in these galaxies' halos. This unexpected result conflicts with findings in other galaxy types and poses a challenge to current galaxy formation theories.	Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; Univ Groningen, Kapteyn Astron Inst, NL-9700 AV Groningen, Netherlands; Astron Observ Capodimonte, INAF, I-80131 Naples, Italy; Astron Observ Pino Torinese, INAF, I-10025 Pino Torinese, Italy; Leiden Observ, NL-2300 RA Leiden, Netherlands; Univ Naples Federico II, Dept Phys Sci, I-80126 Naples, Italy; Mt Stromlo & Siding Spring Observ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia	University of Nottingham; University of Groningen; Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); Leiden University; Leiden University - Excl LUMC; University of Naples Federico II; Australian National University	Romanowsky, AJ (corresponding author), Univ Nottingham, Sch Phys & Astron, Univ Pk, Nottingham NG7 2RD, England.	aaron.romanowsky@nottingham.ac.uk	Kuijken, Konrad/AAF-6025-2021; Napolitano, Nicola R./ADU-3813-2022	Kuijken, Konrad/0000-0002-3827-0175; Napolitano, Nicola R./0000-0003-0911-8884; Arnaboldi, Magda/0000-0001-7214-3009; Merrifield, Michael/0000-0002-4202-4727; Freeman, Kenneth/0000-0001-6280-1207				BEASLEY MR, UNPUB; BENDER R, 1994, MON NOT R ASTRON SOC, V269, P785, DOI 10.1093/mnras/269.3.785; BERTIN G, 1994, ASTRON ASTROPHYS, V292, P381; CAPACCIOLI M, 1990, ASTRON J, V99, P1813, DOI 10.1086/115459; CAPACCIOLI M, IN PRESS P SAKH C PH; CIARDULLO R, 1993, ASTROPHYS J, V414, P454, DOI 10.1086/173092; DEVAUCOULEURS G, 1991, 3 REFERENCE CATALOGU; Douglas NG, 2002, PUBL ASTRON SOC PAC, V114, P1234, DOI 10.1086/342765; FABER SM, 1989, ASTROPHYS J SUPPL S, V69, P763, DOI 10.1086/191327; Gebhardt K, 2000, ASTRON J, V119, P1157, DOI 10.1086/301240; Gerhard O, 2001, ASTRON J, V121, P1936, DOI 10.1086/319940; HUI XH, 1995, ASTROPHYS J, V449, P592, DOI 10.1086/176082; Jacoby GH, 1996, ASTROPHYS J, V462, P1, DOI 10.1086/177122; JEDRZEJEWSKI R, 1989, ASTRON J, V98, P147, DOI 10.1086/115133; Keeton CR, 2001, ASTROPHYS J, V561, P46, DOI 10.1086/323237; Kleyna J, 2002, MON NOT R ASTRON SOC, V330, P792, DOI 10.1046/j.1365-8711.2002.05155.x; Kronawitter A, 2000, ASTRON ASTROPHYS SUP, V144, P53, DOI 10.1051/aas:2000199; Loewenstein M, 1999, ASTROPHYS J, V518, P50, DOI 10.1086/307256; Madgwick DS, 2002, MON NOT R ASTRON SOC, V333, P133, DOI 10.1046/j.1365-8711.2002.05393.x; Magorrian J, 2001, MON NOT R ASTRON SOC, V322, P702, DOI 10.1046/j.1365-8711.2001.04150.x; Mendez RH, 2001, ASTROPHYS J, V563, P135, DOI 10.1086/323794; Natarajan P, 2002, ASTROPHYS J, V580, pL11, DOI 10.1086/345399; Navarro JF, 1997, ASTROPHYS J, V490, P493, DOI 10.1086/304888; Ostriker JP, 2003, SCIENCE, V300, P1909, DOI 10.1126/science.1085976; Persic M, 1996, MON NOT R ASTRON SOC, V281, P27, DOI 10.1093/mnras/278.1.27; Rix HW, 1999, ASTROPHYS J, V513, pL25, DOI 10.1086/311894; Rix HW, 1997, ASTROPHYS J, V488, P702, DOI 10.1086/304733; Romanowsky AJ, 2001, ASTROPHYS J, V553, P722, DOI 10.1086/320947; SCHNEIDER SE, 1989, ASTRON J, V97, P666, DOI 10.1086/115012; Statler TS, 1999, ASTRON J, V117, P839, DOI 10.1086/300745; Statler TS, 2001, ASTRON J, V121, P244, DOI 10.1086/318047; Tonry JL, 2001, ASTROPHYS J, V546, P681, DOI 10.1086/318301; WEINBERG DH, IN PRESS ASTROPHYS J; Wilson G, 2001, ASTROPHYS J, V555, P572, DOI 10.1086/321441; [No title captured]	35	329	329	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 19	2003	301	5640					1696	1698		10.1126/science.1087441	http://dx.doi.org/10.1126/science.1087441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	722QN	12947033	Green Published			2022-12-28	WOS:000185387700036
J	Williams, BG; Dye, C				Williams, BG; Dye, C			Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS	SCIENCE			English	Article							HIV-INFECTION; CELL DECLINE; AIDS; SURVIVAL; THERAPY; PROGRESSION; EVOLUTION; PREDICT; AFRICA; TIME	Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/ AIDS) has dramatically increased the incidence of tuberculosis (TB) in sub-Saharan Africa, where up to 60% of TB patients are coinfected with HIV and each year 200,000 TB deaths are attributable to HIV coinfection. Now HIV threatens control of TB in Asia, Eastern Europe, and Latin America. Antiretroviral ( ARV) drugs can prevent TB by preserving immunity, but cohort analysis shows that early therapy, plus high levels of coverage and compliance, will be needed to avert a significant fraction of TB cases. However, ARV drugs could enhance the treatment of TB, and TB programs provide an important entry point for the treatment of HIV/ AIDS.	WHO, Communicable Dis, CH-1211 Geneva 27, Switzerland	World Health Organization	Williams, BG (corresponding author), WHO, Communicable Dis, CH-1211 Geneva 27, Switzerland.	williamsbg@who.int	Dye, Christopher/AIC-4659-2022	Williams, Brian/0000-0002-3174-4876; Dye, Christopher/0000-0002-2957-1793				ANTONUCCI G, 1995, JAMA-J AM MED ASSOC, V274, P143, DOI 10.1001/jama.274.2.143; Babiker A, 2000, LANCET, V355, P1131, DOI 10.1016/S0140-6736(00)02061-4; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Cohen J, 2002, SCIENCE, V296, P2320, DOI 10.1126/science.296.5577.2320; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; CURRIE CSM, IN PRESS AIDS; De Cock KM, 1999, INT J TUBERC LUNG D, V3, P457; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Dorrucci M, 1999, EUR J EPIDEMIOL, V15, P317, DOI 10.1023/A:1007503018729; DRABICK JJ, 1992, AIDS RES HUM RETROV, V8, P2039, DOI 10.1089/aid.1992.8.2039; EASTERBROOK PJ, 1993, AIDS, V7, P959, DOI 10.1097/00002030-199307000-00009; Gottlieb GS, 2002, J INFECT DIS, V185, P905, DOI 10.1086/339295; Harries AD, 2001, INT J TUBERC LUNG D, V5, P1109; LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63; Lepri AC, 1997, J INFECT DIS, V175, P775, DOI 10.1086/513970; Levi GC, 2002, AIDS, V16, P2373, DOI 10.1097/00002030-200212060-00001; Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005; McNeil AJ, 1996, STAT MED, V15, P75, DOI 10.1002/(SICI)1097-0258(19960115)15:1&lt;75::AID-SIM142&gt;3.0.CO;2-8; Morgan D, 2002, AIDS, V16, P597, DOI 10.1097/00002030-200203080-00011; MSF, 2002, EQ ACC SCAL HIV AIDS; Pilheu JA, 1997, INT J TUBERC LUNG D, V1, P422; Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7; Salamon R, 2002, J ACQ IMMUN DEF SYND, V29, P149, DOI 10.1097/00042560-200202010-00007; SCHELLEKENS PTA, 1992, AIDS, V6, P665, DOI 10.1097/00002030-199207000-00008; Tan Darrell HS, 2003, BMC Int Health Hum Rights, V3, P2, DOI 10.1186/1472-698X-3-2; *UNAIDS, 2003, UNAIDS0226E UNAIDS; *WHO, 2003, WHOCDSTB2001287; WILLIAMS BG, UNPUB; World Health Organization, 2002, SCAL ANT THER RES LT; Yamashita TE, 2001, AIDS, V15, P735, DOI 10.1097/00002030-200104130-00009; Yazdanpanah Y, 2001, INT J EPIDEMIOL, V30, P864, DOI 10.1093/ije/30.4.864	31	181	191	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 12	2003	301	5639					1535	1537		10.1126/science.1086845	http://dx.doi.org/10.1126/science.1086845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	720HL	12920302				2022-12-28	WOS:000185255300050
J	Ribisl, KM; Williams, RS; Kim, AE				Ribisl, KM; Williams, RS; Kim, AE			Internet sales of cigarettes to minors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context There is growing concern that the Internet might become a source of tobacco products for minors. Although researchers have studied tobacco sales to minors at retail outlets for more than a decade, there are no published studies of tobacco sales to minors via the Internet. Objective To determine the proportion of Internet cigarette vendors that will sell cigarettes to minors. Design, Setting, and Participants Cross-sectional study conducted in April-July 2001. Under adult supervision, 4 adolescents aged 11 to 15 years attempted to purchase cigarettes via 55 Internet cigarette vendors located in 12 states. These minors made a total of 83 purchase attempts, paying by credit card (n=47) and by money order (n=36). Main Outcome Measure Proportion of Internet cigarette vendors that sold cigarettes to minors. Results Minors successfully received cigarettes for 93.6% of credit card purchase attempts and for 88.9% of money order purchase attempts. Age was never verified for any of these deliveries. Internet vendors sent a total of 1650 packs of cigarettes to the underage adolescents in this study. Conclusion Minors appear to have easy access to cigarettes via the Internet because many Internet vendors have weak or nonexistent age verification procedures.	Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ribisl, KM (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, CB 7440,Rosenau Hall, Chapel Hill, NC 27599 USA.	kurt_ribisl@unc.edu	Ribisl, Kurt M/C-4867-2015	Ribisl, Kurt M/0000-0003-3318-8524; kim, annice/0000-0001-6585-5876				Abrams SM, 2003, PREV MED, V36, P731, DOI 10.1016/S0091-7435(03)00056-2; ALTMAN DG, 1989, JAMA-J AM MED ASSOC, V261, P80, DOI 10.1001/jama.261.1.80; *AM LUNG ASS, 1998, STAT LAWS TOB PEN MI; Centers of Disease Control and Prevention, 2001, MMWR Recomm Rep, V50, P1, DOI 10.1103/PhysRevE.106.055304; Bryant JA, 2002, TOB CONTROL, V11, P226, DOI 10.1136/tc.11.3.226; Cohen JE, 2001, TOB CONTROL, V10, P364, DOI 10.1136/tc.10.4.364; Connolly GN, 2001, TOB CONTROL, V10, P299, DOI 10.1136/tc.10.4.299; DIFRANZA JR, 1987, JAMA-J AM MED ASSOC, V257, P3387, DOI 10.1001/jama.257.24.3387; Fisher L, 2000, CANCER CAUSE CONTROL, V11, P675, DOI 10.1023/A:1008930701943; LINDBLOM E, ELEMENTS MODEL STATE; MICHEL L, 2003, BUFFALO NEWS    0619, pB1; *OFF APPL STUD, 2002, YOUTHS GET CIG NHSDA; PRECIOUS T, 2003, BUFFALO NEWS    0611, pB1; Ribisl K. M., 2003, TOB CONTROL S1, V12, pi148, DOI [DOI 10.1136/TC.12.SUPPL_L.I48, 10.1136/tc.12.suppl_1.i48]; Ribisl KM, 2002, AM J PUBLIC HEALTH, V92, P940, DOI 10.2105/AJPH.92.6.940; Ribisl KM, 2001, TOB CONTROL, V10, P352, DOI 10.1136/tc.10.4.352; SCHERER R, 2000, CHRISTIAN SCI M 1108, P2; *TOB LAW PROJ, 2002, SMOK WEB CAN CHILDR; Unger JB, 2001, TOB CONTROL, V10, P360, DOI 10.1136/tc.10.4.360; 1996, FED REG, V61, P44396; 2000, GLOBE MAIL      0928, pT2	21	46	46	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1356	1359		10.1001/jama.290.10.1356	http://dx.doi.org/10.1001/jama.290.10.1356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966128				2022-12-28	WOS:000185188600029
J	McNally, N; Kerrison, S; Pollock, AM				McNally, N; Kerrison, S; Pollock, AM			Reforming clinical research and development in England	BRITISH MEDICAL JOURNAL			English	Article							CONFLICTS-OF-INTEREST	The United Kingdom is trying to bring more non-governmental funding into NHS research through partnerships with the commercial and voluntary sectors. But it is still unclear exactly how the reforms in England will work and how trusts will resolve the tensions between patients' needs, financial viability, and the commercial exploitation of research findings.	UCL Hosp NHS Trust, London NW1 2LT, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	McNally, N (corresponding author), UCL Hosp NHS Trust, London NW1 2LT, England.	nick.mcnally@uclh.nhs.uk		McNally, Nick/0000-0002-0434-2302; pollock, allyson/0000-0002-7388-3110				ARNOLD E, 1999, IMPLEMENTING CULYER; Culyer A., 1994, SUPPORTING RES DEV N; *DEP HLTH, 2001, SCI INN STRAT; *DEP HLTH, 2001, NHS PRIOR NEEDS R D; *DEP HLTH, 2000, NHS R D FUND CONS PA; Department of Health, 2000, NHS CANC PLAN; Department of Health, 2002, NHS INN ORG FRAM GUI; Department of Health, 2000, RES DEV 1 CLASS SERV; HARRISON A, 2001, HLTH CARE UK 2001 KI, P26; Harrison A, 2002, PUBLIC INTEREST PRIV; *HL SEL COMM SCI T, 1988, PRIOR MED RES, V1; Kerrison S, 2003, BRIT MED J, V327, P553, DOI 10.1136/bmj.327.7414.553; Korn D, 2000, JAMA-J AM MED ASSOC, V284, P2234, DOI 10.1001/jama.284.17.2234; McCollum C, 2003, LANCET, V361, P1906, DOI 10.1016/S0140-6736(03)13511-8; Morin K, 2002, JAMA-J AM MED ASSOC, V287, P78, DOI 10.1001/jama.287.1.78; *NAT CANC RES I, 2002, STRAT AN 2002; *OFF SCI TECHN, PUBL SECT RES EXPL F; *PHARM IND COMP TA, 2002, CLIN RES REP; Pharmaceutical Industry Competitiveness Task Force, 2001, FIN REP; Walt G, 2002, BRIT MED J, V325, P432, DOI 10.1136/bmj.325.7361.432	20	14	16	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2003	327	7414					550	553		10.1136/bmj.327.7414.550	http://dx.doi.org/10.1136/bmj.327.7414.550			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720WW	12958118	Green Published			2022-12-28	WOS:000185283700023
J	Hupert, N; Bearman, GML; Mushlin, AI; Callahan, MA				Hupert, N; Bearman, GML; Mushlin, AI; Callahan, MA			Accuracy of screening for inhalational anthrax after a bioterrorist attack	ANNALS OF INTERNAL MEDICINE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; NEW-YORK-CITY; RESPIRATORY SYNCYTIAL VIRUS; CLINICAL-FEATURES; BIOLOGICAL WEAPON; INFLUENZA-A; MANAGEMENT; DIAGNOSIS; INFECTION; EPIDEMIC	Background: Bioterrorism using anthrax claimed five lives in the United States in 2001 and remains a potential public health threat. In the aftermath of a large-scale anthrax attack, mass screening to identify early inhalational anthrax may improve both the management of individual cases and the efficiency of health resource utilization. Purpose: To develop the evidence base for outpatient anthrax screening protocols by quantifying differences in clinical presentation between inhalational anthrax and common viral respiratory tract infections. Design: Review, compilation, and data extraction from English-language case reports of inhalational anthrax and epidemiologic studies of influenza and other viral respiratory infections. Data Sources: 13 reports of 28 cases of inhalational anthrax from 1920 to 2001 and 5 studies reporting on the clinical features of 2762 cases of influenza and 1932 cases of noninfluenza viral respiratory disease. Data Synthesis: Characterization of presenting clinical symptoms in anthrax and viral disease and calculation of likelihood ratios for the presence of selected clinical features. Results: Fever and cough do not reliably discriminate between inhalational anthrax and viral respiratory tract infection. Features suggestive of anthrax include the presence of nonheadache neurologic symptoms (positive likelihood ratio cannot be calculated), dyspnea (positive likelihood ratio, 5.3 [95% Cl, 3.7 to 7.4]), nausea or vomiting (positive likelihood ratio, 5.1 [Cl, 3.0 to 8.5]), and finding of any abnormality on lung auscultation (positive likelihood ratio, 8.1 [Cl, 5.3 to 12.5]). In contrast, rhinorrhea (positive likelihood ratio, 0.2 [Cl, 0.1 to 0.4]) and sore throat (positive likelihood ratio, 0.2 [Cl, 0.1 to 0.5]) are more suggestive of viral respiratory tract infection. Conclusion: Inhalational anthrax has characteristic clinical features that are distinct from those seen in common viral respiratory tract infections. Screening protocols based on these features may improve rapid identification of patients with presumptive inhalational anthrax in the setting of a large-scale anthrax attack.	Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA; New York Presbyterian Hosp, New York, NY USA	Cornell University; NewYork-Presbyterian Hospital	Hupert, N (corresponding author), Cornell Univ, Weill Med Coll, Dept Publ Hlth, 3rd Floor,411 E 69th St, New York, NY 10021 USA.	nah2005@med.cornell.edu	Bearman, Gonzalo/ABB-2443-2020		PHS HHS [290-00-0013] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barakat LA, 2002, JAMA-J AM MED ASSOC, V287, P863, DOI 10.1001/jama.287.7.863; Bartlett JG, 2002, CLIN INFECT DIS, V35, P851, DOI 10.1086/341902; Bloem K, 2001, PUBLIC HEALTH REP, V116, P34; Boivin G, 2000, CLIN INFECT DIS, V31, P1166, DOI 10.1086/317425; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; BRACHMAN PS, 1961, NEW ENGL J MED, V265, P203, DOI 10.1056/NEJM196108032650501; Brookmeyer R, 2002, SCIENCE, V295, P1861, DOI 10.1126/science.1068474; Brooksher WR, 1920, J AMER MED ASSOC, V74, P323, DOI 10.1001/jama.1920.26210050002012a; Carrat F, 1999, CLIN INFECT DIS, V28, P283, DOI 10.1086/515117; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P909; Church DL, 2002, CLIN INFECT DIS, V34, P790, DOI 10.1086/338960; COWDERY JS, 1947, ARCH PATHOL, V43, P396; Fine AD, 2001, CLIN INFECT DIS, V32, P1784, DOI 10.1086/320747; Gerberding JL, 2002, JAMA-J AM MED ASSOC, V287, P898, DOI 10.1001/jama.287.7.898; GOLD H, 1955, ARCH INTERN MED, V96, P387, DOI 10.1001/archinte.1955.00250140109012; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; Govaert TME, 1998, FAM PRACT, V15, P16, DOI 10.1093/fampra/15.1.16; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; HAIGHT TH, 1952, AM J MED SCI, V224, P57, DOI 10.1097/00000441-195207000-00009; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Hall CB, 2001, CLIN INFECT DIS, V33, P792, DOI 10.1086/322657; Hupert N, 2002, MED DECIS MAKING, V22, pS17, DOI 10.1177/027298902237709; Inglesby TV, 2002, JAMA-J AM MED ASSOC, V287, P2236, DOI 10.1001/jama.287.17.2236; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; Khan AS, 2000, LANCET, V356, P1179, DOI 10.1016/S0140-6736(00)02769-0; Kuehnert MJ, 2003, CLIN INFECT DIS, V36, P328, DOI 10.1086/346035; LAFORCE FM, 1969, ARCH ENVIRON HEALTH, V18, P798, DOI 10.1080/00039896.1969.10665490; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Mayer TA, 2001, JAMA-J AM MED ASSOC, V286, P2549, DOI 10.1001/jama.286.20.2549; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; Metlay JP, 2003, ANN INTERN MED, V138, P109, DOI 10.7326/0003-4819-138-2-200301210-00012; Mina B, 2002, JAMA-J AM MED ASSOC, V287, P858, DOI 10.1001/jama.287.7.858; Monto AS, 2000, ARCH INTERN MED, V160, P3243, DOI 10.1001/archinte.160.21.3243; MOOLENAAR RL, 1995, CLIN INFECT DIS, V21, P643, DOI 10.1093/clinids/21.3.643; *NIH OFF PUBL HLTH, 2001, OPT POST PREV INH AN; Oliveira EC, 2001, CHEST, V119, P1717, DOI 10.1378/chest.119.6.1717; Plotkin SA, 2002, AM J MED, V112, P4, DOI 10.1016/S0002-9343(01)01050-6; PLOTKIN SA, 2002, AM J MED, V112, P2, DOI DOI 10.1016/S0002-9343(01)01050-6; Sackett D. L, 2000, EVIDENCE BASED MED T; SEVERN M, 1976, BRIT MED J, V1, P748, DOI 10.1136/bmj.1.6012.748; Shafazand S, 1999, CHEST, V116, P1369, DOI 10.1378/chest.116.5.1369; SUFFIN SC, 1978, HUM PATHOL, V9, P594, DOI 10.1016/S0046-8177(78)80140-3; Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892; van Elden LJR, 2001, BRIT J GEN PRACT, V51, P630; VESSAL K, 1975, CLIN RADIOL, V26, P471, DOI 10.1016/S0009-9260(75)80100-0; Vlahov D, 2002, J URBAN HEALTH, V79, P2, DOI 10.1093/jurban/79.1.2; Yang Q K, 1979, Zhonghua Fang She Xue Za Zhi, V13, P242; Zambon M, 2001, ARCH INTERN MED, V161, P2116, DOI 10.1001/archinte.161.17.2116; 2001, MMWR MORB MORTAL WKL, V50, P1077; 2001, MMWR MORB MORTAL WKL, V50, P893; 2001, MMWR MORB MORTAL WKL, V50, P984; 1928, N ENGL J MED, V198, P148	56	33	33	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	1				337	345		10.7326/0003-4819-139-5_Part_1-200309020-00009	http://dx.doi.org/10.7326/0003-4819-139-5_Part_1-200309020-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	716PL	12965942				2022-12-28	WOS:000185037500004
J	Abbott, RJ				Abbott, RJ			Sex, sunflowers, and speciation	SCIENCE			English	Editorial Material									Univ St Andrews, Sch Biol, St Andrews KY16 9TH, Fife, Scotland	University of St Andrews	Abbott, RJ (corresponding author), Univ St Andrews, Sch Biol, St Andrews KY16 9TH, Fife, Scotland.	rja@st-and.ac.uk						Abbott RJ, 2003, PHILOS T R SOC B, V358, P1123, DOI 10.1098/rstb.2003.1289; Buerkle CA, 2000, HEREDITY, V84, P441, DOI 10.1046/j.1365-2540.2000.00680.x; GRANT V, 1981, PLANT SPECIATION; Gutierrez-Marcos JF, 2003, PHILOS T ROY SOC B, V358, P1105, DOI 10.1098/rstb.2003.1292; Levin D. A, 2002, OX ECOL EV; Rieseberg LH, 1997, ANNU REV ECOL SYST, V28, P359, DOI 10.1146/annurev.ecolsys.28.1.359; Rieseberg LH, 2003, SCIENCE, V301, P1211, DOI 10.1126/science.1086949; West SA, 1999, J EVOLUTION BIOL, V12, P1003	8	20	22	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1189	1190		10.1126/science.1089292	http://dx.doi.org/10.1126/science.1089292			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947185				2022-12-28	WOS:000185003500026
J	Katou, Y; Kanoh, Y; Bando, M; Noguchi, H; Tanaka, H; Ashikari, T; Sugimoto, K; Shirahige, K				Katou, Y; Kanoh, Y; Bando, M; Noguchi, H; Tanaka, H; Ashikari, T; Sugimoto, K; Shirahige, K			S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-DAMAGE; CHROMOSOME-VI; PROGRESSION; GENOME; YEAST; TRANSCRIPTION; LOCATION; ORIGINS; KINASE	The checkpoint regulatory mechanism has an important role in maintaining the integrity of the genome(1-5). This is particularly important in S phase of the cell cycle, when genomic DNA is most susceptible to various environmental hazards(3,6,7). When chemical agents damage DNA, activation of checkpoint signalling pathways results in a temporary cessation of DNA replication. A replication-pausing complex is believed to be created at the arrested forks to activate further checkpoint cascades, leading to repair of the damaged DNA. Thus, checkpoint factors are thought to act not only to arrest replication but also to maintain a stable replication complex at replication forks(6-9). However, the molecular mechanism coupling checkpoint regulation and replication arrest is unknown. Here we demonstrate that the checkpoint regulatory proteins Tof1 and Mrc1 interact directly with the DNA replication machinery in Saccharomyces cerevisiae. When hydroxyurea blocks chromosomal replication, this assembly forms a stable pausing structure that serves to anchor subsequent DNA repair events.	Yokohama City Univ, RIKEN, Genom Sci Ctr,Human Genome Res Grp, Genome Struct & Funct Team, Kanagawa 2300045, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan; Yokohama City Univ, Kihara Inst Biol Res, Div Biochem, Totsuka Ku, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Kanagawa 2440813, Japan; Suntory Ltd, Inst Adv Technol, Shimamoto, Osaka 6188503, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Nagoya, Aichi 4640814, Japan	RIKEN; Yokohama City University; Yokohama City University; Yokohama City University; Yokohama City University; Suntory Holdings Ltd; Nagoya University	Shirahige, K (corresponding author), Yokohama City Univ, RIKEN, Genom Sci Ctr,Human Genome Res Grp, Genome Struct & Funct Team, 1-7-22 Suehiro Cho, Kanagawa 2300045, Japan.			Shirahige, Katsuhiko/0000-0002-7862-1144				Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Cimbora DM, 2000, MOL CELL BIOL, V20, P5581, DOI 10.1128/MCB.20.15.5581-5591.2000; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Foss EJ, 2001, GENETICS, V157, P567; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lengronne A, 2001, NUCLEIC ACIDS RES, V29, P1433, DOI 10.1093/nar/29.7.1433; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Melo JA, 2001, GENE DEV, V15, P2809; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Winzeler EA, 1998, SCIENCE, V281, P1194, DOI 10.1126/science.281.5380.1194; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	26	531	546	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 28	2003	424	6952					1078	1083		10.1038/nature01900	http://dx.doi.org/10.1038/nature01900			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715QR	12944972				2022-12-28	WOS:000184984200049
J	Prestwood, KM; Kenny, AM; Kleppinger, A; Kulldorff, M				Prestwood, KM; Kenny, AM; Kleppinger, A; Kulldorff, M			Ultralow-dose micronized 17 beta-estradiol and bone density and bone metabolism in older women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTMENOPAUSAL WOMEN; ELDERLY WOMEN; ESTROGEN REPLACEMENT; VERTEBRAL FRACTURES; MINERAL DENSITY; OSTEOPOROSIS; THERAPY; CALCIUM; RISK; ALENDRONATE	Context Estrogen therapy is known to prevent osteoporosis, but studies have shown that conventional doses increase adverse events. Whether lower doses, one quarter of standard treatment, prevent bone loss is not known. Objective To examine the effect of 3 years of treatment with 0.25 mg/d of micronized 17beta-estradiol on bone mineral density (BMD) and bone turnover in healthy older postmenopausal women. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted from July 24, 1998, through June 14, 2002, at a university general clinical research center in the United States. Healthy, community-dwelling women (N = 167) who were older than 65 years at enrollment. Intervention Dosage of 0.25 mg/d of micronized 17beta-estradiol (n = 83) or placebo (n = 84); all women who had not had a hysterectomy received 100 mg/d of oral micronized progesterone for 2-week periods every 6 months. Main Outcome Measures The BMD of the hip, spine, wrist, and total body measured annually for 3 years. Serum and urine biochemical markers of bone resorption and formation and sex hormones were measured at baseline, 3 months, and during years 1 and 3 of treatment. Results Mean BMD increased at all sites for participants taking low-dose estrogen (17beta-estradiol) compared with placebo (P<.001). Compared with participants receiving placebo, participants taking low-dose estrogen had BMD increases of 2.6% for the femoral neck; 3.6%, total hip; 2.8%, spine; and 1.2%, total body. Markers of bone turnover, N-telopeptides of type 1 collagen, and bone alkaline phosphatase decreased significantly (P<.001) in participants taking low-dose estrogen compared with placebo. Estradiol, estrone, and sex hormone-binding globulin levels increased in the estrogen-treated group compared with placebo. The adverse effect profile was similar; specifically, there were no statistically significant differences in breast tenderness, changes in endometrial thickness or pathological effects, or annual mammographic results between the 2 groups. The number of abnormal mammograms over 3 years was 15 for the low-dose estrogen group and 10 for the placebo group (8 occurred at baseline) (P =.26). There were no reports of breast cancer during the study. Conclusions In older women, a dosage of 0.25 mg/d of 17beta-estradiol increased bone density of the hip, spine, and total body, and reduced bone turnover, with minimal adverse effects. Future studies evaluating the effect of low-dose estrogen on fractures are indicated.	Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Community Med, Div Biostat, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Prestwood, KM (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT 06030 USA.		Kulldorff, Martin/H-4282-2011	Kulldorff, Martin/0000-0002-5284-2993	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG013631] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-06192] Funding Source: Medline; NIA NIH HHS [5P60AG13631] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Ettinger B, 1998, J CLIN ENDOCR METAB, V83, P2239, DOI 10.1210/jc.83.7.2239; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lindsay R, 2002, JAMA-J AM MED ASSOC, V287, P2668, DOI 10.1001/jama.287.20.2668; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; Mizunuma H, 1997, MATURITAS, V27, P69, DOI 10.1016/S0378-5122(97)01110-9; Prestwood KM, 1999, J CLIN ENDOCR METAB, V84, P179, DOI 10.1210/jc.84.1.179; PRESTWOOD KM, 1994, J CLIN ENDOCR METAB, V79, P366, DOI 10.1210/jc.79.2.366; Prestwood KM, 2000, J CLIN ENDOCR METAB, V85, P4462, DOI 10.1210/jc.85.12.4462; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Stone K, 1998, J BONE MINER RES, V13, P1167, DOI 10.1359/jbmr.1998.13.7.1167; Villareal DT, 2001, JAMA-J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815; Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9; Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001-5002	22	141	147	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2003	290	8					1042	1048		10.1001/jama.290.8.1042	http://dx.doi.org/10.1001/jama.290.8.1042			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	715FA	12941676	Bronze			2022-12-28	WOS:000184958900022
J	Ng, J; Cleland, J; Bergin, P				Ng, J; Cleland, J; Bergin, P			Retinal detachment	LANCET			English	Editorial Material									Auckland Hosp, Dept Neurol, Auckland, New Zealand; Univ Rochester, Strong Mem Hosp, Rochester, NY 14642 USA	Auckland City Hospital; University of Rochester	Ng, J (corresponding author), Auckland Hosp, Dept Neurol, Park Rd,Private Bag 92024, Auckland, New Zealand.								0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 23	2003	362	9384					639	639		10.1016/S0140-6736(03)14185-2	http://dx.doi.org/10.1016/S0140-6736(03)14185-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714GJ	12944065	Bronze			2022-12-28	WOS:000184904100025
J	Egan, ES; Waldor, MK				Egan, ES; Waldor, MK			Distinct replication requirements for the two vibrio cholerae chromosomes	CELL			English	Article							ESCHERICHIA-COLI CHROMOSOME; PLASMID DNA-REPLICATION; DAM METHYLTRANSFERASE; PROTEIN; ORIGIN; INITIATION; BACTERIAL; SEQUENCE; BINDING; GENOME	Studies of prokaryotic chromosome replication have focused almost exclusively on organisms with one chromosome. We defined and characterized the origins of replication of the two Vibrio cholerae chromosomes, oriCI(vc), and oriCII(vc). OriCII(vc) differs from the origin assigned by bioinformatic analysis and is unrelated to oriCI(vc). OriCII(vc)-based replication requires an internal 12 base pair repeat and two hypothetical genes that flank oriCII(vc). One of these genes is conserved among diverse genera of the family Vibrionaceae and encodes an origin binding protein. The other gene codes for an RNA and not a protein. OriCII(vc)- but not oriCI(vc)-based replication is negatively regulated by a DNA sequence adjacent to oriCII(vc). There is an unprecedented requirement for DNA adenine methyltransferase in both oriCI(vc)- and oriCII(vc)-based replication. Our studies of replication in V. cholerae indicate that microorganisms having multiple chromosomes may utilize unique mechanisms for the control of replication.	Tufts Univ, Sch Med, Dept Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Genet, Boston, MA 02111 USA; Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University; Howard Hughes Medical Institute	Waldor, MK (corresponding author), Tufts Univ, Sch Med, Dept Microbiol, 136 Harrison Ave, Boston, MA 02111 USA.			Waldor, Matthew/0000-0003-1843-7000	NIAID NIH HHS [AI-42347] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042347, R37AI042347] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABELES A, 1993, J BACTERIOL, V175, P7801, DOI 10.1128/JB.175.24.7801-7807.1993; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Chattoraj DK, 2000, MOL MICROBIOL, V37, P467, DOI 10.1046/j.1365-2958.2000.01986.x; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DelVecchio VG, 2002, P NATL ACAD SCI USA, V99, P443, DOI 10.1073/pnas.221575398; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; Guo FB, 2003, NUCLEIC ACIDS RES, V31, P1780, DOI 10.1093/nar/gkg254; HANSEN EB, 1986, P NATL ACAD SCI USA, V83, P4423, DOI 10.1073/pnas.83.12.4423; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; JENSEN MR, 1990, J MOL BIOL, V215, P257, DOI 10.1016/S0022-2836(05)80344-4; Julio SM, 2001, INFECT IMMUN, V69, P7610, DOI 10.1128/IAI.69.12.7610-7615.2001; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Kitagawa R, 1996, MOL MICROBIOL, V19, P1137, DOI 10.1046/j.1365-2958.1996.453983.x; KITATSUKAMOTO K, 1993, INT J SYST BACTERIOL, V43, P8, DOI 10.1099/00207713-43-1-8; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; LESSL M, 1992, J BACTERIOL, V174, P2493, DOI 10.1128/jb.174.8.2493-2500.1992; LobnerOlesen A, 1996, EMBO J, V15, P5999; LOBNEROLESEN A, 1992, MOL MICROBIOL, V6, P1841, DOI 10.1111/j.1365-2958.1992.tb01356.x; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; Marinus M.G., 1996, E COLI SALMONELLA CE, P782; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Moyer KE, 2001, MOL MICROBIOL, V41, P311, DOI 10.1046/j.1365-2958.2001.02517.x; NOVICK RP, 1987, MICROBIOL REV, V51, P381, DOI 10.1128/MMBR.51.4.381-395.1987; PAPP PP, 1994, J BIOL CHEM, V269, P23563; PEARSON GDN, 1993, P NATL ACAD SCI USA, V90, P3750, DOI 10.1073/pnas.90.8.3750; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Slominska M, 2001, MOL MICROBIOL, V40, P1371, DOI 10.1046/j.1365-2958.2001.02480.x; Trucksis M, 1998, P NATL ACAD SCI USA, V95, P14464, DOI 10.1073/pnas.95.24.14464; Weitao T, 2000, EMBO REP, V1, P494; Yamaichi Y, 1999, MOL MICROBIOL, V31, P1513, DOI 10.1046/j.1365-2958.1999.01296.x; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	37	135	140	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 22	2003	114	4					521	530		10.1016/S0092-8674(03)00611-1	http://dx.doi.org/10.1016/S0092-8674(03)00611-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	714TD	12941279	Bronze			2022-12-28	WOS:000184928800014
J	Schofield, RMS; Nesson, MH				Schofield, RMS; Nesson, MH			Comment on "High abrasion resistance with sparse mineralization: Copper biomineral in worm jaws"	SCIENCE			English	Editorial Material							HARDNESS		Univ Oregon, Dept Phys, Eugene, OR 97403 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	University of Oregon; Oregon State University	Schofield, RMS (corresponding author), Univ Oregon, Dept Phys, Eugene, OR 97403 USA.		Nesson, Michael/AAA-2929-2020; Nesson, Michael/B-7825-2009					Lichtenegger HC, 2002, SCIENCE, V298, P389, DOI 10.1126/science.1075433; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; Schofield RMS, 2002, NATURWISSENSCHAFTEN, V89, P579, DOI 10.1007/s00114-002-0381-4; Schofield RMS, 2001, SCORPION BIOLOGY AND RESEARCH, P234	4	10	10	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636												1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12933994				2022-12-28	WOS:000184872400020
J	Hetherington, AM; Woodward, FI				Hetherington, AM; Woodward, FI			The role of stomata in sensing and driving environmental change	NATURE			English	Review							LEAF WATER STATUS; ELEVATED CO2; GAS-EXCHANGE; ABSCISIC-ACID; GUARD-CELLS; PHOTOCHEMICAL EFFICIENCY; ATMOSPHERIC CO2; QUERCUS-RUBRA; DESERT SHRUB; BLUE-LIGHT	Stomata, the small pores on the surfaces of leaves and stalks, regulate the flow of gases in and out of leaves and thus plants as a whole. They adapt to local and global changes on all timescales from minutes to millennia. Recent data from diverse fields are establishing their central importance to plant physiology, evolution and global ecology. Stomatal morphology, distribution and behaviour respond to a spectrum of signals, from intracellular signalling to global climatic change. Such concerted adaptation results from a web of control systems, reminiscent of a 'scale-free' network, whose untangling requires integrated approaches beyond those currently used.	Univ Lancaster, Dept Biol Sci, Lancaster Environm Ctr, Lancaster LA1 4YQ, England; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	Lancaster University; University of Sheffield	Hetherington, AM (corresponding author), Univ Lancaster, Dept Biol Sci, Lancaster Environm Ctr, Lancaster LA1 4YQ, England.	A.hetherington@lancaster.ac.uk	Woodward, Frank Ian/P-4530-2019; Woodward, Ian F/B-7762-2008	Hetherington, Alistair/0000-0001-6060-9203	Biotechnology and Biological Sciences Research Council [P18229] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Aasamaa K, 2001, AUST J PLANT PHYSIOL, V28, P765, DOI 10.1071/PP00157; Adam L, 1999, MOL PLANT MICROBE IN, V12, P1031, DOI 10.1094/MPMI.1999.12.12.1031; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Allen MT, 2000, OECOLOGIA, V122, P470, DOI 10.1007/s004420050968; Anderson LJ, 2001, GLOBAL CHANGE BIOL, V7, P693, DOI 10.1046/j.1354-1013.2001.00438.x; Aronne G, 2001, ANN BOT-LONDON, V87, P789, DOI 10.1006/anbo.2001.1407; AVERY L, 1992, TRENDS GENET, V8, P312, DOI 10.1016/0168-9525(92)90263-4; BARBASI AL, 2002, LINKED NEW SCI NETWO, V280; Beerling DJ, 1997, BOT J LINN SOC, V124, P137, DOI 10.1006/bojl.1997.0098; BLANKE MM, 1994, ANN BOT-LONDON, V73, P651, DOI 10.1006/anbo.1994.1082; Bredenkamp GJ, 2002, PLANT ECOL, V163, P209, DOI 10.1023/A:1020957807971; Case AL, 2001, ECOLOGY, V82, P2601, DOI 10.1890/0012-9658(2001)082[2601:EDOCAS]2.0.CO;2; Cavender-Bares J, 2000, OECOLOGIA, V124, P8, DOI 10.1007/PL00008865; Chen XB, 2003, PLANT CELL, V15, P1170, DOI 10.1105/tpc.010926; Ciais P, 1997, J GEOPHYS RES-ATMOS, V102, P5857, DOI 10.1029/96JD02360; Cramer W, 2001, GLOBAL CHANGE BIOL, V7, P357, DOI 10.1046/j.1365-2486.2001.00383.x; Dudley SA, 1996, EVOLUTION, V50, P92, DOI [10.2307/2410783, 10.1111/j.1558-5646.1996.tb04475.x]; Edwards D, 1998, J EXP BOT, V49, P255, DOI 10.1093/jexbot/49.suppl_1.255; Ellsworth DS, 1999, PLANT CELL ENVIRON, V22, P461, DOI 10.1046/j.1365-3040.1999.00433.x; ESCALONA MH, 2002, ANN BOT, V89, P895; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Fetene M, 1997, NEW PHYTOL, V137, P453, DOI 10.1046/j.1469-8137.1997.00844.x; Franco AC, 2002, OECOLOGIA, V131, P356, DOI 10.1007/s00442-002-0903-y; Frechilla S, 2002, J EXP BOT, V53, P545, DOI 10.1093/jexbot/53.368.545; Garcia RL, 1998, PLANT CELL ENVIRON, V21, P659, DOI 10.1046/j.1365-3040.1998.00320.x; GINDEL I, 1969, PHYSIOL PLANTARUM, V22, P1143, DOI 10.1111/j.1399-3054.1969.tb09103.x; Giorio P, 1999, ENVIRON EXP BOT, V42, P95, DOI 10.1016/S0098-8472(99)00023-4; GRANTZ DA, 1991, PLANT CELL ENVIRON, V14, P683, DOI 10.1111/j.1365-3040.1991.tb01541.x; Gray JE, 2000, NATURE, V408, P713, DOI 10.1038/35047071; Hamerlynck EP, 2002, ENVIRON EXP BOT, V48, P93, DOI 10.1016/S0098-8472(02)00012-6; HEICHEL GH, 1978, PLANT PHYSIOL, V62, P387, DOI 10.1104/pp.62.3.387; Hetherington AM, 2001, CELL, V107, P711, DOI 10.1016/S0092-8674(01)00606-7; Hill RS, 1994, HIST AUSTR VEGETATIO; Hirasawa T, 1999, FIELD CROP RES, V62, P53, DOI 10.1016/S0378-4290(99)00005-2; Hunt L, 2003, PLANT J, V34, P47, DOI 10.1046/j.1365-313X.2003.01698.x; Huxman TE, 2001, OECOLOGIA, V128, P193, DOI 10.1007/s004420100658; Jackson RB, 2001, ECOL APPL, V11, P1027, DOI 10.1890/1051-0761(2001)011[1027:WIACW]2.0.CO;2; JANIS CM, 1993, ANNU REV ECOL SYST, V24, P467, DOI 10.1146/annurev.es.24.110193.002343; Jarvis AJ, 1999, PLANT CELL ENVIRON, V22, P639, DOI 10.1046/j.1365-3040.1999.00407.x; Jiang GM, 2001, PHOTOSYNTHETICA, V39, P257, DOI 10.1023/A:1013797023938; JONES HG, 1977, J EXP BOT, V28, P162, DOI 10.1093/jxb/28.1.162; Kaiser H, 2000, J EXP BOT, V51, P1741, DOI 10.1093/jexbot/51.351.1741; Kazda M, 2000, TREE PHYSIOL, V20, P1029; Kellogg EA, 2001, PLANT PHYSIOL, V125, P1198, DOI 10.1104/pp.125.3.1198; Kinoshita T, 2001, NATURE, V414, P656, DOI 10.1038/414656a; KNAPP AK, 1993, ECOLOGY, V74, P113, DOI 10.2307/1939506; KNAPP AK, 1994, ANN BOT-LONDON, V74, P595, DOI 10.1006/anbo.1994.1159; Lake JA, 2002, J EXP BOT, V53, P183, DOI 10.1093/jexbot/53.367.183; Lake JA, 2001, NATURE, V411, P154, DOI 10.1038/35075660; Leckie CP, 1998, P NATL ACAD SCI USA, V95, P15837, DOI 10.1073/pnas.95.26.15837; Lee TD, 2001, NEW PHYTOL, V150, P405, DOI 10.1046/j.1469-8137.2001.00095.x; Leymarie J, 1998, AUST J PLANT PHYSIOL, V25, P785, DOI 10.1071/PP98031; Leymarie J, 1998, PLANT PHYSIOL BIOCH, V36, P539, DOI 10.1016/S0981-9428(98)80180-0; Leymarie J, 1999, PLANT CELL ENVIRON, V22, P301, DOI 10.1046/j.1365-3040.1999.00403.x; Li WL, 1996, AM J BOT, V83, P15, DOI 10.2307/2445949; Lodge RJ, 2001, PLANT CELL ENVIRON, V24, P77, DOI 10.1046/j.1365-3040.2001.00659.x; LOHSE G, 1992, PLANTA, V188, P206, DOI 10.1007/BF00216815; Lu ZM, 1998, J EXP BOT, V49, P453, DOI 10.1093/jexbot/49.suppl_1.453; Maldonado AM, 2002, NATURE, V419, P399, DOI 10.1038/nature00962; Mast AR, 2002, AM J BOT, V89, P1311, DOI 10.3732/ajb.89.8.1311; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; McCarron JK, 2001, AM J BOT, V88, P1818, DOI 10.2307/3558358; MCCONATHY RK, 1983, FOREST SCI, V29, P139; Medlyn BE, 2002, PLANT CELL ENVIRON, V25, P1155, DOI 10.1046/j.1365-3040.2002.00890.x; Medlyn BE, 2001, NEW PHYTOL, V149, P247, DOI 10.1046/j.1469-8137.2001.00028.x; Meidner H., 1968, PHYSL STOMATA; Millar, 1998, BIOL RHYTHMS PHOTOPE, P69; Mishra MK, 1997, ANN BOT-LONDON, V80, P689, DOI 10.1006/anbo.1997.0491; Mitton JB, 1998, AM J BOT, V85, P1262, DOI 10.2307/2446636; Mott KA, 2000, TRENDS PLANT SCI, V5, P258, DOI 10.1016/S1360-1385(00)01648-4; Paakkonen E, 1998, PLANT CELL ENVIRON, V21, P671, DOI 10.1046/j.1365-3040.1998.00303.x; Palevitz B. A., 1981, Stomatal physiology., P1; Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103; Raschke K., 1979, Encyclopedia of Plant Physiology, New Series, Volume 7. Physiology of movements [Haupt, W.; Feinleib, M.E. (Editors)]., P383; Raven JA, 2002, NEW PHYTOL, V153, P371, DOI 10.1046/j.0028-646X.2001.00334.x; Retallack GJ, 2001, J GEOL, V109, P407, DOI 10.1086/320791; Roelfsema MRG, 1995, PHYSIOL PLANTARUM, V95, P373, DOI 10.1111/j.1399-3054.1995.tb00851.x; Royer DL, 2001, REV PALAEOBOT PALYNO, V114, P1, DOI 10.1016/S0034-6667(00)00074-9; Schroeder JI, 2001, ANNU REV PLANT PHYS, V52, P627, DOI 10.1146/annurev.arplant.52.1.627; SEIDMAN G, 1968, NATURE, V217, P684, DOI 10.1038/217684a0; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; SUGDEN AM, 1985, BOT J LINN SOC, V90, P231, DOI 10.1111/j.1095-8339.1985.tb00383.x; Talbott LD, 1998, J EXP BOT, V49, P329, DOI 10.1093/jexbot/49.suppl_1.329; TANNER EVJ, 1982, BIOTROPICA, V14, P16, DOI 10.2307/2387756; THIEL G, 1992, J MEMBRANE BIOL, V126, P1; Turnbull MH, 2002, OECOLOGIA, V130, P515, DOI 10.1007/s00442-001-0842-z; Webb AAR, 1997, PLANT PHYSIOL, V114, P1557, DOI 10.1104/pp.114.4.1557; Webb AAR, 2001, PLANT J, V26, P351, DOI 10.1046/j.1365-313X.2001.01032.x; Wever LA, 2002, AGR FOREST METEOROL, V112, P31, DOI 10.1016/S0168-1923(02)00041-2; Weyers JDB, 1997, ADV BOT RES, V26, P317, DOI 10.1016/S0065-2296(08)60124-X; Willmer C., 1996, STOMATA, DOI DOI 10.1007/978-94-011-0579-8; WILLMER CM, 1979, PROTOPLASMA, V100, P113, DOI 10.1007/BF01276305; Woodward FI, 1998, J EXP BOT, V49, P471, DOI 10.1093/jexbot/49.suppl_1.471; WOODWARD FI, 1995, NEW PHYTOL, V131, P311, DOI 10.1111/j.1469-8137.1995.tb03067.x; Woodward FI, 2002, NEW PHYTOL, V153, P477, DOI 10.1046/j.0028-646X.2001.00338.x; Woodward FI, 2002, CURR OPIN PLANT BIOL, V5, P207, DOI 10.1016/S1369-5266(02)00253-4; Wullschleger SD, 2002, PLANT CELL ENVIRON, V25, P319, DOI 10.1046/j.1365-3040.2002.00796.x; YODER BJ, 1994, FOREST SCI, V40, P513; Yu GR, 2001, J PLANT PHYSIOL, V158, P861, DOI 10.1078/0176-1617-00177	99	1384	1579	51	902	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 21	2003	424	6951					901	908		10.1038/nature01843	http://dx.doi.org/10.1038/nature01843			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713EH	12931178				2022-12-28	WOS:000184843600031
J	Schiffer, CA				Schiffer, CA			Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Wayne State Univ, Sch Med, Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Schiffer, CA (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI 48202 USA.								0	26	27	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					727	729		10.1056/NEJMp030076	http://dx.doi.org/10.1056/NEJMp030076			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930923				2022-12-28	WOS:000184843300001
J	Garcia, HH; Gonzalez, AE; Evans, CAW; Gilman, RH				Garcia, HH; Gonzalez, AE; Evans, CAW; Gilman, RH		Cysticercosis Working Grp Peru	Talenia solium cysticercosis	LANCET			English	Review							LINKED IMMUNOELECTROTRANSFER BLOT; TAENIA-SOLIUM; CEREBRAL CYSTICERCOSIS; PORCINE CYSTICERCOSIS; ALBENDAZOLE THERAPY; SEIZURE RECURRENCE; MEDICAL-TREATMENT; HUMAN NEUROCYSTICERCOSIS; IMMUNOSORBENT-ASSAY; TOMOGRAPHIC LESIONS	The larval stage of the pork tapeworm (Taenia sollum) infects the human nervous system, causing neurocysticercosis. This disease is one of the main causes of epileptic seizures in many less developed countries and is also increasingly Seen in more developed countries because of immigration from endemic areas. Little information is available on the natural evolution of taeniasis or cysticercosis. Available therapeutic measures include steroids, treatments for symptoms, surgery, and, more controversially, antiparasitic drugs to kill brain parasites. Efforts to control and eliminate this disease are underway through antiparasitic treatment of endemic populations, development of pig vaccines, and other measures.	Inst Nacl Ciencias Neurol, Cysticercosis Unit, Lima, Peru; Univ Peruana Cayetano Heredia, Dept Microbiol, Lima, Peru; Univ Nacl Mayor San Marcos, Sch Vet Med, Dept Publ Hlth, Lima 14, Peru; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ London Imperial Coll Sci Technol & Med, London, England	Universidad Peruana Cayetano Heredia; Universidad Nacional Mayor de San Marcos; Johns Hopkins University; Imperial College London	Garcia, HH (corresponding author), Inst Nacl Ciencias Neurol, Cysticercosis Unit, Jr Ancash 1271, Lima, Peru.	hgarcia@terra.com.pe	Evans, Carlton/AAI-1653-2020	Evans, Carlton/0000-0002-6873-5447; Gonzalez, Armando/0000-0003-1909-1873	Wellcome Trust [057434] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acevedo-Hernandez A., 1982, Cysticercosis: present state of knowledge and perspectives. (Proc. Internat. workshop on cysticercosis, San Miguel de Allende, Guanajuato, Mexico, Nov. 16-18, 1981)., P63; ADAMOLEKUM B, 1994, EPILEPSIA, V35, P89; Allan JC, 1996, ANN TROP MED PARASIT, V90, P157, DOI 10.1080/00034983.1996.11813039; ALLAN JC, 1990, PARASITOLOGY, V101, P473, DOI 10.1017/S0031182000060686; Allan JC, 1997, T ROY SOC TROP MED H, V91, P595, DOI 10.1016/S0035-9203(97)90042-0; Allan JC, 1996, AM J TROP MED HYG, V54, P352, DOI 10.4269/ajtmh.1996.54.352; Baranwal AK, 1998, PEDIATR INFECT DIS J, V17, P696, DOI 10.1097/00006454-199808000-00007; Baranwal AK, 2001, J CHILD NEUROL, V16, P443, DOI 10.2310/7010.2001.7057; BARRINAGARREMEN.F, 2002, TAENIA SOLIUM CYSTIC, P221; Bern C, 1999, CLIN INFECT DIS, V29, P1203, DOI 10.1086/313470; BICKERSTAFF ER, 1952, BRAIN, V75, P1, DOI 10.1093/brain/75.1.1; BOTERO D, 1982, AM J TROP MED HYG, V31, P811, DOI 10.4269/ajtmh.1982.31.811; CARDENAS F, 1992, ANN OPHTHALMOL, V24, P25; CARPIO A, 1995, ARCH INTERN MED, V155, P1982, DOI 10.1001/archinte.155.18.1982; Carpio A, 2002, NEUROLOGY, V59, P1730, DOI 10.1212/01.WNL.0000036320.69823.EA; Carpio A, 2002, LANCET INFECT DIS, V2, P751, DOI 10.1016/S1473-3099(02)00454-1; Chandra S, 2000, AM J NEURORADIOL, V21, P198; Chang GY, 2001, NEUROLOGY, V57, P545, DOI 10.1212/WNL.57.3.545; Corona T, 1996, NEW ENGL J MED, V334, P125, DOI 10.1056/NEJM199601113340216; CORREA D, 1989, T ROY SOC TROP MED H, V83, P814, DOI 10.1016/0035-9203(89)90340-4; CRUZ M, 1989, B WORLD HEALTH ORGAN, V67, P401; Cruz ME, 1999, INT J EPIDEMIOL, V28, P799, DOI 10.1093/ije/28.4.799; Cuetter AC, 1997, CLIN INFECT DIS, V24, P157, DOI 10.1093/clinids/24.2.157; Del Brutto OH, 2001, NEUROLOGY, V57, P177, DOI 10.1212/WNL.57.2.177; DELBRUTTO OH, 1995, ARCH NEUROL-CHICAGO, V52, P102, DOI 10.1001/archneur.1995.00540250110021; DELBRUTTO OH, 1992, ARCH NEUROL-CHICAGO, V49, P535, DOI 10.1001/archneur.1992.00530290123021; DELBRUTTO OH, 1992, NEUROLOGY, V42, P389, DOI 10.1212/WNL.42.2.389; DELBRUTTO OH, 1994, NEUROLOGY, V44, P1706, DOI 10.1212/WNL.44.9.1706; DIETRICHS E, 1993, ACTA NEUROL SCAND, V88, P296, DOI 10.1111/j.1600-0404.1993.tb04240.x; DIWAN AR, 1982, AM J TROP MED HYG, V31, P364, DOI 10.4269/ajtmh.1982.31.364; Dixon H.B, 1961, CYSTICERCOSIS ANAL F; Dixon HBF, 1934, Q J MED, V3, P603, DOI 10.1093/qjmed/3.4.603; Dixon HBF, 1944, Q J MED, V13, P107; Escobar A., 1983, CYSTICERCOSIS CENTRA, P27; ESCOBEDO F, 1987, ARCH INTERN MED, V147, P738, DOI 10.1001/archinte.147.4.738; ESTRADA JJ, 1985, J NEUROL SCI, V71, P39, DOI 10.1016/0022-510X(85)90035-8; EVANS CAW, 1999, TAENIA SOLIUM TAENIA, P25; FLISSER A, 1988, PARASITOL TODAY, V4, P131, DOI 10.1016/0169-4758(88)90187-1; FLISSER A, 1993, LANCET, V342, P748, DOI 10.1016/0140-6736(93)91743-6; Flisser A, 1994, Prog Clin Parasitol, V4, P77; GARCIA HH, 1994, AM J TROP MED HYG, V50, P152, DOI 10.4269/ajtmh.1994.50.152; Garcia HH, 2000, T ROY SOC TROP MED H, V94, P673, DOI 10.1016/S0035-9203(00)90228-1; Garcia HH, 1999, NEUROLOGY, V53, P1582, DOI 10.1212/WNL.53.7.1582; Garcia HH, 2001, AM J TROP MED HYG, V65, P31, DOI 10.4269/ajtmh.2001.65.31; Garcia HH, 1998, T ROY SOC TROP MED H, V92, P411, DOI 10.1016/S0035-9203(98)91069-0; GARCIA HH, 1991, LANCET, V338, P549; Garcia HH, 1997, T ROY SOC TROP MED H, V91, P176, DOI 10.1016/S0035-9203(97)90213-3; Garcia HH, 1997, J INFECT DIS, V175, P486, DOI 10.1093/infdis/175.2.486; GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Garcia HH, 2003, AM J TROP MED HYG, V68, P268, DOI 10.4269/ajtmh.2003.68.268; Garcia HH, 2002, CLIN MICROBIOL REV, V15, P747, DOI 10.1128/CMR.15.4.747-756.2002; Garcia HH, 1997, NEUROLOGY, V48, P1421, DOI 10.1212/WNL.48.5.1421; Garcia HH, 1999, ACTA TROP, V73, P31, DOI 10.1016/S0001-706X(99)00011-X; Garcia HH, 1998, AM J TROP MED HYG, V59, P902, DOI 10.4269/ajtmh.1998.59.902; Garcia HH, 2000, INFECT DIS CLIN N AM, V14, P97, DOI 10.1016/S0891-5520(05)70220-8; Garcia-Noval J, 2001, ANN TROP MED PARASIT, V95, P167, DOI 10.1080/00034980120050260; GarciaNoval J, 1996, AM J TROP MED HYG, V55, P282, DOI 10.4269/ajtmh.1996.55.282; Gauci CGP, 1998, INT J PARASITOL, V28, P757, DOI 10.1016/S0020-7519(98)00034-4; Gekeler F, 2002, EUR J CLIN MICROBIOL, V21, P227, DOI 10.1007/s10096-002-0695-3; Gemmell MA, 1983, GUIDELINES SURVEILLA; Gilman RH, 2000, NEUROLOGY, V55, P1062, DOI 10.1212/WNL.55.7.1062; Gilman RHGHH., 1999, TAENIA SOLIUM TAENIA, P313; Gonzales AE, 1996, AM J TROP MED HYG, V54, P391, DOI 10.4269/ajtmh.1996.54.391; Gonzalez AE, 1997, VET REC, V141, P420, DOI 10.1136/vr.141.16.420; GONZALEZ AE, 1990, AM J TROP MED HYG, V43, P194, DOI 10.4269/ajtmh.1990.43.194; Gonzalez AE, 1998, AM J TROP MED HYG, V59, P832, DOI 10.4269/ajtmh.1998.59.832; GONZALEZ AE, 1993, B WORLD HEALTH ORGAN, V71, P223; Gonzalez AE, 2001, AM J TROP MED HYG, V65, P15, DOI 10.4269/ajtmh.2001.65.15; Gonzalez LM, 2000, J CLIN MICROBIOL, V38, P737; Gupta RK, 2002, EPILEPSIA, V43, P1502, DOI 10.1046/j.1528-1157.2002.21302.x; HALL A, 1981, PARASITOLOGY, V83, P91, DOI 10.1017/S003118200005006X; Hennenberg R, 1912, HDB NEUROLOGIE, V3, P642; Huerta M, 2001, VACCINE, V20, P262, DOI 10.1016/S0264-410X(01)00249-3; Jimenez I, 1991, ACTA MED COL, V16, P5; Kelley R, 2002, NEUROSURGERY, V50, P757, DOI 10.1097/00006123-200204000-00014; KRAMER J, 1992, J NEUROSURG, V77, P956, DOI 10.3171/jns.1992.77.6.0956; KRAMER LD, 1995, ARCH NEUROL-CHICAGO, V52, P101, DOI 10.1001/archneur.1995.00540250109020; KRAMER LD, 1989, RADIOLOGY, V171, P459, DOI 10.1148/radiology.171.2.2704811; Lightowlers MW, 2000, PARASITOL TODAY, V16, P191, DOI 10.1016/S0169-4758(99)01633-6; Lightowlers MW, 2001, VET PARASITOL, V101, P337, DOI 10.1016/S0304-4017(01)00559-3; LOBATO RD, 1981, J NEUROSURG, V55, P786, DOI 10.3171/jns.1981.55.5.0786; Mac Arthur WP., 1934, T R SOC TROP MED HYG, V27, P343; MARTINEZ HR, 1989, AM J NEURORADIOL, V10, P1011; Martinez MJ, 2000, J MED ENTOMOL, V37, P489, DOI 10.1603/0022-2585-37.4.489; Mayta H, 2000, J CLIN MICROBIOL, V38, P133; MEDINA MT, 1990, ARCH INTERN MED, V150, P325, DOI 10.1001/archinte.150.2.325; Merchant MT, 1998, J PARASITOL, V84, P681, DOI 10.2307/3284569; MOODLEY M, 1989, LANCET, V1, P262, DOI 10.1016/S0140-6736(89)91268-3; Murrell K D, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P377; NAIDOO DV, 1987, S AFR MED J, V72, P837; NASH TE, 1984, NEW ENGL J MED, V311, P1492, DOI 10.1056/NEJM198412063112307; Nash TE, 1999, NEUROLOGY, V53, P777, DOI 10.1212/WNL.53.4.777; Nash TE, 2001, CLIN INFECT DIS, V33, P1649, DOI 10.1086/323670; NEAL JH, 1995, NEUROSURGERY, V36, P1040, DOI 10.1097/00006123-199505000-00026; Nicoletti A, 2002, NEUROLOGY, V58, P1256, DOI 10.1212/WNL.58.8.1256; Ong S, 2002, EMERG INFECT DIS, V8, P608, DOI 10.3201/eid0806.010377; OSUNTOKUN B O, 1982, Neuroepidemiology, V1, P143, DOI 10.1159/000110696; Padma M. V., 1995, National Medical Journal of India, V8, P255; PADMA MV, 1994, NEUROLOGY, V44, P1344, DOI 10.1212/WNL.44.7.1344; Parmar H, 2001, NEURORADIOLOGY, V43, P961, DOI 10.1007/s002340100615; Pawlowski Z., 1972, Advances Parasit, V10, P269, DOI 10.1016/S0065-308X(08)60176-1; PEARSON RD, 1985, ANN INTERN MED, V102, P550, DOI 10.7326/0003-4819-102-4-550; PLACENCIA M, 1992, BRAIN, V115, P783, DOI 10.1093/brain/115.3.783; Plancarte A, 1999, INT J PARASITOL, V29, P643, DOI 10.1016/S0020-7519(99)00021-1; Pretell EJ, 2001, CLIN NEUROL NEUROSUR, V103, P175, DOI 10.1016/S0303-8467(01)00137-8; Proano JV, 2001, NEW ENGL J MED, V345, P879, DOI 10.1056/NEJMoa010212; Proano-Narvaez JV, 2002, J CLIN MICROBIOL, V40, P2115, DOI 10.1128/JCM.40.6.2115-2118.2002; Rabiela-Cervantes M. T., 1982, Cysticercosis: present state of knowledge and perspectives. (Proc. Internat. workshop on cysticercosis, San Miguel de Allende, Guanajuato, Mexico, Nov. 16-18, 1981), P179; Rahalkar MD, 2000, CLIN RADIOL, V55, P668, DOI 10.1053/crad.2000.0494; RANGEL R, 1987, AM J TROP MED HYG, V36, P387, DOI 10.4269/ajtmh.1987.36.387; RICHARDS F, 1985, NEW ENGL J MED, V312, P787, DOI 10.1056/NEJM198503213121211; Robles C, 1979, Salud Publica Mex, V21, P603; Roman G, 2000, B WORLD HEALTH ORGAN, V78, P399; ROSAS N, 1986, ARCH NEUROL-CHICAGO, V43, P353, DOI 10.1001/archneur.1986.00520040039016; Sahai K, 2002, POSTGRAD MED J, V78, P165, DOI 10.1136/pmj.78.917.165; SALINAS R, 2003, COCHRANE DB SYST REV, V2; Sanchez AL, 1999, ANN TROP MED PARASIT, V93, P247, DOI 10.1080/00034989958500; Sarti E, 1997, AM J TROP MED HYG, V56, P127, DOI 10.4269/ajtmh.1997.56.127; Sarti E, 2000, T ROY SOC TROP MED H, V94, P85, DOI 10.1016/S0035-9203(00)90451-6; Schantz P M, 1993, Bull Pan Am Health Organ, V27, P397; SCHANTZ PM, 1994, CLIN INFECT DIS, V18, P879, DOI 10.1093/clinids/18.6.879; SCHANTZ PM, 1992, NEW ENGL J MED, V327, P692, DOI 10.1056/NEJM199209033271004; Schantz PM, 1998, EMERG INFECT DIS, V2, P213, DOI [10.1128/9781555816957.ch12, DOI 10.1128/9781555816957.CH12]; Sheth TN, 1998, AM J NEURORADIOL, V19, P79; Singh G, 1997, ARQ NEURO-PSIQUIAT, V55, P349, DOI 10.1590/S0004-282X1997000300001; SOTELO J, 1990, J NEUROL, V237, P69, DOI 10.1007/BF00314663; SOTELO J, 1988, ARCH NEUROL-CHICAGO, V45, P532, DOI 10.1001/archneur.1988.00520290064015; SOTELO J, 1985, ARCH INTERN MED, V145, P442, DOI 10.1001/archinte.145.3.442; SOTELO J, 1984, NEW ENGL J MED, V310, P1001, DOI 10.1056/NEJM198404193101601; Trelles JO., 1952, REV NEURO-PSIQ-LIMA, V15, P1; TSANG VCW, 1991, VET IMMUNOL IMMUNOP, V29, P69, DOI 10.1016/0165-2427(91)90053-F; TSANG VCW, 1989, J INFECT DIS, V159, P50, DOI 10.1093/infdis/159.1.50; Vasconcelos D, 1990, Gac Med Mex, V126, P401; Verastegui M, 2000, VET PARASITOL, V94, P33, DOI 10.1016/S0304-4017(00)00369-1; Verastegui M, 2002, VET PARASITOL, V108, P49, DOI 10.1016/S0304-4017(02)00182-6; WADIA N, 1988, BRAIN, V111, P597, DOI 10.1093/brain/111.3.597; White AC, 2000, ANNU REV MED, V51, P187, DOI 10.1146/annurev.med.51.1.187; Wilkins PP, 1999, AM J TROP MED HYG, V60, P199, DOI 10.4269/ajtmh.1999.60.199; WILSON M, 1991, J INFECT DIS, V164, P1007, DOI 10.1093/infdis/164.5.1007; Yoshino K, 1933, J MED ASS FORMOSA, V32, p166 ; Zee CS, 2000, NEUROIMAG CLIN N AM, V10, P391	141	460	487	4	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					547	556		10.1016/S0140-6736(03)14117-7	http://dx.doi.org/10.1016/S0140-6736(03)14117-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	712UW	12932389	Green Accepted			2022-12-28	WOS:000184817600023
J	Abeyagunawardena, AS; Goldblatt, D; Andrews, N; Trompeter, RS				Abeyagunawardena, AS; Goldblatt, D; Andrews, N; Trompeter, RS			Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome	LANCET			English	Article								In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.	Great Ormond St Hosp Children NHS Trust, Renal Unit, London WC1N 3JH, England; Inst Child Hlth, Nephrourol Unit, London, England; Inst Child Hlth, Immunobiol Unit, London, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Hlth Protect Agcy, London NW9 5EQ, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London; Health Protection Agency; Public Health England	Trompeter, RS (corresponding author), Great Ormond St Hosp Children NHS Trust, Renal Unit, Great Ormond St, London WC1N 3JH, England.		Goldblatt, David/C-5972-2008	Goldblatt, David/0000-0002-0769-5242				Goldblatt D, 2000, CLIN EXP IMMUNOL, V119, P1, DOI 10.1046/j.1365-2249.2000.01109.x; SCHNAPER HW, 1989, PEDIATR NEPHROL, V3, P101, DOI 10.1007/BF00859637; TROMPETER RS, 1985, LANCET, V1, P368; Yap HK, 1999, J AM SOC NEPHROL, V10, P529	4	39	43	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 9	2003	362	9382					449	450		10.1016/S0140-6736(03)14072-X	http://dx.doi.org/10.1016/S0140-6736(03)14072-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	709XD	12927434				2022-12-28	WOS:000184651100014
J	Stuart, JM; Segal, E; Koller, D; Kim, SK				Stuart, JM; Segal, E; Koller, D; Kim, SK			A gene-coexpression network for global discovery of conserved genetic modules	SCIENCE			English	Article							EXPRESSION; TOOL	To elucidate gene function on a global scale, we identified pairs of genes that are coexpressed over 3182 DNA microarrays from humans,flies, worms, and yeast. We found 22,163 such coexpression relationships, each of which has been conserved across evolution. This conservation implies that the coexpression of these gene pairs confers a selective advantage and therefore that these genes are functionally related. Many of these relationships provide strong evidence for the involvement of new genes in core biological functions such as the cell cycle, secretion, and protein expression. We experimentally confirmed the predictions implied by some of these links and identified cell proliferation functions for several genes. By assembling these links into a gene-coexpression network, we found several components that were animal-specific as well as interrelationships between newly evolved and ancient modules.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Med Informat, Stanford, CA 94305 USA; Stanford Univ, Dept Comp Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.	koller@cs.stanford.edu; kim@cmgm.stanford.edu	Rosa, Bruce/F-6393-2010; Segal, Eran/AAF-4855-2019	Stuart, Joshua/0000-0002-2171-565X				Alter O, 2003, P NATL ACAD SCI USA, V100, P3351, DOI 10.1073/pnas.0530258100; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Axtell RL, 2001, SCIENCE, V293, P1818, DOI 10.1126/science.1062081; Davidson GS, 1998, J INTELL INF SYST, V11, P259, DOI 10.1023/A:1008690008856; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gabaix X, 2003, NATURE, V423, P267, DOI 10.1038/nature01624; Garlaschelli D, 2003, NATURE, V423, P165, DOI 10.1038/nature01604; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gomez SM, 2001, GENETICS, V159, P1291; Grinstead C. M., 1997, INTRO PROBABILITY; Guarente L, 2000, GENE DEV, V14, P1021; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Jiang M, 2001, P NATL ACAD SCI USA, V98, P218, DOI 10.1073/pnas.011520898; Kim SK, 2001, SCIENCE, V293, P2087, DOI 10.1126/science.1061603; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; SEGAL E, 2003, NATURE GENET; SIEGRIST K, 1997, VIRUTAL LAB PROBABIL; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Teichmann SA, 2002, TRENDS BIOTECHNOL, V20, P407, DOI 10.1016/S0167-7799(02)02032-2; van Noort V, 2003, TRENDS GENET, V19, P238, DOI 10.1016/S0168-9525(03)00056-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Zalevsky J, 1999, GENETICS, V153, P1271; ZIPF GK, 1949, HUMAN BEHAV PRINCIP	30	1507	1539	5	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 10	2003	302	5643					249	255		10.1126/science.1087447	http://dx.doi.org/10.1126/science.1087447			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	730HT	12934013				2022-12-28	WOS:000185825900032
J	Polydefkis, M; Griffin, JW; McArthur, J				Polydefkis, M; Griffin, JW; McArthur, J			New insights into diabetic polyneuropathy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPAIRED GLUCOSE-TOLERANCE; NERVE-FIBER DENSITY; DEGENERATIVE COMPLICATIONS; CUTANEOUS INNERVATION; CARDIOVASCULAR-DISEASE; SENSORY NEUROPATHIES; MEISSNERS CORPUSCLES; RISK-FACTOR; CAPSAICIN; MELLITUS	Patients with complaints of numbness, tingling, and dysesthesias in the toes and feet are frequently referred to neurologists. Often, the only objective evidence for peripheral nerve dysfunction in these patients is limited to small-caliber sensory nerve fibers. On examination these patients may have reduced distal pinprick sensation, and distal leg skin biopsies show loss of small-caliber nerve fibers. Studies focusing on small-caliber nerve fibers have led to a growing impression that neuropathy can be associated with early diabetes or impaired glucose tolerance (IGT). Often, neuropathy can be the presenting symptom of either diabetes or IGT. Furthermore, the oral glucose tolerance test appears to be a more sensitive measure of glucose dys-metabolism in these patients than levels of fasting blood glucose or glycated hemoglobin. Patients with IGT-associated neuropathy may represent an attractive target population for future regenerative studies given that their neuropathy is less severe and presumably more easily reversed than neuropathy occurring in patients with diabetes. Historically, small-caliber fibers have not been extensively evaluated due to a lack of objective measures. Several measures to evaluate these fibers are emerging, including skin biopsy with visualization of epidermal nerve fibers. The accessibility of epidermal nerve fibers makes them an attractive target for nerve injury models, which have potential for development as novel outcome measures. Such approaches may address some of the challenges of past diabetic polyneuropathy trials.	Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Neurosci, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Epidemiol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Polydefkis, M (corresponding author), Johns Hopkins Univ Hosp, Dept Neurol, 600 N Wolfe St, Baltimore, MD 21287 USA.	mpolyde@jhmi.edu			NCRR NIH HHS [M01-RR00052] Funding Source: Medline; NINDS NIH HHS [NS41374] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS041374] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERS JW, 1995, ANN NEUROL, V38, P478; American Diabetes Association, 2001, Diabetes Care, V24, P775; American Diabetes Association, 2002, DIABETES CARE S1, V25, pS33, DOI DOI 10.2337/DIACARE.25.2007.S33; Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; Balkau B, 1998, DIABETES CARE, V21, P360, DOI 10.2337/diacare.21.3.360; Barrett-Connor E, 1998, DIABETES CARE, V21, P1236, DOI 10.2337/diacare.21.8.1236; BOLTON CF, 1966, NEUROLOGY, V16, P1; Caro JJ, 2002, DIABETES CARE, V25, P476, DOI 10.2337/diacare.25.3.476; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Clark N, 2003, DIABETES CARE, V26, P3333; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; DALSGAARD CJ, 1989, HISTOCHEMISTRY, V92, P385, DOI 10.1007/BF00492495; de Vegt F, 1999, DIABETOLOGIA, V42, P926, DOI 10.1007/s001250051249; DYCK PJ, 1966, NEUROLOGY, V16, P10, DOI 10.1212/WNL.16.1.10; DYCK PJ, 1993, NEUROLOGY, V43, P817, DOI 10.1212/WNL.43.4.817; Fagot-Campagna A, 2000, J PEDIATR ENDOCR MET, V13, P1395; Fisman EZ, 2001, AM HEART J, V141, P485, DOI 10.1067/mhj.2001.113219; Gordis L, 2000, EPIDEMIOLOGY, P184; Griffin JW, 2001, CURR OPIN NEUROL, V14, P655, DOI 10.1097/00019052-200110000-00016; Hanefeld M, 1999, ATHEROSCLEROSIS, V144, P229, DOI 10.1016/S0021-9150(99)00059-3; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; HAUPT WF, 1993, J HAND SURG-BRIT EUR, V18B, P471, DOI 10.1016/0266-7681(93)90149-A; Herrmann DN, 1999, NEUROLOGY, V53, P1634, DOI 10.1212/WNL.53.8.1634; Holland NR, 1998, ANN NEUROL, V44, P47, DOI 10.1002/ana.410440111; Holland NR, 1997, NEUROLOGY, V48, P708, DOI 10.1212/WNL.48.3.708; JACKSON CA, 1992, DIABETES RES CLIN PR, V17, P111, DOI 10.1016/0168-8227(92)90156-L; Kennedy JM, 2000, BRAIN, V123, P2118, DOI 10.1093/brain/123.10.2118; Kennedy W R, 2000, J Clin Neuromuscul Dis, V1, P196, DOI 10.1097/00131402-200006000-00008; Kennedy WR, 1996, NEUROLOGY, V47, P1042, DOI 10.1212/WNL.47.4.1042; KENNEDY WR, 1993, J NEUROL SCI, V115, P184, DOI 10.1016/0022-510X(93)90223-L; Kennedy WR, 1996, SEMIN NEUROL, V16, P163, DOI 10.1055/s-2008-1040972; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOZAK GP, 1984, MANAGEMENT DIABETIC, P1; Lauria G, 1999, J NEUROL SCI, V164, P172, DOI 10.1016/S0022-510X(99)00063-5; LOW P, 2001, PER NERV SOC M 2001; McArthur JC, 1998, ARCH NEUROL-CHICAGO, V55, P1513, DOI 10.1001/archneur.55.12.1513; MCCARTHY BG, 1995, NEUROLOGY, V45, P1848, DOI 10.1212/WNL.45.10.1848; Meigs JB, 2002, DIABETES CARE, V25, P1845, DOI 10.2337/diacare.25.10.1845; Nolano M, 1999, PAIN, V81, P135, DOI 10.1016/S0304-3959(99)00007-X; Novella SP, 2001, MUSCLE NERVE, V24, P1229, DOI 10.1002/mus.1137; Ozkul Y, 2002, ACTA NEUROL SCAND, V106, P168, DOI 10.1034/j.1600-0404.2002.01320.x; Periquet MI, 1999, NEUROLOGY, V53, P1641, DOI 10.1212/WNL.53.8.1641; PFEIFER MA, 1995, DIABETES, V44, P1355, DOI 10.2337/diabetes.44.12.1355; PIRART J, 1977, DIABETES METAB, V3, P97; PIRART J, 1977, DIABETES METAB, V3, P173; PIRART J, 1977, DIABETES METAB, V3, P245; Polydefkis M, 2002, NEUROLOGY, V58, P115, DOI 10.1212/WNL.58.1.115; POLYDEFKIS M, 2003, J PERIPHER NERV S S1, V8, P1; Polydefkis Michael, 2003, Neurology, V60, pA502; Rajan B, 2003, J COMP NEUROL, V457, P24, DOI 10.1002/cne.10460; Russell JW, 2001, MUSCLE NERVE, V24, P1109, DOI 10.1002/mus.1122; Simone DA, 1998, J NEUROSCI, V18, P8947; Singleton JR, 2001, DIABETES CARE, V24, P1448, DOI 10.2337/diacare.24.8.1448; Singleton JR, 2001, MUSCLE NERVE, V24, P1225, DOI 10.1002/mus.1136; Smith AG, 2001, NEUROLOGY, V57, P1701, DOI 10.1212/WNL.57.9.1701; Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Tuomilehto J, 2002, DIABETES CARE, V25, P1880, DOI 10.2337/diacare.25.10.1880; WANG LX, 1990, CELL TISSUE RES, V261, P25, DOI 10.1007/BF00329435; WOOD JN, 1988, J NEUROSCI, V8, P3208	60	81	82	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 10	2003	290	10					1371	1376		10.1001/jama.290.10.1371	http://dx.doi.org/10.1001/jama.290.10.1371			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	719DP	12966130				2022-12-28	WOS:000185188600031
J	Burns, SJ; Fleitmann, D; Matter, A; Kramers, J; Al-Subbary, AA				Burns, SJ; Fleitmann, D; Matter, A; Kramers, J; Al-Subbary, AA			Indian Ocean climate and an absolute chronology over Dansgaard/Oeschger events 9 to 13	SCIENCE			English	Article							ICE-CORE; SUMMER MONSOON; OXYGEN-ISOTOPE; GREENLAND; OSCILLATIONS; RECORD; GISP2; SPELEOTHEM; STALAGMITE; EUROPE	Oxygen-isotope ratios of a stalagmite from Socotra Island in the Indian Ocean provide a record of changes in monsoon precipitation and climate for the time period from 42 to 55 thousand years before the present. The pattern of precipitation bears a striking resemblance to the oxygen-isotope record from Greenland ice cores, with increased tropical precipitation associated with warm periods in the high northern latitudes. The largest change, at the onset of interstadial 12, occurred very rapidly, in about 25 years. The chronology of the events found in our record requires a reevaluation of previously published time scales for climate events during this period.	Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA; Univ Bern, Inst Geol Sci, Bern, Switzerland; Sanaa Univ, Fac Sci, Dept Earth & Environm Sci, Sanaa, Yemen	University of Massachusetts System; University of Massachusetts Amherst; University of Bern	Burns, SJ (corresponding author), Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA.	sburns@geo.umass.edu	Burns, Stephen/H-9419-2013	Al Subbary, Abdulkarim/0000-0001-5031-7880				Allen JRM, 1999, NATURE, V400, P740, DOI 10.1038/23432; Altabet MA, 2002, NATURE, V415, P159, DOI 10.1038/415159a; Bamzai AS, 1999, J CLIMATE, V12, P3117, DOI 10.1175/1520-0442(1999)012<3117:RBESCS>2.0.CO;2; Bard E, 1997, NATURE, V385, P707, DOI 10.1038/385707a0; Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; Burns SJ, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD001281; Burns SJ, 2001, GEOLOGY, V29, P623, DOI 10.1130/0091-7613(2001)029<0623:SEFOFC>2.0.CO;2; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; DANSGAARD W, 1964, TELLUS, V16, P436; Fleitmann D, 2003, SCIENCE, V300, P1737, DOI 10.1126/science.1083130; Friedman I., 1977, COMPILATION STABLE I, P1; Genty D, 2003, NATURE, V421, P833, DOI 10.1038/nature01391; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HASTENRATH S, 1985, CLIMATE CIRCULATION; Johnsen SJ, 2001, J QUATERNARY SCI, V16, P299, DOI 10.1002/jqs.622; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Lang C, 1999, SCIENCE, V286, P934, DOI 10.1126/science.286.5441.934; MEESE DA, 1994, SCIENCE, V266, P1680, DOI 10.1126/science.266.5191.1680; Mies B., 1998, P 1 INT S SOQ ISL PR, V1, P35; Peterson LC, 2000, SCIENCE, V290, P1947, DOI 10.1126/science.290.5498.1947; Robock A, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003245; ROZANSKI K, 1993, CLIMATE CHANGE CONTI; Schulz H, 1998, NATURE, V393, P54, DOI 10.1038/31750; Severinghaus JP, 1999, SCIENCE, V286, P930, DOI 10.1126/science.286.5441.930; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618; Webster PJ, 1998, J GEOPHYS RES-OCEANS, V103, P14451, DOI 10.1029/97JC02719; Yiou F, 1997, J GEOPHYS RES-OCEANS, V102, P26783, DOI 10.1029/97JC01265	28	200	221	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2003	301	5638					1365	1367		10.1126/science.1086227	http://dx.doi.org/10.1126/science.1086227			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958357				2022-12-28	WOS:000185116400037
J	Yin, Y; Manoury, B; Fahraeus, R				Yin, Y; Manoury, B; Fahraeus, R			Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1	SCIENCE			English	Article							CLASS-I MOLECULES; NUCLEAR ANTIGEN-1; PEPTIDE; DEGRADATION; TRANSLATION; INITIATION; PROTEINS; DRIPS; CELLS	The glycine-alanine repeat domain (GAr) of Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1) prevents major histocompatibility complex (MHC) class I restricted presentation of EBNA1 epitopes to cytotoxic T cells. This effect has previously been attributed to the ability of GAr to inhibit its own proteasomal degradation. Here we show, both in vitro and in vivo, that GAr also inhibits messenger RNA translation of EBNA1 in cis and that this effect can be distinguished from its effect on proteasomal degradation. Hence, inhibition of messenger RNA translation, but not protein degradation, is essential to prevent antigen presentation on MHC class I molecules. Thus, by minimizing translation of the EBNA1 transcript, cells expressing EBNA1 avoid cytotoxic T cell recognition. At the same time, blocking degradation maintains the EBNA1 expression level.	Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland; Univ Dundee, Fac Life Sci, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Fahraeus, R (corresponding author), Univ Dundee, Fac Life Sci, Div Mol Physiol, Dundee DD1 5EH, Scotland.		fahraeus, robin/K-8726-2014	Manoury, Benedicte/0000-0001-7784-3389; , robin/0000-0003-0402-8492				Blake N, 1997, IMMUNITY, V7, P791, DOI 10.1016/S1074-7613(00)80397-0; Blake N, 2000, J IMMUNOL, V165, P7078, DOI 10.4049/jimmunol.165.12.7078; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; DILLNER J, 1984, P NATL ACAD SCI-BIOL, V81, P4652, DOI 10.1073/pnas.81.15.4652; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6021; Khanna R, 1995, VIROLOGY, V214, P633, DOI 10.1006/viro.1995.0076; Levitskaya J, 1997, P NATL ACAD SCI USA, V94, P12616, DOI 10.1073/pnas.94.23.12616; LEVITSKAYA J, 1995, NATURE, V375, P685, DOI 10.1038/375685a0; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; PEERY T, 2000, TRANSLATIONAL CONTRO; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sharipo A, 1998, NAT MED, V4, P939, DOI 10.1038/nm0898-939; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Wu H, 2002, J VIROL, V76, P2480, DOI 10.1128/JVI.76.5.2480-2490.2002; Yewdell JW, 2002, NAT IMMUNOL, V3, P1019, DOI 10.1038/ni1102-1019; Yewdell JW, 1996, J IMMUNOL, V157, P1823; Yewdell JW, 2001, J CELL SCI, V114, P845; Yin Y.G., UNPUB	23	203	219	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 5	2003	301	5638					1371	1374		10.1126/science.1088902	http://dx.doi.org/10.1126/science.1088902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717XQ	12958359				2022-12-28	WOS:000185116400039
J	Batterham, RL; Cohen, MA; Ellis, SM; Le Roux, CW; Withers, DJ; Frost, GS; Ghatei, MA; Bloom, SR				Batterham, RL; Cohen, MA; Ellis, SM; Le Roux, CW; Withers, DJ; Frost, GS; Ghatei, MA; Bloom, SR			Inhibition of food intake in obese subjects by peptide YY3-36	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA GHRELIN LEVELS; WEIGHT-LOSS; GASTRIC BYPASS; GUT HORMONE; YY PYY; RELEASE; APPETITE; HUMANS; LEPTIN; INDEX	Background: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. Methods: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. Results: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r=-0.84, P<0.001). Conclusions: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.	Univ London Imperial Coll Sci & Technol, Fac Med, Dept Metab Med, London W12 0NN, England	Imperial College London	Batterham, RL (corresponding author), Univ London Imperial Coll Sci & Technol, Fac Med, Dept Metab Med, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.		Withers, Dominic J/D-7671-2014	Withers, Dominic J/0000-0002-8009-7521; Batterham, Rachel/0000-0002-5477-8585				ADRIAN TE, 1987, SURGERY, V101, P715; ADRIAN TE, 1976, GUT, V17, P940, DOI 10.1136/gut.17.12.940; ADRIAN TE, 1985, GASTROENTEROLOGY, V89, P1070, DOI 10.1016/0016-5085(85)90211-2; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; BLACKBURN G, 1995, OBES RES, V3, pS211, DOI 10.1002/j.1550-8528.1995.tb00466.x; Chicurel M, 2000, NATURE, V404, P538, DOI 10.1038/35007253; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; FUESSL HS, 1988, KLIN WOCHENSCHR, V66, P985, DOI 10.1007/BF01738114; GARNER DM, 1979, PSYCHOL MED, V9, P273, DOI 10.1017/S0033291700030762; Imamura M, 2002, PEPTIDES, V23, P403, DOI 10.1016/S0196-9781(01)00618-0; KREYMANN B, 1987, LANCET, V2, P1300; Mun EC, 2001, GASTROENTEROLOGY, V120, P669, DOI 10.1053/gast.2001.22430; Naslund E, 1997, INT J OBESITY, V21, P387, DOI 10.1038/sj.ijo.0800418; Peeters A, 2003, ANN INTERN MED, V138, P24, DOI 10.7326/0003-4819-138-1-200301070-00008; RABEN A, 1995, BRIT J NUTR, V74, P283; RABEN A, 1995, BRIT J NUTR, V73, P517, DOI 10.1079/BJN19950056; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; SAVAGE AP, 1987, GUT, V28, P166, DOI 10.1136/gut.28.2.166; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 2002, NATURE, V418, P595, DOI 10.1038/418595a; TROSTLER N, 1995, OBES SURG, V5, P39, DOI 10.1381/096089295765558141; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; VANSTRIEN T, 1986, INT J OBESITY, V10, P29; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540	27	1156	1241	1	63	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					941	948		10.1056/NEJMoa030204	http://dx.doi.org/10.1056/NEJMoa030204			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954742	Green Published			2022-12-28	WOS:000185081400005
J	Iglehart, JK				Iglehart, JK			Prescription-drug coverage for Medicare beneficiaries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	4	4	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 4	2003	349	10					923	925		10.1056/NEJMp038139	http://dx.doi.org/10.1056/NEJMp038139			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717HJ	12954738				2022-12-28	WOS:000185081400001
J	Levine, SA; Boal, J; Boling, PA				Levine, SA; Boal, J; Boling, PA			Home care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEALTH-CARE; ELDERLY PEOPLE; COST-EFFECTIVENESS; COMMUNITY; TRIAL; INTERVENTION; ADMISSION; OUTCOMES; DEMENTIA; PATIENT		Boston Univ, Sch Med, Dept Med, Geriatr Serv,Boston Med Ctr, Boston, MA 02118 USA; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA	Boston Medical Center; Boston University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University	Levine, SA (corresponding author), Boston Univ, Sch Med, Dept Med, Geriatr Serv,Boston Med Ctr, 88 E Newton St,Robinson 2, Boston, MA 02118 USA.			Levine, Sharon/0000-0002-7208-6021				*AM MED ASS, 1998, MED MAN HOM CAR PAT; Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; BOLING PA, 1997, PHYSICIANS ROLE HOME, P107; BROOKFIELD SD, 1991, UNDERSTANDING FACILI; Chen Q, 2000, INQUIRY-J HEALTH CAR, V37, P359; Cotterill PG, 2002, HEALTH CARE FINANC R, V24, P1; Donelan K, 2002, HEALTH AFFAIR, V21, P222, DOI 10.1377/hlthaff.21.4.222; Eggert G M, 1988, Health Care Financ Rev, VSpec No, P57; GALLAGHER P, 2003, MEDICARE RBRVS PHYSI; HALEY WE, 1987, J AM GERIATR SOC, V35, P405, DOI 10.1111/j.1532-5415.1987.tb04661.x; Kassner E, 1998, MIDLIFE OLDER AM DIS; LeBlanc AJ, 2001, HEALTH CARE FINANC R, V22, P155; LEVINE SA, 2003, GERIATRIC MED EVIDEN; *LLC NAT HLTH INF, 2003, CAP RAT DAT, V4; McCall N, 2002, HEALTH CARE FINANC R, V24, P57; *MED PAYM ADV COMM, 2003, C VAR INN MED WASH D, P71; *MED PAYM ADV COMM, 2001, C MED RUR AM WASH DC, P105; Meredith S, 2002, J AM GERIATR SOC, V50, P1484, DOI 10.1046/j.1532-5415.2002.50402.x; Mueser KT, 1998, SCHIZOPHRENIA BULL, V24, P37, DOI 10.1093/oxfordjournals.schbul.a033314; Murkofsky RL, 2003, JAMA-J AM MED ASSOC, V289, P2841, DOI 10.1001/jama.289.21.2841; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; RAMSDELL JW, 1989, J AM GERIATR SOC, V37, P17, DOI 10.1111/j.1532-5415.1989.tb01563.x; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Rizzo JA, 1996, MED CARE, V34, P954, DOI 10.1097/00005650-199609000-00007; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P187; Shaughnessy PW, 2002, J AM GERIATR SOC, V50, P1354, DOI 10.1046/j.1532-5415.2002.50356.x; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VANDERWALDE L, HLTH CARE IND MARKET; WEISSERT WG, 1985, HEALTH SERV RES, V20, P423; Welch HG, 1996, NEW ENGL J MED, V335, P324, DOI 10.1056/NEJM199608013350506; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090; Yang JC, 2001, J GEN INTERN MED, V16, P112	35	51	51	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1203	1207		10.1001/jama.290.9.1203	http://dx.doi.org/10.1001/jama.290.9.1203			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	717LK	12953004				2022-12-28	WOS:000185090400017
J	Stillman, MJ				Stillman, MJ			A difference of degrees	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1135	1136		10.1001/jama.290.9.1135	http://dx.doi.org/10.1001/jama.290.9.1135			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12952989	Bronze			2022-12-28	WOS:000185090400001
J	Wusthoff, C				Wusthoff, C			The dilemma of confidentiality in Huntington disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISCLOSURE		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wusthoff, C (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.			Wusthoff, Courtney/0000-0002-1882-5567				ADAMS J, 1990, J MED ETHICS, V16, P195; BALL D, 1993, J MED GENET, V30, P1028; Bernstein T, 1994, RADON RENTAL HOUSING; BLOCH M, 1993, AM J MED GENET, V47, P368, DOI 10.1002/ajmg.1320470314; Evers-Kiebooms G, 1998, PATIENT EDUC COUNS, V35, P15, DOI 10.1016/S0738-3991(98)00086-X; Hakimian R, 2000, GENET TEST, V4, P359, DOI 10.1089/109065700750065090; Knoppers BM, 1998, AM J HUM GENET, V62, P474; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, SCREEN COUNS GEN CON	8	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2003	290	9					1219	1220		10.1001/jama.290.9.1219	http://dx.doi.org/10.1001/jama.290.9.1219			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	717LK	12953009				2022-12-28	WOS:000185090400022
J	Murray, MD; Callahan, CM				Murray, MD; Callahan, CM			Improving medication use for older adults: An integrated research agenda	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	8th Regenstrief Conference	SEP 30-OCT 02, 2002	MARSHALL, IN				CONVERTING ENZYME-INHIBITOR; ADVERSE DRUG EVENTS; ELDERLY PATIENTS; PRIMARY-CARE; PRESCRIPTION COVERAGE; PROPENSITY SCORES; HEART-FAILURE; QUALITY; HEALTH; PREVENTABILITY	Effective health care is a core determinant of successful aging, and medications are one of the most important therapeutic tools of health care providers. Most older adults use at least one prescription drug. Costs for these drugs are a substantial out-of-pocket expense for Medicare beneficiaries, and low-income older adults must weigh these costs against those of other basic needs. Although medications bring welcome relief to millions of elderly persons with age-related conditions, adverse drug events are an important cause of illness and death in these patients. Thus, the appropriate, cost-effective use of medication is central to successful aging. Despite increasing attention to geriatric pharmacotherapy, there is an enormous need for additional research to improve the use of medications among older adults. The necessary research agenda encompasses much more than just the discovery of new drugs; better use of the current pharmacopeia has great potential to improve the lives of older adults. We review four domains of pharmaceutical research: drug discovery and delivery, drug efficacy and safety, pharmacoepidemiology and drug policy, and improved access to and use of drugs. These domains encompass both the pre- and postmarketing phases of drug research. Premarketing research currently has greater magnitude and a better infrastructure than postmarketing research, yet issues arising in the two phases of research are equally important to the health and safety of older adults. A national, federally supported pharmaceutical database could greatly enhance the infrastructure of postmarketing research. However, many major improvements in medication use among older adults will also depend on closing the gap between knowledge and practice and increasing the ability of older adults to manage their medications.	Purdue Univ, Sch Med, Regenstrief Inst, Indianapolis, IN 46202 USA; Indiana Univ, Ctr Aging Res, Indianapolis, IN 46204 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Purdue University System; Purdue University; Indiana University System; Indiana University-Purdue University Indianapolis	Murray, MD (corresponding author), Purdue Univ, Sch Med, Regenstrief Inst, 1050 Wishard Blvd RG-6, Indianapolis, IN 46202 USA.	mmurray@regenstrief.org			NHLBI NIH HHS [R01 HL69399] Funding Source: Medline; NIA NIH HHS [R01 AG07631, R01 AG19105, R01 AG007631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019105, R01AG007631] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avorn J, 2001, JAMA-J AM MED ASSOC, V286, P2866, DOI 10.1001/jama.286.22.2866; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Bell RA, 2002, J GEN INTERN MED, V17, P817, DOI 10.1046/j.1525-1497.2002.10319.x; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; Bikowski RM, 2001, J AM GERIATR SOC, V49, P1353, DOI 10.1046/j.1532-5415.2001.49265.x; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodkin JA, 2002, AM J PSYCHIAT, V159, P1869, DOI 10.1176/appi.ajp.159.11.1869; Bull SA, 2002, JAMA-J AM MED ASSOC, V288, P1403, DOI 10.1001/jama.288.11.1403; Chertow GM, 2001, JAMA-J AM MED ASSOC, V286, P2839, DOI 10.1001/jama.286.22.2839; DARNELL JC, 1986, J AM GERIATR SOC, V34, P1; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Gattis WA, 1998, AM HEART J, V136, P43, DOI 10.1016/S0002-8703(98)70180-2; Gattis WA, 1999, ARCH INTERN MED, V159, P1939, DOI 10.1001/archinte.159.16.1939; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hwang W, 2001, HEALTH AFFAIR, V20, P267, DOI 10.1377/hlthaff.20.6.267; Ihara E, 2002, CHALLENGES 21 CENTUR, P1; KASSBARTELMES B, 2002, RES ACTION, P1; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Knickman JR, 2002, HEALTH SERV RES, V37, P849, DOI 10.1034/j.1600-0560.2002.56.x; Knight EL, 2001, ANN INTERN MED, V135, P703, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00009; KRELING D, 2000, PRESCRIPTION DRUG TR, P1; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Lemaitre RN, 2002, ARCH INTERN MED, V162, P1395, DOI 10.1001/archinte.162.12.1395; McCormick D, 2001, ARCH INTERN MED, V161, P2458, DOI 10.1001/archinte.161.20.2458; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; MORROW D, 1991, J GERONTOL, V46, pP378, DOI 10.1093/geronj/46.6.P378; MURRAY MD, 1986, DRUG INTEL CLIN PHAR, V20, P146, DOI 10.1177/106002808602000210; Murray MD, 2000, AM J HEALTH-SYST PH, V57, P565, DOI 10.1093/ajhp/57.6.565; *NAT ASS CHAIN DRU, IND FACTS AT A GLANC; Perkins SM, 2000, PHARMACOEPIDEM DR S, V9, P93, DOI 10.1002/(SICI)1099-1557(200003/04)9:2<93::AID-PDS474>3.0.CO;2-I; Phelan EA, 2002, J AM GERIATR SOC, V50, P1519, DOI 10.1046/j.1532-5415.2002.50407.x; *PHRMA RES DEV, DRAM GROWTH RES DEV; Rollman BL, 1999, INT J PSYCHIAT MED, V29, P267, DOI 10.2190/7CCY-D8JB-53XK-PPTK; Rothschild JM, 2000, ARCH INTERN MED, V160, P2717, DOI 10.1001/archinte.160.18.2717; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Soumerai SB, 2001, J GEN INTERN MED, V16, P864, DOI 10.1046/j.1525-1497.2001.11015.x; Steinman MA, 2001, J GEN INTERN MED, V16, P793, DOI 10.1046/j.1525-1497.2001.10412.x; Strom BL, 2000, PHARMACOEPIDEMIOLOGY; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Tu K, 2002, AM J MED, V113, P52, DOI 10.1016/S0002-9343(02)01144-0; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823; ZIMMER AW, 1985, ANN INTERN MED, V103, P276, DOI 10.7326/0003-4819-103-2-276	51	58	60	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 2	2003	139	5	2	S			425	429		10.7326/0003-4819-139-5_Part_2-200309021-00009	http://dx.doi.org/10.7326/0003-4819-139-5_Part_2-200309021-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	718FE	12965970				2022-12-28	WOS:000185133800009
J	Coleman, DA; Fernsler, J; Chattham, N; Nakata, M; Takanishi, Y; Korblova, E; Link, DR; Shao, RF; Jang, WG; Maclennan, JE; Mondainn-Monval, O; Boyer, C; Weissflog, W; Pelzl, G; Chien, LC; Zasadzinski, J; Watanabe, J; Walba, DM; Takezoe, H; Clark, NA				Coleman, DA; Fernsler, J; Chattham, N; Nakata, M; Takanishi, Y; Korblova, E; Link, DR; Shao, RF; Jang, WG; Maclennan, JE; Mondainn-Monval, O; Boyer, C; Weissflog, W; Pelzl, G; Chien, LC; Zasadzinski, J; Watanabe, J; Walba, DM; Takezoe, H; Clark, NA			Polarization-modulated smectic liquid crystal phases	SCIENCE			English	Article							CHIRAL-SYMMETRY-BREAKING; SYNCHROTRON X-RAY; HELICAL SUPERSTRUCTURES; LAYER STRUCTURE; TRANSITIONS; FIELD; INSTABILITY; SCATTERING; MESOPHASE; DOMAINS	Any polar-ordered material with a spatially uniform polarization field is internally frustrated: The symmetry-required local preference for polarization is to be nonuniform, i.e., to be locally bouquet-like or "splayed." However, it is impossible to achieve splay of a preferred sign everywhere in space unless appropriate defects are introduced into the field. Typically, in materials like ferroelectric crystals or liquid crystals, such defects are not thermally stable, so that the local preference is globally frustrated and the polarization field remains uniform. Here, we report a class of fluid polar smectic liquid crystals in which local splay prevails in the form of periodic supermolecular-scale polarization modulation stripes coupled to layer undulation waves. The polar domains are locally chiral, and organized into patterns of alternating handedness and polarity. The fluid-layer undulations enable an extraordinary menagerie of. lament and planar structures that identify such phases.	Univ Colorado, Dept Phys, Boulder, CO 80309 USA; Univ Colorado, Ferroelect Liquid Crystal Mat Res Ctr, Boulder, CO 80309 USA; Tokyo Inst Technol, Dept Organ & Polymer Mat, Meguro Ku, Tokyo 1528552, Japan; Univ Colorado, Dept Chem, Boulder, CO 80309 USA; Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; CNRS, Ctr Rech Paul Pascal, F-33600 Pessac, France; Univ Halle Wittenberg, Inst Phys Chem, D-06108 Halle An Der Saale, Germany; Kent State Univ, Dept Chem Phys, Inst Liquid Crystal, Kent, OH 44242 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Tokyo Institute of Technology; University of Colorado System; University of Colorado Boulder; University of California System; University of California Santa Barbara; Centre de Recherche Paul Pascal; Centre National de la Recherche Scientifique (CNRS); Martin Luther University Halle Wittenberg; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Clark, NA (corresponding author), Univ Colorado, Dept Phys, Boulder, CO 80309 USA.	noel.clark@colorado.edu	Korblova, Eva/AAC-3502-2021; Clark, Noel A./E-9011-2010; Boyer, Cyrille A/A-5436-2009; Maclennan, Joseph E/A-9836-2013; Takanishi, Yoichi/Z-1287-2019; Walba, David/F-7284-2013; Clark, Noel A/AAP-9116-2020	Korblova, Eva/0000-0002-3818-4373; Clark, Noel A./0000-0001-9301-5540; Boyer, Cyrille A/0000-0002-4564-4702; Maclennan, Joseph E/0000-0002-3587-554X; Takanishi, Yoichi/0000-0003-4976-0652; 				AKUTAGAWA T, 1994, LIQ CRYST, V17, P659, DOI 10.1080/02678299408037337; Bedel JP, 2000, LIQ CRYST, V27, P1411, DOI 10.1080/026782900750018555; BLATTER G, 1994, REV MOD PHYS, V66, P1125, DOI 10.1103/RevModPhys.66.1125; Brunet M, 2002, EUR PHYS J E, V7, P5, DOI [10.1007/s10189-002-8211-4, 10.1140/epjc/i200101038]; CHEN CM, 1995, PHYS REV E, V51, P504, DOI 10.1103/PhysRevE.51.504; Choi SW, 1999, MOL CRYST LIQ CRYS A, V328, P185, DOI 10.1080/10587259908026058; CLARK N, 1998, 17 INT LIQ CRYST C I; CLARK NA, 1973, APPL PHYS LETT, V22, P493, DOI 10.1063/1.1654481; COLEMAN DA, 2003, THESIS U COLORADO; Crooker PP, 2001, PART ORDER, P186; Eremin A, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.021702; Eremin A, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.020702; GULIKKRZYWICKI T, 1997, J MICROSC-OXFORD, V112, P103; HANDSCHY MA, 1983, PHYS REV LETT, V51, P471, DOI 10.1103/PhysRevLett.51.471; Hauser A, 2000, LIQ CRYST, V27, P629, DOI 10.1080/026782900202471; HINSHAW GA, 1988, PHYS REV LETT, V60, P1864, DOI 10.1103/PhysRevLett.60.1864; HINSHAW GA, 1989, PHYS REV A, V39, P5914, DOI 10.1103/PhysRevA.39.5914; Jakli A, 2000, LIQ CRYST, V27, P1405, DOI 10.1080/026782900750018546; Jakli A, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051702; Jakli A, 2001, PHYS REV LETT, V86, P5715, DOI 10.1103/PhysRevLett.86.5715; Kamien RD, 2001, J PHYS-CONDENS MAT, V13, pR1, DOI 10.1088/0953-8984/13/3/201; Kraus I, 1999, PHYS REV LETT, V82, P3815, DOI 10.1103/PhysRevLett.82.3815; LANGER SA, 1986, PHYS REV A, V34, P5035, DOI 10.1103/PhysRevA.34.5035; Lee CK, 1999, LIQ CRYST, V26, P609, DOI 10.1080/026782999205074; Lee CK, 2001, LIQ CRYST, V28, P1293, DOI 10.1080/0267890110058623; Link DR, 1997, SCIENCE, V278, P1924, DOI 10.1126/science.278.5345.1924; LINK DR, 1999, B AM PHYS SOC, V44, P1043; MCMILLAN WL, 1971, PHYS REV A-GEN PHYS, V4, P1238, DOI 10.1103/PhysRevA.4.1238; Meyer RB, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.061704; MEYER RB, 1973, SOLID STATE COMMUN, V13, P989, DOI 10.1016/0038-1098(73)90415-8; Nakata M, 2001, LIQ CRYST, V28, P1301, DOI 10.1080/0267890110048741; NAKATA M, UNPUB; Niori T, 1996, J MATER CHEM, V6, P1231, DOI 10.1039/jm9960601231; Ortega J, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.011707; Pakhomov S, 2003, P NATL ACAD SCI USA, V100, P3040, DOI 10.1073/pnas.0030051100; PANG J, 1995, THESIS U COLORADO; PANG JH, 1994, PHYS REV LETT, V73, P2332, DOI 10.1103/PhysRevLett.73.2332; Pelzl G, 1999, LIQ CRYST, V26, P135, DOI 10.1080/026782999205641; Pelzl G, 1999, ADV MATER, V11, P707, DOI 10.1002/(SICI)1521-4095(199906)11:9<707::AID-ADMA707>3.0.CO;2-D; PINDAK R, 1980, PHYS REV LETT, V45, P1193, DOI 10.1103/PhysRevLett.45.1193; Rao DSS, 2001, LIQ CRYST, V28, P1239, DOI 10.1080/02678290110051567; Reddy RA, 2002, LIQ CRYST, V29, P1365, DOI 10.1080/0267829021000017997; RENN SR, 1988, PHYS REV A, V38, P2132, DOI 10.1103/PhysRevA.38.2132; RIEKER TP, 1987, PHYS REV LETT, V59, P2658, DOI 10.1103/PhysRevLett.59.2658; SAFINYA CR, 1985, MOL CRYST LIQ CRYST, V123, P205, DOI 10.1080/00268948508074778; SAFINYA CR, 1984, PHYS REV LETT, V53, P1172, DOI 10.1103/PhysRevLett.53.1172; SELINGER JV, 1993, PHYS REV LETT, V71, P4091, DOI 10.1103/PhysRevLett.71.4091; SELINGER JV, 1995, PHYS REV E, V51, pR860, DOI 10.1103/PhysRevE.51.R860; SELINGER JV, 1993, PHYS REV LETT, V70, P1139, DOI 10.1103/PhysRevLett.70.1139; Stannarius R, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.031709; Szydlowska J, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.031702; Tabe Y, 1999, PHYS REV LETT, V82, P759, DOI 10.1103/PhysRevLett.82.759; Takanishi Y, 1999, J MATER CHEM, V9, P2771, DOI 10.1039/a904774c; Thomas BN, 1999, PHYS REV E, V59, P3040, DOI 10.1103/PhysRevE.59.3040; Walba DM, 2000, SCIENCE, V288, P2181, DOI 10.1126/science.288.5474.2181; YOUNG CY, 1978, PHYS REV LETT, V40, P773, DOI 10.1103/PhysRevLett.40.773; ZASADZINSKI JAN, 1990, J PHYS-PARIS, V51, P747, DOI 10.1051/jphys:01990005108074700	57	269	271	1	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 29	2003	301	5637					1204	1211		10.1126/science.1084956	http://dx.doi.org/10.1126/science.1084956			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	715ZC	12947191				2022-12-28	WOS:000185003500032
J	Belotserkovskaya, R; Oh, S; Bondarenko, VA; Orphanides, G; Studitsky, VM; Reinberg, D				Belotserkovskaya, R; Oh, S; Bondarenko, VA; Orphanides, G; Studitsky, VM; Reinberg, D			FACT facilitates transcription-dependent nucleosome alteration	SCIENCE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; IN-VIVO; ELONGATION; CHROMATIN; PROTEIN; COMPLEX; POB3; SSRP1; CDC68	The FACT (facilitates chromatin transcription) complex is required for transcript elongation through nucleosomes by RNA polymerase II (Pol II) in vitro. Here, we show that FACT facilitates Pol II-driven transcription by destabilizing nucleosomal structure so that one histone H2A-H2B dimer is removed during enzyme passage. We also demonstrate that FACT possesses intrinsic histone chaperone activity and can deposit core histones onto DNA. Importantly, FACT activity requires both of its constituent subunits and is dependent on the highly acidic C terminus of its larger subunit, Spt16. These findings define the mechanism by which Pol II can transcribe through chromatin without disrupting its epigenetic status.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem,Div Nucl Acids enzymol, Piscataway, NJ 08854 USA; Wayne State Univ, Sch Med, Dept Biochem, Detroit, MI 48201 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Wayne State University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Dept Biochem,Div Nucl Acids enzymol, Piscataway, NJ 08854 USA.		Studitsky, Vasily/A-9382-2014; Bondarenko, Vladimir/AFY-8370-2022	Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM37120, GM58650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650, R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELOTSERKOVSKAY.R, UNPUB; BONDARENKO VA, UNPUB; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Evans DRH, 1998, GENETICS, V150, P1393; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Formosa T, 2002, GENETICS, V162, P1557; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Keller DM, 2002, J BIOL CHEM, V277, P50206, DOI 10.1074/jbc.M209820200; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Lindstrom DL, 2001, GENETICS, V159, P487; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; Okuhara K, 1999, CURR BIOL, V9, P341, DOI 10.1016/S0960-9822(99)80160-2; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SAUNDERS, 2003, SCIENCE, V301, P1094; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; TENHEGGELERBORDIER B, 1995, EMBO J, V14, P2561, DOI 10.1002/j.1460-2075.1995.tb07254.x; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553; Yarnell AT, 2001, J BIOL CHEM, V276, P25736, DOI 10.1074/jbc.M101208200	28	629	645	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 22	2003	301	5636					1090	1093		10.1126/science.1085703	http://dx.doi.org/10.1126/science.1085703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	713RP	12934006				2022-12-28	WOS:000184872400038
J	Mauro, MJ				Mauro, MJ			Hyperleukocytosis in acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Oregon Hlth & Sci Univ, Portland, OR 97239 USA	Oregon Health & Science University	Mauro, MJ (corresponding author), Oregon Hlth & Sci Univ, Portland, OR 97239 USA.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 21	2003	349	8					767	767		10.1056/NEJMicm010149	http://dx.doi.org/10.1056/NEJMicm010149			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	713EE	12930929				2022-12-28	WOS:000184843300007
J	van Ommeren, M; Saxena, S; Loretti, A; Saraceno, B				van Ommeren, M; Saxena, S; Loretti, A; Saraceno, B			Ensuring care for patients in custodial psychiatric hospitals in emergencies	LANCET			English	Editorial Material									WHO, Dept Mental Hlth & Subst Dependence, CH-1211 Geneva, Switzerland; WHO, Hlth Act Crises, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization	van Ommeren, M (corresponding author), WHO, Dept Mental Hlth & Subst Dependence, Ave Appia, CH-1211 Geneva, Switzerland.	vanommerenm@who.int		Saraceno, Benedetto/0000-0001-7119-5712				BISE G, 2001, MALADES MENTAUX GUER; Silove D, 2000, LANCET, V355, P1548, DOI 10.1016/S0140-6736(00)02177-2; WEISS MG, IN PRESS J NERV MENT; WHO, 2001, WORLD HLTH REPORT 20	4	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2003	362	9383					574	574		10.1016/S0140-6736(03)14123-2	http://dx.doi.org/10.1016/S0140-6736(03)14123-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	712UW	12938670				2022-12-28	WOS:000184817600029
